<SEC-DOCUMENT>0001213900-25-082027.txt : 20250829
<SEC-HEADER>0001213900-25-082027.hdr.sgml : 20250829
<ACCEPTANCE-DATETIME>20250828214752
ACCESSION NUMBER:		0001213900-25-082027
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		118
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250829
DATE AS OF CHANGE:		20250828

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALTERITY THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001131343
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-49843
		FILM NUMBER:		251275682

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		STATE:			C3
		ZIP:			VIC 3000
		BUSINESS PHONE:		61 3 9349 4906

	MAIL ADDRESS:	
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		STATE:			C3
		ZIP:			VIC 3000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRANA BIOTECHNOLOGY LTD
		DATE OF NAME CHANGE:	20010105
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>ea0254438-20f_alterity.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 29 01:27:05 UTC 2025 -->
<html xmlns:athe="http://pranabio.com/20250630" xmlns:compsci="http://compsciresources.com" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-23370">20-F</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentRegistrationStatement" id="ixv-23371">&#9744;</ix:nonNumeric> REGISTRATION STATEMENT PURSUANT TO SECTION
12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport" id="ixv-23372">&#9746;</ix:nonNumeric> ANNUAL REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-23373"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-23374">June 30</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-23375">2025</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-23376">&#9744;</ix:nonNumeric> TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the transition period from __________ to
__________</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentShellCompanyReport" id="ixv-23377">&#9744;</ix:nonNumeric> SHELL COMPANY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of event requiring this shell company report
___________</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission file number <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-23378">000-49843</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-102"><b>ALTERITY THERAPEUTICS LIMITED</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of Registrant as specified in its charter
and translation of Registrant&#8217;s name into English)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-110"><b>Australia</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Jurisdiction of incorporation or organization)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-23379">Level 14, 350 Collins Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-23380">Melbourne</ix:nonNumeric>, VIC
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-23381">3000</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-23382">Australia</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-23383">David Stamler</ix:nonNumeric>, Chief Executive Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-23384">Level 14, 350 Collins Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-23385">Melbourne</ix:nonNumeric>, VIC
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-23386">3000</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-23387">Australia</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-23388">+61</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-23389">3 9349 4906</ix:nonNumeric> (phone) </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, telephone, e-mail and/or facsimile number
and address of company contact person)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(b) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="vertical-align: top; width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol</b></span></td> <td style="vertical-align: top; width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-159"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>American Depositary Shares, each representing 600 Ordinary Shares</b></span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-164"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ATHE</b></span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName" id="ixv-23390">NASDAQ</ix:nonNumeric> Capital Market</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(g) of the Act: <b>None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act: <b>None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate the number of outstanding shares of each of the issuer&#8217;s
classes of capital or common stock as of the close of the period covered by the annual report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Ordinary Shares, as of June 30, 2025 <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-23391">9,127,370,686</ix:nonFraction></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is a well-known seasoned issuer,
as defined in Rule 405 of the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-23392">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this report is an annual or transition report, indicate by check
mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-23393">No</ix:nonNumeric> &#9746;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note &#8211; Checking the box above will not relieve any registrant
required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-23394">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-23395">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221;
&#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</span></td> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-23396">&#9744;</ix:nonNumeric></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-23397">Non-accelerated filer</ix:nonNumeric> &#9746;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company that prepares its financial statements
in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8224; The term &#8220;new or revised financial accounting standard&#8221;
refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant has filed a report on
and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section
404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" id="ixv-23398">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If securities are registered pursuant to Section 12(b) of the Act,
indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to
previously issued financial statements. &#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-23399">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether any of those error corrections are restatements
that required a recovery analysis of incentive based compensation received by any of the registrant&#8217;s executive officers during
the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark which basis of accounting the registrant has
used to prepare the financial statements included in this filing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. GAAP &#9744;</span></td> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:DocumentAccountingStandard" id="ixv-23400">International Financial Reporting Standards</ix:nonNumeric> as issued by the International Accounting Standards Board &#9746;</span></td> <td style="width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other &#9744;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &#8220;Other&#8221; has been checked in response to the previous
question, indicate by check mark which financial statement item the registrant has elected to follow:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Item 17 &#9744; Item 18 &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this is an annual report, indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-23401">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Annual Report on Form 20-F is incorporated by reference into our
Registration Statements on Form S-8 (File Nos. 333-228671, 333-248980 and 333-251073) and our Registration Statements on Form F-3 (File
No. 333-274816).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">INTRODUCTION</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Alterity Therapeutics Limited (formerly Prana Biotechnology
Limited) was incorporated under the laws of the Commonwealth of Australia on November 11, 1997. Our mission is to develop therapeutic
drugs designed to treat neurogenerative diseases, currently focusing on Parkinsonian and other movement disorders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The principal listing of our ordinary shares and
listed options to purchase our ordinary shares is on the Australian Securities Exchange, or ASX. Since September 5, 2002, our American
Depository Shares, or ADSs, have traded on the NASDAQ Capital Market under the symbol &#8220;PRAN.&#8221; On April 8, 2019, we changed
our name to Alterity Therapeutics Limited and our ADSs have traded under the symbol &#8220;ATHE&#8221; since that date. The Bank of New
York, acting as depositary, issues American Depository Receipts, or ADRs, each of which evidences an ADS, which in turn represents 600
of our ordinary shares. As used in this annual report, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221;, &#8220;the Company&#8221;,
&#8220;the Group&#8221; and &#8220;Alterity&#8221; mean Alterity Therapeutics Limited and its subsidiaries, unless otherwise indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our consolidated financial statements appearing
in this annual report are prepared in Australian dollars and in accordance with the International Financial Reporting Standards, or IFRS,
as issued by the International Accounting Standards Board, or IASB and Australian equivalents to International Financial Reporting Standards
as issued by the Australian Accounting Standards Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Australian Disclosure Requirements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our ordinary shares are primarily quoted on the
Australian Securities Exchange (&#8220;ASX&#8221;) in addition to our listing of our ADSs on the NASDAQ Capital Market. As part of our
ASX listing, we are required to comply with various disclosure requirements as set out under the Australian <i>Corporations Act 2001 </i>and
the <i>ASX Listing Rules</i>. Information furnished under the sub-heading &#8220;Australian Disclosure Requirements&#8221; is intended
to comply with the <i>ASX Listing Rules</i> and <i>Corporations Act 2001 </i>disclosure requirements and is not intended to fulfill information
required by this Annual Report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In this annual report, all references to &#8220;U.S.
dollars&#8221; or &#8220;U.S.$&#8221; are to the currency of the United States, and all references to &#8220;Australian dollars&#8221;
or &#8220;A$&#8221; are to the currency of Australia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Statements made in this annual report concerning
the contents of any contract, agreement or other document are summaries of such contracts, agreements or documents and are not complete
descriptions of all of their terms. If we filed any of these documents as an exhibit to this annual report or to any registration statement
or annual report that we previously filed, you may read the document itself for a complete description of its terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Forward-Looking Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except for the historical information contained
in this annual report, the statements contained in this annual report are &#8220;forward-looking statements&#8221; within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange
Act, and the Private Securities Litigation Reform Act of 1995, as amended, with respect to our business, financial condition and results
of operations. Such forward-looking statements reflect our current view with respect to future events and financial results. We urge you
to consider that statements which use the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;do not believe,&#8221; &#8220;expect,&#8221;
&#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; and similar expressions are intended to identify forward-looking statements.
We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors
and involve known and unknown risks that could cause the actual results, performance, levels of activity, or our achievements, or industry
results, to be materially different from any future results, performance, levels of activity, or our achievements expressed or implied
by such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak
only as of the date hereof. Except as required by applicable law, including the securities laws of the United States, we undertake no
obligation to publicly release any update or revision to any forward-looking statements to reflect new information, future events or circumstances,
or otherwise after the date hereof. We have attempted to identify significant uncertainties and other factors affecting forward-looking
statements in the Risk Factors section that appears in Item 3.D. &#8220;<i>Key Information-Risk Factors.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">TABLE OF CONTENTS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 10%">&#160;</td>
    <td style="vertical-align: top; width: 80%">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>PART I</b></span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">ITEM 1.</span></td>
    <td style="vertical-align: top"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">ITEM 2.</span></td>
    <td style="vertical-align: top"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">OFFER STATISTICS AND EXPECTED TIMETABLE</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">ITEM 3.</span></td>
    <td style="vertical-align: top"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">KEY INFORMATION</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization and Indebtedness</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasons for the Offer and Use of Proceeds</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">ITEM 4.</span></td>
    <td style="vertical-align: top"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">INFORMATION ON THE COMPANY</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">History and Development of the Company</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Overview</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organizational Structure</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, Plant and Equipment</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">ITEM 4A.</span></td>
    <td style="vertical-align: top"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">UNRESOLVED STAFF COMMENTS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">ITEM 5.</span></td>
    <td style="vertical-align: top"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Results</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity and Capital Resources</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and Development, Patents and Licenses</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trend Information</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical Accounting Estimates</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">ITEM 6.</span></td>
    <td style="vertical-align: top"><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors and Senior Management</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">Compensation</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board Practices</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_025">Employees</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Ownership</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_075"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure of a registrant&#8217;s action to recover erroneously awarded compensation</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">ITEM 7.</span></td>
    <td style="vertical-align: top"><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major Shareholders</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party Transactions</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interests of Experts and Counsel</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">ITEM 8.</span></td>
    <td style="vertical-align: top"><a href="#a_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">FINANCIAL INFORMATION</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Other Financial Information</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant Changes</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">ITEM 9.</span></td>
    <td style="vertical-align: top"><a href="#a_074"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">THE OFFER AND LISTING</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_034"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer and Listing Details</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_035"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span>2</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_036">Markets</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_037"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Shareholders</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_038">Dilution</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_039"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses of the Issue</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">ITEM 10.</span></td>
    <td style="vertical-align: top"><a href="#a_040"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">ADDITIONAL INFORMATION</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_041"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Capital</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_042"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Memorandum and Articles of Association</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_043"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Contracts</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_044"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Controls</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_045">Taxation</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_046"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends and Paying Agents</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_047"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement by Experts</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_048"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documents on Display</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_049"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary Information</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span></td>
    <td style="vertical-align: top; padding-left: 9pt"><a href="#a_050"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual Report to Security Holders</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="background-color: #CCEEFF">
    <td style="text-align: left; vertical-align: top; width: 10%">ITEM 11.</td>
    <td style="text-align: left; vertical-align: top; width: 80%; padding-left: 9pt; text-indent: -9pt"><a href="#a_051">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></td>
    <td style="vertical-align: top; width: 10%; text-align: center">71</td></tr>
  <tr>
    <td style="vertical-align: top">ITEM 12.</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#a_052">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</a></td>
    <td style="vertical-align: bottom; text-align: center">72</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#a_053">PART II</a></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">73</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">ITEM 13.</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#a_054">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</a></td>
    <td style="vertical-align: bottom; text-align: center">73</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top">ITEM 14.</td>
    <td style="vertical-align: top; padding-left: 0in; text-indent: 0in"><a href="#a_055">MATERIAL MODIFICATIONS TO THE RIGHTS OF
    SECURITY HOLDERS AND USE OF PROCEEDS</a></td>
    <td style="vertical-align: bottom; text-align: center">73</td></tr>
  <tr>
    <td style="vertical-align: top">ITEM 15.</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#a_056">CONTROLS AND PROCEDURES</a></td>
    <td style="vertical-align: bottom; text-align: center">73</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top">ITEM 16.</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#a_057">RESERVED</a></td>
    <td style="vertical-align: bottom; text-align: center">74</td></tr>
  <tr>
    <td style="vertical-align: top">ITEM 16A.</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#a_058">AUDIT COMMITTEE FINANCIAL EXPERT</a></td>
    <td style="vertical-align: bottom; text-align: center">74</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top">ITEM 16B.</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#a_059">CODE OF ETHICS</a></td>
    <td style="vertical-align: bottom; text-align: center">74</td></tr>
  <tr>
    <td style="vertical-align: top">ITEM 16C.</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#a_060">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></td>
    <td style="vertical-align: bottom; text-align: center">74</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top">ITEM 16D.</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#a_061">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</a></td>
    <td style="vertical-align: bottom; text-align: center">74</td></tr>
  <tr>
    <td style="vertical-align: top">ITEM 16E.</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#a_062">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</a></td>
    <td style="vertical-align: bottom; text-align: center">74</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top">ITEM 16F.</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#a_063">CHANGES IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</a></td>
    <td style="vertical-align: bottom; text-align: center">75</td></tr>
  <tr>
    <td style="vertical-align: top">ITEM 16G.</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#a_064">CORPORATE GOVERNANCE</a></td>
    <td style="vertical-align: bottom; text-align: center">75</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top">ITEM 16H.</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#a_065">MINE SAFETY DISCLOSURE</a></td>
    <td style="vertical-align: bottom; text-align: center">75</td></tr>
  <tr>
    <td style="vertical-align: top">ITEM 16I&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#a_066">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></td>
    <td style="vertical-align: bottom; text-align: center">75</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 16J</td>
    <td style="vertical-align: top"><a href="#a_067">INSIDER TRADING POLICIES</a></td>
    <td style="vertical-align: bottom; text-align: center">75</td></tr>
  <tr>
    <td style="vertical-align: top">ITEM 16K</td>
    <td style="vertical-align: top"><a href="#a_068">CYBER SECURITY</a></td>
    <td style="vertical-align: bottom; text-align: center">75</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="#a_069">PART III</a></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">77</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">ITEM 17.</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#a_070">FINANCIAL STATEMENTS</a></td>
    <td style="vertical-align: bottom; text-align: center">77</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">ITEM 18.</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#a_071">FINANCIAL STATEMENTS</a></td>
    <td style="vertical-align: bottom; text-align: center">77</td></tr>
  <tr>
    <td style="vertical-align: top">ITEM 19.</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#a_072">EXHIBITS</a></td>
    <td style="vertical-align: bottom; text-align: center">79</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_073">SIGNATURES</a></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">80</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-indent: -49.5pt"><span style="font-variant: small-caps">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><span style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>ITEM 1.</b></span><b> IDENTITY
OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><span style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>ITEM 2.</b></span><b> OFFER
STATISTICS AND EXPECTED TIMETABLE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><span style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>ITEM 3.</b></span><b> KEY
INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_005"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>[Reserved]</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><div><a id="a_006"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Capitalization and Indebtedness</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_007"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Reasons for the Offer and Use of Proceeds</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_008"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Risk Factors</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Investing in our securities involves a high
degree of risk and uncertainty. You should carefully consider the risks and uncertainties described below before investing in our securities.
Additional risks and uncertainties not presently known to us or that we believe to be immaterial may also adversely affect our business.
If any of the following risks actually occurs, our business, prospects, financial condition and results of operations could be harmed.
In that case, the daily price of our securities could decline, and you could lose all or part of your investment. These risk factors include:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Financial Condition </b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a history of operating losses and will continue to incur losses whilst conducting clinical trials. However, we also have a history
of successfully raising funds via equity capital raisings, and as a result, we have a strong cash position for the fiscal year ended
June 30, 2025. The continuing viability of the Group is subject to its ability to raise additional capital to finance the continuation
of its planned research and development programs, maintaining implemented cost containment and deferment strategies, and successfully
commercializing its initiatives. The Group successfully raised new equity funding during the 2025 financial year to enable progression
of its planned research and development programs for at least the next 12 months.</span></td>
</tr></table><div>



</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will still need additional funding to operate our business in the future; such funding may not be available or, if it is available, such
financing is likely to substantially dilute our existing shareholders.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
are a development stage company engaged in the development of pharmaceutical products and our success is uncertain.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">We rely on research institutions to conduct our clinical
trials and we may not be able to secure and maintain research institutions to conduct our future trials. The institutions that we work
with have their own limits and procedures that will influence or limit our ability to conduct research and development and the conduct
of clinical trials.</td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are faced with uncertainties related to our research.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials as they relate to our business are expensive and time consuming and their outcome is uncertain.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 41.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience delays in our clinical trials that could adversely affect our business and operations.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.65pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to complete the development of our products candidates or develop other pharmaceutical products.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may need to prioritise the development of our most promising candidates at the expense of the development of other products.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development efforts will be seriously jeopardised if we are unable to retain key personnel and cultivate key academic and
scientific collaborations.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to successfully keep pace with technological change or with the advances of our competitors, our technology and products
may become obsolete or non-competitive.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptance
of our products in the marketplace is uncertain and failure to achieve market acceptance will negatively impact our business and operations.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 41.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited large scale manufacturing experience with our product candidates.&#160;&#160;Delays in manufacturing sufficient quantities
of such materials to the required standards for non-clinical and clinical development may negatively impact our business and operations.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 41.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure to establish sales, marketing and distribution capability would materially impair our ability to successfully market and sell
our pharmaceutical products.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
healthcare insurers and other organisations do not pay for our products, or impose limits on reimbursement, our future business may suffer.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be exposed to product liability claims, which could harm our business.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breaches
of network or information technology security, natural disasters or terrorist attacks could have an adverse effect on our business.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Government Regulation</b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not obtain the necessary governmental approvals, we will be unable to develop or commercialise our pharmaceutical products.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not be able to commercialise any current or future product candidates if we fail to adequately demonstrate their safety and efficacy.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Positive
results in previous clinical trials of product candidates may not be replicated in future clinical trials, which could result in development
delays or a failure to obtain marketing approval.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 41.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if approved, any product candidates that we or our subsidiaries may develop and market may be later withdrawn from the market or subject
to promotional limitations.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -15.5pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
reform measures and other statutory or regulatory changes could adversely affect our business.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends upon our ability to protect our intellectual property and our proprietary technology, to operate without infringing the
proprietary rights of third parties and to obtain marketing exclusivity for our products and technologies.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may face difficulties in certain jurisdictions in protecting our intellectual property rights, which may diminish the value of our intellectual
property rights in those jurisdictions.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
property rights do not address all potential threats to our competitive advantage.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in patent laws or patent jurisprudence could diminish the value of our patents, thereby impairing our ability to protect our products
or product candidates.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidentiality
agreements with employees and others may not adequately prevent disclosure of our trade secrets and protect our other proprietary information.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Compliance with the Sarbanes-Oxley Act of 2002</b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may fail to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of
2002, which could adversely affect our operating results, investor confidence in our reported financial information, and the market price
of our ordinary shares and ADSs.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
weaknesses in our disclosure controls and procedures could negatively affect shareholder and customer confidence.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5pt">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Ownership of Our Securities</b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
stock price may be volatile and the&#160;trading markets for our securities is limited.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 41.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ownership
interest in our company may be further diluted as a result of additional financings.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a substantial risk that we are a passive foreign investment company, or PFIC, to some U.S. investors which will subject those investors
to adverse tax rules</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate paying dividends on our ordinary shares.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 41.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency
fluctuations may adversely affect the price of our securities.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 41.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to maintain compliance with NASDAQ&#8217;s continued listing requirements, our shares may be delisted from the NASDAQ Capital
Market.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Location in Australia</b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
may be difficult to enforce a judgment in the United States against us and our officers and directors or to assert U.S. securities laws
claims in Australia or serve process on our officers and directors.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 41.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a foreign private issuer whose shares are listed on the NASDAQ Capital Market, we may follow certain home country corporate governance
practices instead of certain NASDAQ requirements.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have a majority of independent directors serving on our Board of Directors, which may afford less protection to our
shareholders than if our Board of Directors had a majority of independent directors.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australian
takeovers laws may discourage takeover offers being made for us or may discourage the acquisition of large numbers of our ordinary shares.</span></td>
</tr></table><div>


</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 41.15pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Constitution and other Australian laws and regulations applicable to us may adversely affect our ability to take actions that could be
beneficial to our shareholders.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>We rely on research institutions to conduct
our clinical trials and we may not be able to secure and maintain research institutions to conduct our future trials. The institutions
that we work with have their own limits and procedures that may influence or limit our ability to conduct research and development and
the conduct of clinical trials.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our reliance upon research institutions, including
public and private hospitals and clinics, provides us with less control over the timing and cost of clinical trials, clinical study management
personnel and the ability to recruit subjects. If we are unable to reach agreements with suitable research institutions on acceptable
terms, or if any resulting agreement is terminated, we may be unable to secure, maintain or quickly replace the research institution with
another qualified institution on acceptable terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>We are faced with uncertainties related to our
research. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our research programs are based on scientific hypotheses
and experimental approaches that may not lead to desired results. In addition, the timeframe for obtaining proof of principle and other
results may be considerably longer than originally anticipated, or may not be possible given time, resource, financial, strategic and
collaborator scientific constraints. Success in one stage of testing is not necessarily an indication that a particular program will succeed
in later stages of testing and development. It is not possible to predict whether any of the candidate products designed for these programs
will prove to be safe, effective, and suitable for human use. Each candidate product will require additional research and development,
scale-up, formulation and extensive clinical testing in humans. Unsatisfactory results obtained from any of these activities relating
to a program may cause us to abandon our commitment to that program or product candidate being tested. The discovery of toxicities, lack
of sufficient efficacy, unacceptable pharmacology, inability to increase scale of manufacture, market attractiveness, regulatory hurdles,
competition, as well as other factors, may make our targets, lead therapies or product candidates unattractive for further development
or unsuitable for human use, and we may abandon our commitment to that program, target, or product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Clinical trials as they relate to our business
are expensive and time consuming and their outcome is uncertain.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to obtain approvals to market a new drug
product, we or our potential partners must demonstrate proof of safety and efficacy in humans. To meet these requirements, we or our potential
partners will have to conduct extensive non-clinical testing and &#8220;adequate and well-controlled&#8221; clinical trials. Conducting
clinical trials is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity,
novelty and intended use of the product candidate, and often can be several years or more per trial. Even if we obtain positive results
from such non-clinical or initial clinical trials, we may not achieve the same success in future trials. Clinical trials may not demonstrate
adequate safety or sufficient effectiveness to obtain the requisite regulatory approvals for product candidates employing our technology.
The failure of clinical trials to demonstrate safety and efficacy for a particular desired indication could harm development of that product
candidate for other indications as well as other product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect to commence new clinical trials from
time to time as our product development work continues. Any change in, or termination of, our clinical trials could materially harm our
business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>We may experience delays in our clinical trials
that could adversely affect our business and operations.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not know whether planned clinical trials
will begin on time or whether we will complete any of our clinical trials on schedule or at all. Our ability to commence and complete
clinical trials may be delayed by many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">government or regulatory delays, including delays in obtaining approvals from applicable hospital ethics committees and internal review boards;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower than expected patient enrollment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to manufacture sufficient quantities of our new proprietary compound or our other product candidates or matching controls;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen safety issues; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of efficacy or unacceptable toxicity during the clinical trials or non-clinical studies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Patient enrollment is a function of, among other
things, the nature of the clinical trial protocol, the existence of competing protocols, the size and longevity of the target patient
population, and the availability of patients who comply with the eligibility criteria for the clinical trial. Delays in planned patient
enrollment may result in increased costs, delays or termination of the clinical trials. Moreover, we rely on third parties such as clinical
research organisations to assist us in clinical trial management functions including; clinical trial database management, statistical
analyses, site management and monitoring. Any failure by these third parties to perform under their agreements with us may cause the trials
to be delayed or result in a failure to complete the trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we experience delays in testing or approvals
or if we need to perform more, larger or more complex clinical trials than planned, our product development costs will likely increase.
Significant delays could adversely affect the commercial prospects of our product candidates and our business, financial condition and
results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>We may not be able to complete the development
of our product candidates or develop other pharmaceutical products.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may not be able to progress with the development
of our current or any future pharmaceutical product candidates to a stage that will attract a suitable collaborative partner for the development
of any current or future pharmaceutical product candidates. The projects initially specified in connection with any such collaboration
and any associated funding may change or be discontinued as a result of changing interests of either the collaborator or us, and any such
change may change the budget for the projects under the collaboration. Additionally, our research may not lead to the discovery of additional
product candidates, and any of our current and future product candidates may not be successfully developed, prove to be safe and efficacious
in clinical trials, meet applicable regulatory standards and receive regulatory approval, be capable of being produced in commercial quantities
at reasonable costs, or be successfully or profitably marketed, either by us or a collaborative partner. The products we develop may not
be able to penetrate the potential market for a particular therapy or indication or gain market acceptance among health care providers,
patients and third-party payers. We cannot predict if or when the development of our current product candidates or any future product
candidates will be completed or commercialised, whether funded by us, as part of a collaboration or through a grant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>We may need to prioritise the development of
our most promising candidates at the expense of the development of other products.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may need to prioritise the allocation of development
resources and/or funds towards what we believe to be our most promising candidate product or products. The nature of the drug development
process is such that there is a constant availability of new information and data which could positively or adversely affect a product
in development. We cannot predict how such new information and data may impact in the future the prioritisation of the development of
our current or future product candidates or that any of our products, regardless of its development stage or the investment of time and
funds in its development, will continue to be funded or developed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Our research and development efforts will be
seriously jeopardised if we are unable to retain key personnel and cultivate key academic and scientific collaborations.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our future success depends to a large extent on
the continued services of our senior management and key scientific personnel. We have entered into employment or consultancy agreements
with these individuals. The loss of their services could negatively affect our business. Competition among biotechnology and pharmaceutical
companies for qualified employees is intense, including competition from larger companies with greater resources, and we may not be able
to continue to attract and retain qualified management, technical and scientific personnel critical to our success. Our success is highly
dependent on our ability to develop and maintain important relationships with leading academic institutions and scientists who conduct
research at our request or assist us in formulating our research and development strategies. These academic and scientific collaborators
are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability
to us. In addition, these collaborators may have arrangements with other companies to assist such companies in developing technologies
that may prove competitive to ours.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>If we are unable to successfully keep pace with
technological change or with the advances of our competitors, our technology and products may become obsolete or non-competitive.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The biotechnology and pharmaceutical industries
are subject to rapid and significant technological change. Our competitors are numerous and include major pharmaceutical companies, biotechnology
firms, universities and other research institutions. These competitors may develop technologies and products that are more effective than
any that we are developing, or which would render our technology and products obsolete or non-competitive. Many of these competitors have
greater financial and technical resources and manufacturing and marketing capabilities than we do. In addition, many of our competitors
have much more experience than we do in pre-clinical testing and human clinical trials of new or improved drugs, as well as in obtaining
regulatory approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We know that competitors are developing or manufacturing
various technologies or products for the treatment of diseases that we have targeted for product development. Some of these competitive
products use therapeutic approaches that compete directly with our product candidates. Our ability to further develop our products may
be adversely affected if any of our competitors were to succeed in obtaining regulatory approval for their competitive products sooner
than us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Acceptance of our products in the marketplace
is uncertain, and failure to achieve market acceptance will negatively impact our business and operations.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our current or future candidate products may not
achieve market acceptance even if they are approved by regulatory authorities. The degree of market acceptance of such products will depend
on a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the receipt and timing of regulatory approvals for the uses that we are studying;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the establishment and demonstration to the medical community of the safety, clinical efficacy or cost-effectiveness of our product candidates and their potential advantages over existing therapeutics and technologies; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the pricing and reimbursement policies of governments and third-party payors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Physicians, patients, payors or the medical community
in general may be unwilling to accept, use or recommend any of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>We lack the resources to manufacture any of
our product candidates and rely on collaborators and third party contractors. Delays in manufacturing sufficient quantities of such materials
to the required standards for pre-clinical and clinical trials may negatively impact our business and operations.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We lack the resources to manufacture any of our
product candidates on a clinical or commercial scale and do not currently have, nor do we plan to acquire the infrastructure or capability
internally to manufacture our clinical drug supplies for use in the conduct of our clinical trials. We rely on collaborators and/or third
parties for development, scale-up, formulation, optimisation, management of clinical trial and commercial scale manufacturing and commercialisation.
There are no assurances we can scale-up, formulate or manufacture any product candidate in sufficient quantities with acceptable specifications
for the conduct of our clinical trials or for the regulatory agencies to grant approval of such product candidate. We have not yet commercialized
any products and have no commercial manufacturing experience. To be successful, our products must be properly formulated, scalable, stable
and safely manufactured in clinical trial and commercial quantities in compliance with good manufacturing practices (&#8220;GMP&#8221;)
and other regulatory requirements and at acceptable costs. Should any of our suppliers or our collaborators be unable to supply or be
delayed in supplying us with sufficient supplies, no assurance can be given that we will be able to find alternative means of supply in
a short period of time. Should such parties&#8217; operations suffer a material adverse event, the manufacturing of our products would
also be adversely affected. Furthermore, key raw materials could become scarce or unavailable. We may not be able to meet specifications
previously established for product candidates during scale-up and manufacturing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There may be a limited number of third parties
who can manufacture our products. Our reliance on third parties to manufacture our product candidates will expose us and our partners
to risks including the following, any of which could delay or prevent the commercialisation of our products, result in higher costs, or
deprive us of potential product revenue:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract manufacturers can encounter difficulties in achieving the scale-up, optimisation, formulation, or volume production of a compound as well as maintaining quality control with appropriate quality assurance. They may also experience shortages of qualified personnel. Contract manufacturers are required to undergo a satisfactory GMP inspection prior to regulatory approval and are obliged to operate in accordance with the U.S. Food &amp; Drug Administration, or FDA, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (&#8220;ICH&#8221;), European and other nationally mandated GMP regulations and/or guidelines governing manufacturing processes, stability testing, record keeping and quality standards. A failure of these contract manufacturers to follow GMP and to document their adherence to such practices or failure of an inspection by a regulatory agency may lead to significant delays in the availability of our product candidate materials for clinical study, leading to delays in our trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For each of our current product candidates we will initially rely on a limited number of contract manufacturers. Changing these or identifying future manufacturers may be difficult. Changing manufacturers requires re-validation of the manufacturing processes and procedures in accordance with FDA, ICH, European and other mandated GMP regulations and/or guidelines. Such re-validation may be costly and time-consuming. It may be difficult or impossible for us to quickly find replacement manufacturers on acceptable terms, if at all.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to produce, store and distribute our products successfully.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>The failure to establish sales, marketing and
distribution capability would materially impair our ability to successfully market and sell our pharmaceutical products.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We currently have no experience in marketing, sales
or distribution of pharmaceutical products. If we develop any commercially marketable pharmaceutical products and decide to perform our
own sales and marketing activities, we will require additional management, will need to hire sales and marketing personnel and will require
additional capital. Qualified personnel may not be available in adequate numbers or at a reasonable cost. Further, our sales staff may
not achieve success in their marketing efforts. Alternatively, we may be required to enter into marketing arrangements with other parties
who have established appropriate marketing, sales and distribution capabilities. We may not be able to enter into marketing arrangements
with any marketing partner, or if such arrangements are established, our marketing partners may not be able to commercialise our products
successfully. Other companies offering similar or substitute products may have well-established and well-funded marketing and sales operations
in place that will allow them to market their products more successfully. Failure to establish sufficient marketing capabilities would
materially impair our ability to successfully market and sell our pharmaceutical products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>If healthcare insurers and other organisations
do not pay for the products we hope to develop, or impose limits on reimbursement, our future business may suffer.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The drugs we hope to develop may be rejected by
the marketplace due to many factors, including cost. The continuing efforts of governments, insurance companies, health maintenance organisations
and other payors of healthcare costs to contain or reduce healthcare costs may affect our future revenues and profitability and those
of our potential customers, suppliers and collaborative partners, as well as the availability of capital. In Australia and certain foreign
markets, the pricing or profitability of prescription pharmaceuticals is already subject to government control. We expect initiatives
for similar government control at both the state and federal level to continue in the United States and elsewhere. The adoption of any
such legislative or regulatory proposals could adversely affect our business and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our ability to commercially exploit our products
successfully will depend in part on the extent to which reimbursement for the cost of our products and related treatment will be available
from government health administration authorities, private health coverage insurers and other organisations. Third-party payors, such
as government and private health insurers, are increasingly challenging the price of medical products and services. Uncertainty exists
as to the reimbursement status of newly approved health care products and in foreign markets, including the United States. If third-party
coverage is not available to patients for any of the products we develop, alone or with collaborators, the market acceptance of these
products may be reduced, which may adversely affect our future revenues and profitability. In addition, cost containment legislation and
reductions in government insurance programs may result in lower prices for our products and could materially adversely affect our ability
to operate profitably.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the U.S. and some jurisdictions outside the
U.S., there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could impact
our business. Generally, there has been increasing legislative and enforcement interest in the U.S. with respect to drug pricing, including
specialty drug pricing practices, in light of the rising cost of prescription drugs and biologics. Specifically, there have been U.S.
Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing,
review the relationship between pricing and manufacturer patient programs, reduce the price of drugs under Medicare, and reform government
program reimbursement methodologies for drugs and biologics. In addition, the concept of most-favored nation pricing has been raised that
would seek to establish drug prices in the U.S. to the lowest level paid by comparable countries. Such policy action could cause us to
amend, suspend or terminate the development of any or all of our product candidates if a viable commercial market did not exist, which
could have a material adverse impact on our business and ability to operate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If future legislation were to impose direct governmental
price controls and access restrictions, it could have a significant adverse impact on our business and financial results. Managed care
organizations, as well as Medicaid and other government authorities, continue to seek price discounts. At the state level, legislatures
have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biologic product pricing, including
price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, to encourage importation from other countries and bulk purchasing.&#160;Due to the volatility in the current
economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory, payor or policy
actions, which may include cost containment and healthcare reform measures. Such policy actions could have a material adverse impact on
our business and ability to operate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>We may be exposed to product liability claims,
which could harm our business.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The testing, marketing and sale of human health
care products also entails an inherent risk of product liability. We may incur substantial liabilities or be required to limit development
or commercialisation of our candidate products if we cannot successfully defend ourselves against product liability claims. We have historically
obtained no fault compensation insurance for our clinical trials and intend to obtain similar coverage for future clinical trials. Such
coverage may not be available in the future on acceptable terms, or at all. This may result in our inability to pursue further clinical
trials or to obtain adequate protection in the event of a successful claim. We may not be able to obtain product liability insurance in
the event of the commercialisation of a candidate product or such insurance may not be available on commercially reasonable terms. Even
if we have adequate insurance coverage, product liability claims or recalls could result in negative publicity or force us to devote significant
time, attention and financial resources to those matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Breaches of network or information technology
security, natural disasters or terrorist attacks could have an adverse effect on our business.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;Our business and operations would suffer
in the event of IT system failures, cybersecurity attacks, data breaches, or vulnerabilities in our or our third-party vendors&#8217;
information security program or defenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business relies upon information technology
systems operated by us and by our third-party service providers. These systems may fail or experience operational disruption, experience
cybersecurity attacks, or be damaged by computer viruses and unauthorized access. In the ordinary course of business, we collect, store
and transmit confidential information (including but not limited to intellectual property, proprietary business information and personal
information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information.
If we fail to develop and maintain adequate policies and procedures for the protection of our information technology systems and confidential
and proprietary information, we may be vulnerable to security breaches or disruptions and system breakdowns or other damage or interruptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also have outsourced elements of our operations
to third parties, and as a result we manage a number of third-party vendors and other contractors and consultants who have access to or
store our confidential information. We do not conduct audits or formal evaluations of our third-party vendors&#8217; information technology
systems and cannot be sure that our third-party vendors have sufficient measures in place to ensure the security and integrity of their
information technology systems and our confidential and proprietary information. If our third-party vendors fail to protect their information
technology systems and our confidential and proprietary information, we may be vulnerable to disruptions in service and unauthorized access
to our confidential or proprietary information and we could incur liability and reputational damage and the further development and commercialization
of our product candidates could be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have been subject, and will likely continue
to be subject, to attempts to breach the security of our networks and IT infrastructure through cyber-attack, malware, computer viruses
and other means of unauthorised access. However, to date, we have not been subject to cyber-attacks or other cyber incidents which, individually
or in the aggregate, resulted in a material impact to our operations or financial condition. We cannot assure you that our data protection
efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems or those
of our third-party vendors and other contractors and consultants, or other cyber incidents that could have a material adverse effect upon
our reputation, business, operations or financial condition. Furthermore, cyberattacks and security incidents are expected to accelerate
in both frequency and impact as the use of AI increases and attackers become increasingly sophisticated and utilize tools and techniques
that are designed to circumvent controls, avoid detection, and remove or obfuscate forensic evidence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If such an event were to occur and cause interruptions
in our operations, it could result in a material disruption of our development programs, business operations, a breach of sensitive personal
information or a loss or corruption of critical data assets including trade secrets or other proprietary information. For example, the
loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase
our costs to recover or reproduce the data. Such IT system failures, cybersecurity attacks or vulnerabilities to our or our third-party
vendors&#8217; information security programs or defenses could result in legal liability, reputational damage, business interruption,
and our competitive position could be harmed and the further development and commercialization of our products or any future products
could be delayed or disrupted. Moreover, containing and remediating any IT system failure, cybersecurity attack or vulnerability may require
significant investment of resources. Furthermore, significant security breaches or disruptions of our internal information technology
systems or those of our third-party vendors and other contractors and consultants could result in the loss, misappropriation and/or unauthorized
access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual
property, proprietary business information and personal information), which could result in financial, legal, business and reputational
harm to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>We and the third parties with whom we work are
subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, industry standards, policies and
other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations (or that of the
third parties with whom we work) could lead to regulatory investigations or actions; litigation (including class actions); mass arbitration
demands; fines and penalties; a disruption of our business operations; reputational harm; loss of revenue or profits; and other adverse
business consequences.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the ordinary course of business, we collect,
receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively,
&#8220;process&#8221;) personal data and other sensitive information including proprietary and confidential business data, trade secrets,
intellectual property, data we collect about trial participants in connection with clinical trials,and other sensitive third-party data.
Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations guidance,
industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data
privacy and security.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In the United States, federal, state, and
local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data
privacy laws, consumer protection laws (e.g. Section 5 of the Federal Trade Commission Act), and other similar laws (e.g.,
wiretapping laws). For example HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and
transmission of individually identifiable health information. In the past few years, numerous U.S. states-including California,
Virginia, Colorado, Connecticut, and Utah-have enacted comprehensive privacy laws that impose certain obligations on covered
businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their
personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out
of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these
rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements
for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These
state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018
(&#8220;CCPA&#8221;) applies to personal data of consumers, business representatives, and employees, and requires businesses to
provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The
CCPA provides for civil penalties of up to $7,500 per violation and allows private litigants affected by certain data breaches to
recover significant statutory damages. Similar laws are being considered in several other states, as well as at the federal and
local levels, and we expect more states to pass similar laws in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The CCPA and other comprehensive U.S. state privacy
laws exempt some data processed in the context of clinical trials, but these developments may further complicate compliance efforts and
increase legal risk and compliance costs for us and the third parties with whom we work.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Outside the United States, an increasing number
of laws, regulations, and industry standards govern data privacy and security. For example, the European Union&#8217;s General Data Protection
Regulation (&#8220;EU GDPR&#8221;), the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;)(collectively, &#8220;GDPR&#8221;), Brazil&#8217;s
General Data Protection Law (Lei Geral de Protec&#227;o de Dados Pessoais, or &#8220;LGPD&#8221;) (Law No. 13,709/2018), and China&#8217;s
Personal Information Protection Law (&#8220;PIPL&#8221;) impose strict requirements for processing personal data. For example, under the
GDPR, companies may face temporary or definitive bans on data processing and other corrective actions, fines of up to 20 million Euros
/ 17.5 million pounds sterling, or 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal
data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. China&#8217;s
PIPL imposes a set of specific obligations on covered businesses in connection with their processing and transfer of personal data and
imposes fines of up to RMB 50 million or 5% of the prior year&#8217;s total annual revenue of the violator. In Canada, the Personal Information
Protection and Electronic Documents Act (&#8220;PIPEDA&#8221;) and various related provincial laws, as well as Canada&#8217;s Anti-Spam Legislation
(&#8220;CASL&#8221;), may apply to our operations. We may be subject to new and emerging data privacy and security regimes, including
Australia&#8217;s Privacy Act, China&#8217;s Personal Information Protection Law, Japan&#8217;s Act on the Protection of Personal Information, and Singapore&#8217;s
Personal Data Protection Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the ordinary course of business, we may transfer
personal data from Europe and other jurisdictions to the United States or other countries. Europe and other jurisdictions have enacted
laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic
Area (&#8220;EEA&#8221;) and the United Kingdom (&#8220;UK&#8221;) have significantly restricted the transfer of personal data to the
United States and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations
of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer
personal data from the EEA and UK to the United States in compliance with law, such as the EEA standard contractual clauses, the UK&#8217;s
International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for
transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject
to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the
United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK or other jurisdictions to the United
States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including
the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to
other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to
transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal
data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions,
particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some
European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe for allegedly violating
the GDPR&#8217;s cross-border data transfer limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our employees and personnel may use generative
artificial intelligence (&#8220;AI&#8221;) technologies to perform their work, and the disclosure and use of personal data in generative
AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional
laws regulating generative AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions,
and lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to data privacy and security
laws, we are or may become contractually subject to industry standards adopted by industry groups. We are also bound by contractual
obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. For
example, certain data privacy laws, such as the GDPR and the CCPA, require covered businesses to impose specific contractual
restrictions on their service providers. We publish privacy policies, marketing materials and other statements, such as compliance
with certain certifications or self-regulatory principles, regarding data privacy and security. If these policies, materials or
statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be
subject to investigation, enforcement actions by regulators or other adverse consequences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Obligations related to data privacy and security
(and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally,
these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions.
Preparing for and complying with these obligations requires us to devote significant resources, which may necessitate changes to our services,
information technologies, systems, and practices and to those of any third parties with whom we work. In addition, these obligations may
require us to change our business model.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may at times fail (or be perceived to have failed)
in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties
with whom we work may fail to comply with such obligations, which could negatively impact our business operations. If we or the third
parties with whom we work fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations,
we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties,
audits, inspections, and similar); litigation (including class-action claims) or mass arbitration demands; additional reporting requirements
and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of these events could have a material adverse
effect on our reputation, business, or financial condition including but not limited to: loss of customers; interruptions or stoppages
in our business operations (including clinical trials); inability to process personal data or to operate in certain jurisdictions; limited
ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity,
or substantial changes to our business model or operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>If we do not obtain the necessary governmental
approvals, we will be unable to develop or commercialise our pharmaceutical products.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our ongoing research and development activities
are, and the production and marketing of our pharmaceutical product candidates derived from such activities will be, subject to regulation
by numerous international regulatory authorities. Prior to marketing, any therapeutic product developed must undergo rigorous pre-clinical
testing and clinical trials and, to the extent that any of our pharmaceutical products under development are marketed abroad, by the relevant
international regulatory authorities. For example, in Australia, principally the Therapeutics Goods Administration, or TGA; the FDA, in
the United States; the Medicines and Healthcare products Regulatory Agency, or MHRA, in the United Kingdom; the Medical Products Agency,
or MPA, in Sweden; and the European Medicines Agency, or EMA. These processes can take many years and require the expenditure of substantial
resources. Governmental authorities may not grant regulatory approval due to matters arising from pre-clinical animal toxicology, safety
pharmacology, drug formulation and purity, insufficient efficacy, clinical side effects or patient risk profiles, or medical contraindications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Failure or delay in obtaining regulatory approvals
would adversely affect the development and commercialisation of our pharmaceutical product candidates. We may not be able to obtain the
clearances and approvals necessary for clinical testing or for manufacturing and marketing our pharmaceutical product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Even if regulatory authorities approve any of our
product candidates, the manufacture, labeling, storage, recordkeeping, reporting, distribution, advertising, promotion, marketing, sale,
import and export of these drugs will be subject to strict and ongoing regulation. If we, our partners, our product candidates or the
manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may suspend
any ongoing clinical trials; issue warning letters or untitled letters; suspend or withdraw regulatory approval; refuse to approve pending
applications or supplements to applications; suspend or impose restrictions on operations; seize or detain products, prohibit the export
or import of products, or require us to initiate a product recall; seek other monetary or injunctive remedies; or impose civil or criminal
penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>We will not be able to commercialise any current
or future product candidates if we fail to adequately demonstrate their safety and efficacy.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Before obtaining regulatory approvals for the commercial
sale of any of our pharmaceutical products, we must demonstrate through pre-clinical testing and clinical studies that our product candidates
are safe and effective for use in humans for each target indication. Results from early clinical trials may not be predictive of results
obtained in large-scale, later-stage clinical testing. Even though a candidate product shows promising results in clinical trials, regulatory
authorities may not grant the necessary approvals without sufficient safety and efficacy data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may not be able to undertake further clinical
trials of our current and future product candidates as therapies for Parkinsonian disorders or other indications or to demonstrate the
safety and efficacy or superiority of any of these product candidates over existing therapies or other therapies under development, or
enter into any collaborative arrangement to commercialise our current or future product candidates on terms acceptable to us, or at all.
Clinical trial results that show insufficient safety and efficacy could adversely affect our business, financial condition and results
of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Positive results in a clinical trial of a product
candidate may not be replicated in future clinical trials, which could result in development delays or a failure to obtain marketing approval.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Positive results in a clinical trial of a product
candidate may not be predictive of similar results in future clinical trials. A number of companies in the biopharmaceutical industry
have suffered significant setbacks in late-stage clinical trials even after achieving promising results in early-stage development. Accordingly,
the results from the completed pre-clinical studies and clinical trials for our product candidates may not be predictive of the results
we may obtain in later stage trials. Our clinical trials may produce negative or inconclusive results, and we may decide, or regulators
may require us, to conduct additional clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses,
and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have
nonetheless failed to obtain FDA or EMA approval for their products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Even if approved, any product candidates that
we or our subsidiaries may develop and market may be later withdrawn from the market or subject to promotional limitations. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may not be able to obtain the labeling claims
necessary or desirable for the promotion of our product candidates if approved. We may also be required to undertake post-marketing clinical
trials. If the results of such post-marketing studies are not satisfactory or if adverse events or other safety issues arise after approval,
the FDA or a comparable regulatory agency in another country may withdraw marketing authorisation or may condition continued marketing
on commitments from us or our subsidiaries that may be expensive or time consuming to complete. In addition, if we or others identify
adverse side effects after any of our products are on the market, or if manufacturing problems occur, regulatory approval may be withdrawn
and reformulation of our or our subsidiaries&#8217; products, additional clinical trials, changes in labeling of our or our subsidiaries&#8217;
products and additional marketing applications may be required. Any reformulation or labeling changes may limit the marketability of such
products if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Healthcare reform measures and other statutory
or regulatory changes could adversely affect our business. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In both the United States and certain foreign jurisdictions,
there have been a number of legislative and regulatory proposals to change the healthcare system in ways that could impact our business.
For example, the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act of 2010
(collectively, the &#8220;ACA&#8221;), enacted in March 2010, substantially changes the way healthcare is financed by both governmental
and private insurers, and significantly impacts the pharmaceutical industry. With regard to pharmaceutical products, among other things,
the ACA is expected to expand and increase industry rebates for drugs covered under Medicaid programs and make changes to the coverage
requirements under the Medicare D program. Legislative and regulatory proposals impacting upon the healthcare system are submitted regularly
and the existing framework in force in various jurisdictions may not apply in the short to long term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We still cannot fully predict the impact of the
ACA on our company as many of the ACA reforms require the promulgation of detailed regulations implementing the statutory provisions which
has not yet been completed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since its enactment, there have been judicial,
executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent
judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision,
President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes
of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies
to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid
demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining
access to health insurance coverage through Medicaid or the ACA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, other legislative changes have been
proposed and adopted since the Affordable Care Act was enacted. For example, the Budget Control Act of 2011, among other things, included
reductions to Medicare payments to providers, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to
the statute, will remain in effect into 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless
additional Congressional action is taken. Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced Medicare
payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments
to providers from three to five years. In addition, the Medicare Access and CHIP Reauthorization Act of 2015 enacted on April 16, 2015,
repealed the formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with fixed annual
updates and a new system of incentive payments began in 2019 that are based on various performance measures and physicians&#8217; participation
in alternative payment models such as accountable care organizations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect additional state, federal, and foreign
healthcare reform measures to be adopted in the future, any of which could limit the amounts that federal, state, and foreign governments
will pay for healthcare products and services, which could result in reduced demand for our future products or additional pricing pressure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we fail to comply with our reporting and payment
obligations under the Medicaid program or other governmental pricing programs, we could be subject to additional reimbursement requirements,
penalties, sanctions and fines which could have a material adverse effect on our business, financial condition, results of operations
and growth prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pricing and rebate calculations vary among products
and programs. The calculations are complex and will often be subject to interpretation by us, governmental or regulatory agencies and
the courts. If we become aware that our reporting of pricing data for a prior quarter was incorrect, we will be obligated to resubmit
the corrected data. For the Medicaid drug rebate program, corrected data must be submitted for a period not to exceed twelve quarters
from the quarter in which the data originally were due. Such restatements and recalculations increase our costs for complying with the
laws and regulations governing the Medicaid drug rebate program and other governmental pricing programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may be liable for errors associated with our
submission of pricing data. If we are found to have knowingly submitted false pricing data to the Medicaid program, we may be liable for
civil monetary penalties in the amount of up to U.S.$100,000 per item of false information. Our failure to submit pricing data to the
Medicaid program on a timely basis could result in a civil monetary penalty of U.S.$10,000 per day for each day the information is late.
Such failure also could be grounds to terminate our Medicaid drug rebate agreement, which is the agreement under which we might participate
in the Medicaid drug rebate program. In the event that our rebate agreement is terminated, federal payments may not be available under
Medicaid for our covered outpatient drugs. We cannot assure you that our submissions will not be found to be incomplete or incorrect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we obtain FDA approval for any of our product
candidates and begin commercializing those products in the United States, our operations may be directly or indirectly through our customers,
subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal
False Claims Act, and physician sunshine laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Biden administration also introduced various
measures in 2021 focusing on healthcare and drug pricing, in particular. For example, on January 28, 2021, former President Biden issued
an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable
Care Act marketplace, which began on February 15, 2021, and remained open through August 15, 2021. The executive order also instructed
certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among
others, reexamining Medicaid demonstration projects and waiver programs that include work requirements and policies that create unnecessary
barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. On the legislative front, the American
Rescue Plan Act of 2021 was signed into law on March 11, 2021, which, in relevant part, eliminates the statutory Medicaid drug rebate
cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source drugs and innovator multiple source drugs,
which began on January 1, 2024. And, in July 2021, the Biden administration released an executive order entitled, &#8220;Promoting Competition
in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response, on September 9, 2021, HHS released
a &#8220;Comprehensive Plan for Addressing High Drug Prices&#8221; that outlines principles for drug pricing reform and sets out a variety
of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these
principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">More recently, on August 16, 2022, former President
Biden signed into law the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;), which, among other provisions, included several measures
intended to lower the cost of prescription drugs and related healthcare reforms. Specifically, the IRA authorizes and directs the Department
of Health and Human Services (the &#8220;DHHS&#8221;) to set drug price caps for certain high-cost Medicare Part B and Part D qualified
drugs, with the initial list of drugs announced on August 29, 2023, and the first year of maximum price applicability to begin in 2026.
The IRA further authorizes the DHHS to penalize pharmaceutical manufacturers that increase the price of certain Medicare Part B and Part
D drugs faster than the rate of inflation. Finally, the IRA creates significant changes to the Medicare Part D benefit design by capping
Part D beneficiaries&#8217; annual out-of-pocket spending at $2,000 beginning in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 15, 2025, the Trump Administration released
an executive order entitled, &#8220;Lower Drug Prices by Once Again Putting Americans First,&#8221; which among other things, included
multiple directives to various agencies aimed at lowering prescription drug prices. These directives included reports and proposals for
new regulations related to reforming the IRA&#8217;s Medicare Drug Price Negotiation Program, reducing the prices of high-cost drugs,
and enhancing price transparency. On May 12, 2025, President Trump issued an executive order implementing the concept of most-favored
nation pricing. Under this order, DHHS, in coordination with other federal agencies, is directed to take actions to ensure that the price
of prescription drugs paid by federal health insurers, including Medicare and Medicaid, is in line with the prices paid in comparable
nations. Any reduction in reimbursement from Medicare, Medicaid, or other government programs may result in a similar reduction in payments
from private payors. Further, on July 4, 2025, President Trump signed the One Big Beautiful Bill Act into law which, among other things,
is expected to reduce funding to federal healthcare programs, imposes additional requirements to be eligible for healthcare, and clarifies
exclusions for orphan drugs under IRA&#8217;s Drug Price Negotiation Program. Current and future legislative and regulatory changes to
further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for healthcare products and treatments
that could significantly impact pharmaceutical companies and the success of our product candidates. At the state level, legislatures have
increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including
price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The pharmaceutical and biotechnology industries
are subject to extensive regulation, and from time to time legislative bodies and governmental agencies consider changes to such regulations
that could have significant impact on industry participants. For example, in light of certain highly-publicised safety issues regarding
certain drugs that had received marketing approval, the U.S. Congress has considered various proposals regarding drug safety, including
some which would require additional safety studies and monitoring and could make drug development more costly. The implementation of cost
containment measures or other healthcare system reforms may prevent us from being able to generate revenue, attain profitability, or commercialise
our products. Such reforms could have an adverse effect on anticipated revenues from product candidates we may successfully develop and
for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.
In addition, it is possible that there will be further legislation or regulation that could harm our business, financial condition and
several results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Disruptions at the FDA and other government
agencies caused by leadership changes, changes to regulatory approach, layoffs, funding shortages or global health concerns could negatively
impact our business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ability of the FDA to review proposed clinical
trials or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory,
and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that
may otherwise affect the FDA&#8217;s ability to perform routine functions. In addition, government funding of other government agencies
that fund research and development activities is subject to the political process, including executive and congressional priorities, the
impacts of which are inherently fluid and unpredictable. Disruptions at the FDA and other agencies may slow the time necessary for new
product candidates to be reviewed and/or approved, which would adversely affect our business. For example, over the last several years,
including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies,
such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, the current administration has
proposed substantial reductions in force at various government agencies including the FDA, which could significantly reduce the FDA&#8217;s
capacity to perform its functions in a manner consistent with its past practices and could delay reviews and negatively impact our business.
There has been significant turnover and recent changes in senior leadership at the FDA and other government agencies including the division
of the FDA that would oversee and review solutions like those we currently develop and plan to continue to develop. We believe these changes
could result in changes in the FDA&#8217;s perception of the approvability of therapies, the perceived value of certain therapies or therapeutic
modalities, which could create material challenges for our development efforts. At this time, there is significant uncertainty and risks
associated with future FDA regulatory policies and actions that could have a material negative impact on our business. Any or all of these
factors could cause us to amend, suspend or terminate the development of certain of our preclinical or clinical programs, which could
have material adverse impacts on our business, our product candidates or our ability to continue operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>We could be adversely affected by violations
of the U.S. Foreign Corrupt Practices Act.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business operations may be subject to anti-corruption
laws and regulations, including restrictions imposed by the U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;). The FCPA and
similar anti-corruption laws in other jurisdictions such as the U.K. Bribery Act generally prohibit companies and their intermediaries
from making improper payments to government officials for the purpose of obtaining or retaining business. We cannot provide assurance
that our internal controls and procedures will always protect us from criminal acts committed by our employees or third parties with whom
we work. If we are found to be liable for violations of the FCPA or similar anti-corruption laws in international jurisdictions, either
due to our own acts or out of inadvertence, or due to the acts or inadvertence of others, we could suffer from criminal or civil penalties
which could have a material and adverse effect on our results of operations, financial condition and cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Our success depends upon our ability to protect
our intellectual property and our proprietary technology, to operate without infringing the proprietary rights of third parties and to
obtain marketing exclusivity for our products and technologies.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Any future success will depend in large part on whether we
can:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain and maintain patents to protect our own product candidates and technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain licenses to the patented technologies of third parties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operate without infringing on the proprietary rights of third parties; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">protect our trade secrets, know-how and other confidential information.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Patent matters in biotechnology are highly uncertain
and involve complex legal and factual questions. Accordingly, the availability and breadth of claims allowed in biotechnology and pharmaceutical
patents cannot be predicted. Any of the pending or future patent applications filed by us or on our behalf may not be approved, we may
not develop additional proprietary products or processes that are patentable, or we may not be able to license any other patentable products
or processes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our products may be eligible for orphan designation
for particular therapeutic indications that are of relatively low prevalence. Orphan drug designation affords market exclusivity post
marketing authorisation for a product for a specified therapeutic utility. The period of orphan protection is dependent on jurisdiction,
for example, seven years in the United States and ten years in Europe. The opportunity to gain orphan drug designation depends on a variety
of requirements specific to each marketing jurisdiction and can include; a showing of improved benefit relative to marketed products,
that the mechanism of action of the product would provide plausible benefit and the nature of the unmet medical need within a therapeutic
indication. It is uncertain if our products will be able to obtain orphan drug designation for the appropriate indications and in the
jurisdictions sought.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There is a risk that the U.S. Congress, for example,
could amend laws to significantly shorten the exclusivity period. Once any regulatory period of exclusivity expires, depending on the
status of our patent coverage and the nature of the product, we may not be able to prevent others from marketing products that are similar
to or interchangeable with our products, which would materially adversely affect us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our commercial success will also depend, in part,
on our ability to avoid infringement of patents issued to others. If a court determines that we were infringing any third-party patents,
we could be required to pay damages, alter our products or processes, obtain licenses or cease certain activities. Licenses required under
patents held by third parties may not be made available on terms acceptable to us or at all. To the extent that we are unable to obtain
such licenses, we could be foreclosed from the development, export, manufacture or commercialisation of the product requiring such license
or encounter delays in product introductions while we attempt to design around such patents, and any of these circumstances could adversely
affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may have to resort to litigation to enforce
any patents issued or licensed to us or to determine the scope and validity of third-party proprietary rights. We may have to defend the
validity of our patents in order to protect or enforce our rights against a third party. Third parties may in the future assert against
us infringement claims or claims that we have infringed a patent, copyright, trademark or other proprietary right belonging to them. Any
infringement claim, even if not meritorious, could result in the expenditure of significant financial and managerial resources and could
negatively affect our profitability. While defending our patents, the scope of the claim may be reduced in breadth and inventorship of
the claimed subject matter, and proprietary interests in the claimed subject matter may be altered or reduced. Some of our competitors
may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater
financial resources. Any such litigation, regardless of outcome, could be expensive and time consuming, and adverse determinations in
any such proceedings could prevent us from developing, manufacturing or commercialising our products and could adversely affect our business,
financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The patents for our product candidates have varying
expiration dates and, if these patents expire, we may be subject to increased competition and we may not be able to recover our development
costs or market any of our approved products profitably. In some of the larger potential market territories, such as the United States
and Europe, patent term extension or restoration may be available to compensate for time taken during aspects of the product&#8217;s development
and regulatory review or by procedural delays before the relevant patent office. However, such an extension may not be granted, or if
granted, the applicable time period or the scope of patent protection afforded during any extension period may not be sufficient. In addition,
even though some regulatory authorities may provide some other exclusivity for a product under their own laws and regulations, we may
not be able to qualify the product or obtain the exclusive time period. If we are unable to obtain patent term extension/restoration or
some other exclusivity, we could be subject to increased competition and our opportunity to establish or maintain product revenue could
be substantially reduced or eliminated. Furthermore, we may not have sufficient time to recover our development costs prior to the expiration
of our U.S. and non-U.S. patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Tariff policies and potential countermeasures
could increase our costs and disrupt our global supply chain, which could negatively impact the results of our operations.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">President Trump has increased, and has indicated
his willingness to continue to increase, the use of tariffs by the U.S. to accomplish certain U.S. policy goals. Such tariffs and any
countermeasures could increase the cost of raw materials and components necessary for our operations, disrupt our global supply chain
and create additional operational challenges. Further, it is possible that government policy changes and related uncertainty about policy
changes could increase market volatility. Because of these dynamics, we cannot predict the impact of any future changes to the U.S.&#8217;s
or other countries&#8217; trading relationships or the impact of new laws or regulations adopted by the U.S. or other countries on our business.
Such changes in tariffs and trade regulations could have a material adverse effect on our financial condition, results of operations and
cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>We may face difficulties in certain jurisdictions
in protecting our intellectual property rights, which may diminish the value of our intellectual property rights in those jurisdictions.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The laws of some jurisdictions do not protect intellectual
property rights to the same extent as the laws in the United States and the European Union, and many companies have encountered significant
difficulties in protecting and defending such rights in such jurisdictions. If we or our collaboration partners encounter difficulties
in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in
such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many countries have compulsory licensing laws under
which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents
against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially
diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents
relevant to our business, our competitive position may be impaired and our business, financial condition and results of operations may
be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Intellectual property rights do not address
all potential threats to our competitive advantage.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The degree of future protection afforded by our
intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately permit us to maintain
our competitive advantage. The following examples are illustrative:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others may be able to make products that are similar to ours but that are not covered by the claims of the patents that we own.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies without infringing our intellectual property rights.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We or any of our collaboration partners might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we own, license or will own or license.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We or any of our collaboration partners might not have been the first to file patent applications covering certain of the patents or patent applications that we or they own or have obtained a license, or will own or will have obtained a license.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It is possible that our pending patent applications will not result in issued patents.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compulsory licensing provisions of certain governments to patented technologies that are deemed necessary for the government to access.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -14.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Changes in patent laws or patent jurisprudence
could diminish the value of our patents, thereby impairing our ability to protect our products or product candidates.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As is the case with other biotechnology and pharmaceutical
companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical
industry involves both technological and legal complexity, it is costly, time-consuming and inherently uncertain. The U.S. Supreme Court
has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances
or weakening the rights of patent owners in certain situations. Depending on decisions by the U.S. Congress, the federal courts, and the
U.S. Patent and Trademark Office, or USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken
our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Similarly, the complexity
and uncertainty of European patent laws has also increased in recent years. In addition, the European patent system is relatively stringent
with regard to the type of amendments that are allowed during prosecution. These changes could limit our ability to obtain new patents
in the future that may be important for our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Confidentiality agreements with employees and
others may not adequately prevent disclosure of our trade secrets and protect our other proprietary information.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We consider proprietary trade secrets and/or confidential
know-how and unpatented know-how to be important to our business. We may rely on trade secrets and/or confidential know-how to protect
our technology, especially where patent protection is believed by us to be of limited value. However, trade secrets and/or confidential
know-how can be difficult to maintain as confidential.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To protect this type of information against disclosure
or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality
agreements with us. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose
our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized
disclosure of confidential information. Enforcing a claim that a third-party obtained illegally and is using trade secrets and/or confidential
know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to
jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Failure to obtain or maintain trade secrets and/or
confidential know-how trade protection could adversely affect our competitive position. Moreover, our competitors may independently develop
substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining
such patent protection, our competitors could limit our use of our trade secrets and/or confidential know-how.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Compliance with the Sarbanes-Oxley Act of 2002</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>We may fail to maintain effective internal control
over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002, which could adversely affect our operating
results, investor confidence in our reported financial information, and the market price of our ordinary shares and ADSs.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Sarbanes-Oxley Act of 2002 imposes certain
duties on us and our executives and directors. To comply with this statute, we are required to document and test our internal control
over financial reporting. Our efforts to comply with the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, governing internal
control and procedures for financial reporting, have resulted in increased general and administrative expenses and a diversion of management
time and attention, and we expect these efforts to require the continued commitment of significant resources. We may identify material
weaknesses or significant deficiencies in our assessments of our internal control over financial reporting. Failure to maintain effective
internal control over financial reporting, or conclusion that our disclosure controls and procedures are ineffective, could result in
investigations or sanctions by regulatory authorities and could adversely affect our operating results, investor confidence in our reported
financial information, and the market price of our ordinary shares and ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Ownership of Our Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Our stock price may be volatile and the trading
market for our securities is limited.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The market price for our securities, like that
of the securities of other pharmaceutical and biotechnology companies, has fluctuated substantially and may continue to be highly volatile
in the future. The market price for our securities has been affected by both broad market developments and announcements relating to actual
or potential developments concerning products under development. We believe that the following factors, in addition to other risk factors
described above and elsewhere in this annual report, will continue to significantly affect the market price of our ordinary shares:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of pre-clinical testing and clinical trials by us and our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments concerning research and development, manufacturing, and marketing alliances or collaborations by us and our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of technological innovations or new commercial products by us and our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determinations regarding our patent applications, patents and those of others;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">publicity regarding actual or potential results relating
to medicinal products under development by us and our competitors;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-indent: 0in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">proposed governmental regulations and developments in Australia,
the U.S. and elsewhere;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-indent: 0in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">litigation;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-indent: 0in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">economic and other external factors; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-indent: 0in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">period-to-period fluctuations in our operating results.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-indent: 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In addition, stock markets have experienced extreme price and volume fluctuations. These fluctuations have especially affected
the stock market price of many high technology and healthcare related companies, including pharmaceutical and biotechnology companies,
and, in many cases, are unrelated to the operating performance of the particular companies. Market fluctuations, as well as general political
and economic conditions, such as a recession, interest rate or currency rate fluctuations, could adversely affect the market price of
our securities. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-left: 0in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-left: -0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Ownership
interest in our company may be further diluted as a result of additional financings.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-left: 0in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-left: -0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Potential
dilution as a result of additional financings.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-left: 0in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-left: 0in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Ownership interest in our company may be diluted as a result of financings in the near
future or over the longer term.&#160; We will need additional funding to complete our clinical trials and to operate our business; such
funding may not be available or, if it is available, such financing is likely to substantially dilute our existing shareholders.&#160;
Additional financing will comply with the relevant requirements of ASX listing rules and NASDAQ listing requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-left: 0in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Without shareholder approval, we may not issue more than 25% of our
outstanding ordinary shares in any twelve month period other than by a pro rata rights offering or a share purchase plan offer (of shares
with a value at the issue price of up to A$30,000 per shareholder to a maximum of 30% of our outstanding shares) in each case to the then
existing shareholders in accordance with the listing rules of the ASX. Sales of our ADSs offered through our &#8220;At-The-Market&#8221;
facility and future equity offerings may result in substantial dilution to the interests of our current shareholders. The sale of a substantial
number of securities to investors, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related
securities in the future at a time and at a price that we might otherwise wish to effect sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>There is a substantial risk that we are a passive
foreign investment company, or PFIC, to some U.S. investors which will subject those investors to adverse tax rules</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Holders of our ADSs who are U.S. residents face
income tax risks. There is a substantial risk that we are a passive foreign investment company, commonly referred to as a PFIC to some
U.S. investors, and a controlled foreign corporation, or CFC to other U.S. investors. Our treatment as a PFIC could result in a reduction
in the after-tax return to the holders of our ADSs and would likely cause a reduction in the value of such ADSs. For U.S. federal income
tax purposes, we will be classified as a PFIC for any taxable year in which either (i) 75% or more of our gross income is passive income,
or (ii) at least 50% of the average value of all of our assets for the taxable year produce or are held for the production of passive
income. For this purpose, cash is considered to be an asset that produces passive income. As a result of our substantial cash position
and the decline in the value of our stock, we believe that we became a PFIC during the taxable year ended June 30, 2005, and were classified
as a PFIC during each of the following fiscal years. We believe that we once again will be classified as a PFIC for the taxable year ended
June 30, 2025 for some U.S. investors. Highly complex rules will apply to U.S. holders owning ADSs. Accordingly, you are urged to consult
your tax advisors regarding the application of such rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>We do not anticipate paying dividends on our
ordinary shares.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have never declared or paid cash dividends on
our ordinary shares and do not expect to do so in the foreseeable future. The declaration of dividends is subject to the discretion of
our Board of Directors and will depend on various factors, including our operating results, financial condition, future prospects and
any other factors deemed relevant by our board of directors. You should not rely on an investment in our company if you require dividend
income from your investment in our company. The success of your investment will likely depend entirely upon any future appreciation of
the market price of our ordinary shares, which is uncertain and unpredictable. There is no guarantee that our ordinary shares will appreciate
in value or even maintain the price at which you purchased your ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Currency fluctuations may adversely affect the
price of our securities.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our ordinary shares are quoted in Australian dollars
on the ASX and our ADSs trade on the NASDAQ Capital Market in U.S. dollars. Movements in the Australian dollar/U.S. dollar exchange rate
may adversely affect the U.S. dollar price of our ordinary shares. In the past year the Australian dollar weakened against the U.S. dollar.
If the Australian dollar further weakens against the U.S. dollar, this may negatively affect the U.S. dollar price of our ordinary shares,
even if the price of our ordinary shares in Australian dollars decreases or remains unchanged. If the Australian dollar strengthens against
the U.S. dollar, the U.S. dollar price of the ordinary shares could increase, even if the price of our ordinary shares in Australian dollars
decreases or remains unchanged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>If we fail to maintain compliance with NASDAQ&#8217;s
continued listing requirements, our shares may be delisted from the NASDAQ Capital Market.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our ordinary shares are quoted on the ASX and our
ADSs trade on the NASDAQ Capital Market. To continue to be listed on the NASDAQ Capital Market, we need to satisfy a number of conditions,
including a minimum closing bid price per ADS of $1.00 for 30 consecutive business days and shareholders&#8217; equity of at least $2.5
million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We could in the future fail to meet this or other
NASDAQ continued listing requirements and fail to cure such noncompliance, resulting in the delisting of our ADSs from NASDAQ. If we are
delisted from NASDAQ, trading in our ordinary shares could be conducted on a U.S. market where an investor would likely find it significantly
more difficult to dispose of, or to obtain accurate quotations as to the value of, our ordinary shares (such delisting should not affect
the trading over the ASX).&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>We are currently operating in a period of economic
uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military
conflicts such as in the Middle East and between Russia and Ukraine.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">U.S. and global markets are experiencing volatility
and disruption following the escalation of geopolitical tensions and the start of military conflicts in the Middle East and the ongoing
conflict between Russia and Ukraine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In February 2022, Russia launched a full-scale
military invasion of Ukraine. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in
Ukraine could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets. Additionally,
Russia&#8217;s prior annexation of Crimea, recent recognition of two separatist republics in the Donetsk and Luhansk regions of Ukraine
and subsequent military interventions in Ukraine have led to sanctions and other penalties being levied by the United States, European
Union and other countries against Russia, including agreement to remove certain Russian financial institutions from the Society for Worldwide
Interbank Financial Telecommunication (SWIFT) payment system. Additional potential sanctions and penalties have also been proposed and/or
threatened. Russian military actions and the resulting sanctions could adversely affect the global economy and financial markets and lead
to instability and lack of liquidity in capital markets, potentially making it more difficult for us to obtain additional funds. Any of
the abovementioned factors could affect our business, prospects, financial condition, and operating results. The extent and duration of
the military action, sanctions and resulting market disruptions are impossible to predict, but could be substantial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, economic and political instability
in other regions, e.g., the Israel-Hamas conflict and the related instability in the Middle East, may result in unavoidable uncertainties
that could negatively affect costs of business and cause volatility in exchange rates, commodity prices, inflation and interest rates.
Such events could also impact worldwide political, regulatory, economic or market conditions, as well as causing instability in political
institutions, regulatory agencies and financial markets, any of which could have a material adverse effect on our business, operating
results, cash flows and financial position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any such disruptions may also magnify the impact
of other risks described in this Annual Report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Location in Australia</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>It may be difficult to enforce a judgment in
the United States against us and our officers and directors or to assert U.S. securities laws claims in Australia or serve process on
our officers and directors.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are incorporated in Australia. More than half
of our executive officers and directors are non-residents of the United States. Therefore, it may be difficult for an investor, or any
other person or entity, to enforce a U.S. court judgment based upon the civil liability provisions of the U.S. federal securities laws
in an Australian court against us or any of those persons or to effect service of process upon these persons in the United States. Additionally,
it may be difficult for an investor, or any other person or entity, to enforce civil liabilities under U.S. federal securities laws in
original actions instituted in Australia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Australian companies may not have standing to initiate
a shareholder derivative action in a federal court of the United States. The circumstances in which any such action may be brought, and
the procedures and defenses that may be available in respect to any such action, may result in the rights of shareholders of an Australian
company being more limited than those of shareholders of a company organized in the United States. Accordingly, shareholders may have
fewer alternatives available to them if they believe that corporate wrongdoing has occurred. Australian courts are also unlikely to recognize
or enforce against us judgments of courts in the United States based on certain liability provisions of U.S. securities law and to impose
liabilities against us, in original actions brought in Australia, based on certain liability provisions of U.S. securities laws that are
penal in nature. There is no statutory recognition in Australia of judgments obtained in the United States, although the courts of Australia
may recognize and enforce the non-penal judgment of a foreign court of competent jurisdiction without retrial on the merits, upon being
satisfied about all the relevant circumstances in which that judgment was obtained.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>As a foreign private issuer whose shares are
listed on the NASDAQ Capital Market, we may follow certain home country corporate governance practices instead of certain NASDAQ requirements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a foreign private issuer whose shares are listed
on the NASDAQ Capital Market, we are permitted to follow certain home country corporate governance practices instead of certain requirements
of The NASDAQ Stock Market Rules. Among other things, as a foreign private issuer we may follow home country practice with regard to the
composition of the board of directors, director nomination procedure, and quorum at shareholders&#8217; meetings. In addition, we may
follow our home country law, instead of the NASDAQ Stock Market Rules, which require that we obtain shareholder approval for certain dilutive
events such as for the establishment or amendment of certain equity based compensation plans, an issuance that will result in a change
of control of the company, certain transactions other than a public offering involving issuances of a 20% or more interest in the company,
and certain acquisitions of the stock or assets of another company. A foreign private issuer that elects to follow a home country practice
instead of NASDAQ requirements must submit to NASDAQ in advance a written statement from an independent counsel in such issuer&#8217;s
home country certifying that the issuer&#8217;s practices are not prohibited by the home country&#8217;s laws. In addition, a foreign
private issuer must disclose in its annual reports filed with the SEC each such requirement that it does not follow and describe the home
country practice followed by the issuer instead of any such requirement. Accordingly, our shareholders may not be afforded the same protection
as provided under NASDAQ&#8217;s corporate governance rules</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>We currently do not have a majority of independent
directors serving on our Board of Directors, which may afford less protection to our shareholders than if our Board of Directors had a
majority of independent directors. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of the date of this annual report, a majority
of our directors did not satisfy the standards for independence as specified by the SEC and the listing standards of the NASDAQ Stock
Market pursuant to which we evaluate director independence. If our Board of Directors is not made up of a majority of independent directors,
there may be a lower level of oversight on executive management, and our Board of Directors may be influenced by the concerns, issues
or objectives of management, including compensation and governance issues, to a greater extent than would occur with a majority of independent
directors. As a result, the composition of our Board of Directors may afford less protection to our shareholders than if our Board of
Directors were composed of a majority of independent directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A lack of independent directors may also make it
difficult to create board committees meeting the requirements of our board committee charters and the NASDAQ Rules pursuant to which we
evaluate director independence. Historically, we have strived to have an audit committee comprised of at least three independent directors
and other board committees comprised solely of independent directors. Currently, our audit committee has only two members, both of who
are independent under the NASDAQ Rules and applicable SEC requirements. Due to the lack of independent directors, it may be difficult
to establish effective operating board committees comprised of independent members to oversee committee functions. This structure gives
our executive officers additional control over certain corporate governance issues, including compensation matters and audit issues for
internal control and reporting purposes, with more limited oversight of our executive officers&#8217; decisions and activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Australian takeovers laws may discourage takeover
offers being made for us or may discourage the acquisition of large numbers of our ordinary shares.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are incorporated in Australia and are subject
to the takeover&#8217;s laws of Australia. Among other things, we are subject to the Australian Corporations Act 2001, or the Corporations
Act. Subject to a range of exceptions, the Corporations Act prohibits the acquisition of a direct or indirect interest in our issued voting
shares if the acquisition of that interest will lead to a person&#8217;s voting power in us increasing from 20% or below to more than
20%, or increasing from a starting point that is above 20% and below 90%. Australian takeovers laws may discourage takeover offers being
made for us or may discourage the acquisition of large numbers of our ordinary shares. This may have the ancillary effect of entrenching
our board of directors and may deprive or limit our shareholders&#8217; strategic opportunities to sell their ordinary shares and may
restrict the ability of our shareholders to obtain a premium from such transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Our Constitution and other Australian laws and
regulations applicable to us may adversely affect our ability to take actions that could be beneficial to our shareholders.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As an Australian company we are subject to different
corporate requirements than a corporation organized under the laws of the United States. Our Constitution, as well as the Corporations
Act, set forth various rights and obligations that are unique to us as an Australian company. These requirements operate differently than
from many U.S. companies and may limit or otherwise adversely affect our ability to take actions that could be beneficial to our shareholders.
For more information, you should carefully review the summary of these matters set forth under the section entitled, &#8220;Item 10.B
- Additional Information - Memorandum and Articles of Association&#8221; as well as our Constitution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps; text-transform: uppercase"><b>ITEM
4.</b></span><b> <span style="text-transform: uppercase">Information on the Company</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_010"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>History and Development of the Company</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our legal and commercial name is Alterity Therapeutics
Limited (formerly Prana Biotechnology Limited). We were incorporated under the laws of the Commonwealth of Australia on November 11, 1997
and began limited operations shortly thereafter. On April 8, 2019, we changed our name to Alterity Therapeutics Limited. Our registered
and principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria, 3000, Australia and our telephone number
is +-61-3-9349-4906. Our website address is www.alteritytherapeutics.com. The information in our website is not incorporated by reference
into this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Alterity&#8217;s mission from inception was to
treat neurodegenerative diseases and its mission has remained focused on this class of diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Alterity is developing first-in-class therapies
to treat neurodegenerative diseases. Our lead drug candidate, ATH434, is designed to block the accumulation and aggregation of &#945;-synuclein,
a protein implicated in neurodegeneration. ATH434 has been shown preclinically to redistribute excess labile iron in the central nervous
system (CNS), reduce &#945;-synuclein aggregation and preserve neurons and support cells, to stabilize or improve function. In this way,
it has potential to treat iron-mediated diseases including Parkinson&#8217;s disease as well as Multiple System Atrophy (MSA), a rare
Parkinsonian disorder. ATH434 has been granted Fast Track designation by the US FDA in MSA. The Fast Track Designation is intended to
facilitate and expedite the development and review of new drugs for serious conditions with unmet medical needs. The company has also
been granted Orphan drug designation for ATH434 for the treatment of MSA by both the US FDA and European Commission. The exclusivity conferred
by the Orphan drug designation is expected to persist beyond the term of the patents comprising the ATH434 global patent portfolio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In MSA, two Phase 2 clinical trials have been completed
with topline results reported in the randomized, double-blind, placebo-controlled Phase 2 study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our technology is the outcome of many years of
intense research from leading scientists in neurodegenerative disorders and other diseases. Beginning with the discovery and patenting
of our initial clinical drug candidate, PBT2, the company continued to apply its expertise to inventing and patenting novel molecules
with potential to treat neurodegenerative diseases which resulted in ATH434.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 2019 and 2020, we invented next generation iron
chaperones, a technology designed to redistribute excess labile iron in the central nervous system including for the treatment of Parkinson&#8217;s
disease and related disorders. These compounds are the subject of composition of matter claims in patent families which either are filed
in countries and regions that represent the commercially significant economies or are earmarked to be filed in those countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 2021, we invented next generation zinc ionophores,
a technology capable of modulating zinc for the treatment of various diseases such as cancer, neurological diseases and infectious diseases.
These compounds are the subject of composition of matter claims in a patent family which is earmarked for filing in countries and regions
that represent the commercially significant economies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our technology has progressed to create a diversified
library of chemical compounds and we continue to strengthen our intellectual property portfolio with new patents generated by our discovery
and research efforts. This may yield future product candidates across various neurodegenerative and other indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since inception, we have not been required to invest
material amounts for capital expenditures since our development efforts have taken place at research facilities operated by institutions
with which we have relationships. In the three fiscal years ended June 30, 2025, our capital expenditures have totalled A$13,033.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_011"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Business Overview</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Alterity&#8217;s Background</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our technology has been developed over an extended
period and continues to develop through the collaborative efforts of highly regarded scientists, company employees as well as representatives
of research institutions in this field.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since completing our initial public offering and
listing process of our ordinary shares on the ASX on March 28, 2000, we have concentrated our resources toward the pursuit of neurological
diseases and creation of a chemical library of proprietary molecules. Currently, our research and clinical development efforts are primarily
focused on Parkinson&#8217;s disease and related disorders where we are identifying and developing novel compounds that address the underlying
pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein (or &#945; -synuclein) aggregation,
and rescuing neurons in the brain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our clinical development program is led by two
Phase 2 clinical trials in Multiple System Atrophy, or MSA, a rare Parkinsonian disorder with no approved treatments that address the
underlying pathology of the disease. We have also conducted a Natural History Study in MSA and have a preclinical program in Parkinson&#8217;s
disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we have a robust discovery platform
with over 1000 validated compounds from different chemical scaffolds in our chemical library.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since 2009, our chemistry program is undertaken
within laboratories leased from The University of Melbourne&#8217;s Bio21 Molecular Science and Biotechnology Institute, which is a multidisciplinary
research center that specializes in medical, agricultural and environmental biotechnology. Accommodating more than 500 research scientists,
students and industry participants, the Bio21 Institute is one of the largest biotechnology research centers in Australia.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Candidate product discovery and translational Biology Programs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Alterity&#8217;s intellectual property is considered
&#8220;platform technology&#8221; based on our approach that a broad spectrum of neurodegenerative and age-related diseases can be addressed
by targeting the interrelationship of metals and proteins. Historically, the majority of our research efforts have been directed at research
into potential therapeutics for the treatment of Parkinsonian disorders, Alzheimer&#8217;s disease, and Huntington disease. Published
data together with our initial findings have provided strong indications that the pathology for other certain age-related and degenerative
disorders may also be based on the interaction between certain metals and proteins, and we believe that the platform technology may also
be applicable for certain cancers, age-related macular degeneration, diabetes mellitus, cardiovascular disease and other neurodegenerative
diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To date, we have performed <i>in vivo</i> evaluations
of our product candidates in a range of animal models of disease including Parkinsonian disorders, Alzheimer&#8217;s disease, Huntington
disease, and brain cancer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Product candidates are selected from our chemical
library on the basis of rational drug design. Product candidates are designed to fulfil very specific criteria such as oral bioavailability,
ability to cross the blood-brain barrier, and demonstrate significant effectiveness in both nonclinical <i>in vitro</i> and <i>in vivo</i>
testing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To increase the depth and breadth of our pipeline
into new neurodegenerative indications, we have continued to develop our &#8216;two tier&#8217; Translational Research program structure.
The first tier encompasses core new chemical entity design, synthesis and characterization, the &#8216;discovery phase&#8217; of the new
entities as potential novel agents of interest based on their mechanism of action profile. Our discovery research has established Structure
Activity Relationships (&#8220;SAR&#8221;) within chemical moieties that guide our chemists towards the design of novel therapeutics.
The discovery phase also includes preliminary bioavailability and metabolic characterization. The second tier comprises &#8216;translational&#8217;
animal modeling programs to test and validate new candidates as potential development product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our chemical library currently includes more than
1000 novel compounds. Using SAR that has been developed over years of testing and validation by Alterity scientists, new compounds have
been generated that retain functionality across diverse and novel chemical scaffolds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left">New compounds from various scaffolds
are synthesized and mechanistically profiled. These compounds are initially screened for activity in biological systems relevant to the
candidate diseases of interest. New screens are investigated and assessed for their ability to intercede in the steps thought to underly
the pathogenesis of target diseases. Such steps include pathologic protein aggregation and downstream activities such as oxidative stress
and cell death. Promising candidates arising from the Translational Research program may be progressed as back up compounds in Parkinson&#8217;s
disease and/or new indications in neurodegeneration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">We continue to strengthen our intellectual property
portfolio with new patents that will be instrumental in supporting Alterity&#8217;s drug development portfolio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>Our Target Neurodegenerative Diseases</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>Multiple System Atrophy</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">We believe that drug candidates in
our library affect the aggregation of the proteins implicated in the pathology of neurodegenerative diseases including Parkinson&#8217;s
disease and related movement disorders such as MSA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Currently, we are primarily focusing on
the treatment of Parkinsonian disorders, a group of neurodegenerative disorders which have parkinsonism as a feature.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 28.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Parkinsonism is a general term for slowed
movement, stiffness and tremor, which occurs most commonly in Parkinson&#8217;s disease and also in less common Parkinsonian disorders
such as MSA and dementia with Lewy bodies, among others. These Parkinsonian disorders have a limited response to available drugs for treating
symptoms of Parkinson&#8217;s disease and prominent non-motor symptoms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">MSA is a rare, neurodegenerative disease
characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of function
and death of different types of neurons in the brain and spinal cord. It is a rapidly progressive disease which causes profound disability.
It is sporadic (not inherited) and typically presents in individuals between 50 and 60 years old. MSA is characterized by a variable combination
of Parkinsonism, autonomic instability that affects involuntary functions such as blood pressure maintenance and bowel/bladder control,
and impaired balance and/or coordination that predisposes to falls. A pathological hallmark of MSA is the accumulation of the protein
&#945;-synuclein within glia, the support cells of the central nervous system, and neuron loss in multiple brain regions. According to
the U.S. National Institutes of Health, MSA affects up to 50,000 individuals in the U.S., thus it is considered an Orphan Disease. While
some of the symptoms of MSA can be treated with medications, currently there are no drugs that are able to slow disease progression and
there is no cure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Because early MSA is not well characterized,
Alterity conducted a natural history study called &#8220;Biomarkers of progression in Multiple System Atrophy (bioMUSE)&#8221; to track
the progression of patients with MSA. The study was conducted in collaboration with Vanderbilt University Medical Center in the U.S. under
the direction of Daniel Claassen, MD, Professor of Neurology and Principal Investigator. Natural history studies are important for characterizing
disease progression in selected patient populations. The study provided vital information on early stage MSA patients, enabling the selection
of biomarkers suitable for evaluation of target engagement and preliminary efficacy of drug candidates, and clinical data to characterize
disease progression in patients that mirrored those enrolled in Alterity&#8217;s ATH434-201 Phase 2 clinical trial. To date, the study
has provided rich data for optimizing the design of Alterity&#8217;s clinical program (see below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Alterity&#8217;s lead candidate, ATH434,
is a small molecule drug candidate designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434
has been shown preclinically to reduce &#945;-synuclein pathology and preserve nerve cells by restoring normal iron balance in the brain.
In this way, it has potential to treat Parkinson&#8217;s disease and related disorders such as MSA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">A comprehensive nonclinical program
to evaluate ATH434&#8217;s profile to support clinical development is ongoing. ATH434 has also been profiled in mouse models of Parkinsonian
disorders, including MSA. In one animal model, ATH434 prevented &#945;-synuclein aggregation and preserved neurons in the <i>substantia
nigra</i> and decreased the number of glial cell inclusions in the brains of treated animals. Glial cell inclusions are the pathological
hallmark of MSA and contain abundant aggregated &#945;-synuclein that is associated with neurodegeneration. The benefits shown on pathological
examination were associated with improved motor function in treated animals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Nonclinical safety pharmacology and toxicology
studies of ATH434 that have been reviewed by regulatory authorities support clinical administration at doses predicted to provide efficacy
in MSA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">We successfully completed Phase 1 clinical studies
with ATH434 demonstrating that it is well tolerated, orally bioavailable, and achieved brain levels comparable to efficacious levels in
animal models of MSA. During FY 2025 we also successfully completed two Phase 2 clinical trials with ATH434 (see below). ATH434 has been
granted Orphan designation by the FDA and the European Commission and has received a Fast Track designation from the FDA for the treatment
of MSA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Parkinson&#8217;s Disease</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Parkinson&#8217;s disease, a neurodegenerative
disease of the aging population, causes a progressive slowing of movement, tremors and the loss of fine motor control due to the death
of <i>substantia nigra</i> cells in the brain. These cells produce the neurotransmitter dopamine in the brain, which is required for normal
motor control. Existing therapies, such as dopaminergic agents, may provide symptomatic relief, but do not address the underlying pathology
of the disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">During 2009 and 2010, our lead Parkinson&#8217;s
disease treatment candidate emerged, ATH434 (described below), based on significant improvement in motor function and coordination in
both models. Importantly, ATH434 demonstrated improved relevant indices when administered after toxins had destroyed significant amounts
of <i>substantia nigra</i> nerve cells, indicating that the compound can preserve normal neuronal function. Mechanistic work during this
period demonstrated that ATH434 reduced the aggregation of toxic &#945;-synuclein species as well as markers of oxidative stress.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Since 2011, we have continually progressed
our understanding of the mechanism of action of ATH434 and its potential to treat other movement disorders characterized by the aggregation
of &#945;-synuclein. Our non-clinical research and development activities in Parkinson&#8217;s disease were supported by a USD $206,000
grant from the New York-based Michael J. Fox Foundation entitled, &#8216;ATH434, a Novel Neuroprotective Drug For Parkinson&#8217;s Disease;
Completion of Pre-Clinical Studies to Enable Human Clinical Trials.&#8217;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">In 2017, Doctors Finkelstein, Cherny
and colleagues published data indicating that ATH434 prevented cell death in the <i>substantia nigra </i>in a dose-dependent manner. The
data also demonstrated the therapeutic potential of ATH434 to slow neurodegeneration with results in multiple Parkinson&#8217;s disease
models, including a transgenic model of Parkinson&#8217;s disease (A53T) in which mice over-expressed the &#945;-synuclein protein. In
A53T mice, animals treated with ATH434 exhibited significantly increased numbers of <i>s. nigra </i>neurons and a significant reduction
in insoluble &#945;-synuclein and incidence of clasping behavior. Encouragingly, these results showed that ATH434 lowered &#945;-synuclein,
preserved neurons and simultaneously improved motor performance. The paper was entitled, &#8220;The novel compound ATH434 prevents iron
mediated neurodegeneration and &#945; -synuclein toxicity in multiple models of Parkinson&#8217;s disease&#8221; and was published in
Acta Neuropathol Comm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">In February 2021, the Michael J. Fox
Foundation awarded Alterity a second grant, entitled &#8220;Pharmacologic Evaluation of ATH434 in a Hemiparkinsonian Nonhuman Primate
Model for Dose Optimization in PD Clinical Trials&#8221; in the amount of USD $495,000. The goal of the study was to evaluate the pharmacologic
profile of ATH434 for determining the optimal doses of ATH434 for future Parkinson&#8217;s disease clinical trials. The study was completed
in late 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Multiple presentations have been delivered on ATH434 in Parkinson&#8217;s
Disease:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">In December 2023, we announced that
promising new data on the effect of ATH434 in a Parkinson&#8217;s disease primate model was presented at the Future of Parkinson&#8217;s
Disease Conference 2023. The poster, entitled, &#8220;Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron,
in Hemiparkinsonian Macaques&#8221;, was presented in collaboration from Vanderbilt University Medical Center and the Florey Institute
of Neuroscience in Melbourne. The presentation showed that ATH434 can reduce parkinsonism in a higher order animal, the monkey, with symptoms
that closely parallel human disease. ATH434 treatment improved motor performance and general function in monkeys with experimentally induced
Parkinson&#8217;s disease. Importantly, these improvements were associated with reductions in abnormal iron in affected brain regions.
These favorable parkinsonian outcomes observed in the ATH434-treated monkeys were also associated with increased levels of striatal synaptophysin,
a protein marker that reflects functional connections between neurons, suggesting functional recovery of nerve endings in this critical
motor pathway. The data was also presented in September 2024 at the International Congress of Parkinson&#8217;s Disease and Movement Disorders
(MDS), Title: &#8220;Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in Hemiparkinsonian Macaques&#8221;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">In September 2022, the peer-reviewed
journal, <i>Neurotherapeutics,</i> published data that demonstrated ATH434 was neuroprotective in a genetic model of Parkinson&#8217;s
disease (PD)<i>. </i>The publication, entitled &#8220;ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism&#8221; assessed
the impact of ATH434 on motor and non-motor deficits in mice with genetically induced PD. Hyposmia, defined as reduced sensitivity to
odor, is an early and common non-motor symptom of PD that precedes the typical motor symptoms by several years, occurring in approximately
90% of early-stage cases of PD. The study found that ATH434 prevented a loss of smell in the younger mice and rescued it in older mice.
More importantly, the authors also demonstrated that ATH434 prevented the development of motor impairment in older animals, which was
associated with a reduction in iron levels and preservation of neurons in the substantia nigra, the brain region affected in Parkinson&#8217;s.
These data support other studies indicating that ATH434 has a beneficial effect on the motor and non-motor symptoms in animal models of
PD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">In October 2021, The Journal of Parkinson&#8217;s
Disease published the results from a preclinical study investigating the effect of ATH434 on gastrointestinal complications titled &#8220;ATH434
Reverses Colorectal Dysfunction in the A53T Mouse Model of Parkinson&#8217;s Disease&#8221;. Non-motor symptoms are common in patients
with Parkinsonian disorders, such as Parkinson&#8217;s disease and MSA. Parkinson&#8217;s disease patients experience gastrointestinal
complications, cognitive deficits, autonomic dysfunction, and mood disturbance and these non-motor manifestations are an important source
of morbidity and reduced quality of life.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Friedreich&#8217;s Ataxia </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">In April 2024, a poster was presented
at the World Orphan Drug Congress, entitled &#8220;Biophysical Characteristics of ATH434, a Unique Iron-Targeting Drug for Treating Friedreich&#8217;s
Ataxia&#8221;. The study evaluated the ability of ATH434 to target the toxic form of iron that drives the pathology of Friedreich&#8217;s
Ataxia, a rare neurodegenerative disease that affects young children to young adults. The study also evaluated traditional iron chelators
that are designed to bind iron and remove iron from the body. Conversely, an iron chaperone is designed to bind and redistribute iron
within the body. The results confirmed that ATH434 has properties consistent with a chaperone. These studies were published in the peer-reviewed
journal <i>Metallomics</i> entitled &#8220;ATH434, a promising iron-targeting compound for treating iron regulation disorders&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Alzheimer&#8217;s disease</i></b>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">PBT2 was our product candidate for Alzheimer&#8217;s
disease. The drug candidate is orally bioavailable and has been shown to cross the blood-brain barrier. While PBT2 was found to be well
tolerated in Phase 1 and Phase 2a trials, a Phase 2 trial did not meet its primary endpoint and the program was ended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">In March 2023, we announced a sub-licensing
agreement for PBT2 to Professor Colin Masters, M.D., A.O., to advance compounds for the treatment of Alzheimer&#8217;s and related diseases.
Under the license agreement, Alterity granted the entire rights to the acyl hydrazone patent protecting novel zinc modulators mentioned
above, as well as an exclusive worldwide license to develop and commercialize both the novel zinc modulators and PBT2 in Alzheimer&#8217;s
disease. In exchange, Alterity is entitled to future royalties of net sales from the assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Huntington&#8217;s disease</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">PBT2 was also evaluated as a treatment
for Huntington&#8217;s disease. Preclinically, PBT2 has demonstrated efficacy in the R6/2 mouse model of Huntington disease. In 2012 a
Phase 2 trial to test PBT2 in patients with Huntington disease over six months was undertaken under an U.S. IND application and achieved
its primary objective with PBT2 being demonstrated as safe and well tolerated. During 2015 and 2016, three new PBT2 Phase 1 trials were
completed providing further safety, pharmacokinetic and pharmacodynamic information on PBT2. In 2015 we reported that the FDA had placed
PBT2 on Partial Clinical Hold, based on toxicology findings that limited the dose of PBT2 that could be used in future trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Non-neurodegenerative applications</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Antibiotic Resistance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">In December 2020, Alterity acquired an exclusive world-wide license
from UniQuest, the commercialisation company of The University of Queensland (UQ), for the development and commercialisation of novel
zinc ionophore technology to combat antimicrobial resistance in superbugs. Under the license, Alterity has the rights to develop and commercialise
therapies that re-sensitize bacteria to antibiotics. The licensed technology combines Alterity&#8217;s PBT2 and other zinc ionophores
with commonly used antibiotics to treat infections caused by multidrug resistant bacteria. A published article in the high-impact journal
<i>Science Translational Medicine</i>, showed that PBT2 could reverse antibiotic resistance to critical superbugs and demonstrate efficacy
in an animal model of sepsis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Clinical Trials for Our Product Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our Current Pipeline</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_001.jpg" style="width: 671px; height: 265px"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>ATH434</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">In July 2019 we announced the completion
of a clinical trial evaluating the safety and pharmacokinetics of ATH434 in healthy volunteers. The Phase 1 study, conducted in Australia,
recruited 80 adult volunteers which included ten elderly people (over 65 years) with the key goals of assessing the safety, tolerability
and drug disposition within the body (pharmacokinetics) of ATH434 after single and multiple oral dose administration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The volunteers in the single ascending
dose phase of the study, made up of four individual dose levels in ascending order, received a single oral dose of ATH434 and a blood
sampling over the next 72 hours. In the multiple ascending dose phase of the study, volunteers received eight days dosing with ATH434,
administered as three successively higher dose levels, with intensive blood sampling for pharmacokinetics on days 1 and 8. At the two
highest multiple dose levels, cerebrospinal fluid was collected at steady state to determine drug penetration to the site of action in
the brain. The older adults (&#8805;65 years) received the highest dose level for 8 days as well.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The study was successfully completed
with systemic exposure to the drug comparable between adult and older adult volunteers. ATH434 was found to be safe and well tolerated.
Adverse event rates were found to be comparable with placebo and no subject experienced a serious adverse event or an adverse event that
led to discontinuation of the study drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The clinical data were presented at
the American Academy of Neurology Annual Meeting in May 2019. The presentation was based on an abstract entitled <i>A phase 1 Study of
ATH434, a Novel Small Molecule Inhibitor of &#945;-synuclein Aggregation, in Adult and Older Adult Volunteers </i>published in the journal
<i>Neurology</i>. In September 2019, we presented a poster titled: <i>A First in Human Study of ATH434, a Novel Small Molecule Inhibitor
of &#945;-Synuclein Aggregation</i> at the 2019 International Congress of Parkinson&#8217;s Disease and Movement Disorders (MDS Congress)
in Nice, France. The poster presented findings from the completed Phase 1 trial based on an abstract published in the journal <i>Movement
Disorders</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-align: justify; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Alterity applied
to the FDA for Orphan Drug designation for the proposed use of ATH434 for the treatment of MSA, and the designation was granted in January
2019. Orphan designation entitles Alterity to seven years of market exclusivity following approval for the use of ATH434 in the treatment
of MSA and qualifies the sponsor of the drug for various development incentives of the Orphan Drug Act, including tax credits for qualified
clinical testing. In May 2025, ATH434 was granted Fast Track designation by the US FDA in MSA based on trial data. The Fast Track Designation
is intended to facilitate and expedite the development and review of new drugs for serious conditions with unmet medical needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-align: justify; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">In January 2020
it was announced that the European Commission, or EC, granted Orphan Drug designation to ATH434, which entitles Alterity to ten years
of market exclusivity in the European Union, or EU, for the use of ATH434 in the treatment of MSA and other benefits including assistance
in developing clinical protocols, reduced fees and access to EU-funded research grants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><b><i>ATH434-201 Phase 2 Clinical Trial</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In July 2022, we commenced our first
Phase 2 clinical trial of ATH434 in patients with MSA. The trial, known as ATH434-201, is a randomized, double-blind, placebo-controlled
investigation that explored the effect of ATH434 treatment on clinical and biomarker endpoints. Activity in the outpatient setting was
assessed with wearable movement sensors. The study was expected to enrol 60 adult patients with MSA to receive 12 months treatment with
one of two dose levels (50 mg and 75 mg twice daily) of ATH434 or matching placebo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In November 2023, we announced completion
of enrollment in the ATH434-201 clinical trial. The study enrolled 77 adults with MSA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 28.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In May 2024, we announced that an independent
Data Monitoring Committee (DMC) completed its third prespecified review of unblinded clinical trial data from the ATH434-201 Phase 2 study.
Consistent with the first two reviews, the DMC expressed no concerns about safety and recommended that the study continue as planned without
modification. This recommendation is an important milestone as participants were able to safely tolerate ATH434 as their time on study
increased.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 28.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In December 2024, we reported the completion
of the ATH434-201 study as the last patient finished all clinical evaluations leading to the announcement of the topline results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 28.6pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In January 2025, we announced topline results for the trial and have
since published additional data supporting the positive results for ATH434 in the treatment of MSA. ATH434 demonstrated significant slowing
of clinical progression and a favorable safety profile in MSA. The results show that ATH434&#8217;s targeting of labile iron may have
a disease modifying effect. The fact that we achieved statistical significance on the key clinical endpoint, Modified Unified MSA Rating
Scale Part 1 (UMSARS Part 1), is extremely meaningful because it assesses the functional areas affected in MSA and it is the endpoint
needed to support drug approval by the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In May 2025, additional analyses evaluated the clinical analysis population
(n=71) who had at least one post-baseline assessment of the key clinical endpoint, the modified UMSARS part I activities of daily living
scale. On this endpoint, ATH434 demonstrated a clinically significant reduction in disease severity versus placebo, with a 48% relative
treatment effect at the 50 mg dose (p=0.02) and a 30% relative treatment effect at the 75 mg dose at 52 weeks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">Additional efficacy assessments showed
improvement consistent with the UMSARS I findings. The Clinical Global Impression of Severity Scale demonstrated improvement compared
to placebo at both dose levels, with difference at 50 mg achieving nominal statistical significance (p=0.0088). On the Orthostatic Hypotension
Symptom Assessment (a patient reported outcome), on average, placebo patients worsened by approximately 6 points over 52 weeks whereas
both ATH434 treatment groups improved over the same period (p=0.08 at 50 mg, p=0.14 at 75 mg). Baseline differences in disease severity
likely explain the different responses in 50 mg and 75 mg treatment groups.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">Increased activity in the outpatient
setting was observed at both dose levels as compared to placebo as measured by the wearable sensors utilized in the trial, with clinically
meaningful improvements in step count, bouts of walking, total walking time, and total standing time. ATH434 was well tolerated with similar
adverse event rates compared to placebo and no serious or severe adverse events attributed to ATH434. Regarding neuroimaging in 61 participants,
ATH434 demonstrated target engagement by stabilizing or reducing iron accumulation at both dose levels compared to placebo in MSA affected
brain regions. In addition, ATH434 demonstrated trends in reducing brain atrophy at both dose levels compared to placebo. Overall, the
study results support continued advancement of ATH434 for the treatment of MSA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">Multiple presentations have been delivered
on the ATH434-201 trial:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>May 2025 &#8211; International MSA Congress, Title: &#8220;ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System
Atrophy&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>April 2025&#8211; American Academy of Neurology (AAN), Title: &#8220;Topline Data from a Randomized, Double Blind, Placebo Controlled
Phase 2 Study of ATH434 in Multiple System Atrophy&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>April 2025&#8211; American Academy of Neurology (AAN), Title: Association Between Wearable Sensor Data and Clinical Scores in Individuals
with Early-stage Multiple System Atrophy&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>April 2025 &#8211; MSA Research Symposium, Title: &#8220;A Randomized, Double Blind, Placebo Controlled Study of ATH434 in MSA&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>September 2024 - International Congress of Parkinson&#8217;s Disease and Movement Disorders&#174; (MDS), Title: &#8220;A Phase 2 Study
of ATH434, a Novel Inhibitor of &#945;-Synuclein Aggregation, for the Treatment of Multiple System Atrophy&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>April 2024 &#8211; American Academy of Neurology (AAN), Title: &#8220;A Phase 2 Study of ATH434, a Novel Inhibitor of &#945;-Synuclein
Aggregation, for the Treatment of Multiple System Atrophy&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in"><b><i>ATH434-202 Phase 2 Clinical Trial</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In May 2023, we initiated a second
Phase 2 clinical trial entitled, &#8220;A Biomarker Study of ATH434 in Participants with MSA&#8221;, known as ATH434-202. The Biomarker
trial is a single arm open label study that will enroll up to 15 individuals with advanced MSA. ATH434-202 study participants received
treatment with ATH434 for 12-months. The study was designed to assess the effect of ATH434 treatment on clinical and biomarker endpoints,
safety, and pharmacokinetics. The selected biomarkers include brain iron which is an important contributor to MSA pathology. The primary
objective of this study is to evaluate the impact of 12 months treatment with ATH434 on brain iron by MRI (QSM/R2*).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">The 202 study gives us the opportunity
to evaluate the effects of ATH434 treatment in an MSA population more advanced than individuals enrolled in the ATH434-201 study. Individuals
with more advanced disease face severe challenges due to the stage of their illness. Data from this study will help Alterity guide the
MSA development program given the differences between the open-label 202 study and the double-blind trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In July 2024, we reported positive
interim data from the ATH434-202 trial in participants with advanced MSA. The interim analysis included clinical and biomarker data on
7 participants treated with ATH434 for 6 months and neuroimaging data on 3 participants who were treated for 12 months. After 6 months
of treatment, 43% of participants showed improvement on the UMSARS, indicating reduced disability on activities of daily living. Over
the same period, 29% of participants had stable or improved neurological symptoms (clinical responders) as assessed by the global impression
of change by both the treating physician and the patient. The clinical responders on average had reduced accumulation of iron on MRI in
the substantia nigra, putamen and globus pallidus and stable levels of Neurofilament Light Chain (NFL), a marker of axonal injury, when
compared to participants who declined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In September 2024, we presented positive
interim data from the ATH434-202 trial as both a late-breaking oral presentation and poster session entitled &#8220;Preliminary Efficacy
and Safety of ATH434 in Multiple System Atrophy&#8221; at the MDS meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In March 2025, we announced that the
last patient in the ATH434-202 Phase 2 trial completed the&#160;study. Subsequent to the end of the period, in July 2025, we reported
positive topline data that showed ATH434 conferred a clinical benefit on areas of impairment in MSA and stabilized key biomarkers that
underpin the pathology of the disease. Based on the observed clinical and neuroimaging data, ATH434 improved overall neurological symptoms
and slowed disease progression compared to historical data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">Over the 12-month treatment period,
disease progression as assessed with UMSARS I was reduced by approximately half as compared to historical controls. The mean (SD) UMSARS
scores increased from baseline to 12 months by 3.5&#160;(4.7) points. These study data compare favorably to historical data in a similar
MSA population, where an increase (worsening) of 6.5 (6.0) points over 12 months was observed. 43% (3/7) of participants who completed
the study had stable UMSARS scores. In addition, 30% of participants reported stable neurological symptoms over the course of the study.
On the important symptom of orthostatic hypotension, ATH434 on average stabilized low blood pressure symptoms in study participants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">Biomarker endpoints were used to evaluate
potential drug effect and target engagement. Neuroimaging outcomes indicate that ATH434 slowed brain atrophy in MSA affected areas, as
measured by the MSA Atrophy Index (MSA-AI), when compared to placebo-treated participants in Study 201. Moreover, the effects on brain
volume were comparable to those observed in participants in the 75 mg dose group in Study 201. In addition, ATH434 led to lower iron accumulation
in the putamen and globus pallidus as compared to placebo treated patients in Study 201, providing further evidence of target engagement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">ATH434 was well tolerated with no serious
adverse events related to ATH434 reported, and most adverse events were mild to moderate in severity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">Importantly, the aggregate data indicates
that ATH434 has similar clinical efficacy in this advanced MSA population as was observed in the earlier stage patients in Study ATH434-201.
<span style="font-family: Times New Roman, Times, Serif">T</span>hese outcomes are potentially promising as stabilization of MSA symptoms
is unexpected in this patient population.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in"><b><i>bioMUSE natural history study for individuals
with MSA </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">Biomarkers of progression in Multiple
system atrophy (bioMUSE) is a natural history study to track the progression of individuals with early MSA. The study was conducted in
collaboration with Vanderbilt University Medical Center in the US under the direction of Daniel Claassen, MD, Professor of Neurology and
Principal Investigator. Natural history studies are important for characterizing disease progression in target patient populations. The
goal of the bioMUSE observational study was to optimize patient selection and choose endpoints in our Phase 2 clinical trials, and the
data generated was invaluable in informing and reducing risk in these trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In May 2024, we hosted a webinar to
discuss data from the bioMUSE Natural History Study. The study enrolled 21 individuals who were observed for 12 months to characterize
early-stage MSA in terms of various biomarkers. In particular, the focus is on brain iron, brain volume, and the pathology in glial support
cells. Utilizing novel MRI technology, Alterity&#8217;s partners at Vanderbilt have optimized specialized MRI methods, including machine
learning (a form of artificial intelligence), to establish standardized methods to analyze brain iron and brain volumes with precision.
Importantly, they developed a new, novel imaging biomarker to assess brain volume in MSA affected regions. The bioMUSE data showed a statistically
significant increase in iron over 12 months in the substantia nigra, and statistically significant decreases in brain volume observed
in affected regions at 12 months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">Key data from bioMUSE have been presented
at major medical and scientific meetings listed below. The study continues to generate important scientific data validating our state-of-the-art
approach to utilizing various biomarkers to improve the accuracy of diagnosing MSA. Advanced MRI methods employed in the study, referred
to as quantitative susceptibility mapping (QSM), have allowed us to measure iron accumulation in multiple areas of the brain affected
in MSA patients. Similarly, standardized methods have been established to analyze brain volumes with precision.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">Findings to date indicate that advanced
MRI methods for measuring iron may improve patient selection in clinical trials of disease modifying therapy and have potential to serve
as a biomarker for assessing treatment induced changes. Analysis also demonstrated that wearable sensors can quantify motor impairment
in individuals with MSA that is not captured by neurological examination. This means that wearable sensors can be used to assess disease
progression in clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">Multiple publications and presentations
have been delivered on the bioMUSE natural history study:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>July 2025 &#8211; <i>Annals of Clinical and Translational Neurology</i>, Title: &#8220;The MSA Atrophy Index (MSA-AI): An Imaging
Marker for Diagnosis and Clinical Progression in Multiple System Atrophy</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.55pt">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>May 2025 &#8211; International MSA Congress, Title: &#8220;MSA Atrophy Index (MSA-AI): A Quantitative Imaging Marker for Diagnosis
and Monitoring of Multiple System Atrophy&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>May 2025 &#8211; International MSA Congress, Title: &#8220;Cutaneous Phosphorylated Alpha-Synuclein Deposition Informs Autonomic Function
in Individuals with Early-Stage Multiple System Atrophy&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>November 2024 - International Symposium on the Autonomic Nervous System, Title: &#8220;The MSA Atrophy Index: A Marker of Clinical
Progression in Multiple System Atrophy&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>September 2024 - International Congress of Parkinson&#8217;s Disease and Movement Disorders (MDS), Title: &#8220;Association Between
Clinical Progression in Multiple System Atrophy and Brain Volume Changes Evaluated via Deep Learning Segmentation&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>April 2024 &#8211; American Academy of Neurology (AAN), Title: &#8220;Neurofilament Light Chain and Clinical Progression in Early
Multiple System Atrophy&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>November 2023 &#8211; American Autonomic Society (AAS) 34th International Symposium on the Autonomic Nervous System, Title: &#8220;Relationship
between N-acetylaspartate and neurofilament light chain in multiple system atrophy&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>August 2023 &#8211; International Congress of Parkinson&#8217;s Disease and Movement Disorders (MDS), Titles: &#8220;A multimodal
approach for diagnosis of early Multiple System Atrophy&#8221;; &#8220;Preliminary evidence for evolution of myoinositol and N-acetylaspartate
as biomarkers of disease severity in early-stage Multiple System Atrophy&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>April 2023 - American Neurological Association, Title: &#8220;Wearable Sensors for Quantitative Motor Assessments in MSA&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>November 2022 - American Autonomic Society, Title: &#8220;Urinary symptom profile in early Multiple System Atrophy&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>October 2022 - American Neurological Association, Title: &#8220;Deep Learning Segmentation Improves Precision of Volume Assessment
of Subcortical Structures in early MSA&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>April 2022 - American Academy of Neurology, Title: &#8220;Iron Accumulation Correlates with Disease Severity in Patients with Multiple
System Atrophy&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td>September 2021 - The International Parkinson and Movement Disorder Society Congress, Title: &#8220;Non-invasive imaging markers of
iron accumulation in Multiple System Atrophy&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>ATH434 Scientific Peer Validation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">Scientific interest in ATH434 and validation
of our approach to treating neurodegenerative diseases continue to grow, with data from ATH434 presented at global scientific and clinical
conferences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In November 2024, the peer-reviewed
journal <i>Metallomics</i> published data on the importance of iron and iron-targeting agents like ATH434 to treat neurodegenerative diseases.
The publication, entitled &#8220;ATH434, a promising iron-targeting compound for treating iron regulation disorders&#8221;, demonstrates
the novel way in which ATH434 targets the labile, or reactive, form of iron which can be so damaging to cells when in excess. The iron
binding properties of ATH434 presented in the publication support the characterization of ATH434 as an iron chaperone. The publication
also describes how ATH434 targets the toxic form of iron that drives the pathology of a rare neurodegenerative disease known as Friedreich&#8217;s
Ataxia. This toxic form of iron is also involved in the pathogenesis of Parkinson&#8217;s disease and MSA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In October 2024, promising new data related to
ATH434 were presented at the Society for Neuroscience 2024 that further the understanding of ATH434&#8217;s potential as a disease modifying
treatment for neurodegenerative diseases, including Parkinson&#8217;s disease and related disorders. The poster presentation, entitled
&#8220;Potent Antioxidant and Mitochondrial-protectant Effects of ATH434, a Novel Inhibitor of &#945;-Synuclein Aggregation with Moderate
Iron-binding Affinity,&#8221; demonstrated that the neuroprotective and mitochondrial protectant properties of ATH434 include reducing
lipid damage in two distinct and disease-relevant neuronal injury models. ATH434&#8217;s antioxidant properties were distinguished from
those of another iron binding agent approved for treating iron overload.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In November 2023, a poster was presented at the
Society for Neuroscience, entitled: &#8220;Potent Antioxidant and Mitochondrial- protectant Effects of ATH434, a Novel Inhibitor of &#945;-Synuclein
Aggregation with Moderate Iron- binding Affinity&#8221;. The study presented new data indicating that ATH434 can preserve mitochondrial
function after oxidative injury and exert direct anti-oxidant activity independent of its iron binding properties, features that were
not observed with another iron binding agent approved for treating iron overload that was also investigated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In January 2022, data in an animal
model of MSA was published in the Journal of Parkinson&#8217;s Disease. The publication, entitled, &#8220;The Compound ATH434 Prevents
Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy&#8221; described a study evaluating the efficacy of ATH434 in genetically
altered mice that develop manifestations of MSA. The investigation demonstrated that in the studied brain region, ATH434 treatment reduced
both the toxic oligomeric and aggregated forms of &#945;-synuclein, a central nervous system protein important for normal function of
nerve cells. ATH434 treatment also reduced the cardinal pathology of MSA (glial cell inclusions), reduced brain iron, preserved neurons,
and improved motor performance. The results independently confirmed the previous findings from a study published in <i>Movement Disorders</i>
in 2021. The 2022 publication concluded that ATH434 is a promising small molecule drug candidate that has potential for treating MSA.
The study was led by David I. Finkelstein, Ph.D., Head of Parkinson&#8217;s Disease Laboratory at the Florey Institute of Neuroscience
and Mental Health and the University of Melbourne.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In November 2021, a poster was presented
at the American Autonomic Society 32nd Annual International Symposium. The poster, entitled &#8220;Cardiovascular safety and pharmacokinetics
of ATH434, a novel small molecule inhibitor of &#945;-synuclein aggregation, in adults and older adults, described results from the Phase
1 clinical trial conducted in healthy volunteers. In this trial, ATH434 was well tolerated in adult and &#8805; 65- year-old volunteers and
demonstrated no cardiac adverse event signal and no clinically significant changes in blood pressure or heart rate at any dose. ATH434
also demonstrated dose dependent pharmacokinetics (PK) after single and multiple oral doses and a half-life that supports twice-daily
dosing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.7pt; text-indent: 29.85pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In July 2021, <i>Plos ONE</i> published
an in vitro study concluding that the novel mechanism of action of ATH434 provides a compelling case for its continued development as
a therapeutic agent in neurodegenerative diseases associated with iron accumulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">In June 2021, <i>Movement Disorders</i>,
published results from a study demonstrating that ATH434 reduces &#945;-synuclein related neurodegeneration in a widely accepted murine
model of MSA. The study was performed at the Laboratory for Translational Neurodegeneration Research, Department of Neurology, Medical
University of Innsbruck in Austria, a leading laboratory of animal research in MSA, under the direction of Professor Nadia Stefanova.
The pre-clinical study showed that treatment with ATH434 was neuroprotective and improved motor function.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Patents and Licenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Patent Matters</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Patent matters in biotechnology are highly uncertain
and involve complex legal and factual questions. Accordingly, the availability and breadth of claims allowed in biotechnology and pharmaceutical
patents cannot be predicted. Statutory differences in patentable subject matter may limit the protection we can obtain on some or all
of our inventions outside Australia or prevent us from obtaining patent protection outside Australia, either of which could adversely
affect our business, financial condition and results of operations. For example, methods of treating humans are not patentable in many
countries outside Australia and the United States. Moreover, since patent applications are not published until at least 18 months from
their first filing date and the publication of discoveries in the scientific literature often lags behind actual discoveries, we cannot
be certain that we or any of our licensors were the first creator of inventions covered by pending patent applications or that we or our
licensors were the first to file patent applications for such inventions. Additionally, the grant and enforceability of a patent is dependent
on a number of factors that may vary between jurisdictions. These factors may include the novelty of the invention, the requirement that
the invention not be obvious in the light of prior art (including prior use or publication of the invention), the utility of the invention,
and the extent to which the patent clearly describes the best method of working the invention.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While we intend to seek patent protection for our
therapeutic candidate products and technologies, we cannot be certain that any of the pending or future patent applications filed by us
or on our behalf will be granted, or that we will develop additional proprietary products or processes that are patentable or that we
will be able to license any other patentable products or processes. We also cannot be certain that others will not independently develop
similar products or processes, duplicate any of the products or processes developed or being developed by us or licensed to us, or design
around the patents owned or licensed by us, or that any patents owned or licensed by us will provide us with competitive advantages. Furthermore,
we cannot be certain that patents held by third parties will not prevent the commercialisation of products incorporating the technology
developed by us or licensed to us, or that third parties will not challenge or seek to narrow, invalidate or circumvent any of the issued,
pending or future patents owned or licensed by us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">Our commercial success will also depend, in part,
on our ability to avoid infringement of patents issued to others. If a court of competent jurisdiction determines that we were infringing
any third party patents, we could be required to pay damages, alter our products or processes, obtain licenses or cease certain activities.
We cannot be certain that the licenses required under patents held by third parties would be made available on terms acceptable to us
or at all. To the extent that we are unable to obtain such licenses, we could be barred from the development, export, manufacture or commercialisation
of the product requiring such license or encounter delays in product introductions while we attempt to design acceptable alternatives
to such patents, and any of these circumstances could adversely affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-indent: 0.5in">We may have to resort to litigation to enforce
any patents issued or licensed to us or to determine the scope and validity of third-party proprietary rights. Such litigation could result
in substantial costs and diversion of effort by us. We may have to participate in opposition proceedings before the Australian Patent
and Trademark Office or another foreign patent office, or in interference proceedings declared by the U.S. Patent and Trademark Office,
to determine the priority of invention for patent applications filed by competitors. Any such litigation, interference or opposition proceeding,
regardless of outcome, could be expensive and time consuming, and adverse determinations in any such proceedings could prevent us from
developing, manufacturing or commercializing our products and could adversely affect our business, financial condition and results of
operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to patent protection, we rely on unpatented
trade secrets, know-how and other confidential information as well as proprietary technological innovation and expertise. Although we
have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties,
and confidential information and inventions agreements with employees, consultants and advisers, third parties may still obtain this information
or come upon this same or similar information independently.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Patent Portfolio </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since July 1, 2024, we have continued to advance
our patent portfolio that aligns with our development programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We previously reported the filing of a patent family
claiming over 150 imidazo[l,5-a]pyridine compounds that modulate biological iron and are potentially useful for the treatment of neurological
diseases such as Parkinson&#8217;s disease and Alzheimer&#8217;s disease. The patent was filed under the United States expedited review
procedure, known as Track One, and we announced allowance of the United States application No. 16/818,641 on November 16, 2020 and its
granting on July 1, 2021. In securing the patent grant, no prior art was cited against the application. A national phase application driving
priority from PCT application, No. PCT/AU2020/050235 was filed in September 2021 in each of Europe, Japan, China, Canada, Australia and
India. On August 23, 2023, a European Patent was granted, patent number 3938364. An appeal to a rejection was filed in Japan in March
2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also previously reported that on June 18, 2020,
we filed a provisional application to register a patent that claims an additional 80 novel compounds, also that modulate biological iron
and also titled &#8220;Compounds for and Methods of Treating Diseases&#8221;. This application matured to a PCT application No. PCT/AU2021/050633
on June 18, 2021. Similar to the first mentioned patent application, contemporaneously with filing the PCT application on April 23, 2021,
we also filed United States complete, application No. 17/239,375, under Track One. We announced allowance of the United States application
on August 4, 2021, and in securing the allowance, no prior art was cited against the application. On October 26, 2021, the application
was granted as US patent no. 11155547. The application is currently under examination in Europe. An application has been filed in Australia
and awaits examination. The filed application is in the examination process in the European Patent Office and Japan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On August 27, 2021, we filed a PCT application
No. PCT/AU2021/050,986 to register a patent that claims an additional 150 novel compounds, all of which modulate biological Zinc for the
potential treatment of cancer, neurological diseases and infectious diseases, and is titled &#8220;Compounds for and Methods of Treating
Diseases&#8221;. On the same date we also filed a United States complete application, application No. 17/459854, under United States track
1 expedited review procedure. The patent was granted in the US on February 23, 2023, patent number 11603364. This patent was transferred
to Adjuvant Therapeutics in March 2023 as noted above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.55pt">On September 24, 2023, we filed a provisional
application in the USA to register a patent that claims a method of use ATH434 and related compounds in non-neurologic diseases. The application
was filed in the US as PCT/AU2024/051009 in September 2024. Responses to a subsequent search report will be addressed prior to March 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.7pt; text-indent: 29.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.7pt; text-indent: 29.85pt">On July 12, 2024, we filed a provisional
application No. 63/670299 to register a patent that claims a dosing method for use by ATH434 for the treatment of neurological disease
supported by clinical data. An amendment to the provisional application was filed in January 2025. PCT/AU2025/050750 was filed on July
11, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.55pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.55pt">On July 31, 2024, we filed a provisional application
with No. 2024902369 claiming 39 novel compounds potentially useful for the treatment of neurological and non-neurological diseases. This
application will be allowed to lapse and will be refiled when additional data are available to support the claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.55pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.7pt; text-indent: 29.85pt">On July 12, 2024, we filed a provisional
application No. 2025900800 to register a patent that claims a novel salt form (HCl) and crystalline form of ATH434 potentially useful
for the treatment of neurological diseases. The application was filed as PCT/AU2025/05074 July 10, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.7pt; text-indent: 29.85pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 29%; text-align: left"><span style="font-size: 10pt"><b>Patent</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; width: 30%; text-align: center"><span style="font-size: 10pt"><b>Status</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; width: 39%; text-align: center"><span style="font-size: 10pt"><b>Invention</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8220;8-Hydroxyquinoline Derivatives&#8221;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Filed: July 16, 2003</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">PCT/AU03/00914</p></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Patent in the USA has been Granted. </span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">The invention is directed to chemical scaffolds of the 8-Hydroxyquinoline compounds class and their utility in the treatment of neurological conditions.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">8-hydroxy and 8-mercapto quinazolinones</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Filed October 3, 2003</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">PCT/AU2003/001303</p></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Expiry June 7, 2026</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">The Invention is directed towards Follow-up Scaffolds and their utility in the treatment of neurological conditions, it covers ATH434 composition of matter.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8220;Neurologically - Active Compounds&#8221;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Filed: April 1, 2005</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">PCT/AU2005/000477</p></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Patents have been Granted in Australia, the USA, Germany, Spain, France, Great Britain, and Italy. </span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">The invention is directed to &#8216;F4&#8217; quinazolinone chemical structures and their utility in the treatment of neurological conditions and includes Parkinson&#8217;s Disease lead compounds. It covers the ATH434 composition of matter.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8220;Quinazolinone compounds&#8221;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Filed: December 24, 2008</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">PCT/AU2009/001701</p></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Patents have been Granted in Australia, the USA, Germany, Spain, France, Great Britain, and Italy. </span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0in; text-align: left">The invention is directed to 2,3
    disubstituted quinazolinone compounds used in the treatment of Parkinson&#8217;s Disease.</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8220;Method of treating immunoglobulin light chain
    amyloidosis&#8221;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed: July 1, 2016</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCT/AU2017/050678</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent in the USA and Japan has been Granted. </span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The invention is directed to the treatment of light chain amyloidosis with a known compound.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8220;Compounds for Methods of Treating</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Diseases&#8221;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Filed: March 13, 2020</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">PCT/AU2020/050235</p></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">A US patent and an EP patent have been granted. National phase applications have been filed in Germany, Spain, France, Great Britain, and Italy. Examination processes are underway in Japan, and Australia.</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">The invention is directed to 150 novel compounds and their utility in the treatment of neurodegenerative diseases. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8220;Compounds for Methods of Treating Diseases&#8221;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Filed: June 18, 2021</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">PCT/AU2021/050633</p></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">A US patent has been granted. An application has been filed in Australia and awaits examination. The filed application is in the exam process in EP and Japan.</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">The invention is directed to 80 novel compounds and their utility in the treatment of neurodegenerative diseases </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8220;Novel Therapy&#8221;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Filed: September 24, 2023</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">PCT/AU2025/051009</p></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Nonprovisional PCT application filed in the US</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">This invention is directed to method of use of ATH434 and related compounds in non-neurologic diseases. Co-inventorship with personnel from State University of Buffalo in New York (USA).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8220;Novel Therapy&#8221;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Filed: July 12, 2024, amended Jan 2025</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">PCT/AU2025/050750</p></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Nonprovisional PCT application filed in the US with results from ATH434-201 and 202.</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">This invention is directed to clinical method of dosing of ATH434 in neurological disorders such as Multiple System Atrophy.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8220;Compounds for and Methods of Treating Disease&#8221;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Filed: July 31, 2024</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">PCT application No. 2024902369</p></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Provisional PCT application will lapse and be refiled when more data are available.</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">This invention is directed to 39 novel compounds and their utility in the treatment of neurodegenerative diseases.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8220;Novel Salt and Crystalline Form&#8221;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Filed: Mar 14, 2025</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">PCT application No. 2025900800</p></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Provisional PCT application</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">This invention is directed to a novel salt and crystalline form of ATH434.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The pharmaceutical industry is extremely competitive.
We believe that we will face competition in differing levels of intensity in all of the areas in which we are conducting research. ATH434,
if approved for the treatment of MSA, may compete in a highly competitive market. Our competitors, which are located worldwide, are numerous
and include, among others, major pharmaceutical companies, biotechnology firms, universities and other research institutions. These competitors
may develop technologies and products that are more effective than any that we are developing, or which would render our technology and
products obsolete or non-competitive. Many of these competitors have greater financial, research and screening capabilities, technical
resources and manufacturing and marketing capabilities than we do. In addition, many of our competitors may have more experience than
we do in non-clinical and human clinical trials of new or improved drugs, as well as in obtaining FDA, EMA, TGA and other regulatory approvals.
We cannot provide assurance that we can compete effectively with these other competitor companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are currently no approved drugs for the treatment
of Multiple System Atrophy (MSA). If we are able to successfully develop ATH434 and gain approval for the treatment of MSA, we may compete
with the following drug candidates which are in development:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lu AF82422: This product is being developed by H. Lundbeck A/S. It is administered by injection and is thought to act by interfering with the extracellular spread of the &#945;-synuclein protein. In January 2024, Lundbeck reported that their Phase 2 trial did not show statistical significance on its primary endpoint of slowing the rate of progression of MSA but have commenced a Phase 3 clinical trial with patient recruitment ongoing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAK-341/MEDI341: This product is being developed by Takeda in partnership with AstraZeneca. It is administered by injection and is thought to act by interfering with the extracellular spread of the &#945;-synuclein protein. A Phase 2 clinical trial is ongoing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ono-2808: Ono Pharmaceuticals is developing this S1P5 receptor agonist. It is an oral agent thought to act by promoting myelin synthesis. A Phase 2 clinical trial is ongoing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TEV-56286 (formerly Anle138b): This product is being developed by Teva Pharmaceuticals. It is an oral agent and is thought to act as a non-specific inhibitor of protein aggregation. A Phase 2 clinical trial is ongoing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YA-101: Yoda Therapeutics is developing a GluN1 inhibitor. It is an oral agent thought to inhibit neuroinflammation and enhance neural plasticity. A Phase 2 clinical trial is ongoing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AAV-GDNF: AskBio is developing this gene therapy. It is administered in spinal fluid and is thought to reduce abnormal protein accumulation. A Phase 1/2 clinical trial is ongoing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_012"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Organizational Structure</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have two wholly-owned subsidiaries, Alterity
Therapeutics Inc. and Alterity Therapeutics UK Limited, incorporated in the United States and the United Kingdom, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_013"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Property, Plant and Equipment</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our executive offices are located at Level 14,
350 Collins Street, Melbourne, VIC 3000, Australia, where we occupy approximately 105 square meters. The lease for the facility, which
expires on May 31, 2026 has an annual rent of A$56,228. Our United States office is located at Suite 360, 39899 Balentine Drive, Newark,
California 94560, United States of America, where we occupy approximately 911 square feet. The lease for the facility, which expired on
May 31, 2025, and has been extended to June 30, 2027 has an annual rent of U.S.$30,610. We also utilize a facility at 30 Flemington Rd,
Parkville, VIC 3010, Australia, where we occupy approximately 44 square meters. The lease for the facility has been extended to July 31,
2026 and has an annual rent of A$17,055.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 4A. UNRESOLVED STAFF
COMMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><span style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps; text-transform: uppercase"><b>ITEM
5.</b></span><b> <span style="text-transform: uppercase">Operating and FINANCIAL review and Prospects</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>The following discussion and analysis includes
certain forward-looking statements with respect to the business, financial condition and results of operations of our company. The words
&#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;expect&#8221; and similar expressions are intended to identify
forward-looking statements within the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ materially from those contemplated by such forward-looking statements,
including those risk factors contained in Item 3.D. of this annual report. You should read the following discussion and analysis in conjunction
with our consolidated financial statements and the notes thereto included in this annual report. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_016"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Operating Results</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Background</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were incorporated under the laws of the Commonwealth
of Australia on November 11, 1997. The principal listing of our ordinary shares and listed options to purchase our ordinary shares is
on the ASX. From September 5, 2002 until April 8, 2019, our ADSs traded on the NASDAQ Capital Market under the symbol &#8220;PRAN.&#8221;
On April 8, 2019 we changed our name to Alterity Therapeutics Limited and our ADSs have traded under the symbol &#8220;ATHE&#8221; and
our ordinary shares have traded under the symbol &#8220;ATH&#8221; since that date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our consolidated financial statements appearing
in this annual report comply with IFRS as issued by IASB. In this annual report, all references to &#8220;U.S. dollars&#8221; or &#8220;U.S.$&#8221;
are to the currency of the United States, and all references to &#8220;Australian dollars&#8221; or &#8220;A$&#8221; are to the currency
of Australia. All of our revenues are generated in Australian dollars, except for interest earned on foreign currency bank accounts, and
the majority of our expenses are incurred in Australian dollars.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a development stage enterprise at an early
to mid-stage in the development of our pharmaceutical products that are designed to treat the underlying causes of neurodegeneration of
the brain. We have incurred net losses since inception and expect to incur substantial and increasing losses for the next several years
as we expand our research and development activities and move our product candidates into later stages of development. All of our product
candidates are in discovery phase or early and mid-stage of development and we face the risks of failure inherent in developing drugs
based on new technologies. The process of carrying out the development of our products to later stages of development may require significant
additional research and development expenditures, including nonclinical testing and clinical trials, as well as for obtaining regulatory
approval. To date, we have funded our operations primarily through the sale of equity securities, proceeds from the exercise of options,
government grants, licensing and research collaborations and interest income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since completing our initial public offering and
listing process on the ASX on March 28, 2000, we have concentrated our resources toward the pursuit of our disease targets. For details
regarding clinical trials for our lead compounds, see Item 4.B. &#8220;Information on the Company - Business Overview - Clinical Trials
for Our Product Candidates.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Going Concern Basis</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group is a development stage medical biotechnology company and
as such expects to be utilizing sources of cash funding until its research activities have become marketable. The Group has incurred recurring
losses since inception including a net loss of $12,147,828 in the year ended June 30, 2025 (2024: $19,123,464) and a net operating cash
outflow of $11,451,248 in the year ended June 30, 2025 (2024: $12,605,824). The Group expects to continue incurring losses into the foreseeable
future and will need to raise additional capital to continue the development of its planned research and development programs. The continuing
viability of the Group is subject to its ability to raise additional capital to finance the continuation of its planned research and development
programs, maintaining implemented cost containment and deferment strategies, and successfully commercializing its initiatives. The Group
successfully raised new equity funding during the 2025 financial year to enable progression of its planned research and development programs
for at least the next 12 months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Significant Costs and Expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Research and development expenses</i>. Our research
and development expenses consist primarily of expenses for contracted research and development activities conducted by third parties on
our behalf. Research and development expenses also include costs associated with the acquisition, development of patents and salaries
and fees paid to employees and consultants involved in research and development activities.&#160;&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>General and administration expenses.</i> Our
general and administration expenses consist of (i) personnel expenses such as directors&#8217; fees, salaries and benefits paid to employees
and officers and equity-based payments awarded to directors, officers and employees; (ii) auditor and accounting expenses which are fees
paid to our auditors for services related to annual reports and interim reports filed or submitted in Australia and the United States
and fees paid to other accounting firms in respect of tax and other accounting advice; (iii) public relations and marketing expenses which
are fees paid to outside consultants for services related to ASX and SEC announcements and presentations; (iv) depreciation expenses;
and (v) other administrative and office expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Intellectual property expenses</i>. Our intellectual
property expenses consist of fees paid to our outside counsel for legal fees associated with patent applications and for the defence of
patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Other gains and losses</i>. Other gains and
losses consist of foreign exchange gain (loss) which are the net unrealized gain or loss on cash balances and trade and other payables
held in foreign currencies (primarily U.S. dollars, British Pounds and Euros) as well as net realized gains and losses on foreign currency
transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Year ended June 30, 2025 compared to year ended June 30, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Interest income</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Interest income increased to A$446,291 for the
year ended June 30, 2025 from A$268,419 for the year ended June 30, 2024, an increase of A$177,872, or 66.3%. The increase in interest
income is primarily attributable to higher Australian dollar cash balances with higher interest rates during the current fiscal year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Other income</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the year ended June 30, 2024, we recognised
a receivable and other income of A$4,019,285 for the R&amp;D Tax Incentive refundable cash offset in relation to eligible expenditure
for the year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have recognised a receivable and other income
of A$3,928,563 for the R&amp;D Tax Incentive refundable cash offset in relation to eligible expenditure for the year ended June 30, 2025,
on which we are entitled to a 43.5% refundable offset under an Australian R&amp;D tax incentive scheme that was introduced on July 1,
2019. In 2025, we recognised other income of $1,513,590 from the ATO for settlement of the claim relating to the dispute regarding the
R&amp;D Tax Incentive refundable tax offset for the year ended June 30, 2020. In 2025, we recognised other income of $1,975,056 in relation
to settlement of a dispute with Catalent and recognised other income of $227,542 in relation to settlement of an insurance claim in relation
to a US employment case.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Research and development expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our research and development expenses decreased
to A$14,404,282 for the year ended June 30, 2025 from A$18,644,047 for the year ended June 30, 2024, a decrease of A$4,239,765 or 22.7%.
The decrease is attributable to the finalization of certain research and development studies during the current year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>General and administrative expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and administrative expenses increased to
A$5,481,399 for the year ended June 30, 2025 from A$4,762,643 for the year ended June 30, 2024, an increase of A$718,756 or 15.1%. The
increase is mainly attributable to an increase in staffing costs, audit compliance expenses and consulting expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Intellectual property expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Intellectual property expenses, which include patent
portfolio costs and intellectual property related legal costs, decreased to A$127,523 for the year ended June 30, 2025 from A$214,304
for the year ended June 30, 2024, a decrease of A$86,781 or 40.5%. This decrease is mainly due to management&#8217;s efforts to reduce
expenses and preserve cash<i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Foreign exchange gain (loss)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We recorded a foreign exchange gain of A$259,433
for the year ended June 30, 2025 compared to a foreign exchange gain of A$261,152 for the year ended June 30, 2024. Foreign exchange gain
(loss) reflects the impact of changes in foreign currency exchange rates on cash that we hold in U.S. dollars, British Pounds and Euros.
In the 2025 and 2024 fiscal years, the Australian dollar slightly depreciated against the U.S. dollar, which had a favorable impact on
the Australian dollar value of our cash held in U.S. dollars. In the 2025 fiscal year, we incurred a foreign exchange gain of A$255,876
attributable to the cash balances that we held in U.S. dollars, and a foreign exchange gain of A$3,557 attributable to foreign currency
transactions. In the 2024 fiscal year, we incurred a foreign exchange gain of A$260,356 attributable to the cash balances that we held
in U.S. dollars, and a foreign exchange gain of A$796 attributable to foreign currency transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>For a comparison of our results of operations
between year ended June 30, 2024 and year ended June 2023, see Item 5.A. &#8220;Results of Operations&#8221; of our annual report on Form
20-F as filed with the SEC on September 30, 2024.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Inflation and Seasonality</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Management believes inflation has not had a material
impact on our company&#8217;s operations or financial condition and that our operations are not currently subject to seasonal influences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Conditions in Australia</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are incorporated under the laws of, and our
principal offices and research and development facilities are located in, the Commonwealth of Australia. Therefore, we are directly affected
by political and economic conditions in Australia. See Item 3.D. &#8220;Key Information &#8211; Risk Factors &#8211; Risks Relating to
Our Location in Australia&#8221; for a description of factors that could materially affect our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recently Issued International Accounting Standards and Pronouncements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">New and amended Accounting Standards and Interpretations issued
and effective</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There were no new or amended standards adopted
by the Group in the year ended June 30, 2025 that materially impacted the Group. These financial statements follow the same accounting
policies as used in the June 30, 2024 consolidated financial statements and related notes as filed with the Australian Securities Exchange
and the Securities and Exchange Commission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Australian Disclosure Requirements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No dividends have been paid during the financial
year (2025: nil). The Directors do not recommend the payment of a dividend in respect of the current financial year (2024: nil).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Significant changes in the state of affairs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There have been no significant changes in the state
of affairs of the Group during the year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Events since the end of the financial year</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No other matters or circumstances have arisen since
June 30, 2025 that have significantly affected the Group&#8217;s operations, results or state of affairs, or may do so in future years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Likely developments and expected results of operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The likely developments in our operations, to the
extent that such matters can be commented upon, are covered in Item 5A of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Environmental regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are involved in scientific research and development,
and the activities do not create any significant environmental impact to any material extent. Our scientific research activities are in
full compliance with all prescribed environmental regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_017"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>Liquidity and Capital Resources</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a development stage company, have had no
sales income to date and as of June 30, 2025, our accumulated deficit totaled A$225,888,680. We had A$33,158,642 of cash and cash equivalents,
and A$7,500,000 in longer dated term deposits as of June 30, 2025, compared to A$12,638,885 as of June 30, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From inception until our initial public offering
in March 2000 we financed our operations primarily through borrowings from two of our then directors, which were repaid from the proceeds
of such offering. Since our initial public offering, we have financed our operations primarily through sales of equity securities, proceeds
from the exercise of options, government grants, licensing and research collaborations and interest earned on investments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In November 2023, we received commitments for a
capital raising of $4.8 million by means of a private placement. The private placement was conducted at 0.0035 per new share. For every
new share issued, one free attaching short-dated option was issued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In February 2024, we received commitments for a
capital raising of $3.25 million by means of a placement. The placement was conducted at 0.0038 per new share. For every three new share
issued, one free attaching listed option was issued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In February 2024, we received commitments for a
capital raising of $2 million by means of a Securities Purchase Plan. The number of securities issued to the participants on 2 February
2024 following the scaleback and pursuant to ASX Listing Rule 7.1, and which were within the volumes approved by shareholders at the EGM,
are:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">571,428,556 SPP Shares at A$0.0035 (0.35 Australian cents)
per SPP Share (ASX:ATH); and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">571,428,556 unlisted Short-Dated Options (each with an exercise
price of A$0.007, expiring on 31 August 2024) (ASX: ATHAAI); and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">190,476,123 listed Long-Dated Options (each with an exercise
price of A$0.01, expiring on 31 August 2026) (ASX: ATHO).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 15, 2024 we entered into a sales agreement
with JonesTrading Institutional Services LLC, or JonesTrading, under which we may issue and sell ADSs from time to time in &#8220;at the
market offerings&#8221; pursuant to a Prospectus Supplement. Subject to the terms and conditions of the sales agreement, JonesTrading
agreed to use its commercially reasonable efforts to sell the ADSs from time to time as agent, based upon our instructions. JonesTrading
is entitled to a commission at a fixed commission rate equal to 3.0% of the gross sales price per shares sold. On February 15, 2024, we
filed a Prospectus Supplement relating to the offering of up to US$6,000,000 in ADSs with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On July 18, 2024, 75,220,800 ordinary shares were
issued under the ADS Sales Agreement, raising $366k net of security issuance costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 3, 2025, 164,242,200 ordinary shares
were issued under the ADS Sales Agreement, raising $2,058k net of security issuance costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In February 2025, we received commitments for a
capital raising of approximately $40 million by means of a two tranche placement (the <b>Placement</b>) of fully paid ordinary shares.
For every three new shares issued, one free attaching option was issued. The number of securities issued to the Placement participants
on February 17, 2025 (Tranche 1), April 4, 2025 (Tranche 2) and April 23,2025 (Options) pursuant to ASX Listing Rule 7.1, and which are
within the volumes approved by shareholders at the EGM on March 31, 2025, are:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td><span style="font-family: Times New Roman, Times, Serif">3,636,363,636 ordinary shares at A$0.011 (1.1 Australian cents) per share
(ASX:ATH); and</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td><span style="font-family: Times New Roman, Times, Serif">1,222,300,911 listed Long-Dated Options (each with an exercise price of A$0.028,
expiring on February 26, 2027) (ASX: ATHOA).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 17, 2025, 1,165,841,830 ordinary shares
were issued under Tranche 1 of the Placement, raising $12.028 million, net of security issuance costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 4, 2025, 2,470,521,806 ordinary shares
were issued under Tranche 2 of the Placement, raising $25.474m net of security issuance costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;As of June 30, 2025, we had a total of 2,683.5
million unlisted and listed unexercised options outstanding. The options have exercise prices ranging from A$0.004 to A$0.09. If all unlisted
options were exercised in full, we would receive consideration of A$52,792,222 in total.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From inception to June 30, 2025, our capital expenditures
have totaled A$849,729, consisting of computer equipment, furniture and fixtures, fit-out costs and laboratory equipment that is being
used in connection with our research facility at The University of Melbourne. Capital expenditures for equipment are depreciated on a
straight-line basis over the estimated useful lives of 3 to 20 years, with a net balance as of June 30, 2025 of A$3,848. We currently
do not have significant capital spending requirements, but we expect to continue to engage in capital spending consistent with anticipated
growth in our operations and personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe the Australian Government tax incentive
scheme relating to eligible research and development activities, introduced on July 1, 2011, will provide us with significant benefits
in future years. Such eligible R&amp;D activities include but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core activities, which are experimental activities whose outcome cannot be known or determined in advance, but can only be determined by applying a systematic progression of work;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Core activities conducted for the purpose of generating new knowledge (including new knowledge in the form of new or improved processes and materials); or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supporting activities that are directly related and designed to support the above.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the research and development tax incentive
scheme, entities with an aggregated turnover for the income year of less than A$20 million are entitled to a 43.5% refundable tax incentive.
In the year ended June 30, 2025, we recorded A$3.9 million in other income with respect to funds we expect to receive in relation to
the 2025 financial year under the research and development tax incentive scheme.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have incurred recurring losses since inception,
including operating losses of $12.1 million and $19.1 million for the years ended June 30, 2025 and 2024, respectively, and an operating
cash outflow of $11.5 million and $12.6 million, respectively for such years. We expect to continue incurring losses into the foreseeable
future and will need to raise additional capital to continue the development of our planned research and development programs. The consolidated
financial statements have been prepared assuming that we will continue as a going concern as a result of the funds raised during the financial
year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash Flows</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes our cash flows for
the periods presented, which contemplates the realisation of its assets and the satisfaction of our liabilities in the normal course of
business :</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash (used) in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(11,451,248</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(12,605,824</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(20,035,837</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net cash (used) in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,500,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,722</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36,461</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash generated from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,669,380</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,216,292</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124,340</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net increase(decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,218,232</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,395,254</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,947,958</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash and cash equivalents at beginning of period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,638,885</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,773,783</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,806,799</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Exchange rate adjustments on cash held in foreign currencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(198,375</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,356</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">914,942</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash and cash equivalents at end of period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,158,642</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,638,885</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,773,783</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash used in operating activities was A$11,451,248, A$12,605,824
and A$20,035,837 during the years ended June 30, 2025, 2024 and 2023, respectively. Our payments to suppliers and employees during the
years ended June 30, 2025, 2024 and 2023 were A$17,459,061, A$21,393,136 and A$19,943,617, respectively. Our operating activity receipts
for the years ended June 30, 2025, 2024 and 2023 of A$5,629,577, A$8,583,477 and Nil consisted of R&amp;D tax incentive refunds. The A$3,934,075
decrease in payments to suppliers and employees for the year ended June 30, 2025 when compared to the year ended June 30, 2024 reflects
the decrease in activity during the year due to finalization of the Phase 2 study of ATH434. During the years ended June 30, 2025, 2024
and 2023, our payments to suppliers and employees was offset in part by interest received of A$446,291, A$269,075 and A$15,798 respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash used in investing activities was A$7,500,000, A$5,722 and
A$36,461 during the years ended June 30, 2025, 2024 and 2023, respectively. Cash flows used for investing activities was primarily attributable
to payments for term deposit in the year ended June 30, 2025 and purchase of property and equipment for the years ended June 30, 2024
and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash generated from financing&#160;activities
was A$39,669,380, A$9,216,292 and A$124,340 for the years ended June 30, 2025, 2024 and 2023. Cash generated from financing activities
in the year ended June 30, 2025, 2024 and 2023 related to proceeds from the issuance of shares amounting to A$42,570,645, A$10,144,682
and A$316,675 respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An unrealized foreign exchange loss of A$198,375 was incurred for the
year ended June 30, 2025, an unrealized foreign exchange gain of A$260,356 was incurred for the year ended June 30, 2024 and an unrealized
foreign exchange gain of A$914,942 was incurred for the year ended June 30, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_018"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>c.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Research and Development, Patents and Licenses</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In recent years, we have continued our practice
of building valuable research collaborations with institutes based in Australia, the United States and other countries to enable us to
investigate a variety of therapeutic indications including Alzheimer&#8217;s disease, Huntington disease, Parkinsonian movement disorders
and selected cancers. These collaborative arrangements ensure that we work with well-respected laboratories with specific expertise in
screening and animal modelling of relevance to the particular indication, without incurring ongoing administrative and personnel costs.
We maintain in-house patent counsel and research and development project expertise to coordinate these research collaborations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our research and development expenses consist primarily
of expenses for contracted research and development activities conducted by third parties on our behalf, including personnel, testing
facilities and other payments in accordance with our research and clinical agreements. Research and development expenses also include
costs associated with the acquisition and development of patents. Due to the numerous variables and the uncertain nature of the development
of a clinical compound, including obtaining regulatory approvals, we are not able to reasonably estimate the nature, timing and costs
of the future expenditures necessary to complete our research and development projects, the anticipated completion dates of each project
and when material net cash flows from our research and development programs will commence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When a product candidate is identified as suitable
for clinical development, we establish a project team to coordinate all non-clinical and clinical development and manufacturing activities.
Typically, we engage a clinical research organization to manage patient enrollment, data management, clinical site coordination and statistical
analysis, as is the case with the development of our lead compound ATH434 through Phase 1 and 2 development. We manage our manufacturing
campaigns through clinical manufacturing organisations for quality assurance and GMP compliance. All clinical, non-clinical, clinical
development and manufacturing of our compounds is performed in compliance with the appropriate governing authorities, regulators and standards
(for example, the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our technology does not currently require the licensing
of enabling technology licenses or freedom to operate licenses. Our product candidates are designed and synthesised by our employees and
the intellectual property of such product candidates is owned by us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><div><a id="a_019"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Trend Information</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a development stage company and while we
believe that our technology will offer novel therapeutic strategies into an expanding market, we cannot predict with any degree of accuracy
the outcome of our research or commercialisation efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have not commercialised any products to date.
Accordingly, any trends within the markets in which we operate are expected to have more direct impact on our business in the event that
we are successful in commercialising our product candidates, including ATH434 and new candidate products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will need substantial additional funding in
order to complete the development, testing and commercialisation of our product candidates. The commitment to these projects will require
additional external funding, at least until we are able to generate sufficient cash flow from sale of one or more of our products to support
our continued operations. If adequate funding is not available, we may be required to delay, scale back or eliminate certain aspects of
our operations or attempt to obtain funds through unfavorable arrangements with partners or others that may force us to relinquish rights
to certain of our technologies, products or potential markets or that could impose onerous financial or other terms. Management is continuing
its efforts to obtain additional funds so that we can meet our obligations and sustain operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48.95pt">&#160;</p><div>

</div><div><a id="a_020"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Critical Accounting Estimates</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Estimates and judgments are continually evaluated
and are based on historical experience and other factors, including expectations of future events that may have a financial impact on
the entity and that are believed to be reasonable under the circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We make estimates and assumptions concerning the
future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions
that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial
year are discussed below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Share-based Payments</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The value attributed to share options and remuneration
shares issued is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models
and the resultant option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options
to shares and the value and volatility of the price of the underlying shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Clinical Trial Accruals </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Clinical trial costs are charged to research and
development expense as incurred. We accrue for expenses resulting from contracts with CROs, investigators and consultants, and under certain
other agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which
vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided.
Our objective is to reflect the appropriate trial expense in the financial statements by matching the appropriate expenses with the period
in which services and efforts are expended. In the event advance payments are made to a CRO, the payments will be recorded as a prepaid
clinical trial expenses, which will be expensed as services are rendered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The CRO contracts generally include pass-through
fees including, but not limited to, regulatory expenses, investigator fees, travel costs and other miscellaneous costs, including shipping
and printing fees. We estimate our clinical accruals based on reports from and discussion with clinical personnel and outside services
providers as to the progress or state of completion of trials, or the services completed. We estimate accrued expenses as of each balance
sheet date based on the facts and circumstances known at that time. Our clinical trial accrual is dependent, in part, upon the receipt
of timely and accurate reporting from the CROs and other third-party vendors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>R&amp;D Tax Incentives</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Australian Government replaced the research
and development tax concession with the research and development tax incentive from July 1, 2011. The provisions provide refundable or
non-refundable tax offsets. The research and development tax incentive applies to expenditure incurred and the use of depreciating assets
in an income year commencing on or after July 1, 2011. A 43.5% refundable tax offset will be available to eligible small companies with
an annual aggregate turnover of less than $20 million. Management has assessed these activities and expenditures to determine which are
likely to be eligible under the incentive scheme. For the period to June 30, 2025 the Group has recorded an item in other income of A$3.9
million (2024: A$4.0 million, 2023: A$3.9 million) to recognize this amount which relates to this period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>ITEM 6. DIRECTORS,
SENIOR MANAGEMENT AND EMPLOYEES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(Start of the Remuneration Report for Australian Disclosure Requirements)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_022"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Directors and Senior Management</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our directors are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey P. Kempler</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David A. Stamler</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence B. Gozlan</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter A. Marks<sup>(1) (2)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian D. Meltzer<sup>(1)(2)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Outsourced Company Secretary and Chief Financial
Officer were as follows during the period:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 48%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip Hains <sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Secretary and Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abby Macnish Niven <sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Secretary and Chief Financial Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Member of the Audit Committee</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Member of the Remuneration Committee and Share Plan Committee</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip Hains resigned as CFO on 30 September 2024 and as Company Secretary on 17 November 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abby Macnish Niven was appointed as CFO on 30 September 2024 and as Company Secretary on 18 November 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Mr. Geoffrey Kempler</b> has served as Chairman
of our Board of Directors since November 1997; between November 1997 and August 2004 he served as our Chief Executive Officer and again
assumed the position of Chief Executive Officer from June 2005 until January 2021. Mr. Kempler is one of the founders of our company.
Mr. Kempler qualified as a psychologist with extensive experience in investment and business development. He served as a Chairman and
Non-Executive Director of Opthea Limited (NASDAQ:OPT), from November 2015 until October 2020, is immediate past Chairman of Ausbiotech,
Australia&#8217;s biotechnology organization, and is a member of the Industry Advisory Board at the Turner Institute of Brain and Mental
Health at Monash University, and Chair of Hexima Ltd. Mr. Kempler holds a B.Sc degree in science from Monash University, Grad. Dip. App.
Soc. Psych. degree from Swinburne University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Dr. David Stamler</b>, M.D. was appointed&#160;Chief
Executive Officer in January 2021 and previously served as our Chief Medical Officer and Senior Vice President, Clinical Development since
May 2017.&#160; Prior to joining Alterity, Dr. Stamler served as the Vice President, Clinical Development and Therapeutic Head for Movement
Disorders at Teva Pharmaceutical Industries from 2015 to 2017 after Teva acquired Auspex Pharmaceuticals.&#160;Dr Stamler was the Chief
Medical Officer of Auspex from January 2011 until 2015. Dr. Stamler received an M.D. from the University of Chicago&#8212;The Pritzker
School of Medicine and a B.A. in Biology from the University of Chicago.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Mr. Lawrence Gozlan</b> has served as a director
of our Group since August 2011. Mr. Gozlan, a leading biotechnology investor and advisor, is the Chief Investment Officer and Founder
of Scientia Capital, a specialised global investment fund focused exclusively in life sciences. Scientia Capital was founded to provide
high level expertise and to manage investments for high net worth individuals, family offices and institutional investors wanting exposure
to the biotechnology industry. Prior to this, Mr. Gozlan was responsible for the largest biotechnology investment portfolio in Australia
as the institutional biotechnology analyst at QIC (&#8220;the Queensland Investment Corporation&#8221;), an investment fund with over
A$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking Pty
Ltd and gained senior corporate finance experience advising life sciences companies at Deloitte. Mr. Gozlan is currently a Director of
Opthea Limited, (NASDAQ:OPT). He holds a Bachelor of Science with Honors in microbiology and immunology from the University of Melbourne.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Mr. Peter Marks </b>has served as a director
of our Group since July 2005. Peter has over 35 years&#8217; experience in corporate advisory and investment banking. Over the course of his
long career, he has specialised in capital raisings, IPOs, cross border, M&amp;A transactions, corporate underwriting and venture capital
transactions for companies in Australia, the United States and Israel. He has been involved in a broad range of transactions with a special
focus in the life sciences, biotechnology, medical technology and high tech segments. Mr. Marks served as a director on the Board of Elsight
Limited (ASX:ELS) between January 2020 and October 2021, on the Board of Nyrada Inc. (ASX:NYR) between January 2020 and August 2022, and
currently serves on the Board of Noxopharm Limited (ASX:NOX) (appointed in March 2016), Iris Metals Limited (ASX:IR1) (appointed in December
2020) and EverGreen Lithium Limited (ASX:EG1) (appointed in January 2022). Mr. Marks has a MBA, Bachelor of Economics, Bachelor of Law,
and Grad Dip in Commercial Law Experience and expertise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Mr. Brian Meltzer </b>has served as a director
of our Group since December 1999. Subsequent to several years as Chief Economist of ICI Australia (now Orica), Mr. Meltzer spent 25 years
in investment banking. His breadth of expertise includes major property transactions, corporate advisory, corporate finance, management
buyouts, venture capital and large-scale syndications. He has held a number of Board and Board Advisory roles for private companies in
the human resources, health and wellness, aged care, software, entertainment and finance sectors, including Director of a federal government
licensed Innovation Investment Fund. In 2015 he acquired a corporate health division of an American multinational then grew it five-fold
before selling it in 2021 to the subsidiary of a Canadian multinational. Mr. Meltzer is also a Director of the Australia-Israel Chamber
of Commerce and Chairman of Independence Australia, a social enterprise. <b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 32.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Ms Abby Macnish Niven</b> was appointed as Chief
Financial Officer for our Group in September 2024 and as Company Secretary in November 2024. Ms Macnish Niven&#160;is a Chartered Finance
Analyst and holds Bachelor of Commerce and Bachelor of Science degrees from the University of Western Australia. She has extensive experience
in private wealth management with groups including ANZ, UBS and Ord Minnett, and consults to a range of listed and unlisted companies
in governance, finance and corporate structure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 32.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no family relationships among our directors
and senior executives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>Directors&#8217; Interests</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The relevant interest of each director, as defined
by section 608 of the Corporations Act, in the share capital of the Group, as notified by the directors to the ASX in accordance with
section 205G(1) of the Corporations Act, at the date of this report is as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-indent: 24.5pt">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Director</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> ordinary<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> options over<br/> ordinary<br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Geoffrey Kempler</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,011,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">74,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Lawrence Gozlan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,545,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,515,152</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Peter Marks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,004,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,987,013</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Brian Meltzer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,742,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,138,528</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>Meeting of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The number of meetings our board of directors (including
committee meetings of directors) held during the year ended June 30, 2025 and the number of meetings attended by each director were:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-indent: 24.5pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Board Meetings</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Audit Committee<br/> Meetings</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Remuneration<br/> Committee Meetings</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Director</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">B</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">B</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">B</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Geoffrey Kempler</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Lawrence Gozlan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Peter Marks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Brian Meltzer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-indent: 24.5pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>A</i></span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>=</i></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Number of meetings held during the time the director held office or was a member of the committee.</i></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>B</i></span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>= </i></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Number of meetings attended</i></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#8212;</i></span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>= </i></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Not a member of the relevant committee</i></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.5pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt; text-indent: 24.5pt">&#160;</p><div>

</div><div><a id="a_023"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Compensation</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The remuneration report is set out under the following
main headings:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principles used to determine the nature and amount of remuneration</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details of remuneration</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based compensation</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key management personnel disclosure</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment contracts of Directors and other key management personnel</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-indent: -17.85pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles used to determine the nature and amount of remuneration</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b><i>Remuneration policy</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Remuneration of all Executive and Non-Executive
Directors, Officers and Employees of our Group is determined by the Board following recommendation by the Remuneration Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are committed to remunerating Senior Executives
and Executive Directors in a manner that is market- competitive and consistent with &#8220;Best Practice&#8221; including the interests
of Shareholders. Remuneration packages are based on fixed and variable components, determined by the Executives&#8217; position, experience
and performance, and may be satisfied via cash or equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with the approval of our shareholders
at our 2004 annual general meeting of shareholders, the aggregate amount available per annum for the remuneration of our non-executive
directors for their services (payable in cash, ordinary shares or options) is A$1,250,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; font-variant: small-caps; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-variant: small-caps; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-variant: small-caps">&#160;</td><td style="font-weight: bold; font-variant: small-caps; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-variant: small-caps; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-variant: small-caps">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Base fees</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Board &#8211; member (inclusive of Superannuation)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">70,000</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">70,000</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Board Chairman (exclusive of Superannuation)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">100,000</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">100,000</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b><i>Remuneration policy versus financial performance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Group&#8217;s remuneration policy is not entirely
based on our performance, but rather on industry practice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Group&#8217;s primary focus is research activities
with a long-term objective of developing and commercializing our research and development results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The tables below set out summary information about
our earnings and movement in shareholder wealth for the five years to June 30, 2025:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-variant: small-caps; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-variant: small-caps; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-variant: small-caps">&#160;</td><td style="font-weight: bold; font-variant: small-caps; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-variant: small-caps; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-variant: small-caps">&#160;</td><td style="font-weight: bold; font-variant: small-caps; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-variant: small-caps; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-variant: small-caps">&#160;</td><td style="font-weight: bold; font-variant: small-caps; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-variant: small-caps; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-variant: small-caps">&#160;</td><td style="font-weight: bold; font-variant: small-caps; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-variant: small-caps; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-variant: small-caps">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Interest income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">446,291</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">268,419</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,436</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,504</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20,676</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total comprehensive loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,147,828</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,123,464</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,806,515</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,847,061</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15,309,353</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No dividends have been paid for the five years
to June 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-variant: small-caps; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-variant: small-caps; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-variant: small-caps">&#160;</td><td style="font-weight: bold; font-variant: small-caps; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-variant: small-caps; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-variant: small-caps">&#160;</td><td style="font-weight: bold; font-variant: small-caps; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-variant: small-caps; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-variant: small-caps">&#160;</td><td style="font-weight: bold; font-variant: small-caps; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-variant: small-caps; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-variant: small-caps">&#160;</td><td style="font-weight: bold; font-variant: small-caps; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-variant: small-caps; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-variant: small-caps">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">ASX share price at start of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.03</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.03</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">ASX share price at end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Basic and diluted loss per share (cents)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.19</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.52</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.57</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.53</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.90</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that our performance in terms of earnings
will remain negative while we continue in the research and/or trial phase. Shareholder wealth reflects this speculative and volatile market
sector. This pattern is indicative of our performance over the past 5 years. Due to the stage of the Company, remuneration has remained
consistent over this period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b><i>Performance based remuneration</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The purpose of a performance bonus is to reward
individual performance in line with our Group&#8217;s objectives. Consequently, performance-based remuneration is paid to an individual
where the individual&#8217;s performance clearly contributes to a successful outcome for our Group. This is regularly measured in respect
of performance against key performance indicators (&#8220;KPI&#8217;s&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We use a variety of KPI&#8217;s to determine achievement,
depending on the role of the Executive being assessed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For details of remuneration refer to Employment
Contracts of Directors and Key Management Personnel below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Details of remuneration</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth all compensation
we paid for the year ended June 30, 2025 with respect to each of our directors and executive officers during the 2025 fiscal year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Short Term <br/>
Benefits</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Post- <br/>
Employment <br/>
Superannuation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Long Term<br/>
 Benefits <br/>
Long- <br/>
service</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Termination</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Base Fee</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Contribution</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leave</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Benefit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">2025</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Directors&#8217; remuneration</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 16%; text-align: left">Mr. Geoffrey Kempler&#160;(2)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">201,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">164,772</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">377,672</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Mr. Brian Meltzer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,780</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,220</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152,386</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Mr. Peter Marks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152,386</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Mr. Lawrence Gozlan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">70,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">137,310</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">207,310</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">404,180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">466,854</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">889,754</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other key management personnel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Dr. David Stamler (1)(3)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">858,898</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">259,472</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">335,274</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,453,644</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">858,898</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">259,472</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">335,274</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,453,644</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Base Fee includes movements in the annual leave provision
for Dr. David Stamler in accordance with his employment contract.</td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
$101,400 corporate advisory fees paid to an associate entity of Mr. Geoffrey Kempler for business advisory services including investor
relations, marketing and business development.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">Dr. David Stamler gets paid in US dollars.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth all compensation
we paid for the year ended June 30, 2024 with respect to each of our directors and executive officers during the 2024 fiscal year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Short Term<br/> Benefits</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Post-<br/> Employment<br/> Superannuation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Long Term<br/> Benefits<br/> Long-<br/> service</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Termination</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Base Fee</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Contribution</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Leave</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Benefit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">2024</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Directors&#8217; remuneration</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%; text-align: left; text-indent: -9pt; padding-left: 9pt">Mr. Geoffrey Kempler&#160;(2)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">269,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">280,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Mr. Brian Meltzer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,063</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,937</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Mr. Peter Marks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Mr. Lawrence Gozlan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">70,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">70,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">472,063</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,937</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">490,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other key management personnel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Dr. David Stamler (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">716,615</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166,063</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,232</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">552,622</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,422,068</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Ms. Kathryn Andrews (1)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">196,334</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,549</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,616</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(32,567</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">201,147</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">912,949</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">166,063</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,549</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,616</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">520,055</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,623,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,385,012</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">166,063</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,486</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,616</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">520,055</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,113,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Kathryn Andrews resigned 30 January 2024 and served out her notice period accordingly. The unvested FY21 equity options for Kathryn Andrews were forfeited due to cessation of employment.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="width: 97%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes $169,000 corporate advisory fees paid to an associate entity of Mr. Geoffrey Kempler for business advisory services including investor relations, marketing and business development.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">Dr. David Stamler gets paid in US dollars.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b><i>Performance income as a proportion of total remuneration</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All executives are eligible to receive incentives
as determined by the Board from time to time. Their performance payments are based on a set monetary value, set number of shares or options
or as a portion of base salary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Non-Executive Directors are not entitled to receive
bonuses and/or incentives. In the current year, the Directors have received equity as part of their total remuneration. Employees have
received equity as recommended by the Remuneration Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fixed remuneration</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">STI</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">LTI</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Directors</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mr. Geoffrey Kempler</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">56</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">100</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">-</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">-</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">44</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">-</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 28%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Mr. Brian Meltzer</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">46</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">54</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Mr. Peter Marks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Mr. Lawrence Gozlan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Other key management personnel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Dr. David Stamler</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Ms. Kathryn Andrews</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Long-term incentive (&#8220;LTI&#8221;) related
to remuneration were provided in the form of share-based payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Short-term incentives (&#8220;STI&#8221;) related
to remuneration were provided in the form of cash bonus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-based compensation</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have an Employee and Consultant Plan designed
to reward Executives, Employees and/or Consultants for their contributions. Due to our United States presence, a United States plan,
and an Australian plan were also developed. At June 30, 2025, equity had been issued to four (4) Directors, one (1) Key Management Personnel,
seven (7) employees and three (3) consultants&#160;under the 2004 ASX Plan and 2018 ADS Plan which is described on page 59.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The term and conditions of each grant of options
affecting Directors and Key Management Personnel remuneration in this reporting period are as follows:</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Grant date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date vested and<br/> exercisable</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Expiry date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise<br/> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Vested</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value per<br/> option at grant
    date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 21%">September 18, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: center">September 18, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 18%; text-align: center">September 17, 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.09</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center">Yes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.03</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>January 7, 2021</td><td>&#160;</td>
    <td style="text-align: center">January 6, 2023 onwards</td><td>&#160;</td>
    <td style="text-align: center">January 6, 2026</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Partially</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>July 31, 2021</td><td>&#160;</td>
    <td style="text-align: center">July 31, 2021</td><td>&#160;</td>
    <td style="text-align: center">July 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Yes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap">November 29, 2021</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: center">November 29, 2022 onwards</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: center">November 29, 2026</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">$</td><td style="white-space: nowrap; text-align: right">0.02</td><td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: center">Partially</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">$</td><td style="white-space: nowrap; text-align: right">0.02</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>November 29, 2021</td><td>&#160;</td>
    <td style="text-align: center">November 29, 2022 onwards</td><td>&#160;</td>
    <td style="text-align: center">November 29, 2026</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Partially</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.02</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 21, 2023</td><td>&#160;</td>
    <td style="text-align: center">December 21, 2023</td><td>&#160;</td>
    <td style="text-align: center">December 19, 2026</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Yes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.005</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>March 13, 2024</td><td>&#160;</td>
    <td style="text-align: center">March 13, 2024 onwards</td><td>&#160;</td>
    <td style="text-align: center">March 13, 2029</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Partially</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>March 13, 2024</td><td>&#160;</td>
    <td style="text-align: center">March 13, 2024 onwards</td><td>&#160;</td>
    <td style="text-align: center">March 13, 2029</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.005</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Partially</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>March 21, 2024</td><td>&#160;</td>
    <td style="text-align: center">March 21, 2024 onwards</td><td>&#160;</td>
    <td style="text-align: center">March 21, 2029</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.003</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Partially</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 30, 2024*</td><td>&#160;</td>
    <td style="text-align: center">December 30, 2024</td><td>&#160;</td>
    <td style="text-align: center">December 30, 2027</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Yes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.003</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Options granted under the plan carry no dividend
or voting rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When exercisable, each option is convertible into
one ordinary share as soon as practical after the receipt by us of the completed exercise form and full payment of such exercise price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The exercise price of options will be equal to
or less than the weighted average price at which our shares are traded on the Australian Securities Exchange during the 5 days up to and
including the grant date or such other exercise price that the Remuneration Committee determines to be appropriate under the circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The plan rules contain a restriction on removing
the &#8216;at risk&#8217; aspect of the instruments granted to executives. Plan participants may not enter any transaction designed to
remove the &#8216;at risk&#8217; aspect of an instrument before it vests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">*</td><td style="text-align: left">As of June 30, 2025, 170,000,000 options over ordinary shares
were issued to the directors during the current financial year, separate to the 2004 ASX Plan, following approval of the resolutions
to issue same at the AGM in November 2024. The value per option in the table above is at 30 September 2024, as approved by the shareholders
at the AGM in November 2024. There were no options over ordinary shares issued as remuneration to any other key management personnel
of our Group during the current financial year (2024: 120,000,000).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No ordinary shares were issued as a result of exercise
of remuneration options by Directors and Key Management Personnel of Alterity Therapeutics Limited during the current or previous financial
year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key management personnel disclosure</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b><i>Options and right holdings</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The number of options over ordinary shares of our
Group held during the financial year by each Director of Alterity Therapeutics Limited and other Key Management Personnel of our Group,
including their personally related parties, are set out below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Share Options of the Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance <br/> July 1, <br/> 2024 <br/> No.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Granted as<br/> Remuneration <br/> No.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options<br/> Expired <br/> No.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other<br/> movements (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance <br/> June 30,<br/> 2025 <br/> No.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> Vested and<br/> Exercisable <br/> June 30,<br/> 2025 <br/> No.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> Unvested <br/> June 30,<br/> 2025<br/> No.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: left; text-indent: -9pt; padding-left: 9pt">Mr. Geoffrey Kempler</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">14,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">60,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">74,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">74,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Mr. Lawrence Gozlan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,515,152</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,515,152</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,515,152</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Mr. Brian Meltzer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,523,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,142,857</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">757,576</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,138,528</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,138,528</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Mr. Peter Marks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,523,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,142,857</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">606,061</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,987,013</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,987,013</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Dr. David Stamler</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">220,916,529</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,142,857</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,515,152</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">215,288,824</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">161,960,719</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,328,105</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">274,964,147</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">170,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,428,571</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,393,941</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">427,929,517</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">374,601,412</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">53,328,105</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All vested options are exercisable at the end of
the year and there were 53,328,105 options unvested as of June 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Other movements include options acquired through participation
in the placement.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; padding-left: 0in; text-indent: 0in; font-weight: bold">Share Options of<br/>
 the Group</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance <br/> July 1, <br/> 2023<br/> No.</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Granted as<br/> Remuneration <br/> No.</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options<br/> Expired <br/> No.</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other<br/> movements (2)</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance <br/> June 30,<br/> 2024 <br/> No.</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> Vested and<br/> Exercisable <br/> June 30,<br/> 2024 <br/> No.</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> Unvested <br/> June 30,<br/> 2024<br/> No.</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Mr. Geoffrey Kempler</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">14,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">14,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">14,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Mr. Lawrence Gozlan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Mr. Brian Meltzer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,523,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,523,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,523,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Mr. Peter Marks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,523,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,523,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,523,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Ms. Kathryn Andrews (1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,000,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Dr. David Stamler</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">91,392,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,523,809</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">220,916,529</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">104,740,244</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">116,176,285</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">131,392,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,571,427</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">274,964,147</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">158,787,862</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">116,176,285</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All vested options are exercisable at the end of
the year and there were 116,176,285 options unvested as of June 30, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options held by Kathryn Andrews were forfeited upon resignation on 30 January, 2024.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Other movements include options acquired through participation
in the placement.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b><i>Shares provided on exercise of remuneration options</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No ordinary shares were issued to key management
personnel as a result of the exercise of remuneration options during the financial year ended June 30, 2025 and June 30, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b><i>Shareholdings</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The number of our ordinary shares held during the
financial year by each Director of our Group and other Key Management Personnel other than for remuneration, including their personally
related parties, are set out below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Fully Paid Ordinary Shares of the Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance<br/> July 1,<br/> 2024<br/> No.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Received as<br/> Remuneration<br/> No.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Received on<br/> Exercise of<br/> Options<br/> No.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net Change<br/> Other<br/> No. (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance<br/> June 30,<br/> 2025<br/> No.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Mr. Geoffrey Kempler</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,011,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,011,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Mr. Lawrence Gozlan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,545,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,545,455</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mr. Brian Meltzer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,469,523</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,272,727</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,742,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Mr. Peter Marks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,185,968</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,818,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,004,150</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Dr. David Stamler</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,697,857</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,545,455</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,243,312</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,364,348</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,181,819</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">56,546,167</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Net Change Other; include shares acquired through participation
in the placement.</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Fully Paid Ordinary Shares of the Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance<br/> July 1,<br/> 2023<br/> No.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Received as<br/> Remuneration<br/> No.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Received on<br/> Exercise of Options<br/> No.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net Change<br/> Other<br/> No. (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance<br/> June 30,<br/> 2024<br/> No.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Mr. Geoffrey Kempler</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,011,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,011,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Mr. Lawrence Gozlan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mr. Brian Meltzer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">326,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,142,857</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,469,523</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Mr. Peter Marks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,142,857</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,185,968</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ms. Kathryn Andrews</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Dr. David Stamler</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,555,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,142,857</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,697,857</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,935,777</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,428,571</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,364,348</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Change Other; include shares acquired through participation in the placement.</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b><i>Loans to key management personnel</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">There were no loans made to the Directors or other Key Management
Personnel, including their personally related parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment contracts of Directors and other key management personnel</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following Directors and Key Management Personnel
were under contract at June 30, 2025:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 20%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key management personnel</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Duration</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notice Requirements</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 31%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Termination</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Stamler</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until termination by either party. Signed 6 January 2021.</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each party will be required to provide 6 months&#8217; notice of termination unless otherwise agreed to in writing. </span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued entitlements including all unreimbursed business expenses</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vested but unexercised options shall be exercisable within 30 days
    after the date of termination &#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unvested options will terminate automatically without further notice</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For Good Reason, Dr. Stamler may terminate at any time upon written notice, with 6 months&#8217; notice.</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of accrued salary, accrued but unused vacation pay and approved
    but unreimbursed expenses that are owed to date of termination &#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment equivalent to 100% of current annualized salary &#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vested but unexercised options shall be exercisable within 30 days
    after the date of termination</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unvested options will terminate automatically without further
    notice</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With Cause, the Group may terminate at any time upon written notice</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment limited to accrued salary, accrued but unused vacation pay and approved but unreimbursed expenses that are owed to date of termination. &#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;All options shall be canceled upon date of termination</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.5pt; text-indent: -10.5pt"><b><i>(End of Remuneration Report)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_024"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Board Practices</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Introduction</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors is elected by and accountable
to our shareholders. Our Board of Directors&#8217; responsibilities are divided into operating activities, financial and capital markets
activities and scientific activities. The Chairman of our Board of Directors, currently Mr. Geoffrey Kempler, is responsible for the management
of the Board of Directors and its functions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Election of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Directors are elected at our annual general meeting
of shareholders. Under our Constitution, the term of office of our directors are staggered, such that at every annual general meeting
of shareholders one-third, rounded down to the nearest whole number, of the directors, except a Managing Director, must retire from office
and may offer himself/herself for re-election. No director, except a Managing Director, shall retain office for a period in excess of
three years without submitting for re-election. Our Board of Directors has the power to appoint any person to be a director, either to
fill a vacancy or as an additional director (provided that the total number of directors does not exceed the maximum allowed by law),
and any director so appointed may hold office only until the next annual general meeting when he or she shall be eligible for election.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Non-Executive and Independent Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Australian law does not require a company to appoint
a certain number of independent directors to its board of directors or audit committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the rules of the NASDAQ Stock Market, a majority
of our Board of Directors must qualify as independent directors within the meaning of the rules of the NASDAQ Stock Market, each of whom
satisfies the respective &#8220;independence&#8221; requirements of the NASDAQ Stock Market Rules and the Securities and Exchange Commission.
Our Board of Directors has determined that each of Messrs. Peter Marks and Brian Meltzer qualifies as an independent director under the
NASDAQ Stock Market and the Securities and Exchange Commission. As a foreign private issuer whose shares are listed on The NASDAQ Capital
Market, we are permitted to follow certain home country corporate governance practices instead of certain requirements of the NASDAQ Stock
Market Rules. This includes NASDAQ rule 5605(b)(1) requiring a majority of independent directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Committees of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors has established the following
committees:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Audit Committee</i>.</b> The NASDAQ Stock
Market rules require us to establish an audit committee comprised of at least three members, each of whom is financially literate and
satisfies the respective &#8220;independence&#8221; requirements of the Securities and Exchange Commission and NASDAQ and one of whom
has accounting or related financial management expertise at senior levels within a company. As a foreign private issuer whose shares are
listed on the NASDAQ Capital Market, we are permitted to follow certain home country corporate governance practices instead of certain
requirements of the NASDAQ Stock Market Rules. This includes the Rule related to Audit Committee Composition rule 5605(c)(2)(A)): we may
have an audit committee composed of two members instead of &#8220;at least three members&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Audit Committee assists our Board of Directors
in overseeing the accounting and financial reporting processes of our company and audits of our financial statements, including the integrity
of our financial statements, compliance with legal and regulatory requirements, our independent public accountants&#8217; qualifications
and independence, the performance of our internal audit function and independent public accountants, and such other duties as may be directed
by our Board of Directors. The Audit Committee is also required to assess risk management. The audit committee meets at least four times
per year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Audit Committee currently consists of two board
members, each of whom satisfies the &#8220;independence&#8221; requirements of the Securities and Exchange Commission and the NASDAQ Market
Rules. Our Audit Committee is currently composed of Messrs. Marks and Meltzer. Our Board of Directors has determined that Mr. Meltzer
meets the definition of an audit committee financial expert, as defined by rules of the Securities and Exchange Commission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Remuneration Committee</i></b><i>. </i>Our
Board of Directors has established a Remuneration Committee, which is comprised solely of independent directors, within the meaning of
the NASDAQ Stock Market Rules. The Remuneration Committee is responsible for reviewing the salary, incentives and other benefits of our
executive officers and to make recommendations on such matters for approval by our Board of Directors. The Remuneration Committee is also
responsible for overseeing and advising our Board of Directors with regard to the adoption of policies that govern our compensation programs,
including share and ADS option and employee benefit plans. Additionally, the Remuneration Committee administers our share and ADS option
plans and any other employee benefit plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Directors&#8217; Service Contracts</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no arrangements or understandings between
us and any of our subsidiaries, on the one hand, and any of our directors, on the other hand, providing for benefits upon termination
of their employment or service as directors of our company or any of our subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Indemnification of Directors and Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Constitution provides that, subject to the
Australian Corporations Act, every director, secretary, manager or officer of our company or any person employed by our company as auditor
shall be indemnified out of our funds against all liability incurred by such person as a director or officer in defending proceedings,
whether civil or criminal, in which judgment is given in the persons favor or in which the person is acquitted in connection with any
application under the Australian Corporations Act in which relief is granted to the person by a Court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under our Constitution no director, auditor or
other officer shall be liable for (i) any acts, receipts, neglect or defaults of any other director or officer for joining in any receipt
or other act for conformity; (ii) any loss or expense that may happen to us through the inefficiency or deficiency of title to any property
acquired by order of the directors or on our behalf; (iii) the inefficiency or deficiency of any security in or upon which any of our
monies shall be invested; (iv) any loss or damage arising from bankruptcy, insolvency or tortuous act of any person with whom any monies,
securities or effects shall be deposited; (v) any loss occasioned by any error of judgment, omission, default or oversight on the persons
part; or (vi) any other loss damage or misfortune whatsoever which shall happen in relation to those things unless the same shall happen
through the persons own negligence, default, breach or duty, breach of trust or dishonesty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, our Constitution provides that to
the extent permitted by law, we may pay, or agree to pay, a premium in respect of a contract insuring a person who is or has been an officer
of our company or one of our subsidiaries against a liability:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incurred by the person in his or her capacity as an officer of our company or a subsidiary of our company provided that the liability does not arise out of a conduct involving a willful breach of duty in relation to our company or a subsidiary of our company; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for costs and expenses incurred by that person defending proceedings, whatever their outcome.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We maintain a directors&#8217; and officers&#8217;
liability insurance policy. We have established a policy for the indemnification of our directors and officers against certain liabilities
incurred as a director or officer, including costs and expenses associated in successfully defending legal proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_025"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Employees</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; ">We consider our employees
the most valuable asset of our company. We offer competitive compensation and comprehensive benefits to attract and retain our employees.
We believe that an engaged workforce is key to maintaining our ability to innovate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">As of June 30, 2025, we had 9 employees. Of such
employees, seven persons are employed in research and development and two persons in management and administration. Five employees are
located in Australia and four employees are located in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">As of June 30, 2024, we had 10 employees. Of
such employees, eight persons are employed in research and development and two persons in management and administration. Seven employees
are located in Australia and three employees are located in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">As of June 30, 2023, we had 11 employees. Of
such employees, eight persons are employed in research and development and three persons in management and administration. Seven employees
are located in Australia and four employees are located in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Australian and US labor laws and regulations apply
to our employees accordingly. The laws concern various matters, including severance pay rights at termination, retirement or death, length
of work day and work week, minimum wage, overtime payments and insurance for work-related accidents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_026"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Share Ownership</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Beneficial Ownership of Executive Officers and Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth certain information
as of August 22, 2025 regarding the beneficial ownership of our ordinary shares by each of our directors and executive officers and by
all our directors and executive officers as a group:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Ordinary<br/> Shares<br/> Beneficially<br/> Owned&#160;<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage of<br/> Ownership&#160;<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey P. Kempler <sup>(3)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">92,011,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.95</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David A. Stamler <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">353,915,757</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.65</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence B. Gozlan <sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,545,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.63</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter A. Marks <sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,004,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.47</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian D. Meltzer <sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,742,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.48</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">All directors and executive officers as a group (5 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">600,218,612</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.19</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission, and generally includes voting or investment power with respect to securities. Ordinary shares relating to options currently exercisable or exercisable within 60 days of the date of the above table are deemed outstanding for computing the percentage of the person holding such securities but are not deemed outstanding for computing the percentage of any other person. Except as indicated by footnote, and subject to community property laws where applicable, the persons named in the table above have sole voting and investment power with respect to all shares shown as beneficially owned by them.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The percentages shown are based on 9,693,247,308 consisting of 9,208,749,666 ordinary shares and 484,497,642 unlisted options, issued and outstanding as of August 22, 2025.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 14,000,000 ordinary shares that are exercisable for A$0.09 each on or before September 17, 2025, and options to purchase 60,000,000 ordinary shares that are exercisable for A$0.01 each on or before December 30, 2027. Of the 18,011,000 outstanding ordinary shares, 30,000 ordinary shares are held of record by Mr. Kempler, 14,165,000 ordinary shares are held by Baywick Pty Ltd., an Australian corporation owned by Mr. Kempler, 756,000 ordinary shares are held by Sadarajak Pty Ltd., an Australian corporation owned by Mr. Kempler, 90,000 ordinary shares are held of record by Crystal Triangle Pty Ltd., an Australian corporation owned by Mr. Kempler and 2,970,000 ordinary shares are held of record by NRB Developments Pty Ltd., an Australian corporation in which Mr. Kempler holds a 50% interest. Mr. Kempler may be deemed to be the beneficial owner of the ordinary shares held of record by Baywick Pty Ltd., Crystal Triangle Pty Ltd. and NRB Developments Pty Ltd. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes vested options to purchase 81,872,645 ordinary shares that are exercisable for A$0.03 each on or before January 6, 2026, vested options to purchase 200 ordinary shares that are exercisable for US$0.003 each on or before March 21, 2029 and vested options granted in August 2025 to purchase 96,800,000 ordinary shares that are exercisable for US$0.0086 each on or before August 8, 2030.&#160;Also includes 139,258 ADSs representing 83,554,800 ordinary shares. Includes 4,545,455 ordinary shares issued as part of the placements during the 2025 year. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 7,000,000 ordinary shares that are exercisable for A$0.09 each on or before September 17, 2025 and options to purchase 50,000,000 ordinary shares that are exercisable for A$0.01 each on or before December 30, 2027. All options are held by Montoya Pty Ltd, an Australian corporation owned by Mr. Gozlan, The 4,545,455 outstanding ordinary shares are held of record by Montoya Pty Ltd. Includes 4,545,455 shares issued as part of the placements during the 2025 year, as well as 50,000,000 options separately granted by resolution at the AGM.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 7,000,000 ordinary shares that are exercisable for A$0.09 each on or before September 17, 2025 and options to purchase 30,000,000 ordinary shares that are exercisable for A$0.01 each on or before December 30, 2027. Of the 9,004,150 outstanding ordinary shares, 7,185,968 ordinary shares are held of record by Lampam Pty Ltd., an Australian corporation owned by Mr. Peter Marks, and 1,818,182 ordinary shares are held of record by Shanti Capital Pty Ltd &lt;Peter Marks Super Fund A/C&gt;. Includes 1,818,182 shares issued as part of the placements during the 2025 year, as well as 30,000,000 options separately granted by resolution at the AGM. &#160;&#160;&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes options to purchase 7,000,000 ordinary shares that are exercisable for A$0.09 each on or before September 17, 2025 andoptions to purchase 30,000,000 ordinary shares that are exercisable for A$0.01 each on or before December 30, 2027. Of the 9,742,250 outstanding ordinary shares, 326,666 ordinary shares are held of record by BT Panorama Investment, a superannuation fund of Mr. Meltzer, and 9,415,584 are held of record by Mr. Meltzer. Includes 2,272,727 shares issued as part of the placements during the 2025 year, as well as 30,000,000 options separately granted by resolution at the AGM.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock Option Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In November 2004, we adopted the 2004 Employees&#8217;,
Directors&#8217; and Consultants&#8217; Share and Option Plan, or the 2004 ASX Plan, and the 2004 American Depository Share (ADS) Option
Plan, or the 2004 ADS Plan. In November 2018, we adopted an updated ADS plan with substantially the same terms as the 2004 ADS Plan for
a new ten-year term. For the description below, the 2004 ASX Plan and 2018 ADS Plan are referred to together as the Stock Option Plans.
Under the 2004 ASX Plan we may issue ordinary shares and under the 2018 ADS Plan we may issue ADSs. We were initially authorized to issue
under the Stock Option Plans up to an aggregate 12,000,000 ordinary shares or ADSs representing 12,000,000 ordinary shares. Pursuant to
subsequent shareholder approvals, the most recent of which was in November 2024, we are entitled to issue up to an aggregate 450,000,000
ordinary shares (or ADSs representing 240,000,000 ordinary shares) under the Stock Option Plans. Any increase in such maximum number of
ordinary shares or ADSs issuable under the Stock Option Plans is subject to shareholder approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>2004 ASX Plan.</i></b> The purpose of the
2004 ASX Plan is to promote the interest of our company and the interest of the employees, directors and consultants of our company and
its subsidiaries. Under the 2004 ASX Plan, we may issue to employees, directors and consultants of our company and its subsidiaries, from
time to time, ordinary shares, either by issuance of ordinary shares or under options to purchase ordinary shares granted under the 2004
ASX Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The 2004 ASX Plan is administered by the Share
Plan Committee, a sub-committee of the Remuneration Committee. For the purpose of the disclosure below, the term &#8220;Remuneration Committee&#8221;
shall refer to the Remuneration Committee or Share Plan Committee, as applicable. Subject to Board approval where required by applicable
law, the Remuneration Committee has the authority, in its sole discretion, to grant options under the 2004 ASX Plan, to interpret the
provisions of the 2004 ASX Plan and to prescribe, amend, and rescind rules and regulations relating to the 2004 ASX Plan or any issue
or grant thereunder as it may deem necessary or advisable, subject to any other approval if required by applicable law. All decisions
made by the Remuneration Committee pursuant to the provisions of the 2004 ASX Plan will be final, conclusive and binding on all persons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The number of shares issued or options granted,
the exercise price and option term or options granted, the vesting schedule and escrow periods of shares issued and options granted, under
the 2004 ASX Plan are determined by the Remuneration Committee, in accordance with the provisions of the ASX Plan, and specified in an
offer document from our company and accepted by the eligible person, subject to the terms of the 2004 ASX Plan. Options granted under
the 2004 ASX Plan will be unlisted and exercisable at an exercise price equal to less than market value of an ordinary share on the ASX
at the date of grant, or such other exercise price that the Remuneration Committee determines to be appropriate under the circumstances.
The term of an option granted under the 2004 ASX Plan will be determined by the Remuneration Committee; however, no option will be exercisable
after the expiration of ten years from the date of its grant. Except as otherwise provided in the 2004 ASX Plan or determined by the Remuneration
Committee and set forth in an offer document, the issuance of shares and exercise of options granted under the 2004 ASX Plan will either
(i) be subject to an escrow, under which such shares or options cannot be disposed of or exercised, respectively, within six months from
the date of issue or grant (or 12 months if issued or granted to a director); or (ii) will vest over a four year period in four equal
installments, 25% at the end of each year from the date of grant. Shares issued and options granted under the 2004 ASX Plan may be subject
to other performance criteria and hurdles, as determined by the Remuneration Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>2018 ADS Plan. </i></b>The purpose of the
2018 ADS Plan is to promote the interests of our company and non-Australian based employees, officers, consultants, independent contractors
and directors. Options granted under the 2018 ADS Plan may be incentive stock options, as provided in Section 422 of the Internal Revenue
Code of 1986, as amended, or the Code, or non-qualified stock options. Incentive stock options may only be granted to employees of our
company and its subsidiaries (including, without limitation, officers and directors who are also employees of our company and its subsidiaries)
and may not be granted to any owner of 10% or more of the total combined voting power of all classes of stock of our company and subsidiaries,
or a 10% Holder. To the extent that the aggregate fair market value, determined on the date that an option is granted, of ADSs, with respect
to which incentive stock options are exercisable for the first time by an optionee during any calendar year exceeds U.S.$100,000, such
option shall be treated as a non-qualified stock option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the 2018 ADS Plan, we may grant to employees,
officers, consultants, independent contractors and directors of our company or any of its subsidiaries, from time to time, options to
purchase ADSs representing our ordinary shares. ADSs that are forfeited under the terms of the 2018 ADS Plan and ADSs that are the subject
to options that expire unexercised or which are otherwise surrendered by an optionee without receiving any payment or other benefit with
respect to such option may again become available for new option grants under the 2018 ADS Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The 2018 ADS Plan is administered by our Share
Plan Committee. Subject to Board approval where required by applicable law, the Remuneration Committee has authority, in its sole discretion,
to grant options under the 2018 ADS Plan, to interpret the provisions of the 2018 ADS Plan and to prescribe, amend, and rescind rules
and regulations relating to the 2018 ADS Plan or any options granted thereunder as it may deem necessary or advisable, subject to any
other approval if required by applicable law. All decisions made by the Remuneration Committee pursuant to the provisions of the 2018
ADS Plan shall be final, conclusive and binding on all persons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The type of option (incentive stock option or non-qualified
stock option), exercise price, option term and vesting schedule of options granted under the 2018 ADS Plan are determined by the Remuneration
Committee, in accordance with the provisions of the ADS Plan, and specified in an option agreement by and between our company and the
optionee, subject to the terms of the 2018 ADS Plan. The exercise price per each ADS will be determined by the Remuneration Committee
at the time any option is granted, however the exercise price of an incentive stock option will not be less than 100% of the fair market
value of such ADS on the date of the grant and the price of an incentive stock option granted to a 10% Holder will not be less than 110%
of the fair market value of such ADS on the date of the grant. Options granted under the 2018 ADS Plan will not be exercisable after the
expiration of ten years from the date of grant, and in the case of an incentive stock option granted to a 10% Holder, the term of the
option will be five years from the date of grant or such shorter term as may be provided in the option agreement. The options will vest
over a four-year period in four equal installments, 25% at the end of each year from the date of grant, unless otherwise provided by the
Remuneration Committee in an option agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Options granted under the 2018 ADS Plan are not
assignable or transferable by the grantee, other than by will or the laws of descent and distribution, and may be exercised during the
lifetime of the grantee only by the grantee or his guardian or legal representative.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A summary of the status of the Stock Option Plans
as of June 30, 2025, 2024 and 2023, and changes during the years ended on those dates, is presented below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> average<br/> exercise<br/> price <br/> (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> average<br/> exercise<br/> price <br/> (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> average<br/> exercise<br/> price<br/> (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Options outstanding at the beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">381,542,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.05</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">170,042,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.05</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">184,692,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.05</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">217,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,333,333</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Expired/forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,650,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,500,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,150,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Lapsed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,000,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,500,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,500,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.02</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Options outstanding at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">358,559,387</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.02</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">381,542,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.02</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,042,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.05</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Options exercisable at the end of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">275,689,612</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">195,708,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87,280,755</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.06</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Australian Disclosure Requirements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Indemnifying directors and officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the financial year, we maintained an insurance
policy to indemnify all current Directors and Officers against certain liabilities incurred as a Director or Officer, including costs
and expenses associated in successfully defending legal proceedings. The contract of insurance prohibits disclosure of the nature of the
liability and the amount of the premium. We have not otherwise, during or since the financial year, indemnified or agreed to indemnify
an Officer or Auditor of our Group or any related body corporate against a liability incurred as such an Officer or Auditor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Share options on issue during or since the end of the financial
year</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During or since the end of the financial year the
unissued ordinary shares of Alterity Therapeutics Limited under options were as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; white-space: nowrap; font-weight: bold; vertical-align: bottom">Date of expiry</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; text-align: center; font-weight: bold">Exercise <br/>
price <br/>
(A$)</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; text-align: center; font-weight: bold">Number <br/>
under<br/>
 options</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">September 17, 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.09</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">35,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>January 6, 2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,392,720</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>November 29, 2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>November 29, 2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.02</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>December 19, 2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>August 31, 2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">931,232,089</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>February 26, 2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.028</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,222,300,911</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>December 30, 2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>March 13, 2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,166,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>March 13, 2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.005</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>March 21, 2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.003</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000,200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>July 1, 2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>August 8, 2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.013</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">August 8, 2030</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.013</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">312,400,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,940,992,787</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Shares issued as a result of the exercise of options</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the year ended June 30, 2025, 6,428,732
of our ordinary shares were issued as a result of the exercise of options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since June 30, 2025, 79,999,800 ordinary shares
were issued as a result of the exercise of options by Dr. David Stamler, and a further 1,379,180 ordinary shares were issued as a result
of the exercise of options by other holders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no amounts unpaid on the shares issued
as a result of the exercise of the options during and since the end of the current financial year. The amount paid per share is the same
as the exercise price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Proceedings on behalf of our Group</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No proceedings have been brought or intervened
in on behalf of our Group with leave of the Court under section 237 of the <i>Corporations Act 2001.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Non-audit services</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may decide to employ the auditor on assignments
additional to their statutory audit duties where the auditor&#8217;s expertise and experience with our Group are important, subject to
the limitations imposed by the Sarbanes Oxley Act of 2002.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Auditor&#8217;s independence declaration</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A copy of the auditor&#8217;s independence declaration
as required under section 307C of the Corporations Act 2001 in relation to the audit for the year ended June 30, 2025 is included in Exhibit
15.2&#160;of this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Corporate governance statement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with ASX listing Rule 4.10.3, the
Group&#8217;s 2025 Corporate Governance Statements can be found on its website at www.alteritytherapeutics.com.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Signed in accordance with a resolution of the Directors
made pursuant to s298(2) of the Corporations Act 2001.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 40%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Geoffrey Kempler</span></td>
    <td style="width: 60%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey Kempler</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman </span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melbourne</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 29, 2025</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_075"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Disclosure of a Registrant&#8217;s Action to Recover Erroneously Awarded Compensation.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>ITEM 7.</b></span><b> MAJOR
SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_028"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Major Shareholders</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no shareholders known to us who own beneficially
more than 5% of our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Significant Changes in the Ownership of Major Shareholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">JPMorgan Chase &amp; Co. reported on Schedule 13G
filed on May 2, 2025, that it was the beneficial owner of 429,671,484 Ordinary Shares, representing approximately 6.3% of our outstanding
Ordinary Shares. On May 5, 2025, JPMorgan Chase &amp; Co. reported that it was the beneficial owner of 366,034,937 Ordinary Shares, representing
approximately 4.0% of our outstanding Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Major Shareholders Voting Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A major shareholder would not have different voting
rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Record Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of August 22, 2025, there were 5,851 holders
of record of our ordinary shares, of which 24 record holders, holding approximately 35.33% of our ordinary shares, had registered addresses
in the United States. These numbers are not representative of the number of beneficial holders of our shares nor are they representative
of where such beneficial holders reside, since many of these ordinary shares were held of record by brokers or other nominees. The majority
of trading by our U.S. investors is done by means of ADSs that are held of record by HSBC Custody Nominees Ltd., which held 35.1% of our
ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_029"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Related Party Transactions</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Several of the Directors participated in the placement
in April 2025. These placement shares were at arm&#8217;s length and purchased for cash. There were no other related party transactions
other than those related to Director and Key Management Personnel remuneration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_030"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Interests of Experts and Counsel</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.<span style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>ITEM 8.</b></span><b> FINANCIAL
INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_032"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Financial Statements and Other Financial Information</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See our consolidated financial statements, including
the notes thereto, in Item 18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are not involved in any legal proceedings nor
are we subject to any threatened litigation that is material to our business or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dividend Distribution Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have never paid cash dividends to our shareholders.
We intend to retain future earnings for use in our business and do not anticipate paying cash dividends on our ordinary shares in the
foreseeable future. Any future dividend policy will be determined by the Board of Directors and will be based upon various factors, including
our results of operations, financial condition, current and anticipated cash needs, future prospects, contractual restrictions and other
factors as the Board of Directors may deem relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_033"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Significant Changes</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_074"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>ITEM 9.</b></span><b> THE
OFFER AND LISTING</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_034"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Offer and Listing Details</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Australian Securities Exchange</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our ordinary shares have traded on the ASX since
our initial public offering on March 29, 2000 under the symbol &#8220;PBT&#8221;. On April 8, 2019 we changed our name to Alterity Therapeutics
Limited and our shares have traded under the symbol &#8220;ATH&#8221; since that date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NASDAQ Capital Market</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 5, 2002 our ADSs began trading on
the NASDAQ Capital Market under the symbol &#8220;PRAN.&#8221; On April 8, 2019 we changed our name to Alterity Therapeutics Limited and
our ADSs have traded under the symbol &#8220;ATHE&#8221; since that date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_035"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Plan of Distribution</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_036"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Markets</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The principal listing of our ordinary shares and
listed options to purchase ordinary shares is on the ASX. As of April 5, 2002, our ADSs were eligible to trade on the NASDAQ Capital OTC
Bulletin Board in the United States and until September 5, 2002, our ADSs traded on the NASDAQ Capital Market under the symbol &#8220;PRAN.&#8221;
On April 8, 2019 we changed our name to Alterity Therapeutics Limited and our ADSs have traded under the symbol &#8220;ATHE&#8221; since
that date. We entered into a Deposit Agreement with the Bank of New York under which the Bank of New York, acting as depositary, issues
ADRs. Prior to March 24, 2016, each ADR represented ten of our ordinary shares. On March 24, 2016, we effected a ratio change so that
each ADS represented 60 ordinary shares (representing a 6-for-1 reverse split). On January 9, 2023, we effected a ratio change so that
each ADS now represents 600 ordinary shares (representing a 10-for-1 reverse split).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_037"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Selling Shareholders</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_038"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Dilution</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_039"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Expenses of the Issue</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&#160;</p><div>

</div><div><a id="a_040"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>ITEM 10.</b></span><b> ADDITIONAL
INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_041"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Share Capital</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_042"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Memorandum and Articles of Association</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were registered on November 11, 1997 as Prana
Pty Ltd and on November 26, 1999 we converted to a public company and changed our name to Prana Corporation Ltd. On January 1, 2000, we
changed our name to Prana Biotechnology Limited. On April 8, 2019 we changed our name to Alterity Therapeutics Limited. Our registration
number is ACN 080699065.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Alterity&#8217;s Purposes and Objects</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a public company we have all the rights, powers
and privileges of a natural person. Our Constitution does not specify any purposes or objects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Powers of the Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the provisions of our Constitution our directors
may exercise all of the powers of our company, other than those that are required by our Constitution or the Corporations Act of Australia
to be exercised at a general meeting of shareholders. A director may participate in a meeting and vote on a proposal, arrangement or contract
in which he or she is materially interested, so long as the director&#8217;s interest is declared in accordance with the Corporations
Act. The authority of our directors to enter into borrowing arrangements on our behalf is not limited, except in the same manner as any
other transaction by us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Annual and Extraordinary Meetings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors must convene an annual meeting
of shareholders at least once every calendar year, within five months of our last fiscal year-end balance sheet date. Notice of at least
28 days prior to the date of the meeting is required. An extraordinary meeting may be convened by the board of directors,or upon a demand
of any directors, or of one or more shareholders holding in the aggregate at least five percent of our issued capital. An extraordinary
meeting must be called not more than 21 days after the request is made. The meeting must be held not later than two months after the request
is given.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Please refer to Exhibit 2.3 for Items 10.B.3, B.4, B.6, B.7, B.8,
B.9 and B.10.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_043"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Material Contracts</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not deem any individual contract to be a
material contract which is not already discussed and filed as an exhibit or in the ordinary course of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_044"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Exchange Controls</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Australia has largely abolished exchange controls
on investment transactions. The Australian dollar is freely convertible into U.S. dollars. In addition, there are currently no specific
rules or limitations regarding the export from Australia of profits, dividends, capital, or similar funds belonging to foreign investors,
except that certain payments to non-residents must be reported to the Australian Cash Transaction Reports Agency, which monitors such
transactions, and amounts on account of potential Australian tax liabilities may be required to be withheld unless a relevant taxation
treaty can be shown to apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Foreign Acquisitions and Takeovers Act 1975</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under Australian law, in certain circumstances
foreign persons are prohibited from acquiring more than a limited percentage of the shares in an Australian company without notification
to or approval from the Australian Treasurer. These limitations are set forth in the Australian Foreign Acquisitions and Takeovers Act,
or the Takeovers Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Takeovers Act, as currently in effect,
any foreign person, together with associates, is prohibited from acquiring 15% or more of the shares in any company having total assets
exceeding A$266 million or more. In addition, a foreign person may not acquire shares in a company having total assets of A$266 million
or more if, as a result of that acquisition, the total holdings of all foreign persons and their associates will exceed 40% in aggregate
without the approval of the Australian Treasurer. However, for &#8220;U.S. Investors&#8221; and investors from certain other countries,
a threshold of A$1,154 million applies (except in certain circumstances) to each of the previous acquisitions. A &#8220;U.S. Investor&#8221;
is defined by the Takeovers Act as a U.S. national or a U.S. enterprise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the necessary approvals are not obtained, the
Treasurer may make an order requiring the acquirer to dispose of the shares it has acquired within a specified period of time. Under the
current Australian foreign investment policy, however, it is unlikely that the Treasurer would make such an order where the level of foreign
ownership exceeds 40% in the ordinary course of trading, unless the Treasurer finds that the acquisition is contrary to the national interest.
The same rule applies if the total holdings of all foreign persons and their associates already exceeds 40% and a foreign person (or its
associate) acquires any further shares, including in the course of trading in the secondary market of the ADSs. At present, we do not
have total assets of A$266 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the level of foreign ownership exceeds 40% at
any time, we would be considered a foreign person under the Takeovers Act. In such event, we would be required to obtain the approval
of the Treasurer for our company, together with our associates, to acquire (i) more than 15% of an Australian company or business with
assets totaling over A$252 million; or (ii) any direct or indirect ownership interest in Australian residential real estate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The percentage of foreign ownership in our company
would also be included in determining the foreign ownership of any Australian company or business in which it may choose to invest. Since
we have no current plans for any such acquisitions and do not own any property, any such approvals required to be obtained by us as a
foreign person under the Takeovers Act will not affect our current or future ownership or lease of property in Australia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Constitution does not contain any additional
limitations on a non-resident&#8217;s right to hold or vote our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Australian law requires the transfer of shares
in our company to be made in writing. No stamp duty will be payable in Australia on the transfer of ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_045"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Taxation</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following is a discussion of Australian and
U.S. tax consequences material to our shareholders. To the extent that the discussion is based on tax legislation which has not been subject
to judicial or administrative interpretation, the views expressed in the discussion might not be accepted by the tax authorities in question
or by court. The discussion is not intended, and should not be construed, as legal or professional tax advice and does not exhaust all
possible tax considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Holders of our ADSs should consult their own tax advisors as to
the United States, Australian or other tax consequences of the purchase, ownership and disposition of ADSs, including, in particular,
the effect of any foreign, state or local taxes.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>AUSTRALIAN TAX CONSEQUENCES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In this section we discuss the material Australian
tax considerations that apply to non-Australian tax residents with respect to the acquisition, ownership and disposal of the absolute
beneficial ownership of ADSs, which are evidenced by ADRs. This discussion is based upon existing Australian tax law as of the date of
this annual report, which is subject to change, possibly retrospectively. This discussion does not address all aspects of Australian income
tax law which may be important to particular investors in light of their individual investment circumstances, such as ADSs or shares held
by investors subject to special tax rules (for example, financial institutions, insurance companies or tax exempt organisations). In addition,
this summary does not discuss any foreign or state tax considerations, other than stamp duty. Prospective investors are urged to consult
their tax advisors regarding the Australian and foreign income and other tax considerations of the purchase, ownership and disposition
of the ADSs or shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Nature of ADSs for Australian Taxation Purposes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Holders of our ADSs are treated as the owners of
the underlying ordinary shares for Australian income tax and capital gains tax purposes. Therefore, dividends paid on the underlying ordinary
shares will be treated for Australian tax purposes as if they were paid directly to the owners of ADSs, and the disposal of ADSs will
be treated for Australian tax purposes as the disposal of the underlying ordinary shares. In the following analysis we discuss the application
of the Australian income tax and capital gains tax rules to non-Australian resident holders of ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Taxation of Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Australia operates a dividend imputation system
under which dividends may be declared to be &#8216;franked&#8217; to the extent of tax paid on company profits.&#160; Fully franked dividends
are not subject to dividend withholding tax.&#160; Dividends that are not franked or are partly franked and are paid to non-Australian
resident shareholders are subject to dividend withholding tax, but only to the extent the dividends are not franked.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unfranked dividends paid to a non-resident shareholder
are subject to withholding tax at 30%, unless the shareholder is a resident of a country with which Australia has a double taxation agreement.&#160;
In accordance with the provisions of the Double Taxation Convention between Australia and the United States., the maximum rate of Australian
tax on unfranked dividends to which a resident of the United States is beneficially entitled is 15%, where the U.S. resident holds less
than 10% of the voting rights in our company, or 5% where the U.S. resident holds 10% or more of the voting rights in our company.&#160;
The Double Taxation Convention between Australia and the United States does not apply to limit the tax rate on dividends where the ADSs
are effectively connected to a permanent establishment or a fixed base carried on by the owner of the ADSs in Australia through which
the shareholder carries on business or provides independent personal services, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Tax on Sales or other Dispositions of Shares - Capital Gains Tax</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Australian capital gains derived by non-Australian
residents in respect of the disposal of capital assets that are not taxable Australian property will be disregarded.&#160; Non-Australian
resident shareholders will not be subject to Australian capital gains tax on the capital gain made on a disposal of our shares, unless
they, together with associates, hold 10% or more of our issued capital, tested either at the time of disposal or over any continuous 12
month period in the 24 months prior to disposal, and the value of our shares at the time of disposal are wholly or principally attributable
to Australian real property assets.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Australian capital gains tax applies to net capital
gains at a taxpayer&#8217;s marginal tax rate. Previously, certain shareholders, such as individuals were entitled to a discount of 50%
for capital gains on shares held for greater than 12 months. However, as part of the 2012-2013 Federal Budget measures, the Australian
Government announced changes to the application of the CGT discount for foreign resident individuals on taxable Australian assets, including
shares. These changes became effective on June 29, 2013.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The effect of the change is to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retain access to the full CGT discount for discount capital gains of foreign resident individuals in respect of the increase in the value of a CGT asset that occurred before May 9, 2013; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remove the CGT discount for discount capital gains for foreign resident individuals that arise after May 8, 2013.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Foreign residents will still have access to a discount
on capital gains accrued prior to May 8, 2013 provided they choose to obtain a market valuation for their assets as of that date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net capital gains are calculated after reduction
for capital losses, which may only be offset against capital gains.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Tax on Sales or other Dispositions of Shares - Shareholders Holding
Shares on Revenue Account </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some non-Australian resident shareholders may hold
shares on revenue rather than on capital account, for example, share traders.&#160; These shareholders may have the gains made on the
sale or other disposal of the shares included in their assessable income under the ordinary income provisions of the income tax law, if
the gains are sourced in Australia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Non-Australian resident shareholders assessable
under these ordinary income provisions in respect of gains made on shares held on revenue account would be assessed for such gains at
the Australian tax rates for non-Australian residents, which start at a marginal rate of 32.5% for non-Australian resident individuals.&#160;
Some relief from the Australian income tax may be available to such non-Australian resident shareholders under the Double Taxation Convention
between the United States and Australia, for example, because the shareholder does not have a permanent establishment in Australia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the extent an amount would be included in a
non-Australian resident shareholder&#8217;s assessable income under both the capital gains tax provisions and the ordinary income provisions,
the capital gain amount would generally be reduced, so that the shareholder would not be subject to double tax on any part of the income
gain or capital gain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dual Residency</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a shareholder were a resident of both Australia
and the United States under those countries&#8217; domestic taxation laws, that shareholder may be subject to tax as an Australian resident.
If, however, the shareholder is determined to be a U.S. resident for the purposes of the Double Taxation Convention between the United
States and Australia, the Australian tax applicable would be limited by the Double Taxation Convention. Shareholders should obtain specialist
taxation advice in these circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stamp Duty</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A transfer of shares of a company listed on the
ASX is not subject to Australian stamp duty except in some circumstances where one person, or associated persons, acquires 90% or more
of the shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Australian Death Duty</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Australia does not have estate or death duties.
No capital gains tax liability is realised upon the inheritance of a deceased person&#8217;s shares. The disposal of inherited shares
by beneficiaries, may, however, give rise to a capital gains tax liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Goods and Services Tax</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The issue or transfer of shares will not incur
Australian goods and services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>UNITED STATES FEDERAL INCOME TAX CONSEQUENCES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following is a summary of certain material
U.S. federal income tax consequences that generally apply to U.S. Holders (as defined below) who hold ADSs as capital assets. This summary
is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code, Treasury regulations promulgated thereunder, judicial and
administrative interpretations thereof, and the bilateral taxation convention between Australia and the United States, or the Tax Treaty,
all as in effect on the date hereof and all of which are subject to change either prospectively or retroactively. This summary does not
discuss all the tax consequences that may be relevant to an investment in ADSs by a U.S. Holder in light of such holder&#8217;s particular
circumstances or to U.S. Holders subject to special rules, including broker-dealers, financial institutions, certain insurance companies,
investors liable for alternative minimum tax, tax-exempt organisations, regulated investment companies, non-resident aliens of the U.S.
or taxpayers whose functional currency is not the U.S. dollar, persons who hold the ADSs through partnerships or other pass-through entities,
persons who acquired their ADSs through the exercise or cancellation of any employee stock options or otherwise as compensation for their
services, investors that actually or constructively own 10% or more of our shares by vote or value, investors holding ADSs as part of
a straddle or appreciated financial position or as part of a hedging or conversion transaction , and persons required to accelerate the
recognition of any item of income with respect to the ADSs as a result of such income being recognized on an applicable financial statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a partnership or an entity treated as a partnership
for U.S. federal income tax purposes owns ADSs, the U.S. federal income tax treatment of a partner in such a partnership will generally
depend upon the status of the partner and the activities of the partnership. A partnership that owns ADSs and the partners in such partnership
should consult their own tax advisors about the U.S. federal income tax consequences of holding and disposing of ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This summary does not address the effect of any
U.S. federal taxation other than U.S. federal income taxation. In addition, this summary does not include any discussion of U.S. federal
estate and gift tax, state, local or foreign taxation. You are urged to consult your tax advisors regarding the foreign and U.S. federal,
state and local tax considerations of an investment in ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For purposes of this summary, the term &#8220;U.S.
Holder&#8221; means an individual who is a citizen or, for U.S. federal income tax purposes, a resident of the United States, a corporation
or other entity taxable as a corporation created or organized in or under the laws of the United States or any political subdivision thereof,
an estate whose income is subject to U.S. federal income tax regardless of its source, or a trust if (a) a court within the United States
is able to exercise primary supervision over administration of the trust, and one or more U.S. persons have the authority to control all
substantial decisions of the trust or (b) it has a valid election in effect under applicable U.S. Treasury regulations to be treated as
a U.S. person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>For purposes of the discussion below, it is
assumed that the representations contained in the deposit agreement governing the ADSs are true and that the obligations in the deposit
agreement and any related agreement will be complied with in accordance with their terms.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Taxation of Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For U.S. federal income tax purposes, U.S. Holders
of ADSs will be treated as owning the underlying ordinary shares represented by the ADSs held by them. Subject to the passive foreign
investment company, or PFIC, rules discussed below, the gross amount of any distributions received with respect to the underlying ordinary
shares represented by the ADSs, including the amount of any Australian taxes withheld therefrom, will constitute dividends for U.S. federal
income tax purposes, to the extent of our current and accumulated earnings and profits, as determined under U.S. federal income tax principles.
You will be required to include this amount of dividends in gross income as ordinary income. Distributions in excess of our earnings and
profits will be treated as a non-taxable return of capital to the extent of your tax basis in the ADSs. Any amount in excess of your tax
basis will be treated as gain from the sale of ADSs. See &#8220;Disposition of ADSs&#8221; below for the discussion on the taxation of
capital gains. Dividends will not qualify for the dividends-received deduction generally available to corporations under Section 243 of
the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dividends that we pay in Australian dollars, including
the amount of any Australian taxes withheld therefrom, will be included in your income in a U.S. dollar amount calculated by reference
to the exchange rate in effect on the day such dividends are received. A U.S. Holder who receives payment in Australian dollars&#160;and
converts Australian dollars into U.S. dollars at an exchange rate other than the rate in effect on such day will likely have a foreign
currency exchange gain or loss, which would be treated as U.S.-source ordinary income or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to complex limitations, any Australian
withholding tax imposed on our dividends will be a foreign income tax eligible for credit against a U.S. Holder&#8217;s U.S. federal income
tax liability (or, alternatively, for deduction against income in determining such tax liability). The limitations set forth in the Code
include computational rules under which foreign tax credits allowable with respect to specific classes of income cannot exceed the U.S.
federal income taxes otherwise payable with respect to each such class of income. Dividends generally will be treated as foreign-source
passive category income or general category income for U.S. foreign tax credit purposes, depending upon the holder&#8217;s circumstances.
A U.S. Holder will be denied a foreign tax credit with respect to Australian income tax withheld from dividends received with respect
to the underlying ordinary shares represented by the ADSs to the extent such U.S. Holder has not held the ADSs for at least 16 days of
the 31-day period beginning on the date that is 15 days before the ex-dividend date or to the extent such U.S. Holder is under an obligation
to make related payments with respect to substantially similar or related property. Any days during which a U.S. Holder has substantially
diminished its risk of loss on the ADSs are not counted toward meeting the 16-day holding period required by the statute. The rules relating
to the determination of the foreign tax credit are complex. You should consult with your own tax advisors to determine whether and to
what extent you would be entitled to this credit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to certain limitations, &#8220;qualified
dividend income&#8221; received by a non-corporate U.S. Holder will be subject to tax at a reduced maximum tax rate of 20 percent. Distributions
taxable as dividends generally qualify for the 20 percent rate provided that either: (i) the issuer is entitled to benefits under the
Tax Treaty or (ii) the ADSs are readily tradable on an established securities market in the United States and certain other requirements
are met. We believe that we are entitled to benefits under the Tax Treaty and that the ADSs currently are readily tradable on an established
securities market in the United States. However, no assurance can be given that the ADSs will remain readily tradable. Furthermore, the
reduced rate does not apply to dividends received from PFICs. The amount of foreign tax credit is limited in the case of foreign qualified
dividend income. U.S. Holders of ADSs should consult their own tax advisors regarding the effect of these rules in their particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Disposition of ADSs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you sell or otherwise dispose of ADSs, you will
recognize a gain or loss for U.S. federal income tax purposes in an amount equal to the difference between the amount realized on the
sale or other disposition and your adjusted tax basis in the ADSs. Subject to the PFIC rules discussed below, such gain or loss generally
will be capital gain or loss and will be long-term capital gain or loss if you have held the ADSs for more than one year at the time of
the sale or other disposition. In general, any gain that you recognize on the sale or other disposition of ADSs will be U.S.-source for
purposes of the foreign tax credit limitation; losses will generally be allocated against U.S.-source income. Deduction of capital losses
is subject to certain limitations under the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the case of a cash basis U.S. Holder who receives
Australian dollars in connection with the sale or disposition of ADSs, the amount realized will be based on the U.S. dollar value of the
Australian dollars received with respect to the ADSs as determined on the settlement date of such exchange. A U.S. Holder who receives
payment in Australian dollars and converts them into U.S. dollars at a conversion rate other than the rate in effect on the settlement
date may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An accrual basis U.S. Holder may elect the same
treatment of foreign currency gain or loss required of cash basis taxpayers with respect to a sale or disposition of ADSs, provided that
the election is applied consistently from year to year. Such election may not be changed without the consent of the Internal Revenue Service,
or IRS. In the event that an accrual basis U.S. Holder does not elect to be treated as a cash basis taxpayer (pursuant to the Treasury
regulations applicable to foreign currency transactions), such U.S. Holder may have a foreign currency gain or loss for U.S. federal income
tax purposes because of differences between the U.S. dollar value of the Australian dollars received prevailing on the trade date and
the settlement date. Any such currency gain or loss would be treated as ordinary income or loss and would be in addition to gain or loss,
if any, recognised by such U.S. Holder on the sale or other disposition of such ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Passive Foreign Investment Companies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are likely a PFIC for U.S. federal income tax
purposes for some U.S. Holders of our ADSs and a controlled foreign corporation (CFC) to other U.S Holders of our ADSs. Our treatment
as a PFIC could result in a reduction in the after-tax return to those U.S. Holders of our ADSs and may affect the value of the securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For U.S. federal income tax purposes, we will be
classified as a PFIC for any taxable year in which either (i) 75% or more of our gross income is passive income, or (ii) at least 50%
of the average value of all of our assets for the taxable year produce or are held for the production of passive income. For this purpose,
cash is considered to be an asset that produces passive income. Passive income generally includes dividends, interest, royalties, rents,
annuities and the excess of gains over losses from the disposition of assets that produce passive income. As a result of our substantial
cash position and the decline in the value of our stock, we believe that we became a PFIC during the taxable year ended June 30, 2005.
We believe that we continued to be classified as a PFIC during the taxable year ended June 30, 2025 for some U.S Holders of our ADSs and
may continue to be a PFIC for each of the subsequent fiscal years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we are a PFIC with respect to you, our dividends
(if any are paid) will not qualify for the reduced maximum tax rate, discussed above, and, unless you timely elect to &#8220;mark-to-market&#8221;
your ADSs, as described below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">you will be required to allocate &#8220;excess distributions&#8221; or gain recognised upon the disposition of ADRs ratably over your holding period for the ADSs. An &#8220;excess distribution&#8221; is the amount by which distributions during a taxable year in respect of an ADS exceed 125% of the average annual distributions during the three preceding taxable years (or, if shorter, your holding period for the ADSs),</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to each year during which we are considered a PFIC, other than the year of the distribution or disposition, will be subject to tax at the highest individual or corporate tax rate, as the case may be, in effect for that year and an interest charge will be imposed with respect to the resulting tax liability allocated to each such year,</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to the current taxable year and any taxable year before we became a PFIC will be taxable as ordinary income in the current year, and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">you will be required to file an annual return on IRS Form 8621.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The PFIC provisions discussed above apply to U.S.
persons who directly or indirectly hold stock in a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Generally, a U.S. person is considered an indirect
shareholder of a PFIC if it is:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a direct or indirect owner of a pass-through entity, including a trust or estate, that is a direct or indirect shareholder of a PFIC,</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a shareholder of a PFIC that is a shareholder of another PFIC, or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a 50%-or-more shareholder of a foreign corporation that is not a PFIC and that directly or indirectly owns stock of a PFIC.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An indirect shareholder may be taxed on a distribution
paid to the direct owner of the PFIC and on a disposition of the stock indirectly owned. Indirect shareholders are strongly urged to consult
their tax advisors regarding the application of these rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we cease to be a PFIC in a future year, a U.S.
Holder may avoid the continued application of the tax treatment described above by electing to be treated as if it sold its ADSs on the
last day of the last taxable year in which we were a PFIC. Any gain would be recognised and subject to tax under the rules described above
and any loss would not be recognised. A U.S. Holder&#8217;s basis in its ADSs would be increased by the amount of gain, if any, recognised
on the sale. Solely for purposes of the PFIC rules, a U.S. Holder would be required to treat its holding period for its ADSs as beginning
on the day following the last day of the last taxable year in which we were a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the ADSs are considered &#8220;marketable stock&#8221;
and if you elect to &#8220;mark-to-market&#8221; your ADSs, you would not be subject to the rules described above. Instead, you will generally
include in income any excess of the fair market value of the ADSs at the close of each tax year over your adjusted basis in the ADSs.
If the fair market value of the ADSs has depreciated below your adjusted basis at the close of the tax year, you may generally deduct
the excess of the adjusted basis of the ADSs over its fair market value at that time. However, such deductions generally would be limited
to the net mark-to-market gains, if any, that you included in income with respect to such ADSs in prior years. Income recognised and deductions
allowed under the mark-to-market provisions, as well as any gain or loss on the disposition of ADSs with respect to which the mark-to-market
election is made, are treated as ordinary income or loss (except that loss is treated as capital loss to the extent the loss exceeds the
net mark-to-market gains, if any, that a U.S. Holder included in income with respect to such ADSs in prior years). However, gain or loss
from the disposition of ADSs (as to which a &#8220;mark-to-market&#8221; election was made) in a year in which we are no longer a PFIC
will be capital gain or loss. Our ADSs should be considered &#8220;marketable stock&#8221; if they traded at least 15 days during each
calendar quarter of the relevant calendar year in more than <i>de minimis</i> quantities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A U.S. Holder of ADSs will not be able to avoid
the tax consequences described above by electing to treat us as a qualified electing fund, or QEF, because we do not intend to prepare
the information that U.S. Holders would need to make a QEF election.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Additional Tax on Investment Income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">U.S. Holders that are individuals, estates, or
trusts and whose income exceeds certain thresholds will be subject to a 3.8% Medicare contribution tax on net investment income, which
will include dividends on and capital gains from the sale or other taxable disposition of ADSs, subject to certain limitations and exceptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Backup Withholding and Information Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Payments in respect of ADSs may be subject to information
reporting to the IRS and to U.S. backup withholding tax at a rate equal to the fourth lowest income tax rate applicable to individuals
(which, under current law, is 24%). Backup withholding will not apply, however, if you (i) are a corporation or come within certain exempt
categories and demonstrate the fact when so required or (ii) furnish a correct taxpayer identification number and make any other required
certification.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Backup withholding is not an additional tax. Amounts
withheld under the backup withholding rules may be credited against a U.S. Holder&#8217;s U.S. tax liability. A U.S. Holder may obtain
a refund of any excess amounts withheld under the backup withholding rules by filing the appropriate claim for refund with the IRS, which
is generally an annual income tax return.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">U.S. individuals who hold certain specified foreign
financial assets, including stock in a foreign corporation, with values in excess of certain thresholds are required to file IRS Form
8938 with their U.S. federal income tax return. Such form requires disclosure of information concerning such foreign assets, including
their value. Failure to file the form when required is subject to penalties. An exemption from reporting applies to foreign assets held
through a U.S. financial institution, generally including a non-U.S. branch or subsidiary of a U.S. institution and a U.S. branch of a
non-U.S. institution. Investors are encouraged to consult with their own tax advisors regarding the possible application of this disclosure
requirement to their investment in our ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_046"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Dividends and Paying Agents</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_047"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Statement by Experts</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_048"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Documents on Display</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are subject to the reporting requirements of
the Exchange Act, as applicable to &#8220;foreign private issuers&#8221; as defined in Rule 3b-4 thereunder. As a foreign private issuer,
we are exempt from certain provisions of the Exchange Act. Accordingly, our proxy solicitations are not subject to the disclosure and
procedural requirements of Regulation 14A under the Exchange Act, transactions in our equity securities by our officers and directors
are exempt from reporting and the &#8220;short-swing&#8221; profit recovery provisions contained in Section 16 of the Exchange Act. In
addition, we are not required to file periodic reports and financial statements as frequently or as promptly as U.S. companies whose securities
are registered under the Exchange Act. However, we file with the Securities and Exchange Commission an annual report on Form 20-F containing
financial statements that have been examined and reported on, with an opinion expressed by, an independent registered public accounting
firm, and we submit reports to the Securities and Exchange Commission on Form 6-K containing (among other things) press releases and unaudited
financial information for the first six months of each fiscal year. We post our annual report on Form 20-F on our website (www.alteritytherapeutics.com)
promptly following the filing of our annual report with the Securities and Exchange Commission. The information on our website is not
incorporated by reference into this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The documents concerning our company referred to
in this annual report may also be inspected at our registered office located at Level 14, 350 Collins Street, Melbourne, Victoria 3000,
Australia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_049"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Subsidiary Information</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_050"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Annual Report to Security Holders.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_051"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>ITEM 11.</b></span><b> QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We invest our excess cash and cash equivalents
in interest-bearing accounts and term deposits with banks in Australia. Our management believes that the financial institutions that hold
our investments are financially sound and accordingly, minimal credit risk exists with respect to these investments. Certain of our cash
equivalents are subject to interest rate risk. Due to the short duration and conservative nature of these instruments, we do not believe
that we have a material exposure to interest rate risk. Our major market risk is changes in foreign exchange rates as we had approximately
A$1,544,448, A$225,722, and A$15,473,231 cash held in U.S. dollars, which is our major foreign currency, as of June 30, 2025, 2024 and
2023, respectively. A hypothetical 7.41% adverse movement, based on average of highest and lowest exchange rate during the year, would
reduce the cash balance at the end of each year by approximately A$176,668.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We conduct our activities mostly in Australia and
the USA. We are required to make certain payments in U.S. dollars and other currencies, however we believe an adverse movement in end-of-period
exchange rates would not have a material impact on our operating results. In the twelve months ended June 30, 2025, the Australian dollar
depreciated against the U.S. dollar by 1.77%. In the financial years 2024 and 2023, the Australian dollar depreciated by 0.35% and 3.6%
against the U.S. dollar, respectively. A hypothetical 7.41% adverse movement in the U.S. dollar would increase the cost of our foreign
currency payables by approximately A$56,635.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not currently utilize derivative financial
instruments or other financial instruments subject to market risk.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><span style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_052"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>ITEM 12.</b></span><b> DESCRIPTION
OF SECURITIES OTHER THAN EQUITY SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Fees and Charges Payable by ADS Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below summarizes the fees and charges
that a holder of our ADSs may have to pay, directly or indirectly, to our depositary, The Bank of New York Mellon, or BNYM, pursuant to
the Deposit Agreement, which was filed as Exhibit 2.1 to our Registration Statement on Form F-6 filed with the SEC on December&#160;21,
2007, and the types of services and the amount of the fees or charges paid for such services. The disclosure under this heading &#8220;Fees
and Charges Payable by ADS Holders&#8221; is subject to and qualified in its entirety by reference to the full text of the Deposit Agreement.
The holder of an ADS may have to pay the following fees and charges to BNYM in connection with ownership of the ADS:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Persons Depositing or Withdrawing Shares Must Pay:</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For:</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.$3.00 (or less) per 100 ADSs (or portion of 100 ADSs)</span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.$0.03 (or less) per ADS</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any cash distribution to you</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution of securities distributed to holders of deposited securities which are distributed by the depositary to ADS holders</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.$1.50 (or less) per ADS</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfers, combination and split-up of ADSs</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses of the depositary</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement)</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Converting foreign currency to U.S. dollars</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes and other governmental charges the depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, stock transfer taxes, stamp duty or withholding taxes</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As necessary</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any charges incurred by the depositary or its agents for servicing the deposited securities</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As necessary</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The depositary collects its fees for delivery and
surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries
acting for them.&#160; The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed
or by selling a portion of distributable property to pay the fees.&#160; The depositary may collect its annual fee for depositary services
by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting
for them. The depositary may collect any of its fees by deduction from any cash distribution payable to ADS holders that are obligated
to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From time to time, the depositary may make payments
to us to reimburse and/or share revenue from the fees collected from ADS holders, or waive fees and expenses for services provided, generally
relating to costs and expenses arising out of establishment and maintenance of the ADS program.&#160; In performing its duties under the
deposit agreement, the depositary may use brokers, dealers or other service providers that are affiliates of the depositary and that may
earn or share fees or commissions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Fees and Payments Made by the Company to the Depositary</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We incurred expenses in relation to services for
our annual general meeting and special general meeting of shareholders. For the year ended June 30, 2025, we paid BNYM a total of U.S.$44,805
(comprised of payments for the distribution and printing of meeting material and proxy vote tabulation). For the year ended June 30, 2024,
we paid BNYM a total of U.S.$43,498 (comprised of payments for the distribution and printing of meeting material and proxy vote tabulation).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_053"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><span style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_054"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>ITEM 13.</b></span><b> DEFAULTS,
DIVIDEND ARREARAGES AND DELINQUENCIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><span style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_055"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>ITEM 14.</b></span><b> MATERIAL
MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><span style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_056"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps; text-transform: uppercase"><b>ITEM
15.</b></span><b> <span style="text-transform: uppercase">Controls and Procedures</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We maintain disclosure controls and procedures
that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities
Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) is recorded, processed, summarised and reported within the time periods
specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information required to be disclosed by us
in the reports that we file or submit under the Exchange Act is accumulated and communicated to our chief executive officer and chief
financial officer to allow timely decisions regarding required disclosure. Our management, including our chief executive officer and chief
financial officer, conducted an evaluation of our disclosure controls and procedures, as defined under Exchange Act Rule 13a-15(e) and
15d-15(e), &#160;as of the end of the period covered by this Annual Report on Form 20-F. Based upon that evaluation, our chief executive
officer and chief financial officer concluded that, as of June 30, 2025, our disclosure controls and procedures were effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Management&#8217;s Annual Report on Internal Control over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f)
or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the company&#8217;s principal executive
and principal financial officers and effected by the company&#8217;s board of directors, management and other personnel, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles and includes those policies and procedures that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because of its inherent limitations, internal control
over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies
or procedures may deteriorate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our management assessed the effectiveness of our
internal control over financial reporting as of June 30, 2025. In making this assessment, our management used the criteria set forth by
the Committee of Sponsoring Organisations of the Treadway Commission (COSO) in <i>Internal Control-Integrated Framework</i> (2013). Based
on that assessment, our management concluded that as of June 30, 2025, our internal control over financial reporting is effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Changes in Internal Control over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There were no changes in our internal control over
financial reporting that occurred during the period covered by this annual report on Form 20-F that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_057"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps; text-transform: uppercase"><b>ITEM
16.</b></span><b> <span style="text-transform: uppercase">Reserved</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_058"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 16A. Audit Committee
Financial Expert</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors has determined that Mr.
Brian Meltzer, an independent director, meets the definition of an audit committee financial expert, as defined by rules of the Securities
and Exchange Commission. For a brief listing of Mr. Meltzer&#8217;s relevant experience, see Item 6.A. &#8220;Directors, Senior Management
and Employees - Directors and Senior Management.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_059"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 16B. Code Of Ethics</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have adopted a code of ethics that applies to
all senior financial officers of our company, including our chief executive officer, chief financial officer, chief accounting officer
or controller, or persons performing similar functions. The code of ethics is publicly available on our website at www.alteritytherapeutics.com.
Written copies are available upon request. If we make any substantive amendment to the code of ethics or grant any waivers, including
any implicit waiver, from a provision of the codes of ethics, we will disclose the nature of such amendment or waiver on our website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_060"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 16C. Principal Accountant
Fees And Services</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Fees Paid to Independent Public Accountants</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth, for each of the
years indicated, the fees billed by PricewaterhouseCoopers, which has served as our principal independent registered public accounting
firm since November 30, 2006.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
                                            Ended June 30,</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; width: 76%; font-weight: bold; text-align: left">Services Rendered</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center">2025</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center">2024</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit and review of financial
    statements <sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">A$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">248,000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">A$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">248,200</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other audit services</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">A$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">A$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95,500</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">A$</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration-style: double">320,000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">A$</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration-style: double">343,700</span></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees consist of services that would normally be provided in connection with statutory and regulatory filings or engagements, including services that generally only the independent accountant can reasonably provide.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Pre-Approval Policies and Procedures </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Audit Committee has adopted policies and procedures
for the pre-approval of audit and non-audit services rendered by our independent registered public accounting firm. Pre-approval of an
audit or non-audit service may be given as a general pre-approval, as part of the audit committee&#8217;s approval of the scope of the
engagement of our independent registered public accounting firm, or on an individual basis. Any proposed services exceeding general pre-approved
levels also requires specific pre-approval by our audit committee. The policy prohibits retention of the independent registered public
accounting firm to perform the prohibited non-audit functions defined in Section 201 of the Sarbanes-Oxley Act or the rules of the Securities
and Exchange Commission, and also requires the audit committee to consider whether proposed services are compatible with the independence
of the registered public accounting firm. All of the fees described above were pre-approved by our Audit Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_061"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 16D. Exemptions From
The Listing STANDARDS For Audit CommitteeS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.3pt; text-indent: -76.3pt"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_062"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>ITEM 16E. PurchaseS Of Equity
Securities By The Issuer And AffiliateD Purchasers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Issuer Purchase of Equity Securities </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Neither we, nor any affiliated purchaser of our
company, has purchased any of our securities during the year ended June 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.3pt; text-indent: -76.3pt"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_063"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16F. CHANGES IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_064"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16G. CORPORATE GOVERNANCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.7pt">Under NASDAQ Stock Market Rule 5615(a)(3), foreign
private issuers, such as our company, are permitted to follow certain home country (Australian) corporate governance practices instead
of certain provisions of the NASDAQ Stock Market Rules. A foreign private issuer that elects to follow a home country practice instead
of any NASDAQ rule must submit to NASDAQ, in advance, a written statement from an independent counsel in such issuer&#8217;s home country
certifying that the issuer&#8217;s practices are not prohibited by the home country&#8217;s laws. We have submitted a notice to NASDAQ
informing them of that we elect to follow home country practice instead of the following NASDAQ rules:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-indent: -17.85pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Rule related to Audit Committee Composition rule 5605(c)(2)(A)): we may have an audit committee composed of two members instead of &#8220;at least three members&#8221;. We may not follow NASDAQ rules regarding independence of such members (as long as we comply with Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, subject to the exemptions provided in rule 10A-3(c)), and we may not have a financially sophisticated member as defined.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Rule requiring maintaining a majority of independent directors (Rule 5605(b)(1))</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Rule requiring that our independent directors have regularly scheduled meetings at which only independent directors are present (Rule 56505(b)(2)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Rule regarding independent director oversight of director nominations process for directors (Rule 5605(e)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Rule regarding independent director oversight of executive officer compensation (Rule 5605(d)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirement to obtain shareholder approval for the establishment or amendment of certain equity based compensation plans (Rule 5635(c), an issuance that will result in a change of control of the company (Rule 5635(b), certain transactions other than a public offering involving issuances of a 20% or more interest in the company (Rule 5635(d) and certain acquisitions of the stock or assets of another company (Rule 5635(a)).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_065"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16H. MINE SAFETY DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_066"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICATIONS THAT PREVENT
INSPECTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">.</p><div>

</div><div><a id="a_067"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16J. INSIDER TRADING POLICIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our board of directors has <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="ixv-23402">adopted</ix:nonNumeric> a securities
trading policy which outlines when directors, senior management and other employees may deal in our securities and procedures to reduce
the risk of insider trading. A copy of the insider trading policy is attached as Exhibit 11.1 to this annual report.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_068"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16K. CYBERSECURITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="ixv-10728"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cybersecurity Risk Management and Strategy</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="ixv-10734"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cybersecurity risk management is an integral part
of our risk management framework. Our approach aligns with industry standards, including the National Institute of Standards and Technology
(NIST) Cybersecurity Framework (CSF), to effectively manage cybersecurity threats and incidents, including those related to third-party
applications and services.</p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_3" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our framework includes:</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_4" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Assessing the severity of cybersecurity threats</td>
</tr></table></ix:continuation><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_5" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Identifying the sources of cybersecurity threats</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_6" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Implementing countermeasures and mitigation strategies</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_7" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Reporting material cybersecurity threats and incidents to
management</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_8" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Processes for Assessing, Identifying, and Managing
Material Risks from Cybersecurity Threats</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_9" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_8"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(i)</td><td style="text-align: justify">Integration into Overall Risk Management:</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_10" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="ixv-23403">Cybersecurity risk management is <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="ixv-23404">integrated</ix:nonNumeric>
into our broader risk management system. Regular risk assessments and business impact analyses are conducted to identify critical
systems, applications, and data, as well as potential disruptions and their consequences.</ix:nonNumeric> The Information Security Officer (ISO)
conducts these assessments, which inform the development of contingency plans including redundancy, backup and recovery, alternate
site operations, and data restoration.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_11" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_10"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(ii)</td><td style="text-align: justify">Engagement &amp; Oversight of Third Parties:</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_12" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="ixv-23405">engage</ix:nonNumeric> <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="ixv-23406">third-party assessors</ix:nonNumeric>, consultants, auditors,
and experts to strengthen our cybersecurity processes. For example, we utilize third-party services for continuous vulnerability scanning,
perimeter testing, Dynamic Application Security Testing (DAST), and penetration testing to identify and address potential security weaknesses
in our systems. Additionally, we engage expert architects to help design and maintain secure cloud infrastructures.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_13" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our third-party engagement and oversight process
includes conducting thorough due diligence, performing vendor risk assessments, and maintaining continuous monitoring to ensure that service
providers adhere to our security standards and comply with contractual obligations.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_14" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Material Effects of Cybersecurity Threats</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_15" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="ixv-10834"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the past year, we did <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="ixv-23407">not</ix:nonNumeric> encounter any cybersecurity
threats that materially affected or are likely to materially affect our business strategy, results of operations, or financial condition.
Nonetheless, we continuously enhance our cybersecurity posture to mitigate potential material impacts. Our risk management program outlines
procedures for regular log reviews, incident detection, and remediation to ensure ongoing protection of our information systems.</p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_16" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cybersecurity Governance</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_17" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_16"><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="ixv-10845"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Board of Directors&#8217; Oversight</p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_18" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_17"><ix:continuation id="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors plays a critical role in
overseeing cybersecurity risks as part of its broader risk oversight responsibilities. The Information Security Officer (ISO) provides
the board with updates on cybersecurity risks and incidents. Significant cybersecurity incidents are reported to the board to ensure appropriate
and timely responses.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_19" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Management&#8217;s Role in Assessing and Managing Cybersecurity
Risks</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_20" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_19"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(i)</td><td style="text-align: justify">Management Positions and Committees:</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_21" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="ixv-10871"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="ixv-10872"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="ixv-10873"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ISO is responsible for developing and maintaining
our cybersecurity and contingency plans, coordinating risk assessments, and managing incident responses. <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="ixv-23408">The ISO has extensive experience
in building secure web applications for healthcare. In addition to the ISO, we engage consultants and DevOps engineers with relevant degrees
and certifications to support our cybersecurity efforts.</ix:nonNumeric> System Owners are <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="ixv-23409">responsible</ix:nonNumeric> for identifying critical systems, assessing risks,
and implementing appropriate security controls.</p></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_22" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_21"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(ii)</td><td style="text-align: justify">Processes for Information and Monitoring:</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_23" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_22"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="ixv-10888"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have established comprehensive processes for
continuous monitoring and information sharing. These include regular reviews of audit logs, system activity analysis, and the deployment
of Security Information and Event Management (SIEM) tools for centralized monitoring. These processes facilitate the timely detection
and response to potential security incidents.</p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_24" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_23"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(iii)</td><td style="text-align: justify">Reporting to the Board:</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ISO regularly reports to executive management
and the Board of Directors. These reports include findings from risk assessments, incident reports, and updates on the status of ongoing
security initiatives, ensuring that the board is well-informed about our cybersecurity posture.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_069"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 89.5pt; text-indent: -0.75in"><span style="font-variant: small-caps; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_070"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>ITEM 17.</b></span><b> FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our company has elected to furnish financial statements
and related information specified in Item 18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_071"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>ITEM 18.</b></span><b> FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 90%; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#F_01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Index to Consolidated Financial Statements</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><a href="#F_02"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm (PricewaterhouseCoopers, Melbourne, Australia, Auditor Firm ID: 1379)</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#F_03"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Financial Position</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#F_04"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Profit or Loss and Other Comprehensive Loss</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#F_05"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Cash Flow Statements</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#F_06"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Shareholders&#8217; Equity</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#F_07"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Australian Disclosure Requirements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All press releases, financial reports and other information are available
on our website: https://alteritytherapeutics.com/</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="F_01"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 89%">&#160;</td> <td style="width: 1%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page <br/>
Number</b></span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><a href="#F_02"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm (ID: <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-23410">1379</ix:nonNumeric>)</span></a></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><a href="#F_03"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Financial Position</span></a></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><a href="#F_04"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Profit or Loss and Other Comprehensive Loss</span></a></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><a href="#F_05"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Cash Flow Statements</span></a></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><a href="#F_06"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Shareholders&#8217; Equity</span></a></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><a href="#F_07"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 83; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="F_02"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Report of Independent Registered
Public Accounting Firm </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and Shareholders of Alterity Therapeutics
Limited</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AuditorOpinionTextBlock-c0_cont_1" escape="true" name="dei:AuditorOpinionTextBlock" id="ixv-11172"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Opinion on the Financial Statements</i></b></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_AuditorOpinionTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying consolidated statements of financial
position of Alterity Therapeutics Limited and its subsidiaries (the &#8220;Company&#8221;) as of June 30, 2025 and 2024, and the related
consolidated statements of profit or loss and other comprehensive loss, of changes in shareholders&#8217; equity and of cash flows for
each of the three years in the period ended June 30, 2025, including the related notes (collectively referred to as the &#8220;consolidated
financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company as of June 30, 2025 and 2024, and the results of its operations and its cash flows for each of the three years
in the period ended June 30, 2025 in conformity with International Financial Reporting Standards as issued by the International Accounting
Standards Board and Australian equivalents to International Financial Reporting Standards as issued by the Australian Accounting Standards
Board.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis for Opinion</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These consolidated financial statements are the responsibility of the
Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based
on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and
are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules
and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audits of these consolidated financial statements
in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance
about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we
are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audits included performing procedures to assess the risks of material
misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those
risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for
our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Critical Audit Matters</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The critical audit matter communicated below is a matter arising from
the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee
and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially
challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the
consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate
opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Research and development tax incentive receivable </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As described in Notes 1, 2 and 5 to the consolidated financial statements,
the Company&#8217;s research and development (&#8220;R&amp;D&#8221;) tax incentive receivable was $3.9 million as of June 30, 2025, which
was recorded as other income for the year ended June 30, 2025. Management, with input from an independent specialist, assessed the Company&#8217;s
R&amp;D activities and related expenditures and applied significant judgement in determining which are eligible for a refundable tax offset
under the Australian Government R&amp;D tax incentive scheme, and then recorded the expected R&amp;D tax incentive amount as a receivable
in the consolidated statement of financial position and as other income in the consolidated statement of profit or loss and other comprehensive
loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The principal considerations for our determination that performing
procedures relating to the R&amp;D tax incentive receivable is a critical audit matter are the significant judgements made by management
to determine whether the R&amp;D activities and related expenditures are eligible for a refundable tax offset under the Australian Government
R&amp;D tax incentive scheme. This in turn led to a high degree of auditor subjectivity, judgement and effort in performing procedures
to evaluate the audit evidence related to the valuation of the R&amp;D tax incentive receivable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Addressing the matter involved performing procedures and evaluating
audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, amongst
others, testing management&#8217;s process for determining the R&amp;D tax incentive receivable, which included: (i) evaluating the appropriateness
of the methodology used to estimate the amount of the R&amp;D tax incentive receivable; (ii) performing a retrospective comparison of
the prior year R&amp;D tax incentive receivable estimate to the amount of cash received in the current year after lodgment of the R&amp;D
tax incentive claim to assess the historical accuracy of management&#8217;s estimation; (iii) assessing the completeness of the underlying
expense data used to determine the R&amp;D tax incentive receivable; and (iv) evaluating, for a selection of eligible expenditures, the
accuracy of the expenditure and the reasonableness of management&#8217;s assessment of eligibility. The work of management&#8217;s specialist
was used in performing the procedures to evaluate the reasonableness of the R&amp;D tax incentive receivable. As a basis for using this
work, the specialist&#8217;s qualifications were understood and the Company&#8217;s relationship with the specialist was assessed. The
procedures performed also included an evaluation of the methods and significant assumptions used by the specialist and an evaluation of
the specialist&#8217;s findings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-23411">PricewaterhouseCoopers</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-23412">Melbourne, Australia</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 29, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2006.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="F_03"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF FINANCIAL
POSITION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;(in Australian dollars, except number
of shares)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Current Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="aud" id="ixv-23413">33,158,642</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="aud" id="ixv-23414">12,638,885</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other receivables</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="0" unitRef="aud" id="ixv-23415">3,937,607</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="0" unitRef="aud" id="ixv-23416">4,041,675</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="0" unitRef="aud" id="ixv-23417">8,774,937</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="0" unitRef="aud" id="ixv-23418">2,356,300</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Current Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="0" unitRef="aud" id="ixv-23419">45,871,186</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="0" unitRef="aud" id="ixv-23420">19,036,860</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-Current Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Property and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" unitRef="aud" id="ixv-23421">3,848</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" unitRef="aud" id="ixv-23422">32,154</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="0" unitRef="aud" id="ixv-23423">151,326</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="0" unitRef="aud" id="ixv-23424">154,729</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Non-Current Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="0" unitRef="aud" id="ixv-23425">155,174</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="0" unitRef="aud" id="ixv-23426">186,883</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="aud" id="ixv-23427">46,026,360</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="aud" id="ixv-23428">19,223,743</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" unitRef="aud" id="ixv-23429">2,575,490</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" unitRef="aud" id="ixv-23430">4,619,947</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Provisions</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentProvisions" scale="0" unitRef="aud" id="ixv-23431">875,908</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentProvisions" scale="0" unitRef="aud" id="ixv-23432">530,699</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentLiabilities" scale="0" unitRef="aud" id="ixv-23433">139</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentLiabilities" scale="0" unitRef="aud" id="ixv-23434">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="0" unitRef="aud" id="ixv-23435">66,912</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="0" unitRef="aud" id="ixv-23436">107,131</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Current tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTaxLiabilities" scale="0" unitRef="aud" id="ixv-23437">16,280</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTaxLiabilities" scale="0" unitRef="aud" id="ixv-23438">15,995</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Current Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="0" unitRef="aud" id="ixv-23439">3,534,729</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="0" unitRef="aud" id="ixv-23440">5,373,772</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-Current Liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="0" unitRef="aud" id="ixv-23441">88,545</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="0" unitRef="aud" id="ixv-23442">51,914</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Non-Current Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLiabilities" scale="0" unitRef="aud" id="ixv-23443">88,545</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLiabilities" scale="0" unitRef="aud" id="ixv-23444">51,914</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="aud" id="ixv-23445">3,623,274</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="aud" id="ixv-23446">5,425,686</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NetAssetsLiabilities" scale="0" unitRef="aud" id="ixv-23447">42,403,086</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NetAssetsLiabilities" scale="0" unitRef="aud" id="ixv-23448">13,798,057</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Equity</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><div style="-sec-ix-hidden: hidden-fact-0"><div style="-sec-ix-hidden: hidden-fact-1">Issued capital</div></div></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="aud" id="ixv-23449">262,949,462</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="aud" id="ixv-23450">223,152,985</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025: 9,127,370,686 fully paid ordinary shares</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nil options over fully paid ordinary shares</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024: 5,245,115,318 fully paid ordinary shares</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nil options over fully paid ordinary shares</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Reserves</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="0" unitRef="aud" id="ixv-23451">5,342,304</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="0" unitRef="aud" id="ixv-23452">4,806,203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Accumulated deficit during the development stage</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">12</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" sign="-" unitRef="aud" id="ixv-23453">225,888,680</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" sign="-" unitRef="aud" id="ixv-23454">214,161,131</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Total Equity</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="aud" id="ixv-23455">42,403,086</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="aud" id="ixv-23456">13,798,057</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>The accompanying notes are an integral part of the consolidated
financial statements. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="F_04"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND
OTHER COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in"><b>(in Australian dollars, except
number of share and per share amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left; text-indent: -9pt; padding-left: 9pt">Interest income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">2</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromInterest" scale="0" unitRef="aud" id="ixv-23457">446,291</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromInterest" scale="0" unitRef="aud" id="ixv-23458">268,419</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromInterest" scale="0" unitRef="aud" id="ixv-23459">16,436</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud" id="ixv-23460">7,641,516</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud" id="ixv-23461">4,019,285</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud" id="ixv-23462">3,916,333</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Intellectual property expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:IntellectualPropertyExpenses" scale="0" unitRef="aud" id="ixv-23463">127,523</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:IntellectualPropertyExpenses" scale="0" unitRef="aud" id="ixv-23464">214,304</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:IntellectualPropertyExpenses" scale="0" unitRef="aud" id="ixv-23465">285,067</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">General and administration expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="aud" id="ixv-23466">5,481,399</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="aud" id="ixv-23467">4,762,643</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="aud" id="ixv-23468">5,056,571</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="aud" id="ixv-23469">14,404,282</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="aud" id="ixv-23470">18,644,047</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="aud" id="ixv-23471">13,198,583</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other operating expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="0" unitRef="aud" id="ixv-23472">87,265</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="0" unitRef="aud" id="ixv-23473">5,238</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="0" unitRef="aud" id="ixv-23474">29,404</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other gains / (losses)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" sign="-" unitRef="aud" id="ixv-23475">67,111</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" unitRef="aud" id="ixv-23476">261,152</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherGainsLosses" scale="0" unitRef="aud" id="ixv-23477">917,650</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Forfeited options from reserves</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:ForfeitedOptionsFromReserves" scale="0" unitRef="aud" id="ixv-23478">17,150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss before income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="0" sign="-" unitRef="aud" id="ixv-23479">12,079,773</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="0" sign="-" unitRef="aud" id="ixv-23480">19,077,376</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="0" sign="-" unitRef="aud" id="ixv-23481">13,702,056</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income tax expense</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="0" unitRef="aud" id="ixv-23482">68,055</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="0" unitRef="aud" id="ixv-23483">46,088</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="0" unitRef="aud" id="ixv-23484">104,459</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss for the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud" id="ixv-23485">12,147,828</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud" id="ixv-23486">19,123,464</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud" id="ixv-23487">13,806,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total comprehensive loss for the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud" id="ixv-23488">12,147,828</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud" id="ixv-23489">19,123,464</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud" id="ixv-23490">13,806,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Loss per share (basic and diluted - cents per share)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares" id="ixv-23491"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares" id="ixv-23492">0.19</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares" id="ixv-23493"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares" id="ixv-23494">0.52</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares" id="ixv-23495"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares" id="ixv-23496">0.57</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares" id="ixv-23497"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-23498">6,396,924,117</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares" id="ixv-23499"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-23500">3,648,875,564</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares" id="ixv-23501"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-23502">2,427,841,917</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>The accompanying notes are an integral part of the consolidated
financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><div><a id="F_05"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED CASH FLOW STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in Australian dollars)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash Flows from Operating Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Payments to suppliers and employees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" scale="0" unitRef="aud" id="ixv-23503">17,459,061</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" scale="0" unitRef="aud" id="ixv-23504">21,393,136</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" scale="0" unitRef="aud" id="ixv-23505">19,943,617</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest received</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="0" unitRef="aud" id="ixv-23506">446,291</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="0" unitRef="aud" id="ixv-23507">269,075</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="0" unitRef="aud" id="ixv-23508">15,798</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">R&amp;D tax refund</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:ProceedsFromResearchAndDevelopmentTaxRefund" scale="0" unitRef="aud" id="ixv-23509">5,629,577</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:ProceedsFromResearchAndDevelopmentTaxRefund" scale="0" unitRef="aud" id="ixv-23510">8,583,477</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="0" unitRef="aud" id="ixv-23511">7,217</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="0" unitRef="aud" id="ixv-23512">4,565</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Income tax paid</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxesPaidRefund" scale="0" unitRef="aud" id="ixv-23513">68,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxesPaidRefund" scale="0" unitRef="aud" id="ixv-23514">58,023</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxesPaidRefund" scale="0" unitRef="aud" id="ixv-23515">103,453</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash flows used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">14(a)</td><td style="padding-bottom: 1.5pt; text-align: left"/><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="aud" id="ixv-23516">11,451,248</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="aud" id="ixv-23517">12,605,824</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="aud" id="ixv-23518">20,035,837</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash Flows from Investing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Payments for rental security deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:PaymentsForRentalSecurityDeposits" scale="0" unitRef="aud" id="ixv-23519">29,150</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Payments for purchase of plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="0" unitRef="aud" id="ixv-23520">5,722</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="0" unitRef="aud" id="ixv-23521">7,311</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Payments for term deposit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" scale="0" sign="-" unitRef="aud" id="ixv-23522">7,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash flows used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="0" sign="-" unitRef="aud" id="ixv-23523">7,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="0" sign="-" unitRef="aud" id="ixv-23524">5,722</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="0" sign="-" unitRef="aud" id="ixv-23525">36,461</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash Flows from Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Proceeds from issue of ordinary shares and other equity securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingOtherEquityInstruments" scale="0" unitRef="aud" id="ixv-23526">42,570,645</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingOtherEquityInstruments" scale="0" unitRef="aud" id="ixv-23527">10,144,682</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingOtherEquityInstruments" scale="0" unitRef="aud" id="ixv-23528">316,675</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Payment of share issue costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsForShareIssueCosts" scale="0" unitRef="aud" id="ixv-23529">2,774,168</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsForShareIssueCosts" scale="0" unitRef="aud" id="ixv-23530">918,020</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsForShareIssueCosts" scale="0" unitRef="aud" id="ixv-23531">132,413</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Principal elements of lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="0" unitRef="aud" id="ixv-23532">127,097</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="0" unitRef="aud" id="ixv-23533">10,370</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="0" unitRef="aud" id="ixv-23534">59,922</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash flows generated from financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" unitRef="aud" id="ixv-23535">39,669,380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" unitRef="aud" id="ixv-23536">9,216,292</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" unitRef="aud" id="ixv-23537">124,340</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Net (decrease)/increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="0" unitRef="aud" id="ixv-23538">20,718,132</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="0" sign="-" unitRef="aud" id="ixv-23539">3,395,254</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="0" sign="-" unitRef="aud" id="ixv-23540">19,947,958</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents at beginning of period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="aud" id="ixv-23541">12,638,885</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="aud" id="ixv-23542">15,773,783</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="aud" id="ixv-23543">34,806,799</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Exchange rate adjustments on cash and cash equivalents held in foreign currencies</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" sign="-" unitRef="aud" id="ixv-23544">198,375</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" unitRef="aud" id="ixv-23545">260,356</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" unitRef="aud" id="ixv-23546">914,942</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents at end of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">14(b)</td><td style="padding-bottom: 1.5pt; text-align: left"/><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="aud" id="ixv-23547">33,158,642</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="aud" id="ixv-23548">12,638,885</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="aud" id="ixv-23549">15,773,783</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>The accompanying notes are an integral part of the consolidated
financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="F_06"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217;
EQUITY </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in Australian dollars, except for number of
shares)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number&#160;of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued<br/> Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Reserves</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Deficit<br/> During<br/> Development<br/> Stage</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-weight: bold; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance, June 30, 2022</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 5%; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23550">2,406,874,578</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="aud" id="ixv-23551">213,787,061</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="aud" id="ixv-23552">3,565,918</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" sign="-" unitRef="aud" id="ixv-23553">181,884,388</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="aud" id="ixv-23554">35,468,591</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Transactions with owners in their capacity as owners:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Issuance of shares</td><td>&#160;</td>
    <td style="text-align: center">10(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuanceOfSharesNetOfCostsShares" scale="0" unitRef="shares" id="ixv-23555">33,023,040</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuanceOfSharesNetOfCostsValue" scale="0" unitRef="aud" id="ixv-23556">316,675</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuanceOfSharesNetOfCostsValue" scale="0" unitRef="aud" id="ixv-23557">316,675</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Non-cash issuance of options to directors and employees</td><td>&#160;</td>
    <td style="text-align: center">11(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" scale="0" unitRef="aud" id="ixv-23558">983,721</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" scale="0" unitRef="aud" id="ixv-23559">983,721</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Non-cash issuance of options to consultants</td><td>&#160;</td>
    <td style="text-align: center">11(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of shares in connection with exercise of options, net of costs</td><td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10(b) &amp; 11(b)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Transaction costs from issuance of shares</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" sign="-" unitRef="aud" id="ixv-23560">132,413</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" sign="-" unitRef="aud" id="ixv-23561">132,413</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expired options</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" scale="0" sign="-" unitRef="aud" id="ixv-23562">560,014</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" scale="0" unitRef="aud" id="ixv-23563">560,014</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited options of reversed to profit or loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="athe:ForfeitedOptionsReversedToProfitOrLoss" scale="0" sign="-" unitRef="aud" id="ixv-23564">17,150</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:ForfeitedOptionsReversedToProfitOrLoss" scale="0" sign="-" unitRef="aud" id="ixv-23565">17,150</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="athe:TransactionsWithOwnersInTheirCapacitySharesAsOwners" scale="0" unitRef="shares" id="ixv-23566">33,023,040</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="0" unitRef="aud" id="ixv-23567">184,262</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="0" unitRef="aud" id="ixv-23568">406,557</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="0" unitRef="aud" id="ixv-23569">560,014</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="0" unitRef="aud" id="ixv-23570">1,150,833</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud" id="ixv-23571">13,806,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud" id="ixv-23572">13,806,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total comprehensive loss for the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud" id="ixv-23573">13,806,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud" id="ixv-23574">13,806,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance, June 30, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23575">2,439,897,618</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="aud" id="ixv-23576">213,971,323</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="aud" id="ixv-23577">3,972,475</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" sign="-" unitRef="aud" id="ixv-23578">195,130,889</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="aud" id="ixv-23579">22,812,909</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Transactions with owners in their capacity as owners:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Issuance of shares</td><td>&#160;</td>
    <td style="text-align: center">10(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuanceOfSharesNetOfCostsShares" scale="0" unitRef="shares" id="ixv-23580">2,798,120,281</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuanceOfSharesNetOfCostsValue" scale="0" unitRef="aud" id="ixv-23581">10,050,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuanceOfSharesNetOfCostsValue" scale="0" unitRef="aud" id="ixv-23582">10,050,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Non-cash issuance of options to directors and employees</td><td>&#160;</td>
    <td style="text-align: center">11(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" scale="0" unitRef="aud" id="ixv-23583">881,950</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" scale="0" unitRef="aud" id="ixv-23584">881,950</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Contributions of equity/Shares to be issued</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="aud" id="ixv-23585">45,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="aud" id="ixv-23586">45,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of shares in connection with exercise of options, net of costs</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10(b) &amp; 11(b)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-23587">7,097,419</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" scale="0" unitRef="aud" id="ixv-23588">49,682</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" scale="0" unitRef="aud" id="ixv-23589">49,682</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Transaction costs from issuance of shares</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" sign="-" unitRef="aud" id="ixv-23590">918,020</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" sign="-" unitRef="aud" id="ixv-23591">918,020</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expired options</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited options reversed to profit or loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="athe:ForfeitedOptionsReversedToProfitOrLoss" scale="0" sign="-" unitRef="aud" id="ixv-23592">93,222</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="athe:ForfeitedOptionsReversedToProfitOrLoss" scale="0" unitRef="aud" id="ixv-23593">93,222</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="athe:TransactionsWithOwnersInTheirCapacitySharesAsOwners" scale="0" unitRef="shares" id="ixv-23594">2,805,217,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="0" unitRef="aud" id="ixv-23595">9,181,662</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="0" unitRef="aud" id="ixv-23596">833,728</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="0" unitRef="aud" id="ixv-23597">93,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="0" unitRef="aud" id="ixv-23598">10,108,612</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud" id="ixv-23599">19,123,464</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud" id="ixv-23600">19,123,464</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total comprehensive loss for the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud" id="ixv-23601">19,123,464</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud" id="ixv-23602">19,123,464</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance, June 30, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23603">5,245,115,318</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="aud" id="ixv-23604">223,152,985</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="aud" id="ixv-23605">4,806,203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" sign="-" unitRef="aud" id="ixv-23606">214,161,131</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="aud" id="ixv-23607">13,798,057</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Transactions with owners in their capacity as owners:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Issuance of shares</td><td>&#160;</td>
    <td style="text-align: center">10(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuanceOfSharesNetOfCostsShares" scale="0" unitRef="shares" id="ixv-23608">3,875,826,636</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuanceOfSharesNetOfCostsValue" scale="0" unitRef="aud" id="ixv-23609">42,547,105</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuanceOfSharesNetOfCostsValue" scale="0" unitRef="aud" id="ixv-23610">42,547,105</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Non-cash issuance of options to directors and employees</td><td>&#160;</td>
    <td style="text-align: center">11(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" scale="0" unitRef="aud" id="ixv-23611">979,920</ix:nonFraction></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" scale="0" unitRef="aud" id="ixv-23612">979,920</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Contributions of equity/ <br/>Shares to be issued</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Issuance of shares in connection with exercise of options, net of costs</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10(b) &amp; 11(b)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-23613">6,428,732</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" scale="0" unitRef="aud" id="ixv-23614">23,540</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" scale="0" sign="-" unitRef="aud" id="ixv-23615">23,540</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Transaction costs from issuance of shares</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" sign="-" unitRef="aud" id="ixv-23616">2,774,168</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" sign="-" unitRef="aud" id="ixv-23617">2,774,168</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expired options</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" scale="0" sign="-" unitRef="aud" id="ixv-23618">326,544</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" scale="0" unitRef="aud" id="ixv-23619">326,544</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="athe:ForfeitedOptionsReversedToProfitOrLoss" scale="0" sign="-" unitRef="aud" id="ixv-23620">93,735</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="athe:ForfeitedOptionsReversedToProfitOrLoss" scale="0" unitRef="aud" id="ixv-23621">93,735</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="athe:TransactionsWithOwnersInTheirCapacitySharesAsOwners" scale="0" unitRef="shares" id="ixv-23622">3,882,255,368</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="0" unitRef="aud" id="ixv-23623">39,796,477</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="0" unitRef="aud" id="ixv-23624">536,101</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="0" unitRef="aud" id="ixv-23625">420,279</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="0" unitRef="aud" id="ixv-23626">40,752,857</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud" id="ixv-23627">12,147,828</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud" id="ixv-23628">12,147,828</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total comprehensive loss for the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud" id="ixv-23629">12,147,828</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="aud" id="ixv-23630">12,147,828</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance, June 30, 2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23631">9,127,370,686</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="aud" id="ixv-23632">262,949,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="aud" id="ixv-23633">5,342,304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" sign="-" unitRef="aud" id="ixv-23634">225,888,680</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="aud" id="ixv-23635">42,403,086</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>The accompanying notes are an integral part of the consolidated
financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="F_07"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory" id="ixv-14020"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Background</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alterity Therapeutics Limited and its controlled subsidiaries, Alterity
Therapeutics Inc. and Alterity Therapeutics UK Limited (referred to collectively as &#8220;Alterity&#8221; or the &#8220;Group&#8221;),
is a development stage enterprise engaged in the research and development of therapeutic drugs designed to treat the underlying cause
of degeneration of the brain focusing on Alzheimer&#8217;s disease, Huntington disease, Parkinson&#8217;s disease and other neurological
disorders. Alterity Therapeutics Limited, the parent entity, was incorporated on November 11, 1997 in Melbourne, Australia and the UK
and U.S. subsidiaries were incorporated in August 2004.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Financial Reporting Framework</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial report of Alterity Therapeutics Limited for the year
ended June 30, 2025 was authorized for issue on August 29, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alterity Therapeutics Limited is a for-profit entity for the purpose
of preparing the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements of the Group comply with International
Financial Reporting Standards (&#8220;IFRS Accounting Standards&#8221;) as issued by the International Accounting Standards Board (IASB)
and Australian equivalents to International Financial Reporting Standards, as issued by the Australian Accounting Standards Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These financial statements have been prepared under the historical
cost convention, as modified by the revaluation of financial liabilities at fair value through profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounting policies are selected and applied in a manner which ensures
that the resulting financial information satisfies the concepts of relevance and reliability, thereby ensuring that the substance of the
underlying transactions or other events is reported.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accounting policies set out below have been applied in preparing
the financial statements for the year ended June 30, 2025 and the comparative information presented in these financial statements for
the years ended June 30, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical accounting estimates, judgments and assumptions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Estimates and judgments are continually evaluated and are based on
historical experience and other factors, including expectations of future events that may have a financial impact on the entity and that
are believed to be reasonable under the circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group makes estimates and assumptions concerning the future. The
resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a
significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are
discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Share-based Payments</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The value attributed to share options and remuneration shares issued
is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models and the resultant
option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options to shares and the
value and volatility of the price of the underlying shares.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
&#8211; in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical accounting estimates, judgments and assumptions (continued)</b><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_2" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>R&amp;D Tax Incentives</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Australian Government adopted a research and development tax incentive
in July 2011. The provisions provide refundable or non-refundable tax offsets. The research and development tax incentive applies to expenditures
incurred and the use of depreciating assets. <ix:nonNumeric contextRef="c0" name="athe:TaxRateEffectFromChangesInTaxRate" id="ixv-23636">A 43.5% refundable tax offset is available to eligible small companies with an annual aggregate
turnover of less than $20 million.</ix:nonNumeric> Management has assessed these activities and expenditure to determine which are likely to be eligible
under the incentive scheme. For the period to June 30, 2025, the Group has recorded an item in other income of A$<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="athe:EligibleAmountUnderTheTaxIncentiveScheme" scale="6" unitRef="aud" id="ixv-23637">5.4</ix:nonFraction> million (2024: A$<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="athe:EligibleAmountUnderTheTaxIncentiveScheme" scale="6" unitRef="aud" id="ixv-23638">4.0</ix:nonFraction>
million, 2023: A$<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="athe:EligibleAmountUnderTheTaxIncentiveScheme" scale="6" unitRef="aud" id="ixv-23639">3.9</ix:nonFraction> million) to recognize the amount which relates to this period (A$<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="6" unitRef="aud" id="ixv-23640">3.9</ix:nonFraction> million).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Going Concern Basis</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group is a development stage medical biotechnology company and
as such expects to be utilizing sources of cash funding until its research activities have become marketable. The Group has incurred recurring
losses since inception including a net loss of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:ProfitLossBeforeTax1" scale="0" unitRef="aud" id="ixv-23641">12,147,828</ix:nonFraction> in the year ended June 30, 2025 (2024: $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:ProfitLossBeforeTax1" scale="0" unitRef="aud" id="ixv-23642">19,123,464</ix:nonFraction>) and a net operating cash
outflow of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:ProfitLossBeforeTax2" scale="0" unitRef="aud" id="ixv-23643">11,451,248</ix:nonFraction> in the year ended June 30, 2025 (2024: $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:ProfitLossBeforeTax2" scale="0" unitRef="aud" id="ixv-23644">12,605,824</ix:nonFraction>). The Group expects to continue incurring losses into the foreseeable
future and will need to raise additional capital to continue the development of its planned research and development programs. The continuing
viability of the Group is subject to its ability to raise additional capital to finance the continuation of its planned research and development
programs, maintaining implemented cost containment and deferment strategies, and successfully commercializing its initiatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group raised new equity funding, net proceeds totaling $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" unitRef="aud" id="ixv-23645">39,669,380</ix:nonFraction>
(see Note 10), during the financial year to enable progression of its planned research and development programs.</p>

<p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company believes the cash and cash equivalents as of June&#160;30,
2025 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the
date of issuance of these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The inability to raise additional capital, as and when needed on acceptable
terms, or if at all would have a negative impact on the Group&#8217;s financial condition and ability to pursue its business strategies.
If the Group is unable to obtain the required funding to operate and to develop and commercialize its product candidates, it could be
forced to delay, reduce or eliminate some or all of its research and development programs, which would adversely affect its business prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These consolidated financial statements have been prepared assuming
the Group will continue as a going concern which contemplates the continuity of operations, realization of assets and the satisfaction
of liabilities in the ordinary course of business and do not include adjustments that would result if the Group were unable to continue
as a going concern.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
&#8211; in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_3" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of these consolidated financial statements requires
the Group to make estimates and judgments that affect the reported amounts of assets, liabilities, income and expenses and related disclosures.
On an ongoing basis, the Group evaluates its significant accounting policies and estimates. Estimates are based on historical experience
and on various market-specific and other relevant assumptions that the Group believes to be reasonable under the circumstances, the results
of which form the basis for making judgments about the carrying values of assets and liabilities. Estimates are assessed each period and
updated to reflect current information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Development Stage &#8211; Risks and Uncertainties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a development stage enterprise, the Group&#8217;s prospects are
subject to the risks, expenses and uncertainties frequently encountered by companies which have not yet commercialized any applications
of their technology, particularly in new and evolving markets. Alterity&#8217;s operating results may fluctuate significantly in the future
as a result of a variety of factors, including capital expenditure and other costs relating to establishing, maintaining and expanding
the operations, the number and mix of potential customers, potential pricing of future products by the Group and its competitors, new
technology introduced by the Group and its competitors, delays or expense in obtaining necessary equipment, economic and social conditions
in the biotechnology industry and general economic conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group cannot be certain that it will be able to raise any required
funding or capital, on favorable terms or at all, or that it will be able to establish corporate collaborations on acceptable terms, if
at all. If the Group is unable to obtain such additional funding or capital, it may be required to reduce the scope of its development
plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group&#8217;s experience in exploiting its technology is limited
and it cannot be certain that its operations will be profitable in the short-term, or at all. If the Group fails in its efforts to establish
or expand its business, the results of operations, financial condition and liquidity of the Group could be materially adversely affected.
The Group cannot be certain that it will be able to sell and deliver its technology or to obtain or retain any permits required in the
market in which it operates. Any of these factors could result in the reduction or cessation of the Group&#8217;s operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Material Accounting Policies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounting policies are selected and applied in a manner which ensures
that the resulting financial information satisfies the concepts of relevance and reliability, thereby ensuring that the substance of the
underlying transactions or other events is reported.</p></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
&#8211; in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_4" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following material accounting policies have been adopted in the
preparation and presentation of the financial report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock-c0_cont_1" escape="true" name="athe:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" id="ixv-14198"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(a) Principles of Consolidation</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock-c0_cont_2" id="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements are prepared by combining the
financial statements of all the entities that comprise the Group, being Alterity Therapeutics Limited and its subsidiaries as defined
in Accounting Standard IFRS10 (AASB 10): <i>Consolidated Financial Statements</i>. Consistent accounting policies are employed in the
preparation and presentation of the consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock-c0_cont_3" id="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsidiaries are all those entities (including special purpose entities)
over which the Group has control. The Group controls an entity where the group is exposed to, or has rights to, variable returns from
its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity.
The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether
the Group controls another entity.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock-c0_cont_4" id="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsidiaries are fully consolidated from the date on which control
is transferred to the Group. They are de-consolidated from the date that control ceases.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In preparing the consolidated financial statements, all inter-company
balances and transactions, and unrealized profits/losses arising within the Group are eliminated in full. Investments in subsidiaries
are accounted for at cost in the individual financial statements of Alterity Therapeutics Limited.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory" id="ixv-14215"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(b) Segment Reporting</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating segments are reported in a manner consistent with the internal
reporting provided to the chief operating decision maker (the &#8220;CODM&#8221;). The CODM, who is responsible for allocating resources
and assessing performance of the operating segments, has been identified as the Chief Executive Officer of Alterity Therapeutics Limited.
For the current and previous reporting periods, the Group operated in one segment, being research and development into Parkinsonian and
other neurodegenerative disorders.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" id="ixv-14223"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(c) Income Tax</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Current tax</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Current tax is calculated by reference to the amount of income taxes
payable or recoverable in respect of the taxable profit or loss for the period. It is calculated using tax rates and tax laws that have
been enacted or substantively enacted by reporting date. Current tax for current and prior periods is recognised as a liability (or asset)
to the extent that it is unpaid (or refundable).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Deferred tax</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax is accounted for using the liability method in respect
of temporary differences arising from differences between the carrying amount of assets and liabilities in the financial statements and
the corresponding tax base of those items.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><b>(c) Income Tax (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_5" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_4"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In principle, deferred tax assets and liabilities are recognised for
all taxable temporary differences. Deferred tax assets are recognised to the extent that it is probable that sufficient taxable amounts
will be available against which deductible temporary differences or unused tax losses and tax offsets can be utilized. However, deferred
tax assets and liabilities are not recognised if the temporary differences giving rise to them arise from the initial recognition of assets
and liabilities (other than as a result of a business combination) which affects neither taxable income nor accounting profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax liabilities are recognised for taxable temporary differences
arising on investments in subsidiaries except where the Group is able to control the reversal of the temporary differences and it is probable
that the temporary differences will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences
associated with these investments are only recognised to the extent that it is probable that there will be sufficient taxable profits
against which to utilize the benefits of the temporary differences and they are expected to reverse in the foreseeable future.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax assets and liabilities are measured at the tax rates that
are expected to apply to the period(s) when the asset and liability giving rise to them are realized or settled, based on tax rates (and
tax laws) that have been enacted or substantively enacted by reporting date. The measurement of deferred tax liabilities and assets reflects
the tax consequences that would follow from the manner in which the Group expects, at the reporting date, to recover or settle the carrying
amount of its assets and liabilities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax assets and liabilities are offset when there is a legally
enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.
Current tax assets and tax liabilities are offset when the entity has a legally enforceable right to offset and intends either to settle
on a net basis or to realize the asset and settle the liability simultaneously.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Current and deferred tax for the period</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_11" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Current and deferred tax is recognised as an expense or income in the
Statement of Profit or Loss and Other Comprehensive Loss except when it relates to items credited or debited directly to equity, in which
case the deferred tax is also recognised directly in equity, or where it arises from the initial accounting for a business combination,
in which case it is taken into account in the determination of goodwill.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group has significant unused tax losses and as such a significant
deferred tax asset; however, the deferred tax asset has not been recognised, as it is not probable that future taxable profit will be
available against which the unused losses and unused tax credits can be utilized, given the nature of the Group&#8217;s business (research
and development) and its history of losses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="ixv-14301"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Property and Equipment</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment is measured at historical cost less accumulated
depreciation and impairment and consists of laboratory equipment, computer equipment, furniture and fittings and leasehold improvements
attributable to the Group&#8217;s premises at Melbourne, Victoria, Australia and San Francisco, U.S.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Historical cost includes expenditure that is directly attributable
to the acquisition of the item.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Subsequent costs are included in the asset&#8217;s carrying amount
or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will
flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate
asset is derecognised when replaced. All other repairs and maintenance are charged to the income statement during the reporting period
in which they are incurred.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Property and Equipment (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_6" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_5"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Depreciation</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation is provided on property and equipment. Depreciation is
calculated on a straight-line method to allocate their cost, net of their residual values, over their estimated useful lives.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="ixv-14355"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following estimated useful lives, ranging from <ix:nonNumeric contextRef="c29" format="ixt-sec:duryear" name="athe:EstimatedUsefulEconomicLife" id="ixv-23646">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c30" format="ixt-sec:duryear" name="athe:EstimatedUsefulEconomicLife" id="ixv-23647">20</ix:nonNumeric> years are
used in the calculation of depreciation:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_7"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Class of Fixed Asset</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Depreciation Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fittings</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c31" decimals="2" format="ixt:num-dot-decimal" name="athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments" scale="-2" unitRef="pure" id="ixv-23648">5</ix:nonFraction>-<ix:nonFraction contextRef="c32" decimals="2" format="ixt:num-dot-decimal" name="athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments" scale="-2" unitRef="pure" id="ixv-23649">33</ix:nonFraction>%</span></td><td style="text-align: left"/></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left">Computer equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c33" decimals="2" format="ixt:num-dot-decimal" name="athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments" scale="-2" unitRef="pure" id="ixv-23650">33</ix:nonFraction>%</td><td style="width: 1%; text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Plant and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments" scale="-2" unitRef="pure" id="ixv-23651">10</ix:nonFraction>-<ix:nonFraction contextRef="c35" decimals="2" format="ixt:num-dot-decimal" name="athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments" scale="-2" unitRef="pure" id="ixv-23652">33</ix:nonFraction>%</span></td><td style="text-align: left"/></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c36" decimals="2" format="ixt:num-dot-decimal" name="athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments" scale="-2" unitRef="pure" id="ixv-23653">33</ix:nonFraction>%</td><td style="text-align: left"/></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leasehold improvements are depreciated over the shorter of the lease
term and useful life.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The depreciation method, residual values and useful lives are reviewed,
and adjusted if appropriate, at each annual reporting period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="ixv-14405"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(e) Leases</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accounting policies for the Group&#8217;s lease recognition are
explained in Note 13.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="ixv-14413"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(f) Investments and other financial assets </b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Classification </span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group classifies its financial assets in the following measurement
categories:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">those to be measured subsequently at fair value (either through OCI or through profit or loss), and</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">those to be measured at amortized cost.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The classification depends on the entity&#8217;s business model for
managing the financial assets and the contractual terms of the cash flow. For assets measured at fair value, gains and losses will either
be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, this will depend on whether
the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through
other comprehensive income.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recognition and derecognition</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regular way purchases and sales of financial assets are recognised
on trade-date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognised when the rights to
receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the
risks and rewards of ownership.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Measurement</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At initial recognition, the Group measures a financial asset at its
fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs that are directly attributable
to the acquisition of the financial asset. Transaction costs of financial assets carried at fair value through profit or loss are expensed
in profit or loss.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(f) Investments and other financial assets (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_7" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_6"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_11" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assets that are held for collection of contractual cash flows where
those cash flows represent solely payments of principal and interest are measured at amortised cost. Interest income from these financial
assets is included in finance income using the effective interest method. Any gain or loss arising on derecognition is recognised directly
in profit or loss and presented in other gains/(losses) together with foreign exchange gains and losses. Impairment losses are presented
as a separate line item in the consolidated statement of profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_12" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Impairment</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_13" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group assesses on a forward looking basis the expected credit losses
associated with its debt instruments carried at amortized cost and fair value through other comprehensive income. The impairment methodology
applied depends on whether there has been a significant increase in credit risk.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For trade receivables, the Group applies the simplified approach which
requires expected lifetime losses to be recognised from initial recognition of the receivables, see Note 5 for further details.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" id="ixv-14511"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(g) Impairment of Assets</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At each reporting date, the Group reviews the carrying amounts of its
tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If any such indication
exists, the recoverable amount of the asset is estimated to determine the extent of the impairment loss (if any).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where the asset does not generate cash flows that are independent from
other assets, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recoverable amount is the higher of fair value less costs of disposal
and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount
rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of
future cash flows have not been adjusted.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the recoverable amount of an asset (or cash-generating unit) is
estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable
amount. An impairment loss is recognised in the consolidated statement of profit or loss and other comprehensive loss immediately.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where an impairment loss subsequently reverses, the carrying amount
of the asset (or cash-generating unit) is reversed to the revised estimate of its recoverable amount, but only to the extent that the
increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for
the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised in the consolidated statement of profit
or loss and other comprehensive loss immediately.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No impairment charges were incurred during the year ended June 30,
2025.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_8" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="ixv-14565"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(h) Intangible Assets - Research and Development </b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Expenditure during the research phase of a project is recognised as
an expense when incurred. Where no internally generated intangible assets can be recognised, development expenditure is recognised as
an expense in the period as incurred. Development costs are capitalised if and only if, all of the following are demonstrated:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the technical feasibility of completing the intangible asset so that it will be available for use or sale;</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the intention to complete the intangible asset and use or sell it;</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to use or sell the intangible asset;</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">how the intangible asset will generate probable future economic benefits;</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_7"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to measure reliably the expenditure attributable to the intangible asset during its development.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Internally-generated intangible assets (capitalised development costs)
are stated at cost less accumulated amortisation and impairment, and are amortised on a straight-line basis over their useful lives over
a maximum of five years.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2025, 2024 and 2023, the Group had no capitalized research
and development costs.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="ixv-14634"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(i) Foreign Currency Transactions and Balances</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Functional and Presentation Currency</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements are presented in Australian dollars
($), which is Alterity Therapeutics Limited&#8217;s functional and presentation currency.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Foreign currency transactions</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All foreign currency transactions during the financial year are brought
to account using the exchange rate in effect at the date of the transaction. Foreign currency monetary items at each reporting date are
translated at the exchange rate existing at each reporting date. Non-monetary assets and liabilities carried at fair value that are denominated
in foreign currencies are translated at the rates prevailing at the date when the fair value was determined.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exchange differences are recognised in profit or loss in the period
in which they arise except for exchange differences on monetary items receivable from or payable to a foreign operation for which settlement
is neither planned or likely to occur, which form part of the net investment in a foreign operation, are recognised in the foreign currency
translation reserve and recognised in profit or loss on disposal of the net investment.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><b>(i) Foreign Currency Transactions
and Balances (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_9" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_8"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Subsidiaries</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The results and financial position of all the Group&#8217;s entities
that have a functional currency difference from the presentation currency are translated into the presentation currency as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_8"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet, and</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_9"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">income and expenses for each income statement are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions), and</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_10"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all resulting exchange differences are recognised as a separate component of equity.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" id="ixv-14727"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(j) Employee Benefits</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Short-term obligations</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Short-term employee benefits are benefits (other than termination benefits)
that are expected to be settled wholly before 12 months after the end of the annual reporting period in which the employees render the
related service, including wages, and salaries. Short-term employee benefits are measured at the (undiscounted) amounts expected to be
paid when the obligation is settled. The Group&#8217;s obligations for short-term employee benefits such as wages and salaries are recognised
as a part of current trade and other payables in the statement of financial position.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group&#8217;s obligations for annual leave are presented as part
of provisions in the Statement of Financial Position. The obligations are presented as current liabilities in the Statement of Financial
Position if the Group does not have an unconditional right to defer settlement for at least twelve months after the reporting period regardless
of when the actual settlement is expected to occur.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Other long-term obligations</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The liability for long service leave is not expected to be settled
wholly within twelve months after the end of the period in which the employees render the related service. The liability is therefore
recognised in the provision for employee benefits and measured as the present value of expected future payments to be made in respect
of services provided by employees up to the end of the reporting period using the projected unit credit method. Consideration is given
to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted
using market yields at the end of the reporting period of high quality corporate bonds with terms and currencies that match, as closely
as possible, the estimated future cash outflows. Re-measurements as a result of experience adjustments and changes in actuarial assumptions
are recognised in profit or loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The obligations are presented as current liabilities in the balance
sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless
of when the actual settlement is expected to occur.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_10" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_9"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" id="ixv-14784"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(k) Provisions</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Provisions are recognised when the Group has a present obligation,
the future sacrifice of economic benefits is probable, and the amount of the provision can be measured reliably.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amount recognised as a provision is the best estimate of the consideration
required to settle the present obligation at reporting date, taking into account the risks and uncertainties surrounding the obligation.
Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value
of those cash flows.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForProvisionsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">When some or all of the economic benefits required to settle a provision
are expected to be recovered from a third party, the receivable is recognised as an asset if it is virtually certain that recovery will
be received and the amount of the receivable can be measured reliably.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" id="ixv-14797"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(l) Cash and Cash Equivalents</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash and cash equivalents include cash on hand, deposits held at call
with banks and other short-term highly liquid investments with original maturities of three months or less.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome-c0_cont_1" escape="true" name="athe:DescriptionOfAccountingPolicyForRecognitionOfOtherIncome" id="ixv-14804"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><b>(m) Interest income</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other income is made up of interest income which is recognised on a
time proportion basis using the effective interest method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForGovernmentGrants-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants" id="ixv-14811"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(n) Grants</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForGovernmentGrants-c0_cont_2" id="_DescriptionOfAccountingPolicyForGovernmentGrants-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Grants are recognised when there is reasonable assurance that the grant
will be received and all grant conditions will be complied with.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForGovernmentGrants-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">When the grant relates to an expense item, it is recognised as income
over the periods necessary to match the grant on a systematic basis to the costs that it is expected to compensate.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" id="ixv-14821"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(o) Goods and Services Tax (&#8220;GST&#8221;)</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenues, expenses and assets are recognised net of the amount of GST,
except where the amount of GST incurred is not recoverable from the taxation authority. In these circumstances the GST is recognised as
part of the cost of acquisition of the asset or as part of an item of expense.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Receivables and payables in the Statement of Financial Position are
shown inclusive of GST. The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables
or payables.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash flows are included in the Cash Flow Statement on a gross basis.
The GST component of cash flows arising from investing and financing activities which is recoverable from, or payable to, the taxation
authority is classified as operating cash flows.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_11" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_10"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" id="ixv-14865"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(p) Trade and Other Payables</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These amounts represent liabilities for goods and services provided
to the Group prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of
recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months from the reporting
date. They are recognised initially at their fair value and subsequently measured at amortized cost using the effective interest method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="ixv-14872"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(q) Share-Based Payments</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The measurement date is determined for share-based payments issued
to directors, employees and consultants as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Directors</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The issuance of share-based payments to directors is subject to approval
by shareholders as per ASX Listing Rule 10.11. The measurement date for share-based payments issued to directors is the grant date, being
the date at which the share-based payments are approved by shareholders.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="athe_Employeesdescription-c0_cont_1" name="athe:Employeesdescription" id="ixv-14887"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Employees</span></p></ix:nonNumeric></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_5"><ix:continuation id="athe_Employeesdescription-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The issuance of share-based payments to employees may be subject to
shareholder approval per ASX Listing Rule 7.1 which prohibits the issuance of more than 15% of the Group&#8217;s shares in a 12 month
period without shareholder approval. The measurement date for share-based payments issued to employees is the grant date, being the date
at which a shared understanding of the terms and conditions of the arrangement is reached. However, if an issuance to an employee is subject
to shareholder approval because it exceeds the 15% threshold per ASX Listing Rule 7.1, then the measurement date of these share-based
payments is the date at which the share-based payments are approved by shareholders.</p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Consultants</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The issuance of share-based payments to consultants may be subject
to shareholder approval per ASX Listing Rule 7.1 which prohibits the issuance of more than 15% of the Group&#8217;s shares in a 12 month
period without shareholder approval. The measurement date for share-based payments issued to consultants who provide services considered
to be similar to employees is deemed to be the date at which a shared understanding of the terms and conditions of the arrangement is
reached. The measurement date for share-based payments issued to consultants who provide services considered to be differentiated from
those provided by employees is deemed to be the date at which the entity obtains the goods or the counterparty renders the service. If
a service period applies and the work is continually provided over the service period, and if the share price of the Group does not change
significantly during the service period, then the average share price, volatility and risk-free rate over the service period are used
in calculating the value of the share-based payments issued. However, if the underlying share price of the Group does change significantly
during the service period, then the value of share-based payments are calculated at each individual date that goods and services are provided,
using the actual valuation inputs at that date. Shares issued to consultants for services are recorded as non-cash compensation and are
recognised at either the fair value of the services rendered, or if this cannot be reasonably estimated, the fair value of the underlying
equity instruments issued. Equity-based compensation benefits are provided to directors, employees and consultants under the 2004 ASX
Plan (the &#8220;2004 ASX Plan&#8221;) and the 2018 American Depository Share (ADS) Option Plan (the &#8220;2018 ADS Plan&#8221;). Information
relating to this plan is set out in Note 16.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(q) Share-Based Payments (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_11"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value of options granted under these plans is recognised as
an expense with a corresponding increase in equity. The fair value is measured at grant date and recognised over the period during which
the recipients become unconditionally entitled to the options.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value at grant date is independently determined using a Black-Scholes
(for options without market condition) and Barrier Pricing (for options with market conditions) model that takes into account the exercise
price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share,
the expected dividend yield and the risk free interest rate for the term of the option. The expected life used in the model has been adjusted,
based on management&#8217;s best estimate, for the effects of non-transferability, exercise restrictions, and behavioral considerations.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value determined at the grant date of the equity-settled share-based
payments is expensed on a straight-line basis over the vesting period, based on the Group&#8217;s estimate of shares that will eventually
vest.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="ixv-14948"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(r) Loss Per Share</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic loss per share is determined by dividing the net loss after income
tax expense by the weighted average number of ordinary shares outstanding during the financial period. For all periods presented, diluted
loss per share is equivalent to basic loss per share as the potentially dilutive securities are excluded from the computation of diluted
loss per share because the effect is anti-dilutive.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" id="ixv-14955"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(s) Share Capital</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ordinary share capital is recognised as the fair value of the consideration
received by the Group. Any transaction costs arising on the issue of ordinary shares are recognised directly in equity as a reduction
of the share proceeds received.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" id="ixv-14962"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(t) Trade and Other Receivables</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Trade and other receivables are recognised initially at fair value
and subsequently measured at amortized cost using the effective interest rate method less provision for impairment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock-c0_cont_1" escape="true" name="athe:DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock" id="ixv-14969"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(u) Comparative Figures</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Comparative figures, are, where appropriate, reclassified to be comparable
with figures presented in the current financial year.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock-c0_cont_1" escape="true" name="athe:DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock" id="ixv-14976"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(v) New Accounting Standards and Interpretations </b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock-c0_cont_2" id="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group has adopted all of the new or amended Accounting Standards
and Interpretations issued by the International Accounting Standards Board &#8216;IASB&#8217; and Australian Accounting Standards Board
&#8216;AASB&#8217; that are mandatory for the current reporting period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock-c0_cont_3" id="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The adoption of these standards has not had any material impact on
the disclosures or amounts reported in these financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock-c0_cont_4" id="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2024, IFRS 18, &#8220;Presentation and Disclosure in Financial
Statements&#8221; was issued to achieve comparability of the financial performance of similar entities. The standard, which replaces IAS
1 &#8220;Presentation of Financial Statements&#8221;, impacts the presentation of primary financial statements and notes, including the
statement of earnings where companies will be required to present separate categories of income and expense for operating, investing,
and financing activities with prescribed subtotals for each new category. The standard will also require management-defined performance
measures to be explained and included in a separate note within the consolidated financial statements. The standard is effective for annual
reporting periods beginning on or after January 1, 2027, including interim financial statements, and requires retrospective application.
The Group is currently assessing the impact of the new standard.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no other new accounting standards and interpretations not
yet adopted by the Group for the June 30, 2025 reporting period that are expected to materially impact the Group.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfInterestIncomeExplanatory" id="ixv-15015"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. INTEREST AND OTHER INCOME FROM CONTINUING OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="athe:ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock" id="ixv-15019"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Interest income</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Interest income</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromInterest" scale="0" unitRef="aud" id="ixv-23654">446,291</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromInterest" scale="0" unitRef="aud" id="ixv-23655">268,419</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromInterest" scale="0" unitRef="aud" id="ixv-23656">16,436</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total interest income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherRevenue" scale="0" unitRef="aud" id="ixv-23657">446,291</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherRevenue" scale="0" unitRef="aud" id="ixv-23658">268,419</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherRevenue" scale="0" unitRef="aud" id="ixv-23659">16,436</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D Tax Incentive (1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="athe:ResearchAndDevelopmentTaxIncentive" scale="0" unitRef="aud">5,438,918</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="athe:ResearchAndDevelopmentTaxIncentive" scale="0" unitRef="aud">4,019,285</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_2_fact" name="athe:ResearchAndDevelopmentTaxIncentive" scale="0" unitRef="aud">3,914,230</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Miscellaneous income (2)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_3_fact" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="0" unitRef="aud">2,202,598</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_4_fact" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="0" unitRef="aud">2,103</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud" id="ixv-23665">7,641,516</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud" id="ixv-23666">4,019,285</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="aud" id="ixv-23667">3,916,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total interest and other income from continuing operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueAndOperatingIncome" scale="0" unitRef="aud" id="ixv-23668">8,087,807</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueAndOperatingIncome" scale="0" unitRef="aud" id="ixv-23669">4,287,704</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueAndOperatingIncome" scale="0" unitRef="aud" id="ixv-23670">3,932,769</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:TaxRateEffectFromChangeInTaxRate" scale="-2" unitRef="pure" id="ixv-23671">43.5</ix:nonFraction>% R&amp;D Tax incentive refundable tax offset, is available to eligible small companies with an annual aggregate turnover of less than $<ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="athe:TurnoverRevenue" scale="6" unitRef="usd" id="ixv-23672">20</ix:nonFraction> million. For the years ended June 30, 2025, June 30, 2024 and June 30, 2023, the Group was eligible to receive the refundable tax offset. Management, with input from an independent expert, has applied judgement when assessing activities and expenditures that are likely to be eligible under the incentive scheme and therefore recorded $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:EligibleAmountUnderTaxIncentiveScheme" scale="0" unitRef="usd" id="ixv-23673">5,438,918</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:EligibleAmountUnderTaxIncentiveScheme" scale="0" unitRef="usd" id="ixv-23674">4,019,285</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:EligibleAmountUnderTaxIncentiveScheme" scale="0" unitRef="usd" id="ixv-23675">3,914,230</ix:nonFraction> in other income, respectively.</span></ix:footnote></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:footnote id="ix_1_footnote" xml:lang="en-US">Miscellaneous income is comprised of other income of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:MiscellaneousIncomeDisputeWithCatalent" scale="0" unitRef="usd" id="ixv-23677">1,975,056</ix:nonFraction> in relation to settlement of a dispute with Catalent, and other income of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:MiscellaneousIncomeSettlementOfAnInsuranceClaim" scale="0" unitRef="usd" id="ixv-23678">227,542</ix:nonFraction> in relation to settlement of an insurance claim in relation to a U.S. employment case.</ix:footnote></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td></tr> </table></ix:nonNumeric></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfExpensesExplanatory" id="ixv-15227"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>3. EXPENSES FROM ORDINARY ACTIVITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfExpensesByNatureExplanatory" id="ixv-15231"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Research and Development Expenses (1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Employee expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_5_fact" name="ifrs-full:EmployeeBenefitsExpense" scale="0" unitRef="aud">2,424,781</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_6_fact" name="ifrs-full:EmployeeBenefitsExpense" scale="0" unitRef="aud">2,456,230</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_7_fact" name="ifrs-full:EmployeeBenefitsExpense" scale="0" unitRef="aud">2,720,345</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_8_fact" name="athe:OtherResearchAndDevelopmentExpenses" scale="0" unitRef="aud">12,107,024</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_9_fact" name="athe:OtherResearchAndDevelopmentExpenses" scale="0" unitRef="aud">16,187,817</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_10_fact" name="athe:OtherResearchAndDevelopmentExpenses" scale="0" unitRef="aud">10,478,238</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">General and Administration Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Depreciation on fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="0" unitRef="aud" id="ixv-23685">28,307</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="0" unitRef="aud" id="ixv-23686">35,344</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="0" unitRef="aud" id="ixv-23687">37,854</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Depreciation on leased assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" unitRef="aud" id="ixv-23688">111,408</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" unitRef="aud" id="ixv-23689">112,185</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" unitRef="aud" id="ixv-23690">64,409</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Employee expenses (non R&amp;D related)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherEmployeeExpense" scale="0" unitRef="aud" id="ixv-23691">1,046,530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherEmployeeExpense" scale="0" unitRef="aud" id="ixv-23692">515,803</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherEmployeeExpense" scale="0" unitRef="aud" id="ixv-23693">926,314</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Consultant and director expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:ConsultantAndDirectorExpenses" scale="0" unitRef="aud" id="ixv-23694">652,260</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:ConsultantAndDirectorExpenses" scale="0" unitRef="aud" id="ixv-23695">321,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:ConsultantAndDirectorExpenses" scale="0" unitRef="aud" id="ixv-23696">320,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Audit, internal control and other assurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:AuditInternalControlAndOtherAssuranceExpenses" scale="0" unitRef="aud" id="ixv-23697">460,254</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:AuditInternalControlAndOtherAssuranceExpenses" scale="0" unitRef="aud" id="ixv-23698">241,828</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:AuditInternalControlAndOtherAssuranceExpenses" scale="0" unitRef="aud" id="ixv-23699">238,728</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Corporate compliance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:CorporateComplianceExpenses" scale="0" unitRef="aud" id="ixv-23700">780,320</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:CorporateComplianceExpenses" scale="0" unitRef="aud" id="ixv-23701">790,350</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:CorporateComplianceExpenses" scale="0" unitRef="aud" id="ixv-23702">457,215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceExpense" scale="0" unitRef="aud" id="ixv-23703">549,408</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceExpense" scale="0" unitRef="aud" id="ixv-23704">676,219</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InsuranceExpense" scale="0" unitRef="aud" id="ixv-23705">721,732</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Office rental</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:OfficeRentalExpenses" scale="0" sign="-" unitRef="aud" id="ixv-23706">2,253</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:OfficeRentalExpenses" scale="0" sign="-" unitRef="aud" id="ixv-23707">9,674</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:OfficeRentalExpenses" scale="0" unitRef="aud" id="ixv-23708">68,634</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other administrative and office expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdministrativeExpense" scale="0" unitRef="aud" id="ixv-23709">520,142</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdministrativeExpense" scale="0" unitRef="aud" id="ixv-23710">1,028,638</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdministrativeExpense" scale="0" unitRef="aud" id="ixv-23711">1,032,843</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Share based payment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" unitRef="aud" id="ixv-23712">979,920</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" unitRef="aud" id="ixv-23713">881,950</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" unitRef="aud" id="ixv-23714">966,571</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Corporate advisory expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:CorporateAdvisoryExpenses" scale="0" unitRef="aud" id="ixv-23715">355,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:CorporateAdvisoryExpenses" scale="0" unitRef="aud" id="ixv-23716">169,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:CorporateAdvisoryExpenses" scale="0" unitRef="aud" id="ixv-23717">204,621</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Other gains and losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Foreign exchange (gain)/loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" sign="-" unitRef="aud" id="ixv-23718">259,433</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" sign="-" unitRef="aud" id="ixv-23719">261,152</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" sign="-" unitRef="aud" id="ixv-23720">917,650</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses mainly consist of expenses paid for contracted research and development activities conducted by third parties on behalf of the Group.</span></ix:footnote></td></tr> </table></ix:nonNumeric></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="ixv-15560"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. INCOME TAX</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="athe:DisclosureOfIncomeTaxExplanatoryTableTextBlock" id="ixv-15564"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>(a) Income tax expense:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Current tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTaxExpenseIncome" scale="0" unitRef="aud" id="ixv-23721">77,411</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTaxExpenseIncome" scale="0" unitRef="aud" id="ixv-23722">58,463</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTaxExpenseIncome" scale="0" unitRef="aud" id="ixv-23723">33,808</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustment for current tax of prior periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" scale="0" sign="-" unitRef="aud" id="ixv-23724">9,356</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" scale="0" sign="-" unitRef="aud" id="ixv-23725">12,375</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" scale="0" unitRef="aud" id="ixv-23726">70,651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">(b) Numerical reconciliation of income tax expense to prima facie tax payable:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Prima facie tax on net loss before income tax at <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="athe:PrimaFacieTaxOnNetLossBeforeIncomeTax" scale="-2" unitRef="pure" id="ixv-23727">25</ix:nonFraction>% (2024: <ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="athe:PrimaFacieTaxOnNetLossBeforeIncomeTax" scale="-2" unitRef="pure" id="ixv-23728">25</ix:nonFraction>%, 2023: <ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="athe:PrimaFacieTaxOnNetLossBeforeIncomeTax" scale="-2" unitRef="pure" id="ixv-23729">25</ix:nonFraction>%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:PrimaFaciesTaxOnNetLossBeforeIncomeTax" scale="0" unitRef="aud" id="ixv-23730">3,019,943</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:PrimaFaciesTaxOnNetLossBeforeIncomeTax" scale="0" unitRef="aud" id="ixv-23731">4,769,344</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:PrimaFaciesTaxOnNetLossBeforeIncomeTax" scale="0" unitRef="aud" id="ixv-23732">3,446,718</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Effect of lower tax rates of tax on overseas income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TaxEffectOfForeignTaxRates" scale="0" sign="-" unitRef="aud" id="ixv-23733">14,745</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TaxEffectOfForeignTaxRates" scale="0" sign="-" unitRef="aud" id="ixv-23734">11,134</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TaxEffectOfForeignTaxRates" scale="0" sign="-" unitRef="aud" id="ixv-23735">6,440</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Add tax effect of:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Under/(Over) provision of income tax in previous year relating to a revision of estimates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" scale="0" sign="-" unitRef="aud" id="ixv-23736">9,356</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" scale="0" sign="-" unitRef="aud" id="ixv-23737">12,375</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" scale="0" unitRef="aud" id="ixv-23738">70,651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenditure (net of tax incentive)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:TaxEffectOfResearchAndDevelopmentExpenditure" scale="0" sign="-" unitRef="aud" id="ixv-23739">898,066</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:TaxEffectOfResearchAndDevelopmentExpenditure" scale="0" sign="-" unitRef="aud" id="ixv-23740">1,305,112</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:TaxEffectOfResearchAndDevelopmentExpenditure" scale="0" sign="-" unitRef="aud" id="ixv-23741">1,267,940</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="0" unitRef="aud" id="ixv-23742">464,299</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="0" unitRef="aud" id="ixv-23743">377,405</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="0" unitRef="aud" id="ixv-23744">413,976</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred tax asset not recognised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:TaxEffectOfDeferredTaxAssetNotRecognized" scale="0" unitRef="aud" id="ixv-23745">1,749,734</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:TaxEffectOfDeferredTaxAssetNotRecognized" scale="0" unitRef="aud" id="ixv-23746">3,156,424</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:TaxEffectOfDeferredTaxAssetNotRecognized" scale="0" unitRef="aud" id="ixv-23747">1,805,050</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Income tax expense attributable to loss before income tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="0" unitRef="aud" id="ixv-23748">68,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="0" unitRef="aud" id="ixv-23749">46,088</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="0" unitRef="aud" id="ixv-23750">104,459</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">(c) Potential deferred tax asset as of June 30, 2025, 2024 and 2023 in respect of: tax losses not brought to account is (1)(2):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_11_fact" name="ifrs-full:DeferredTaxAssets" scale="0" unitRef="aud">49,885,043</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_12_fact" name="ifrs-full:DeferredTaxAssets" scale="0" unitRef="aud">47,758,242</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_13_fact" name="ifrs-full:DeferredTaxAssets" scale="0" unitRef="aud">44,056,899</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Temporary differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_14_fact" name="ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" scale="0" unitRef="aud">6,798,561</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_15_fact" name="ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" scale="0" unitRef="aud">6,660,171</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_16_fact" name="ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" scale="0" unitRef="aud">3,675,742</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><ix:footnote id="ix_3_footnote" xml:lang="en-US">As of June 30, 2025, the Group had a potential tax benefit related to gross tax losses carried forward of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" scale="0" unitRef="aud" id="ixv-23758">187,632,492</ix:nonFraction> (2024: $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" scale="0" unitRef="aud" id="ixv-23759">179,125,289</ix:nonFraction>) and a non-refundable R&amp;D tax offset of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" scale="0" unitRef="aud" id="ixv-23760">2,126,801</ix:nonFraction> (2024: $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" scale="0" unitRef="aud" id="ixv-23761">3,703,478</ix:nonFraction>).</ix:footnote></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td><ix:footnote id="ix_4_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unused tax loss amounts are only attributable to the Group&#8217;s operations in Australia, as the subsidiary in the United States has no carryforward tax losses as of June 30, 2025. Tax losses can be carried forward indefinitely subject to continuity of ownership and same business test rules.</span></ix:footnote></td></tr> </table></ix:nonNumeric></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory" id="ixv-15900"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. TRADE AND OTHER RECEIVABLES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="athe:DisclosureOfTradeAndOtherReceivableTableTextBlock" id="ixv-15904"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued interest income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAccruedIncomeIncludingCurrentContractAssets" scale="0" unitRef="aud" id="ixv-23762">157</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">R&amp;D tax incentive receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="athe:ResearchAndDevelopmentTaxIncentiveReceivable" scale="0" unitRef="aud" id="ixv-23763">3,928,563</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="athe:ResearchAndDevelopmentTaxIncentiveReceivable" scale="0" unitRef="aud" id="ixv-23764">4,019,286</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Goods and services tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentValueAddedTaxReceivables" scale="0" unitRef="aud" id="ixv-23765">9,044</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentValueAddedTaxReceivables" scale="0" unitRef="aud" id="ixv-23766">22,232</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="0" unitRef="aud" id="ixv-23767">3,937,607</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="0" unitRef="aud" id="ixv-23768">4,041,675</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">R&amp;D tax incentive receivable represents the amount of the financial
year 2025 R&amp;D tax incentive the Group expects to recover. For further details, see Note 2.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfOtherAssetsExplanatory" id="ixv-15983"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6. OTHER CURRENT ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory" id="ixv-15987"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Years Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Prepayments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepayments" scale="0" unitRef="aud" id="ixv-23769">1,233,122</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepayments" scale="0" unitRef="aud" id="ixv-23770">2,315,632</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Term deposit (1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_17_fact" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="0" unitRef="aud">7,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="0" unitRef="aud" id="ixv-23772">41,815</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="0" unitRef="aud" id="ixv-23773">40,668</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="0" unitRef="aud" id="ixv-23774">8,774,937</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="0" unitRef="aud" id="ixv-23775">2,356,300</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify"><ix:footnote id="ix_5_footnote" xml:lang="en-US">Term deposit of <ix:nonNumeric contextRef="c0" format="ixt-sec:durday" name="athe:TermDeposit" id="ixv-23777">150</ix:nonNumeric>-day term and maturity date of <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="athe:MaturityDate" id="ixv-23778">October
17, 2025</ix:nonNumeric>.</ix:footnote></td>
</tr></table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="ixv-16059"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>7. TRADE AND OTHER PAYABLES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="athe:ScheduleOfTradeAndOtherPayableTableTextBlock" id="ixv-16063"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Trade creditors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="0" unitRef="aud" id="ixv-23779">538,276</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="0" unitRef="aud" id="ixv-23780">581,137</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="athe:AccruedResearchAndDevelopmentExpenses" scale="0" unitRef="aud" id="ixv-23781">1,684,726</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="athe:AccruedResearchAndDevelopmentExpenses" scale="0" unitRef="aud" id="ixv-23782">3,499,960</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="athe:AccruedProfessionalFees" scale="0" unitRef="aud" id="ixv-23783">193,095</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="athe:AccruedProfessionalFees" scale="0" unitRef="aud" id="ixv-23784">234,899</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued corporate personnel expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" scale="0" unitRef="aud" id="ixv-23785">139,240</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" scale="0" unitRef="aud" id="ixv-23786">166,063</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="athe:OtherCurrentAccruedExpenses" scale="0" unitRef="aud" id="ixv-23787">900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="athe:OtherCurrentAccruedExpenses" scale="0" unitRef="aud" id="ixv-23788">123,457</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="0" unitRef="aud" id="ixv-23789">19,253</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="0" unitRef="aud" id="ixv-23790">14,431</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" unitRef="aud" id="ixv-23791">2,575,490</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" unitRef="aud" id="ixv-23792">4,619,947</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfProvisionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfProvisionsExplanatory" id="ixv-16182"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8. PROVISIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" id="ixv-16186"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="text-decoration:underline">Current</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Annual leave (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" id="ix_18_fact" name="ifrs-full:CurrentProvisions" scale="0" unitRef="aud">631,941</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" id="ix_19_fact" name="ifrs-full:CurrentProvisions" scale="0" unitRef="aud">318,694</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Long service leave (1)(2)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" id="ix_20_fact" name="ifrs-full:CurrentProvisions" scale="0" unitRef="aud">243,967</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" id="ix_21_fact" name="ifrs-full:CurrentProvisions" scale="0" unitRef="aud">212,005</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentProvisions" scale="0" unitRef="aud" id="ixv-23797">875,908</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentProvisions" scale="0" unitRef="aud" id="ixv-23798">530,699</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline">Non-Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long service leave (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A provision has been recognised for employee entitlements relating
to long service leave. In calculating the present value of future cash flows in respect of long service leave, the probability of long
service leave being taken is based on historical data. The measurement and recognition criteria relating to employee benefits have been
included in Note 1 to this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory-c0_cont_2" id="_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(1) <ix:footnote id="ix_6_footnote" xml:lang="en-US">Movements in provisions</ix:footnote></b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="athe:DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock" id="ixv-16297"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Movements in each class of provision during the financial year are
set out below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Annual leave</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Carrying amount at start of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Provisions" scale="0" unitRef="aud" id="ixv-23800">318,694</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Provisions" scale="0" unitRef="aud" id="ixv-23801">420,380</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Provisions" scale="0" unitRef="aud" id="ixv-23802">371,877</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Charged/(credited) to profit or loss -additional provisions recognised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="0" unitRef="aud" id="ixv-23803">409,646</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="0" unitRef="aud" id="ixv-23804">179,923</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="0" unitRef="aud" id="ixv-23805">272,502</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amounts used during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="0" unitRef="aud" id="ixv-23806">97,011</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="0" unitRef="aud" id="ixv-23807">280,618</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="0" unitRef="aud" id="ixv-23808">232,747</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in foreign exchange</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" scale="0" unitRef="aud" id="ixv-23809">612</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" scale="0" sign="-" unitRef="aud" id="ixv-23810">991</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" scale="0" unitRef="aud" id="ixv-23811">8,748</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Carrying amount at end of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Provisions" scale="0" unitRef="aud" id="ixv-23812">631,941</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Provisions" scale="0" unitRef="aud" id="ixv-23813">318,694</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Provisions" scale="0" unitRef="aud" id="ixv-23814">420,380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Long service leave</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Carrying amount at start of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Provisions" scale="0" unitRef="aud" id="ixv-23815">212,005</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Provisions" scale="0" unitRef="aud" id="ixv-23816">328,325</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Provisions" scale="0" unitRef="aud" id="ixv-23817">298,143</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Charged/(credited) to profit or loss -additional provisions recognised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="0" unitRef="aud" id="ixv-23818">32,901</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="0" unitRef="aud" id="ixv-23819">30,308</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="0" unitRef="aud" id="ixv-23820">30,182</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Amounts used during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="0" unitRef="aud" id="ixv-23821">939</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="0" unitRef="aud" id="ixv-23822">146,628</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Carrying amount at end of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Provisions" scale="0" unitRef="aud" id="ixv-23823">243,967</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Provisions" scale="0" unitRef="aud" id="ixv-23824">212,005</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Provisions" scale="0" unitRef="aud" id="ixv-23825">328,325</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:AnnualLeaveAndLongServiceLeaveCarryingAmount" scale="0" unitRef="aud" id="ixv-23826">875,908</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:AnnualLeaveAndLongServiceLeaveCarryingAmount" scale="0" unitRef="aud" id="ixv-23827">530,699</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:AnnualLeaveAndLongServiceLeaveCarryingAmount" scale="0" unitRef="aud" id="ixv-23828">748,705</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8. PROVISIONS (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation id="_DisclosureOfProvisionsExplanatory-c0_cont_1"><ix:continuation id="_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(2) <ix:footnote id="ix_7_footnote" xml:lang="en-US">Amounts not expected to be settled within the next 12 months</ix:footnote></b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The current provision for long service leave includes all unconditional
entitlements where employees have completed the required period of service and also those where employees are entitled to pro-rata payments
in certain circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The entire amount is presented as current, since the Group does not
have an unconditional right to defer settlement. However, based on past experience, the Group does not expect all employees to take the
full amount of accrued long service leave or require payment within the next 12 months.<b>&#160;</b></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" id="ixv-16554"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>9. COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There are no contingent liabilities at the date of this report. The
Group is not involved in any legal or arbitration proceedings and, so far as management is aware, no such proceedings are pending or threatened
against the Group.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In respect of expenditure commitments, refer to Note 15.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfIssuedCapitalExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfIssuedCapitalExplanatory" id="ixv-16564"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>10. ISSUED CAPITAL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In February 2025, we received commitments for a
capital raising of approximately $<ix:nonFraction contextRef="c51" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:CapitalCommitments" scale="6" unitRef="usd" id="ixv-23830">40</ix:nonFraction> million by means of a two tranche placement (the <b>Placement</b>) of fully paid ordinary shares.
For every three new shares issued, one free attaching option was issued. The number of securities issued to the Placement participants
on February 17, 2025 (Tranche 1), April 4, 2025 (Tranche 2) and April 23,2025 (Options) pursuant to ASX Listing Rule 7.1, and which are
within the volumes approved by shareholders at the EGM on March 31, 2025, are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapitalOrdinaryShares" scale="0" unitRef="usd" id="ixv-23831">3,636,363,636</ix:nonFraction> ordinary shares at A$<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="audPershares" id="ixv-23832">0.011</ix:nonFraction> (<ix:nonFraction contextRef="c2" decimals="1" format="ixt:num-dot-decimal" name="athe:ordinarySharesPerShareCents" scale="0" unitRef="pure" id="ixv-23833">1.1</ix:nonFraction> Australian cents) per share (ASX:ATH); and</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" unitRef="pure" id="ixv-23834">1,222,300,911</ix:nonFraction> listed Long-Dated Options (each with an exercise price of A$<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="audPershares" id="ixv-23835">0.028</ix:nonFraction>, expiring on February 26, 2027) (ASX: ATHOA).</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="ixv-16587"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">(a) Issued Capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><ix:nonFraction contextRef="c52" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" unitRef="shares" id="ixv-23836">9,127,370,686</ix:nonFraction> (2024: <ix:nonFraction contextRef="c53" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" unitRef="shares" id="ixv-23837">5,245,115,318</ix:nonFraction>) fully paid ordinary shares</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">10(b)</td><td style="width: 1%; text-align: left"/><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c52" decimals="INF" format="ixt:num-dot-decimal" name="athe:SharesOfIssuedCapital" scale="0" unitRef="shares" id="ixv-23838">262,949,462</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c53" decimals="INF" format="ixt:num-dot-decimal" name="athe:SharesOfIssuedCapital" scale="0" unitRef="shares" id="ixv-23839">223,152,985</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c54" decimals="INF" format="ixt:num-dot-decimal" name="athe:SharesOfIssuedCapital" scale="0" unitRef="shares" id="ixv-23840">213,971,323</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Nil (2024: Nil) options for fully paid ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">10(c)</td><td style="padding-bottom: 1.5pt; text-align: left"/><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85"><span style="-sec-ix-hidden: hidden-fact-88">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86"><span style="-sec-ix-hidden: hidden-fact-89">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="aud" id="ixv-23841">262,949,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="aud" id="ixv-23842">223,152,985</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="aud" id="ixv-23843">213,971,323</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10. ISSUED CAPITAL (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfIssuedCapitalExplanatory-c0_cont_2" id="_DisclosureOfIssuedCapitalExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(b) <ix:nonNumeric contextRef="c0" continuedAt="athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock-c0_cont_1" escape="true" name="athe:ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock" id="ixv-23844">Movements in Issued Shares</ix:nonNumeric></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c53" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" unitRef="shares" id="ixv-23845">5,245,115,318</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="aud" id="ixv-23846">223,152,985</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c54" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" unitRef="shares" id="ixv-23847">2,439,897,618</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="aud" id="ixv-23848">213,971,323</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c58" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" unitRef="shares" id="ixv-23849">2,406,874,578</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="aud" id="ixv-23850">213,787,061</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Movement during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="INF" format="ixt:num-dot-decimal" name="athe:MovementDuringTheYearNoOfSharesinShares" scale="0" unitRef="shares" id="ixv-23851">3,882,255,368</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="athe:ValueOfIncreaseDecreaseInSharesOutstanding" scale="0" unitRef="aud" id="ixv-23852">39,796,477</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="INF" format="ixt:num-dot-decimal" name="athe:MovementDuringTheYearNoOfSharesinShares" scale="0" unitRef="shares" id="ixv-23853">2,805,217,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="athe:ValueOfIncreaseDecreaseInSharesOutstanding" scale="0" unitRef="aud" id="ixv-23854">9,181,662</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c61" decimals="INF" format="ixt:num-dot-decimal" name="athe:MovementDuringTheYearNoOfSharesinShares" scale="0" unitRef="shares" id="ixv-23855">33,023,040</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="athe:ValueOfIncreaseDecreaseInSharesOutstanding" scale="0" unitRef="aud" id="ixv-23856">184,262</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">End of the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c52" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" unitRef="shares" id="ixv-23857">9,127,370,686</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="aud" id="ixv-23858">262,949,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c53" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" unitRef="shares" id="ixv-23859">5,245,115,318</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="aud" id="ixv-23860">223,152,985</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c54" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" scale="0" unitRef="shares" id="ixv-23861">2,439,897,618</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="aud" id="ixv-23862">213,971,323</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" id="ixv-16923"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Details of share issuances are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Date</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Details</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Notes</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Number</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Issue<br/> Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%; font-weight: bold; padding-bottom: 1.5pt">Year end June 30, 2022</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 30%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1.5pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c58" decimals="INF" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseInNumberOfShareOutstanding" scale="0" unitRef="shares" id="ixv-23863">322,857,900</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapitalPreferenceShares" scale="0" unitRef="aud" id="ixv-23864">16,339,071</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>September 21, 2022</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c62" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23865">Issue of shares under ATM Facility</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c62" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23866">9,543,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c62" decimals="4" format="ixt:num-dot-decimal" name="athe:NumberofSharesIssuePricePerShare" scale="0" unitRef="audPershares" id="ixv-23867">0.0135</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" unitRef="aud" id="ixv-23868">128,842</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>March 15, 2023</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c63" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23869">Issue of shares under ATM Facility</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c63" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23870">23,479,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c63" decimals="4" format="ixt:num-dot-decimal" name="athe:NumberofSharesIssuePricePerShare" scale="0" unitRef="audPershares" id="ixv-23871">0.0080</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" unitRef="aud" id="ixv-23872">187,834</ix:nonFraction></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">June 30, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c64" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23873">Security issuance costs</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" unitRef="aud" id="ixv-23874">132,413</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Year end June 30, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c54" decimals="INF" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseInNumberOfShareOutstanding" scale="0" unitRef="shares" id="ixv-23875">33,023,040</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapitalPreferenceShares" scale="0" unitRef="aud" id="ixv-23876">184,263</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>November 29,2023</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c65" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23877">Issue of shares under ATM Facility</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23878">362,462,762</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="4" format="ixt:num-dot-decimal" name="athe:NumberofSharesIssuePricePerShare" scale="0" unitRef="audPershares" id="ixv-23879">0.0035</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" unitRef="aud" id="ixv-23880">1,268,620</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>January 8,2024</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c66" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23881">Issue of shares under ATM Facility</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c66" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23882">1,008,965,805</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c66" decimals="4" format="ixt:num-dot-decimal" name="athe:NumberofSharesIssuePricePerShare" scale="0" unitRef="audPershares" id="ixv-23883">0.0035</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" unitRef="aud" id="ixv-23884">3,531,380</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>February 2,2024</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c67" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23885">Issue of shares under ATM Facility</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c67" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23886">571,428,556</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c67" decimals="4" format="ixt:num-dot-decimal" name="athe:NumberofSharesIssuePricePerShare" scale="0" unitRef="audPershares" id="ixv-23887">0.0035</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" unitRef="aud" id="ixv-23888">2,000,000</ix:nonFraction></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>March 4, 2024</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c68" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23889">Issue of shares under ATM Facility</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c68" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23890">855,263,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c68" decimals="4" format="ixt:num-dot-decimal" name="athe:NumberofSharesIssuePricePerShare" scale="0" unitRef="audPershares" id="ixv-23891">0.0038</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" unitRef="aud" id="ixv-23892">3,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>April 22, 2024</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c69" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23893">Issue of shares under options exercised</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c69" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23894">7,097,419</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c69" decimals="4" format="ixt:num-dot-decimal" name="athe:NumberofSharesIssuePricePerShare" scale="0" unitRef="audPershares" id="ixv-23895">0.0070</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" unitRef="aud" id="ixv-23896">49,682</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>June 30, 2024</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c70" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23897">Security issuance costs</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" sign="-" unitRef="aud" id="ixv-23898">918,020</ix:nonFraction></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 1.5pt">Year end June 30, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c53" decimals="INF" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseInNumberOfShareOutstanding" scale="0" unitRef="shares" id="ixv-23899">2,805,217,700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapitalPreferenceShares" scale="0" unitRef="aud" id="ixv-23900">9,181,662</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>July 18,2024</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c71" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23901">Issue of shares under ATM Facility</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c71" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23902">75,220,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c71" decimals="4" format="ixt:num-dot-decimal" name="athe:NumberofSharesIssuePricePerShare" scale="0" unitRef="audPershares" id="ixv-23903">0.0054</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" unitRef="aud" id="ixv-23904">398,645</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>January 22,2025</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c72" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23905">Issue of shares under options exercised</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c72" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23906">95,238</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c72" decimals="4" format="ixt:num-dot-decimal" name="athe:NumberofSharesIssuePricePerShare" scale="0" unitRef="audPershares" id="ixv-23907">0.0100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" unitRef="aud" id="ixv-23908">952</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>January 30,2025</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c73" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23909">Issue of shares under options exercised</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23910">6,333,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="3" format="ixt:num-dot-decimal" name="athe:NumberofSharesIssuePricePerShare" scale="0" unitRef="audPershares" id="ixv-23911">0.004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" unitRef="aud" id="ixv-23912">48,873</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>February 3,2025</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c74" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23913">Issue of shares under ATM Facility</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23914">164,242,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="4" format="ixt:num-dot-decimal" name="athe:NumberofSharesIssuePricePerShare" scale="0" unitRef="audPershares" id="ixv-23915">0.0129</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" unitRef="aud" id="ixv-23916">2,122,173</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>February 17,2025</td><td>&#160;</td> <td><ix:nonNumeric contextRef="c75" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23917">Issue of Placement shares</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23918">1,165,841,830</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="4" format="ixt:num-dot-decimal" name="athe:NumberofSharesIssuePricePerShare" scale="0" unitRef="audPershares" id="ixv-23919">0.0110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" unitRef="aud" id="ixv-23920">12,824,260</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>March 14, 2025</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c76" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23921">Issue of shares under options exercised</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c76" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23922">161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c76" decimals="4" format="ixt:num-dot-decimal" name="athe:NumberofSharesIssuePricePerShare" scale="0" unitRef="audPershares" id="ixv-23923">0.0100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" unitRef="aud" id="ixv-23924">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>April 4, 2025</td><td>&#160;</td> <td><ix:nonNumeric contextRef="c77" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23925">Issue of Placement shares</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c77" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-23926">2,470,521,806</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c77" decimals="4" format="ixt:num-dot-decimal" name="athe:NumberofSharesIssuePricePerShare" scale="0" unitRef="audPershares" id="ixv-23927">0.0110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" unitRef="aud" id="ixv-23928">27,175,740</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">June 30, 2025</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c78" name="athe:NumberOfSharesIssuedDuringTheYear" id="ixv-23929">Security issuance costs</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="athe:IssuedCapitalPreferenceShare" scale="0" sign="-" unitRef="aud" id="ixv-23930">2,774,168</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; font-weight: bold">Year end June 30, 2025</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c52" decimals="INF" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseInNumberOfShareOutstanding" scale="0" unitRef="shares" id="ixv-23931">3,882,255,368</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapitalPreferenceShares" scale="0" unitRef="aud" id="ixv-23932">39,796,477</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr> </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>10. ISSUED CAPITAL (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfIssuedCapitalExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(c) Terms and Conditions of Issued Capital</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Ordinary shares</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ordinary shares have the right to receive dividends as declared and,
in the event of a winding up of the Group, to participate in the proceeds from the sale of all surplus assets in proportion to the number
of and amounts paid up on shares held. Ordinary shares entitle their holder to vote, either in person or by proxy, at a meeting of the
Group&#8217;s shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Options</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Option holders do not have the right to receive dividends and are not
entitled to vote at a meeting of the Group&#8217;s shareholders. Options may be exercised at any time from the date they vest to the date
of their expiration. Share options convert into ordinary shares on a one for one basis on the date they are exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Shares Issued after Reporting Date</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No shares have been issued after the reporting date.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="ixv-17422"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>11. RESERVES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock-c0_cont_1" escape="true" name="athe:ScheduleOfReserveOfShareBasedPaymentsTableTextBlock" id="ixv-17427"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">(a) Share Based Payments</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="athe:OptionsForFullyPaidOrdinaryShares1" scale="0" unitRef="Options" id="ixv-23933">2,683,471,567</ix:nonFraction> (2024: <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="athe:OptionsForFullyPaidOrdinaryShares1" scale="0" unitRef="Options" id="ixv-23934">3,250,009,092</ix:nonFraction>, 2023: <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="athe:OptionsForFullyPaidOrdinaryShares1" scale="0" unitRef="Options" id="ixv-23935">170,042,720</ix:nonFraction>) options for fully paid ordinary shares</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1.5pt; text-align: center">11(c)</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"/><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c132" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="0" unitRef="aud" id="ixv-23936">5,342,304</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c133" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="0" unitRef="aud" id="ixv-23937">4,806,203</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c134" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="0" unitRef="aud" id="ixv-23938">3,972,475</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="0" unitRef="aud" id="ixv-23939">5,342,304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="0" unitRef="aud" id="ixv-23940">4,806,203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="0" unitRef="aud" id="ixv-23941">3,972,475</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The share-based payment reserve is used to recognize the fair value
of options issued to directors, executives, employees and consultants but not exercised. Amounts are transferred out of the reserve and
into issued capital when the options are exercised. When options expire, the amount is transferred from reserve to accumulated losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">(b) Warrants/Free-attaching options</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" id="ix_22_fact" name="athe:FreeattachingOptionsForFullyPaidOrdinaryShares" scale="0" unitRef="FreeAttachingOptions">2,154,912,180</ix:nonFraction> free-attaching options (2024: <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" id="ix_23_fact" name="athe:FreeattachingOptionsForFullyPaidOrdinaryShares" scale="0" unitRef="FreeAttachingOptions">2,868,466,372</ix:nonFraction> free-attaching options, 2023: <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" id="ix_24_fact" name="athe:FreeattachingOptionsForFullyPaidOrdinaryShares" scale="0" unitRef="FreeAttachingOptions">674,694,939</ix:nonFraction>) for fully paid ordinary shares <sup>(1)</sup></span></td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1.5pt; text-align: center">11(c)</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td> <ix:footnote id="ix_8_footnote" xml:lang="en-US"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 8, 2024 a total of <ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-23945">457,142,830</ix:nonFraction> free attaching options with an exercise price of A$<ix:nonFraction contextRef="c80" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-23946">0.01</ix:nonFraction>, expiring on August 31, 2026 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 8, 2024 a total of <ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-23947">1,371,428,567</ix:nonFraction> free attaching options with an exercise price of A$<ix:nonFraction contextRef="c81" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-23948">0.007</ix:nonFraction>, expiring on August 31, 2024 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 2, 2024 a total of <ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-23949">190,476,123</ix:nonFraction> free attaching options with an exercise price of A$<ix:nonFraction contextRef="c83" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-23950">0.002</ix:nonFraction>, expiring on August 31, 2026 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 2, 2024 a total of <ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-23951">571,428,556</ix:nonFraction> free attaching options with an exercise price of A$<ix:nonFraction contextRef="c85" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-23952">0.007</ix:nonFraction>, expiring on August 31, 2024 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 15, 2024 a total of <ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-23953">285,087,715</ix:nonFraction> free attaching options with an exercise price of A$<ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-23954">0.01</ix:nonFraction>, expiring on August 31, 2026 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 23, 2025 a total of <ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-23955">1,222,300,911</ix:nonFraction> free attaching options with an exercise price if A$<ix:nonFraction contextRef="c89" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-23956">0.028</ix:nonFraction>, expiring on February 26, 2027 were issued.</p></ix:footnote></td></tr> </table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>11. RESERVES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_2" id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock-c0_cont_1" escape="true" name="athe:ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock" id="ixv-17712"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Movements in Options for Fully Paid Ordinary Shares</b></span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:continuation id="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="23" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(A$)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(A$)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(A$)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="athe:NumberOfSharesOptionsOutstanding" scale="0" unitRef="Options" id="ixv-23957">3,250,009,092</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="0" unitRef="aud" id="ixv-23958">4,806,203</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="athe:NumberOfSharesOptionsOutstanding" scale="0" unitRef="Options" id="ixv-23959">170,042,720</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="0" unitRef="aud" id="ixv-23960">3,972,475</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="athe:NumberOfSharesOptionsOutstanding" scale="0" unitRef="Options" id="ixv-23961">184,692,720</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="0" unitRef="aud" id="ixv-23962">3,565,918</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Options issued during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="athe:ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear" scale="0" unitRef="Options" id="ixv-23963">1,392,300,911</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="athe:ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear" scale="0" unitRef="Options" id="ixv-23964">3,092,563,791</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Expired during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="athe:ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare" scale="0" sign="-" unitRef="Options" id="ixv-23965">1,947,759,704</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="athe:ReserveOfShareBasedPaymentsExpiredDuringTheYear" scale="0" sign="-" unitRef="aud" id="ixv-23966">326,544</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="athe:ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare" scale="0" sign="-" unitRef="Options" id="ixv-23967">13,150,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="athe:ReserveOfShareBasedPaymentsExpiredDuringTheYear" scale="0" sign="-" unitRef="aud" id="ixv-23968">560,014</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Forfeited during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="athe:NumberOfOptionsForfeitedDuringTheYear" scale="0" sign="-" unitRef="Options" id="ixv-23969">4,650,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="athe:ReserveOfSharebasedPaymentsForfeitedDuringYear" scale="0" sign="-" unitRef="aud" id="ixv-23970">93,735</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="athe:NumberOfOptionsForfeitedDuringTheYear" scale="0" sign="-" unitRef="Options" id="ixv-23971">5,500,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="athe:ReserveOfSharebasedPaymentsForfeitedDuringYear" scale="0" sign="-" unitRef="aud" id="ixv-23972">93,222</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="athe:NumberOfOptionsForfeitedDuringTheYear" scale="0" sign="-" unitRef="Options" id="ixv-23973">1,500,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="athe:ReserveOfSharebasedPaymentsForfeitedDuringYear" scale="0" sign="-" unitRef="aud" id="ixv-23974">17,150</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Options exercised during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="athe:NumberOfOptionsOptionsExercisedDuringTheYear" scale="0" sign="-" unitRef="Options" id="ixv-23975">6,428,732</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="athe:OptionsExercisedDuringTheYear" scale="0" sign="-" unitRef="aud" id="ixv-23976">23,540</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Shares to be issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="athe:SharesToBeIssued" scale="0" unitRef="aud" id="ixv-23977">45,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Share Based Payment expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" unitRef="aud" id="ixv-23978">979,920</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" unitRef="aud" id="ixv-23979">881,950</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" unitRef="aud" id="ixv-23980">983,721</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">End of the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="athe:NumberOfSharesOptionsOutstanding" scale="0" unitRef="Options" id="ixv-23981">2,683,471,567</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="0" unitRef="aud" id="ixv-23982">5,342,304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="athe:NumberOfSharesOptionsOutstanding" scale="0" unitRef="Options" id="ixv-23983">3,250,009,092</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="0" unitRef="aud" id="ixv-23984">4,806,203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="athe:NumberOfSharesOptionsOutstanding" scale="0" unitRef="Options" id="ixv-23985">170,042,720</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="0" unitRef="aud" id="ixv-23986">3,972,475</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Details of option grants are summarized as follows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Year ended June 30, 2023:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 14, 2022, <ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-23987">12,450,000</ix:nonFraction> options expired.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 31, 2023, <ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-23988">700,000</ix:nonFraction> options expired.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 3, 2023, <ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-23989">1,500,000</ix:nonFraction> options were forfeited upon resignation
of an employee.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Year ended June 30, 2024:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 11, 2023, <ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-23990">500,000</ix:nonFraction> options were forfeited upon resignation of an employee.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On December 21, 2023, <ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-23991">8,000,000</ix:nonFraction> options were
issued to the Group&#8217;s employees based in Australia under the 2004 ASX Plan. The options are exercisable at A$<ix:nonFraction contextRef="c95" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-23992">0.0105</ix:nonFraction> and expire
on <ix:nonNumeric contextRef="c96" format="ixt:date-monthname-day-year-en" name="athe:ExpiredTerm" id="ixv-23993">December 19, 2026</ix:nonNumeric>. The fair value of the options is A$<ix:nonFraction contextRef="c94" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-23994">0.005</ix:nonFraction> per option.</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On January 08, 2024, <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-23995">457,142,830</ix:nonFraction> long dated
options were issued as per the placement. The options are exercisable at A$<ix:nonFraction contextRef="c80" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-23996">0.01</ix:nonFraction> and expire on <ix:nonNumeric contextRef="c97" format="ixt:date-monthname-day-year-en" name="athe:ExpiredTerm" id="ixv-23997">August 31, 2026</ix:nonNumeric>.</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On January 08, 2024, <ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-23998">1,371,418,567</ix:nonFraction> free attaching short - dated options were issued as per the placement. The options are exercisable at A$<ix:nonFraction contextRef="c99" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-23999">0.007</ix:nonFraction> and expire on <ix:nonNumeric contextRef="c100" format="ixt:date-monthname-day-year-en" name="athe:ExpiredTerm" id="ixv-24000">August 31, 2024</ix:nonNumeric>.</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On February 02, 2024, <ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24001">190,476,123</ix:nonFraction> long dated options were issued as per the securities placement plan. The options are exercisable at A$<ix:nonFraction contextRef="c102" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24002">0.002</ix:nonFraction> and expire on <ix:nonNumeric contextRef="c103" format="ixt:date-monthname-day-year-en" name="athe:ExpiredTerm" id="ixv-24003">August 31, 2026</ix:nonNumeric>.</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On February 02, 2024, <ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24004">571,428,556</ix:nonFraction> short - dated options were issued as per the securities placement plan. The options are exercisable at A$<ix:nonFraction contextRef="c104" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24005">0.007</ix:nonFraction> and expire on <ix:nonNumeric contextRef="c105" format="ixt:date-monthname-day-year-en" name="athe:ExpiredTerm" id="ixv-24006">August 31, 2024</ix:nonNumeric>.</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On April 15, 2024, <ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24007">285,087,725</ix:nonFraction> short &#8211; free attaching options were issued as per the securities placement plan. The options are exercisable at A$<ix:nonFraction contextRef="c107" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24008">0.01</ix:nonFraction> and expire on <ix:nonNumeric contextRef="c108" format="ixt:date-monthname-day-year-en" name="athe:ExpiredTerm" id="ixv-24009">August 31, 2024</ix:nonNumeric></p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 22, 2024, <ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24010">7,097,419</ix:nonFraction> options were exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 21, 2024, <ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24011">5,000,000</ix:nonFraction> options were forfeited upon resignation of an employee.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On June 27, 2024, <ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24012">26,500,000</ix:nonFraction> options were issued to the Group&#8217;s employees based under the 2004 ASX Plan. The options are exercisable at A$<ix:nonFraction contextRef="c111" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24013">0.004</ix:nonFraction> and expire on <ix:nonNumeric contextRef="c112" format="ixt:date-monthname-day-year-en" name="athe:ExpiredTerm" id="ixv-24014">March 13, 2029</ix:nonNumeric>. The fair value of the options is A$<ix:nonFraction contextRef="c113" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24015">0.004</ix:nonFraction> per option.</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On June 27, 2024, <ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24016">62,500,000</ix:nonFraction> options were issued to the Group&#8217;s employees based under the Company&#8217;s 2018 American Depositary Share (ADS) Option Plan. The options are exercisable at US$<ix:nonFraction contextRef="c115" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-24017">0.0031</ix:nonFraction> (A$<ix:nonFraction contextRef="c115" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24018">0.0046</ix:nonFraction>) and expire on March 13, 2029. The fair value of the options is A$<ix:nonFraction contextRef="c116" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24019">0.0037</ix:nonFraction> per option.</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On June 27, 2024, <ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24020">120,000,000</ix:nonFraction> options were issued to the Group&#8217;s key management personnel based under the Company&#8217;s 2018 American Depositary Share (ADS) Option Plan. The options are exercisable at US$<ix:nonFraction contextRef="c117" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-24021">0.003</ix:nonFraction> (A$<ix:nonFraction contextRef="c117" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24022">0.0044</ix:nonFraction>) and expire on March 21, 2029. The fair value of the options is A$<ix:nonFraction contextRef="c118" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24023">0.0037</ix:nonFraction> per option.</p></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>11. RESERVES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(c) Movements in Options for Fully Paid Ordinary Shares (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Year ended June 30, 2025:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 1, 2024, <ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24024">12,000,000</ix:nonFraction> options expired.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 31, 2024, <ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24025">1,935,759,704</ix:nonFraction> options expired.</span></td> </tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 30, 2024, <ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24026">170,000,000</ix:nonFraction> options were issued to the Group&#8217;s directors as per resolutions passed at the AGM in November 2024. The options are exercisable at A$<ix:nonFraction contextRef="c121" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24027">0.01</ix:nonFraction> and expire on <ix:nonNumeric contextRef="c122" format="ixt:date-monthname-day-year-en" name="athe:ExpiredTerm" id="ixv-24028">December 30, 2027</ix:nonNumeric>.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 22, 2025, <ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24029">95,238</ix:nonFraction> options were exercised.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 30, 2025, <ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24030">6,333,333</ix:nonFraction> options were exercised.</span></td> <td/></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#9679;</td> <td>On January 4, 2022, <ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24031">14,000,000</ix:nonFraction> options were forfeited upon resignation of two Non-Executive Directors. </td></tr><tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 14, 2025, <ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24032">161</ix:nonFraction> options were exercised.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 23, 2025, <ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24033">1,222,300,911</ix:nonFraction> free-attaching options were issued
as per the securities placement plan. The options are exercisable at A$<ix:nonFraction contextRef="c128" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24034">0.028</ix:nonFraction> and expire on <ix:nonNumeric contextRef="c129" format="ixt:date-monthname-day-year-en" name="athe:ExpiredTerm" id="ixv-24035">February 26, 2027</ix:nonNumeric>.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 30, 2025, <ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24036">4,650,000</ix:nonFraction> options were forfeited upon resignation of employees.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Terms and Conditions of Reserves </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Options and warrants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Option holders and warrant holders do not have the right to receive
dividends and are not entitled to vote at a meeting of the Group&#8217;s shareholders. Options and warrants may be exercised at any time
from the date they vest to the date of their expiration. Share options are exercisable into ordinary shares on a one for one basis on
the date they are exercised. Options granted under the 2018 ADS Plan are exercisable into ADRs, being one option for one ADR, which equals
<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:ReserveOfOrdinaryShares" scale="0" unitRef="shares" id="ixv-24037">600</ix:nonFraction> ordinary shares, on the date they are exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Expired options are reclassified into accumulated losses. Options forfeited
due to failure of a vesting condition result in a reversal of the accumulated expense through the statement of profit or loss and other
comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In Australia, there is not a set number of authorized shares, shares
are not reserved for the exercise of options, and shares do not have a par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(e) Options and Warrants Issued after Reporting Date</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24038">15,000,000</ix:nonFraction> options were issued under the 2004 ASX Plan after reporting
date.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="athe:AccumulatedDeficitDuringDevelopmentStageTextBlock" id="ixv-18283"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. ACCUMULATED DEFICIT DURING DEVELOPMENT STAGE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="athe:ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock" id="ixv-18287"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Balance at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="0" sign="-" unitRef="aud" id="ixv-24039">214,161,131</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="0" sign="-" unitRef="aud" id="ixv-24040">195,130,889</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="0" sign="-" unitRef="aud" id="ixv-24041">181,884,388</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud" id="ixv-24042">12,147,828</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud" id="ixv-24043">19,123,464</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud" id="ixv-24044">13,806,515</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Reclassify expired options from reserves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:ReclassifyExpiredOptionsFromReservesOne" scale="0" unitRef="aud" id="ixv-24045">326,544</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:ReclassifyExpiredOptionsFromReservesOne" scale="0" unitRef="aud" id="ixv-24046">560,014</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Reclassify forfeited options from reserves</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:ReclassifyForfeitedOptionsFromReserves" scale="0" sign="-" unitRef="aud" id="ixv-24047">93,735</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:ReclassifyForfeitedOptionsFromReserves" scale="0" sign="-" unitRef="aud" id="ixv-24048">93,222</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Balance at end of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="0" sign="-" unitRef="aud" id="ixv-24049">225,888,680</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="0" sign="-" unitRef="aud" id="ixv-24050">214,161,131</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="0" sign="-" unitRef="aud" id="ixv-24051">195,130,889</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfLeasesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfLeasesExplanatory" id="ixv-18414"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>13. LEASES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amounts recognised in the statement of financial position</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="athe:ScheduleOfAmountsRelatingToLeasesTableTextBlock" id="ixv-18427"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statement of financial position shows the following amounts relating
to leases:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"/><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><b><i>Right-of-use assets</i></b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="0" unitRef="aud" id="ixv-24052">151,326</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="0" unitRef="aud" id="ixv-24053">154,729</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="0" unitRef="aud" id="ixv-24054">207,087</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="0" unitRef="aud" id="ixv-24055">66,912</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="0" unitRef="aud" id="ixv-24056">107,131</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="0" unitRef="aud" id="ixv-24057">107,177</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="0" unitRef="aud" id="ixv-24058">88,545</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="0" unitRef="aud" id="ixv-24059">51,914</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="0" unitRef="aud" id="ixv-24060">103,207</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="0" unitRef="aud" id="ixv-24061">155,457</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="0" unitRef="aud" id="ixv-24062">159,045</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="0" unitRef="aud" id="ixv-24063">210,384</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additions to the right-of-use assets during the current financial year
were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="0" unitRef="aud" id="ixv-24064">106,834</ix:nonFraction> (2024:$<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="0" unitRef="aud" id="ixv-24065">59,031</ix:nonFraction>, 2023:$<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="0" unitRef="aud" id="ixv-24066">152,817</ix:nonFraction>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td>
    <td style="width: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amounts recognised in the statement of profit or loss</i></span></td>
    <td style="width: 1%">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="athe:DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases" id="ixv-18546"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statement of profit or loss shows the following amounts relating
to leases:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation of right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" unitRef="aud" id="ixv-24067">111,408</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" unitRef="aud" id="ixv-24068">112,185</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" unitRef="aud" id="ixv-24069">64,409</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpense" scale="0" unitRef="aud" id="ixv-24070">6,188</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpense" scale="0" unitRef="aud" id="ixv-24071">7,217</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpense" scale="0" unitRef="aud" id="ixv-24072">4,565</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expenses relating to short-term leases (included in general and administration expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:ExpensesRelatingToShorttermLeases" scale="0" sign="-" unitRef="aud" id="ixv-24073">9,674</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:ExpensesRelatingToShorttermLeases" scale="0" unitRef="aud" id="ixv-24074">68,634</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expenses relating to variable lease payments not included in lease liabilities (included in general and administration expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The total cash outflow for leases in 2025 was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashOutflowForLeases" scale="0" unitRef="aud" id="ixv-24075">127,097</ix:nonFraction> (2024: $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashOutflowForLeases" scale="0" unitRef="aud" id="ixv-24076">7,913</ix:nonFraction>,
2023: $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashOutflowForLeases" scale="0" unitRef="aud" id="ixv-24077">133,121</ix:nonFraction>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
Group&#8217;s leasing activities and how these are accounted for</i></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leases are recognised as a right-of-use asset and a corresponding liability
at the date at which the leased asset is available for use by the Group. Each lease payment is allocated between the liability and finance
cost. The finance cost is charged to profit or loss over the lease year so as to produce a constant periodic rate of interest on the remaining
balance of the liability for each year. The right-of-use asset is depreciated over the shorter of the asset&#8217;s useful life and the
lease term on a straight-line basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assets and liabilities arising from a lease are initially measured
on a present value basis. Lease liabilities include the net present value of the following lease payments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fixed payments (including in-substance fixed payments), less any lease incentives receivable</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variable lease payments that are based on an index or a rate</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amounts expected to be payable by the lessee under residual value guarantees</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option.</span></td></tr>
  </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>13. LEASES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfLeasesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The lease payments are discounted using the interest rate implicit
in the lease, if that rate can be determined, or the Group&#8217;s incremental borrowing rate applied at the commencement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Right-of-use assets are measured at cost comprising the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount of the initial measurement of lease liability</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any lease payments made at or before the commencement date, less any lease incentives received</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any initial direct costs, and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restoration costs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payments associated with short-term leases and leases of low-value
assets are recognised on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of <ix:nonNumeric contextRef="c0" name="athe:ShortTermLeaseTerm" id="ixv-24078">12 months</ix:nonNumeric>
or less.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfCashFlowStatementExplanatory" id="ixv-18757"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>14. CASH FLOW INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="ixv-18761"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">(a) Reconciliation of Net Loss to Net Cash Flows Used In Operations</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud" id="ixv-24079">12,147,828</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud" id="ixv-24080">19,123,464</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="aud" id="ixv-24081">13,806,515</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Non-cash items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="0" unitRef="aud" id="ixv-24082">28,307</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="0" unitRef="aud" id="ixv-24083">35,344</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="0" unitRef="aud" id="ixv-24084">37,854</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation on leased assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" unitRef="aud" id="ixv-24085">111,408</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" unitRef="aud" id="ixv-24086">112,185</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" unitRef="aud" id="ixv-24087">64,409</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCashPaymentsFromOperatingActivities" scale="0" unitRef="aud" id="ixv-24088">450,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based payment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" unitRef="aud" id="ixv-24089">979,920</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" unitRef="aud" id="ixv-24090">881,950</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" unitRef="aud" id="ixv-24091">966,571</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Foreign exchange loss/(gain)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:ForeignExchangegainLoss" scale="0" sign="-" unitRef="aud" id="ixv-24092">259,433</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:ForeignExchangegainLoss" scale="0" sign="-" unitRef="aud" id="ixv-24093">261,152</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:ForeignExchangegainLoss" scale="0" sign="-" unitRef="aud" id="ixv-24094">917,650</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Fixed asset write off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:FixedAssetWriteOff" scale="0" unitRef="aud" id="ixv-24095">10,232</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Changes in assets and liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Decrease/(increase) in trade and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseInTradeAndOtherReceivables" scale="0" unitRef="aud" id="ixv-24096">104,068</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseInTradeAndOtherReceivables" scale="0" unitRef="aud" id="ixv-24097">4,624,029</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:IncreaseDecreaseInTradeAndOtherReceivables" scale="0" sign="-" unitRef="aud" id="ixv-24098">3,940,343</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Decrease/(increase) in other current assets (excepting term deposit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" scale="0" unitRef="aud" id="ixv-24099">1,081,363</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" scale="0" unitRef="aud" id="ixv-24100">252,986</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" scale="0" sign="-" unitRef="aud" id="ixv-24101">968,207</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">(Decrease)/increase in trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="0" sign="-" unitRef="aud" id="ixv-24102">2,044,457</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24103">1,102,239</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="0" sign="-" unitRef="aud" id="ixv-24104">1,560,873</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">(Decrease) in other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24105">99,861</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24106">11,935</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Increase/(decrease) in provision for employee entitlements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForProvisions" scale="0" unitRef="aud" id="ixv-24107">345,209</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForProvisions" scale="0" sign="-" unitRef="aud" id="ixv-24108">218,006</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForProvisions" scale="0" unitRef="aud" id="ixv-24109">78,685</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash flows used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="aud" id="ixv-24110">11,451,248</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="aud" id="ixv-24111">12,605,824</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="aud" id="ixv-24112">20,035,837</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">(b) Reconciliation of Cash and Cash Equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents balance comprises:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">- cash and cash equivalents on hand</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashOnHand" scale="0" unitRef="aud" id="ixv-24113">33,158,642</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashOnHand" scale="0" unitRef="aud" id="ixv-24114">12,638,885</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashOnHand" scale="0" unitRef="aud" id="ixv-24115">15,773,783</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Closing cash and cash equivalents balance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashEquivalents" scale="0" unitRef="aud" id="ixv-24116">33,158,642</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashEquivalents" scale="0" unitRef="aud" id="ixv-24117">12,638,885</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashEquivalents" scale="0" unitRef="aud" id="ixv-24118">15,773,783</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(c) Non-Cash Financing and Investing Activities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no non-cash financing and investing activities during the
years ended June 30, 2025, 2024 and 2023.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfCommitmentsExplanatory" id="ixv-19174"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>15. EXPENDITURE COMMITMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2025 and 2024, the Group no longer has short term leases
contracted for but not capitalized in the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The majority of our contracts for research and development programs
have a termination notice period of <ix:nonNumeric contextRef="c0" format="ixt-sec:durday" name="athe:TerminationNoticePeriodForResearchAndDevelopmentContracts" id="ixv-24119">30</ix:nonNumeric> days. As of June 30, 2025, we had research and development termination commitments approximating
A$<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="athe:ResearchAndDevelopmentTerminationCommitments" scale="6" unitRef="aud" id="ixv-24120">1.7</ix:nonFraction> million. No liability has been recognised within our financial statements for this period. In addition, we have the ability to scale
down our operations and prioritise our research and development programs to reduce expenditures.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Details in relation to commitments under employee service agreements
with Directors and Key Management Personnel are outlined in Note 21.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="ixv-19187"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>16. SHARE BASED PAYMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the Annual General Meeting held on November 17, 2004, the shareholders
approved the establishment of employee and consultant plans designed to reward directors, employees and consultants for their contributions
to the Group. The plans are to be used as a method of retaining key personnel for the growth and development of the Group. Due to Alterity&#8217;s
U.S. presence, a U.S. plan (the 2018 ADS Plan) and an Australian plan (the 2004 ASX Plan) were developed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2025, equity had been issued to <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="athe:NumberOfDirector" scale="0" unitRef="pure" id="ixv-24121">4</ix:nonFraction> Directors, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="athe:NumberOfKeyManagementPersonnel" scale="0" unitRef="pure" id="ixv-24122">1</ix:nonFraction> Key Management
Personnel, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfEmployees" scale="0" unitRef="pure" id="ixv-24123">7</ix:nonFraction> employees and <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="athe:NumberOfConsultant" scale="0" unitRef="pure" id="ixv-24124">3</ix:nonFraction> consultants under the 2004 ASX Plan and 2018 ADS Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2024, equity had been issued to <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="athe:NumberOfDirector" scale="0" unitRef="pure" id="ixv-24125">3</ix:nonFraction> Directors, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="athe:NumberOfKeyManagementPersonnel" scale="0" unitRef="pure" id="ixv-24126">1</ix:nonFraction> Key Management
Personnel, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfEmployees" scale="0" unitRef="pure" id="ixv-24127">7</ix:nonFraction> employees and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="athe:NumberOfConsultant" scale="0" unitRef="pure" id="ixv-24128">4</ix:nonFraction> consultants under the 2004 ASX Plan and 2018 ADS Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2023, equity had been issued to <ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="athe:NumberOfDirector" scale="0" unitRef="pure" id="ixv-24129">4</ix:nonFraction> Directors, <ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="athe:NumberOfKeyManagementPersonnel" scale="0" unitRef="pure" id="ixv-24130">2</ix:nonFraction> Key Management
Personnel, <ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfEmployees" scale="0" unitRef="pure" id="ixv-24131">9</ix:nonFraction> employees and <ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="athe:NumberOfConsultant" scale="0" unitRef="pure" id="ixv-24132">3</ix:nonFraction> consultants under the 2004 ASX Plan and 2018 ADS Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the 2004 Annual General Meeting, shareholders authorized the Group
to issue in the aggregate up to <ix:nonFraction contextRef="c135" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="6" unitRef="shares" id="ixv-24133">12</ix:nonFraction> million ordinary shares under the two plans. This was increased to <ix:nonFraction contextRef="c136" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="6" unitRef="shares" id="ixv-24134">22</ix:nonFraction> million ordinary shares at the
2005 Annual General Meeting and further increased to <ix:nonFraction contextRef="c137" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="6" unitRef="shares" id="ixv-24135">30</ix:nonFraction> million ordinary shares at the 2007 Annual General Meeting, <ix:nonFraction contextRef="c138" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="6" unitRef="shares" id="ixv-24136">45</ix:nonFraction> million ordinary
shares at the 2008 Annual General Meeting and <ix:nonFraction contextRef="c139" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="6" unitRef="shares" id="ixv-24137">60</ix:nonFraction> million ordinary shares at the 2009 Annual General Meeting. At the September 2020 General
Meeting, shareholders authorized the Group to issue up to <ix:nonFraction contextRef="c140" decimals="-5" format="ixt:num-dot-decimal" name="athe:ShareholdersAuthorizedSecurities" scale="6" unitRef="shares" id="ixv-24138">157.5</ix:nonFraction> million securities. At the 2020 Annual General Meeting, shareholders authorized
the Group to issue up to <ix:nonFraction contextRef="c141" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="6" unitRef="shares" id="ixv-24139">200</ix:nonFraction> million ordinary shares. At the 2022 Annual General Meeting, shareholders authorized the Group to issue up
to <ix:nonFraction contextRef="c7" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="6" unitRef="shares" id="ixv-24140">240</ix:nonFraction> million ordinary shares. At the 2024 Annual General Meeting, shareholders authorized the Group to issue up to <ix:nonFraction contextRef="c3" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="6" unitRef="shares" id="ixv-24141">450</ix:nonFraction> million ordinary
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Share Plan Committee, a sub-committee of the Remuneration Committee,
administers the two plans and is able to change the terms of the equity issued under them from the default terms<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the 2018 ADS Plan, the exercise price must equal or exceed the
fair value of the ADS on the date the options are awarded. The option expiration date cannot exceed ten years from the date the options
were awarded. The default vesting conditions are <ix:nonFraction contextRef="c142" decimals="2" format="ixt:num-dot-decimal" name="athe:PercentageOfDefaultVestingConditionsPerYear" scale="-2" unitRef="pure" id="ixv-24142">25</ix:nonFraction>% per year on the date the options were awarded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the 2004 ASX Plan, the exercise price must be equal or be less
than the market value of the ordinary shares on ASX on the date of grant. The option expiration date cannot exceed ten years from the
date the options were granted. The default vesting conditions are <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="athe:PercentageOfDefaultVestingConditionsPerYear" scale="-2" unitRef="pure" id="ixv-24143">25</ix:nonFraction>% per year on the date the options were granted.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>16. SHARE BASED PAYMENTS (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="ixv-19241"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Information with respect to the number of options granted under the
2004 ASX Plan and 2018 ADS Plan as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24144">381,542,720</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c143" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24145">0.022</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24146">170,042,720</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c144" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24147">0.047</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24148">184,692,720</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24149">0.05</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issued during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24150">217,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c147" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24151">0.004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Exercised during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24152">6,333,333</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c146" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24153">0.004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expired during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24154">12,000,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c146" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24155">.07</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24156">13,150,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24157">0.11</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24158">4,650,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c146" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24159">0.036</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24160">5,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c147" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24161">0.036</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24162">1,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24163">0.02</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Outstanding at year end</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24164">358,559,387</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c149" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24165">0.021</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24166">381,542,720</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c143" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24167">0.022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24168">170,042,720</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24169">0.05</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Vested and Exercisable at year end</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24170">275,689,612</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c149" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24171">0.024</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24172">195,708,100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c143" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24173">0.033</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" unitRef="Options" id="ixv-24174">87,280,755</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="audPershares" id="ixv-24175">0.06</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="athe:ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock" id="ixv-19537"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Options outstanding at the end of the year have the following expiry
date and exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold"/><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"/><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"/><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><b>Series</b></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>Grant Date</b></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Expiry Date</b></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$A</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%">ATHAAB</td><td style="width: 1%">&#160;</td> <td style="text-align: center; width: 20%; vertical-align: bottom"><ix:nonNumeric contextRef="c150" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24176">September 18, 2020</ix:nonNumeric></td><td style="width: 1%">&#160;</td> <td style="text-align: center; width: 20%"><ix:nonNumeric contextRef="c150" name="athe:ExpiryDateOfOutstandingShareOptions" id="ixv-24177">September 17, 2025</ix:nonNumeric></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c151" decimals="2" format="ixt:num-dot-decimal" name="athe:ExercisePriceOfOutstandingShareOption1" scale="0" unitRef="audPershares" id="ixv-24178">0.09</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24179">35,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c152" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24180">35,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>ATHAAD</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom"><ix:nonNumeric contextRef="c153" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24181">January 7, 2021</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c153" name="athe:ExpiryDateOfOutstandingShareOptions" id="ixv-24182">January 6, 2026</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c154" decimals="2" format="ixt:num-dot-decimal" name="athe:ExercisePriceOfOutstandingShareOption1" scale="0" unitRef="audPershares" id="ixv-24183">0.03</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24184">91,392,720</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c155" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24185">91,392,720</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>ATHAAE</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom"><ix:nonNumeric contextRef="c156" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24186">November 29, 2021</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c156" name="athe:ExpiryDateOfOutstandingShareOptions" id="ixv-24187">November 29, 2026</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" name="athe:ExercisePriceOfOutstandingShareOption1" scale="0" unitRef="audPershares" id="ixv-24188">0.04</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24189">10,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c158" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24190">14,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>ATHAAF</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom"><ix:nonNumeric contextRef="c159" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24191">July 31, 2021</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c159" name="athe:ExpiryDateOfOutstandingShareOptions" id="ixv-24192">July 31, 2024</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="athe:ExercisePriceOfOutstandingShareOption1" scale="0" unitRef="audPershares" id="ixv-24193">0.07</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c161" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24194">12,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>ATHAAG</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom"><ix:nonNumeric contextRef="c162" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24195">November 21, 2021</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c162" name="athe:ExpiryDateOfOutstandingShareOptions" id="ixv-24196">November 29, 2026</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="2" format="ixt:num-dot-decimal" name="athe:ExercisePriceOfOutstandingShareOption1" scale="0" unitRef="audPershares" id="ixv-24197">0.02</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24198">11,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c164" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24199">11,900,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>ATHAAH</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom"><ix:nonNumeric contextRef="c165" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24200">December 21, 2023</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c165" name="athe:ExpiryDateOfOutstandingShareOptions" id="ixv-24201">December 19, 2026</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c166" decimals="3" format="ixt:num-dot-decimal" name="athe:ExercisePriceOfOutstandingShareOption1" scale="0" unitRef="audPershares" id="ixv-24202">0.001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24203">8,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c167" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24204">8,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>ATHAA</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom"><ix:nonNumeric contextRef="c168" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24205">March 13, 2024</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c168" name="athe:ExpiryDateOfOutstandingShareOptions" id="ixv-24206">March 13, 2029</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="3" format="ixt:num-dot-decimal" name="athe:ExercisePriceOfOutstandingShareOption1" scale="0" unitRef="audPershares" id="ixv-24207">0.004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24208">20,166,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24209">26,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>ATHAB</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom"><ix:nonNumeric contextRef="c171" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24210">March 13, 2024</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c171" name="athe:ExpiryDateOfOutstandingShareOptions" id="ixv-24211">March 13, 2029</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="3" format="ixt:num-dot-decimal" name="athe:ExercisePriceOfOutstandingShareOption1" scale="0" unitRef="audPershares" id="ixv-24212">0.005</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24213">62,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24214">62,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">ATHAC</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><ix:nonNumeric contextRef="c174" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24215">March 21, 2024</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c174" name="athe:ExpiryDateOfOutstandingShareOptions" id="ixv-24216">March 21, 2029</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c175" decimals="3" format="ixt:num-dot-decimal" name="athe:ExercisePriceOfOutstandingShareOption1" scale="0" unitRef="audPershares" id="ixv-24217">0.003</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24218">120,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c176" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24219">120,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-137; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24220">358,559,387</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c143" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="Options" id="ixv-24221">381,542,720</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="8" style="text-align: left">Weighted average remaining contractual life of options outstanding at end of period.</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c146" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-24222">2.37</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c147" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-24223">3.28</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Risk free interest rate </i>&#8211; This is the government bond
rate (having a term that most closely resembles the expected life of the option) in effect at the grant date. The Australian government
bond rate has been used for options which are exercisable for fully paid ordinary shares and the U.S. government bond rate has been used
for options which are exercisable for ADRs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Dividend yield </i>&#8211; Alterity has never declared or paid dividends
on its ordinary shares and does not anticipate paying any dividends in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Expected volatility </i>&#8211; Alterity estimates expected volatility
based on historical volatility over the estimated life of the option and other factors. Historical volatility has been the basis for determining
expected share price volatility as it is assumed that this is indicative of future movements. The life of the options is based on historical
exercise patterns, which may not eventuate in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Expected life </i>&#8211; This is the period of time that the options
granted are expected to remain outstanding. This estimate is based primarily on historical trend of option holders to exercise their option
near the date of expiry. As a result, the expected life is considered to equal the period from grant date to expiry date.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>16. SHARE BASED PAYMENTS (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><ix:continuation id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Model inputs &#8211;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<ix:nonNumeric contextRef="c0" escape="true" name="athe:ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock" id="ixv-19822"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The model inputs for the valuations of options approved and issued
during the current and previous financial years are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold; vertical-align: bottom"/><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"/><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price <br/> per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share Price <br/> at Grant<br/> Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Expected Share <br/> Price </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Years to<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Dividend<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Risk-free<br/> Interest </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value<br/> per Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom"><b>Series</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>Grant Date</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>A$</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>A$</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Volatility</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Expiry</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Yield</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Rate</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>A$</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 6%; vertical-align: bottom">ATHAAB</td><td style="width: 1%">&#160;</td> <td style="text-align: center; white-space: nowrap; width: 16%; vertical-align: bottom"><ix:nonNumeric contextRef="c177" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24224">September 18,2020</ix:nonNumeric></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="audPershares" id="ixv-24225">0.09</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="athe:SharePriceAtGrantDate" scale="0" unitRef="audPershares" id="ixv-24226">0.05</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c177" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24227">98.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonNumeric contextRef="c177" format="ixt-sec:duryear" name="athe:YearsToExpiry" id="ixv-24228">5.00</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24229">0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c177" decimals="4" format="ixt:num-dot-decimal" name="athe:RiskfreeInterestRate" scale="-2" unitRef="pure" id="ixv-24230">0.43</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c177" decimals="3" format="ixt:num-dot-decimal" name="athe:FairValuePerOptions" scale="0" unitRef="audPershares" id="ixv-24231">0.032</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: bottom">ATHAAD</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom"><ix:nonNumeric contextRef="c178" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24232">January 7,2021</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="audPershares" id="ixv-24233">0.03</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="3" format="ixt:num-dot-decimal" name="athe:SharePriceAtGrantDate" scale="0" unitRef="audPershares" id="ixv-24234">0.032</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24235">139.52</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c178" format="ixt-sec:duryear" name="athe:YearsToExpiry" id="ixv-24236">5.00</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24237">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="4" format="ixt:num-dot-decimal" name="athe:RiskfreeInterestRate" scale="-2" unitRef="pure" id="ixv-24238">0.38</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="3" format="ixt:num-dot-decimal" name="athe:FairValuePerOptions" scale="0" unitRef="audPershares" id="ixv-24239">0.028</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">ATHAAE</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom"><ix:nonNumeric contextRef="c179" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24240">November 29, 2021</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c179" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="audPershares" id="ixv-24241">0.04</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c179" decimals="3" format="ixt:num-dot-decimal" name="athe:SharePriceAtGrantDate" scale="0" unitRef="audPershares" id="ixv-24242">0.025</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c179" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24243">138.47</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c179" format="ixt-sec:duryear" name="athe:YearsToExpiry" id="ixv-24244">5.00</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c179" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24245">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c179" decimals="4" format="ixt:num-dot-decimal" name="athe:RiskfreeInterestRate" scale="-2" unitRef="pure" id="ixv-24246">1.35</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c179" decimals="3" format="ixt:num-dot-decimal" name="athe:FairValuePerOptions" scale="0" unitRef="audPershares" id="ixv-24247">0.021</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: bottom">ATHAAF</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom"><ix:nonNumeric contextRef="c180" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24248">July 31, 2021</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="audPershares" id="ixv-24249">0.07</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="3" format="ixt:num-dot-decimal" name="athe:SharePriceAtGrantDate" scale="0" unitRef="audPershares" id="ixv-24250">0.034</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24251">169.42</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c180" format="ixt-sec:duryear" name="athe:YearsToExpiry" id="ixv-24252">5.00</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24253">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="4" format="ixt:num-dot-decimal" name="athe:RiskfreeInterestRate" scale="-2" unitRef="pure" id="ixv-24254">0.13</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="3" format="ixt:num-dot-decimal" name="athe:FairValuePerOptions" scale="0" unitRef="audPershares" id="ixv-24255">0.027</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">ATHAAG</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom"><ix:nonNumeric contextRef="c181" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24256">November 29, 2021</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="audPershares" id="ixv-24257">0.02</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c181" decimals="4" format="ixt:num-dot-decimal" name="athe:SharePriceAtGrantDate" scale="0" unitRef="audPershares" id="ixv-24258">0.0238</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c181" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24259">138.47</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c181" format="ixt-sec:duryear" name="athe:YearsToExpiry" id="ixv-24260">5.00</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24261">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c181" decimals="4" format="ixt:num-dot-decimal" name="athe:RiskfreeInterestRate" scale="-2" unitRef="pure" id="ixv-24262">1.35</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c181" decimals="3" format="ixt:num-dot-decimal" name="athe:FairValuePerOptions" scale="0" unitRef="audPershares" id="ixv-24263">0.021</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: bottom">ATHAAH</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom"><ix:nonNumeric contextRef="c182" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24264">December 21, 2023</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c182" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="audPershares" id="ixv-24265">0.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c182" decimals="4" format="ixt:num-dot-decimal" name="athe:SharePriceAtGrantDate" scale="0" unitRef="audPershares" id="ixv-24266">0.0065</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c182" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24267">133.87</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c182" format="ixt-sec:duryear" name="athe:YearsToExpiry" id="ixv-24268">3.00</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c182" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24269">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c182" decimals="4" format="ixt:num-dot-decimal" name="athe:RiskfreeInterestRate" scale="-2" unitRef="pure" id="ixv-24270">3.67</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c182" decimals="3" format="ixt:num-dot-decimal" name="athe:FairValuePerOptions" scale="0" unitRef="audPershares" id="ixv-24271">0.005</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">ATHAA</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom"><ix:nonNumeric contextRef="c183" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24272">March 13, 2024</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c183" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="audPershares" id="ixv-24273">0.004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c183" decimals="3" format="ixt:num-dot-decimal" name="athe:SharePriceAtGrantDate" scale="0" unitRef="audPershares" id="ixv-24274">0.004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c183" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24275">158.31</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c183" format="ixt-sec:duryear" name="athe:YearsToExpiry" id="ixv-24276">5.00</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c183" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24277">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c183" decimals="4" format="ixt:num-dot-decimal" name="athe:RiskfreeInterestRate" scale="-2" unitRef="pure" id="ixv-24278">3.47</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c183" decimals="3" format="ixt:num-dot-decimal" name="athe:FairValuePerOptions" scale="0" unitRef="audPershares" id="ixv-24279">0.004</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: bottom">ATHAB</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom"><ix:nonNumeric contextRef="c184" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24280">March 13, 2024</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c184" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="audPershares" id="ixv-24281">0.004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c184" decimals="3" format="ixt:num-dot-decimal" name="athe:SharePriceAtGrantDate" scale="0" unitRef="audPershares" id="ixv-24282">0.004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c184" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24283">158.31</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c184" format="ixt-sec:duryear" name="athe:YearsToExpiry" id="ixv-24284">5.00</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24285">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c184" decimals="4" format="ixt:num-dot-decimal" name="athe:RiskfreeInterestRate" scale="-2" unitRef="pure" id="ixv-24286">3.47</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c184" decimals="3" format="ixt:num-dot-decimal" name="athe:FairValuePerOptions" scale="0" unitRef="audPershares" id="ixv-24287">0.004</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">ATHAC</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom"><ix:nonNumeric contextRef="c185" name="ifrs-full:DateOfGrantOfSharebasedPaymentArrangement" id="ixv-24288">March 21, 2024</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c185" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" unitRef="audPershares" id="ixv-24289">0.003</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c185" decimals="3" format="ixt:num-dot-decimal" name="athe:SharePriceAtGrantDate" scale="0" unitRef="audPershares" id="ixv-24290">0.004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c185" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24291">158.83</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c185" format="ixt-sec:duryear" name="athe:YearsToExpiry" id="ixv-24292">5.00</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c185" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-24293">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c185" decimals="4" format="ixt:num-dot-decimal" name="athe:RiskfreeInterestRate" scale="-2" unitRef="pure" id="ixv-24294">3.48</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c185" decimals="3" format="ixt:num-dot-decimal" name="athe:FairValuePerOptions" scale="0" unitRef="audPershares" id="ixv-24295">0.004</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="athe:ScheduleOfNumberOfSharesIssuedTableTextBlock" id="ixv-20197"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Information with respect to the number of shares issued under the stock
option plan as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-24296">13,277,715</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-24297">13,277,715</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-24298">13,277,715</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Issued during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">End of the financial year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-24299">13,277,715</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-24300">13,277,715</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-24301">13,277,715</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No shares were granted during the year ended June 30, 2025, 2024 and
2023.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="ixv-20292"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>17. SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 3, 2025, the Group issued <ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-24302">15,000,000</ix:nonFraction> options with exercise
price of $<ix:nonFraction contextRef="c192" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24303">0.01</ix:nonFraction> and <ix:nonNumeric contextRef="c193" format="ixt-sec:duryear" name="athe:ExercisePriceExpiryTerm" id="ixv-24304">5</ix:nonNumeric> year expiry under the Group&#8217;s ASX Employee Share Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 28, 2025, Alterity Therapeutics announced positive topline
data form the open-label phase 2 clinical trial of ATH434 in Multiple System Atrophy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 15, 2025, the Group issued <ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-24305">11,500,000</ix:nonFraction> options with exercise
price of $<ix:nonFraction contextRef="c194" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24306">0.013</ix:nonFraction> and <ix:nonNumeric contextRef="c195" format="ixt-sec:duryear" name="athe:ExercisePriceExpiryTerm" id="ixv-24307">5</ix:nonNumeric> year expiry under the Group&#8217;s ASX Employee Share Plan, and <ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-24308">314,400,200</ix:nonFraction> options with exercise price of US$<ix:nonFraction contextRef="c196" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24309">0.0086</ix:nonFraction>
and <ix:nonNumeric contextRef="c197" format="ixt-sec:duryear" name="athe:ExercisePriceExpiryTerm" id="ixv-24310">5</ix:nonNumeric> year expiry under the Group&#8217;s ADS Employee Share Plan,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No other matter or circumstance has occurred subsequent to year end
that has significantly affected, or may</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">significantly affect, the operations of the Group, the results of those
operations or the state of affairs of the Group or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">economic entity in subsequent financial years.&#160;</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="ixv-20331"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>18. LOSS PER SHARE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:EarningsPerShareExplanatory" id="ixv-20335"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Basic and diluted loss per share (cents per share)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares" id="ixv-24311"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares" id="ixv-24312">0.19</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares" id="ixv-24313"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares" id="ixv-24314">0.52</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares" id="ixv-24315"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="audPershares" id="ixv-24316">0.57</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted average number of ordinary shares on issue used in the calculation of basic and diluted loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares" id="ixv-24317"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-24318">6,396,924,117</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares" id="ixv-24319"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-24320">3,648,875,564</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" unitRef="shares" id="ixv-24321"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-24322">2,427,841,917</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options and warrants in place do not have the effect of diluting
the loss per share. Therefore, they have been excluded from the calculation of diluted loss per share. Please refer to Note 11 and Note
16 for options and warrants on issue which were assessed to be antidilutive.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" id="ixv-20411"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>19. KEY MANAGEMENT PERSONNEL COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="athe:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" id="ixv-20415"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Short-term employee benefits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="0" unitRef="aud" id="ixv-24323">1,522,550</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="0" unitRef="aud" id="ixv-24324">1,551,075</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="0" unitRef="aud" id="ixv-24325">1,727,020</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Post-employment benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="0" unitRef="aud" id="ixv-24326">18,720</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="0" unitRef="aud" id="ixv-24327">38,486</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="0" unitRef="aud" id="ixv-24328">42,444</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="athe:KeyManagementPersonnelCompensationLongtermBenefits" scale="0" sign="-" unitRef="aud" id="ixv-24329">6,616</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="athe:KeyManagementPersonnelCompensationLongtermBenefits" scale="0" unitRef="aud" id="ixv-24330">7,215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Termination benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" scale="0" unitRef="aud" id="ixv-24331">10,215</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Share-based payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="0" unitRef="aud" id="ixv-24332">802,128</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="0" unitRef="aud" id="ixv-24333">520,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="0" unitRef="aud" id="ixv-24334">764,175</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="0" unitRef="aud" id="ixv-24335">2,343,398</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="0" unitRef="aud" id="ixv-24336">2,113,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="0" unitRef="aud" id="ixv-24337">2,540,854</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfAuditorsRemunerationExplanatory" id="ixv-20534"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>20. AUDITORS&#8217; REMUNERATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="athe:ScheduleOfAuditorRemunerationTableTextBlock" id="ixv-20538"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">- Audit and review of financial statements (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_25_fact" name="ifrs-full:AuditorsRemunerationForAuditServices" scale="0" unitRef="aud">248,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_26_fact" name="ifrs-full:AuditorsRemunerationForAuditServices" scale="0" unitRef="aud">248,200</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_27_fact" name="ifrs-full:AuditorsRemunerationForAuditServices" scale="0" unitRef="aud">246,400</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">- Other audit services (2)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_28_fact" name="ifrs-full:AuditorsRemunerationForOtherServices" scale="0" unitRef="aud">72,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_29_fact" name="ifrs-full:AuditorsRemunerationForOtherServices" scale="0" unitRef="aud">95,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_30_fact" name="ifrs-full:AuditorsRemunerationForOtherServices" scale="0" unitRef="aud">52,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AuditorsRemuneration" scale="0" unitRef="aud" id="ixv-24344">320,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AuditorsRemuneration" scale="0" unitRef="aud" id="ixv-24345">343,700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AuditorsRemuneration" scale="0" unitRef="aud" id="ixv-24346">298,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="ix_9_footnote" xml:lang="en-US">Audit and review of financial statements consist of fees billed for assurance and related services that generally only the statutory auditor could reasonably provide to a client.</ix:footnote> </span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="ix_10_footnote" xml:lang="en-US">Included in the balance are amounts related to additional regulatory filings during the 2025 financial year. All services provided are considered audit services for the purpose of SEC classification.</ix:footnote> </span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PricewaterhouseCoopers was appointed as the Group&#8217;s principal
independent registered public accounting firm on November 30, 2006. Australian law does not require the Group&#8217;s Auditors to be appointed
at the Group&#8217;s annual general meeting of shareholders. There is an annual engagement letter which is signed, subject to the Group&#8217;s
audit committee approval, with PricewaterhouseCoopers for audit and review work. No non-audit services were provided by PricewaterhouseCoopers
during the 2025, 2024 and 2023 financial years.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="ixv-20664"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>21. RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity Interests in Subsidiaries</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alterity Therapeutics Limited owns <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure" id="ixv-24349">100</ix:nonFraction>% of its subsidiaries, Alterity
Therapeutics Inc. and Alterity Therapeutics UK Ltd.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key Management Personnel Remuneration</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Directors of Alterity during the year:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Geoffrey Kempler, Chairman</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Brian Meltzer, Independent Non-Executive Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Peter Marks, Independent Non-Executive Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Lawrence Gozlan, Non-Executive Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Key Management Personnel of the Group during the year:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. David Stamler</span></td>
    <td style="width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Remuneration of all key management personnel of the Group is determined
by the Board of Directors following recommendation by the Remuneration Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group is committed to remunerating senior executives in a manner
that is market competitive and consistent with &#8216;best practice&#8217; including the interests of shareholders. Remuneration packages
are based on fixed and variable components, determined by the executive&#8217;s position, experience and performance, and may be satisfied
via cash or equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please refer to Note 19 for Key Management Personnel Remuneration detail.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="ixv-20737"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>22. SEGMENT INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group&#8217;s Chief Executive Officer (Chief Operating Decision
Maker) examines internal reports to assess the Group&#8217;s performance and determine the allocation of resources. The Group has identified
<ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="athe:NumberOfReportableSegment" scale="0" unitRef="pure" id="ixv-24350">one</ix:nonFraction> reportable segment as a whole and this covers research into Parkinsonian movement disorders, Alzheimer&#8217;s disease, Huntington
disease, and other neurodegenerative disorders.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="ixv-20746"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>23. FINANCIAL INSTRUMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group&#8217;s activities expose it to a variety of financial risks
including market risk, credit risk and liquidity risk. The Group&#8217;s overall risk management program focuses on the unpredictability
of financial markets and seeks to minimize potential adverse effects on the financial performance of the Group. Risk management is carried
out under policies approved by the Board of Directors and overseen by the Audit Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><b>(a)</b></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market Risk</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">(i)</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign Currency Risk</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group engages in international purchase transactions and is exposed
to foreign currency risk arising from various currency exposures, primarily with respect to the Australian dollar. The parent entity also
has exposure to foreign exchange risk in the currency cash reserves it holds to meet its foreign currency payments. The Group does not
make use of derivative financial instruments to hedge foreign exchange risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory" id="ixv-20770"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following financial assets and liabilities are subject to foreign
currency risk, the currency of the original amounts are displayed in brackets, all the amounts in the table below are displayed in A$
at year-end spot rates:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Consolidated Entity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents (USD)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="athe:FinancialInstrumentsTotalExposure" scale="0" unitRef="aud" id="ixv-24351">1,544,448</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="athe:FinancialInstrumentsTotalExposure" scale="0" unitRef="aud" id="ixv-24352">225,722</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other payables (USD)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="athe:FinancialInstrumentsTotalExposure" scale="0" sign="-" unitRef="aud" id="ixv-24353">495,145</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="athe:FinancialInstrumentsTotalExposure" scale="0" sign="-" unitRef="aud" id="ixv-24354">507,820</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade and other payables (&#163;GBP)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="athe:FinancialInstrumentsTotalExposure" scale="0" unitRef="aud" id="ixv-24355">796</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="athe:FinancialInstrumentsTotalExposure" scale="0" sign="-" unitRef="aud" id="ixv-24356">3,834</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Trade and other payables (JPY)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="athe:FinancialInstrumentsTotalExposure" scale="0" sign="-" unitRef="aud" id="ixv-24357">2,992</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total exposure</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="athe:FinancialInstrumentsTotalExposure" scale="0" unitRef="aud" id="ixv-24358">1,050,099</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="athe:FinancialInstrumentsTotalExposure" scale="0" sign="-" unitRef="aud" id="ixv-24359">288,924</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As shown in the table above, the Group is primarily exposed to changes
in USD/AUD exchange rates. The sensitivity of profit or loss to changes in the exchange rates arises mainly from US-dollar denominated
financial instruments and there is no impact on other components of equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Based on the financial instruments held as of June 30, 2025, had the
Australian dollar weakened/strengthened by <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="athe:AverageAnnualMovementForeignExchangeRate" scale="-2" unitRef="pure" id="ixv-24360">1.77</ix:nonFraction>%<br/> (2024: <ix:nonFraction contextRef="c198" decimals="4" format="ixt:num-dot-decimal" name="athe:AverageAnnualMovementForeignExchangeRate" scale="-2" unitRef="pure" id="ixv-24361">0.35</ix:nonFraction>%, 2023: <ix:nonFraction contextRef="c199" decimals="3" format="ixt:num-dot-decimal" name="athe:AverageAnnualMovementForeignExchangeRate" scale="-2" unitRef="pure" id="ixv-24362">3.6</ix:nonFraction>%) against the USD with all other variables held constant, the
Group&#8217;s post-tax loss for the year would have been A$<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="athe:SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar" scale="0" unitRef="aud" id="ixv-24363">18,933</ix:nonFraction> higher/lower (2024: A$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="athe:SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar" scale="0" unitRef="aud" id="ixv-24364">1,000</ix:nonFraction> higher/lower).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">(ii)</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest Rate Risk</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interest rate risk is the risk to the Group&#8217;s earnings and equity
arising from movements in interest rates. The Group&#8217;s main interest rate risk arises from cash deposits.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>23. FINANCIAL INSTRUMENTS (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market Risk (continued)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_2" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group&#8217;s exposure to interest rate risk has not changed since
the prior year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At June 30, 2025, the Group had the following cash accounts:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$<ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24365">2,423,027</ix:nonFraction> in an Australian dollar transaction account at an interest rate of <ix:nonFraction contextRef="c201" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24366">0.00</ix:nonFraction>% as of June 30, 2025;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$<ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24367">40,142</ix:nonFraction> in an Australian dollar transaction account at an interest rate of <ix:nonFraction contextRef="c203" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24368">0.00</ix:nonFraction>% as of June 30, 2025;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$<ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24369">8,027,852</ix:nonFraction> in an Australian dollar cash maximiser account at an interest rate of <ix:nonFraction contextRef="c205" decimals="3" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24370">3.6</ix:nonFraction>%&#160;as of June 30, 2025;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$<ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24371">500,266</ix:nonFraction> in an Australian dollar transaction account at an interest rate of <ix:nonFraction contextRef="c207" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24372">1.05</ix:nonFraction>% as of June 30, 2025;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A$<ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24373">28,125,744</ix:nonFraction> in six Australian dollar term deposit accounts with interest rates within a range of <ix:nonFraction contextRef="c209" decimals="3" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24374">1.5</ix:nonFraction>% to <ix:nonFraction contextRef="c210" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24375">4.82</ix:nonFraction>%</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">as of June 30, 2025;</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.$<ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="usd" id="ixv-24376">160,769</ix:nonFraction> (A$<ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24377">246,146</ix:nonFraction>) in a U.S. checking account at an interest rate of <ix:nonFraction contextRef="c212" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24378">0.00</ix:nonFraction>% as of June 30, 2025;</span></td> </tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.$<ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="usd" id="ixv-24379">29,069</ix:nonFraction> (A$<ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24380">44,381</ix:nonFraction>) in U.S. Airwallex accounts at an interest rate of <ix:nonFraction contextRef="c214" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24381">0.00</ix:nonFraction>% as of June 30, 2025;</span></td> </tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.$<ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="usd" id="ixv-24382">821,384</ix:nonFraction> (A$<ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24383">1,254,022</ix:nonFraction>) in a U.S. checking account at an interest rate of <ix:nonFraction contextRef="c216" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24384">0.00</ix:nonFraction>% as of June 30, 2025;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(A$<ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="usd" id="ixv-24385">2,835</ix:nonFraction>) in a Visa Credit card account at an interest rate of <ix:nonFraction contextRef="c218" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24386">0.00</ix:nonFraction>% as of June 30, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At June 30, 2024, the Group had the following cash accounts:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24387">11,529,456</ix:nonFraction> in an Australian dollar cash maximiser account at an interest rate of <ix:nonFraction contextRef="c220" decimals="3" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24388">2.7</ix:nonFraction>%&#160;as of June 30, 2024;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$<ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24389">705,952</ix:nonFraction> in an Australian dollar transaction account at an interest rate of <ix:nonFraction contextRef="c222" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24390">0.00</ix:nonFraction>% as of June 30, 2024;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$<ix:nonFraction contextRef="c223" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24391">182,048</ix:nonFraction> in an Australian dollar transaction account at an interest rate of <ix:nonFraction contextRef="c224" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24392">0.00</ix:nonFraction>% as of June 30, 2024;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.$<ix:nonFraction contextRef="c225" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="usd" id="ixv-24393">138,388</ix:nonFraction> (A$<ix:nonFraction contextRef="c225" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24394">207,581</ix:nonFraction>) in U.S. checking accounts at an interest rate of <ix:nonFraction contextRef="c226" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24395">0.00</ix:nonFraction>% as of June 30, 2024;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.$<ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="usd" id="ixv-24396">12,094</ix:nonFraction> (A$<ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24397">18,141</ix:nonFraction>) in U.S. Airwallex accounts at an interest rate of <ix:nonFraction contextRef="c228" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24398">0.00</ix:nonFraction>% as of June 30, 2024</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A$<ix:nonFraction contextRef="c229" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24399">4,293</ix:nonFraction>) in a Visa Credit card account at an interest rate of <ix:nonFraction contextRef="c230" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24400">0.00</ix:nonFraction>% as of June 30, 2024.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At June 30, 2023, the Group had the following cash accounts:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$<ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24401">27,457</ix:nonFraction> in an Australian dollar cash maximiser account at an interest rate of <ix:nonFraction contextRef="c232" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24402">1.44</ix:nonFraction>%&#160;as of June 30, 2023;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$<ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24403">61,518</ix:nonFraction> in an Australian dollar transaction account at an interest rate of <ix:nonFraction contextRef="c234" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24404">0.00</ix:nonFraction>% as of June 30, 2023;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$<ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24405">18,864</ix:nonFraction> in an Australian dollar transaction account at an interest rate of <ix:nonFraction contextRef="c236" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24406">0.00</ix:nonFraction>% as of June 30, 2023;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.$<ix:nonFraction contextRef="c237" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="usd" id="ixv-24407">10,279,099</ix:nonFraction> (A$<ix:nonFraction contextRef="c237" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24408">15,473,231</ix:nonFraction>) in U.S. checking accounts at an interest rate of <ix:nonFraction contextRef="c238" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24409">0.00</ix:nonFraction>% as of June 30, 2023;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$<ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24410">42,713</ix:nonFraction> in a 90 days term deposit at a fixed interest rate of <ix:nonFraction contextRef="c240" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24411">3.85</ix:nonFraction>% which matures on <ix:nonNumeric contextRef="c240" format="ixt:date-monthname-day-year-en" name="athe:MaturityDate" id="ixv-24412">August 28, 2023</ix:nonNumeric>;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$<ix:nonFraction contextRef="c241" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="aud" id="ixv-24413">150,000</ix:nonFraction> in a 90 days term deposit at a fixed interest rate of <ix:nonFraction contextRef="c242" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24414">3.85</ix:nonFraction>% which matures on <ix:nonNumeric contextRef="c242" format="ixt:date-monthname-day-year-en" name="athe:MaturityDate" id="ixv-24415">September 2, 2023</ix:nonNumeric>;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The weighted average interest rate is <ix:nonFraction contextRef="c243" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24416">3.36</ix:nonFraction>% for cash and cash equivalents
and <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="athe:PercentageOfInterestRate" scale="-2" unitRef="pure" id="ixv-24417">4.75</ix:nonFraction>% for other current assets and apart from usual variances in general rates of interest the Group is not exposed to any significant
interest rate risk.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>23. FINANCIAL INSTRUMENTS (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market Risk (continued)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_3" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Receivables and payables are non-interest bearing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="ixv-21162"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group&#8217;s exposure to interest rates and the effective weighted
average interest rate for classes of financial assets and liabilities is set out below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold"/><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Floating <br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fixed Interest <br/> Maturing in<br/> (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Non-Interest<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"/><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Average<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><b>June 30, 2025</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Interest&#160;Rate <br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>1 year<br/> or less</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>1-5 years</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>bearing<br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total<br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Interest Rate</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Financial Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24418">30,698,409</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" sign="-" unitRef="aud" id="ixv-24419">2,835</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24420">2,463,168</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24421">33,158,642</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c257" decimals="5" format="ixt:num-dot-decimal" name="athe:AverageInterestRate" scale="-2" unitRef="pure" id="ixv-24422">3.130</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c261" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24423">3,937,607</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c262" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24424">3,937,607</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c264" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24425">7,531,050</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c266" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24426">10,765</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c267" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24427">7,541,815</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c268" decimals="4" format="ixt:num-dot-decimal" name="athe:AverageInterestRate" scale="-2" unitRef="pure" id="ixv-24428">4.40</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Financial Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24429">30,698,409</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c270" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24430">7,528,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24431">6,411,540</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24432">44,638,064</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c276" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24433">2,575,490</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c277" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24434">2,575,490</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c279" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24435">66,912</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24436">88,545</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c282" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24437">155,457</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Financial Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c270" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24438">66,912</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24439">88,545</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24440">2,575,490</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24441">2,730,947</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold"/><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Floating <br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fixed Interest <br/> Maturing in<br/> (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Non-Interest<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"/><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Average<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><b>June 30, 2024</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Interest&#160;Rate <br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>1 year<br/> or less</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>1-5 years</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>bearing<br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total<br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Interest Rate</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Financial Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c283" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24442">11,529,456</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" sign="-" unitRef="aud" id="ixv-24443">4,293</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c286" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24444">1,113,722</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c287" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24445">12,638,885</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c288" decimals="5" format="ixt:num-dot-decimal" name="athe:AverageInterestRate" scale="-2" unitRef="pure" id="ixv-24446">2.463</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c292" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24447">4,041,675</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c293" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24448">4,041,675</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c295" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24449">30,091</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c297" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24450">10,577</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c298" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24451">40,668</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c299" decimals="5" format="ixt:num-dot-decimal" name="athe:AverageInterestRate" scale="-2" unitRef="pure" id="ixv-24452">3.515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Financial Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c300" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24453">11,529,456</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24454">25,798</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c303" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24455">5,165,974</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="aud" id="ixv-24456">16,721,228</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c307" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24457">4,619,947</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c308" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24458">4,619,947</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c310" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24459">107,131</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24460">51,914</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c313" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24461">159,045</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c317" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24462">100,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c318" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24463">100,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Financial Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24464">107,131</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c302" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24465">51,914</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c303" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24466">4,719,947</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialLiabilities" scale="0" sign="-" unitRef="aud" id="ixv-24467">4,878,992</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit Risk</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Credit risk refers to the risk that a counterparty will default on
its contractual obligations resulting in financial loss to the Group. The Group has no significant concentration of credit risk and it
is not the Group&#8217;s policy to hedge credit risk.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>23. FINANCIAL INSTRUMENTS (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit Risk (continued)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_4" id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group ensures that surplus cash is invested with financial institutions
of appropriate credit worthiness and limits the amount of credit exposure to any one counter party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There has been no significant change in the Group&#8217;s exposure
to credit risk since the previous year. The carrying amount of the Group&#8217;s financial assets represents the maximum credit exposure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity Risk</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prudent liquidity risk management implies maintaining sufficient cash
and the availability of funding through an adequate amount of committed credit facilities. The Group manages liquidity risk by maintaining
sufficient bank balances to fund its operations and the availability of funding through committed credit facilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="ixv-22035"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Management monitors rolling forecasts of the Group&#8217;s liquidity
reserve on the basis of expected cash flows. See Note 1 (Going Concern Basis) of our accompanying financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturities of Financial Liabilities</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">2025</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than <br/> 6 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">6-12 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Greater than <br/>
12 months <br/>
and less than
    <br/>
5 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> contracted<br/> cash flows</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Carrying<br/> amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Trade and other payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c319" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24468">2,575,490</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c322" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24469">2,575,490</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c323" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24470">2,575,490</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c324" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24471">33,456</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c325" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24472">33,456</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c326" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24473">88,545</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24474">155,457</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c328" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24475">155,457</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24476">2,608,946</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24477">33,456</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c331" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24478">88,545</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c332" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24479">2,730,947</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24480">2,730,947</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">2024</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than<br/> 6 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">6-12 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Greater than<br/>
 12 months <br/>
and less than<br/>

    5 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> contracted<br/> cash flows</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Carrying<br/> amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Trade and other payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c334" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24481">4,619,947</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c337" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24482">4,619,947</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c338" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24483">4,619,947</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c339" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24484">53,566</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c340" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24485">53,565</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c341" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24486">51,914</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c342" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24487">159,045</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c343" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24488">159,045</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c344" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24489">4,673,513</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c345" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24490">53,565</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c346" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24491">51,914</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c347" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24492">4,778,992</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c348" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="aud" id="ixv-24493">4,778,992</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALTERITY THERAPEUTICS LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8211;
in Australian dollars (unless otherwise noted)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>23. FINANCIAL INSTRUMENTS (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfFinancialInstrumentsExplanatory-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital Risk Management</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group&#8217;s objectives when managing capital are to safeguard
the Group&#8217;s ability to continue as a going concern and to maintain an optimal capital structure so as to maximize shareholder value.
In order to maintain or achieve an optimal capital structure, the Group may issue new shares or reduce its capital, subject to the provisions
of the Group&#8217;s constitution. The capital structure of the Group consists of equity attributed to equity holders of the Group, comprising
contributed equity, reserves and accumulated losses disclosed in Notes 10, 11 and 12. By monitoring undiscounted cash flow forecasts and
actual cash flows provided to the Board by the Group&#8217;s Management, the Board monitors the need to raise additional equity from the
equity markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(e)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Estimation</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying amount of financial assets and financial liabilities recorded
in the financial statements represents their respective fair values, determined in accordance with the accounting policies disclosed in
Note 1 to the financial statements.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfInterimFinancialReportingExplanatory" id="ixv-22322"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>24. PARENT ENTITY FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="athe:DisclosureOfParentEntityFinancialStatementsExplanatory" id="ixv-22326"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The individual financial statements for the parent entity show the
following aggregate amounts:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Statement of financial position</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="0" unitRef="usd" id="ixv-24494">44,678,130</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="0" unitRef="usd" id="ixv-24495">19,018,719</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-24496">68,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-24497">147,018</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="usd" id="ixv-24498">44,746,459</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="usd" id="ixv-24499">19,165,737</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-24500">3,514,494</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-24501">5,101,935</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-24502">1,421</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-24503">1,151,157</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" sign="-" unitRef="usd" id="ixv-24504">3,515,915</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" sign="-" unitRef="usd" id="ixv-24505">6,253,092</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Shareholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Contributed equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="usd" id="ixv-24506">262,948,046</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="usd" id="ixv-24507">223,151,570</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Reserves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="0" unitRef="usd" id="ixv-24508">5,342,304</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ReserveOfSharebasedPayments" scale="0" unitRef="usd" id="ixv-24509">4,806,203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="0" sign="-" unitRef="usd" id="ixv-24510">227,059,806</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="0" sign="-" unitRef="usd" id="ixv-24511">215,045,128</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="usd" id="ixv-24512">41,230,544</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="usd" id="ixv-24513">12,912,645</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Statement of profit or loss and other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c351" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-24514">12,448,395</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c352" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-24515">19,355,765</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total comprehensive loss for the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c351" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="usd" id="ixv-24516">12,448,395</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c352" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="usd" id="ixv-24517">19,355,765</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ADDITIONAL AUSTRALIAN FINANCIAL REPORTING REQUIREMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONSOLIDATED ENTITY DISCLOSURE STATEMENT</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; vertical-align: bottom">Name of entity</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Type of entity</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Trustee,<br/>
 partner or JV</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">% of <br/>
Share<br/>
 Capital</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Place of<br/>
 Incorporation</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Australian <br/>
or foreign<br/>
 resident</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Foreign<br/>
 jurisdiction<br/>
 of foreign<br/>
 residents</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; width: 20%; text-align: left">Alterity Therapeutics Limited</td><td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: left; padding-left: 5.4pt">Body Corporate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 13%; padding-left: 5.4pt">Australia</td><td style="width: 1%">&#160;</td>
    <td style="width: 13%; padding-left: 5.4pt">Australian</td><td style="width: 1%">&#160;</td>
    <td style="width: 13%; padding-left: 5.4pt">n/a</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left">Alterity Therapeutics Inc</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 5.4pt">Body Corporate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 5.4pt">United States of America</td><td>&#160;</td>
    <td style="padding-left: 5.4pt">Foreign</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 5.4pt">United States of America</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 0.125in; text-indent: -0.125in; text-align: left">Alterity Therapeutics UK Ltd</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 5.4pt">Body Corporate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 5.4pt">United Kingdom</td><td>&#160;</td>
    <td style="padding-left: 5.4pt">Foreign</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 5.4pt">United Kingdom</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Basis of preparation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This consolidated entity disclosure statement (CEDS) has been prepared
in accordance with the Corporations Act 2001 and includes information for each entity that was part of the consolidated entity as at the
end of the financial year in accordance with AASB 10 Consolidated Financial Statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Determination of tax residency </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 295 (3A)(vi) of the Corporation Act 2001 defines tax residency
as having the meaning in the Income Tax Assessment Act 1997. The determination of tax residency involves judgement as there are different
interpretations that could be adopted, and which could give rise to a different conclusion on residency. In determining tax residency,
the consolidated entity has applied the following interpretations:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Australian tax residency. The consolidated entity has applied
current legislation and judicial precedent, including having regard to the Tax Commissioner&#8217;s public guidance in Tax Ruling TR 2018/5</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Foreign tax residency. Where necessary, the consolidated
entity has used independent tax advisers in foreign jurisdictions to assist in its determination of tax residency to ensure applicable
foreign tax legislation has been complied with (see section 295(3A)(vii) of the Corporations Act 2001).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 124; Options: NewSection; Value: 42 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Australian Disclosure Requirements</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Directors&#8217; Declaration</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the Directors&#8217; opinion:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the financial statements and notes set out on pages F-1 to F-41 are in accordance with the <i>Corporations Act 2001</i>, including:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complying with Accounting Standards, the <i>Corporations Regulations 2001 </i>and other mandatory professional reporting requirements, and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">giving a true and fair view of the consolidated entity&#8217;s financial position as at June 30, 2025 and of its performance for the financial year ended on that date, and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 47px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">there are reasonable grounds to believe that the Group will be
able to pay its debts as and when they become due and payable.</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the consolidated entity disclosure statement on page
    F-42 is true and correct.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Note 1 confirms that the consolidated financial
statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Directors have been given the declarations
by the Chief Executive Officer and Chief Financial Officer required by section 295A of the <i>Corporations Act 2001</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This declaration is made in accordance with a resolution
of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Geoffrey Kempler</span></td>
    <td style="width: 60%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melbourne</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 29, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 125; Options: NewSection; Value: 78 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><div><a id="a_072"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>ITEM 19.</b></span><b> EXHIBITS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Index to Exhibits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporated by<br/>
Reference</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
Number</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit Description</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing&#160;Date/ <br/>
Period&#160;End <br/>
Date</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 59%"><a href="http://www.sec.gov/Archives/edgar/data/1131343/000117891309002255/exhibit_1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Constitution of Registrant.</span></a></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-F</span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/30/09</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1131343/000101915507000384/pranadacomptobefiled.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposit Agreement dated March 23, 2001, as amended and restated as of December 21, 2007, among the Registrant, the Bank of New York, as Depositary, and owners and holders from time to time of ADRs issued thereunder, including the Form of American Depositary Receipts.</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6 POS</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/21/07</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_ex4-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Registration on Change of Name.</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/19</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1131343/000121390024082281/ea021506101ex2-3_alterity.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights Attached to Ordinary Shares.</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">20-F</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">2.3</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">09/26/24</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1131343/000091066204000495/prana6k1103.txt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018 American Depository Share (ADS) Option Plan.</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annexure A to Item 1</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/3/04</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1131343/000091066204000495/prana6k1103.txt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2004 Employees&#8217;, Directors&#8217; and Consultants&#8217; Share and Option Plan.</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-K</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annexure B to Item 1</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/3/04</span></td></tr>

<tr>
    <td style="width: 9%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 59%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td>4.3</td>
    <td/>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390024014643/ea193745ex1-1_alterity.htm">Sales Agreement dated February 15, 2024 between Alterity Therapeutics Limited and JonesTrading Institutional Services LLC</a></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">6-K</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">1.1</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;02/15/2024</td></tr>

<tr>
    <td style="vertical-align: top; width: 9%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 59%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; width: 9%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; width: 9%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; width: 10%">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1131343/000121390024082281/ea021506101ex8-1_alterity.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries of the Registrant.</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">20-F</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">8.1</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">09/26/24</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#8239;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1131343/000121390024082281/ea021506101ex11-1_alterity.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Trading Policy </span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">20-F</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">11.1</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">09/26/24</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">12.1*</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="ea025443801ex12-1_alterity.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act, as amended.</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="ea025443801ex12-2_alterity.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act, as amended.</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="ea025443801ex13-1_alterity.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="ea025443801ex13-2_alterity.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="ea025443801ex15-1_alterity.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of PricewaterhouseCoopers.</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="ea025443801ex15-2_alterity.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditor&#8217;s independence declaration.</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">97.1*</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/1131343/000121390024082281/ea021506101ex97-1_alterity.htm">Incentive-Based Compensation Recovery Policy Effective November 1, 2023</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="margin: 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="white-space: nowrap; width: 9%">101.INS</td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 90%">Inline XBRL Instance Document</td></tr>
  <tr style="vertical-align: top; ">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">101.SCH</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Inline XBRL Taxonomy Extension Schema Document.</td></tr>
  <tr style="vertical-align: top; ">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">101.CAL</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td></tr>
  <tr style="vertical-align: top; ">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">101.DEF</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Inline XBRL Taxonomy Extension Definition Linkbase Document.</td></tr>
  <tr style="vertical-align: top; ">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">101.LAB</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Inline XBRL Taxonomy Extension Label Linkbase Document.</td></tr>
  <tr style="vertical-align: top; ">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">101.PRE</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td></tr>
  <tr style="vertical-align: top; ">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">104</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 126; Value: 78 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_073"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>SIGNATURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Registrant hereby certifies that it meets all
of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this report on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alterity Therapeutics Limited </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David A. Stamler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David A. Stamler</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated August 29, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="margin-left: -0.125in; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">80</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" decimals="0" id="hidden-fact-0" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" unitRef="shares">5245115318</ix:nonFraction>
<ix:nonFraction contextRef="c2" decimals="0" id="hidden-fact-1" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" unitRef="shares">9127370686</ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-2" name="athe:ForfeitedOptionsFromReserves" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-3" name="athe:ForfeitedOptionsFromReserves" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-4" name="ifrs-full:OtherComprehensiveIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-5" name="ifrs-full:OtherComprehensiveIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-6" name="ifrs-full:OtherComprehensiveIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-7" name="athe:ProceedsFromResearchAndDevelopmentTaxRefund" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-8" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-9" name="athe:PaymentsForRentalSecurityDeposits" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-10" name="athe:PaymentsForRentalSecurityDeposits" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-11" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-12" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-13" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-14" name="athe:IssuanceOfSharesNetOfCostsValue" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-15" name="athe:IssuanceOfSharesNetOfCostsValue" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-16" name="athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-17" name="athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-18" name="athe:IncreaseDecreaseThroughIssuanceOfOptionsToConsultants" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-19" name="athe:IncreaseDecreaseThroughIssuanceOfOptionsToConsultants" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-20" name="athe:IncreaseDecreaseThroughIssuanceOfOptionsToConsultants" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-21" name="athe:IncreaseDecreaseThroughIssuanceOfOptionsToConsultants" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-22" name="athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-23" name="athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-24" name="athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-25" name="athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-26" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-27" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-28" name="athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-29" name="athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-30" name="athe:ForfeitedOptionsReversedToProfitOrLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-31" name="athe:ForfeitedOptionsReversedToProfitOrLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-32" name="ifrs-full:ProfitLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-33" name="ifrs-full:ProfitLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-34" name="ifrs-full:ComprehensiveIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-35" name="ifrs-full:ComprehensiveIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-36" name="athe:IssuanceOfSharesNetOfCostsValue" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-37" name="athe:IssuanceOfSharesNetOfCostsValue" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-38" name="athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-39" name="athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-40" name="ifrs-full:IssueOfEquity" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-41" name="ifrs-full:IssueOfEquity" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-42" name="athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-43" name="athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-44" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-45" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-46" name="athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-47" name="athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-48" name="athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-49" name="athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-50" name="athe:ForfeitedOptionsReversedToProfitOrLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-51" name="athe:ForfeitedOptionsReversedToProfitOrLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-52" name="ifrs-full:ProfitLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-53" name="ifrs-full:ProfitLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-54" name="ifrs-full:ComprehensiveIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-55" name="ifrs-full:ComprehensiveIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-56" name="athe:IssuanceOfSharesNetOfCostsValue" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-57" name="athe:IssuanceOfSharesNetOfCostsValue" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-58" name="athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-59" name="athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-60" name="ifrs-full:IssueOfEquity" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-61" name="ifrs-full:IssueOfEquity" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-62" name="ifrs-full:IssueOfEquity" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-63" name="ifrs-full:IssueOfEquity" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-64" name="athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-65" name="athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-66" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-67" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-68" name="athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-69" name="athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-70" name="athe:ForfeitedOptionsReversedToProfitOrLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-71" name="athe:ForfeitedOptionsReversedToProfitOrLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-72" name="ifrs-full:ProfitLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-73" name="ifrs-full:ProfitLoss" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-74" name="ifrs-full:ComprehensiveIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-75" name="ifrs-full:ComprehensiveIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-76" name="ifrs-full:MiscellaneousOtherOperatingIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-77" name="ifrs-full:DeferredTaxExpenseIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-78" name="ifrs-full:DeferredTaxExpenseIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-79" name="ifrs-full:DeferredTaxExpenseIncome" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-80" name="ifrs-full:CurrentAccruedIncomeIncludingCurrentContractAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-81" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-82" name="ifrs-full:NoncurrentProvisions" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-83" name="ifrs-full:NoncurrentProvisions" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-84" name="ifrs-full:AdditionalProvisionsOtherProvisions" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-85" name="athe:SharesOfIssuedCapital" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-86" name="athe:SharesOfIssuedCapital" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-87" name="athe:SharesOfIssuedCapital" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-88" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-89" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-90" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c78" id="hidden-fact-91" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c132" id="hidden-fact-92" name="ifrs-full:WarrantReserve" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c133" id="hidden-fact-93" name="ifrs-full:WarrantReserve" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c134" id="hidden-fact-94" name="ifrs-full:WarrantReserve" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-95" name="ifrs-full:WarrantReserve" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-96" name="ifrs-full:WarrantReserve" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-97" name="ifrs-full:WarrantReserve" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-98" name="athe:ReserveOfOptionsIssuedDuringTheYear" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-99" name="athe:ReserveOfOptionsIssuedDuringTheYear" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-100" name="athe:ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear" unitRef="Options" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-101" name="athe:ReserveOfOptionsIssuedDuringTheYear" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-102" name="athe:ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare" unitRef="Options" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-103" name="athe:ReserveOfShareBasedPaymentsExpiredDuringTheYear" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-104" name="athe:NumberOfOptionsOptionsExercisedDuringTheYear" unitRef="Options" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-105" name="athe:OptionsExercisedDuringTheYear" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-106" name="athe:NumberOfOptionsOptionsExercisedDuringTheYear" unitRef="Options" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-107" name="athe:OptionsExercisedDuringTheYear" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-108" name="athe:NumberOfOptionsSharesToBeIssued" unitRef="Options" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-109" name="athe:SharesToBeIssued" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-110" name="athe:NumberOfOptionsSharesToBeIssued" unitRef="Options" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-111" name="athe:NumberOfOptionsSharesToBeIssued" unitRef="Options" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-112" name="athe:SharesToBeIssued" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-113" name="athe:ShareBasedPaymentExpenseForOptionsIssuedI" unitRef="Options" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-114" name="athe:ShareBasedPaymentExpenseForOptionsIssuedI" unitRef="Options" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-115" name="athe:ShareBasedPaymentExpenseForOptionsIssuedI" unitRef="Options" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-116" name="athe:ReclassifyExpiredOptionsFromReservesOne" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-117" name="athe:ReclassifyForfeitedOptionsFromReserves" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-118" name="athe:ExpensesRelatingToShorttermLeases" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-119" name="ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-120" name="ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-121" name="ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-122" name="ifrs-full:OtherCashPaymentsFromOperatingActivities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-123" name="ifrs-full:OtherCashPaymentsFromOperatingActivities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-124" name="athe:FixedAssetWriteOff" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-125" name="athe:FixedAssetWriteOff" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-126" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c146" id="hidden-fact-127" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" unitRef="Options" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c148" id="hidden-fact-128" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" unitRef="Options" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c148" id="hidden-fact-129" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" unitRef="audPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c147" id="hidden-fact-130" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" unitRef="Options" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c147" id="hidden-fact-131" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" unitRef="audPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c148" id="hidden-fact-132" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" unitRef="Options" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c148" id="hidden-fact-133" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" unitRef="audPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c147" id="hidden-fact-134" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" unitRef="Options" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c147" id="hidden-fact-135" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" unitRef="audPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c160" id="hidden-fact-136" name="ifrs-full:NumberOfOutstandingShareOptions" unitRef="Options" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c149" id="hidden-fact-137" name="athe:ExercisePriceOfOutstandingShareOption1" unitRef="audPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c189" id="hidden-fact-138" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c190" id="hidden-fact-139" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c191" id="hidden-fact-140" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-141" name="athe:KeyManagementPersonnelCompensationLongtermBenefits" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-142" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-143" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c250" id="hidden-fact-144" name="athe:FinancialInstrumentsTotalExposure" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c254" id="hidden-fact-145" name="ifrs-full:FinancialAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c258" id="hidden-fact-146" name="ifrs-full:FinancialAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c259" id="hidden-fact-147" name="ifrs-full:FinancialAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c260" id="hidden-fact-148" name="ifrs-full:FinancialAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c263" id="hidden-fact-149" name="ifrs-full:FinancialAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c265" id="hidden-fact-150" name="ifrs-full:FinancialAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c271" id="hidden-fact-151" name="ifrs-full:FinancialAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c273" id="hidden-fact-152" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c274" id="hidden-fact-153" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c275" id="hidden-fact-154" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c278" id="hidden-fact-155" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c281" id="hidden-fact-156" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c269" id="hidden-fact-157" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c285" id="hidden-fact-158" name="ifrs-full:FinancialAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c289" id="hidden-fact-159" name="ifrs-full:FinancialAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c290" id="hidden-fact-160" name="ifrs-full:FinancialAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c291" id="hidden-fact-161" name="ifrs-full:FinancialAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c294" id="hidden-fact-162" name="ifrs-full:FinancialAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c296" id="hidden-fact-163" name="ifrs-full:FinancialAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c302" id="hidden-fact-164" name="ifrs-full:FinancialAssets" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c304" id="hidden-fact-165" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c305" id="hidden-fact-166" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c306" id="hidden-fact-167" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c309" id="hidden-fact-168" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c312" id="hidden-fact-169" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c314" id="hidden-fact-170" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c315" id="hidden-fact-171" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c316" id="hidden-fact-172" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c300" id="hidden-fact-173" name="ifrs-full:FinancialLiabilities" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c320" id="hidden-fact-174" name="ifrs-full:TradeAndOtherPayables" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c321" id="hidden-fact-175" name="ifrs-full:TradeAndOtherPayables" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c335" id="hidden-fact-176" name="ifrs-full:TradeAndOtherPayables" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c336" id="hidden-fact-177" name="ifrs-full:TradeAndOtherPayables" unitRef="aud" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-24698">0001131343</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-24699">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-24700">FY</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="athe-20250630.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact ix_2_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_3_fact hidden-fact-76 ix_4_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_5_fact ix_6_fact ix_7_fact ix_8_fact ix_9_fact ix_10_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_11_fact ix_12_fact ix_13_fact ix_14_fact ix_15_fact ix_16_fact" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_11_fact ix_12_fact ix_13_fact ix_14_fact ix_15_fact ix_16_fact" toRefs="ix_4_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_17_fact hidden-fact-81" toRefs="ix_5_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_18_fact ix_19_fact ix_20_fact ix_21_fact" toRefs="ix_6_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_20_fact ix_21_fact hidden-fact-82 hidden-fact-83" toRefs="ix_7_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-92 hidden-fact-93 hidden-fact-94 ix_22_fact ix_23_fact ix_24_fact" toRefs="ix_8_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_25_fact ix_26_fact ix_27_fact" toRefs="ix_9_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_28_fact ix_29_fact ix_30_fact" toRefs="ix_10_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:RangesAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:RangesAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:RangesAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">athe:PlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:RangesAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">athe:PlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:AnnualLeaveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:AnnualLeaveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:LongServiceLeaveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:LongServiceLeaveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:AnnualLeaveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:AnnualLeaveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:AnnualLeaveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:AnnualLeaveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:AnnualLeaveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:LongServiceLeaveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:LongServiceLeaveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:LongServiceLeaveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:LongServiceLeaveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:LongServiceLeaveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">athe:OptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">athe:OptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">athe:OptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:September212022Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:March152023Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:June302023Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:November292023Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:January82024Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:February22024Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:March42024Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:April222024Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:June302024Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:July182024Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:January222025Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:January302025Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:February32025Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:February172025Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:March142025Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:April42025Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:June302025Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">athe:AugustThirtyFirstTwoThousandTwentySixMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:FreeAttachingOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">athe:AugustThirtyFirstTwoThousandTwentySixMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:FreeAttachingOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:FreeAttachingOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:FreeAttachingOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:FreeAttachingOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-04-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-04-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-14</xbrli:startDate>
    <xbrli:endDate>2022-12-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-31</xbrli:startDate>
    <xbrli:endDate>2023-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:EmployeeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-03</xbrli:startDate>
    <xbrli:endDate>2023-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-09-11</xbrli:startDate>
    <xbrli:endDate>2023-09-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:DirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-21</xbrli:startDate>
    <xbrli:endDate>2023-12-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-08</xbrli:startDate>
    <xbrli:endDate>2024-01-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:FreeAttachingOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ConsultantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-08</xbrli:startDate>
    <xbrli:endDate>2024-01-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:LongDatedOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ChiefExecutiveOfficersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-02</xbrli:startDate>
    <xbrli:endDate>2024-02-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:ShortDatedOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:ShortDatedOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-02</xbrli:startDate>
    <xbrli:endDate>2024-02-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ShortFreeAttachingOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:ShortFreeAttachingOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:ShortFreeAttachingOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-15</xbrli:startDate>
    <xbrli:endDate>2024-04-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-22</xbrli:startDate>
    <xbrli:endDate>2024-04-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:EmployeeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-21</xbrli:startDate>
    <xbrli:endDate>2024-05-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-27</xbrli:startDate>
    <xbrli:endDate>2024-06-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:DirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">athe:AdsPlanTwoThousandEighteenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ChiefExecutiveOfficersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:EmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-01</xbrli:startDate>
    <xbrli:endDate>2024-08-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-31</xbrli:startDate>
    <xbrli:endDate>2024-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-30</xbrli:startDate>
    <xbrli:endDate>2024-12-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-22</xbrli:startDate>
    <xbrli:endDate>2025-01-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-30</xbrli:startDate>
    <xbrli:endDate>2025-01-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:NonExecutiveDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-04</xbrli:startDate>
    <xbrli:endDate>2022-01-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-14</xbrli:startDate>
    <xbrli:endDate>2025-03-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-08</xbrli:startDate>
    <xbrli:endDate>2021-12-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-06-30</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">athe:SubsequentsEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-07-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2004-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2005-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2007-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2008-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2009-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:PlanAxis">athe:AdsPlanTwoThousandEighteenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:PlanAxis">athe:AdsPlanTwoThousandEighteenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAABOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAABOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAABOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAADOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAADOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAADOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAEMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAEMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAEMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAFOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAFOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAFOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAGOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAGOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAGOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAHMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAHMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAHMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHABMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHABMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHABMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHACMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHACMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHACMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAABMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
<!-- [WMV6][ALB9/lpEK+WOwVGLSbbksZdFECvA6LFLglIL9IZkOgs8FWW1if/Hh+z7oqcwQEZclMNp3+uzr7BF3Se5qx6pS6zd3hbyMx5kPNklJe2eni5cwb5XPjWzfi8LenvPDfNFLJ0389W+QHxy8Tl3kPs5Dn/FT1o6tSMEbbxeQxwx4DonCYUeP0uEoA+qqqMpf7Bhtvsc1hUmGXUwCh09nx/xiXwagqf2wlszPl/WafTIUUYK/DCYe42guyOig6TluYHKBaiKwfTCd5ebJSX+FNPrvlNukeMALjBiAO7KxzLcG3qa3pDsmkJwX2sdJioTfrN8s6YKZDsZBVXpyLMdK+S1qlfcK41lE9IXA28XC6Mo3Uyh/GS+] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAADMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAEMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAFMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAGMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAHMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHABMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHACMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:PlanAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:PlanAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:PlanAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:PlanAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:PlanAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="athe:PlanAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ASXEmployeeSharePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">athe:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-07-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ASXEmployeeSharePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">athe:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-03</xbrli:startDate>
    <xbrli:endDate>2025-07-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ASXEmployeeSharePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">athe:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-08-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ASXEmployeeSharePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">athe:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-08-15</xbrli:startDate>
    <xbrli:endDate>2025-08-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ADSEmployeeSharePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">athe:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-08-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ADSEmployeeSharePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">athe:SubsequentEventsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-08-15</xbrli:startDate>
    <xbrli:endDate>2025-08-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:ForeignCurrencyRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:ForeignCurrencyRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000OnePercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000OnePercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRate36PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRate36PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRate105PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRate105PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf15To482PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf15To482PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf15To482PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000TwoPercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000TwoPercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000ThreePercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000ThreePercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000FourPercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000FourPercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000PercentFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000PercentFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf27Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf27Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000OnePercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000OnePercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000TwoPercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000TwoPercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000ThreePercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000ThreePercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000FourPercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000FourPercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRate144PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRate144PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000PercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000OnePercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000OnePercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000TwoPercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000TwoPercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:InterestRate385PercentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:InterestRate385PercentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRate385OnePercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRate385OnePercentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c301">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c302">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c303">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c304">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c305">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c306">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c307">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c308">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c309">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c310">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c311">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c312">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c313">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c314">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentLiabilitieMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c315">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentLiabilitieMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c316">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentLiabilitieMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c317">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentLiabilitieMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c318">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentLiabilitieMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c319">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:LessThenSixMonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c320">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:SixToTowelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c321">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:GreaterThanTowelMonthsAndLessThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c322">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:TotalContractedCashFlowsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c323">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CarryingAmountsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c324">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:LessThenSixMonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c325">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:SixToTowelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c326">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:GreaterThanTowelMonthsAndLessThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c327">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:TotalContractedCashFlowsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c328">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CarryingAmountsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c329">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:LessThenSixMonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c330">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:SixToTowelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c331">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:GreaterThanTowelMonthsAndLessThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c332">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:TotalContractedCashFlowsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c333">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CarryingAmountsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c334">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:LessThenSixMonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c335">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:SixToTowelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c336">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:GreaterThanTowelMonthsAndLessThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c337">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:TotalContractedCashFlowsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c338">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CarryingAmountsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c339">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:LessThenSixMonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c340">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:SixToTowelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c341">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:GreaterThanTowelMonthsAndLessThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c342">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:TotalContractedCashFlowsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c343">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CarryingAmountsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c344">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:LessThenSixMonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c345">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:SixToTowelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c346">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:GreaterThanTowelMonthsAndLessThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c347">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:TotalContractedCashFlowsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c348">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CarryingAmountsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c349">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c350">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c351">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c352">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001131343</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="aud">
  <xbrli:measure>iso4217:AUD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="audPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:AUD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="Options">
  <xbrli:measure>athe:Options</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="FreeAttachingOptions">
  <xbrli:measure>athe:FreeAttachingOptions</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>2
<FILENAME>ea025443801ex12-1_alterity.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Rule 13a-14(a) under the Securities
Exchange Act of 1934, as amended</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">I, David A, Stamler, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: left">I have reviewed this annual report on Form 20-F of Alterity Therapeutics Limited;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: left">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: left">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: left">The registrant&rsquo;s other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: left">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 35.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: left">Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 35.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: left">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: 35.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: left">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: left">The registrant&rsquo;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee
of the registrant&rsquo;s board of directors (or persons performing the equivalent function):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: left">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: 38.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: left">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Date: 29 August 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">/s/ David A. Stamler</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt">David A. Stamler</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: left">The originally executed copy of this Certification will be maintained
at the Registrant&rsquo;s offices and will be made available for inspection upon request.</TD>
</TR></TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>3
<FILENAME>ea025443801ex12-2_alterity.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION OF CHIEF FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Rule 13a-14(a) under the Securities
Exchange Act of 1934, as amended</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">I, Abby Macnish Niven, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1.</TD><TD>I have reviewed this annual report on Form 20-F of Alterity Therapeutics Limited;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: left">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: left">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: left">The registrant&rsquo;s other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: left">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 35.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: left">Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 35.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: left">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: 35.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: left">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: left">The registrant&rsquo;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee
of the registrant&rsquo;s board of directors (or persons performing the equivalent function):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: left">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: left">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Date: 29 August 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">/s/ Abby Macnish Niven</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt">Abby Macnish Niven</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Chief Financial Officer </TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: left">The originally executed copy of this Certification will be maintained
at the Registrant&rsquo;s offices and will be made available for inspection upon request.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>4
<FILENAME>ea025443801ex13-1_alterity.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 150.6pt; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C.
SECTION 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.05pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In connection with the Annual Report
of Alterity Therapeutics Limited (the &ldquo;Company&rdquo;) on Form 20- F for the year ended June 30, 2025, as filed with the Securities
and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, David A. Stamler, Chief Executive Officer of the Company, certify,
pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: left">The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: left">The information contained in the Report fairly presents, in
all material respects, the financial condition and result of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Date: 29 August 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">/s/ David A. Stamler</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt">David A. Stamler</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: left">The originally executed copy of this Certification will be maintained
at the Company&rsquo;s offices and will be made available for inspection upon request.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>5
<FILENAME>ea025443801ex13-2_alterity.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 13.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C.
SECTION 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.05pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: left; text-indent: 0.5in">In connection with the Annual Report
of Alterity Therapeutics Limited (the &ldquo;Company&rdquo;) on Form 20-F for the year ended June 30, 2025, as filed with the Securities
and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Abby Macnish Niven, Chief Financial Officer of the Company,
certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: left">The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: left">The information contained in the Report fairly presents, in
all material respects, the financial condition and result of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Date: 29 August 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">/s/ Abby Macnish Niven</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt">Abby Macnish Niven</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Chief Financial Officer </TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: left">The originally executed copy of this Certification will be maintained
at the Company&rsquo;s offices and will be made available for inspection upon request.</TD>
</TR></TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>6
<FILENAME>ea025443801ex15-1_alterity.htm
<DESCRIPTION>CONSENT OF PRICEWATERHOUSECOOPERS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
15.1</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8 (Nos. 333-228671, 333-248980, 333-251073) and Form F-3 (No. 333-274816) of Alterity Therapeutics Limited of our
report dated August 29, 2025 relating to the financial statements, which appears in this Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PricewaterhouseCoopers<BR>
Melbourne, Australia<BR>
August 29, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>7
<FILENAME>ea025443801ex15-2_alterity.htm
<DESCRIPTION>AUDITOR'S INDEPENDENCE DECLARATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: bold 10pt Times New Roman, Times, Serif; margin: 0">Exhibit 15.2</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This page is required for Australian Disclosure Requirements and has
been intentionally left blank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $) JD# 2(  A$! Q$!_\0
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M9!'(X^TZE?VMOYA7RX_-\R5DC5G7<]?\_P"?T_G7!_$9[R+PY UC<>(K6?\
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MVC6L 0CR+TSW#3WBBYKL[[X*?#;4M&M_#U[X=CGT>U\2>)_%L%DUU>"--?\
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MU'Z?_%TO:+R_\#I__+!7_JTO_D!]%,W'U'Z?_%T;CZC]/_BZ/:+R_P# Z?\
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M)*+V"Q#YT."XCT-E1M.,:>BUYC\'S9'P'8_V</" M?[=\;[?^$$-V?#7F_\
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M:<5&%6:M%6;:<M4CZ?/[2<0S_P 4M,3TQ_:*C]=E0']IF(''_"*3?^#)>?\
MR%7RZW4_4_SJC)U_#^IK[!<)9#[U\!+317Q&*O?1ZZ>;_(_&JGBWQ[';/8;*
M_P#L.6/>_>6^B/JQOVG8E_YE.8\9_P"0F@_G%4)_:BB )_X1&8X[?VHO_P 9
MKY1?J/I_4U2;[I_#^8K:/"'#[2O@);7NL1BORM_5SBJ>,/B!&5EG].U_^@#*
MWV_O'UJ?VJ(1Q_PA\^?^PHG_ ,9J)OVK(@2/^$.G_P#!I'Z#_IE7R&_WC_GL
M*KO]X_A_(5TPX,X=;_Y%\O-_6<4_TL>=5\:/$:+?+Q%3_P##?E7GY^1]@M^U
M=$H'_%'3\G'_ "%8QU_[95RH_:;ND\6S^(3X>#:7)X>M]'32,6*W:7T.HW-X
M^I'6Q$+Z2WD@FCMETQO]%B>)KI<32N3\QOT'U_H:H/\ =/\ GO6\.">&Y-WR
MZ6G?$XM_+1*WK9GG5?&_Q*@DX\203>FN791Z]S[(/[74/;P9.?\ N*(,?G$:
MC;]KR('_ )$NXX[?VK'CM_TRS_GBOBVH7^\?P_D*WCP/PR[WRZ=M/^8G&;W=
M^G8X9^.WB>MN)J2TE_S+<G>JVWG_ $S[2;]L.%<?\41<'/\ U%H_;_IE43?M
MD0KG_BA[@X[?VO&/?_G@17Q))V_'^E5).K?3^E;1X#X6=KY9-MZ?[UC>^^B.
M"?CYXI+FMQ/25K_\RS)G_P"W'W#_ ,-F0_\ 0BW'_@XC_P#C%0']M*$''_""
M7'_@XC_^,U\.51?[Q_#^0K=>'_"M[?V7*UE_S%XW=[]/(X:GT@O%:+LN*J7_
M (:\E]?YC[M?]M6%1G_A [D]>FLQC&/^V6*@;]MN$!O^* N<8//]LQ>G/!A[
M?6OA*7I^#?TJFW0_0_RK1>'W"=DWE4WI_P!!6-[^AQU?I#^+4=N*Z2_[I62/
MI_B_K[C[1\*?MCW'A_18M+U/PD=7O$OM8NGOK66QT6%H=1UB^U*T@%A90?9T
M>RM+N"REN$Q)?RVSWTX\^YESN/\ MRP*>/A_=$9QSK:=?^_/L<>W6O@5_O'_
M #V%4Y>_^\?ZUM'P\X2:O_9,]O\ H+QR_1G!5^D=XO1E*W%M)=?^11D6K;2_
MGL??[_MUVZ=?A[='G'_(<3TS_P \:B;]O"W49_X5Y='G'_(=C'K_ -,:_/:;
MJ?J/Y55?H/K_ $-=$/#CA!I-Y3-WM_S&8_O;MYG)4^DEXPQ=EQ?3Z_\ ,HR&
MW_I7W'Z'-^WI;CC_ (5U=^__ !/8\].,?N".>.O:H6_;ZMQS_P *YN\=!_Q/
MH_U_T?/ZU^=C_>/X?R%4GZ#Z_P!#6T?#7@YM7RBINUIC,PZ/T.2K])?QDBVE
MQA26C?\ R*,@?3SG<_1Q_P!OZV49_P"%<7?O_P 3Z/T[?N/:H#_P4#ML$_\
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M6M#\17>K6^BZ=H4,^I^*$U6V%M#?V.J7%_;G0([.SFDMB?3_ /AZ'^P-G/\
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MZ'^P-_T<KX(_\%OBS_YGZ:Q/':T4^+/_  +,_P#,E^''AJ]7P1P8_7(,J_\
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M']FK(_XM_/ST'_"7^-NW/)_MSTX[5YW_ ,/0_P!@;_HY7P1_X+?%G_S/T?\
M#T/]@;_HY7P1_P""[Q9_\S]/^TO$/_H+XS7I7S7U_G[_ )Z:D/PC\(WJ_#CP
M^;[OA;)'>^][X=[Z7O>]M;K0]"/[$7[-6"?^%?7'!P,^,/&OK_V&_3MUXZ\Y
MKDHOV/OV>G\=7'AO_A M%_LR+PO!K*(GQ%\;'Q5]MDU.2S9Y=#_MK]WH7DH!
M%J?F?/?![;8-H8Y1_P""H?[ O_1RO@C_ ,%OBO\ /_D7^W6N)B_X*9_L(K\1
M+G5#^TQ\-#8OX0M[!47P;XS76A<KJ\L[-)XJ/AW[/-IIB(":$'\Z.Y+7VTH[
M,!YGXA_]!?&?=?[1FO;_ !=[[?YC7A'X1JZ_XAQX?--6L^%LEZM7M^Y2ULKW
M4D[:Q>CC[P?V(/V:B5S\/ISSE?\ BKO&IQP1D9US(.#VP>< D9!7_AB']FKG
M_BWUP<#_ *&_QJ.O/7^W#Q_A7GG_  ]#_8&_Z.5\$?\ @N\6?_,_1_P]#_8&
M_P"CE?!'_@M\6?\ S/T?VEXAO_F+XR_\'YK_ /)=N^O31:"_XA'X1_\ 1N/#
M[R_XQ;)?5_\ ,/I>7O:6N]7>7O'H(_8C_9JY_P"+?W!],^,/&H 'U_ML$_EU
M[4X?L1?LUX)_X5_<''7_ (K#QKGIS_S'%&.>1S]:\\_X>A?L"_\ 1RO@C_P6
M^+/_ )GZ/^'H?[ W_1RO@C_P6^+/_F?I_P!I>(G3%\9]/^7^:_I+^NH?\0C\
M(^OASX?M;Z\+Y*]>CUH/5=':ZZ-'HG_#$/[-8Q_Q;^?G/_,W^-NF.?\ F.__
M %NN>U(?V(?V:P1GX?W'.?\ F;_&WX9']N$^V!C^=>>?\/0_V!O^CE?!'_@N
M\6?_ #/T?\/0_P!@;_HY7P1_X+O%G_S/TO[2\1/^@OC/S_?YMK_Y/TZ!_P 0
MB\(UMX<>'JMM;A;)-.]K896O=[6W=[IM/A/V@/\ @D]^R)^T!X7&A:GX9\0^
M#=>LG\S1/''ACQ-JUQXATC)S-;1Q>))M8TB]L+G $]G>V,HW 2VTEO,#(?:?
MV./V%O@3^Q)X/U#PY\)=)O[S6O$$L<_BWQ]XHFMM0\9>)WMPPL[>]OK:TL[6
MQTFP5Y!8Z-I5K9Z;!+)/=O#-?W5S<S<C_P /0_V!O^CE?!'_ (+?%G_S/T?\
M/0_V!N<?M*^".A_YAOBS^GAZO5QG%WBWF'#,N#,=G7'&,X5EBHXV>18FKF%;
M 3Q$6IQ<X3A[6=&-5*M#"3Q,L%&NE76#=5*2]'*/#OP\R#-*.=9'PEPQE&9X
M>A/#4,7EN78;!SH4:K;J*A3I2="C4FG*,Z]+#PQ$H2=/V\8-Q?U?\(;:SM/
MEE!8VGAVRMEUSQJZV_A77+GQ%HJR2^-_$4T\D.K7CO/+>SW$DL^L6C-Y>EZS
M+?Z7 %@LHU'IE?F=\._^"FG["6F>%;:SO?VF/AJUPFJ^)YF.C>#O&7A?3S'=
M^*=:N[?R]%G\.I+#/]GGB^W7I0#5[[[1K"Y2_4GM_P#AZ)^P/_T<MX)_\%WB
MS_YGZ^*_L3.E_P R;-?_  @Q'_R+_,^W]K2_Y^4__!D3[ZHKX%_X>B?L#_\
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M*V28Q_\ MY^B'EI_<7_O@?\ QNCRT_N+_P!\#_XW7P'_ ,-7>,_^A?\ #O\
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M_4SI?_+3*7TJ?!V/Q9MG:TO_ ,DUF.W_ (&?JKY:?W%_[X'_ ,;H\M/[B_\
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M@N"L]33C&<Y7<XP@K0IU)V<TW"$Y).,)-?N;Y:?W%_[X'_QNCRT_N+_WP/\
MXW7XJ_\ #S3QT8[F==#^&9@L9%BO)TU#4W@MI&R%CN91K9CA=L?*)&4MC(!I
MNK?\%-O'6@Z=<:OK'A_X=Z?IL%I<WLMW=7&M11"VM+62\G>(G5\S%+:*28)
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M$;5M3/BF6\_M?Q4'?QI:V=OX@,(\5ZV+19XK)#;C3DM! F@NO[R70%TR6?\
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ML^>#45ND^._VR?@7X/\ V?\ XD^'O!GA1/'&G3ZCX T#Q)XM\'?$0:7<^*/
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M=#O;[XARPZ;=>&=%LULOBK:ZWX;TTKX9N[C4+.[N;><R64SZK<6=K?6LUM<
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MBF]LVX,OYYMC_P#YV'X=2]_]X_UJM)]QOI7[EG]C/X!,?F\'7'_@XU,?R/\
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MBGS+^I1_^2%?^K/_ ""BBBCF7]2C_P#)!?\ JS_R"BBBCF7]2C_\D%_ZL_\
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M_96D_P#0-T[V_P!#MN?7K&!^M)_9>D_] S3_ /P#M/\ XBE;+>V;?^#,$_\
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M_P -U_L<<DG_ ).;^"O7N01XVR,^A'(S@\TA_P""C'_!/@YS^W5^QP03D_\
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MV-_P_:<^"N?U\;G^5'_#Q?\ X)\?]'U?L<_^)._!/_YM:^O/[*TK_H'Z?_X
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M ,*O_@[+O_F85ZG>'_@-;_Y8?((_X*,?\$^,_P#)]?['/_B3?P5'ZGQM2_\
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MF?\ X,R[_P"9AVJ?S0^ZK_\ +CX^_P"'C'_!/?\ Z/J_8Z_\2<^"O_S:4?\
M#QC_ ()[_P#1]7['7_B3GP5_^;2OL'^R=*_Z!FG_ /@%;?\ QNC^R=*_Z!FG
M_P#@%;?_ !NCERO^7,__  9EW_S,%JG\T/NJ_P#RX^/O^'C'_!/?_H^K]CK_
M ,2<^"O_ ,VE'_#QC_@GO_T?5^QU_P")-_!3_P";2OL'^R=*_P"@9I__ (!6
MW_QNC^R=*_Z!FG_^ 5M_\;HY<K[9I_X,RW_YF"U3^:'W5?\ Y<?'P_X*,?\
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M_@Q_\VU?7_\ 9.E?] S3_P#P"MO_ (W1_9.E?] S3_\ P"MO_C=+ERSOFO\
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M_D9J/_AH[P*!S;ZW]?L(_I)7Q3-]W_/J*I/T_'_&OK(\%Y'*RMB^NOUOL_\
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M-4T_Q#:74VEZYINLV%]8RA(KR.!\7_!1WP9?Z'\7?$VE_#WQ VB?"3X#:?\
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MGQ+!XR\2'5O&[/%K>H>([KQ5;0ZOH%Y&UEX%TL(MEXD^&GC6".-E_J''QU^
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M *+1\)O_  XG@[_Y<5:XFXPCM/,=[_\ (HJ?_.ST^[S,9>#WAM*_-P]1=_\
MJ9YDO_=X\3_X91E(./'2 8ZGPS(/_<Z>*@;]DR5O^9\CY^7 \,N<^_&NY_K[
M5[G_ ,+[^!O_ $6?X3?^'$\'?_+BC_A??P-_Z+/\)O\ PXG@[_Y<5:XJXS6J
MJYC_ .&B?ZY682\%?#"5^;ARBT];?VKFB7X8\\#/[(DI)QX^3.<\^%Y,>O\
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M %.,X_\ GD?++_L03-D?\++C' &3X.E..0<_\C*#[<CO4#_L,SOP/B;$/?\
MX0V4^GIXES_+ZU]6_P#"^_@;_P!%G^$W_AQ/!W_RXH_X7W\#?^BS_";_ ,.)
MX._^7%6N-^/%MB<R7_=&_P#P28R^COX-3^+A&@^FN<YUM\LS/DB3]A&9S_R5
M",$>O@R7'KS_ ,5-G]*@;]@R=P?^+HQ#@C_D2Y>>#@?\C/\ S_7BOK[_ (7W
M\#?^BS_";_PXG@[_ .7%(?CY\# "3\:/A-CO_P 7$\'?_+C_ /75?Z]\?+3Z
MWF*]<F7GWRGS9F_HX^"TG=\'X>][W_MO.UKIVS3R7W??\'>"/V%;K5O#L%Y)
M\2-+L'?4O$,/V;2]'/B2T"VGB#4[-)5U:'Q*B23W,=NMS>684-I-Y+<:5(SR
M632-TQ_X)_SMD#XK1#_N2)C_ "\4_P"%?17PN^//P&3P=;"W^-OP#N(O[;\7
M'S?"?C'PII&B,_\ PEVN>:L5C/JXD6]24/'J]SCR[_5UOKZ$M#<QL?0O^%]_
M W_HL_PF_P##B>#O_EQ51X[\0*453IXS,8P@E",8Y)[L5&_NKFRJ4K*[LG)O
MNV36^C?X*XFK4K5^#Z-6M6G*I5J2SW.W*I4E;FG)PS*G%N5E?EA!:*T5U^+3
M_P $^)SD?\+8B!QCGP/*>OM_PE0/\JA/_!/&<G/_  MJ+IC_ )$6;W_ZFOWK
M[8_X7W\#?^BS_";_ ,.)X._^7%'_  OOX&_]%G^$W_AQ/!W_ ,N*M>('B*ML
M=F:_[HD?_G0<LOHQ>!<OBX)P_P#X?<^7Y9J?#[?\$Z[@C_DKL0_[D*;OQ_T-
MG]>M0_\ #N:?('_"WH\X_P"A"F_^:WU^O]:^YO\ A??P-_Z+/\)O_#B>#O\
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M_P!%H^$__AQ?!_\ \N*?U7&_] &/_P#"''?_ #$'/#^>'_@<?_DCUZBO(?\
MA?OP._Z+1\)__#B^#_\ Y<4?\+]^!W_1:/A/_P"'%\'_ /RXH^JXW_H Q_\
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MD2./XS?"EY)'6.-$^(7A!Y'=V"HB(NKEG=V(544%F8A0"2!7J?VJU_Y^X/\
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M"FY7:]I/#4[VT;7M:E)RU=FX\UGH[/0\+_X9(_97_P"C:O@%_P"&?^'_ /\
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M'_![I/0^>O\ ADC]E?\ Z-J^ 7_AG_A__P#*"C_ADC]E?_HVKX!?^&?^'_\
M\H*^A:*?US'?]!^/_P#"['?_ #8')#^6/_@,/_D#YZ_X9(_97_Z-J^ 7_AG_
M (?_ /R@H_X9(_97_P"C:O@%_P"&?^'_ /\ *"OH6BCZYCO^@_'_ /A=CO\
MYL#DA_+'_P !A_\ ('SU_P ,D?LK_P#1M7P"_P##/_#_ /\ E!1_PR1^RO\
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M /DRA_PR1^RO_P!&U? +_P ,_P##_P#^4%'_  R1^RO_ -&U? +_ ,,_\/\
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M^6I\^?\ #)'[*_\ T;5\ O\ PS_P_P#_ )04?\,D?LK_ /1M7P"_\,_\/_\
MY05S/Q _:Q^'WPI^+,7PH^(R:UH-WKGAZS\3>#M:T[0=;\166MV9^V0ZI8S0
M:%97]_:W^ESZ=<S3.;=K46+)/-+#L<U<B_:8T;754?#/P#\6/B?/*56&72/
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M)+,H9F)+,0"S$G)+$Y))/))))/)K^L#_ (*L?\$@M9^*'B#Q#^TK^RSI!O\
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MJ?\ 9>@VD<?]IWFG2)*M>Z:U^WKX"L?A_P# 7Q;X>^&_Q2\?^*_VC;7Q+?\
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M"]L\#_KJ:@D_9CN6&/\ A*H@,8YT]^W_ &UKBGX#^*S32X5J:_\ 4QR_O?\
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MQ 2ZM'@NHB8YD-:;?L;7;$X\<0\]O[)8]L8_UY[^U<M7Z/7C [I<(5+IN_\
MPI99??\ ["+[=#MH^+7A\FV^(()-?] .8?IAV?"LO?\ W3_6J;_=/X?S%?=[
M?L77C9_XKF('!'_();O]9C_C4!_8IO=N/^$ZB'3DZ2WZ_O:XY_1V\8Y)I<'U
M?B3US/*[63O;_>#NI>,'AU&R?$,.W^XY@^O_ &#GP'<=6_S_ !&LV7J?Q_\
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M6_-ZQ7KH_P#%;;[14IC[RG'HP]!GHX'^?P!E<_>4CO\ ,OO_ +7]1_C\6_\
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MO?U;?FRKU?Y:7_@RK^D%^1]I^8GJ/S4]?;=2>:GK^H_QKXM_X=P_L'_]&F_
MW_P@M%_^1Z/^'</[!_\ T:;\#?\ P@M%_P#D>G['*/\ H-S?_P ->5__ #S#
M][_+2_\ !E7_ .0/M+S4]?U'^-+YB^H_[Z7_ .*KXL_X=P_L'_\ 1IOP-_\
M""T7_P"1Z/\ AW#^P?\ ]&F_ W_P@M%_^1Z/8Y1_T&YO_P"&O*__ )YA^]_E
MI?\ @RK_ /('VGYB^H_[Z7_XJCS%]1_WTO\ \57Q9_P[A_8/_P"C3?@;_P"$
M%HO_ ,CT?\.X?V#_ /HTWX&_^$%HO_R/1['*/^@W-_\ PV99_P#/,/WO\M+_
M ,&5?_D#[3\Q?4?]]+_\51O7U'_?2?\ Q5?%G_#N']@__HTWX&_^$%HO_P C
MT?\ #N']@_\ Z--^!O\ X06B_P#R/1['*/\ H-S?_P -F6?_ #S#][_+2_\
M!E7_ .0/M/>OJ/\ OI/_ (JCS%]1_P!]+_\ %5\6?\.X?V#_ /HTWX&_^$%H
MO_R/1_P[A_8/_P"C3?@;_P"$%HO_ ,CT>QRC_H-S?_PV99_\\P_>_P M+_P9
M5_\ D#[3\Q?4?]]+_P#%4>8OJ/\ OI?_ (JOBS_AW#^P?_T:;\#?_""T7_Y'
MH_X=P_L'_P#1IOP-_P#""T7_ .1Z/8Y1_P!!N;_^&S+/_GF'[W^6E_X,J_\
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M/^^E_P#BJ/,7U'_?2_\ Q5?%G_#N']@__HTWX&_^$%HO_P CT?\ #N']@_\
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MG_#N']@__HTWX&_^$%HO_P CT?\ #N']@_\ Z--^!O\ X06B_P#R/1['*/\
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MAO4]/\7>(H-+O+/P3?6[V'B5+#47MK.<LOZM_D!]]45\9_"C]NCX$_$KQ?\
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M_P!'73UM1"F@R+^\GT :7//^_EDKOZ++^DO\@"BBBBR_JW^0!11119?U;_(
MHHHHLOZM_D!YE\6)X8/#>F//=:+9HWC/P1$LNO>'Y_$MF\LOB?34B@AT^W1W
MM]1G<K%IFK,!%I%Z\.HRLL=NQKTVO/OB4]\F@Z>=/?Q:D_\ PE?A$.?!EI:7
MFJ_9F\0Z>+I;N*]_=)H+0%QX@G0&X@T@W<MN/-12/0?3V_\ U46\K_=_D!\'
M?MX_MN2?L+^ =,^*FM? _P >_%/X?>:]MXL\1^"]9\)Z;#X+O+K5-%T?P_;:
MI:>(]3L+J]/B&^UAX[233H[B.U^P3->&(2P%^Y_8Z_:CU#]K?X.V7QI3X.^,
M_A1X;\1+'>^"K7QGJ_AG4K[Q;H<L+LFMV0\.:CJ$-E:O=126BP7[07)=/-$?
MDNK5XO\ \%8_V?\ XA?M+_L+?&/X8?"S2VUWQU,/#/BC0O#\<T,-UX@E\'^)
M-,\0SZ-8/.\<!U&_M;">'3XYI84ENFCA,D>\-7\R'QI_:T^-7P!_9(_9&\+?
M##XQ_M1?L[?&3P+IS_"#XN_!+7_"_B/P-X4L[+P]+J6H0^-_#MYK'A:&RU6\
MU>74HK:;[)KES=&. EM'MTC2ZN?Z%X$\,LB\1>!<KPV34\!@N/*W&>-R?,,Q
MQ.8YIB:>%R2EDE?.<NQ>+R3"U4\-3S'$87$Y4LSIX?$82G4C0I550Q>(ISE^
M.\5<:9KP?Q5CJV93Q6(X6I\.8;,,)@Z.$P="=?,JF94LNQ=##YE6IRC5GA*=
M>CCG@JE6C7G&52I"52C2E%?TQ? G_@H+XI^-/[3_ (V_9AG_ &3OB[X"UWX7
M"UG^)OBWQ%XE^'UYX=\':?KFD:GJOA#4+N'2=>NM2OHO%@L(H=.BL+:>: WD
M<MXD,<4Q7ZR^-WQND^#MQ\++6'P3JWC*;XG?$:V^'L(TO5M(TL:#)/X;\0^)
M6UN_.K7%O]KLH;;P]<0-:V/FWKS3PF.(QB1A_*/\(?B?\++'XV_MA_%CQ'^W
M3^U[\+;'7O"/P[M? 'Q'M_"7CR?QW\6-7\)^"+]M4U'Q-]F^&=]H\OACP[JT
MD6G>$X]9N?#TSZ=+<?;9+.#_ $MOUQ_X)[:-\6/VX_\ @GI\/?$7[3OQ3\3+
MXVT[XJZWXQ^&GQ=\(^)-%A\?:;I/ABZ6RTC4M9U"T2_T^/5S+=^+-$U&PUFV
M^V#0I[5+^"&0Q[;XX\,,AX;KX3/O9PR_AG U.$\ESS+IX;BAXK$9OGV08['8
MG'9?B,;6K5,=1P>/PU\;EV Q%/$9;15'#598C%3JPCEPQQOFV<T<3E*J2Q.=
MXF.?9CEN-C5R?ZO1P&5YKAL-1PN+IT*5*.%J5\+7BL-C,33G1QM3VE:FJ5&,
M&?2GA;_@IU\$_%_@/4]9MH=1\+?$/0-&T37/$_PZ\66U^3X>L=2UC2+*\$OB
M;1++4=$U:2RTW58=1;^QI[P;I8()=AD8IWFO?\%+/V-/#]MIES=?%^SNDU:V
M2\M5T[1=?NIA:W&D6NL:?-- ;&*9%U2&]LK/35"N]UJEY;Z<BBZ9D7Y:\7_L
MQ_LD_!X>//%E_P#M$_$3P_HGPV_X0";QMHNAV,/CB3PWH^NQ^$;#PG97^FZ'
MX,\1^(;VU\47OA#3[IKR."[N+F\O[LR7$:7$*#%;]DS]AZ^^!]W\<_!_Q>\6
M6W@_PGX8^-_BF_\ %\,NER>(SX6UJ_U3Q1K7AZ?PMXVT&WO]*OO &I0&'PAI
MUWI&F:YH<UM;:7.P28QGQ_\ 5_PMK/#XGZMX@TL!7QF'P].IA<IQ\Z:Q.,PE
M"I' SQ>)P$I)PG*%?!0ITYUZF'Q<%.=6-JZ]3^V.-Z:J457X4J8JCAZU:<:V
M/PJFZ&'Q%6#Q2H4,2HM2C&5'$RE4C"%:A)QA"5Z;^@O$'_!4+]GRXA\/Q?#;
M5;[Q7JNI^,?AEH]_9ZMX;\6:#%::#\0/$.C6,-S!/-I$K?V]J7A_6;+7/!NE
MWL=G;^*!J>C16]XD=^98?9?V?/VZ?@'^T58^!8/"NO7VC>-_'&BZ/JJ?#OQ!
MI6J6OB31I]8\+W7B^'3]0D%HVF2%=#L+^]AO[:[ET^]@M3):SOYB*?S,\._!
MG]EOXH^#]7_:B?XJ_M*:1HG[-%I\/] U62_@\ +>W]M^S3I_PWUG58[?1?#(
MUG^WK;0_$7@71+_Q"S.L6E>)(_%<WA=X=#U^2ZOONC]FC]D+3?A=\98OBCIW
MB%]>\&>%_@%X"^#/PU?5-4.H>*;S2M,OM7URWU/QA:0V%AI^FZMX6\/ZU:^#
M?#L]O]JU&^\/W%S+JUP)B@DX^),@\/<LRG&T:>&XIR_/,OH8Q3AF2Q-&:SFG
M'#RHY+7^L81X?$P<,33Q,JL%A:]##J<5*JY5(QUR;-^+\=F&%J3K9'C,LQ<\
M-;ZE4P]5?4)2K^TS*G&E75:CK1E049>WA5K.+<*249R_17KT/Y44F/<]^_U_
MQ_E2U^-KKMOT^7DO/3IH?IJ=S^:7_@JU_P $A-?^(GB3Q)^TS^RSHLNL>,?$
M-\VJ_$_X26CVD,^O7LD42W?B[P.DIMHWU>X>-KKQ!H!=IM8N9)]4TLOJ4MQ9
MWO\ /V?V%OVU%+*?V3/VC#M8J<?!SQ\P)4D'!70MK+D'#*2",$,0<G_1:++R
M#MZ]#M_4%@<X]0,4S$7]V+_OF/\ ^*K^N_#SZ:7B9P%PQ@.%<3DW#_&.%RFE
M#"97F&?5\^PN:87+:-.-+#9;6Q&5+DQ]#"4H1H82KBJ:Q-'"PIX:=7$0IPJK
M^:N-?HP<%<79]B\_PN:9IPU7S"I+$8_!Y70RZO@<1C:DW.MC:5'&KFPE7$SE
M*IB84)NC4KRE6A3H2E*#_A,^$VA_\%5_@9X:\)^$/A1\ OVE?!7ASPOXQU?Q
MS=:7HOP5\?VEKXWUK64TVUO8OB'''H@7QCI0TK2K?0K?2M5$EG;Z--?64,:K
M?73RX_AWX<_\%)_"=S\/[CP]^RA\;M*'PPD^*4O@VWM?V?O'*6NE+\7ECC\6
M6XC.C?O+>..**/18V;.EQQJ(S(!Q_>7B+IMBQZ;8_7/][UY^M+^[](_R3_XN
MO3G]-',:F(QV+GX*>%LL5F=:KB,RQ'MN,%7S#$5WB'5KX^K&I"6-JS^M8F/M
M,6L0XT\16HTU3P]6IAY^9'Z+F#A2PU"'B=QK&A@J=.C@Z2P^0NGA*5%4O9T\
M+&5.7U>$'0HR4:#HWG2IU)N=6G"K#^%3P39?\%:OARGPZB\#_!O]JSPW!\-]
M-M]%TRWTKX4?$NV@\1:3;:^?$L.F^-8X]*"^*;--19QY&I;T%K));@!&8UU=
MWK?_  5I.DZQ;Z'^S9\;/ _B7Q+X@M?$GBOXF> OV;O$WA'XH^*M1L)-1DTY
MO$/CO2/#5OK.HFR_M6\C%T\J:E>0NL6HWUXJ@'^W_$0Z+$,=/ECX_P#'J4E"
M,$1D>A"8_+?7'4^F ZU:.)J^ WA#.O"49^T=+B=.I*%>>*BL3&E&A0QM..)J
M3K0H9AA<PPL)O]WA:=-1H1Z8?1I=.G*C#Q9X_C3E"4.5?V.U&,Z7L)^RE5]M
M6P\IT?W<ZF$Q&%K3@Y<]:<Y3JR_@0^-OP;_X*7?M$:OX7UWXN_L\?M.>+M5\
M(^$=(\%Z/>7_ ,'OB'),NDZ1%L2>X>317-QJFH2DW>KZ@Y\[4;QFN9\R'->8
M>&_^"?'[<'BC7--\/Z?^RK\=+.\U2YCM8+KQ%\./$WAC18'=@OG:CKWB#3]-
MT?3;= =TD]]>PQJ@)!+#:?\ 0]Q%_=B_[Y3_ .*H B'18ACIA4X_\>KZ/!?3
MRXRRK+J659-X7^'N4X+"T9T<%A<'BN+:>#P<92K5(^QP4>2C[.->O4K.ASPI
MU)3J)R@JC<?(Q/T1^'\?C9X[,N/>+,PQ%>K"KBJV(PN1O%8IQ5.$G4Q7+*HI
MRITHTU5Y)2BHQ?+-QM+\N_\ @F7_ ,$X?#G[#'@:^UK7[^'Q/\<_B!INGQ^/
MO$%M@Z-HEG;/-=6_A#PP#"LKZ=8W$SO?ZG._G:Q?+]H2.WM(K: >T^'_ /@G
MQ^SWX8^%'A7X3:/IVKVECX5^*GA+XMIXQBB\*P^/M>U_P;\9K+XXZ7I?B3Q#
M!X6A74_#T_BS3[6QO;+[%#=R:#$EM!?V^H1QZFGV]O'JG_CO_P 7[G\Z-X_O
M+^:__%U_'G%_&7$/'?$>:<5\4YA6S3.\WQ'M\5B9TY4Z<(0BJ>'PF%H0I*GA
M<%@L/&GA<'A::Y*&'I0AS5)NI5J?TUPUPWDW".28#A[(,'3P.5Y=2]EAZ$)<
MTI2D^>MB*]64G.OBL36<Z^)KS?-5K5)2Y81Y:</RT^)/_!(;]ESXG?$2Y^*6
MLZE\1+/QEJ?CSQMXVUV_AF^'6M6VN6WC[5_#&N:WX-N]-\9?#KQ1867AZ#5/
M"FGW&D:CHEOI?C73DN=3MH_%K6UXT2U=6_X)#? #5I?[,D^*?[0]M\.=*T[X
MG:5X"^#]OXT\(R?#GX86?Q=U72=:\91>"+*_^'][K\"3:CI$4FEQZ[XAUV+2
M+:XN+"RCCL1;6]O^JN\?WE_-?_BZ-X_O+^:__%U\US^4O_ :G_RH]WYK[U_F
M?FEXZ_X)2_LQ>/OCEXE^/.HS>--.\2>,K%5\4Z%I_P#P@,^@:IXEMOAY<_#3
M3O&T%YKG@+6?&&@^(+#09K2^6U\,^*]&\,7_ (ATK3=;UCP]J%Y'<FZHP_\
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M$YQ@U&FK2E&$I*\FFE?ET3PKX;#XFRKTJ55)-)3L[)[_ &UO9?<?-=Q^R[X
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M[R_FO_Q=/F:2?+*SNE[E6SM:]G[&SW5[-VZVNKGS7WK_ #)**CWC^\OYK_\
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MJZ</_ 5_6^I^PG_#MO\ 8L_Z(I!_X77Q._\ FQH_X=M_L6?]$4@_\+KXG?\
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M?%_A+2/$%[962W,UQ<"TM;G4)8+87%Q/.(8XQ+-+)N=O4Z/[8SG_ *&V9?\
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M/B;XCNBD_C'0XI(VTX^-(_+LIHW>#4M4#;M$TZ6ZUB,"6QC9>[_X=M_L6?\
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MOXFG^7C('\B/J*^YZ0]#UZ'H<'\#V/O1_;&<_P#0VS+_ ,+L0'L:7_/NG_X
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M=_\ -C7W/11_;&<_]#;,O_"[$![&C_SZA_X"CX8_X=M_L6?]$4@_\+KXG?\
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M0'L:7_/JG_X CX8_X=M_L6?]$4@_\+KXG?\ S8T?\.V_V+/^B*0?^%U\3O\
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MCJ@=W9B6.\98\R#S(\Q &4;US$&4LID'.P$?,"P *\C(K^:OP7^P_P#\%$M
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MQ^W_ .2\:C_V2VR_]2>2@#V"BBB@ HHHH **** "D/0_TZ_A[^E+2-T/T/\
M*@#@_AH+U?"%H-07Q<MU_:_BO</'#6;>)!$?%FN&U-R;%FMCIQM?)/A\*?,'
MAXZ4+@"X$H'>UY#\"O\ DFVG_P#8R?$/_P!6+XKKUZ@ HHHH **** "BBB@#
MS_XDB^.@V']GKXO:<>*_")<>"6LUU;[,/$.G_:C=F^(A_L 0>9_PD00FX;1_
MMBVP,Q0'T#_/^?\ )''KBO'?CA_R*.C_ /90OAQ_ZFFC5[%0 4444 %%%% !
.1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>athe-20250630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 29 01:27:04 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://pranabio.com/20250630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:athe="http://pranabio.com/20250630" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="athe-20250630_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="athe-20250630_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="athe-20250630_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="athe-20250630_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://pranabio.com/role/ConsolidatedBalanceSheet" id="athe_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ConsolidatedBalanceSheet_Parentheticals" id="athe_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Consolidated Statements of Financial Position (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ConsolidatedIncomeStatement" id="athe_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Consolidated Statements of Profit or Loss and Other Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ConsolidatedCashFlow" id="athe_r_ConsolidatedCashFlow">
        <link:definition>995304 - Statement - Consolidated Cash Flow Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ShareholdersEquityType2or3" id="athe_r_ShareholdersEquityType2or3">
        <link:definition>995305 - Statement - Consolidated Statements of Changes in Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPolicies" id="athe_r_BackgroundandSummaryofMaterialAccountingPolicies">
        <link:definition>995306 - Disclosure - Background and Summary of Material Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/InterestandOtherIncomefromContinuingOperations" id="athe_r_InterestandOtherIncomefromContinuingOperations">
        <link:definition>995307 - Disclosure - Interest and Other Income from Continuing Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ExpensesfromOrdinaryActivities" id="athe_r_ExpensesfromOrdinaryActivities">
        <link:definition>995308 - Disclosure - Expenses from Ordinary Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/IncomeTax" id="athe_r_IncomeTax">
        <link:definition>995309 - Disclosure - Income Tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/TradeandOtherReceivables" id="athe_r_TradeandOtherReceivables">
        <link:definition>995310 - Disclosure - Trade and Other Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/OtherCurrentAssets" id="athe_r_OtherCurrentAssets">
        <link:definition>995311 - Disclosure - Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/TradeandOtherPayables" id="athe_r_TradeandOtherPayables">
        <link:definition>995312 - Disclosure - Trade and Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/Provisions" id="athe_r_Provisions">
        <link:definition>995313 - Disclosure - Provisions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/CommitmentsandContingencies" id="athe_r_CommitmentsandContingencies">
        <link:definition>995314 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/IssuedCapital" id="athe_r_IssuedCapital">
        <link:definition>995315 - Disclosure - Issued Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/Reserves" id="athe_r_Reserves">
        <link:definition>995316 - Disclosure - Reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStage" id="athe_r_AccumulatedDeficitDuringDevelopmentStage">
        <link:definition>995317 - Disclosure - Accumulated Deficit During Development Stage</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/Leases" id="athe_r_Leases">
        <link:definition>995318 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/CashFlowInformation" id="athe_r_CashFlowInformation">
        <link:definition>995319 - Disclosure - Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ExpenditureCommitments" id="athe_r_ExpenditureCommitments">
        <link:definition>995320 - Disclosure - Expenditure Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ShareBasedPayments" id="athe_r_ShareBasedPayments">
        <link:definition>995321 - Disclosure - Share Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/SubsequentEvents" id="athe_r_SubsequentEvents">
        <link:definition>995322 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/LossPerShare" id="athe_r_LossPerShare">
        <link:definition>995323 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/KeyManagementPersonnelCompensation" id="athe_r_KeyManagementPersonnelCompensation">
        <link:definition>995324 - Disclosure - Key Management Personnel Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/AuditorsRemuneration" id="athe_r_AuditorsRemuneration">
        <link:definition>995325 - Disclosure - Auditors' Remuneration</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/RelatedPartyTransactions" id="athe_r_RelatedPartyTransactions">
        <link:definition>995326 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/SegmentInformation" id="athe_r_SegmentInformation">
        <link:definition>995327 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/FinancialInstruments" id="athe_r_FinancialInstruments">
        <link:definition>995328 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ParentEntityFinancialInformation" id="athe_r_ParentEntityFinancialInformation">
        <link:definition>995329 - Disclosure - Parent Entity Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/AccountingPoliciesByPolicy" id="athe_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesTables" id="athe_r_BackgroundandSummaryofMaterialAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Background and Summary of Material Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsTables" id="athe_r_InterestandOtherIncomefromContinuingOperationsTables">
        <link:definition>996002 - Disclosure - Interest and Other Income from Continuing Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ExpensesfromOrdinaryActivitiesTables" id="athe_r_ExpensesfromOrdinaryActivitiesTables">
        <link:definition>996003 - Disclosure - Expenses from Ordinary Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/IncomeTaxTables" id="athe_r_IncomeTaxTables">
        <link:definition>996004 - Disclosure - Income Tax (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/TradeandOtherReceivablesTables" id="athe_r_TradeandOtherReceivablesTables">
        <link:definition>996005 - Disclosure - Trade and Other Receivables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/OtherCurrentAssetsTables" id="athe_r_OtherCurrentAssetsTables">
        <link:definition>996006 - Disclosure - Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/TradeandOtherPayablesTables" id="athe_r_TradeandOtherPayablesTables">
        <link:definition>996007 - Disclosure - Trade and Other Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ProvisionsTables" id="athe_r_ProvisionsTables">
        <link:definition>996008 - Disclosure - Provisions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/IssuedCapitalTables" id="athe_r_IssuedCapitalTables">
        <link:definition>996009 - Disclosure - Issued Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ReservesTables" id="athe_r_ReservesTables">
        <link:definition>996010 - Disclosure - Reserves (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStageTables" id="athe_r_AccumulatedDeficitDuringDevelopmentStageTables">
        <link:definition>996011 - Disclosure - Accumulated Deficit During Development Stage (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/LeasesTables" id="athe_r_LeasesTables">
        <link:definition>996012 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/CashFlowInformationTables" id="athe_r_CashFlowInformationTables">
        <link:definition>996013 - Disclosure - Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ShareBasedPaymentsTables" id="athe_r_ShareBasedPaymentsTables">
        <link:definition>996014 - Disclosure - Share Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/LossPerShareTables" id="athe_r_LossPerShareTables">
        <link:definition>996015 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/KeyManagementPersonnelCompensationTables" id="athe_r_KeyManagementPersonnelCompensationTables">
        <link:definition>996016 - Disclosure - Key Management Personnel Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/AuditorsRemunerationTables" id="athe_r_AuditorsRemunerationTables">
        <link:definition>996017 - Disclosure - Auditors' Remuneration (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/FinancialInstrumentsTables" id="athe_r_FinancialInstrumentsTables">
        <link:definition>996018 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ParentEntityFinancialInformationTables" id="athe_r_ParentEntityFinancialInformationTables">
        <link:definition>996019 - Disclosure - Parent Entity Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails" id="athe_r_BackgroundandSummaryofMaterialAccountingPoliciesDetails">
        <link:definition>996020 - Disclosure - Background and Summary of Material Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable" id="athe_r_ScheduleofEstimatedUsefulLivesTable">
        <link:definition>996021 - Disclosure - Background and Summary of Material Accounting Policies - Schedule of Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsDetails" id="athe_r_InterestandOtherIncomefromContinuingOperationsDetails">
        <link:definition>996022 - Disclosure - Interest and Other Income from Continuing Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable" id="athe_r_ScheduleofInterestandOtherIncomefromContinuingOperationsTable">
        <link:definition>996023 - Disclosure - Interest and Other Income from Continuing Operations - Schedule of Interest and Other Income from Continuing Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable" id="athe_r_ScheduleofExpensesfromOrdinaryActivitiesTable">
        <link:definition>996024 - Disclosure - Expenses from Ordinary Activities - Schedule of Expenses from Ordinary Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/IncomeTaxDetails" id="athe_r_IncomeTaxDetails">
        <link:definition>996025 - Disclosure - Income Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofIncomeTaxTable" id="athe_r_ScheduleofIncomeTaxTable">
        <link:definition>996026 - Disclosure - Income Tax - Schedule of Income Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofIncomeTaxTable_Parentheticals" id="athe_r_ScheduleofIncomeTaxTable_Parentheticals">
        <link:definition>996027 - Disclosure - Income Tax - Schedule of Income Tax (Parentheticals) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable" id="athe_r_ScheduleofTradeandOtherReceivablesTable">
        <link:definition>996028 - Disclosure - Trade and Other Receivables - Schedule of Trade and Other Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/OtherCurrentAssetsDetails" id="athe_r_OtherCurrentAssetsDetails">
        <link:definition>996029 - Disclosure - Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable" id="athe_r_ScheduleofOtherCurrentAssetsTable">
        <link:definition>996030 - Disclosure - Other Current Assets - Schedule of Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable" id="athe_r_ScheduleofTradeandOtherPayablesTable">
        <link:definition>996031 - Disclosure - Trade and Other Payables - Schedule of Trade and Other Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofProvisionsTable" id="athe_r_ScheduleofProvisionsTable">
        <link:definition>996032 - Disclosure - Provisions - Schedule of Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofMovementsinProvisionsTable" id="athe_r_ScheduleofMovementsinProvisionsTable">
        <link:definition>996033 - Disclosure - Provisions - Schedule of Movements in Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/IssuedCapitalDetails" id="athe_r_IssuedCapitalDetails">
        <link:definition>996034 - Disclosure - Issued Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofIssuedCapitalTable" id="athe_r_ScheduleofIssuedCapitalTable">
        <link:definition>996035 - Disclosure - Issued Capital - Schedule of Issued Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofIssuedCapitalTable_Parentheticals" id="athe_r_ScheduleofIssuedCapitalTable_Parentheticals">
        <link:definition>996036 - Disclosure - Issued Capital - Schedule of Issued Capital (Parentheticals) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofMovementsinIssuedSharesTable" id="athe_r_ScheduleofMovementsinIssuedSharesTable">
        <link:definition>996037 - Disclosure - Issued Capital - Schedule of Movements in Issued Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofShareIssuancesTable" id="athe_r_ScheduleofShareIssuancesTable">
        <link:definition>996038 - Disclosure - Issued Capital - Schedule of Share Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ReservesDetails" id="athe_r_ReservesDetails">
        <link:definition>996039 - Disclosure - Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable" id="athe_r_ScheduleofReservesofShareBasedPaymentsTable">
        <link:definition>996040 - Disclosure - Reserves - Schedule of Reserves of Share Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][TQJYBy+u9PbbisFFTUCuKFDxTHFbzq6+xWrn9y9u8kGHskD9Qz+a+nMsunCqeEeN6lDHxbMZVZC+F2GoP80n/oMrk93WtYApKSF+Mlo7VTlwR34bf4tmccx5DtfhupB8WT0HR+RslA8gHPl5wMleC8QbMSSBcvR7IhNREFD5iZbqAEJllU3SuDu2JEgq/c3n9gp8a+9a+2IB/rBrAVl0BLzjfsifPblmbnN4Hp0zwZdMJnQwk9zYuj5B6X7T5dTX7w8JkAdmwSbLXAG+jtVdYPO8ULIBHFHQSdnMImdGbApZL0hzKGUZbl5OkW+SBmhOgdWsPwKOTBaXmxNHAhaC4/pDgkdvTedRCCuTRRka5SVLjsmKeQ==] CSR-->
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable_Parentheticals" id="athe_r_ScheduleofReservesofShareBasedPaymentsTable_Parentheticals">
        <link:definition>996041 - Disclosure - Reserves - Schedule of Reserves of Share Based Payments (Parentheticals) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable" id="athe_r_ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable">
        <link:definition>996042 - Disclosure - Reserves - Schedule of Movements in Options for Fully Paid Ordinary Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofAccumulatedDeficitDuringDevelopmentStageTable" id="athe_r_ScheduleofAccumulatedDeficitDuringDevelopmentStageTable">
        <link:definition>996043 - Disclosure - Accumulated Deficit During Development Stage - Schedule of Accumulated Deficit During Development Stage (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/LeasesDetails" id="athe_r_LeasesDetails">
        <link:definition>996044 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable" id="athe_r_ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable">
        <link:definition>996045 - Disclosure - Leases - Schedule of Financial Position Shows the Following Amounts Relating to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofProfitorLossShowstheFollowingAmountsRelatingtoLeasesTable" id="athe_r_ScheduleofProfitorLossShowstheFollowingAmountsRelatingtoLeasesTable">
        <link:definition>996046 - Disclosure - Leases - Schedule of Profit or Loss Shows the Following Amounts Relating to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofCashFlowInformationTable" id="athe_r_ScheduleofCashFlowInformationTable">
        <link:definition>996047 - Disclosure - Cash Flow Information - Schedule of Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ExpenditureCommitmentsDetails" id="athe_r_ExpenditureCommitmentsDetails">
        <link:definition>996048 - Disclosure - Expenditure Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ShareBasedPaymentsDetails" id="athe_r_ShareBasedPaymentsDetails">
        <link:definition>996049 - Disclosure - Share Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofOptionsGrantedTable" id="athe_r_ScheduleofOptionsGrantedTable">
        <link:definition>996050 - Disclosure - Share Based Payments - Schedule of Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofOptionsOutstandingTable" id="athe_r_ScheduleofOptionsOutstandingTable">
        <link:definition>996051 - Disclosure - Share Based Payments - Schedule of Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable" id="athe_r_ScheduleofValuationsofOptionsApprovedandIssuedTable">
        <link:definition>996052 - Disclosure - Share Based Payments - Schedule of Valuations of Options Approved and Issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofSharesIssuedunderStockOptionPlanTable" id="athe_r_ScheduleofSharesIssuedunderStockOptionPlanTable">
        <link:definition>996053 - Disclosure - Share Based Payments - Schedule of Shares Issued under Stock Option Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/SubsequentEventsDetails" id="athe_r_SubsequentEventsDetails">
        <link:definition>996054 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofEarningLossPerShareTable" id="athe_r_ScheduleofEarningLossPerShareTable">
        <link:definition>996055 - Disclosure - Loss Per Share - Schedule of Earning Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable" id="athe_r_ScheduleofKeyManagementPersonnelCompensationTable">
        <link:definition>996056 - Disclosure - Key Management Personnel Compensation - Schedule of Key Management Personnel Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofAuditandReviewofFinancialStatementsTable" id="athe_r_ScheduleofAuditandReviewofFinancialStatementsTable">
        <link:definition>996057 - Disclosure - Auditors' Remuneration - Schedule of Audit and Review of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/RelatedPartyTransactionsDetails" id="athe_r_RelatedPartyTransactionsDetails">
        <link:definition>996058 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/SegmentInformationDetails" id="athe_r_SegmentInformationDetails">
        <link:definition>996059 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/FinancialInstrumentsDetails" id="athe_r_FinancialInstrumentsDetails">
        <link:definition>996060 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable" id="athe_r_ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable">
        <link:definition>996061 - Disclosure - Financial Instruments - Schedule of Financial Assets and Liabilities Subject to Foreign Currency Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable" id="athe_r_ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable">
        <link:definition>996062 - Disclosure - Financial Instruments - Schedule of Interest Rates and the Effective Weighted Average Interest Rate for Classes of Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable" id="athe_r_ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable">
        <link:definition>996063 - Disclosure - Financial Instruments - Schedule of Company's Liquidity Reserve on the Basis of Expected Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable" id="athe_r_ScheduleofIndividualFinancialStatementsfortheParentEntityTable">
        <link:definition>996064 - Disclosure - Parent Entity Financial Information - Schedule of Individual Financial Statements for the Parent Entity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pranabio.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:element name="ScheduleOfEstimatedUsefulLivesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfEstimatedUsefulLivesAbstract"/>
  <xs:element name="ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract"/>
  <xs:element name="ScheduleOfExpensesFromOrdinaryActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract"/>
  <xs:element name="ScheduleOfIncomeTaxAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfIncomeTaxAbstract"/>
  <xs:element name="ScheduleOfProvisionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfProvisionsAbstract"/>
  <xs:element name="ScheduleOfMovementsInProvisionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfMovementsInProvisionsAbstract"/>
  <xs:element name="ScheduleOfMovementsInIssuedSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfMovementsInIssuedSharesAbstract"/>
  <xs:element name="ScheduleOfShareIssuancesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfShareIssuancesAbstract"/>
  <xs:element name="ScheduleOfReservesOfShareBasedPaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfReservesOfShareBasedPaymentsAbstract"/>
  <xs:element name="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract"/>
  <xs:element name="ScheduleOfCashFlowInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfCashFlowInformationAbstract"/>
  <xs:element name="ScheduleOfOptionsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfOptionsOutstandingAbstract"/>
  <xs:element name="ScheduleOfValuationsOfOptionsApprovedAndIssuedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedAbstract"/>
  <xs:element name="ScheduleOfSharesIssuedUnderStockOptionPlanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfSharesIssuedUnderStockOptionPlanAbstract"/>
  <xs:element name="ScheduleOfAuditAndReviewOfFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfAuditAndReviewOfFinancialStatementsAbstract"/>
  <xs:element name="ScheduleOfInterestRatesAndTheEffectiveWeightedAverageInterestRateForClassesOfFinancialAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfInterestRatesAndTheEffectiveWeightedAverageInterestRateForClassesOfFinancialAssetsAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfCompanysLiquidityReserveOnTheBasisOfExpectedCashFlowsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfCompanysLiquidityReserveOnTheBasisOfExpectedCashFlowsAbstract"/>
  <xs:element name="ScheduleOfIndividualFinancialStatementsForTheParentEntityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfIndividualFinancialStatementsForTheParentEntityAbstract"/>
  <xs:element name="ResearchAndDevelopmentExpenses1Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ResearchAndDevelopmentExpenses1Abstract"/>
  <xs:element name="GeneralAndAdministrationExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_GeneralAndAdministrationExpensesAbstract"/>
  <xs:element name="OtherGainsAndLossesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_OtherGainsAndLossesAbstract"/>
  <xs:element name="AddTaxEffectOfAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_AddTaxEffectOfAbstract"/>
  <xs:element name="CurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_CurrentAbstract"/>
  <xs:element name="NonCurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_NonCurrentAbstract"/>
  <xs:element name="AnnualLeaveAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_AnnualLeaveAbstract"/>
  <xs:element name="LongServiceLeaveAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_LongServiceLeaveAbstract"/>
  <xs:element name="AIssuedCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_AIssuedCapitalAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_UnlabeledAbstract"/>
  <xs:element name="RightOfUseAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_RightOfUseAssetsAbstract"/>
  <xs:element name="ChangesInAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ChangesInAssetsAndLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_UnlabeledAbstract0"/>
  <xs:element name="FinancialAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_FinancialAssetsAbstract"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_UnlabeledAbstract1"/>
  <xs:element name="FinancialLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_FinancialLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_UnlabeledAbstract2"/>
  <xs:element name="FinancialAssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_FinancialAssetsAbstract0"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_UnlabeledAbstract3"/>
  <xs:element name="FinancialLiabilitiesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_FinancialLiabilitiesAbstract0"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_UnlabeledAbstract4"/>
  <xs:element name="IntellectualPropertyExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_IntellectualPropertyExpenses"/>
  <xs:element name="ForfeitedOptionsFromReserves" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_ForfeitedOptionsFromReserves"/>
  <xs:element name="ProceedsFromResearchAndDevelopmentTaxRefund" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_ProceedsFromResearchAndDevelopmentTaxRefund"/>
  <xs:element name="PaymentsForRentalSecurityDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_PaymentsForRentalSecurityDeposits"/>
  <xs:element name="IssuanceOfSharesNetOfCostsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_IssuanceOfSharesNetOfCostsValue"/>
  <xs:element name="IssuanceOfSharesNetOfCostsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_IssuanceOfSharesNetOfCostsShares"/>
  <xs:element name="IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees"/>
  <xs:element name="IncreaseDecreaseThroughIssuanceOfOptionsToConsultants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants"/>
  <xs:element name="IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars"/>
  <xs:element name="IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement"/>
  <xs:element name="ForfeitedOptionsReversedToProfitOrLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_ForfeitedOptionsReversedToProfitOrLoss"/>
  <xs:element name="TransactionsWithOwnersInTheirCapacitySharesAsOwners" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners"/>
  <xs:element name="AccumulatedDeficitDuringDevelopmentStageTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_AccumulatedDeficitDuringDevelopmentStageTextBlock"/>
  <xs:element name="DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock"/>
  <xs:element name="DescriptionOfAccountingPolicyForRecognitionOfOtherIncome" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome"/>
  <xs:element name="DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock"/>
  <xs:element name="DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock"/>
  <xs:element name="ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock"/>
  <xs:element name="DisclosureOfIncomeTaxExplanatoryTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock"/>
  <xs:element name="DisclosureOfTradeAndOtherReceivableTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_DisclosureOfTradeAndOtherReceivableTableTextBlock"/>
  <xs:element name="ScheduleOfTradeAndOtherPayableTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfTradeAndOtherPayableTableTextBlock"/>
  <xs:element name="DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock"/>
  <xs:element name="ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock"/>
  <xs:element name="ScheduleOfReserveOfShareBasedPaymentsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock"/>
  <xs:element name="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock"/>
  <xs:element name="ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock"/>
  <xs:element name="ScheduleOfAmountsRelatingToLeasesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock"/>
  <xs:element name="DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases"/>
  <xs:element name="ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock"/>
  <xs:element name="ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock"/>
  <xs:element name="ScheduleOfNumberOfSharesIssuedTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfNumberOfSharesIssuedTableTextBlock"/>
  <xs:element name="DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock"/>
  <xs:element name="ScheduleOfAuditorRemunerationTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfAuditorRemunerationTableTextBlock"/>
  <xs:element name="DisclosureOfParentEntityFinancialStatementsExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_DisclosureOfParentEntityFinancialStatementsExplanatory"/>
  <xs:element name="RangesDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_RangesDomainDomain"/>
  <xs:element name="BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable"/>
  <xs:element name="UsefulLivesOrDepreciationRatePropertyPlantAndEquipments" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments"/>
  <xs:element name="ResearchAndDevelopmentTaxIncentive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_ResearchAndDevelopmentTaxIncentive"/>
  <xs:element name="OtherResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_OtherResearchAndDevelopmentExpenses"/>
  <xs:element name="ConsultantAndDirectorExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_ConsultantAndDirectorExpenses"/>
  <xs:element name="AuditInternalControlAndOtherAssuranceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_AuditInternalControlAndOtherAssuranceExpenses"/>
  <xs:element name="CorporateComplianceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_CorporateComplianceExpenses"/>
  <xs:element name="OfficeRentalExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_OfficeRentalExpenses"/>
  <xs:element name="CorporateAdvisoryExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_CorporateAdvisoryExpenses"/>
  <xs:element name="PrimaFaciesTaxOnNetLossBeforeIncomeTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax"/>
  <xs:element name="TaxEffectOfResearchAndDevelopmentExpenditure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_TaxEffectOfResearchAndDevelopmentExpenditure"/>
  <xs:element name="TaxEffectOfDeferredTaxAssetNotRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_TaxEffectOfDeferredTaxAssetNotRecognized"/>
  <xs:element name="PrimaFacieTaxOnNetLossBeforeIncomeTax" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_PrimaFacieTaxOnNetLossBeforeIncomeTax"/>
  <xs:element name="ResearchAndDevelopmentTaxIncentiveReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_ResearchAndDevelopmentTaxIncentiveReceivable"/>
  <xs:element name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_AccruedResearchAndDevelopmentExpenses"/>
  <xs:element name="AccruedProfessionalFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_AccruedProfessionalFees"/>
  <xs:element name="OtherCurrentAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_OtherCurrentAccruedExpenses"/>
  <xs:element name="ProvisionsScheduleofProvisionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_ProvisionsScheduleofProvisionsDetailsTable"/>
  <xs:element name="ProvisionsScheduleofMovementsinProvisionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_ProvisionsScheduleofMovementsinProvisionsDetailsTable"/>
  <xs:element name="AnnualLeaveAndLongServiceLeaveCarryingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_AnnualLeaveAndLongServiceLeaveCarryingAmount"/>
  <xs:element name="IssuedCapitalScheduleofIssuedCapitalDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_IssuedCapitalScheduleofIssuedCapitalDetailsTable"/>
  <xs:element name="SharesOfIssuedCapital" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="athe_SharesOfIssuedCapital"/>
  <xs:element name="IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable"/>
  <xs:element name="IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable"/>
  <xs:element name="MovementDuringTheYearNoOfSharesinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_MovementDuringTheYearNoOfSharesinShares"/>
  <xs:element name="ValueOfIncreaseDecreaseInSharesOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_ValueOfIncreaseDecreaseInSharesOutstanding"/>
  <xs:element name="ShareIssuanceDateDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ShareIssuanceDateDomainDomain"/>
  <xs:element name="IssuedCapitalScheduleofShareIssuancesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_IssuedCapitalScheduleofShareIssuancesDetailsTable"/>
  <xs:element name="IncreaseDecreaseInNumberOfShareOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="athe_IncreaseDecreaseInNumberOfShareOutstanding"/>
  <xs:element name="NumberOfSharesIssuedDuringTheYear" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_NumberOfSharesIssuedDuringTheYear"/>
  <xs:element name="NumberofSharesIssuePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_NumberofSharesIssuePricePerShare"/>
  <xs:element name="IssuedCapitalPreferenceShare" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_IssuedCapitalPreferenceShare"/>
  <xs:element name="ReservesScheduleofReservesofShareBasedPaymentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_ReservesScheduleofReservesofShareBasedPaymentsDetailsTable"/>
  <xs:element name="ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable"/>
  <xs:element name="OptionsForFullyPaidOrdinaryShares1" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_OptionsForFullyPaidOrdinaryShares1"/>
  <xs:element name="FreeattachingOptionsForFullyPaidOrdinaryShares" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_FreeattachingOptionsForFullyPaidOrdinaryShares"/>
  <xs:element name="NumberOfSharesOptionsOutstanding" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="athe_NumberOfSharesOptionsOutstanding"/>
  <xs:element name="ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear"/>
  <xs:element name="ReserveOfOptionsIssuedDuringTheYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_ReserveOfOptionsIssuedDuringTheYear"/>
  <xs:element name="ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare"/>
  <xs:element name="ReserveOfShareBasedPaymentsExpiredDuringTheYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear"/>
  <xs:element name="NumberOfOptionsForfeitedDuringTheYear" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_NumberOfOptionsForfeitedDuringTheYear"/>
  <xs:element name="ReserveOfSharebasedPaymentsForfeitedDuringYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_ReserveOfSharebasedPaymentsForfeitedDuringYear"/>
  <xs:element name="NumberOfOptionsOptionsExercisedDuringTheYear" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_NumberOfOptionsOptionsExercisedDuringTheYear"/>
  <xs:element name="OptionsExercisedDuringTheYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_OptionsExercisedDuringTheYear"/>
  <xs:element name="NumberOfOptionsSharesToBeIssued" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_NumberOfOptionsSharesToBeIssued"/>
  <xs:element name="SharesToBeIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_SharesToBeIssued"/>
  <xs:element name="ShareBasedPaymentExpenseForOptionsIssuedI" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ShareBasedPaymentExpenseForOptionsIssuedI"/>
  <xs:element name="ReclassifyExpiredOptionsFromReservesOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_ReclassifyExpiredOptionsFromReservesOne"/>
  <xs:element name="ReclassifyForfeitedOptionsFromReserves" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_ReclassifyForfeitedOptionsFromReserves"/>
  <xs:element name="ExpensesRelatingToShorttermLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_ExpensesRelatingToShorttermLeases"/>
  <xs:element name="ForeignExchangegainLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_ForeignExchangegainLoss"/>
  <xs:element name="FixedAssetWriteOff" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_FixedAssetWriteOff"/>
  <xs:element name="IncreaseDecreaseInTradeAndOtherReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_IncreaseDecreaseInTradeAndOtherReceivables"/>
  <xs:element name="ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable"/>
  <xs:element name="OptionsSeriesDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_OptionsSeriesDomainDomain"/>
  <xs:element name="ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable"/>
  <xs:element name="ExpiryDateOfOutstandingShareOptions" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ExpiryDateOfOutstandingShareOptions"/>
  <xs:element name="ExercisePriceOfOutstandingShareOption1" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="athe_ExercisePriceOfOutstandingShareOption1"/>
  <xs:element name="ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable"/>
  <xs:element name="SharePriceAtGrantDate" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_SharePriceAtGrantDate"/>
  <xs:element name="YearsToExpiry" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_YearsToExpiry"/>
  <xs:element name="RiskfreeInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_RiskfreeInterestRate"/>
  <xs:element name="FairValuePerOptions" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_FairValuePerOptions"/>
  <xs:element name="PlanDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_PlanDomainDomain"/>
  <xs:element name="ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable"/>
  <xs:element name="KeyManagementPersonnelCompensationLongtermBenefits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_KeyManagementPersonnelCompensationLongtermBenefits"/>
  <xs:element name="FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable"/>
  <xs:element name="FinancialInstrumentsTotalExposure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_FinancialInstrumentsTotalExposure"/>
  <xs:element name="FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable"/>
  <xs:element name="FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems"/>
  <xs:element name="AverageInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_AverageInterestRate"/>
  <xs:element name="FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable"/>
  <xs:element name="BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable"/>
  <xs:element name="TaxRateEffectFromChangesInTaxRate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_TaxRateEffectFromChangesInTaxRate"/>
  <xs:element name="EligibleAmountUnderTheTaxIncentiveScheme" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_EligibleAmountUnderTheTaxIncentiveScheme"/>
  <xs:element name="ProfitLossBeforeTax1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_ProfitLossBeforeTax1"/>
  <xs:element name="ProfitLossBeforeTax2" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="athe_ProfitLossBeforeTax2"/>
  <xs:element name="EstimatedUsefulEconomicLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_EstimatedUsefulEconomicLife"/>
  <xs:element name="Employeesdescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_Employeesdescription"/>
  <xs:element name="TurnoverRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_TurnoverRevenue"/>
  <xs:element name="EligibleAmountUnderTaxIncentiveScheme" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_EligibleAmountUnderTaxIncentiveScheme"/>
  <xs:element name="MiscellaneousIncomeDisputeWithCatalent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_MiscellaneousIncomeDisputeWithCatalent"/>
  <xs:element name="MiscellaneousIncomeSettlementOfAnInsuranceClaim" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim"/>
  <xs:element name="IncomeTaxDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_IncomeTaxDetailsTable"/>
  <xs:element name="TermDeposit" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_TermDeposit"/>
  <xs:element name="MaturityDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_MaturityDate"/>
  <xs:element name="ordinarySharesPerShareCents" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="athe_ordinarySharesPerShareCents"/>
  <xs:element name="ReservesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_ReservesDetailsTable"/>
  <xs:element name="ExpiredTerm" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ExpiredTerm"/>
  <xs:element name="ReserveOfOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ReserveOfOrdinaryShares"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_LeasesDetailsTable"/>
  <xs:element name="ShortTermLeaseTerm" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ShortTermLeaseTerm"/>
  <xs:element name="TerminationNoticePeriodForResearchAndDevelopmentContracts" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_TerminationNoticePeriodForResearchAndDevelopmentContracts"/>
  <xs:element name="ResearchAndDevelopmentTerminationCommitments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_ResearchAndDevelopmentTerminationCommitments"/>
  <xs:element name="ShareBasedPaymentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_ShareBasedPaymentsDetailsTable"/>
  <xs:element name="NumberOfDirector" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="athe_NumberOfDirector"/>
  <xs:element name="NumberOfKeyManagementPersonnel" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="athe_NumberOfKeyManagementPersonnel"/>
  <xs:element name="NumberOfConsultant" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="athe_NumberOfConsultant"/>
  <xs:element name="ShareholdersAuthorizedSecurities" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ShareholdersAuthorizedSecurities"/>
  <xs:element name="PercentageOfDefaultVestingConditionsPerYear" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_PercentageOfDefaultVestingConditionsPerYear"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_SubsequentEventsDetailsTable"/>
  <xs:element name="ExercisePriceExpiryTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ExercisePriceExpiryTerm"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="NumberOfReportableSegment" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_NumberOfReportableSegment"/>
  <xs:element name="FinancialInstrumentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_FinancialInstrumentsDetailsTable"/>
  <xs:element name="AverageAnnualMovementForeignExchangeRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_AverageAnnualMovementForeignExchangeRate"/>
  <xs:element name="SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar"/>
  <xs:element name="PercentageOfInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_PercentageOfInterestRate"/>
  <xs:element name="OptionsSeriesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="athe_OptionsSeriesAxis"/>
  <xs:element name="PlanAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="athe_PlanAxis"/>
  <xs:element name="RangesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="athe_RangesAxis"/>
  <xs:element name="ShareIssuanceDateAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="athe_ShareIssuanceDateAxis"/>
  <xs:element name="ADSEmployeeSharePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ADSEmployeeSharePlanMember"/>
  <xs:element name="ASXEmployeeSharePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ASXEmployeeSharePlanMember"/>
  <xs:element name="ATHAABMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ATHAABMember"/>
  <xs:element name="ATHAABOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ATHAABOneMember"/>
  <xs:element name="ATHAADMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ATHAADMember"/>
  <xs:element name="ATHAADOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ATHAADOneMember"/>
  <xs:element name="ATHAAEMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ATHAAEMember"/>
  <xs:element name="ATHAAFMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ATHAAFMember"/>
  <xs:element name="ATHAAFOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ATHAAFOneMember"/>
  <xs:element name="ATHAAGMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ATHAAGMember"/>
  <xs:element name="ATHAAGOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ATHAAGOneMember"/>
  <xs:element name="ATHAAHMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ATHAAHMember"/>
  <xs:element name="ATHAAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ATHAAMember"/>
  <xs:element name="ATHABMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ATHABMember"/>
  <xs:element name="ATHACMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ATHACMember"/>
  <xs:element name="AdsPlanTwoThousandEighteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_AdsPlanTwoThousandEighteenMember"/>
  <xs:element name="AnnualLeaveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_AnnualLeaveMember"/>
  <xs:element name="April222024Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_April222024Member"/>
  <xs:element name="April42025Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_April42025Member"/>
  <xs:element name="AsxPlan2004Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_AsxPlan2004Member"/>
  <xs:element name="AugustThirtyFirstTwoThousandTwentySixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_AugustThirtyFirstTwoThousandTwentySixMember"/>
  <xs:element name="CarryingAmountsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_CarryingAmountsMember"/>
  <xs:element name="CashAndCashEquivalentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_CashAndCashEquivalentMember"/>
  <xs:element name="ChiefExecutiveOfficersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ChiefExecutiveOfficersMember"/>
  <xs:element name="ConsultantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ConsultantMember"/>
  <xs:element name="DirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_DirectorsMember"/>
  <xs:element name="EmployeeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_EmployeeMember"/>
  <xs:element name="February172025Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_February172025Member"/>
  <xs:element name="February22024Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_February22024Member"/>
  <xs:element name="February32025Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_February32025Member"/>
  <xs:element name="ForeignCurrencyRiskMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ForeignCurrencyRiskMember"/>
  <xs:element name="FreeAttachingOptionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_FreeAttachingOptionMember"/>
  <xs:element name="GreaterThanTowelMonthsAndLessThanFiveYearsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember"/>
  <xs:element name="InterestRate105PercentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_InterestRate105PercentMember"/>
  <xs:element name="InterestRate144PercentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_InterestRate144PercentMember"/>
  <xs:element name="InterestRate36PercentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_InterestRate36PercentMember"/>
  <xs:element name="InterestRate385OnePercentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_InterestRate385OnePercentMember"/>
  <xs:element name="InterestRate385PercentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_InterestRate385PercentMember"/>
  <xs:element name="InterestRateOf000FourPercentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_InterestRateOf000FourPercentMember"/>
  <xs:element name="InterestRateOf000OnePercentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_InterestRateOf000OnePercentMember"/>
  <xs:element name="InterestRateOf000PercentFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_InterestRateOf000PercentFiveMember"/>
  <xs:element name="InterestRateOf000PercentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_InterestRateOf000PercentMember"/>
  <xs:element name="InterestRateOf000ThreePercentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_InterestRateOf000ThreePercentMember"/>
  <xs:element name="InterestRateOf000TwoPercentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_InterestRateOf000TwoPercentMember"/>
  <xs:element name="InterestRateOf15To482PercentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_InterestRateOf15To482PercentMember"/>
  <xs:element name="InterestRateOf27Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_InterestRateOf27Member"/>
  <xs:element name="January222025Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_January222025Member"/>
  <xs:element name="January302025Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_January302025Member"/>
  <xs:element name="January82024Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_January82024Member"/>
  <xs:element name="July182024Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_July182024Member"/>
  <xs:element name="June302023Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_June302023Member"/>
  <xs:element name="June302024Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_June302024Member"/>
  <xs:element name="June302025Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_June302025Member"/>
  <xs:element name="LessThenSixMonthsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_LessThenSixMonthsMember"/>
  <xs:element name="LongDatedOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_LongDatedOptionsMember"/>
  <xs:element name="LongServiceLeaveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_LongServiceLeaveMember"/>
  <xs:element name="March142025Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_March142025Member"/>
  <xs:element name="March152023Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_March152023Member"/>
  <xs:element name="March42024Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_March42024Member"/>
  <xs:element name="NonExecutiveDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_NonExecutiveDirectorsMember"/>
  <xs:element name="NonInterestBearingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_NonInterestBearingMember"/>
  <xs:element name="November292023Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_November292023Member"/>
  <xs:element name="OptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_OptionsMember"/>
  <xs:element name="OtherCurrentAssetMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_OtherCurrentAssetMember"/>
  <xs:element name="OtherCurrentLiabilitieMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_OtherCurrentLiabilitieMember"/>
  <xs:element name="PlantAndEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_PlantAndEquipmentMember"/>
  <xs:element name="ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember"/>
  <xs:element name="September212022Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_September212022Member"/>
  <xs:element name="ShortDatedOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ShortDatedOptionsMember"/>
  <xs:element name="ShortFreeAttachingOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ShortFreeAttachingOptionsMember"/>
  <xs:element name="SixToTowelMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_SixToTowelMember"/>
  <xs:element name="SubsequentEventsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_SubsequentEventsMember"/>
  <xs:element name="SubsequentsEventMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_SubsequentsEventMember"/>
  <xs:element name="TotalContractedCashFlowsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_TotalContractedCashFlowsMember"/>
  <xs:element name="TradeAndOtherPayablesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_TradeAndOtherPayablesMember"/>
  <xs:element name="TradeAndOtherReceivablesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_TradeAndOtherReceivablesMember"/>
  <xs:element name="AccumulatedDeficitDuringDevelopmentStageAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_AccumulatedDeficitDuringDevelopmentStageAbstract"/>
  <xs:element name="CommitmentsAndContingenciesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_CommitmentsAndContingenciesAbstract"/>
  <xs:element name="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsAbstract"/>
  <xs:element name="ExpenditureCommitmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ExpenditureCommitmentsAbstract"/>
  <xs:element name="IncomeTaxLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_IncomeTaxLineItems"/>
  <xs:element name="ParentEntityFinancialInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ParentEntityFinancialInformationAbstract"/>
  <xs:element name="ScheduleOfIssuedCapitalLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfIssuedCapitalLineItems"/>
  <xs:element name="ScheduleOfOptionsOutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfOptionsOutstandingLineItems"/>
  <xs:element name="ScheduleOfShareIssuancesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfShareIssuancesLineItems"/>
  <xs:element name="ScheduleOfSharesIssuedUnderStockOptionPlanLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_ScheduleOfSharesIssuedUnderStockOptionPlanLineItems"/>
  <xs:element name="StatementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_StatementsLineItems"/>
  <xs:element name="StatementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="athe_StatementsTable"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="athe_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>athe-20250630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 29 01:27:04 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ConsolidatedBalanceSheet" roleURI="http://pranabio.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ConsolidatedIncomeStatement" roleURI="http://pranabio.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ConsolidatedCashFlow" roleURI="http://pranabio.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofInterestandOtherIncomefromContinuingOperationsTable" roleURI="http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofTradeandOtherReceivablesTable" roleURI="http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofTradeandOtherPayablesTable" roleURI="http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable" roleURI="http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofCashFlowInformationTable" roleURI="http://pranabio.com/role/ScheduleofCashFlowInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofKeyManagementPersonnelCompensationTable" roleURI="http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofAuditandReviewofFinancialStatementsTable" roleURI="http://pranabio.com/role/ScheduleofAuditandReviewofFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofIndividualFinancialStatementsfortheParentEntityTable" roleURI="http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable"/>
  <calculationLink xlink:role="http://pranabio.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_RightofuseAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentProvisions" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentTaxLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_CurrentLiabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_NoncurrentLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetAssetsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetAssetsLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NetAssetsLiabilities" xlink:to="ifrs-full_Assets" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NetAssetsLiabilities" xlink:to="ifrs-full_Liabilities" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_IssuedCapital" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://pranabio.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_RevenueFromInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_OtherIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherGainsLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_OtherGainsLosses" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="athe_ForfeitedOptionsFromReserves" xlink:href="athe-20250630.xsd#athe_ForfeitedOptionsFromReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="athe_ForfeitedOptionsFromReserves" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="athe_IntellectualPropertyExpenses" xlink:href="athe-20250630.xsd#athe_IntellectualPropertyExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="athe_IntellectualPropertyExpenses" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://pranabio.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="athe_ProceedsFromResearchAndDevelopmentTaxRefund" xlink:href="athe-20250630.xsd#athe_ProceedsFromResearchAndDevelopmentTaxRefund"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="athe_ProceedsFromResearchAndDevelopmentTaxRefund" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefund" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefund" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="athe_PaymentsForRentalSecurityDeposits" xlink:href="athe-20250630.xsd#athe_PaymentsForRentalSecurityDeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="athe_PaymentsForRentalSecurityDeposits" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsForShareIssueCosts" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherRevenue" xlink:to="ifrs-full_RevenueFromInterest" order="1" weight="1"/>
<!-- [WMV6][2xhc83ULvRq1GQZPEN2rUs7yc2B7qtyUiPrwe88q7ehdeqMRKGhpobLgh0FTsaReAEFOZUQT+yEYLs0PwPePj7phDJaNi/v3C3Ii9HwsBNcXX/B9WG3exJeBeyBmZXXOYb/3002spYNTCXTKw8LsdFZOVxdm8LAsNjh8Km/0NzBWeZsFxQ6YBDHybagTuiMvmT/K4jta/ihOAHkJDDBOnZFt/abqafeHCV91O/rY37CvEv//bu1a2Q5VFPIXZhaBG3370Cqgfc0/W02Gsok6/xtZcqE8XWzQxH3rOz0lv0fRIy44aAqMUWG7x5lGWECu/l81S+5182VbMHixa2n+aU1uciM71tISgkAYkdMMlEMew2Y=] CSR-->
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <loc xlink:type="locator" xlink:label="athe_ResearchAndDevelopmentTaxIncentive" xlink:href="athe-20250630.xsd#athe_ResearchAndDevelopmentTaxIncentive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherIncome" xlink:to="athe_ResearchAndDevelopmentTaxIncentive" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAndOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAndOperatingIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_RevenueAndOperatingIncome" xlink:to="ifrs-full_OtherRevenue" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_RevenueAndOperatingIncome" xlink:to="ifrs-full_OtherIncome" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="athe_ResearchAndDevelopmentTaxIncentiveReceivable" xlink:href="athe-20250630.xsd#athe_ResearchAndDevelopmentTaxIncentiveReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="athe_ResearchAndDevelopmentTaxIncentiveReceivable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_CurrentPrepayments" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="athe_AccruedResearchAndDevelopmentExpenses" xlink:href="athe-20250630.xsd#athe_AccruedResearchAndDevelopmentExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="athe_AccruedResearchAndDevelopmentExpenses" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="athe_AccruedProfessionalFees" xlink:href="athe-20250630.xsd#athe_AccruedProfessionalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="athe_AccruedProfessionalFees" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="athe_OtherCurrentAccruedExpenses" xlink:href="athe-20250630.xsd#athe_OtherCurrentAccruedExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="athe_OtherCurrentAccruedExpenses" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_OtherPayables" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://pranabio.com/role/ScheduleofCashFlowInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashPaymentsFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashPaymentsFromOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_OtherCashPaymentsFromOperatingActivities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="athe_ForeignExchangegainLoss" xlink:href="athe-20250630.xsd#athe_ForeignExchangegainLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="athe_ForeignExchangegainLoss" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="athe_FixedAssetWriteOff" xlink:href="athe-20250630.xsd#athe_FixedAssetWriteOff"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="athe_FixedAssetWriteOff" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="athe_IncreaseDecreaseInTradeAndOtherReceivables" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseInTradeAndOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="athe_IncreaseDecreaseInTradeAndOtherReceivables" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForProvisions" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashEquivalents"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOnHand" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOnHand"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashEquivalents" xlink:to="ifrs-full_CashOnHand" order="1" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="athe_KeyManagementPersonnelCompensationLongtermBenefits" xlink:href="athe-20250630.xsd#athe_KeyManagementPersonnelCompensationLongtermBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="athe_KeyManagementPersonnelCompensationLongtermBenefits" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://pranabio.com/role/ScheduleofAuditandReviewofFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemuneration" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemuneration"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemunerationForAuditServices" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForAuditServices"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AuditorsRemuneration" xlink:to="ifrs-full_AuditorsRemunerationForAuditServices" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemunerationForOtherServices" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForOtherServices"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AuditorsRemuneration" xlink:to="ifrs-full_AuditorsRemunerationForOtherServices" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_CurrentLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_NoncurrentLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_IssuedCapital" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_RetainedEarnings" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>athe-20250630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 29 01:27:04 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ConsolidatedBalanceSheet" roleURI="http://pranabio.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://pranabio.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ConsolidatedIncomeStatement" roleURI="http://pranabio.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ConsolidatedCashFlow" roleURI="http://pranabio.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ShareholdersEquityType2or3" roleURI="http://pranabio.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_BackgroundandSummaryofMaterialAccountingPolicies" roleURI="http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_InterestandOtherIncomefromContinuingOperations" roleURI="http://pranabio.com/role/InterestandOtherIncomefromContinuingOperations"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ExpensesfromOrdinaryActivities" roleURI="http://pranabio.com/role/ExpensesfromOrdinaryActivities"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_IncomeTax" roleURI="http://pranabio.com/role/IncomeTax"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_TradeandOtherReceivables" roleURI="http://pranabio.com/role/TradeandOtherReceivables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_OtherCurrentAssets" roleURI="http://pranabio.com/role/OtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_TradeandOtherPayables" roleURI="http://pranabio.com/role/TradeandOtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_Provisions" roleURI="http://pranabio.com/role/Provisions"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_CommitmentsandContingencies" roleURI="http://pranabio.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_IssuedCapital" roleURI="http://pranabio.com/role/IssuedCapital"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_Reserves" roleURI="http://pranabio.com/role/Reserves"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_AccumulatedDeficitDuringDevelopmentStage" roleURI="http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStage"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_Leases" roleURI="http://pranabio.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_CashFlowInformation" roleURI="http://pranabio.com/role/CashFlowInformation"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ExpenditureCommitments" roleURI="http://pranabio.com/role/ExpenditureCommitments"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ShareBasedPayments" roleURI="http://pranabio.com/role/ShareBasedPayments"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_SubsequentEvents" roleURI="http://pranabio.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_LossPerShare" roleURI="http://pranabio.com/role/LossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_KeyManagementPersonnelCompensation" roleURI="http://pranabio.com/role/KeyManagementPersonnelCompensation"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_AuditorsRemuneration" roleURI="http://pranabio.com/role/AuditorsRemuneration"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_RelatedPartyTransactions" roleURI="http://pranabio.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_SegmentInformation" roleURI="http://pranabio.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_FinancialInstruments" roleURI="http://pranabio.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ParentEntityFinancialInformation" roleURI="http://pranabio.com/role/ParentEntityFinancialInformation"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_AccountingPoliciesByPolicy" roleURI="http://pranabio.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_BackgroundandSummaryofMaterialAccountingPoliciesTables" roleURI="http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_InterestandOtherIncomefromContinuingOperationsTables" roleURI="http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ExpensesfromOrdinaryActivitiesTables" roleURI="http://pranabio.com/role/ExpensesfromOrdinaryActivitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_IncomeTaxTables" roleURI="http://pranabio.com/role/IncomeTaxTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_TradeandOtherReceivablesTables" roleURI="http://pranabio.com/role/TradeandOtherReceivablesTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_OtherCurrentAssetsTables" roleURI="http://pranabio.com/role/OtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_TradeandOtherPayablesTables" roleURI="http://pranabio.com/role/TradeandOtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ProvisionsTables" roleURI="http://pranabio.com/role/ProvisionsTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_IssuedCapitalTables" roleURI="http://pranabio.com/role/IssuedCapitalTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ReservesTables" roleURI="http://pranabio.com/role/ReservesTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_AccumulatedDeficitDuringDevelopmentStageTables" roleURI="http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStageTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_LeasesTables" roleURI="http://pranabio.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_CashFlowInformationTables" roleURI="http://pranabio.com/role/CashFlowInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ShareBasedPaymentsTables" roleURI="http://pranabio.com/role/ShareBasedPaymentsTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_LossPerShareTables" roleURI="http://pranabio.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_KeyManagementPersonnelCompensationTables" roleURI="http://pranabio.com/role/KeyManagementPersonnelCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_AuditorsRemunerationTables" roleURI="http://pranabio.com/role/AuditorsRemunerationTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_FinancialInstrumentsTables" roleURI="http://pranabio.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ParentEntityFinancialInformationTables" roleURI="http://pranabio.com/role/ParentEntityFinancialInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofEstimatedUsefulLivesTable" roleURI="http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofInterestandOtherIncomefromContinuingOperationsTable" roleURI="http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofExpensesfromOrdinaryActivitiesTable" roleURI="http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofIncomeTaxTable" roleURI="http://pranabio.com/role/ScheduleofIncomeTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofIncomeTaxTable_Parentheticals" roleURI="http://pranabio.com/role/ScheduleofIncomeTaxTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofTradeandOtherReceivablesTable" roleURI="http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofTradeandOtherPayablesTable" roleURI="http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofProvisionsTable" roleURI="http://pranabio.com/role/ScheduleofProvisionsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofMovementsinProvisionsTable" roleURI="http://pranabio.com/role/ScheduleofMovementsinProvisionsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofIssuedCapitalTable" roleURI="http://pranabio.com/role/ScheduleofIssuedCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofIssuedCapitalTable_Parentheticals" roleURI="http://pranabio.com/role/ScheduleofIssuedCapitalTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofMovementsinIssuedSharesTable" roleURI="http://pranabio.com/role/ScheduleofMovementsinIssuedSharesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofShareIssuancesTable" roleURI="http://pranabio.com/role/ScheduleofShareIssuancesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofReservesofShareBasedPaymentsTable" roleURI="http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofReservesofShareBasedPaymentsTable_Parentheticals" roleURI="http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable" roleURI="http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofAccumulatedDeficitDuringDevelopmentStageTable" roleURI="http://pranabio.com/role/ScheduleofAccumulatedDeficitDuringDevelopmentStageTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable" roleURI="http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofProfitorLossShowstheFollowingAmountsRelatingtoLeasesTable" roleURI="http://pranabio.com/role/ScheduleofProfitorLossShowstheFollowingAmountsRelatingtoLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofCashFlowInformationTable" roleURI="http://pranabio.com/role/ScheduleofCashFlowInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofOptionsGrantedTable" roleURI="http://pranabio.com/role/ScheduleofOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofOptionsOutstandingTable" roleURI="http://pranabio.com/role/ScheduleofOptionsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofValuationsofOptionsApprovedandIssuedTable" roleURI="http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofSharesIssuedunderStockOptionPlanTable" roleURI="http://pranabio.com/role/ScheduleofSharesIssuedunderStockOptionPlanTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofEarningLossPerShareTable" roleURI="http://pranabio.com/role/ScheduleofEarningLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofKeyManagementPersonnelCompensationTable" roleURI="http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofAuditandReviewofFinancialStatementsTable" roleURI="http://pranabio.com/role/ScheduleofAuditandReviewofFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable" roleURI="http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable" roleURI="http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable" roleURI="http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofIndividualFinancialStatementsfortheParentEntityTable" roleURI="http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_BackgroundandSummaryofMaterialAccountingPoliciesDetails" roleURI="http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_InterestandOtherIncomefromContinuingOperationsDetails" roleURI="http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_IncomeTaxDetails" roleURI="http://pranabio.com/role/IncomeTaxDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_OtherCurrentAssetsDetails" roleURI="http://pranabio.com/role/OtherCurrentAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_IssuedCapitalDetails" roleURI="http://pranabio.com/role/IssuedCapitalDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ReservesDetails" roleURI="http://pranabio.com/role/ReservesDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_LeasesDetails" roleURI="http://pranabio.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ExpenditureCommitmentsDetails" roleURI="http://pranabio.com/role/ExpenditureCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ShareBasedPaymentsDetails" roleURI="http://pranabio.com/role/ShareBasedPaymentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_SubsequentEventsDetails" roleURI="http://pranabio.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_RelatedPartyTransactionsDetails" roleURI="http://pranabio.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_SegmentInformationDetails" roleURI="http://pranabio.com/role/SegmentInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_FinancialInstrumentsDetails" roleURI="http://pranabio.com/role/FinancialInstrumentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#DocumentAndEntityInformation" roleURI="http://pranabio.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://pranabio.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="ifrs-full_SegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_OtherCurrentAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CurrentAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_RightofuseAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_NoncurrentAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_Assets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CurrentProvisions" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_OtherCurrentLiabilities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CurrentTaxLiabilities" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CurrentLiabilities" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_NoncurrentLiabilities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_Liabilities" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetAssetsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetAssetsLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_NetAssetsLiabilities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_IssuedCapital" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_Equity" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="ifrs-full_SegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_RevenueFromInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_IntellectualPropertyExpenses" xlink:href="athe-20250630.xsd#athe_IntellectualPropertyExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="athe_IntellectualPropertyExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherGainsLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherGainsLosses" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ForfeitedOptionsFromReserves" xlink:href="athe-20250630.xsd#athe_ForfeitedOptionsFromReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="athe_ForfeitedOptionsFromReserves" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherComprehensiveIncome" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ProceedsFromResearchAndDevelopmentTaxRefund" xlink:href="athe-20250630.xsd#athe_ProceedsFromResearchAndDevelopmentTaxRefund"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="athe_ProceedsFromResearchAndDevelopmentTaxRefund" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefund" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncomeTaxesPaidRefund" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_PaymentsForRentalSecurityDeposits" xlink:href="athe-20250630.xsd#athe_PaymentsForRentalSecurityDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="athe_PaymentsForRentalSecurityDeposits" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PaymentsForShareIssueCosts" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_StatementsLineItems" xlink:href="athe-20250630.xsd#athe_StatementsLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_StatementsTable" xlink:href="athe-20250630.xsd#athe_StatementsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="athe_StatementsLineItems" xlink:to="athe_StatementsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_StatementsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_IssuedCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReservesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_OtherReservesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_Equity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_IssuanceOfSharesNetOfCostsShares" xlink:href="athe-20250630.xsd#athe_IssuanceOfSharesNetOfCostsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="athe_IssuanceOfSharesNetOfCostsShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_IssuanceOfSharesNetOfCostsValue" xlink:href="athe-20250630.xsd#athe_IssuanceOfSharesNetOfCostsValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="athe_IssuanceOfSharesNetOfCostsValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" xlink:href="athe-20250630.xsd#athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ForfeitedOptionsReversedToProfitOrLoss" xlink:href="athe-20250630.xsd#athe_ForfeitedOptionsReversedToProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="athe_ForfeitedOptionsReversedToProfitOrLoss" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners" xlink:href="athe-20250630.xsd#athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_ProfitLoss" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_IssueOfEquity" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/InterestandOtherIncomefromContinuingOperations" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInterestIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInterestIncomeExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:to="ifrs-full_DisclosureOfInterestIncomeExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ExpensesfromOrdinaryActivities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseByNatureAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_DisclosureOfExpensesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/IncomeTax" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/TradeandOtherReceivables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/OtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/TradeandOtherPayables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/Provisions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ProvisionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProvisionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfProvisionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="ifrs-full_DisclosureOfProvisionsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_CommitmentsAndContingenciesAbstract" xlink:href="athe-20250630.xsd#athe_CommitmentsAndContingenciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_CommitmentsAndContingenciesAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/IssuedCapital" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIssuedCapitalExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_DisclosureOfIssuedCapitalExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/Reserves" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReservesWithinEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStage" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:href="athe-20250630.xsd#athe_AccumulatedDeficitDuringDevelopmentStageAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_AccumulatedDeficitDuringDevelopmentStageTextBlock" xlink:href="athe-20250630.xsd#athe_AccumulatedDeficitDuringDevelopmentStageTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:to="athe_AccumulatedDeficitDuringDevelopmentStageTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/CashFlowInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_DisclosureOfCashFlowStatementExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ExpenditureCommitments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_ExpenditureCommitmentsAbstract" xlink:href="athe-20250630.xsd#athe_ExpenditureCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ExpenditureCommitmentsAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ShareBasedPayments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/LossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/KeyManagementPersonnelCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/AuditorsRemuneration" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemunerationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAuditorsRemunerationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AuditorsRemunerationAbstract" xlink:to="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/SegmentInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/FinancialInstruments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ParentEntityFinancialInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_ParentEntityFinancialInformationAbstract" xlink:href="athe-20250630.xsd#athe_ParentEntityFinancialInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInterimFinancialReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInterimFinancialReportingExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ParentEntityFinancialInformationAbstract" xlink:to="ifrs-full_DisclosureOfInterimFinancialReportingExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" xlink:href="athe-20250630.xsd#athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome" xlink:href="athe-20250630.xsd#athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock" xlink:href="athe-20250630.xsd#athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock" xlink:href="athe-20250630.xsd#athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:to="athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ExpensesfromOrdinaryActivitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseByNatureAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/IncomeTaxTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock" xlink:href="athe-20250630.xsd#athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/TradeandOtherReceivablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_DisclosureOfTradeAndOtherReceivableTableTextBlock" xlink:href="athe-20250630.xsd#athe_DisclosureOfTradeAndOtherReceivableTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="athe_DisclosureOfTradeAndOtherReceivableTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/OtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/TradeandOtherPayablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfTradeAndOtherPayableTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfTradeAndOtherPayableTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="athe_ScheduleOfTradeAndOtherPayableTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ProvisionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ProvisionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProvisionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock" xlink:href="athe-20250630.xsd#athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/IssuedCapitalTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ReservesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReservesWithinEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:to="athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:to="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStageTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:href="athe-20250630.xsd#athe_AccumulatedDeficitDuringDevelopmentStageAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:to="athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases" xlink:href="athe-20250630.xsd#athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/CashFlowInformationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfNumberOfSharesIssuedTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfNumberOfSharesIssuedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="athe_ScheduleOfNumberOfSharesIssuedTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/LossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/KeyManagementPersonnelCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" xlink:href="athe-20250630.xsd#athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/AuditorsRemunerationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemunerationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfAuditorRemunerationTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfAuditorRemunerationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AuditorsRemunerationAbstract" xlink:to="athe_ScheduleOfAuditorRemunerationTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ParentEntityFinancialInformationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_ParentEntityFinancialInformationAbstract" xlink:href="athe-20250630.xsd#athe_ParentEntityFinancialInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_DisclosureOfParentEntityFinancialStatementsExplanatory" xlink:href="athe-20250630.xsd#athe_DisclosureOfParentEntityFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ParentEntityFinancialInformationAbstract" xlink:to="athe_DisclosureOfParentEntityFinancialStatementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:href="athe-20250630.xsd#athe_BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="athe_BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_RangesAxis" xlink:href="athe-20250630.xsd#athe_RangesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:to="athe_RangesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_RangesDomainDomain" xlink:href="athe-20250630.xsd#athe_RangesDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="athe_RangesAxis" xlink:to="athe_RangesDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_RangesDomainDomain_0" xlink:href="athe-20250630.xsd#athe_RangesDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="athe_RangesAxis" xlink:to="athe_RangesDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FixturesAndFittingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_FixturesAndFittingsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_ComputerEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_PlantAndEquipmentMember" xlink:href="athe-20250630.xsd#athe_PlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="athe_PlantAndEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_RangesDomainDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_RangesDomainDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments" xlink:href="athe-20250630.xsd#athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract" xlink:to="ifrs-full_RevenueFromInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract" xlink:to="ifrs-full_OtherRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ResearchAndDevelopmentTaxIncentive" xlink:href="athe-20250630.xsd#athe_ResearchAndDevelopmentTaxIncentive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract" xlink:to="athe_ResearchAndDevelopmentTaxIncentive" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract" xlink:to="ifrs-full_OtherIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAndOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAndOperatingIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract" xlink:to="ifrs-full_RevenueAndOperatingIncome" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_OtherResearchAndDevelopmentExpenses" xlink:href="athe-20250630.xsd#athe_OtherResearchAndDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="athe_OtherResearchAndDevelopmentExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="ifrs-full_DepreciationExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEmployeeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEmployeeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="ifrs-full_OtherEmployeeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ConsultantAndDirectorExpenses" xlink:href="athe-20250630.xsd#athe_ConsultantAndDirectorExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="athe_ConsultantAndDirectorExpenses" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_AuditInternalControlAndOtherAssuranceExpenses" xlink:href="athe-20250630.xsd#athe_AuditInternalControlAndOtherAssuranceExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="athe_AuditInternalControlAndOtherAssuranceExpenses" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_CorporateComplianceExpenses" xlink:href="athe-20250630.xsd#athe_CorporateComplianceExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="athe_CorporateComplianceExpenses" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InsuranceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="ifrs-full_InsuranceExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_OfficeRentalExpenses" xlink:href="athe-20250630.xsd#athe_OfficeRentalExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="athe_OfficeRentalExpenses" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="ifrs-full_AdministrativeExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_CorporateAdvisoryExpenses" xlink:href="athe-20250630.xsd#athe_CorporateAdvisoryExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="athe_CorporateAdvisoryExpenses" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofIncomeTaxTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfIncomeTaxAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfIncomeTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfIncomeTaxAbstract" xlink:to="ifrs-full_CurrentTaxExpenseIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfIncomeTaxAbstract" xlink:to="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DeferredTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfIncomeTaxAbstract" xlink:to="ifrs-full_DeferredTaxExpenseIncome" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax" xlink:href="athe-20250630.xsd#athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfIncomeTaxAbstract" xlink:to="athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfIncomeTaxAbstract" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_TaxEffectOfResearchAndDevelopmentExpenditure" xlink:href="athe-20250630.xsd#athe_TaxEffectOfResearchAndDevelopmentExpenditure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfIncomeTaxAbstract" xlink:to="athe_TaxEffectOfResearchAndDevelopmentExpenditure" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfIncomeTaxAbstract" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_TaxEffectOfDeferredTaxAssetNotRecognized" xlink:href="athe-20250630.xsd#athe_TaxEffectOfDeferredTaxAssetNotRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfIncomeTaxAbstract" xlink:to="athe_TaxEffectOfDeferredTaxAssetNotRecognized" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfIncomeTaxAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DeferredTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfIncomeTaxAbstract" xlink:to="ifrs-full_DeferredTaxAssets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfIncomeTaxAbstract" xlink:to="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofIncomeTaxTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfIncomeTaxAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfIncomeTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_PrimaFacieTaxOnNetLossBeforeIncomeTax" xlink:href="athe-20250630.xsd#athe_PrimaFacieTaxOnNetLossBeforeIncomeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfIncomeTaxAbstract" xlink:to="athe_PrimaFacieTaxOnNetLossBeforeIncomeTax" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ResearchAndDevelopmentTaxIncentiveReceivable" xlink:href="athe-20250630.xsd#athe_ResearchAndDevelopmentTaxIncentiveReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="athe_ResearchAndDevelopmentTaxIncentiveReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_AccruedResearchAndDevelopmentExpenses" xlink:href="athe-20250630.xsd#athe_AccruedResearchAndDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="athe_AccruedResearchAndDevelopmentExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_AccruedProfessionalFees" xlink:href="athe-20250630.xsd#athe_AccruedProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="athe_AccruedProfessionalFees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_OtherCurrentAccruedExpenses" xlink:href="athe-20250630.xsd#athe_OtherCurrentAccruedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="athe_OtherCurrentAccruedExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_OtherPayables" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofProvisionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_ProvisionsScheduleofProvisionsDetailsTable" xlink:href="athe-20250630.xsd#athe_ProvisionsScheduleofProvisionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="athe_ProvisionsScheduleofProvisionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfProvisionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ProvisionsScheduleofProvisionsDetailsTable" xlink:to="ifrs-full_ClassesOfProvisionsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfOtherProvisionsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfOtherProvisionsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_AnnualLeaveMember" xlink:href="athe-20250630.xsd#athe_AnnualLeaveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="athe_AnnualLeaveMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_LongServiceLeaveMember" xlink:href="athe-20250630.xsd#athe_LongServiceLeaveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="athe_LongServiceLeaveMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_CurrentProvisions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_NoncurrentProvisions" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofMovementsinProvisionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_ProvisionsScheduleofMovementsinProvisionsDetailsTable" xlink:href="athe-20250630.xsd#athe_ProvisionsScheduleofMovementsinProvisionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="athe_ProvisionsScheduleofMovementsinProvisionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfProvisionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ProvisionsScheduleofMovementsinProvisionsDetailsTable" xlink:to="ifrs-full_ClassesOfProvisionsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfOtherProvisionsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfOtherProvisionsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_AnnualLeaveMember" xlink:href="athe-20250630.xsd#athe_AnnualLeaveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="athe_AnnualLeaveMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_LongServiceLeaveMember" xlink:href="athe-20250630.xsd#athe_LongServiceLeaveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="athe_LongServiceLeaveMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Provisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Provisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_Provisions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_AnnualLeaveAndLongServiceLeaveCarryingAmount" xlink:href="athe-20250630.xsd#athe_AnnualLeaveAndLongServiceLeaveCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="athe_AnnualLeaveAndLongServiceLeaveCarryingAmount" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofIssuedCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfIssuedCapitalLineItems" xlink:href="athe-20250630.xsd#athe_ScheduleOfIssuedCapitalLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_IssuedCapitalScheduleofIssuedCapitalDetailsTable" xlink:href="athe-20250630.xsd#athe_IssuedCapitalScheduleofIssuedCapitalDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="athe_ScheduleOfIssuedCapitalLineItems" xlink:to="athe_IssuedCapitalScheduleofIssuedCapitalDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_IssuedCapitalScheduleofIssuedCapitalDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_OptionsMember" xlink:href="athe-20250630.xsd#athe_OptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="athe_OptionsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_SharesOfIssuedCapital" xlink:href="athe-20250630.xsd#athe_SharesOfIssuedCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfIssuedCapitalLineItems" xlink:to="athe_SharesOfIssuedCapital" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfIssuedCapitalLineItems" xlink:to="ifrs-full_IssuedCapital" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofIssuedCapitalTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfIssuedCapitalLineItems" xlink:href="athe-20250630.xsd#athe_ScheduleOfIssuedCapitalLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable" xlink:href="athe-20250630.xsd#athe_IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="athe_ScheduleOfIssuedCapitalLineItems" xlink:to="athe_IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_OptionsMember" xlink:href="athe-20250630.xsd#athe_OptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="athe_OptionsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfIssuedCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofMovementsinIssuedSharesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable" xlink:href="athe-20250630.xsd#athe_IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="athe_IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_IssuedCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_MovementDuringTheYearNoOfSharesinShares" xlink:href="athe-20250630.xsd#athe_MovementDuringTheYearNoOfSharesinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="athe_MovementDuringTheYearNoOfSharesinShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ValueOfIncreaseDecreaseInSharesOutstanding" xlink:href="athe-20250630.xsd#athe_ValueOfIncreaseDecreaseInSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="athe_ValueOfIncreaseDecreaseInSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofShareIssuancesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfShareIssuancesLineItems" xlink:href="athe-20250630.xsd#athe_ScheduleOfShareIssuancesLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_IssuedCapitalScheduleofShareIssuancesDetailsTable" xlink:href="athe-20250630.xsd#athe_IssuedCapitalScheduleofShareIssuancesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="athe_ScheduleOfShareIssuancesLineItems" xlink:to="athe_IssuedCapitalScheduleofShareIssuancesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_IssuedCapitalScheduleofShareIssuancesDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ShareIssuanceDateAxis" xlink:href="athe-20250630.xsd#athe_ShareIssuanceDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_IssuedCapitalScheduleofShareIssuancesDetailsTable" xlink:to="athe_ShareIssuanceDateAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ShareIssuanceDateDomainDomain" xlink:href="athe-20250630.xsd#athe_ShareIssuanceDateDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="athe_ShareIssuanceDateAxis" xlink:to="athe_ShareIssuanceDateDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ShareIssuanceDateDomainDomain_0" xlink:href="athe-20250630.xsd#athe_ShareIssuanceDateDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="athe_ShareIssuanceDateAxis" xlink:to="athe_ShareIssuanceDateDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_September212022Member" xlink:href="athe-20250630.xsd#athe_September212022Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_September212022Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_March152023Member" xlink:href="athe-20250630.xsd#athe_March152023Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_March152023Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_June302023Member" xlink:href="athe-20250630.xsd#athe_June302023Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_June302023Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_November292023Member" xlink:href="athe-20250630.xsd#athe_November292023Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_November292023Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_January82024Member" xlink:href="athe-20250630.xsd#athe_January82024Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_January82024Member" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_February22024Member" xlink:href="athe-20250630.xsd#athe_February22024Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_February22024Member" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_March42024Member" xlink:href="athe-20250630.xsd#athe_March42024Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_March42024Member" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_April222024Member" xlink:href="athe-20250630.xsd#athe_April222024Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_April222024Member" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_June302024Member" xlink:href="athe-20250630.xsd#athe_June302024Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_June302024Member" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_July182024Member" xlink:href="athe-20250630.xsd#athe_July182024Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_July182024Member" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_January222025Member" xlink:href="athe-20250630.xsd#athe_January222025Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_January222025Member" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_January302025Member" xlink:href="athe-20250630.xsd#athe_January302025Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_January302025Member" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_February32025Member" xlink:href="athe-20250630.xsd#athe_February32025Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_February32025Member" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_February172025Member" xlink:href="athe-20250630.xsd#athe_February172025Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_February172025Member" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_March142025Member" xlink:href="athe-20250630.xsd#athe_March142025Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_March142025Member" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_April42025Member" xlink:href="athe-20250630.xsd#athe_April42025Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_April42025Member" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_June302025Member" xlink:href="athe-20250630.xsd#athe_June302025Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_June302025Member" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_IncreaseDecreaseInNumberOfShareOutstanding" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseInNumberOfShareOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfShareIssuancesLineItems" xlink:to="athe_IncreaseDecreaseInNumberOfShareOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalPreferenceShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalPreferenceShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfShareIssuancesLineItems" xlink:to="ifrs-full_IssuedCapitalPreferenceShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfSharesIssuedDuringTheYear" xlink:href="athe-20250630.xsd#athe_NumberOfSharesIssuedDuringTheYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfShareIssuancesLineItems" xlink:to="athe_NumberOfSharesIssuedDuringTheYear" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfShareIssuancesLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_NumberofSharesIssuePricePerShare" xlink:href="athe-20250630.xsd#athe_NumberofSharesIssuePricePerShare"/>
<!-- [WMV6][OA0bEQd3bRLffH7wh/n5lg401f1cbG58d8467w90v+fmjgTdudC+L+49ybs+PUXX+tLhpTGu266egIPV9IoNf5bA6kZlp1h6DOra4M7tbtpfhE2pfsw0tjOEHUfyb3Pztj32NWSvtAgv2ChMk34gFPucwLRwegWxGez6h7wHkr2O26qUzj4LFOcwczfvdqrJQ8mvIYz3WDnednDlOLxNsC5Bh4ygMOMAPozekJf2RWivACOIN0XE/hIuLc0kO3Umsquv/z7h0lERsNqD+54kbX2lmLf/2w8zwHn547QkitOjCFxjF38Ig3ZyLzhpFk14UzueSAOlsRVm+oD+uf7dlyaX0MPDWCIiJcyKaQcS/PnRnESC] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfShareIssuancesLineItems" xlink:to="athe_NumberofSharesIssuePricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_IssuedCapitalPreferenceShare" xlink:href="athe-20250630.xsd#athe_IssuedCapitalPreferenceShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfShareIssuancesLineItems" xlink:to="athe_IssuedCapitalPreferenceShare" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReservesWithinEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_ReservesScheduleofReservesofShareBasedPaymentsDetailsTable" xlink:href="athe-20250630.xsd#athe_ReservesScheduleofReservesofShareBasedPaymentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="athe_ReservesScheduleofReservesofShareBasedPaymentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReservesWithinEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReservesWithinEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ReservesScheduleofReservesofShareBasedPaymentsDetailsTable" xlink:to="ifrs-full_ReservesWithinEquityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReservesWithinEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReservesWithinEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ReservesWithinEquityAxis" xlink:to="ifrs-full_ReservesWithinEquityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReservesWithinEquityDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReservesWithinEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ReservesWithinEquityAxis" xlink:to="ifrs-full_ReservesWithinEquityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember" xlink:href="athe-20250630.xsd#athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReservesWithinEquityDomain" xlink:to="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantReserve" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_WarrantReserve" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReservesWithinEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable" xlink:href="athe-20250630.xsd#athe_ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="athe_ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_OptionsForFullyPaidOrdinaryShares1" xlink:href="athe-20250630.xsd#athe_OptionsForFullyPaidOrdinaryShares1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="athe_OptionsForFullyPaidOrdinaryShares1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_FreeattachingOptionsForFullyPaidOrdinaryShares" xlink:href="athe-20250630.xsd#athe_FreeattachingOptionsForFullyPaidOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="athe_FreeattachingOptionsForFullyPaidOrdinaryShares" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfSharesOptionsOutstanding" xlink:href="athe-20250630.xsd#athe_NumberOfSharesOptionsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="athe_NumberOfSharesOptionsOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ReserveOfOptionsIssuedDuringTheYear" xlink:href="athe-20250630.xsd#athe_ReserveOfOptionsIssuedDuringTheYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="athe_ReserveOfOptionsIssuedDuringTheYear" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear" xlink:href="athe-20250630.xsd#athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfOptionsForfeitedDuringTheYear" xlink:href="athe-20250630.xsd#athe_NumberOfOptionsForfeitedDuringTheYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="athe_NumberOfOptionsForfeitedDuringTheYear" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ReserveOfSharebasedPaymentsForfeitedDuringYear" xlink:href="athe-20250630.xsd#athe_ReserveOfSharebasedPaymentsForfeitedDuringYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="athe_ReserveOfSharebasedPaymentsForfeitedDuringYear" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfOptionsOptionsExercisedDuringTheYear" xlink:href="athe-20250630.xsd#athe_NumberOfOptionsOptionsExercisedDuringTheYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="athe_NumberOfOptionsOptionsExercisedDuringTheYear" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_OptionsExercisedDuringTheYear" xlink:href="athe-20250630.xsd#athe_OptionsExercisedDuringTheYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="athe_OptionsExercisedDuringTheYear" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfOptionsSharesToBeIssued" xlink:href="athe-20250630.xsd#athe_NumberOfOptionsSharesToBeIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="athe_NumberOfOptionsSharesToBeIssued" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_SharesToBeIssued" xlink:href="athe-20250630.xsd#athe_SharesToBeIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="athe_SharesToBeIssued" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ShareBasedPaymentExpenseForOptionsIssuedI" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentExpenseForOptionsIssuedI"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="athe_ShareBasedPaymentExpenseForOptionsIssuedI" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofAccumulatedDeficitDuringDevelopmentStageTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:href="athe-20250630.xsd#athe_AccumulatedDeficitDuringDevelopmentStageAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:to="ifrs-full_RetainedEarnings" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:to="ifrs-full_ProfitLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ReclassifyExpiredOptionsFromReservesOne" xlink:href="athe-20250630.xsd#athe_ReclassifyExpiredOptionsFromReservesOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:to="athe_ReclassifyExpiredOptionsFromReservesOne" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ReclassifyForfeitedOptionsFromReserves" xlink:href="athe-20250630.xsd#athe_ReclassifyForfeitedOptionsFromReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:to="athe_ReclassifyForfeitedOptionsFromReserves" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_RightofuseAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofProfitorLossShowstheFollowingAmountsRelatingtoLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract" xlink:to="ifrs-full_InterestExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ExpensesRelatingToShorttermLeases" xlink:href="athe-20250630.xsd#athe_ExpensesRelatingToShorttermLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract" xlink:to="athe_ExpensesRelatingToShorttermLeases" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract" xlink:to="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofCashFlowInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfCashFlowInformationAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfCashFlowInformationAbstract" xlink:to="ifrs-full_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfCashFlowInformationAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfCashFlowInformationAbstract" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashPaymentsFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashPaymentsFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfCashFlowInformationAbstract" xlink:to="ifrs-full_OtherCashPaymentsFromOperatingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfCashFlowInformationAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ForeignExchangegainLoss" xlink:href="athe-20250630.xsd#athe_ForeignExchangegainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfCashFlowInformationAbstract" xlink:to="athe_ForeignExchangegainLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_FixedAssetWriteOff" xlink:href="athe-20250630.xsd#athe_FixedAssetWriteOff"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfCashFlowInformationAbstract" xlink:to="athe_FixedAssetWriteOff" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_IncreaseDecreaseInTradeAndOtherReceivables" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseInTradeAndOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfCashFlowInformationAbstract" xlink:to="athe_IncreaseDecreaseInTradeAndOtherReceivables" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfCashFlowInformationAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfCashFlowInformationAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfCashFlowInformationAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfCashFlowInformationAbstract" xlink:to="ifrs-full_AdjustmentsForProvisions" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfCashFlowInformationAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOnHand" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOnHand"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfCashFlowInformationAbstract" xlink:to="ifrs-full_CashOnHand" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfCashFlowInformationAbstract" xlink:to="ifrs-full_CashEquivalents" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofOptionsGrantedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="athe_ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="ifrs-full_ShareOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofOptionsOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfOptionsOutstandingLineItems" xlink:href="athe-20250630.xsd#athe_ScheduleOfOptionsOutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="athe_ScheduleOfOptionsOutstandingLineItems" xlink:to="athe_ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_OptionsSeriesAxis" xlink:href="athe-20250630.xsd#athe_OptionsSeriesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable" xlink:to="athe_OptionsSeriesAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_OptionsSeriesDomainDomain" xlink:href="athe-20250630.xsd#athe_OptionsSeriesDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="athe_OptionsSeriesAxis" xlink:to="athe_OptionsSeriesDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_OptionsSeriesDomainDomain_0" xlink:href="athe-20250630.xsd#athe_OptionsSeriesDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="athe_OptionsSeriesAxis" xlink:to="athe_OptionsSeriesDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAABOneMember" xlink:href="athe-20250630.xsd#athe_ATHAABOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHAABOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAADOneMember" xlink:href="athe-20250630.xsd#athe_ATHAADOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHAADOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAEMember" xlink:href="athe-20250630.xsd#athe_ATHAAEMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHAAEMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAFOneMember" xlink:href="athe-20250630.xsd#athe_ATHAAFOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHAAFOneMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAGOneMember" xlink:href="athe-20250630.xsd#athe_ATHAAGOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHAAGOneMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAHMember" xlink:href="athe-20250630.xsd#athe_ATHAAHMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHAAHMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAMember" xlink:href="athe-20250630.xsd#athe_ATHAAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHAAMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHABMember" xlink:href="athe-20250630.xsd#athe_ATHABMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHABMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHACMember" xlink:href="athe-20250630.xsd#athe_ATHACMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHACMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="ifrs-full_ShareOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfOptionsOutstandingLineItems" xlink:to="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ExpiryDateOfOutstandingShareOptions" xlink:href="athe-20250630.xsd#athe_ExpiryDateOfOutstandingShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfOptionsOutstandingLineItems" xlink:to="athe_ExpiryDateOfOutstandingShareOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ExercisePriceOfOutstandingShareOption1" xlink:href="athe-20250630.xsd#athe_ExercisePriceOfOutstandingShareOption1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfOptionsOutstandingLineItems" xlink:to="athe_ExercisePriceOfOutstandingShareOption1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfOptionsOutstandingLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfOptionsOutstandingLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="athe_ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_OptionsSeriesAxis" xlink:href="athe-20250630.xsd#athe_OptionsSeriesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable" xlink:to="athe_OptionsSeriesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_OptionsSeriesDomainDomain" xlink:href="athe-20250630.xsd#athe_OptionsSeriesDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="athe_OptionsSeriesAxis" xlink:to="athe_OptionsSeriesDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_OptionsSeriesDomainDomain_0" xlink:href="athe-20250630.xsd#athe_OptionsSeriesDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="athe_OptionsSeriesAxis" xlink:to="athe_OptionsSeriesDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAABMember" xlink:href="athe-20250630.xsd#athe_ATHAABMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHAABMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAADMember" xlink:href="athe-20250630.xsd#athe_ATHAADMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHAADMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAEMember" xlink:href="athe-20250630.xsd#athe_ATHAAEMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHAAEMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAFMember" xlink:href="athe-20250630.xsd#athe_ATHAAFMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHAAFMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAGMember" xlink:href="athe-20250630.xsd#athe_ATHAAGMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHAAGMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAHMember" xlink:href="athe-20250630.xsd#athe_ATHAAHMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHAAHMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAMember" xlink:href="athe-20250630.xsd#athe_ATHAAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHAAMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHABMember" xlink:href="athe-20250630.xsd#athe_ATHABMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHABMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ATHACMember" xlink:href="athe-20250630.xsd#athe_ATHACMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_ATHACMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_SharePriceAtGrantDate" xlink:href="athe-20250630.xsd#athe_SharePriceAtGrantDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="athe_SharePriceAtGrantDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_YearsToExpiry" xlink:href="athe-20250630.xsd#athe_YearsToExpiry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="athe_YearsToExpiry" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_RiskfreeInterestRate" xlink:href="athe-20250630.xsd#athe_RiskfreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="athe_RiskfreeInterestRate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_FairValuePerOptions" xlink:href="athe-20250630.xsd#athe_FairValuePerOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="athe_FairValuePerOptions" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofSharesIssuedunderStockOptionPlanTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfSharesIssuedUnderStockOptionPlanLineItems" xlink:href="athe-20250630.xsd#athe_ScheduleOfSharesIssuedUnderStockOptionPlanLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="athe_ScheduleOfSharesIssuedUnderStockOptionPlanLineItems" xlink:to="athe_ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_PlanAxis" xlink:href="athe-20250630.xsd#athe_PlanAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable" xlink:to="athe_PlanAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_PlanDomainDomain" xlink:href="athe-20250630.xsd#athe_PlanDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="athe_PlanAxis" xlink:to="athe_PlanDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_PlanDomainDomain_0" xlink:href="athe-20250630.xsd#athe_PlanDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="athe_PlanAxis" xlink:to="athe_PlanDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_AsxPlan2004Member" xlink:href="athe-20250630.xsd#athe_AsxPlan2004Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_PlanDomainDomain" xlink:to="athe_AsxPlan2004Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfSharesIssuedUnderStockOptionPlanLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfSharesIssuedUnderStockOptionPlanLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofEarningLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_KeyManagementPersonnelCompensationLongtermBenefits" xlink:href="athe-20250630.xsd#athe_KeyManagementPersonnelCompensationLongtermBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="athe_KeyManagementPersonnelCompensationLongtermBenefits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensation" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofAuditandReviewofFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfAuditAndReviewOfFinancialStatementsAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfAuditAndReviewOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemunerationForAuditServices" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForAuditServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfAuditAndReviewOfFinancialStatementsAbstract" xlink:to="ifrs-full_AuditorsRemunerationForAuditServices" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemunerationForOtherServices" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForOtherServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfAuditAndReviewOfFinancialStatementsAbstract" xlink:to="ifrs-full_AuditorsRemunerationForOtherServices" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemuneration" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemuneration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ScheduleOfAuditAndReviewOfFinancialStatementsAbstract" xlink:to="ifrs-full_AuditorsRemuneration" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="athe_FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable" xlink:to="srt_CurrencyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_GBP"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_GBP" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_JPY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_JPY"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_JPY" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_CashAndCashEquivalentMember" xlink:href="athe-20250630.xsd#athe_CashAndCashEquivalentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="athe_CashAndCashEquivalentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_TradeAndOtherPayablesMember" xlink:href="athe-20250630.xsd#athe_TradeAndOtherPayablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="athe_TradeAndOtherPayablesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_FinancialInstrumentsTotalExposure" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsTotalExposure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="athe_FinancialInstrumentsTotalExposure" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems" xlink:to="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable" xlink:to="ifrs-full_MaturityAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInterestRatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInterestRatesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInterestRatesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_CashAndCashEquivalentMember" xlink:href="athe-20250630.xsd#athe_CashAndCashEquivalentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="athe_CashAndCashEquivalentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_TradeAndOtherReceivablesMember" xlink:href="athe-20250630.xsd#athe_TradeAndOtherReceivablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="athe_TradeAndOtherReceivablesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_OtherCurrentAssetMember" xlink:href="athe-20250630.xsd#athe_OtherCurrentAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="athe_OtherCurrentAssetMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_TradeAndOtherPayablesMember" xlink:href="athe-20250630.xsd#athe_TradeAndOtherPayablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="athe_TradeAndOtherPayablesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="ifrs-full_LeaseLiabilitiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_OtherCurrentLiabilitieMember" xlink:href="athe-20250630.xsd#athe_OtherCurrentLiabilitieMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="athe_OtherCurrentLiabilitieMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FloatingInterestRateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FloatingInterestRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="ifrs-full_FloatingInterestRateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FixedInterestRateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixedInterestRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="ifrs-full_FixedInterestRateMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_NonInterestBearingMember" xlink:href="athe-20250630.xsd#athe_NonInterestBearingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="athe_NonInterestBearingMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRateRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRateRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="ifrs-full_InterestRateRiskMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems" xlink:to="ifrs-full_FinancialAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_AverageInterestRate" xlink:href="athe-20250630.xsd#athe_AverageInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems" xlink:to="athe_AverageInterestRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems" xlink:to="ifrs-full_FinancialLiabilities" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="athe_FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_TradeAndOtherPayablesMember" xlink:href="athe-20250630.xsd#athe_TradeAndOtherPayablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="athe_TradeAndOtherPayablesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="ifrs-full_LeaseLiabilitiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_LessThenSixMonthsMember" xlink:href="athe-20250630.xsd#athe_LessThenSixMonthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="athe_LessThenSixMonthsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_SixToTowelMember" xlink:href="athe-20250630.xsd#athe_SixToTowelMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="athe_SixToTowelMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember" xlink:href="athe-20250630.xsd#athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_TotalContractedCashFlowsMember" xlink:href="athe-20250630.xsd#athe_TotalContractedCashFlowsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="athe_TotalContractedCashFlowsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_CarryingAmountsMember" xlink:href="athe-20250630.xsd#athe_CarryingAmountsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="athe_CarryingAmountsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_TradeAndOtherPayables" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_StatementsLineItems" xlink:href="athe-20250630.xsd#athe_StatementsLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_StatementsTable" xlink:href="athe-20250630.xsd#athe_StatementsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="athe_StatementsLineItems" xlink:to="athe_StatementsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_StatementsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_CurrentAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_NoncurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_Assets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_CurrentLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_NoncurrentLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_Liabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_IssuedCapital" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_RetainedEarnings" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_Equity" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_ProfitLoss" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_StatementsLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable" xlink:href="athe-20250630.xsd#athe_BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="athe_BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_TaxRateEffectFromChangesInTaxRate" xlink:href="athe-20250630.xsd#athe_TaxRateEffectFromChangesInTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="athe_TaxRateEffectFromChangesInTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_EligibleAmountUnderTheTaxIncentiveScheme" xlink:href="athe-20250630.xsd#athe_EligibleAmountUnderTheTaxIncentiveScheme"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="athe_EligibleAmountUnderTheTaxIncentiveScheme" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_OtherIncome" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ProfitLossBeforeTax1" xlink:href="athe-20250630.xsd#athe_ProfitLossBeforeTax1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="athe_ProfitLossBeforeTax1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ProfitLossBeforeTax2" xlink:href="athe-20250630.xsd#athe_ProfitLossBeforeTax2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="athe_ProfitLossBeforeTax2" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_EstimatedUsefulEconomicLife" xlink:href="athe-20250630.xsd#athe_EstimatedUsefulEconomicLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="athe_EstimatedUsefulEconomicLife" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_Employeesdescription" xlink:href="athe-20250630.xsd#athe_Employeesdescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="athe_Employeesdescription" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:to="ifrs-full_TaxRateEffectFromChangeInTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_TurnoverRevenue" xlink:href="athe-20250630.xsd#athe_TurnoverRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:to="athe_TurnoverRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_EligibleAmountUnderTaxIncentiveScheme" xlink:href="athe-20250630.xsd#athe_EligibleAmountUnderTaxIncentiveScheme"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:to="athe_EligibleAmountUnderTaxIncentiveScheme" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_MiscellaneousIncomeDisputeWithCatalent" xlink:href="athe-20250630.xsd#athe_MiscellaneousIncomeDisputeWithCatalent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:to="athe_MiscellaneousIncomeDisputeWithCatalent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim" xlink:href="athe-20250630.xsd#athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:to="athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/IncomeTaxDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_IncomeTaxLineItems" xlink:href="athe-20250630.xsd#athe_IncomeTaxLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_IncomeTaxDetailsTable" xlink:href="athe-20250630.xsd#athe_IncomeTaxDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="athe_IncomeTaxLineItems" xlink:to="athe_IncomeTaxDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_IncomeTaxLineItems" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_IncomeTaxLineItems" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/OtherCurrentAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_TermDeposit" xlink:href="athe-20250630.xsd#athe_TermDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="athe_TermDeposit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_MaturityDate" xlink:href="athe-20250630.xsd#athe_MaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="athe_MaturityDate" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/IssuedCapitalDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_CapitalCommitments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_ParValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ordinarySharesPerShareCents" xlink:href="athe-20250630.xsd#athe_ordinarySharesPerShareCents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="athe_ordinarySharesPerShareCents" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ReservesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReservesWithinEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_ReservesDetailsTable" xlink:href="athe-20250630.xsd#athe_ReservesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="athe_ReservesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ReservesDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ReservesDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ReservesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ReservesDetailsTable" xlink:to="ifrs-full_DefinedBenefitPlansAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitPlansDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitPlansDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ReservesDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CreationDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ReservesDetailsTable" xlink:to="ifrs-full_CreationDateAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReservesWithinEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReservesWithinEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ReservesDetailsTable" xlink:to="ifrs-full_ReservesWithinEquityAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReservesWithinEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReservesWithinEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ReservesWithinEquityAxis" xlink:to="ifrs-full_ReservesWithinEquityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReservesWithinEquityDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReservesWithinEquityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ReservesWithinEquityAxis" xlink:to="ifrs-full_ReservesWithinEquityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_FreeAttachingOptionMember" xlink:href="athe-20250630.xsd#athe_FreeAttachingOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="athe_FreeAttachingOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_LongDatedOptionsMember" xlink:href="athe-20250630.xsd#athe_LongDatedOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="athe_LongDatedOptionsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ShortDatedOptionsMember" xlink:href="athe-20250630.xsd#athe_ShortDatedOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="athe_ShortDatedOptionsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ShortFreeAttachingOptionsMember" xlink:href="athe-20250630.xsd#athe_ShortFreeAttachingOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="athe_ShortFreeAttachingOptionsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember" xlink:href="athe-20250630.xsd#athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReservesWithinEquityDomain" xlink:to="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReservesWithinEquityDomain" xlink:to="athe_ShortFreeAttachingOptionsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_SubsequentsEventMember" xlink:href="athe-20250630.xsd#athe_SubsequentsEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="athe_SubsequentsEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_AsxPlan2004Member" xlink:href="athe-20250630.xsd#athe_AsxPlan2004Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefinedBenefitPlansDomain" xlink:to="athe_AsxPlan2004Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_AdsPlanTwoThousandEighteenMember" xlink:href="athe-20250630.xsd#athe_AdsPlanTwoThousandEighteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefinedBenefitPlansDomain" xlink:to="athe_AdsPlanTwoThousandEighteenMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_EmployeeMember" xlink:href="athe-20250630.xsd#athe_EmployeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="athe_EmployeeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_DirectorsMember" xlink:href="athe-20250630.xsd#athe_DirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="athe_DirectorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ConsultantMember" xlink:href="athe-20250630.xsd#athe_ConsultantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="athe_ConsultantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ChiefExecutiveOfficersMember" xlink:href="athe-20250630.xsd#athe_ChiefExecutiveOfficersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="athe_ChiefExecutiveOfficersMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_NonExecutiveDirectorsMember" xlink:href="athe-20250630.xsd#athe_NonExecutiveDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="athe_NonExecutiveDirectorsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_ShareOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_AugustThirtyFirstTwoThousandTwentySixMember" xlink:href="athe-20250630.xsd#athe_AugustThirtyFirstTwoThousandTwentySixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="athe_AugustThirtyFirstTwoThousandTwentySixMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ExpiredTerm" xlink:href="athe-20250630.xsd#athe_ExpiredTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="athe_ExpiredTerm" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ReserveOfOrdinaryShares" xlink:href="athe-20250630.xsd#athe_ReserveOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="athe_ReserveOfOrdinaryShares" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_LeasesDetailsTable" xlink:href="athe-20250630.xsd#athe_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="athe_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_AdditionsToRightofuseAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_CashOutflowForLeases" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ShortTermLeaseTerm" xlink:href="athe-20250630.xsd#athe_ShortTermLeaseTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="athe_ShortTermLeaseTerm" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ExpenditureCommitmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="athe_ExpenditureCommitmentsAbstract" xlink:href="athe-20250630.xsd#athe_ExpenditureCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_TerminationNoticePeriodForResearchAndDevelopmentContracts" xlink:href="athe-20250630.xsd#athe_TerminationNoticePeriodForResearchAndDevelopmentContracts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ExpenditureCommitmentsAbstract" xlink:to="athe_TerminationNoticePeriodForResearchAndDevelopmentContracts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ResearchAndDevelopmentTerminationCommitments" xlink:href="athe-20250630.xsd#athe_ResearchAndDevelopmentTerminationCommitments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_ExpenditureCommitmentsAbstract" xlink:to="athe_ResearchAndDevelopmentTerminationCommitments" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_ShareBasedPaymentsDetailsTable" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="athe_ShareBasedPaymentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_PlanAxis" xlink:href="athe-20250630.xsd#athe_PlanAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_ShareBasedPaymentsDetailsTable" xlink:to="athe_PlanAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_PlanDomainDomain" xlink:href="athe-20250630.xsd#athe_PlanDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="athe_PlanAxis" xlink:to="athe_PlanDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_PlanDomainDomain_0" xlink:href="athe-20250630.xsd#athe_PlanDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="athe_PlanAxis" xlink:to="athe_PlanDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_AdsPlanTwoThousandEighteenMember" xlink:href="athe-20250630.xsd#athe_AdsPlanTwoThousandEighteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="athe_PlanDomainDomain" xlink:to="athe_AdsPlanTwoThousandEighteenMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfDirector" xlink:href="athe-20250630.xsd#athe_NumberOfDirector"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="athe_NumberOfDirector" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfKeyManagementPersonnel" xlink:href="athe-20250630.xsd#athe_NumberOfKeyManagementPersonnel"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="athe_NumberOfKeyManagementPersonnel" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfEmployees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfConsultant" xlink:href="athe-20250630.xsd#athe_NumberOfConsultant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="athe_NumberOfConsultant" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ShareholdersAuthorizedSecurities" xlink:href="athe-20250630.xsd#athe_ShareholdersAuthorizedSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="athe_ShareholdersAuthorizedSecurities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_PercentageOfDefaultVestingConditionsPerYear" xlink:href="athe-20250630.xsd#athe_PercentageOfDefaultVestingConditionsPerYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="athe_PercentageOfDefaultVestingConditionsPerYear" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_SubsequentEventsDetailsTable" xlink:href="athe-20250630.xsd#athe_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="athe_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_SubsequentEventsDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_SubsequentEventsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ASXEmployeeSharePlanMember" xlink:href="athe-20250630.xsd#athe_ASXEmployeeSharePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="athe_ASXEmployeeSharePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ADSEmployeeSharePlanMember" xlink:href="athe-20250630.xsd#athe_ADSEmployeeSharePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="athe_ADSEmployeeSharePlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_SubsequentEventsMember" xlink:href="athe-20250630.xsd#athe_SubsequentEventsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="athe_SubsequentEventsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ExercisePriceExpiryTerm" xlink:href="athe-20250630.xsd#athe_ExercisePriceExpiryTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="athe_ExercisePriceExpiryTerm" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_RelatedPartyTransactionsDetailsTable" xlink:href="athe-20250630.xsd#athe_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="athe_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/SegmentInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfReportableSegment" xlink:href="athe-20250630.xsd#athe_NumberOfReportableSegment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="athe_NumberOfReportableSegment" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <loc xlink:type="locator" xlink:label="athe_FinancialInstrumentsDetailsTable" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="athe_FinancialInstrumentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInterestRatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="athe_FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInterestRatesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInterestRatesDomain_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_ForeignCurrencyRiskMember" xlink:href="athe-20250630.xsd#athe_ForeignCurrencyRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="athe_ForeignCurrencyRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRateRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRateRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_InterestRateRiskMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_CashAndCashEquivalentMember" xlink:href="athe-20250630.xsd#athe_CashAndCashEquivalentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="athe_CashAndCashEquivalentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRate385PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRate385PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="athe_InterestRate385PercentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="athe_CashAndCashEquivalentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRateOf000OnePercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000OnePercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="athe_InterestRateOf000OnePercentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRateOf000PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="athe_InterestRateOf000PercentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRate36PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRate36PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="athe_InterestRate36PercentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRate105PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRate105PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="athe_InterestRate105PercentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRateOf15To482PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf15To482PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="athe_InterestRateOf15To482PercentMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRateOf000TwoPercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000TwoPercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="athe_InterestRateOf000TwoPercentMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRateOf000ThreePercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000ThreePercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="athe_InterestRateOf000ThreePercentMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRateOf000FourPercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000FourPercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="athe_InterestRateOf000FourPercentMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRateOf000PercentFiveMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000PercentFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="athe_InterestRateOf000PercentFiveMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRateOf27Member" xlink:href="athe-20250630.xsd#athe_InterestRateOf27Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="athe_InterestRateOf27Member" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRate144PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRate144PercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="athe_InterestRate144PercentMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRate385OnePercentMember" xlink:href="athe-20250630.xsd#athe_InterestRate385OnePercentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="athe_InterestRate385OnePercentMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_AverageAnnualMovementForeignExchangeRate" xlink:href="athe-20250630.xsd#athe_AverageAnnualMovementForeignExchangeRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="athe_AverageAnnualMovementForeignExchangeRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar" xlink:href="athe-20250630.xsd#athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_Cash" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_PercentageOfInterestRate" xlink:href="athe-20250630.xsd#athe_PercentageOfInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="athe_PercentageOfInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="athe_MaturityDate" xlink:href="athe-20250630.xsd#athe_MaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="athe_MaturityDate" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://pranabio.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorOpinionTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="35" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>athe-20250630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 29 01:27:04 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssets_lbl0" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total Non-Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl0" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Assets_lbl0" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl0" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US">Total Non-Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl0" xml:lang="en-US">Non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Liabilities_lbl0" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetAssetsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetAssetsLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NetAssetsLiabilities_lbl" xml:lang="en-US">Net Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetAssetsLiabilities" xlink:to="ifrs-full_NetAssetsLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Equity_lbl2" xml:lang="en-US">Total equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl2"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">Loss before income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_lbl1" xml:lang="en-US">Loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLoss_lbl2" xml:lang="en-US">Net loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl2"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US">Total comprehensive loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl0" xml:lang="en-US">Total comprehensive loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash flows used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash flows used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash flows generated from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US">Net (decrease)/increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl1" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl1" xml:lang="en-US">Beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl2" xml:lang="en-US">End of the financial year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl2"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xml:lang="en-US">Background and Summary of Material Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_RangesAxis" xlink:href="athe-20250630.xsd#athe_RangesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_RangesAxis_lbl" xml:lang="en-US">Ranges [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_RangesAxis" xlink:to="athe_RangesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract_lbl" xml:lang="en-US">Interest and Other Income from Continuing Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:to="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherRevenue_lbl" xml:lang="en-US">Total interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherRevenue" xlink:to="ifrs-full_OtherRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherIncome_lbl0" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherIncome_lbl1" xml:lang="en-US">Other income related to research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAndOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAndOperatingIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_RevenueAndOperatingIncome_lbl" xml:lang="en-US">Total interest and other income from continuing operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAndOperatingIncome" xlink:to="ifrs-full_RevenueAndOperatingIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseByNatureAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseByNatureAbstract_lbl" xml:lang="en-US">Expenses from Ordinary Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_ExpenseByNatureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xml:lang="en-US">Income Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl0" xml:lang="en-US">(a) Income tax expense:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfIncomeTaxAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfIncomeTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfIncomeTaxAbstract_lbl" xml:lang="en-US">Schedule of Income Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfIncomeTaxAbstract" xlink:to="athe_ScheduleOfIncomeTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract_lbl" xml:lang="en-US">Trade and Other Receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesAbstract_lbl" xml:lang="en-US">Schedule of Trade and Other Receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl0" xml:lang="en-US">Trade and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl0" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherCurrentAssets_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentAssets_lbl0" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract_lbl" xml:lang="en-US">Trade and Other Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" xml:lang="en-US">Schedule of Trade and Other Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl0" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProvisionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProvisionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProvisionsAbstract_lbl" xml:lang="en-US">Provisions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="ifrs-full_ProvisionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfProvisionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfProvisionsAxis_lbl" xml:lang="en-US">Classes of other provisions [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfProvisionsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Provisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Provisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Provisions_lbl" xml:lang="en-US">Carrying amount at start of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Provisions" xlink:to="ifrs-full_Provisions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Provisions_lbl0" xml:lang="en-US">Carrying amount at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Provisions" xlink:to="ifrs-full_Provisions_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_CommitmentsAndContingenciesAbstract" xlink:href="athe-20250630.xsd#athe_CommitmentsAndContingenciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_CommitmentsAndContingenciesAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_CommitmentsAndContingenciesAbstract" xlink:to="athe_CommitmentsAndContingenciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalAbstract_lbl" xml:lang="en-US">Issued Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_IssuedCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US">Classes of share capital [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" xml:lang="en-US">Beginning of the year, No. of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl0" xml:lang="en-US">End of the year, No. of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl1" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl2" xml:lang="en-US">Number of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl2"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US">Beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_IssuedCapital_lbl0" xml:lang="en-US">End of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl1" xml:lang="en-US">Issued capital 2025: 9,127,370,686 fully paid ordinary shares Nil options over fully paid ordinary shares 2024: 5,245,115,318 fully paid ordinary shares Nil options over fully paid ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IssuedCapital_lbl2" xml:lang="en-US">Issued Capital (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_IssuedCapital_lbl3" xml:lang="en-US">Contributed equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl3"/>
    <loc xlink:type="locator" xlink:label="athe_IncreaseDecreaseInNumberOfShareOutstanding" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseInNumberOfShareOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="athe_IncreaseDecreaseInNumberOfShareOutstanding_lbl" xml:lang="en-US">Number, Beginning (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncreaseDecreaseInNumberOfShareOutstanding" xlink:to="athe_IncreaseDecreaseInNumberOfShareOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="athe_IncreaseDecreaseInNumberOfShareOutstanding_lbl0" xml:lang="en-US">Number, Ending (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncreaseDecreaseInNumberOfShareOutstanding" xlink:to="athe_IncreaseDecreaseInNumberOfShareOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalPreferenceShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalPreferenceShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_IssuedCapitalPreferenceShares_lbl" xml:lang="en-US">Amount, Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalPreferenceShares" xlink:to="ifrs-full_IssuedCapitalPreferenceShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_IssuedCapitalPreferenceShares_lbl0" xml:lang="en-US">Amount, Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalPreferenceShares" xlink:to="ifrs-full_IssuedCapitalPreferenceShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_ShareIssuanceDateAxis" xlink:href="athe-20250630.xsd#athe_ShareIssuanceDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ShareIssuanceDateAxis_lbl" xml:lang="en-US">Share Issuance Date [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareIssuanceDateAxis" xlink:to="athe_ShareIssuanceDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReservesWithinEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityAbstract_lbl" xml:lang="en-US">Reserves [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:to="ifrs-full_DisclosureOfReservesWithinEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReservesWithinEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReservesWithinEquityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReservesWithinEquityAxis_lbl" xml:lang="en-US">Reserves within equity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReservesWithinEquityAxis" xlink:to="ifrs-full_ReservesWithinEquityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract_lbl" xml:lang="en-US">Schedule of Movements in Options for Fully Paid Ordinary Shares [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfSharesOptionsOutstanding" xlink:href="athe-20250630.xsd#athe_NumberOfSharesOptionsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="athe_NumberOfSharesOptionsOutstanding_lbl" xml:lang="en-US">Number of Options, Beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfSharesOptionsOutstanding" xlink:to="athe_NumberOfSharesOptionsOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="athe_NumberOfSharesOptionsOutstanding_lbl0" xml:lang="en-US">Number of Options, End of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfSharesOptionsOutstanding" xlink:to="athe_NumberOfSharesOptionsOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl" xml:lang="en-US">Beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl0" xml:lang="en-US">End of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl1" xml:lang="en-US">Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl2" xml:lang="en-US">Reserve of share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl2"/>
    <loc xlink:type="locator" xlink:label="athe_AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:href="athe-20250630.xsd#athe_AccumulatedDeficitDuringDevelopmentStageAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_AccumulatedDeficitDuringDevelopmentStageAbstract_lbl" xml:lang="en-US">Accumulated Deficit During Development Stage [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:to="athe_AccumulatedDeficitDuringDevelopmentStageAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Balance at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="ifrs-full_RetainedEarnings_lbl0" xml:lang="en-US">Balance at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl1" xml:lang="en-US">Accumulated losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract_lbl" xml:lang="en-US">Schedule of Amounts Recognized in Profit or Loss Relating Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract" xlink:to="ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashEquivalents_lbl" xml:lang="en-US">Closing cash and cash equivalents balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashEquivalents" xlink:to="ifrs-full_CashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ExpenditureCommitmentsAbstract" xlink:href="athe-20250630.xsd#athe_ExpenditureCommitmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ExpenditureCommitmentsAbstract_lbl" xml:lang="en-US">Expenditure Commitments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ExpenditureCommitmentsAbstract" xlink:to="athe_ExpenditureCommitmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US">Share Based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="athe-20250630.xsd#athe_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsAbstract_lbl" xml:lang="en-US">Schedule of Options Granted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="athe_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US">Number of Options, Beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl0" xml:lang="en-US">Number of Options, Outstanding at year end</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl1" xml:lang="en-US">Share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl2" xml:lang="en-US">Option shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl2"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning of the year (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at year end (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US">Fair value per option (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_OptionsSeriesAxis" xlink:href="athe-20250630.xsd#athe_OptionsSeriesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_OptionsSeriesAxis_lbl" xml:lang="en-US">Options Series [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OptionsSeriesAxis" xlink:to="athe_OptionsSeriesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_PlanAxis" xlink:href="athe-20250630.xsd#athe_PlanAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_PlanAxis_lbl" xml:lang="en-US">Plan [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PlanAxis" xlink:to="athe_PlanAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract_lbl" xml:lang="en-US">Key Management Personnel Compensation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemunerationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AuditorsRemunerationAbstract_lbl" xml:lang="en-US">Auditors&apos; Remuneration [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemunerationAbstract" xlink:to="ifrs-full_AuditorsRemunerationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfAuditAndReviewOfFinancialStatementsAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfAuditAndReviewOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfAuditAndReviewOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Schedule of Audit and Review of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfAuditAndReviewOfFinancialStatementsAbstract" xlink:to="athe_ScheduleOfAuditAndReviewOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemuneration" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemuneration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_AuditorsRemuneration_lbl" xml:lang="en-US">Total auditors remuneration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemuneration" xlink:to="ifrs-full_AuditorsRemuneration_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" xml:lang="en-US">Segment Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xml:lang="en-US">Financial Instruments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Schedule of Financial Assets and Liabilities Subject to Foreign Currency Risk [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl0" xml:lang="en-US">Statement of financial position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" xml:lang="en-US">Classes of financial assets [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US">Classes of financial instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInterestRatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfInterestRatesAxis_lbl" xml:lang="en-US">Types of interest rates [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAxis_lbl" xml:lang="en-US">Maturity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xml:lang="en-US">Types of risks [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ParentEntityFinancialInformationAbstract" xlink:href="athe-20250630.xsd#athe_ParentEntityFinancialInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ParentEntityFinancialInformationAbstract_lbl" xml:lang="en-US">Parent Entity Financial Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ParentEntityFinancialInformationAbstract" xlink:to="athe_ParentEntityFinancialInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US">Non-Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentProvisions_lbl" xml:lang="en-US">Provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentProvisions" xlink:to="ifrs-full_CurrentProvisions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentProvisions_lbl0" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentProvisions" xlink:to="ifrs-full_CurrentProvisions_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl0" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl" xml:lang="en-US">Current tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxLiabilities" xlink:to="ifrs-full_CurrentTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Non-Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl0" xml:lang="en-US">Non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US">Accumulated deficit during the development stage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromInterest" xlink:to="ifrs-full_RevenueFromInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherGainsLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherGainsLosses_lbl" xml:lang="en-US">Other gains / (losses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_OtherGainsLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ForfeitedOptionsFromReserves" xlink:href="athe-20250630.xsd#athe_ForfeitedOptionsFromReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ForfeitedOptionsFromReserves_lbl" xml:lang="en-US">Forfeited options from reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ForfeitedOptionsFromReserves" xlink:to="athe_ForfeitedOptionsFromReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US">Other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US">Loss per share (basic - cents per share) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl0" xml:lang="en-US">Basic loss per share (cents per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US">Loss per share (Diluted - cents per share) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl0" xml:lang="en-US">Diluted loss per share (cents per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Weighted average number of ordinary shares used in computing basic net loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares on issue used in the calculation of basic loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US">Weighted average number of ordinary shares used in computing diluted net loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares on issue used in the calculation of diluted loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">(a) Reconciliation of Net Loss to Net Cash Flows Used In Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US">Interest received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ProceedsFromResearchAndDevelopmentTaxRefund" xlink:href="athe-20250630.xsd#athe_ProceedsFromResearchAndDevelopmentTaxRefund"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ProceedsFromResearchAndDevelopmentTaxRefund_lbl" xml:lang="en-US">R&amp;D tax refund</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ProceedsFromResearchAndDevelopmentTaxRefund" xlink:to="athe_ProceedsFromResearchAndDevelopmentTaxRefund_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl" xml:lang="en-US">Payments for term deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl" xml:lang="en-US">Proceeds from issue of ordinary shares and other equity securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US">Exchange rate adjustments on cash and cash equivalents held in foreign currencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ChangesInEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ChangesInEquityAbstract_lbl" xml:lang="en-US">Transactions with owners in their capacity as owners:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ChangesInEquityAbstract" xlink:to="ifrs-full_ChangesInEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_IssuanceOfSharesNetOfCostsValue" xlink:href="athe-20250630.xsd#athe_IssuanceOfSharesNetOfCostsValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_IssuanceOfSharesNetOfCostsValue_lbl" xml:lang="en-US">Issuance of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IssuanceOfSharesNetOfCostsValue" xlink:to="athe_IssuanceOfSharesNetOfCostsValue_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_IssuanceOfSharesNetOfCostsShares" xlink:href="athe-20250630.xsd#athe_IssuanceOfSharesNetOfCostsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_IssuanceOfSharesNetOfCostsShares_lbl" xml:lang="en-US">Issuance of shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IssuanceOfSharesNetOfCostsShares" xlink:to="athe_IssuanceOfSharesNetOfCostsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees_lbl" xml:lang="en-US">Non-cash issuance of options to directors and employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" xlink:to="athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants_lbl" xml:lang="en-US">Non-cash issuance of options to consultants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants" xlink:to="athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" xlink:href="athe-20250630.xsd#athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars_lbl" xml:lang="en-US">Issuance of shares in connection with exercise of options, net of costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" xlink:to="athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US">Transaction costs from issuance of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement_lbl" xml:lang="en-US">Expired options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" xlink:to="athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ForfeitedOptionsReversedToProfitOrLoss" xlink:href="athe-20250630.xsd#athe_ForfeitedOptionsReversedToProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ForfeitedOptionsReversedToProfitOrLoss_lbl" xml:lang="en-US">Forfeited options of reversed to profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ForfeitedOptionsReversedToProfitOrLoss" xlink:to="athe_ForfeitedOptionsReversedToProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl" xml:lang="en-US">Total transactions with owners in their capacity as owners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners" xlink:href="athe-20250630.xsd#athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners_lbl" xml:lang="en-US">Total transactions with owners in their capacity as owners (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners" xlink:to="athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US">Contributions of equity/ Shares to be issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xml:lang="en-US">Issuance of shares in connection with exercise of options, net of costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_IntellectualPropertyExpenses" xlink:href="athe-20250630.xsd#athe_IntellectualPropertyExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="athe_IntellectualPropertyExpenses_lbl" xml:lang="en-US">Intellectual property expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IntellectualPropertyExpenses" xlink:to="athe_IntellectualPropertyExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administration expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xml:lang="en-US">Other operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0" xml:lang="en-US">Income tax expense attributable to loss before income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees_lbl" xml:lang="en-US">Payments to suppliers and employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" xlink:to="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefund" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxesPaidRefund_lbl" xml:lang="en-US">Income tax paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefund" xlink:to="ifrs-full_IncomeTaxesPaidRefund_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_PaymentsForRentalSecurityDeposits" xlink:href="athe-20250630.xsd#athe_PaymentsForRentalSecurityDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="athe_PaymentsForRentalSecurityDeposits_lbl" xml:lang="en-US">Payments for rental security deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PaymentsForRentalSecurityDeposits" xlink:to="athe_PaymentsForRentalSecurityDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Payments for purchase of plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US">Payment of share issue costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Principal elements of lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US">Issued Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReservesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReservesMember_lbl" xml:lang="en-US">Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReservesMember" xlink:to="ifrs-full_OtherReservesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit During Development Stage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl" xml:lang="en-US">BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments" xlink:href="athe-20250630.xsd#athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments_lbl" xml:lang="en-US">Estimated useful lives of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments" xlink:to="athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInterestIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInterestIncomeExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInterestIncomeExplanatory_lbl" xml:lang="en-US">INTEREST AND OTHER INCOME FROM CONTINUING OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInterestIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfInterestIncomeExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock_lbl" xml:lang="en-US">Schedule of Interest and Other Income from Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock" xlink:to="athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ResearchAndDevelopmentTaxIncentive" xlink:href="athe-20250630.xsd#athe_ResearchAndDevelopmentTaxIncentive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ResearchAndDevelopmentTaxIncentive_lbl" xml:lang="en-US">R&amp;D Tax Incentive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ResearchAndDevelopmentTaxIncentive" xlink:to="athe_ResearchAndDevelopmentTaxIncentive_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US">Miscellaneous income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfExpensesExplanatory_lbl" xml:lang="en-US">EXPENSES FROM ORDINARY ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xml:lang="en-US">Schedule of Expenses from Ordinary Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ResearchAndDevelopmentExpenses1Abstract" xlink:href="athe-20250630.xsd#athe_ResearchAndDevelopmentExpenses1Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ResearchAndDevelopmentExpenses1Abstract_lbl" xml:lang="en-US">Research and Development Expenses (1)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ResearchAndDevelopmentExpenses1Abstract" xlink:to="athe_ResearchAndDevelopmentExpenses1Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US">Employee expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_OtherResearchAndDevelopmentExpenses" xlink:href="athe-20250630.xsd#athe_OtherResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_OtherResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Other research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OtherResearchAndDevelopmentExpenses" xlink:to="athe_OtherResearchAndDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_GeneralAndAdministrationExpensesAbstract" xlink:href="athe-20250630.xsd#athe_GeneralAndAdministrationExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_GeneralAndAdministrationExpensesAbstract_lbl" xml:lang="en-US">General and Administration Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_GeneralAndAdministrationExpensesAbstract" xlink:to="athe_GeneralAndAdministrationExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US">Depreciation on fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xml:lang="en-US">Depreciation on leased assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl0" xml:lang="en-US">Depreciation of right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEmployeeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEmployeeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherEmployeeExpense_lbl" xml:lang="en-US">Employee expenses (non R&amp;D related)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEmployeeExpense" xlink:to="ifrs-full_OtherEmployeeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ConsultantAndDirectorExpenses" xlink:href="athe-20250630.xsd#athe_ConsultantAndDirectorExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ConsultantAndDirectorExpenses_lbl" xml:lang="en-US">Consultant and director expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ConsultantAndDirectorExpenses" xlink:to="athe_ConsultantAndDirectorExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_AuditInternalControlAndOtherAssuranceExpenses" xlink:href="athe-20250630.xsd#athe_AuditInternalControlAndOtherAssuranceExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_AuditInternalControlAndOtherAssuranceExpenses_lbl" xml:lang="en-US">Audit, internal control and other assurance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AuditInternalControlAndOtherAssuranceExpenses" xlink:to="athe_AuditInternalControlAndOtherAssuranceExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_CorporateComplianceExpenses" xlink:href="athe-20250630.xsd#athe_CorporateComplianceExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_CorporateComplianceExpenses_lbl" xml:lang="en-US">Corporate compliance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_CorporateComplianceExpenses" xlink:to="athe_CorporateComplianceExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InsuranceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InsuranceExpense_lbl" xml:lang="en-US">Insurance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceExpense" xlink:to="ifrs-full_InsuranceExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_OfficeRentalExpenses" xlink:href="athe-20250630.xsd#athe_OfficeRentalExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_OfficeRentalExpenses_lbl" xml:lang="en-US">Office rental</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OfficeRentalExpenses" xlink:to="athe_OfficeRentalExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdministrativeExpense_lbl" xml:lang="en-US">Other administrative and office expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdministrativeExpense" xlink:to="ifrs-full_AdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US">Share based payment expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl0" xml:lang="en-US">Share-based payment expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_CorporateAdvisoryExpenses" xlink:href="athe-20250630.xsd#athe_CorporateAdvisoryExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_CorporateAdvisoryExpenses_lbl" xml:lang="en-US">Corporate advisory expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_CorporateAdvisoryExpenses" xlink:to="athe_CorporateAdvisoryExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_OtherGainsAndLossesAbstract" xlink:href="athe-20250630.xsd#athe_OtherGainsAndLossesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_OtherGainsAndLossesAbstract_lbl" xml:lang="en-US">Other gains and losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OtherGainsAndLossesAbstract" xlink:to="athe_OtherGainsAndLossesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Foreign exchange (gain)/loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US">INCOME TAX</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock" xlink:href="athe-20250630.xsd#athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock" xlink:to="athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl" xml:lang="en-US">Current tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncome" xlink:to="ifrs-full_CurrentTaxExpenseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_lbl" xml:lang="en-US">Adjustment for current tax of prior periods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:to="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_lbl0" xml:lang="en-US">Under/(Over) provision of income tax in previous year relating to a revision of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:to="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DeferredTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxExpenseIncome_lbl" xml:lang="en-US">Deferred tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncome" xlink:to="ifrs-full_DeferredTaxExpenseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract_lbl" xml:lang="en-US">(b) Numerical reconciliation of income tax expense to prima facie tax payable:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract" xlink:to="ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_PrimaFacieTaxOnNetLossBeforeIncomeTax" xlink:href="athe-20250630.xsd#athe_PrimaFacieTaxOnNetLossBeforeIncomeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_PrimaFacieTaxOnNetLossBeforeIncomeTax_lbl" xml:lang="en-US">Prima facie tax on net loss before income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PrimaFacieTaxOnNetLossBeforeIncomeTax" xlink:to="athe_PrimaFacieTaxOnNetLossBeforeIncomeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates_lbl" xml:lang="en-US">Effect of lower tax rates of tax on overseas income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfForeignTaxRates" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_AddTaxEffectOfAbstract" xlink:href="athe-20250630.xsd#athe_AddTaxEffectOfAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_AddTaxEffectOfAbstract_lbl" xml:lang="en-US">Add tax effect of:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AddTaxEffectOfAbstract" xlink:to="athe_AddTaxEffectOfAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_TaxEffectOfDeferredTaxAssetNotRecognized" xlink:href="athe-20250630.xsd#athe_TaxEffectOfDeferredTaxAssetNotRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_TaxEffectOfDeferredTaxAssetNotRecognized_lbl" xml:lang="en-US">Deferred tax asset not recognised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TaxEffectOfDeferredTaxAssetNotRecognized" xlink:to="athe_TaxEffectOfDeferredTaxAssetNotRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DeferredTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xml:lang="en-US">(c) Potential deferred tax asset as of June 30, 2025, 2024 and 2023 in respect of: tax losses not brought to account is:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssets" xlink:to="ifrs-full_DeferredTaxAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_lbl" xml:lang="en-US">Temporary differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:to="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US">TRADE AND OTHER RECEIVABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_DisclosureOfTradeAndOtherReceivableTableTextBlock" xlink:href="athe-20250630.xsd#athe_DisclosureOfTradeAndOtherReceivableTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_DisclosureOfTradeAndOtherReceivableTableTextBlock_lbl" xml:lang="en-US">Schedule of Trade and Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfTradeAndOtherReceivableTableTextBlock" xlink:to="athe_DisclosureOfTradeAndOtherReceivableTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets_lbl" xml:lang="en-US">Accrued interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" xlink:to="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ResearchAndDevelopmentTaxIncentiveReceivable" xlink:href="athe-20250630.xsd#athe_ResearchAndDevelopmentTaxIncentiveReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ResearchAndDevelopmentTaxIncentiveReceivable_lbl" xml:lang="en-US">R&amp;D tax incentive receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ResearchAndDevelopmentTaxIncentiveReceivable" xlink:to="athe_ResearchAndDevelopmentTaxIncentiveReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables_lbl" xml:lang="en-US">Goods and services tax receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentValueAddedTaxReceivables" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory_lbl" xml:lang="en-US">Schedule of Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepayments_lbl" xml:lang="en-US">Prepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepayments" xlink:to="ifrs-full_CurrentPrepayments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl" xml:lang="en-US">Term deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">TRADE AND OTHER PAYABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfTradeAndOtherPayableTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfTradeAndOtherPayableTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ScheduleOfTradeAndOtherPayableTableTextBlock_lbl" xml:lang="en-US">Schedule of Trade and Other Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfTradeAndOtherPayableTableTextBlock" xlink:to="athe_ScheduleOfTradeAndOtherPayableTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US">Trade creditors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_AccruedResearchAndDevelopmentExpenses" xlink:href="athe-20250630.xsd#athe_AccruedResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Accrued research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AccruedResearchAndDevelopmentExpenses" xlink:to="athe_AccruedResearchAndDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_AccruedProfessionalFees" xlink:href="athe-20250630.xsd#athe_AccruedProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_AccruedProfessionalFees_lbl" xml:lang="en-US">Accrued professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AccruedProfessionalFees" xlink:to="athe_AccruedProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued corporate personnel expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_OtherCurrentAccruedExpenses" xlink:href="athe-20250630.xsd#athe_OtherCurrentAccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_OtherCurrentAccruedExpenses_lbl" xml:lang="en-US">Other accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OtherCurrentAccruedExpenses" xlink:to="athe_OtherCurrentAccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPayables_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfProvisionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfProvisionsExplanatory_lbl" xml:lang="en-US">PROVISIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfProvisionsExplanatory" xlink:to="ifrs-full_DisclosureOfProvisionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_lbl" xml:lang="en-US">Schedule of Provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_CurrentAbstract" xlink:href="athe-20250630.xsd#athe_CurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_CurrentAbstract_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_CurrentAbstract" xlink:to="athe_CurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_NonCurrentAbstract" xlink:href="athe-20250630.xsd#athe_NonCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_NonCurrentAbstract_lbl" xml:lang="en-US">Non-Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NonCurrentAbstract" xlink:to="athe_NonCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentProvisions_lbl" xml:lang="en-US">Non-Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentProvisions" xlink:to="ifrs-full_NoncurrentProvisions_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock" xlink:href="athe-20250630.xsd#athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock_lbl" xml:lang="en-US">Schedule of Movements in Provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock" xlink:to="athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_AnnualLeaveAbstract" xlink:href="athe-20250630.xsd#athe_AnnualLeaveAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_AnnualLeaveAbstract_lbl" xml:lang="en-US">Annual leave</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AnnualLeaveAbstract" xlink:to="athe_AnnualLeaveAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_lbl" xml:lang="en-US">Charged/(credited) to profit or loss -additional provisions recognised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_lbl" xml:lang="en-US">Change in foreign exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:to="ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_LongServiceLeaveAbstract" xlink:href="athe-20250630.xsd#athe_LongServiceLeaveAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_LongServiceLeaveAbstract_lbl" xml:lang="en-US">Long service leave</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_LongServiceLeaveAbstract" xlink:to="athe_LongServiceLeaveAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_AnnualLeaveAndLongServiceLeaveCarryingAmount" xlink:href="athe-20250630.xsd#athe_AnnualLeaveAndLongServiceLeaveCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_AnnualLeaveAndLongServiceLeaveCarryingAmount_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AnnualLeaveAndLongServiceLeaveCarryingAmount" xlink:to="athe_AnnualLeaveAndLongServiceLeaveCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIssuedCapitalExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIssuedCapitalExplanatory_lbl" xml:lang="en-US">ISSUED CAPITAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfIssuedCapitalExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US">Schedule of Issued Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_AIssuedCapitalAbstract" xlink:href="athe-20250630.xsd#athe_AIssuedCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_AIssuedCapitalAbstract_lbl" xml:lang="en-US">(a) Issued Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AIssuedCapitalAbstract" xlink:to="athe_AIssuedCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_SharesOfIssuedCapital" xlink:href="athe-20250630.xsd#athe_SharesOfIssuedCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_SharesOfIssuedCapital_lbl" xml:lang="en-US">Issued Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SharesOfIssuedCapital" xlink:to="athe_SharesOfIssuedCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_UnlabeledAbstract" xlink:href="athe-20250630.xsd#athe_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_UnlabeledAbstract" xlink:to="athe_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of Movements in Issued Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock" xlink:to="athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_MovementDuringTheYearNoOfSharesinShares" xlink:href="athe-20250630.xsd#athe_MovementDuringTheYearNoOfSharesinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_MovementDuringTheYearNoOfSharesinShares_lbl" xml:lang="en-US">Movement during the year, No. of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_MovementDuringTheYearNoOfSharesinShares" xlink:to="athe_MovementDuringTheYearNoOfSharesinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ValueOfIncreaseDecreaseInSharesOutstanding" xlink:href="athe-20250630.xsd#athe_ValueOfIncreaseDecreaseInSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ValueOfIncreaseDecreaseInSharesOutstanding_lbl" xml:lang="en-US">Movement during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ValueOfIncreaseDecreaseInSharesOutstanding" xlink:to="athe_ValueOfIncreaseDecreaseInSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_lbl" xml:lang="en-US">Schedule of Details of Share Issuances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfSharesIssuedDuringTheYear" xlink:href="athe-20250630.xsd#athe_NumberOfSharesIssuedDuringTheYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_NumberOfSharesIssuedDuringTheYear_lbl" xml:lang="en-US">Number of shares issued during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfSharesIssuedDuringTheYear" xlink:to="athe_NumberOfSharesIssuedDuringTheYear_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US">Number (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_NumberofSharesIssuePricePerShare" xlink:href="athe-20250630.xsd#athe_NumberofSharesIssuePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_NumberofSharesIssuePricePerShare_lbl" xml:lang="en-US">Issue Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberofSharesIssuePricePerShare" xlink:to="athe_NumberofSharesIssuePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_IssuedCapitalPreferenceShare" xlink:href="athe-20250630.xsd#athe_IssuedCapitalPreferenceShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_IssuedCapitalPreferenceShare_lbl" xml:lang="en-US">Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IssuedCapitalPreferenceShare" xlink:to="athe_IssuedCapitalPreferenceShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US">RESERVES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Reserves of Share Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock" xlink:to="athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_OptionsForFullyPaidOrdinaryShares1" xlink:href="athe-20250630.xsd#athe_OptionsForFullyPaidOrdinaryShares1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_OptionsForFullyPaidOrdinaryShares1_lbl" xml:lang="en-US">Options for fully paid ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OptionsForFullyPaidOrdinaryShares1" xlink:to="athe_OptionsForFullyPaidOrdinaryShares1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantReserve" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WarrantReserve_lbl" xml:lang="en-US">Reserve of Free-attaching options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantReserve" xlink:to="ifrs-full_WarrantReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_FreeattachingOptionsForFullyPaidOrdinaryShares" xlink:href="athe-20250630.xsd#athe_FreeattachingOptionsForFullyPaidOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_FreeattachingOptionsForFullyPaidOrdinaryShares_lbl" xml:lang="en-US">Free-attaching options for fully paid ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FreeattachingOptionsForFullyPaidOrdinaryShares" xlink:to="athe_FreeattachingOptionsForFullyPaidOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock_lbl" xml:lang="en-US">Schedule of Movements in Options for Fully Paid Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock" xlink:to="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear_lbl" xml:lang="en-US">Number of Options , Options issued during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear" xlink:to="athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ReserveOfOptionsIssuedDuringTheYear" xlink:href="athe-20250630.xsd#athe_ReserveOfOptionsIssuedDuringTheYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ReserveOfOptionsIssuedDuringTheYear_lbl" xml:lang="en-US">Options issued during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReserveOfOptionsIssuedDuringTheYear" xlink:to="athe_ReserveOfOptionsIssuedDuringTheYear_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare_lbl" xml:lang="en-US">Number of Options, Options expired during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare" xlink:to="athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear" xlink:href="athe-20250630.xsd#athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear_lbl" xml:lang="en-US">Expired during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear" xlink:to="athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfOptionsForfeitedDuringTheYear" xlink:href="athe-20250630.xsd#athe_NumberOfOptionsForfeitedDuringTheYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_NumberOfOptionsForfeitedDuringTheYear_lbl" xml:lang="en-US">Number of Options, Forfeited during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfOptionsForfeitedDuringTheYear" xlink:to="athe_NumberOfOptionsForfeitedDuringTheYear_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ReserveOfSharebasedPaymentsForfeitedDuringYear" xlink:href="athe-20250630.xsd#athe_ReserveOfSharebasedPaymentsForfeitedDuringYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ReserveOfSharebasedPaymentsForfeitedDuringYear_lbl" xml:lang="en-US">Forfeited during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReserveOfSharebasedPaymentsForfeitedDuringYear" xlink:to="athe_ReserveOfSharebasedPaymentsForfeitedDuringYear_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfOptionsOptionsExercisedDuringTheYear" xlink:href="athe-20250630.xsd#athe_NumberOfOptionsOptionsExercisedDuringTheYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_NumberOfOptionsOptionsExercisedDuringTheYear_lbl" xml:lang="en-US">Number of Options, Options exercised during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfOptionsOptionsExercisedDuringTheYear" xlink:to="athe_NumberOfOptionsOptionsExercisedDuringTheYear_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_OptionsExercisedDuringTheYear" xlink:href="athe-20250630.xsd#athe_OptionsExercisedDuringTheYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_OptionsExercisedDuringTheYear_lbl" xml:lang="en-US">Options exercised during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OptionsExercisedDuringTheYear" xlink:to="athe_OptionsExercisedDuringTheYear_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfOptionsSharesToBeIssued" xlink:href="athe-20250630.xsd#athe_NumberOfOptionsSharesToBeIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_NumberOfOptionsSharesToBeIssued_lbl" xml:lang="en-US">Number of Options, Shares to be issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfOptionsSharesToBeIssued" xlink:to="athe_NumberOfOptionsSharesToBeIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_SharesToBeIssued" xlink:href="athe-20250630.xsd#athe_SharesToBeIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_SharesToBeIssued_lbl" xml:lang="en-US">Shares to be issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SharesToBeIssued" xlink:to="athe_SharesToBeIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ShareBasedPaymentExpenseForOptionsIssuedI" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentExpenseForOptionsIssuedI"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ShareBasedPaymentExpenseForOptionsIssuedI_lbl" xml:lang="en-US">Number of Options, Share Based Payment expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareBasedPaymentExpenseForOptionsIssuedI" xlink:to="athe_ShareBasedPaymentExpenseForOptionsIssuedI_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US">Share Based Payment expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_AccumulatedDeficitDuringDevelopmentStageTextBlock" xlink:href="athe-20250630.xsd#athe_AccumulatedDeficitDuringDevelopmentStageTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_AccumulatedDeficitDuringDevelopmentStageTextBlock_lbl" xml:lang="en-US">ACCUMULATED DEFICIT DURING DEVELOPMENT STAGE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AccumulatedDeficitDuringDevelopmentStageTextBlock" xlink:to="athe_AccumulatedDeficitDuringDevelopmentStageTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock_lbl" xml:lang="en-US">Schedule of Accumulated Deficit During Development Stage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock" xlink:to="athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ReclassifyForfeitedOptionsFromReserves" xlink:href="athe-20250630.xsd#athe_ReclassifyForfeitedOptionsFromReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ReclassifyForfeitedOptionsFromReserves_lbl" xml:lang="en-US">Reclassify forfeited options from reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReclassifyForfeitedOptionsFromReserves" xlink:to="athe_ReclassifyForfeitedOptionsFromReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Financial Position Shows the Following Amounts Relating to Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock" xlink:to="athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_RightOfUseAssetsAbstract" xlink:href="athe-20250630.xsd#athe_RightOfUseAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_RightOfUseAssetsAbstract_lbl" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_RightOfUseAssetsAbstract" xlink:to="athe_RightOfUseAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases" xlink:href="athe-20250630.xsd#athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases_lbl" xml:lang="en-US">Schedule of Profit or Loss Shows the Following Amounts Relating to Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases" xlink:to="athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpense" xlink:to="ifrs-full_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ExpensesRelatingToShorttermLeases" xlink:href="athe-20250630.xsd#athe_ExpensesRelatingToShorttermLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ExpensesRelatingToShorttermLeases_lbl" xml:lang="en-US">Expenses relating to short-term leases (included in general and administration expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ExpensesRelatingToShorttermLeases" xlink:to="athe_ExpensesRelatingToShorttermLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities_lbl" xml:lang="en-US">Expenses relating to variable lease payments not included in lease liabilities (included in general and administration expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:to="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCashFlowStatementExplanatory_lbl" xml:lang="en-US">CASH FLOW INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:to="ifrs-full_DisclosureOfCashFlowStatementExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">Schedule of Cash Flow Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US">Non-cash items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xml:lang="en-US">Depreciation of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashPaymentsFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashPaymentsFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCashPaymentsFromOperatingActivities_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCashPaymentsFromOperatingActivities" xlink:to="ifrs-full_OtherCashPaymentsFromOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ForeignExchangegainLoss" xlink:href="athe-20250630.xsd#athe_ForeignExchangegainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ForeignExchangegainLoss_lbl" xml:lang="en-US">Foreign exchange loss/(gain)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ForeignExchangegainLoss" xlink:to="athe_ForeignExchangegainLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_FixedAssetWriteOff" xlink:href="athe-20250630.xsd#athe_FixedAssetWriteOff"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_FixedAssetWriteOff_lbl" xml:lang="en-US">Fixed asset write off</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FixedAssetWriteOff" xlink:to="athe_FixedAssetWriteOff_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ChangesInAssetsAndLiabilitiesAbstract" xlink:href="athe-20250630.xsd#athe_ChangesInAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ChangesInAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ChangesInAssetsAndLiabilitiesAbstract" xlink:to="athe_ChangesInAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_IncreaseDecreaseInTradeAndOtherReceivables" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseInTradeAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_IncreaseDecreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US">Decrease/(increase) in trade and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncreaseDecreaseInTradeAndOtherReceivables" xlink:to="athe_IncreaseDecreaseInTradeAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Decrease/(increase) in other current assets (excepting term deposit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US">(Decrease)/increase in trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">(Decrease) in other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForProvisions_lbl" xml:lang="en-US">Increase/(decrease) in provision for employee entitlements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForProvisions" xlink:to="ifrs-full_AdjustmentsForProvisions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">(b) Reconciliation of Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract_lbl0" xml:lang="en-US">Cash and cash equivalents balance comprises:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOnHand" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOnHand"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashOnHand_lbl" xml:lang="en-US">- cash and cash equivalents on hand</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOnHand" xlink:to="ifrs-full_CashOnHand_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_UnlabeledAbstract0" xlink:href="athe-20250630.xsd#athe_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_UnlabeledAbstract0" xlink:to="athe_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCommitmentsExplanatory_lbl" xml:lang="en-US">EXPENDITURE COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">SHARE BASED PAYMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US">Schedule of Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Options, Issued during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Issued during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Options shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted Average Exercise Price, Issued during the year (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised during the year (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired during the year (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited during the year (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Options, Vested and Exercisable at year end</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and Exercisable at year end (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Exercisable per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock_lbl" xml:lang="en-US">Schedule of Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock" xlink:to="athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_lbl" xml:lang="en-US">Grant Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:to="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ExpiryDateOfOutstandingShareOptions" xlink:href="athe-20250630.xsd#athe_ExpiryDateOfOutstandingShareOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ExpiryDateOfOutstandingShareOptions_lbl" xml:lang="en-US">Expiry Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ExpiryDateOfOutstandingShareOptions" xlink:to="athe_ExpiryDateOfOutstandingShareOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ExercisePriceOfOutstandingShareOption1" xlink:href="athe-20250630.xsd#athe_ExercisePriceOfOutstandingShareOption1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ExercisePriceOfOutstandingShareOption1_lbl" xml:lang="en-US">Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ExercisePriceOfOutstandingShareOption1" xlink:to="athe_ExercisePriceOfOutstandingShareOption1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Share options, Weighted average remaining contractual life of options outstanding at end of period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock_lbl" xml:lang="en-US">Schedule of Valuations of Options Approved and Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock" xlink:to="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Exercise Price per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl0" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_SharePriceAtGrantDate" xlink:href="athe-20250630.xsd#athe_SharePriceAtGrantDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_SharePriceAtGrantDate_lbl" xml:lang="en-US">Share Price at Grant Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SharePriceAtGrantDate" xlink:to="athe_SharePriceAtGrantDate_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_YearsToExpiry" xlink:href="athe-20250630.xsd#athe_YearsToExpiry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_YearsToExpiry_lbl" xml:lang="en-US">Years to Expiry</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_YearsToExpiry" xlink:to="athe_YearsToExpiry_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_RiskfreeInterestRate" xlink:href="athe-20250630.xsd#athe_RiskfreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_RiskfreeInterestRate_lbl" xml:lang="en-US">Risk-free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_RiskfreeInterestRate" xlink:to="athe_RiskfreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected Share Price Volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US">Dividend Yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_FairValuePerOptions" xlink:href="athe-20250630.xsd#athe_FairValuePerOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_FairValuePerOptions_lbl" xml:lang="en-US">Fair Value per Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FairValuePerOptions" xlink:to="athe_FairValuePerOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfNumberOfSharesIssuedTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfNumberOfSharesIssuedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ScheduleOfNumberOfSharesIssuedTableTextBlock_lbl" xml:lang="en-US">Schedule of Shares Issued under Stock Option Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfNumberOfSharesIssuedTableTextBlock" xlink:to="athe_ScheduleOfNumberOfSharesIssuedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US">LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US">Schedule of Earning Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US">KEY MANAGEMENT PERSONNEL COMPENSATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" xlink:href="athe-20250630.xsd#athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock_lbl" xml:lang="en-US">Schedule of Key Management Personnel Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" xlink:to="athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US">Short-term employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl" xml:lang="en-US">Post-employment benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_KeyManagementPersonnelCompensationLongtermBenefits" xlink:href="athe-20250630.xsd#athe_KeyManagementPersonnelCompensationLongtermBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_KeyManagementPersonnelCompensationLongtermBenefits_lbl" xml:lang="en-US">Long-term benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_KeyManagementPersonnelCompensationLongtermBenefits" xlink:to="athe_KeyManagementPersonnelCompensationLongtermBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_lbl" xml:lang="en-US">Termination benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US">Share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAuditorsRemunerationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_lbl" xml:lang="en-US">AUDITORS&apos; REMUNERATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:to="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfAuditorRemunerationTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfAuditorRemunerationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ScheduleOfAuditorRemunerationTableTextBlock_lbl" xml:lang="en-US">Schedule of Audit and Review of Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfAuditorRemunerationTableTextBlock" xlink:to="athe_ScheduleOfAuditorRemunerationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemunerationForAuditServices" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForAuditServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AuditorsRemunerationForAuditServices_lbl" xml:lang="en-US">- Audit and review of financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemunerationForAuditServices" xlink:to="ifrs-full_AuditorsRemunerationForAuditServices_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemunerationForOtherServices" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForOtherServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AuditorsRemunerationForOtherServices_lbl" xml:lang="en-US">- Other audit services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemunerationForOtherServices" xlink:to="ifrs-full_AuditorsRemunerationForOtherServices_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xml:lang="en-US">SEGMENT INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">FINANCIAL INSTRUMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory_lbl" xml:lang="en-US">Schedule of Financial Assets and Liabilities Subject to Foreign Currency Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory" xlink:to="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_FinancialInstrumentsTotalExposure" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsTotalExposure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_FinancialInstrumentsTotalExposure_lbl" xml:lang="en-US">Total exposure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FinancialInstrumentsTotalExposure" xlink:to="athe_FinancialInstrumentsTotalExposure_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Schedule of Interest Rates and the Effective Weighted Average Interest Rate for Classes of Financial Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_FinancialAssetsAbstract" xlink:href="athe-20250630.xsd#athe_FinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_FinancialAssetsAbstract_lbl" xml:lang="en-US">Financial Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FinancialAssetsAbstract" xlink:to="athe_FinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssets_lbl" xml:lang="en-US">Total Financial Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_AverageInterestRate" xlink:href="athe-20250630.xsd#athe_AverageInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_AverageInterestRate_lbl" xml:lang="en-US">Average Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AverageInterestRate" xlink:to="athe_AverageInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_UnlabeledAbstract1" xlink:href="athe-20250630.xsd#athe_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_UnlabeledAbstract1" xlink:to="athe_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_FinancialLiabilitiesAbstract" xlink:href="athe-20250630.xsd#athe_FinancialLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_FinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FinancialLiabilitiesAbstract" xlink:to="athe_FinancialLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US">Total Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_UnlabeledAbstract2" xlink:href="athe-20250630.xsd#athe_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_UnlabeledAbstract2" xlink:to="athe_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_FinancialAssetsAbstract0" xlink:href="athe-20250630.xsd#athe_FinancialAssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_FinancialAssetsAbstract0_lbl" xml:lang="en-US">Financial Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FinancialAssetsAbstract0" xlink:to="athe_FinancialAssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_UnlabeledAbstract3" xlink:href="athe-20250630.xsd#athe_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_UnlabeledAbstract3" xlink:to="athe_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_FinancialLiabilitiesAbstract0" xlink:href="athe-20250630.xsd#athe_FinancialLiabilitiesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_FinancialLiabilitiesAbstract0_lbl" xml:lang="en-US">Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FinancialLiabilitiesAbstract0" xlink:to="athe_FinancialLiabilitiesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_UnlabeledAbstract4" xlink:href="athe-20250630.xsd#athe_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_UnlabeledAbstract4" xlink:to="athe_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of Company&apos;s Liquidity Reserve on the Basis of Expected Cash Flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInterimFinancialReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInterimFinancialReportingExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInterimFinancialReportingExplanatory_lbl" xml:lang="en-US">PARENT ENTITY FINANCIAL INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInterimFinancialReportingExplanatory" xlink:to="ifrs-full_DisclosureOfInterimFinancialReportingExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_DisclosureOfParentEntityFinancialStatementsExplanatory" xlink:href="athe-20250630.xsd#athe_DisclosureOfParentEntityFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_DisclosureOfParentEntityFinancialStatementsExplanatory_lbl" xml:lang="en-US">Schedule of Individual Financial Statements for the Parent Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfParentEntityFinancialStatementsExplanatory" xlink:to="athe_DisclosureOfParentEntityFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Statement of profit or loss and other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax" xlink:href="athe-20250630.xsd#athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax_lbl" xml:lang="en-US">Prima facie tax on net loss before income tax at 25% (2024: 25%, 2023: 25%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax" xlink:to="athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_TaxEffectOfResearchAndDevelopmentExpenditure" xlink:href="athe-20250630.xsd#athe_TaxEffectOfResearchAndDevelopmentExpenditure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="athe_TaxEffectOfResearchAndDevelopmentExpenditure_lbl" xml:lang="en-US">Research and development expenditure (net of tax incentive)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TaxEffectOfResearchAndDevelopmentExpenditure" xlink:to="athe_TaxEffectOfResearchAndDevelopmentExpenditure_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions_lbl" xml:lang="en-US">Amounts used during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ReclassifyExpiredOptionsFromReservesOne" xlink:href="athe-20250630.xsd#athe_ReclassifyExpiredOptionsFromReservesOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="athe_ReclassifyExpiredOptionsFromReservesOne_lbl" xml:lang="en-US">Reclassify expired options from reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReclassifyExpiredOptionsFromReservesOne" xlink:to="athe_ReclassifyExpiredOptionsFromReservesOne_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Options, Exercised during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Options, Expired during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Options expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Options, Forfeited during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Options forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FixturesAndFittingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FixturesAndFittingsMember_lbl" xml:lang="en-US">Furniture and fittings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FixturesAndFittingsMember" xlink:to="ifrs-full_FixturesAndFittingsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_PlantAndEquipmentMember" xlink:href="athe-20250630.xsd#athe_PlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_PlantAndEquipmentMember_lbl" xml:lang="en-US">Plant and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PlantAndEquipmentMember" xlink:to="athe_PlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US">Bottom of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl0" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US">Top of range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl0" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_AnnualLeaveMember" xlink:href="athe-20250630.xsd#athe_AnnualLeaveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_AnnualLeaveMember_lbl" xml:lang="en-US">Annual Leave [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AnnualLeaveMember" xlink:to="athe_AnnualLeaveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_LongServiceLeaveMember" xlink:href="athe-20250630.xsd#athe_LongServiceLeaveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_LongServiceLeaveMember_lbl" xml:lang="en-US">Long Service Leave [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_LongServiceLeaveMember" xlink:to="athe_LongServiceLeaveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl0" xml:lang="en-US">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_OptionsMember" xlink:href="athe-20250630.xsd#athe_OptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_OptionsMember_lbl" xml:lang="en-US">Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OptionsMember" xlink:to="athe_OptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_September212022Member" xlink:href="athe-20250630.xsd#athe_September212022Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_September212022Member_lbl" xml:lang="en-US">September 21, 2022 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_September212022Member" xlink:to="athe_September212022Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_March152023Member" xlink:href="athe-20250630.xsd#athe_March152023Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_March152023Member_lbl" xml:lang="en-US">March 15, 2023 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_March152023Member" xlink:to="athe_March152023Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_June302023Member" xlink:href="athe-20250630.xsd#athe_June302023Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_June302023Member_lbl" xml:lang="en-US">June 30, 2023 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_June302023Member" xlink:to="athe_June302023Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_November292023Member" xlink:href="athe-20250630.xsd#athe_November292023Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_November292023Member_lbl" xml:lang="en-US">November 29, 2023 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_November292023Member" xlink:to="athe_November292023Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_January82024Member" xlink:href="athe-20250630.xsd#athe_January82024Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_January82024Member_lbl" xml:lang="en-US">January 8, 2024 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_January82024Member" xlink:to="athe_January82024Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_February22024Member" xlink:href="athe-20250630.xsd#athe_February22024Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_February22024Member_lbl" xml:lang="en-US">February 2, 2024 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_February22024Member" xlink:to="athe_February22024Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_March42024Member" xlink:href="athe-20250630.xsd#athe_March42024Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_March42024Member_lbl" xml:lang="en-US">March 4, 2024 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_March42024Member" xlink:to="athe_March42024Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_April222024Member" xlink:href="athe-20250630.xsd#athe_April222024Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_April222024Member_lbl" xml:lang="en-US">April 22, 2024 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_April222024Member" xlink:to="athe_April222024Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_June302024Member" xlink:href="athe-20250630.xsd#athe_June302024Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_June302024Member_lbl" xml:lang="en-US">June 30, 2024 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_June302024Member" xlink:to="athe_June302024Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_July182024Member" xlink:href="athe-20250630.xsd#athe_July182024Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_July182024Member_lbl" xml:lang="en-US">July 18, 2024 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_July182024Member" xlink:to="athe_July182024Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_January222025Member" xlink:href="athe-20250630.xsd#athe_January222025Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_January222025Member_lbl" xml:lang="en-US">January 22, 2025 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_January222025Member" xlink:to="athe_January222025Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_January302025Member" xlink:href="athe-20250630.xsd#athe_January302025Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_January302025Member_lbl" xml:lang="en-US">January 30, 2025 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_January302025Member" xlink:to="athe_January302025Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_February32025Member" xlink:href="athe-20250630.xsd#athe_February32025Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_February32025Member_lbl" xml:lang="en-US">February 3, 2025 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_February32025Member" xlink:to="athe_February32025Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_February172025Member" xlink:href="athe-20250630.xsd#athe_February172025Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_February172025Member_lbl" xml:lang="en-US">February 17, 2025 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_February172025Member" xlink:to="athe_February172025Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_March142025Member" xlink:href="athe-20250630.xsd#athe_March142025Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_March142025Member_lbl" xml:lang="en-US">March 14, 2025 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_March142025Member" xlink:to="athe_March142025Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_April42025Member" xlink:href="athe-20250630.xsd#athe_April42025Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_April42025Member_lbl" xml:lang="en-US">April 4, 2025 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_April42025Member" xlink:to="athe_April42025Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_June302025Member" xlink:href="athe-20250630.xsd#athe_June302025Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_June302025Member_lbl" xml:lang="en-US">June 30, 2025 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_June302025Member" xlink:to="athe_June302025Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember" xlink:href="athe-20250630.xsd#athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember_lbl" xml:lang="en-US">Reserve of Share Based Payments for Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember" xlink:to="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember_lbl0" xml:lang="en-US">Reserve of Share Based Payments for Warrants/Free-attaching options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember" xlink:to="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember_lbl1" xml:lang="en-US">Options for Fully Paid Ordinary Shares/Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember" xlink:to="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareOptionsMember_lbl" xml:lang="en-US">Options [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOptionsMember" xlink:to="ifrs-full_ShareOptionsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShareOptionsMember_lbl0" xml:lang="en-US">Share Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOptionsMember" xlink:to="ifrs-full_ShareOptionsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAABOneMember" xlink:href="athe-20250630.xsd#athe_ATHAABOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ATHAABOneMember_lbl" xml:lang="en-US">ATHAAB [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAABOneMember" xlink:to="athe_ATHAABOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAADOneMember" xlink:href="athe-20250630.xsd#athe_ATHAADOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ATHAADOneMember_lbl" xml:lang="en-US">ATHAAD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAADOneMember" xlink:to="athe_ATHAADOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAEMember" xlink:href="athe-20250630.xsd#athe_ATHAAEMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ATHAAEMember_lbl" xml:lang="en-US">ATHAAE [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAAEMember" xlink:to="athe_ATHAAEMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAFOneMember" xlink:href="athe-20250630.xsd#athe_ATHAAFOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ATHAAFOneMember_lbl" xml:lang="en-US">ATHAAF [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAAFOneMember" xlink:to="athe_ATHAAFOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAGOneMember" xlink:href="athe-20250630.xsd#athe_ATHAAGOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ATHAAGOneMember_lbl" xml:lang="en-US">ATHAAG [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAAGOneMember" xlink:to="athe_ATHAAGOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAHMember" xlink:href="athe-20250630.xsd#athe_ATHAAHMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ATHAAHMember_lbl" xml:lang="en-US">ATHAAH [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAAHMember" xlink:to="athe_ATHAAHMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAMember" xlink:href="athe-20250630.xsd#athe_ATHAAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ATHAAMember_lbl" xml:lang="en-US">ATHAA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAAMember" xlink:to="athe_ATHAAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ATHABMember" xlink:href="athe-20250630.xsd#athe_ATHABMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ATHABMember_lbl" xml:lang="en-US">ATHAB [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHABMember" xlink:to="athe_ATHABMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ATHACMember" xlink:href="athe-20250630.xsd#athe_ATHACMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ATHACMember_lbl" xml:lang="en-US">ATHAC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHACMember" xlink:to="athe_ATHACMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAABMember" xlink:href="athe-20250630.xsd#athe_ATHAABMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ATHAABMember_lbl" xml:lang="en-US">ATHAAB[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAABMember" xlink:to="athe_ATHAABMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAADMember" xlink:href="athe-20250630.xsd#athe_ATHAADMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ATHAADMember_lbl" xml:lang="en-US">ATHAAD[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAADMember" xlink:to="athe_ATHAADMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAFMember" xlink:href="athe-20250630.xsd#athe_ATHAAFMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ATHAAFMember_lbl" xml:lang="en-US">ATHAAF [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAAFMember" xlink:to="athe_ATHAAFMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ATHAAGMember" xlink:href="athe-20250630.xsd#athe_ATHAAGMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ATHAAGMember_lbl" xml:lang="en-US">ATHAAG [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAAGMember" xlink:to="athe_ATHAAGMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_AsxPlan2004Member" xlink:href="athe-20250630.xsd#athe_AsxPlan2004Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_AsxPlan2004Member_lbl" xml:lang="en-US">2004 ASX Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AsxPlan2004Member" xlink:to="athe_AsxPlan2004Member_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="athe_AsxPlan2004Member_lbl0" xml:lang="en-US">Asx Plan 2004 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AsxPlan2004Member" xlink:to="athe_AsxPlan2004Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_USD_lbl" xml:lang="en-US">USD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_CashAndCashEquivalentMember" xlink:href="athe-20250630.xsd#athe_CashAndCashEquivalentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_CashAndCashEquivalentMember_lbl" xml:lang="en-US">Cash and Cash Equivalent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_CashAndCashEquivalentMember" xlink:to="athe_CashAndCashEquivalentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="athe_CashAndCashEquivalentMember_lbl0" xml:lang="en-US">Cash and Cash Equivalents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_CashAndCashEquivalentMember" xlink:to="athe_CashAndCashEquivalentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_TradeAndOtherPayablesMember" xlink:href="athe-20250630.xsd#athe_TradeAndOtherPayablesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_TradeAndOtherPayablesMember_lbl" xml:lang="en-US">Trade and Other Payables [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TradeAndOtherPayablesMember" xlink:to="athe_TradeAndOtherPayablesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="athe_TradeAndOtherPayablesMember_lbl0" xml:lang="en-US">Trade And Other Payables [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TradeAndOtherPayablesMember" xlink:to="athe_TradeAndOtherPayablesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_GBP"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_GBP_lbl" xml:lang="en-US">&#163;GBP [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_GBP" xlink:to="currency_GBP_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_JPY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_JPY"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_JPY_lbl" xml:lang="en-US">JPY [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_JPY" xlink:to="currency_JPY_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_TradeAndOtherReceivablesMember" xlink:href="athe-20250630.xsd#athe_TradeAndOtherReceivablesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_TradeAndOtherReceivablesMember_lbl" xml:lang="en-US">Trade and Other Receivables [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TradeAndOtherReceivablesMember" xlink:to="athe_TradeAndOtherReceivablesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_OtherCurrentAssetMember" xlink:href="athe-20250630.xsd#athe_OtherCurrentAssetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_OtherCurrentAssetMember_lbl" xml:lang="en-US">Other Current Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OtherCurrentAssetMember" xlink:to="athe_OtherCurrentAssetMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="athe_OtherCurrentAssetMember_lbl0" xml:lang="en-US">Other current asset [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OtherCurrentAssetMember" xlink:to="athe_OtherCurrentAssetMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl" xml:lang="en-US">Lease Liabilities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl0" xml:lang="en-US">Lease liabilities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_OtherCurrentLiabilitieMember" xlink:href="athe-20250630.xsd#athe_OtherCurrentLiabilitieMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_OtherCurrentLiabilitieMember_lbl" xml:lang="en-US">Other Current Liabilities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OtherCurrentLiabilitieMember" xlink:to="athe_OtherCurrentLiabilitieMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FloatingInterestRateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FloatingInterestRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FloatingInterestRateMember_lbl" xml:lang="en-US">Floating Interest Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FloatingInterestRateMember" xlink:to="ifrs-full_FloatingInterestRateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US">1 year or less [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FixedInterestRateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixedInterestRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FixedInterestRateMember_lbl" xml:lang="en-US">Fixed Interest Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FixedInterestRateMember" xlink:to="ifrs-full_FixedInterestRateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xml:lang="en-US">1-5 years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_NonInterestBearingMember" xlink:href="athe-20250630.xsd#athe_NonInterestBearingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_NonInterestBearingMember_lbl" xml:lang="en-US">Non-Interest Bearing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NonInterestBearingMember" xlink:to="athe_NonInterestBearingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRateRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRateRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestRateRiskMember_lbl" xml:lang="en-US">Interest Rate Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRateRiskMember" xlink:to="ifrs-full_InterestRateRiskMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_InterestRateRiskMember_lbl0" xml:lang="en-US">Term Deposit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRateRiskMember" xlink:to="ifrs-full_InterestRateRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_InterestRateRiskMember_lbl1" xml:lang="en-US">Interest rate risk [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRateRiskMember" xlink:to="ifrs-full_InterestRateRiskMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="athe_LessThenSixMonthsMember" xlink:href="athe-20250630.xsd#athe_LessThenSixMonthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_LessThenSixMonthsMember_lbl" xml:lang="en-US">Less than 6 Months [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_LessThenSixMonthsMember" xlink:to="athe_LessThenSixMonthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_SixToTowelMember" xlink:href="athe-20250630.xsd#athe_SixToTowelMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_SixToTowelMember_lbl" xml:lang="en-US">6-12 Months [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SixToTowelMember" xlink:to="athe_SixToTowelMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember" xlink:href="athe-20250630.xsd#athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember_lbl" xml:lang="en-US">Greater than 12 Months and Less Than 5 Years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember" xlink:to="athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_TotalContractedCashFlowsMember" xlink:href="athe-20250630.xsd#athe_TotalContractedCashFlowsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_TotalContractedCashFlowsMember_lbl" xml:lang="en-US">Total Contracted Cash Flows [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TotalContractedCashFlowsMember" xlink:to="athe_TotalContractedCashFlowsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_CarryingAmountsMember" xlink:href="athe-20250630.xsd#athe_CarryingAmountsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_CarryingAmountsMember_lbl" xml:lang="en-US">Carrying Amounts [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_CarryingAmountsMember" xlink:to="athe_CarryingAmountsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ParentCompanyMember_lbl" xml:lang="en-US">Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CreationDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CreationDateAxis_lbl" xml:lang="en-US">Creation date [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_CreationDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DefinedBenefitPlansAxis_lbl" xml:lang="en-US">Defined benefit plans [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl" xml:lang="en-US">Types of antidilutive instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US">Non-adjusting events after reporting period [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_TaxRateEffectFromChangesInTaxRate" xlink:href="athe-20250630.xsd#athe_TaxRateEffectFromChangesInTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_TaxRateEffectFromChangesInTaxRate_lbl" xml:lang="en-US">Tax rate change tax rate, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TaxRateEffectFromChangesInTaxRate" xlink:to="athe_TaxRateEffectFromChangesInTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_EligibleAmountUnderTheTaxIncentiveScheme" xlink:href="athe-20250630.xsd#athe_EligibleAmountUnderTheTaxIncentiveScheme"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_EligibleAmountUnderTheTaxIncentiveScheme_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_EligibleAmountUnderTheTaxIncentiveScheme" xlink:to="athe_EligibleAmountUnderTheTaxIncentiveScheme_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ProfitLossBeforeTax1" xlink:href="athe-20250630.xsd#athe_ProfitLossBeforeTax1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ProfitLossBeforeTax1_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ProfitLossBeforeTax1" xlink:to="athe_ProfitLossBeforeTax1_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ProfitLossBeforeTax2" xlink:href="athe-20250630.xsd#athe_ProfitLossBeforeTax2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ProfitLossBeforeTax2_lbl" xml:lang="en-US">Operating cash outflow</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ProfitLossBeforeTax2" xlink:to="athe_ProfitLossBeforeTax2_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_EstimatedUsefulEconomicLife" xlink:href="athe-20250630.xsd#athe_EstimatedUsefulEconomicLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_EstimatedUsefulEconomicLife_lbl" xml:lang="en-US">Estimated useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_EstimatedUsefulEconomicLife" xlink:to="athe_EstimatedUsefulEconomicLife_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_Employeesdescription" xlink:href="athe-20250630.xsd#athe_Employeesdescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_Employeesdescription_lbl" xml:lang="en-US">Employees,description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_Employeesdescription" xlink:to="athe_Employeesdescription_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxRateEffectFromChangeInTaxRate_lbl" xml:lang="en-US">Refundable tax offset rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:to="ifrs-full_TaxRateEffectFromChangeInTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_TurnoverRevenue" xlink:href="athe-20250630.xsd#athe_TurnoverRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_TurnoverRevenue_lbl" xml:lang="en-US">Annual aggregate turnover</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TurnoverRevenue" xlink:to="athe_TurnoverRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_EligibleAmountUnderTaxIncentiveScheme" xlink:href="athe-20250630.xsd#athe_EligibleAmountUnderTaxIncentiveScheme"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_EligibleAmountUnderTaxIncentiveScheme_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_EligibleAmountUnderTaxIncentiveScheme" xlink:to="athe_EligibleAmountUnderTaxIncentiveScheme_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_MiscellaneousIncomeDisputeWithCatalent" xlink:href="athe-20250630.xsd#athe_MiscellaneousIncomeDisputeWithCatalent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_MiscellaneousIncomeDisputeWithCatalent_lbl" xml:lang="en-US">Miscellaneous income, dispute with catalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_MiscellaneousIncomeDisputeWithCatalent" xlink:to="athe_MiscellaneousIncomeDisputeWithCatalent_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim" xlink:href="athe-20250630.xsd#athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim_lbl" xml:lang="en-US">Miscellaneous income, settlement of an insurance claim</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim" xlink:to="athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense_lbl" xml:lang="en-US">Potential tax benefit amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense_lbl" xml:lang="en-US">Non-refundable tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_TermDeposit" xlink:href="athe-20250630.xsd#athe_TermDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_TermDeposit_lbl" xml:lang="en-US">Term deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TermDeposit" xlink:to="athe_TermDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_MaturityDate" xlink:href="athe-20250630.xsd#athe_MaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_MaturityDate_lbl" xml:lang="en-US">Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_MaturityDate" xlink:to="athe_MaturityDate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="athe_MaturityDate_lbl0" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_MaturityDate" xlink:to="athe_MaturityDate_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalCommitments_lbl" xml:lang="en-US">Commitments for a capital raising</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalCommitments" xlink:to="ifrs-full_CapitalCommitments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalOrdinaryShares" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US">Ordinary shares per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl0" xml:lang="en-US">Price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_ordinarySharesPerShareCents" xlink:href="athe-20250630.xsd#athe_ordinarySharesPerShareCents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ordinarySharesPerShareCents_lbl" xml:lang="en-US">Ordinary shares per share cents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ordinarySharesPerShareCents" xlink:to="athe_ordinarySharesPerShareCents_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ExpiredTerm" xlink:href="athe-20250630.xsd#athe_ExpiredTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ExpiredTerm_lbl" xml:lang="en-US">Expired term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ExpiredTerm" xlink:to="athe_ExpiredTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ReserveOfOrdinaryShares" xlink:href="athe-20250630.xsd#athe_ReserveOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ReserveOfOrdinaryShares_lbl" xml:lang="en-US">Reserve of ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReserveOfOrdinaryShares" xlink:to="athe_ReserveOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xml:lang="en-US">Additions to the right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xml:lang="en-US">Total cash outflow for leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ShortTermLeaseTerm" xlink:href="athe-20250630.xsd#athe_ShortTermLeaseTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ShortTermLeaseTerm_lbl" xml:lang="en-US">Short term lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShortTermLeaseTerm" xlink:to="athe_ShortTermLeaseTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_TerminationNoticePeriodForResearchAndDevelopmentContracts" xlink:href="athe-20250630.xsd#athe_TerminationNoticePeriodForResearchAndDevelopmentContracts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_TerminationNoticePeriodForResearchAndDevelopmentContracts_lbl" xml:lang="en-US">Termination notice period for research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TerminationNoticePeriodForResearchAndDevelopmentContracts" xlink:to="athe_TerminationNoticePeriodForResearchAndDevelopmentContracts_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ResearchAndDevelopmentTerminationCommitments" xlink:href="athe-20250630.xsd#athe_ResearchAndDevelopmentTerminationCommitments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ResearchAndDevelopmentTerminationCommitments_lbl" xml:lang="en-US">Research and development termination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ResearchAndDevelopmentTerminationCommitments" xlink:to="athe_ResearchAndDevelopmentTerminationCommitments_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfDirector" xlink:href="athe-20250630.xsd#athe_NumberOfDirector"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_NumberOfDirector_lbl" xml:lang="en-US">Number of director</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfDirector" xlink:to="athe_NumberOfDirector_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfKeyManagementPersonnel" xlink:href="athe-20250630.xsd#athe_NumberOfKeyManagementPersonnel"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_NumberOfKeyManagementPersonnel_lbl" xml:lang="en-US">Key management personnel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfKeyManagementPersonnel" xlink:to="athe_NumberOfKeyManagementPersonnel_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfEmployees_lbl" xml:lang="en-US">Number of employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfEmployees" xlink:to="ifrs-full_NumberOfEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfConsultant" xlink:href="athe-20250630.xsd#athe_NumberOfConsultant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_NumberOfConsultant_lbl" xml:lang="en-US">Number of consultant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfConsultant" xlink:to="athe_NumberOfConsultant_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl" xml:lang="en-US">Number of ordinary shares authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ShareholdersAuthorizedSecurities" xlink:href="athe-20250630.xsd#athe_ShareholdersAuthorizedSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ShareholdersAuthorizedSecurities_lbl" xml:lang="en-US">Shareholders authorized securities (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareholdersAuthorizedSecurities" xlink:to="athe_ShareholdersAuthorizedSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Issued securities value (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl0" xml:lang="en-US">Number of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_PercentageOfDefaultVestingConditionsPerYear" xlink:href="athe-20250630.xsd#athe_PercentageOfDefaultVestingConditionsPerYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_PercentageOfDefaultVestingConditionsPerYear_lbl" xml:lang="en-US">Percentage of default vesting conditions per year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PercentageOfDefaultVestingConditionsPerYear" xlink:to="athe_PercentageOfDefaultVestingConditionsPerYear_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ExercisePriceExpiryTerm" xlink:href="athe-20250630.xsd#athe_ExercisePriceExpiryTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ExercisePriceExpiryTerm_lbl" xml:lang="en-US">Exercise price expiry term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ExercisePriceExpiryTerm" xlink:to="athe_ExercisePriceExpiryTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US">Percentage of ownership interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_NumberOfReportableSegment" xlink:href="athe-20250630.xsd#athe_NumberOfReportableSegment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_NumberOfReportableSegment_lbl" xml:lang="en-US">Reportable segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfReportableSegment" xlink:to="athe_NumberOfReportableSegment_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_AverageAnnualMovementForeignExchangeRate" xlink:href="athe-20250630.xsd#athe_AverageAnnualMovementForeignExchangeRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_AverageAnnualMovementForeignExchangeRate_lbl" xml:lang="en-US">Average annual movement foreign exchange rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AverageAnnualMovementForeignExchangeRate" xlink:to="athe_AverageAnnualMovementForeignExchangeRate_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar" xlink:href="athe-20250630.xsd#athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar_lbl" xml:lang="en-US">Impact of weakened/strengthened of Australian dollar against US Dollar on post-tax loss (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar" xlink:to="athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US">Cash accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_PercentageOfInterestRate" xlink:href="athe-20250630.xsd#athe_PercentageOfInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_PercentageOfInterestRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PercentageOfInterestRate" xlink:to="athe_PercentageOfInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" xlink:href="athe-20250630.xsd#athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" xlink:to="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US">Income Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US">Leases</label>
<!-- [WMV6][jqTXSHDM9aeG6UZUYgzYqi5BhT68+kneViCuiTMMqC4XdO52pehTWf31Aq/0fEQry7JpIjSd5hsRLRN/I2RFq5QzUaOQg7gb/eudg417b+YPSmFhHeQHoQoMMP6ZbLJrkEo5gl+UYY4PH5TInVZRFVzq++Me+IC9OaZyUsLyeufOANYN3exxSJ7KjK5jXLZlN6IWobxaIyxERi2+dTNYSDwfoLItGaTZXhHQpVgeixpowrctWHYO3U4XG1oC7qRiDCBj1McrbOI/A+d/mylSpzg975ieCWHMSDgAOtQd8qZZJXnkKnm4bFdmVW21taG//LWNVXYISUIG/LnI3KF/jYvwy6m5fw5tHgH3HsLRWOuykayW] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Investments and other financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl" xml:lang="en-US">Impairment of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">Intangible Assets - Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US">Foreign Currency Transactions and Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">Employee Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xml:lang="en-US">Provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome" xlink:href="athe-20250630.xsd#athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome" xlink:to="athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl" xml:lang="en-US">Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl" xml:lang="en-US">Goods and Services Tax (&#8220;GST&#8221;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">Trade and Other Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xml:lang="en-US">Share-Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US">Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl" xml:lang="en-US">Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US">Trade and Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock" xlink:href="athe-20250630.xsd#athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock_lbl" xml:lang="en-US">Comparative Figures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock" xlink:to="athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock" xlink:href="athe-20250630.xsd#athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Standards and Interpretations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock" xlink:to="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_AugustThirtyFirstTwoThousandTwentySixMember" xlink:href="athe-20250630.xsd#athe_AugustThirtyFirstTwoThousandTwentySixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_AugustThirtyFirstTwoThousandTwentySixMember_lbl" xml:lang="en-US">August 31 2026 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AugustThirtyFirstTwoThousandTwentySixMember" xlink:to="athe_AugustThirtyFirstTwoThousandTwentySixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_FreeAttachingOptionMember" xlink:href="athe-20250630.xsd#athe_FreeAttachingOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_FreeAttachingOptionMember_lbl" xml:lang="en-US">Free Attaching Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FreeAttachingOptionMember" xlink:to="athe_FreeAttachingOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_EmployeeMember" xlink:href="athe-20250630.xsd#athe_EmployeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_EmployeeMember_lbl" xml:lang="en-US">Employee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_EmployeeMember" xlink:to="athe_EmployeeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_DirectorsMember" xlink:href="athe-20250630.xsd#athe_DirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_DirectorsMember_lbl" xml:lang="en-US">Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DirectorsMember" xlink:to="athe_DirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ConsultantMember" xlink:href="athe-20250630.xsd#athe_ConsultantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ConsultantMember_lbl" xml:lang="en-US">Consultant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ConsultantMember" xlink:to="athe_ConsultantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_LongDatedOptionsMember" xlink:href="athe-20250630.xsd#athe_LongDatedOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_LongDatedOptionsMember_lbl" xml:lang="en-US">Long Dated Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_LongDatedOptionsMember" xlink:to="athe_LongDatedOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ChiefExecutiveOfficersMember" xlink:href="athe-20250630.xsd#athe_ChiefExecutiveOfficersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ChiefExecutiveOfficersMember_lbl" xml:lang="en-US">Chief Executive Office [Memebr]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ChiefExecutiveOfficersMember" xlink:to="athe_ChiefExecutiveOfficersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ShortDatedOptionsMember" xlink:href="athe-20250630.xsd#athe_ShortDatedOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ShortDatedOptionsMember_lbl" xml:lang="en-US">Short Dated Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShortDatedOptionsMember" xlink:to="athe_ShortDatedOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ShortFreeAttachingOptionsMember" xlink:href="athe-20250630.xsd#athe_ShortFreeAttachingOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ShortFreeAttachingOptionsMember_lbl" xml:lang="en-US">Short Free Attaching Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShortFreeAttachingOptionsMember" xlink:to="athe_ShortFreeAttachingOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_AdsPlanTwoThousandEighteenMember" xlink:href="athe-20250630.xsd#athe_AdsPlanTwoThousandEighteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_AdsPlanTwoThousandEighteenMember_lbl" xml:lang="en-US">Ads Plan 2018 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AdsPlanTwoThousandEighteenMember" xlink:to="athe_AdsPlanTwoThousandEighteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_NonExecutiveDirectorsMember" xlink:href="athe-20250630.xsd#athe_NonExecutiveDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_NonExecutiveDirectorsMember_lbl" xml:lang="en-US">Non-Executive Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NonExecutiveDirectorsMember" xlink:to="athe_NonExecutiveDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_SubsequentsEventMember" xlink:href="athe-20250630.xsd#athe_SubsequentsEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_SubsequentsEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SubsequentsEventMember" xlink:to="athe_SubsequentsEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ASXEmployeeSharePlanMember" xlink:href="athe-20250630.xsd#athe_ASXEmployeeSharePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ASXEmployeeSharePlanMember_lbl" xml:lang="en-US">ASX Employee Share Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ASXEmployeeSharePlanMember" xlink:to="athe_ASXEmployeeSharePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_SubsequentEventsMember" xlink:href="athe-20250630.xsd#athe_SubsequentEventsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_SubsequentEventsMember_lbl" xml:lang="en-US">Subsequent Events [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SubsequentEventsMember" xlink:to="athe_SubsequentEventsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ADSEmployeeSharePlanMember" xlink:href="athe-20250630.xsd#athe_ADSEmployeeSharePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ADSEmployeeSharePlanMember_lbl" xml:lang="en-US">ADS Employee Share Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ADSEmployeeSharePlanMember" xlink:to="athe_ADSEmployeeSharePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ForeignCurrencyRiskMember" xlink:href="athe-20250630.xsd#athe_ForeignCurrencyRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_ForeignCurrencyRiskMember_lbl" xml:lang="en-US">Foreign Currency Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ForeignCurrencyRiskMember" xlink:to="athe_ForeignCurrencyRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRateOf000OnePercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000OnePercentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_InterestRateOf000OnePercentMember_lbl" xml:lang="en-US">Interest Rate Of 0.00 One Percent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf000OnePercentMember" xlink:to="athe_InterestRateOf000OnePercentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRateOf000PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000PercentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_InterestRateOf000PercentMember_lbl" xml:lang="en-US">Interest Rate Of 0.00 Percent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf000PercentMember" xlink:to="athe_InterestRateOf000PercentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="athe_InterestRateOf000PercentMember_lbl0" xml:lang="en-US">Interest Rate of 0.05 Percent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf000PercentMember" xlink:to="athe_InterestRateOf000PercentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRate36PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRate36PercentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_InterestRate36PercentMember_lbl" xml:lang="en-US">Interest Rate 3.6 Percent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRate36PercentMember" xlink:to="athe_InterestRate36PercentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRate105PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRate105PercentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_InterestRate105PercentMember_lbl" xml:lang="en-US">Interest Rate 1.05 Percent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRate105PercentMember" xlink:to="athe_InterestRate105PercentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRateOf15To482PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf15To482PercentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_InterestRateOf15To482PercentMember_lbl" xml:lang="en-US">Interest Rate of 1.5 to 4.82 Percent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf15To482PercentMember" xlink:to="athe_InterestRateOf15To482PercentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRateOf000TwoPercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000TwoPercentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_InterestRateOf000TwoPercentMember_lbl" xml:lang="en-US">Interest Rate Of 0.00 Two Percent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf000TwoPercentMember" xlink:to="athe_InterestRateOf000TwoPercentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRateOf000ThreePercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000ThreePercentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_InterestRateOf000ThreePercentMember_lbl" xml:lang="en-US">Interest Rate Of 0.00 Three Percent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf000ThreePercentMember" xlink:to="athe_InterestRateOf000ThreePercentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRateOf000FourPercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000FourPercentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_InterestRateOf000FourPercentMember_lbl" xml:lang="en-US">Interest Rate Of 0.00 Four Percent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf000FourPercentMember" xlink:to="athe_InterestRateOf000FourPercentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRateOf000PercentFiveMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000PercentFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_InterestRateOf000PercentFiveMember_lbl" xml:lang="en-US">Interest Rate of 0.00 Percent Five [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf000PercentFiveMember" xlink:to="athe_InterestRateOf000PercentFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRateOf27Member" xlink:href="athe-20250630.xsd#athe_InterestRateOf27Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_InterestRateOf27Member_lbl" xml:lang="en-US">Interest rate of 2.7% [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf27Member" xlink:to="athe_InterestRateOf27Member_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRate144PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRate144PercentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_InterestRate144PercentMember_lbl" xml:lang="en-US">Interest Rate 1.44 Percent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRate144PercentMember" xlink:to="athe_InterestRate144PercentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRate385PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRate385PercentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_InterestRate385PercentMember_lbl" xml:lang="en-US">Interest Rate 3.85 Percent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRate385PercentMember" xlink:to="athe_InterestRate385PercentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_InterestRate385OnePercentMember" xlink:href="athe-20250630.xsd#athe_InterestRate385OnePercentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_InterestRate385OnePercentMember_lbl" xml:lang="en-US">Interest Rate 3.85 One Percent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRate385OnePercentMember" xlink:to="athe_InterestRate385OnePercentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityDomain_lbl" xml:lang="en-US">Components of equity [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ComponentsOfEquityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_StatementsTable" xlink:href="athe-20250630.xsd#athe_StatementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="athe_StatementsTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_StatementsTable" xlink:to="athe_StatementsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_StatementsLineItems" xlink:href="athe-20250630.xsd#athe_StatementsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_StatementsLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_StatementsLineItems" xlink:to="athe_StatementsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_lbl" xml:lang="en-US">Classes of property, plant and equipment [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_RangesDomainDomain" xlink:href="athe-20250630.xsd#athe_RangesDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_RangesDomainDomain_lbl" xml:lang="en-US">RangesDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_RangesDomainDomain" xlink:to="athe_RangesDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:href="athe-20250630.xsd#athe_BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable_lbl" xml:lang="en-US">Background and Summary of Material Accounting Policies - Schedule of Estimated Useful Lives (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:to="athe_BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain_lbl" xml:lang="en-US">Classes of other provisions [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="ifrs-full_ClassesOfOtherProvisionsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ProvisionsScheduleofProvisionsDetailsTable" xlink:href="athe-20250630.xsd#athe_ProvisionsScheduleofProvisionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ProvisionsScheduleofProvisionsDetailsTable_lbl" xml:lang="en-US">Provisions - Schedule of Provisions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ProvisionsScheduleofProvisionsDetailsTable" xlink:to="athe_ProvisionsScheduleofProvisionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherProvisionsLineItems_lbl" xml:lang="en-US">Disclosure of other provisions [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_DisclosureOfOtherProvisionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ProvisionsScheduleofMovementsinProvisionsDetailsTable" xlink:href="athe-20250630.xsd#athe_ProvisionsScheduleofMovementsinProvisionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ProvisionsScheduleofMovementsinProvisionsDetailsTable_lbl" xml:lang="en-US">Provisions - Schedule of Movements in Provisions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ProvisionsScheduleofMovementsinProvisionsDetailsTable" xlink:to="athe_ProvisionsScheduleofMovementsinProvisionsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherProvisionsLineItems_lbl0" xml:lang="en-US">Movements in Provisions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_DisclosureOfOtherProvisionsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_lbl" xml:lang="en-US">Classes of share capital [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_IssuedCapitalScheduleofIssuedCapitalDetailsTable" xlink:href="athe-20250630.xsd#athe_IssuedCapitalScheduleofIssuedCapitalDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_IssuedCapitalScheduleofIssuedCapitalDetailsTable_lbl" xml:lang="en-US">Issued Capital - Schedule of Issued Capital (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IssuedCapitalScheduleofIssuedCapitalDetailsTable" xlink:to="athe_IssuedCapitalScheduleofIssuedCapitalDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfIssuedCapitalLineItems" xlink:href="athe-20250630.xsd#athe_ScheduleOfIssuedCapitalLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfIssuedCapitalLineItems_lbl" xml:lang="en-US">Schedule of Issued Capital [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfIssuedCapitalLineItems" xlink:to="athe_ScheduleOfIssuedCapitalLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable" xlink:href="athe-20250630.xsd#athe_IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable_lbl" xml:lang="en-US">Issued Capital - Schedule of Issued Capital (Parentheticals) (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable" xlink:to="athe_IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable" xlink:href="athe-20250630.xsd#athe_IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable_lbl" xml:lang="en-US">Issued Capital - Schedule of Movements in Issued Shares (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable" xlink:to="athe_IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US">Schedule of Movements in Issued Shares [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ShareIssuanceDateDomainDomain" xlink:href="athe-20250630.xsd#athe_ShareIssuanceDateDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ShareIssuanceDateDomainDomain_lbl" xml:lang="en-US">ShareIssuanceDateDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareIssuanceDateDomainDomain" xlink:to="athe_ShareIssuanceDateDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_IssuedCapitalScheduleofShareIssuancesDetailsTable" xlink:href="athe-20250630.xsd#athe_IssuedCapitalScheduleofShareIssuancesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_IssuedCapitalScheduleofShareIssuancesDetailsTable_lbl" xml:lang="en-US">Issued Capital - Schedule of Share Issuances (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IssuedCapitalScheduleofShareIssuancesDetailsTable" xlink:to="athe_IssuedCapitalScheduleofShareIssuancesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfShareIssuancesLineItems" xlink:href="athe-20250630.xsd#athe_ScheduleOfShareIssuancesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfShareIssuancesLineItems_lbl" xml:lang="en-US">Schedule of Share Issuances [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfShareIssuancesLineItems" xlink:to="athe_ScheduleOfShareIssuancesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReservesWithinEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReservesWithinEquityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReservesWithinEquityDomain_lbl" xml:lang="en-US">Reserves within equity [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReservesWithinEquityDomain" xlink:to="ifrs-full_ReservesWithinEquityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ReservesScheduleofReservesofShareBasedPaymentsDetailsTable" xlink:href="athe-20250630.xsd#athe_ReservesScheduleofReservesofShareBasedPaymentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ReservesScheduleofReservesofShareBasedPaymentsDetailsTable_lbl" xml:lang="en-US">Reserves - Schedule of Reserves of Share Based Payments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReservesScheduleofReservesofShareBasedPaymentsDetailsTable" xlink:to="athe_ReservesScheduleofReservesofShareBasedPaymentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReservesWithinEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityLineItems_lbl" xml:lang="en-US">Schedule of Reserves of Share Based Payments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_DisclosureOfReservesWithinEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable" xlink:href="athe-20250630.xsd#athe_ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable_lbl" xml:lang="en-US">Reserves - Schedule of Reserves of Share Based Payments (Parentheticals) (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable" xlink:to="athe_ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_lbl" xml:lang="en-US">Types of share-based payment arrangements [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable_lbl" xml:lang="en-US">Share Based Payments - Schedule of Options Granted (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable" xlink:to="athe_ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US">Share Based Payments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_OptionsSeriesDomainDomain" xlink:href="athe-20250630.xsd#athe_OptionsSeriesDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_OptionsSeriesDomainDomain_lbl" xml:lang="en-US">OptionsSeriesDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OptionsSeriesDomainDomain" xlink:to="athe_OptionsSeriesDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable_lbl" xml:lang="en-US">Share Based Payments - Schedule of Options Outstanding (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable" xlink:to="athe_ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfOptionsOutstandingLineItems" xlink:href="athe-20250630.xsd#athe_ScheduleOfOptionsOutstandingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfOptionsOutstandingLineItems_lbl" xml:lang="en-US">Schedule of Options Outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfOptionsOutstandingLineItems" xlink:to="athe_ScheduleOfOptionsOutstandingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable_lbl" xml:lang="en-US">Share Based Payments - Schedule of Valuations of Options Approved and Issued (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable" xlink:to="athe_ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl0" xml:lang="en-US">Schedule of Valuations of Options Approved and Issued [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_PlanDomainDomain" xlink:href="athe-20250630.xsd#athe_PlanDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_PlanDomainDomain_lbl" xml:lang="en-US">PlanDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PlanDomainDomain" xlink:to="athe_PlanDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable_lbl" xml:lang="en-US">Share Based Payments - Schedule of Shares Issued under Stock Option Plan (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable" xlink:to="athe_ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfSharesIssuedUnderStockOptionPlanLineItems" xlink:href="athe-20250630.xsd#athe_ScheduleOfSharesIssuedUnderStockOptionPlanLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfSharesIssuedUnderStockOptionPlanLineItems_lbl" xml:lang="en-US">Schedule of Shares Issued under Stock Option Plan [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfSharesIssuedUnderStockOptionPlanLineItems" xlink:to="athe_ScheduleOfSharesIssuedUnderStockOptionPlanLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain_lbl" xml:lang="en-US">Classes of financial assets [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US">All Currencies [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable_lbl" xml:lang="en-US">Financial Instruments - Schedule of Financial Assets and Liabilities Subject to Foreign Currency Risk (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable" xlink:to="athe_FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl" xml:lang="en-US">Schedule of Financial Assets and Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Classes of financial instruments [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityDomain_lbl" xml:lang="en-US">Maturity [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_MaturityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInterestRatesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfInterestRatesDomain_lbl" xml:lang="en-US">Types of interest rates [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="ifrs-full_TypesOfInterestRatesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable_lbl" xml:lang="en-US">Financial Instruments - Schedule of Interest Rates and the Effective Weighted Average Interest Rate for Classes of Financial Assets and Liabilities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable" xlink:to="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems_lbl" xml:lang="en-US">Financial Instruments - Schedule of Interest Rates and the Effective Weighted Average Interest Rate for Classes of Financial Assets and Liabilities (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems" xlink:to="athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksDomain_lbl" xml:lang="en-US">Types of risks [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_TypesOfRisksDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable_lbl" xml:lang="en-US">Financial Instruments - Schedule of Company&apos;s Liquidity Reserve on the Basis of Expected Cash Flows (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable" xlink:to="athe_FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xml:lang="en-US">Financial Instruments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US">Consolidated Entities [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable" xlink:href="athe-20250630.xsd#athe_BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Background and Summary of Material Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable" xlink:to="athe_BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl" xml:lang="en-US">Background and Summary of Material Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_IncomeTaxDetailsTable" xlink:href="athe-20250630.xsd#athe_IncomeTaxDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_IncomeTaxDetailsTable_lbl" xml:lang="en-US">Income Tax (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncomeTaxDetailsTable" xlink:to="athe_IncomeTaxDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_IncomeTaxLineItems" xlink:href="athe-20250630.xsd#athe_IncomeTaxLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_IncomeTaxLineItems_lbl" xml:lang="en-US">Income Tax [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncomeTaxLineItems" xlink:to="athe_IncomeTaxLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_lbl" xml:lang="en-US">Types of antidilutive instruments [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_lbl" xml:lang="en-US">Categories of related parties [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitPlansDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DefinedBenefitPlansDomain_lbl" xml:lang="en-US">Defined benefit plans [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefinedBenefitPlansDomain" xlink:to="ifrs-full_DefinedBenefitPlansDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_lbl" xml:lang="en-US">Non-adjusting events after reporting period [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember_lbl" xml:lang="en-US">Default financial statements date [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ReservesDetailsTable" xlink:href="athe-20250630.xsd#athe_ReservesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ReservesDetailsTable_lbl" xml:lang="en-US">Reserves (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReservesDetailsTable" xlink:to="athe_ReservesDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityLineItems_lbl0" xml:lang="en-US">Reserves [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_DisclosureOfReservesWithinEquityLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_LeasesDetailsTable" xlink:href="athe-20250630.xsd#athe_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_LeasesDetailsTable" xlink:to="athe_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_ShareBasedPaymentsDetailsTable" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ShareBasedPaymentsDetailsTable_lbl" xml:lang="en-US">Share Based Payments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareBasedPaymentsDetailsTable" xlink:to="athe_ShareBasedPaymentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_SubsequentEventsDetailsTable" xlink:href="athe-20250630.xsd#athe_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SubsequentEventsDetailsTable" xlink:to="athe_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xml:lang="en-US">Subsequents Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_RelatedPartyTransactionsDetailsTable" xlink:href="athe-20250630.xsd#athe_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_RelatedPartyTransactionsDetailsTable" xlink:to="athe_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US">Disclosure of transactions between related parties [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeDomain_lbl" xml:lang="en-US">Range [domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_RangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="athe_FinancialInstrumentsDetailsTable" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_FinancialInstrumentsDetailsTable_lbl" xml:lang="en-US">Financial Instruments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FinancialInstrumentsDetailsTable" xlink:to="athe_FinancialInstrumentsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_AccruedProfessionalFees_lbl0" xml:lang="en-US">The amount of current accrued professional fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AccruedProfessionalFees" xlink:to="athe_AccruedProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_AccruedResearchAndDevelopmentExpenses_lbl0" xml:lang="en-US">The amount of current accrued research and development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AccruedResearchAndDevelopmentExpenses" xlink:to="athe_AccruedResearchAndDevelopmentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_AccumulatedDeficitDuringDevelopmentStageTextBlock_lbl0" xml:lang="en-US">Accumulated deficit during development stage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AccumulatedDeficitDuringDevelopmentStageTextBlock" xlink:to="athe_AccumulatedDeficitDuringDevelopmentStageTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_AnnualLeaveAndLongServiceLeaveCarryingAmount_lbl0" xml:lang="en-US">Annual leave and long service leave carrying amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AnnualLeaveAndLongServiceLeaveCarryingAmount" xlink:to="athe_AnnualLeaveAndLongServiceLeaveCarryingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_AuditInternalControlAndOtherAssuranceExpenses_lbl0" xml:lang="en-US">Represents the amount of expenses related to audit internal control and other assurance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AuditInternalControlAndOtherAssuranceExpenses" xlink:to="athe_AuditInternalControlAndOtherAssuranceExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_AverageAnnualMovementForeignExchangeRate_lbl0" xml:lang="en-US">Represents the average annual movement foreign exchange rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AverageAnnualMovementForeignExchangeRate" xlink:to="athe_AverageAnnualMovementForeignExchangeRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_AverageInterestRate_lbl0" xml:lang="en-US">Percentage of average interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AverageInterestRate" xlink:to="athe_AverageInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ConsultantAndDirectorExpenses_lbl0" xml:lang="en-US">Amount of consultant and director expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ConsultantAndDirectorExpenses" xlink:to="athe_ConsultantAndDirectorExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_CorporateAdvisoryExpenses_lbl0" xml:lang="en-US">Corporate advisory expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_CorporateAdvisoryExpenses" xlink:to="athe_CorporateAdvisoryExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_CorporateComplianceExpenses_lbl0" xml:lang="en-US">Represents the amount of corporate compliance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_CorporateComplianceExpenses" xlink:to="athe_CorporateComplianceExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for basis used for consolidation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" xlink:to="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for comparative figure.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock" xlink:to="athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for new accounting standards and interpretations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock" xlink:to="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome_lbl0" xml:lang="en-US">The description of the entity&apos;s accounting policy for recognizing other income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome" xlink:to="athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases_lbl0" xml:lang="en-US">Schedule of amounts recognized in profit or loss relating leases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases" xlink:to="athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure for income taxes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock" xlink:to="athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of information about key management personnel.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" xlink:to="athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of movements in each class of provision.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock" xlink:to="athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_DisclosureOfParentEntityFinancialStatementsExplanatory_lbl0" xml:lang="en-US">The entire disclosure of parent entity financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfParentEntityFinancialStatementsExplanatory" xlink:to="athe_DisclosureOfParentEntityFinancialStatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_DisclosureOfTradeAndOtherReceivableTableTextBlock_lbl0" xml:lang="en-US">Schedule of trade and other receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfTradeAndOtherReceivableTableTextBlock" xlink:to="athe_DisclosureOfTradeAndOtherReceivableTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_EligibleAmountUnderTaxIncentiveScheme_lbl0" xml:lang="en-US">Represents the amount of expenditure eligible for offset under the tax incentive scheme.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_EligibleAmountUnderTaxIncentiveScheme" xlink:to="athe_EligibleAmountUnderTaxIncentiveScheme_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_EligibleAmountUnderTheTaxIncentiveScheme_lbl0" xml:lang="en-US">Eligible amount under the tax incentive scheme.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_EligibleAmountUnderTheTaxIncentiveScheme" xlink:to="athe_EligibleAmountUnderTheTaxIncentiveScheme_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_Employeesdescription_lbl0" xml:lang="en-US">Employees, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_Employeesdescription" xlink:to="athe_Employeesdescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_EstimatedUsefulEconomicLife_lbl0" xml:lang="en-US">Estimated useful economic life.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_EstimatedUsefulEconomicLife" xlink:to="athe_EstimatedUsefulEconomicLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ExercisePriceExpiryTerm_lbl0" xml:lang="en-US">Exercise price expiry term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ExercisePriceExpiryTerm" xlink:to="athe_ExercisePriceExpiryTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ExercisePriceOfOutstandingShareOption1_lbl0" xml:lang="en-US">Exercise Price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ExercisePriceOfOutstandingShareOption1" xlink:to="athe_ExercisePriceOfOutstandingShareOption1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ExpensesRelatingToShorttermLeases_lbl0" xml:lang="en-US">Expenses relating to short-term leases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ExpensesRelatingToShorttermLeases" xlink:to="athe_ExpensesRelatingToShorttermLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ExpiredTerm_lbl0" xml:lang="en-US">Expired term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ExpiredTerm" xlink:to="athe_ExpiredTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ExpiryDateOfOutstandingShareOptions_lbl0" xml:lang="en-US">Represents expiry date of options oust standing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ExpiryDateOfOutstandingShareOptions" xlink:to="athe_ExpiryDateOfOutstandingShareOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_FairValuePerOptions_lbl0" xml:lang="en-US">Fair value per option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FairValuePerOptions" xlink:to="athe_FairValuePerOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_FinancialInstrumentsTotalExposure_lbl0" xml:lang="en-US">The financial instruments total exposure.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FinancialInstrumentsTotalExposure" xlink:to="athe_FinancialInstrumentsTotalExposure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_FixedAssetWriteOff_lbl0" xml:lang="en-US">The amount of fixed asset write off.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FixedAssetWriteOff" xlink:to="athe_FixedAssetWriteOff_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ForeignExchangegainLoss_lbl0" xml:lang="en-US">The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ForeignExchangegainLoss" xlink:to="athe_ForeignExchangegainLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ForfeitedOptionsFromReserves_lbl0" xml:lang="en-US">Forfeited options from reserves.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ForfeitedOptionsFromReserves" xlink:to="athe_ForfeitedOptionsFromReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ForfeitedOptionsReversedToProfitOrLoss_lbl0" xml:lang="en-US">Forfeited options reversed to profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ForfeitedOptionsReversedToProfitOrLoss" xlink:to="athe_ForfeitedOptionsReversedToProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_FreeattachingOptionsForFullyPaidOrdinaryShares_lbl0" xml:lang="en-US">Free-attaching options for fully paid ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FreeattachingOptionsForFullyPaidOrdinaryShares" xlink:to="athe_FreeattachingOptionsForFullyPaidOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_IncreaseDecreaseInNumberOfShareOutstanding_lbl1" xml:lang="en-US">Increase decrease in number of share outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncreaseDecreaseInNumberOfShareOutstanding" xlink:to="athe_IncreaseDecreaseInNumberOfShareOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_IncreaseDecreaseInTradeAndOtherReceivables_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncreaseDecreaseInTradeAndOtherReceivables" xlink:to="athe_IncreaseDecreaseInTradeAndOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants_lbl0" xml:lang="en-US">Represents the increase in equity through the issue of options to consultants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants" xlink:to="athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees_lbl0" xml:lang="en-US">Represents the increase in equity through the issue of options to employees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" xlink:to="athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement_lbl0" xml:lang="en-US">Represents the increase (decrease) in equity through options expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" xlink:to="athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_IntellectualPropertyExpenses_lbl0" xml:lang="en-US">Represents the expenses associated to cost and fees of intellectual property.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IntellectualPropertyExpenses" xlink:to="athe_IntellectualPropertyExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars_lbl0" xml:lang="en-US">Issuance of shares in connection with exercise of options, net of costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" xlink:to="athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_IssuanceOfSharesNetOfCostsShares_lbl0" xml:lang="en-US">Issuance of shares net of costs, shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IssuanceOfSharesNetOfCostsShares" xlink:to="athe_IssuanceOfSharesNetOfCostsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_IssuanceOfSharesNetOfCostsValue_lbl0" xml:lang="en-US">Issuance of shares net of costs value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IssuanceOfSharesNetOfCostsValue" xlink:to="athe_IssuanceOfSharesNetOfCostsValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_IssuedCapitalPreferenceShare_lbl0" xml:lang="en-US">Issued capital preference shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IssuedCapitalPreferenceShare" xlink:to="athe_IssuedCapitalPreferenceShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_KeyManagementPersonnelCompensationLongtermBenefits_lbl0" xml:lang="en-US">The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_KeyManagementPersonnelCompensationLongtermBenefits" xlink:to="athe_KeyManagementPersonnelCompensationLongtermBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_MaturityDate_lbl1" xml:lang="en-US">Maturity date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_MaturityDate" xlink:to="athe_MaturityDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_MiscellaneousIncomeDisputeWithCatalent_lbl0" xml:lang="en-US">Represents the amount of miscellaneous income, dispute with catalent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_MiscellaneousIncomeDisputeWithCatalent" xlink:to="athe_MiscellaneousIncomeDisputeWithCatalent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim_lbl0" xml:lang="en-US">Represents the amount of Miscellaneous income, settlement of an insurance claim.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim" xlink:to="athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_MovementDuringTheYearNoOfSharesinShares_lbl0" xml:lang="en-US">Number of shares in movement during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_MovementDuringTheYearNoOfSharesinShares" xlink:to="athe_MovementDuringTheYearNoOfSharesinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_NumberOfConsultant_lbl0" xml:lang="en-US">Represents number of consultant of the entity at a date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfConsultant" xlink:to="athe_NumberOfConsultant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_NumberOfDirector_lbl0" xml:lang="en-US">Represents number of directors of the entity at a date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfDirector" xlink:to="athe_NumberOfDirector_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_NumberOfKeyManagementPersonnel_lbl0" xml:lang="en-US">Represents number of directors by the key management personnel of the entity at a date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfKeyManagementPersonnel" xlink:to="athe_NumberOfKeyManagementPersonnel_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_NumberOfOptionsForfeitedDuringTheYear_lbl0" xml:lang="en-US">Number of options, forfeited during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfOptionsForfeitedDuringTheYear" xlink:to="athe_NumberOfOptionsForfeitedDuringTheYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_NumberOfOptionsOptionsExercisedDuringTheYear_lbl0" xml:lang="en-US">Number of Options, Options exercised during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfOptionsOptionsExercisedDuringTheYear" xlink:to="athe_NumberOfOptionsOptionsExercisedDuringTheYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_NumberOfOptionsSharesToBeIssued_lbl0" xml:lang="en-US">Number of options shares to be issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfOptionsSharesToBeIssued" xlink:to="athe_NumberOfOptionsSharesToBeIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_NumberOfReportableSegment_lbl0" xml:lang="en-US">Number of reportable segments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfReportableSegment" xlink:to="athe_NumberOfReportableSegment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_NumberOfSharesIssuedDuringTheYear_lbl0" xml:lang="en-US">Number of shares issued during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfSharesIssuedDuringTheYear" xlink:to="athe_NumberOfSharesIssuedDuringTheYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_NumberOfSharesOptionsOutstanding_lbl1" xml:lang="en-US">The number of shares options outstanding in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfSharesOptionsOutstanding" xlink:to="athe_NumberOfSharesOptionsOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_NumberofSharesIssuePricePerShare_lbl0" xml:lang="en-US">Number of shares issued price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberofSharesIssuePricePerShare" xlink:to="athe_NumberofSharesIssuePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_OfficeRentalExpenses_lbl0" xml:lang="en-US">Office rental Expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OfficeRentalExpenses" xlink:to="athe_OfficeRentalExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_OptionsExercisedDuringTheYear_lbl0" xml:lang="en-US">Options exercised during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OptionsExercisedDuringTheYear" xlink:to="athe_OptionsExercisedDuringTheYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_OptionsForFullyPaidOrdinaryShares1_lbl0" xml:lang="en-US">Options for fully paid ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OptionsForFullyPaidOrdinaryShares1" xlink:to="athe_OptionsForFullyPaidOrdinaryShares1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_OtherCurrentAccruedExpenses_lbl0" xml:lang="en-US">The amount of liabilities representing expense that has been earned but is not yet received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OtherCurrentAccruedExpenses" xlink:to="athe_OtherCurrentAccruedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_OtherResearchAndDevelopmentExpenses_lbl0" xml:lang="en-US">Other research and development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OtherResearchAndDevelopmentExpenses" xlink:to="athe_OtherResearchAndDevelopmentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_PaymentsForRentalSecurityDeposits_lbl0" xml:lang="en-US">Payments for rental security deposits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PaymentsForRentalSecurityDeposits" xlink:to="athe_PaymentsForRentalSecurityDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_PercentageOfDefaultVestingConditionsPerYear_lbl0" xml:lang="en-US">This element represents amount of percentage of default vesting conditions per year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PercentageOfDefaultVestingConditionsPerYear" xlink:to="athe_PercentageOfDefaultVestingConditionsPerYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_PercentageOfInterestRate_lbl0" xml:lang="en-US">The percentage of interest rate on assets exposed to interest rate risk.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PercentageOfInterestRate" xlink:to="athe_PercentageOfInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_PrimaFacieTaxOnNetLossBeforeIncomeTax_lbl0" xml:lang="en-US">Prima facie tax on net loss before income tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PrimaFacieTaxOnNetLossBeforeIncomeTax" xlink:to="athe_PrimaFacieTaxOnNetLossBeforeIncomeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax_lbl0" xml:lang="en-US">Prima facie tax on net loss before income tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax" xlink:to="athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ProceedsFromResearchAndDevelopmentTaxRefund_lbl0" xml:lang="en-US">Represent the cash inflow from research and development tax refund.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ProceedsFromResearchAndDevelopmentTaxRefund" xlink:to="athe_ProceedsFromResearchAndDevelopmentTaxRefund_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ProfitLossBeforeTax1_lbl0" xml:lang="en-US">The profit (loss) before tax expense or income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ProfitLossBeforeTax1" xlink:to="athe_ProfitLossBeforeTax1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ProfitLossBeforeTax2_lbl0" xml:lang="en-US">Profit loss before tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ProfitLossBeforeTax2" xlink:to="athe_ProfitLossBeforeTax2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ReclassifyExpiredOptionsFromReservesOne_lbl0" xml:lang="en-US">The amount of Reclassify expired options from reserves.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReclassifyExpiredOptionsFromReservesOne" xlink:to="athe_ReclassifyExpiredOptionsFromReservesOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ReclassifyForfeitedOptionsFromReserves_lbl0" xml:lang="en-US">Reclassify forfeited options from reserves.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReclassifyForfeitedOptionsFromReserves" xlink:to="athe_ReclassifyForfeitedOptionsFromReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ResearchAndDevelopmentTaxIncentive_lbl0" xml:lang="en-US">R&amp;D tax incentive.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ResearchAndDevelopmentTaxIncentive" xlink:to="athe_ResearchAndDevelopmentTaxIncentive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ResearchAndDevelopmentTaxIncentiveReceivable_lbl0" xml:lang="en-US">The amount of research and development tax incentive receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ResearchAndDevelopmentTaxIncentiveReceivable" xlink:to="athe_ResearchAndDevelopmentTaxIncentiveReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ResearchAndDevelopmentTerminationCommitments_lbl0" xml:lang="en-US">Represents the amount of research and development contract termination commitments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ResearchAndDevelopmentTerminationCommitments" xlink:to="athe_ResearchAndDevelopmentTerminationCommitments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ReserveOfOptionsIssuedDuringTheYear_lbl0" xml:lang="en-US">Options issued during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReserveOfOptionsIssuedDuringTheYear" xlink:to="athe_ReserveOfOptionsIssuedDuringTheYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ReserveOfOrdinaryShares_lbl0" xml:lang="en-US">Reserve of ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReserveOfOrdinaryShares" xlink:to="athe_ReserveOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear_lbl0" xml:lang="en-US">Represents amount of option reserves share based payment expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear" xlink:to="athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ReserveOfSharebasedPaymentsForfeitedDuringYear_lbl0" xml:lang="en-US">Amount of Forfeited options reserves during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReserveOfSharebasedPaymentsForfeitedDuringYear" xlink:to="athe_ReserveOfSharebasedPaymentsForfeitedDuringYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_RiskfreeInterestRate_lbl0" xml:lang="en-US">Percentage of risk-free interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_RiskfreeInterestRate" xlink:to="athe_RiskfreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock_lbl0" xml:lang="en-US">Represents tabular disclosure of accumulated deficit during development stage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock" xlink:to="athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock_lbl0" xml:lang="en-US">Schedule of amounts relating to leases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock" xlink:to="athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ScheduleOfAuditorRemunerationTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of auditor&apos;s remuneration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfAuditorRemunerationTableTextBlock" xlink:to="athe_ScheduleOfAuditorRemunerationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of movements in options for fully paid ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock" xlink:to="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ScheduleOfNumberOfSharesIssuedTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of number of shares issued during period under ASX Plan 2004.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfNumberOfSharesIssuedTableTextBlock" xlink:to="athe_ScheduleOfNumberOfSharesIssuedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of options outstanding at the end of the year having expiry dates and exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock" xlink:to="athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock_lbl0" xml:lang="en-US">Represents the tabular disclosure of movements in issued shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock" xlink:to="athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of components of reserve of share based payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock" xlink:to="athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of revenue and other income from continuing operations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock" xlink:to="athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ScheduleOfTradeAndOtherPayableTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure for trade and other payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfTradeAndOtherPayableTableTextBlock" xlink:to="athe_ScheduleOfTradeAndOtherPayableTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock_lbl0" xml:lang="en-US">Represents tabular disclosure of valuation of options approved and issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock" xlink:to="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar_lbl0" xml:lang="en-US">The hypothetical financial impact of percent change of foreign exchange rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar" xlink:to="athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ShareBasedPaymentExpenseForOptionsIssuedI_lbl0" xml:lang="en-US">Share Based Payment expense for options issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareBasedPaymentExpenseForOptionsIssuedI" xlink:to="athe_ShareBasedPaymentExpenseForOptionsIssuedI_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare_lbl0" xml:lang="en-US">Number of Options, Options expired during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare" xlink:to="athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear_lbl0" xml:lang="en-US">Number of Options , Options issued during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear" xlink:to="athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_SharePriceAtGrantDate_lbl0" xml:lang="en-US">Share price at grant date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SharePriceAtGrantDate" xlink:to="athe_SharePriceAtGrantDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ShareholdersAuthorizedSecurities_lbl0" xml:lang="en-US">Number of shareholders authorized securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareholdersAuthorizedSecurities" xlink:to="athe_ShareholdersAuthorizedSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_SharesOfIssuedCapital_lbl0" xml:lang="en-US">Number of shares issued in capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SharesOfIssuedCapital" xlink:to="athe_SharesOfIssuedCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_SharesToBeIssued_lbl0" xml:lang="en-US">Represent the amount of shares to be issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SharesToBeIssued" xlink:to="athe_SharesToBeIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ShortTermLeaseTerm_lbl0" xml:lang="en-US">Short term lease term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShortTermLeaseTerm" xlink:to="athe_ShortTermLeaseTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_TaxEffectOfDeferredTaxAssetNotRecognized_lbl0" xml:lang="en-US">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to deferred tax asset not recognized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TaxEffectOfDeferredTaxAssetNotRecognized" xlink:to="athe_TaxEffectOfDeferredTaxAssetNotRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_TaxEffectOfResearchAndDevelopmentExpenditure_lbl0" xml:lang="en-US">The amount of research and development expenditure.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TaxEffectOfResearchAndDevelopmentExpenditure" xlink:to="athe_TaxEffectOfResearchAndDevelopmentExpenditure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_TaxRateEffectFromChangesInTaxRate_lbl0" xml:lang="en-US">Description of tax rate effect from changes in tax rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TaxRateEffectFromChangesInTaxRate" xlink:to="athe_TaxRateEffectFromChangesInTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_TermDeposit_lbl0" xml:lang="en-US">Term deposit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TermDeposit" xlink:to="athe_TermDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_TerminationNoticePeriodForResearchAndDevelopmentContracts_lbl0" xml:lang="en-US">Represents the termination notice period for research and development contracts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TerminationNoticePeriodForResearchAndDevelopmentContracts" xlink:to="athe_TerminationNoticePeriodForResearchAndDevelopmentContracts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners_lbl0" xml:lang="en-US">Total transactions with owners in their capacity as owners (in Shares).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners" xlink:to="athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_TurnoverRevenue_lbl0" xml:lang="en-US">When ALL data is continuing and no discontinued values are reported, the &apos;continuing operations&apos; dimension tag need NOT be individually applied.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TurnoverRevenue" xlink:to="athe_TurnoverRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments_lbl0" xml:lang="en-US">The interest rate on depreciation for fixed assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments" xlink:to="athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ValueOfIncreaseDecreaseInSharesOutstanding_lbl0" xml:lang="en-US">The increase (decrease) in the value of shares outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ValueOfIncreaseDecreaseInSharesOutstanding" xlink:to="athe_ValueOfIncreaseDecreaseInSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_YearsToExpiry_lbl0" xml:lang="en-US">Years to expiry.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_YearsToExpiry" xlink:to="athe_YearsToExpiry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ordinarySharesPerShareCents_lbl0" xml:lang="en-US">ordinary shares per share cents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ordinarySharesPerShareCents" xlink:to="athe_ordinarySharesPerShareCents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_OptionsSeriesAxis_lbl0" xml:lang="en-US">The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OptionsSeriesAxis" xlink:to="athe_OptionsSeriesAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_PlanAxis_lbl0" xml:lang="en-US">The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PlanAxis" xlink:to="athe_PlanAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_ShareIssuanceDateAxis_lbl0" xml:lang="en-US">The information related to share issuance date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareIssuanceDateAxis" xlink:to="athe_ShareIssuanceDateAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_AnnualLeaveMember_lbl0" xml:lang="en-US">This member stand for annual leave.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AnnualLeaveMember" xlink:to="athe_AnnualLeaveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_AsxPlan2004Member_lbl1" xml:lang="en-US">Represents information regarding Australian plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AsxPlan2004Member" xlink:to="athe_AsxPlan2004Member_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_DirectorsMember_lbl0" xml:lang="en-US">This member stands for directors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DirectorsMember" xlink:to="athe_DirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_LongServiceLeaveMember_lbl0" xml:lang="en-US">This member stand for Long service leave.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_LongServiceLeaveMember" xlink:to="athe_LongServiceLeaveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="athe_PlantAndEquipmentMember_lbl0" xml:lang="en-US">This member stands for a class of property, plant and equipment representing plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PlantAndEquipmentMember" xlink:to="athe_PlantAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl0" xml:lang="en-US">Equity [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl0" xml:lang="en-US">Issued capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentProvisions_lbl0" xml:lang="en-US">Non-current provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentProvisions" xlink:to="ifrs-full_NoncurrentProvisions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ChiefExecutiveOfficersMember_lbl0" xml:lang="en-US">Chief Executive Officers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ChiefExecutiveOfficersMember" xlink:to="athe_ChiefExecutiveOfficersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ATHAAEMember_lbl0" xml:lang="en-US">ATHAAEMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAAEMember" xlink:to="athe_ATHAAEMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_JPY_lbl0" xml:lang="en-US">Japan, Yen</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_JPY" xlink:to="currency_JPY_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfCompanysLiquidityReserveOnTheBasisOfExpectedCashFlowsAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfCompanysLiquidityReserveOnTheBasisOfExpectedCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfCompanysLiquidityReserveOnTheBasisOfExpectedCashFlowsAbstract_lbl" xml:lang="en-US">Schedule Of Companys Liquidity Reserve On The Basis Of Expected Cash Flows Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfCompanysLiquidityReserveOnTheBasisOfExpectedCashFlowsAbstract" xlink:to="athe_ScheduleOfCompanysLiquidityReserveOnTheBasisOfExpectedCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_MiscellaneousIncomeDisputeWithCatalent_lbl1" xml:lang="en-US">Miscellaneous Income Dispute With Catalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_MiscellaneousIncomeDisputeWithCatalent" xlink:to="athe_MiscellaneousIncomeDisputeWithCatalent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FloatingInterestRateMember_lbl0" xml:lang="en-US">Floating interest rate [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FloatingInterestRateMember" xlink:to="ifrs-full_FloatingInterestRateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_DirectorsMember_lbl1" xml:lang="en-US">Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DirectorsMember" xlink:to="athe_DirectorsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AuditorsRemunerationForAuditServices_lbl0" xml:lang="en-US">Auditor&apos;s remuneration for audit services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemunerationForAuditServices" xlink:to="ifrs-full_AuditorsRemunerationForAuditServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPayables_lbl0" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdministrativeExpense_lbl0" xml:lang="en-US">Administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdministrativeExpense" xlink:to="ifrs-full_AdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates_lbl0" xml:lang="en-US">Tax effect of foreign tax rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfForeignTaxRates" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_OptionsMember_lbl0" xml:lang="en-US">Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OptionsMember" xlink:to="athe_OptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_NumberOfConsultant_lbl1" xml:lang="en-US">Number Of Consultant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfConsultant" xlink:to="athe_NumberOfConsultant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ResearchAndDevelopmentTaxIncentive_lbl1" xml:lang="en-US">Research And Development Tax Incentive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ResearchAndDevelopmentTaxIncentive" xlink:to="athe_ResearchAndDevelopmentTaxIncentive_lbl1"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfSharesIssuedUnderStockOptionPlanAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfSharesIssuedUnderStockOptionPlanAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfSharesIssuedUnderStockOptionPlanAbstract_lbl" xml:lang="en-US">Schedule Of Shares Issued Under Stock Option Plan Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfSharesIssuedUnderStockOptionPlanAbstract" xlink:to="athe_ScheduleOfSharesIssuedUnderStockOptionPlanAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_PrimaFacieTaxOnNetLossBeforeIncomeTax_lbl1" xml:lang="en-US">Prima Facie Tax On Net Loss Before Income Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PrimaFacieTaxOnNetLossBeforeIncomeTax" xlink:to="athe_PrimaFacieTaxOnNetLossBeforeIncomeTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_TotalContractedCashFlowsMember_lbl0" xml:lang="en-US">Total Contracted Cash Flows Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TotalContractedCashFlowsMember" xlink:to="athe_TotalContractedCashFlowsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_PlantAndEquipmentMember_lbl1" xml:lang="en-US">Plant And Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PlantAndEquipmentMember" xlink:to="athe_PlantAndEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ShareIssuanceDateAxis_lbl1" xml:lang="en-US">Share Issuance Date Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareIssuanceDateAxis" xlink:to="athe_ShareIssuanceDateAxis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_February172025Member_lbl0" xml:lang="en-US">February172025 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_February172025Member" xlink:to="athe_February172025Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_AverageAnnualMovementForeignExchangeRate_lbl1" xml:lang="en-US">Average Annual Movement Foreign Exchange Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AverageAnnualMovementForeignExchangeRate" xlink:to="athe_AverageAnnualMovementForeignExchangeRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfEstimatedUsefulLivesAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfEstimatedUsefulLivesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfEstimatedUsefulLivesAbstract_lbl" xml:lang="en-US">Schedule Of Estimated Useful Lives Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfEstimatedUsefulLivesAbstract" xlink:to="athe_ScheduleOfEstimatedUsefulLivesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCashPaymentsFromOperatingActivities_lbl0" xml:lang="en-US">Other cash payments from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCashPaymentsFromOperatingActivities" xlink:to="ifrs-full_OtherCashPaymentsFromOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_OptionsForFullyPaidOrdinaryShares1_lbl1" xml:lang="en-US">Options For Fully Paid Ordinary Shares1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OptionsForFullyPaidOrdinaryShares1" xlink:to="athe_OptionsForFullyPaidOrdinaryShares1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl0" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory_lbl0" xml:lang="en-US">Disclosure of risk management strategy related to hedge accounting [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory" xlink:to="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_RangesAxis_lbl0" xml:lang="en-US">Ranges Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_RangesAxis" xlink:to="athe_RangesAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl0" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl1" xml:lang="en-US">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember_lbl0" xml:lang="en-US">Greater Than Towel Months And Less Than Five Years Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember" xlink:to="athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other receivables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentAssets_lbl1" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_IncreaseDecreaseInTradeAndOtherReceivables_lbl1" xml:lang="en-US">Increase Decrease In Trade And Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncreaseDecreaseInTradeAndOtherReceivables" xlink:to="athe_IncreaseDecreaseInTradeAndOtherReceivables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_AIssuedCapitalAbstract_lbl0" xml:lang="en-US">AIssued Capital Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AIssuedCapitalAbstract" xlink:to="athe_AIssuedCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_OtherGainsAndLossesAbstract_lbl0" xml:lang="en-US">Other Gains And Losses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OtherGainsAndLossesAbstract" xlink:to="athe_OtherGainsAndLossesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl0" xml:lang="en-US">Key management personnel compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfProvisionsAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfProvisionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfProvisionsAbstract_lbl" xml:lang="en-US">Schedule Of Provisions Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfProvisionsAbstract" xlink:to="athe_ScheduleOfProvisionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayables_lbl0" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl1" xml:lang="en-US">Trade and other current receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ChangesInEquityAbstract_lbl0" xml:lang="en-US">Changes in equity [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ChangesInEquityAbstract" xlink:to="ifrs-full_ChangesInEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashEquivalents_lbl0" xml:lang="en-US">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashEquivalents" xlink:to="ifrs-full_CashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_InterestRateOf000PercentFiveMember_lbl0" xml:lang="en-US">Interest Rate Of000 Percent Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf000PercentFiveMember" xlink:to="athe_InterestRateOf000PercentFiveMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfOptionsOutstandingAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfOptionsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfOptionsOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Options Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfOptionsOutstandingAbstract" xlink:to="athe_ScheduleOfOptionsOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOnHand_lbl0" xml:lang="en-US">Cash on hand</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOnHand" xlink:to="ifrs-full_CashOnHand_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments_lbl1" xml:lang="en-US">Useful Lives Or Depreciation Rate Property Plant And Equipments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments" xlink:to="athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0" xml:lang="en-US">Disclosure of earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Provisions_lbl1" xml:lang="en-US">Provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Provisions" xlink:to="ifrs-full_Provisions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl0" xml:lang="en-US">Description of accounting policy for determining components of cash and cash equivalents [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl0" xml:lang="en-US">Employee benefits expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_FairValuePerOptions_lbl1" xml:lang="en-US">Fair Value Per Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FairValuePerOptions" xlink:to="athe_FairValuePerOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_TradeAndOtherPayablesMember_lbl1" xml:lang="en-US">Trade And Other Payables Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TradeAndOtherPayablesMember" xlink:to="athe_TradeAndOtherPayablesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_LongDatedOptionsMember_lbl0" xml:lang="en-US">Long Dated Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_LongDatedOptionsMember" xlink:to="athe_LongDatedOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants_lbl1" xml:lang="en-US">Increase Decrease Through Issuance Of Options To Consultants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants" xlink:to="athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl0" xml:lang="en-US">Disclosure of expenses by nature [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_TradeAndOtherReceivablesMember_lbl0" xml:lang="en-US">Trade And Other Receivables Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TradeAndOtherReceivablesMember" xlink:to="athe_TradeAndOtherReceivablesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxAssets_lbl0" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssets" xlink:to="ifrs-full_DeferredTaxAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of entity&apos;s operating segments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl0" xml:lang="en-US">Foreign exchange gain (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome_lbl1" xml:lang="en-US">Description Of Accounting Policy For Recognition Of Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome" xlink:to="athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_YearsToExpiry_lbl1" xml:lang="en-US">Years To Expiry</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_YearsToExpiry" xlink:to="athe_YearsToExpiry_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for segment reporting [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl0" xml:lang="en-US">Miscellaneous other operating income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0" xml:lang="en-US">Expected dividend as percentage, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ExpiredTerm_lbl1" xml:lang="en-US">Expired Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ExpiredTerm" xlink:to="athe_ExpiredTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_InterestRate385PercentMember_lbl0" xml:lang="en-US">Interest Rate385 Percent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRate385PercentMember" xlink:to="athe_InterestRate385PercentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl0" xml:lang="en-US">Other comprehensive income [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl1" xml:lang="en-US">Depreciation, right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl0" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl0" xml:lang="en-US">Increase (decrease) in number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ADSEmployeeSharePlanMember_lbl0" xml:lang="en-US">ADSEmployee Share Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ADSEmployeeSharePlanMember" xlink:to="athe_ADSEmployeeSharePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl1" xml:lang="en-US">Current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_TaxRateEffectFromChangesInTaxRate_lbl1" xml:lang="en-US">Tax Rate Effect From Changes In Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TaxRateEffectFromChangesInTaxRate" xlink:to="athe_TaxRateEffectFromChangesInTaxRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_InterestRateOf000ThreePercentMember_lbl0" xml:lang="en-US">Interest Rate Of000 Three Percent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf000ThreePercentMember" xlink:to="athe_InterestRateOf000ThreePercentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ProfitLossBeforeTax2_lbl1" xml:lang="en-US">Profit Loss Before Tax2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ProfitLossBeforeTax2" xlink:to="athe_ProfitLossBeforeTax2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ConsultantMember_lbl0" xml:lang="en-US">Consultant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ConsultantMember" xlink:to="athe_ConsultantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ProfitLossBeforeTax1_lbl1" xml:lang="en-US">Profit Loss Before Tax1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ProfitLossBeforeTax1" xlink:to="athe_ProfitLossBeforeTax1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_InterestRateOf15To482PercentMember_lbl0" xml:lang="en-US">Interest Rate Of15 To482 Percent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf15To482PercentMember" xlink:to="athe_InterestRateOf15To482PercentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl0" xml:lang="en-US">Interest paid, classified as operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForProvisions_lbl0" xml:lang="en-US">Adjustments for provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForProvisions" xlink:to="ifrs-full_AdjustmentsForProvisions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Current trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for impairment of assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_FinancialLiabilitiesAbstract_lbl0" xml:lang="en-US">Financial Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FinancialLiabilitiesAbstract" xlink:to="athe_FinancialLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl0" xml:lang="en-US">Key management personnel compensation, post-employment benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalPreferenceShares_lbl1" xml:lang="en-US">Issued capital, preference shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalPreferenceShares" xlink:to="ifrs-full_IssuedCapitalPreferenceShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_InterestRate105PercentMember_lbl0" xml:lang="en-US">Interest Rate105 Percent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRate105PercentMember" xlink:to="athe_InterestRate105PercentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_IssuanceOfSharesNetOfCostsShares_lbl1" xml:lang="en-US">Issuance Of Shares Net Of Costs Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IssuanceOfSharesNetOfCostsShares" xlink:to="athe_IssuanceOfSharesNetOfCostsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_CashAndCashEquivalentMember_lbl1" xml:lang="en-US">Cash And Cash Equivalent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_CashAndCashEquivalentMember" xlink:to="athe_CashAndCashEquivalentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_SharePriceAtGrantDate_lbl1" xml:lang="en-US">Share Price At Grant Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SharePriceAtGrantDate" xlink:to="athe_SharePriceAtGrantDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_AugustThirtyFirstTwoThousandTwentySixMember_lbl0" xml:lang="en-US">August Thirty First Two Thousand Twenty Six Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AugustThirtyFirstTwoThousandTwentySixMember" xlink:to="athe_AugustThirtyFirstTwoThousandTwentySixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_UnlabeledAbstract3" xlink:to="athe_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_IntellectualPropertyExpenses_lbl1" xml:lang="en-US">Intellectual Property Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IntellectualPropertyExpenses" xlink:to="athe_IntellectualPropertyExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_UnlabeledAbstract2" xlink:to="athe_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_GBP_lbl0" xml:lang="en-US">United Kingdom, Pounds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_GBP" xlink:to="currency_GBP_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Date of grant of share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:to="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_UnlabeledAbstract4" xlink:to="athe_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl0" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_UnlabeledAbstract1" xlink:to="athe_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_UnlabeledAbstract0" xlink:to="athe_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ATHAAHMember_lbl0" xml:lang="en-US">ATHAAHMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAAHMember" xlink:to="athe_ATHAAHMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_InterestRateOf000PercentMember_lbl1" xml:lang="en-US">Interest Rate Of000 Percent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf000PercentMember" xlink:to="athe_InterestRateOf000PercentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Non-current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInterimFinancialReportingExplanatory_lbl0" xml:lang="en-US">Disclosure of information about interim financial reporting [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInterimFinancialReportingExplanatory" xlink:to="ifrs-full_DisclosureOfInterimFinancialReportingExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions_lbl0" xml:lang="en-US">Additional provisions, other provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_RightOfUseAssetsAbstract_lbl0" xml:lang="en-US">Right Of Use Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_RightOfUseAssetsAbstract" xlink:to="athe_RightOfUseAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIncome_lbl2" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_InterestRateOf000FourPercentMember_lbl0" xml:lang="en-US">Interest Rate Of000 Four Percent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf000FourPercentMember" xlink:to="athe_InterestRateOf000FourPercentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ForfeitedOptionsFromReserves_lbl1" xml:lang="en-US">Forfeited Options From Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ForfeitedOptionsFromReserves" xlink:to="athe_ForfeitedOptionsFromReserves_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_OptionsExercisedDuringTheYear_lbl1" xml:lang="en-US">Options Exercised During The Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OptionsExercisedDuringTheYear" xlink:to="athe_OptionsExercisedDuringTheYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl0" xml:lang="en-US">Earnings per share [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim_lbl1" xml:lang="en-US">Miscellaneous Income Settlement Of An Insurance Claim</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim" xlink:to="athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentProvisions_lbl1" xml:lang="en-US">Current provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentProvisions" xlink:to="ifrs-full_CurrentProvisions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_AdsPlanTwoThousandEighteenMember_lbl0" xml:lang="en-US">Ads Plan Two Thousand Eighteen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AdsPlanTwoThousandEighteenMember" xlink:to="athe_AdsPlanTwoThousandEighteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl0" xml:lang="en-US">Number of shares reserved for issue under options and contracts for sale of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_OtherCurrentLiabilitieMember_lbl0" xml:lang="en-US">Other Current Liabilitie Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OtherCurrentLiabilitieMember" xlink:to="athe_OtherCurrentLiabilitieMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfMovementsInIssuedSharesAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfMovementsInIssuedSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfMovementsInIssuedSharesAbstract_lbl" xml:lang="en-US">Schedule Of Movements In Issued Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfMovementsInIssuedSharesAbstract" xlink:to="athe_ScheduleOfMovementsInIssuedSharesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees_lbl0" xml:lang="en-US">Payments to suppliers for goods and services and to and on behalf of employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" xlink:to="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl1" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl1" xml:lang="en-US">Par value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl0" xml:lang="en-US">Non-current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0" xml:lang="en-US">Expected volatility, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ExpiryDateOfOutstandingShareOptions_lbl1" xml:lang="en-US">Expiry Date Of Outstanding Share Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ExpiryDateOfOutstandingShareOptions" xlink:to="athe_ExpiryDateOfOutstandingShareOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_NumberOfKeyManagementPersonnel_lbl1" xml:lang="en-US">Number Of Key Management Personnel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfKeyManagementPersonnel" xlink:to="athe_NumberOfKeyManagementPersonnel_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ReclassifyForfeitedOptionsFromReserves_lbl1" xml:lang="en-US">Reclassify Forfeited Options From Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReclassifyForfeitedOptionsFromReserves" xlink:to="athe_ReclassifyForfeitedOptionsFromReserves_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationExpense_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ATHAAGMember_lbl0" xml:lang="en-US">ATHAAGMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAAGMember" xlink:to="athe_ATHAAGMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl0" xml:lang="en-US">Increase (decrease) through transactions with owners, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl1" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ShortTermLeaseTerm_lbl1" xml:lang="en-US">Short Term Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShortTermLeaseTerm" xlink:to="athe_ShortTermLeaseTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_DisclosureOfParentEntityFinancialStatementsExplanatory_lbl1" xml:lang="en-US">Disclosure Of Parent Entity Financial Statements Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfParentEntityFinancialStatementsExplanatory" xlink:to="athe_DisclosureOfParentEntityFinancialStatementsExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense_lbl0" xml:lang="en-US">Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_Employeesdescription_lbl1" xml:lang="en-US">Employeesdescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_Employeesdescription" xlink:to="athe_Employeesdescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0" xml:lang="en-US">Disclosure of classes of share capital [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_lbl0" xml:lang="en-US">Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:to="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_AnnualLeaveMember_lbl1" xml:lang="en-US">Annual Leave Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AnnualLeaveMember" xlink:to="athe_AnnualLeaveMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense_lbl0" xml:lang="en-US">Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce deferred tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_NumberOfOptionsForfeitedDuringTheYear_lbl1" xml:lang="en-US">Number Of Options Forfeited During The Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfOptionsForfeitedDuringTheYear" xlink:to="athe_NumberOfOptionsForfeitedDuringTheYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAbstract_lbl0" xml:lang="en-US">Revenue [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl1" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_UnlabeledAbstract" xlink:to="athe_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfEmployees_lbl0" xml:lang="en-US">Number of employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfEmployees" xlink:to="ifrs-full_NumberOfEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl1" xml:lang="en-US">Number of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_SubsequentEventsMember_lbl0" xml:lang="en-US">Subsequent Events Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SubsequentEventsMember" xlink:to="athe_SubsequentEventsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets_lbl0" xml:lang="en-US">Current accrued income including current contract assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" xlink:to="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl2" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl1" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl0" xml:lang="en-US">Current tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxLiabilities" xlink:to="ifrs-full_CurrentTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl0" xml:lang="en-US">Adjustments for depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_SubsequentsEventMember_lbl0" xml:lang="en-US">Subsequents Event Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SubsequentsEventMember" xlink:to="athe_SubsequentsEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_TermDeposit_lbl1" xml:lang="en-US">Term Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TermDeposit" xlink:to="athe_TermDeposit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy For New Accounting Standards And Interpretations Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock" xlink:to="athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl0" xml:lang="en-US">Expense from share-based payment transactions with employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_FinancialInstrumentsTotalExposure_lbl1" xml:lang="en-US">Financial Instruments Total Exposure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FinancialInstrumentsTotalExposure" xlink:to="athe_FinancialInstrumentsTotalExposure_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ForfeitedOptionsReversedToProfitOrLoss_lbl1" xml:lang="en-US">Forfeited Options Reversed To Profit Or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ForfeitedOptionsReversedToProfitOrLoss" xlink:to="athe_ForfeitedOptionsReversedToProfitOrLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReservesMember_lbl0" xml:lang="en-US">Other reserves [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReservesMember" xlink:to="ifrs-full_OtherReservesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_January222025Member_lbl0" xml:lang="en-US">January222025 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_January222025Member" xlink:to="athe_January222025Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAndOperatingIncome_lbl0" xml:lang="en-US">Revenue and other operating income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAndOperatingIncome" xlink:to="ifrs-full_RevenueAndOperatingIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_AnnualLeaveAndLongServiceLeaveCarryingAmount_lbl1" xml:lang="en-US">Annual Leave And Long Service Leave Carrying Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AnnualLeaveAndLongServiceLeaveCarryingAmount" xlink:to="athe_AnnualLeaveAndLongServiceLeaveCarryingAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Accumulated Deficit During Development Stage Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock" xlink:to="athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_InterestRateOf000OnePercentMember_lbl0" xml:lang="en-US">Interest Rate Of000 One Percent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf000OnePercentMember" xlink:to="athe_InterestRateOf000OnePercentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestRateRiskMember_lbl2" xml:lang="en-US">Interest rate risk [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRateRiskMember" xlink:to="ifrs-full_InterestRateRiskMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_AverageInterestRate_lbl1" xml:lang="en-US">Average Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AverageInterestRate" xlink:to="athe_AverageInterestRate_lbl1"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract_lbl" xml:lang="en-US">Schedule Of Expenses From Ordinary Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ShortFreeAttachingOptionsMember_lbl0" xml:lang="en-US">Short Free Attaching Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShortFreeAttachingOptionsMember" xlink:to="athe_ShortFreeAttachingOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy For Comparative Figures Explanatory Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock" xlink:to="athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AuditorsRemuneration_lbl0" xml:lang="en-US">Auditor&apos;s remuneration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemuneration" xlink:to="ifrs-full_AuditorsRemuneration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_April42025Member_lbl0" xml:lang="en-US">April42025 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_April42025Member" xlink:to="athe_April42025Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxRateEffectFromChangeInTaxRate_lbl0" xml:lang="en-US">Tax rate effect from change in tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:to="ifrs-full_TaxRateEffectFromChangeInTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar_lbl1" xml:lang="en-US">Sensitivity Analysis Of Post Tax Profit Impact Of Percent Change In Australian Dollar Against Us Dollar</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar" xlink:to="athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_lbl0" xml:lang="en-US">Miscellaneous other operating expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_MovementDuringTheYearNoOfSharesinShares_lbl1" xml:lang="en-US">Movement During The Year No Of Sharesin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_MovementDuringTheYearNoOfSharesinShares" xlink:to="athe_MovementDuringTheYearNoOfSharesinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ExercisePriceOfOutstandingShareOption1_lbl1" xml:lang="en-US">Exercise Price Of Outstanding Share Option1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ExercisePriceOfOutstandingShareOption1" xlink:to="athe_ExercisePriceOfOutstandingShareOption1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl0" xml:lang="en-US">Cash flows from (used in) decrease (increase) in short-term deposits and investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_March142025Member_lbl0" xml:lang="en-US">March142025 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_March142025Member" xlink:to="athe_March142025Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ATHAAMember_lbl0" xml:lang="en-US">ATHAAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAAMember" xlink:to="athe_ATHAAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl1" xml:lang="en-US">Basic earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ResearchAndDevelopmentTaxIncentiveReceivable_lbl1" xml:lang="en-US">Research And Development Tax Incentive Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ResearchAndDevelopmentTaxIncentiveReceivable" xlink:to="athe_ResearchAndDevelopmentTaxIncentiveReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_OptionsSeriesAxis_lbl1" xml:lang="en-US">Options Series Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OptionsSeriesAxis" xlink:to="athe_OptionsSeriesAxis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl1" xml:lang="en-US">Comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl0" xml:lang="en-US">Assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_FixedAssetWriteOff_lbl1" xml:lang="en-US">Fixed Asset Write Off</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FixedAssetWriteOff" xlink:to="athe_FixedAssetWriteOff_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl0" xml:lang="en-US">Later than one year and not later than five years [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_NumberOfSharesOptionsOutstanding_lbl2" xml:lang="en-US">Number Of Shares Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfSharesOptionsOutstanding" xlink:to="athe_NumberOfSharesOptionsOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained earnings [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ATHABMember_lbl0" xml:lang="en-US">ATHABMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHABMember" xlink:to="athe_ATHABMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl1" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_NumberOfOptionsOptionsExercisedDuringTheYear_lbl1" xml:lang="en-US">Number Of Options Options Exercised During The Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfOptionsOptionsExercisedDuringTheYear" xlink:to="athe_NumberOfOptionsOptionsExercisedDuringTheYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_TaxEffectOfResearchAndDevelopmentExpenditure_lbl1" xml:lang="en-US">Tax Effect Of Research And Development Expenditure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TaxEffectOfResearchAndDevelopmentExpenditure" xlink:to="athe_TaxEffectOfResearchAndDevelopmentExpenditure_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of commitments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl3" xml:lang="en-US">Reserve of share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_LongServiceLeaveMember_lbl1" xml:lang="en-US">Long Service Leave Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_LongServiceLeaveMember" xlink:to="athe_LongServiceLeaveMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfExpensesExplanatory_lbl0" xml:lang="en-US">Disclosure of expenses [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ShortDatedOptionsMember_lbl0" xml:lang="en-US">Short Dated Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShortDatedOptionsMember" xlink:to="athe_ShortDatedOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0" xml:lang="en-US">Disclosure of income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ATHACMember_lbl0" xml:lang="en-US">ATHACMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHACMember" xlink:to="athe_ATHACMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars_lbl1" xml:lang="en-US">Issuance Of Shares In Connection With Exercise Of Options Net Of Costsin Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" xlink:to="athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract_lbl1" xml:lang="en-US">Cash and cash equivalents [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ShareholdersAuthorizedSecurities_lbl1" xml:lang="en-US">Shareholders Authorized Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareholdersAuthorizedSecurities" xlink:to="athe_ShareholdersAuthorizedSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_FreeattachingOptionsForFullyPaidOrdinaryShares_lbl1" xml:lang="en-US">Freeattaching Options For Fully Paid Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FreeattachingOptionsForFullyPaidOrdinaryShares" xlink:to="athe_FreeattachingOptionsForFullyPaidOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">Lease liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_InterestRate144PercentMember_lbl0" xml:lang="en-US">Interest Rate144 Percent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRate144PercentMember" xlink:to="athe_InterestRate144PercentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_PlanAxis_lbl1" xml:lang="en-US">Plan Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PlanAxis" xlink:to="athe_PlanAxis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Income Tax Explanatory Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock" xlink:to="athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ValueOfIncreaseDecreaseInSharesOutstanding_lbl1" xml:lang="en-US">Value Of Increase Decrease In Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ValueOfIncreaseDecreaseInSharesOutstanding" xlink:to="athe_ValueOfIncreaseDecreaseInSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ShareBasedPaymentExpenseForOptionsIssuedI_lbl1" xml:lang="en-US">Share Based Payment Expense For Options Issued I</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareBasedPaymentExpenseForOptionsIssuedI" xlink:to="athe_ShareBasedPaymentExpenseForOptionsIssuedI_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl1" xml:lang="en-US">Adjustments for share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl0" xml:lang="en-US">Statement of changes in equity [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of prepayments and other assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfShareIssuancesAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfShareIssuancesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfShareIssuancesAbstract_lbl" xml:lang="en-US">Schedule Of Share Issuances Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfShareIssuancesAbstract" xlink:to="athe_ScheduleOfShareIssuancesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_TaxEffectOfDeferredTaxAssetNotRecognized_lbl1" xml:lang="en-US">Tax Effect Of Deferred Tax Asset Not Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TaxEffectOfDeferredTaxAssetNotRecognized" xlink:to="athe_TaxEffectOfDeferredTaxAssetNotRecognized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl0" xml:lang="en-US">Current tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncome" xlink:to="ifrs-full_CurrentTaxExpenseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_lbl0" xml:lang="en-US">Increase (decrease) through foreign exchange, financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:to="ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl1" xml:lang="en-US">Cash flows from (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_StatementsTable_lbl0" xml:lang="en-US">Statements Table</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_StatementsTable" xlink:to="athe_StatementsTable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl0" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_GeneralAndAdministrationExpensesAbstract_lbl0" xml:lang="en-US">General And Administration Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_GeneralAndAdministrationExpensesAbstract" xlink:to="athe_GeneralAndAdministrationExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for issued capital [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_InterestRate36PercentMember_lbl0" xml:lang="en-US">Interest Rate36 Percent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRate36PercentMember" xlink:to="athe_InterestRate36PercentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_lbl1" xml:lang="en-US">Adjustments for current tax of prior periods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:to="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Reconciliation Of Number Of Shares Outstanding Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock" xlink:to="athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_OtherCurrentAssetMember_lbl1" xml:lang="en-US">Other Current Asset Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OtherCurrentAssetMember" xlink:to="athe_OtherCurrentAssetMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_NonInterestBearingMember_lbl0" xml:lang="en-US">Non Interest Bearing Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NonInterestBearingMember" xlink:to="athe_NonInterestBearingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0" xml:lang="en-US">Disclosure of changes in accounting policies [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for trade and other payables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl0" xml:lang="en-US">Other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfProvisionsExplanatory_lbl0" xml:lang="en-US">Disclosure of provisions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfProvisionsExplanatory" xlink:to="ifrs-full_DisclosureOfProvisionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities_lbl0" xml:lang="en-US">Expense relating to variable lease payments not included in measurement of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:to="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy For Basis Of Consolidation Explanatory Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" xlink:to="athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_IssuanceOfSharesNetOfCostsValue_lbl1" xml:lang="en-US">Issuance Of Shares Net Of Costs Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IssuanceOfSharesNetOfCostsValue" xlink:to="athe_IssuanceOfSharesNetOfCostsValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_lbl0" xml:lang="en-US">Key management personnel compensation, termination benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_MaturityDate_lbl2" xml:lang="en-US">Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_MaturityDate" xlink:to="athe_MaturityDate_lbl2"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedAbstract_lbl" xml:lang="en-US">Schedule Of Valuations Of Options Approved And Issued Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedAbstract" xlink:to="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ProceedsFromResearchAndDevelopmentTaxRefund_lbl1" xml:lang="en-US">Proceeds From Research And Development Tax Refund</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ProceedsFromResearchAndDevelopmentTaxRefund" xlink:to="athe_ProceedsFromResearchAndDevelopmentTaxRefund_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1" xml:lang="en-US">Tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfMovementsInProvisionsAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfMovementsInProvisionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfMovementsInProvisionsAbstract_lbl" xml:lang="en-US">Schedule Of Movements In Provisions Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfMovementsInProvisionsAbstract" xlink:to="athe_ScheduleOfMovementsInProvisionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Movements Of Each Class Of Provision Explanatory Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock" xlink:to="athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_NumberOfSharesIssuedDuringTheYear_lbl1" xml:lang="en-US">Number Of Shares Issued During The Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfSharesIssuedDuringTheYear" xlink:to="athe_NumberOfSharesIssuedDuringTheYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl0" xml:lang="en-US">Not later than one year [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_TurnoverRevenue_lbl1" xml:lang="en-US">Turnover Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TurnoverRevenue" xlink:to="athe_TurnoverRevenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_InterestRate385OnePercentMember_lbl0" xml:lang="en-US">Interest Rate385 One Percent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRate385OnePercentMember" xlink:to="athe_InterestRate385OnePercentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ParentCompanyMember_lbl0" xml:lang="en-US">Parent Company [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl1" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_SharesToBeIssued_lbl1" xml:lang="en-US">Shares To Be Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SharesToBeIssued" xlink:to="athe_SharesToBeIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ATHAAFOneMember_lbl0" xml:lang="en-US">ATHAAFOne Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAAFOneMember" xlink:to="athe_ATHAAFOneMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfCashFlowInformationAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfCashFlowInformationAbstract_lbl" xml:lang="en-US">Schedule Of Cash Flow Information Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfCashFlowInformationAbstract" xlink:to="athe_ScheduleOfCashFlowInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssets_lbl0" xml:lang="en-US">Financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ChangesInAssetsAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Changes In Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ChangesInAssetsAndLiabilitiesAbstract" xlink:to="athe_ChangesInAssetsAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInterestIncomeExplanatory_lbl0" xml:lang="en-US">Disclosure of interest income [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInterestIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfInterestIncomeExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of other assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ReserveOfOrdinaryShares_lbl1" xml:lang="en-US">Reserve Of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReserveOfOrdinaryShares" xlink:to="athe_ReserveOfOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ResearchAndDevelopmentTerminationCommitments_lbl1" xml:lang="en-US">Research And Development Termination Commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ResearchAndDevelopmentTerminationCommitments" xlink:to="athe_ResearchAndDevelopmentTerminationCommitments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl0" xml:lang="en-US">Other tax effects for reconciliation between accounting profit and tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_January82024Member_lbl0" xml:lang="en-US">January82024 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_January82024Member" xlink:to="athe_January82024Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_FreeAttachingOptionMember_lbl0" xml:lang="en-US">Free Attaching Option Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FreeAttachingOptionMember" xlink:to="athe_FreeAttachingOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl1" xml:lang="en-US">Non-current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl0" xml:lang="en-US">Current accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract_lbl" xml:lang="en-US">Schedule Of Interest And Other Income From Continuing Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract" xlink:to="athe_ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ASXEmployeeSharePlanMember_lbl0" xml:lang="en-US">ASXEmployee Share Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ASXEmployeeSharePlanMember" xlink:to="athe_ASXEmployeeSharePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl0" xml:lang="en-US">Other current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_InterestRateOf27Member_lbl0" xml:lang="en-US">Interest Rate Of27 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf27Member" xlink:to="athe_InterestRateOf27Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_NonCurrentAbstract_lbl0" xml:lang="en-US">Non Current Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NonCurrentAbstract" xlink:to="athe_NonCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl0" xml:lang="en-US">Disclosure of leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_PercentageOfInterestRate_lbl1" xml:lang="en-US">Percentage Of Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PercentageOfInterestRate" xlink:to="athe_PercentageOfInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl1" xml:lang="en-US">Trade and other current payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_AuditInternalControlAndOtherAssuranceExpenses_lbl1" xml:lang="en-US">Audit Internal Control And Other Assurance Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AuditInternalControlAndOtherAssuranceExpenses" xlink:to="athe_AuditInternalControlAndOtherAssuranceExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables_lbl0" xml:lang="en-US">Current value added tax receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentValueAddedTaxReceivables" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ReserveOfSharebasedPaymentsForfeitedDuringYear_lbl1" xml:lang="en-US">Reserve Of Sharebased Payments Forfeited During Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReserveOfSharebasedPaymentsForfeitedDuringYear" xlink:to="athe_ReserveOfSharebasedPaymentsForfeitedDuringYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement_lbl1" xml:lang="en-US">Increase Decrease Through Options Expired In Share Based Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" xlink:to="athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl0" xml:lang="en-US">Increase (decrease) in number of ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_lbl0" xml:lang="en-US">Increase (decrease) through transfers and other changes, other provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalCommitments_lbl0" xml:lang="en-US">Capital commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalCommitments" xlink:to="ifrs-full_CapitalCommitments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners_lbl1" xml:lang="en-US">Transactions With Owners In Their Capacity Shares As Owners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners" xlink:to="athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares_lbl0" xml:lang="en-US">Issued capital, ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalOrdinaryShares" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_July182024Member_lbl0" xml:lang="en-US">July182024 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_July182024Member" xlink:to="athe_July182024Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ATHAABOneMember_lbl0" xml:lang="en-US">ATHAABOne Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAABOneMember" xlink:to="athe_ATHAABOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_November292023Member_lbl0" xml:lang="en-US">November292023 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_November292023Member" xlink:to="athe_November292023Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl0" xml:lang="en-US">Disclosure of related party [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ReserveOfOptionsIssuedDuringTheYear_lbl1" xml:lang="en-US">Reserve Of Options Issued During The Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReserveOfOptionsIssuedDuringTheYear" xlink:to="athe_ReserveOfOptionsIssuedDuringTheYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax_lbl1" xml:lang="en-US">Prima Facies Tax On Net Loss Before Income Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax" xlink:to="athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ExercisePriceExpiryTerm_lbl1" xml:lang="en-US">Exercise Price Expiry Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ExercisePriceExpiryTerm" xlink:to="athe_ExercisePriceExpiryTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_OtherCurrentAccruedExpenses_lbl1" xml:lang="en-US">Other Current Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OtherCurrentAccruedExpenses" xlink:to="athe_OtherCurrentAccruedExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_SharesOfIssuedCapital_lbl1" xml:lang="en-US">Shares Of Issued Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SharesOfIssuedCapital" xlink:to="athe_SharesOfIssuedCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_AddTaxEffectOfAbstract_lbl0" xml:lang="en-US">Add Tax Effect Of Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AddTaxEffectOfAbstract" xlink:to="athe_AddTaxEffectOfAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ATHAAFMember_lbl0" xml:lang="en-US">ATHAAFMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAAFMember" xlink:to="athe_ATHAAFMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfNumberOfSharesIssuedTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Number Of Shares Issued Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfNumberOfSharesIssuedTableTextBlock" xlink:to="athe_ScheduleOfNumberOfSharesIssuedTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl1" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Disclosure of financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Amounts Relating To Leases Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock" xlink:to="athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpense_lbl0" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpense" xlink:to="ifrs-full_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl0" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases_lbl1" xml:lang="en-US">Disclosure Of Amounts Recognized In Profit Or Loss Relating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases" xlink:to="athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_EligibleAmountUnderTheTaxIncentiveScheme_lbl1" xml:lang="en-US">Eligible Amount Under The Tax Incentive Scheme</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_EligibleAmountUnderTheTaxIncentiveScheme" xlink:to="athe_EligibleAmountUnderTheTaxIncentiveScheme_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees_lbl1" xml:lang="en-US">Increase Decrease Through Issuance Of Options To Employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" xlink:to="athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherEmployeeExpense_lbl0" xml:lang="en-US">Other employee expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEmployeeExpense" xlink:to="ifrs-full_OtherEmployeeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfInterestRatesAndTheEffectiveWeightedAverageInterestRateForClassesOfFinancialAssetsAndLiabilitiesAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfInterestRatesAndTheEffectiveWeightedAverageInterestRateForClassesOfFinancialAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfInterestRatesAndTheEffectiveWeightedAverageInterestRateForClassesOfFinancialAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Interest Rates And The Effective Weighted Average Interest Rate For Classes Of Financial Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfInterestRatesAndTheEffectiveWeightedAverageInterestRateForClassesOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="athe_ScheduleOfInterestRatesAndTheEffectiveWeightedAverageInterestRateForClassesOfFinancialAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_KeyManagementPersonnelCompensationLongtermBenefits_lbl1" xml:lang="en-US">Key Management Personnel Compensation Longterm Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_KeyManagementPersonnelCompensationLongtermBenefits" xlink:to="athe_KeyManagementPersonnelCompensationLongtermBenefits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_AsxPlan2004Member_lbl2" xml:lang="en-US">Asx Plan2004 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AsxPlan2004Member" xlink:to="athe_AsxPlan2004Member_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_LessThenSixMonthsMember_lbl0" xml:lang="en-US">Less Then Six Months Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_LessThenSixMonthsMember" xlink:to="athe_LessThenSixMonthsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for trade and other receivables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_IssuedCapitalPreferenceShare_lbl1" xml:lang="en-US">Issued Capital Preference Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IssuedCapitalPreferenceShare" xlink:to="athe_IssuedCapitalPreferenceShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl0" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ForeignExchangegainLoss_lbl1" xml:lang="en-US">Foreign Exchangegain Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ForeignExchangegainLoss" xlink:to="athe_ForeignExchangegainLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl1" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_March152023Member_lbl0" xml:lang="en-US">March152023 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_March152023Member" xlink:to="athe_March152023Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare_lbl1" xml:lang="en-US">Share Based Payment Number Of Options Options Expired During The Yearin Dollars Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare" xlink:to="athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_lbl1" xml:lang="en-US">Non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_NumberOfReportableSegment_lbl1" xml:lang="en-US">Number Of Reportable Segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfReportableSegment" xlink:to="athe_NumberOfReportableSegment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherRevenue_lbl0" xml:lang="en-US">Other revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherRevenue" xlink:to="ifrs-full_OtherRevenue_lbl0"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfIndividualFinancialStatementsForTheParentEntityAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfIndividualFinancialStatementsForTheParentEntityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfIndividualFinancialStatementsForTheParentEntityAbstract_lbl" xml:lang="en-US">Schedule Of Individual Financial Statements For The Parent Entity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfIndividualFinancialStatementsForTheParentEntityAbstract" xlink:to="athe_ScheduleOfIndividualFinancialStatementsForTheParentEntityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ATHAADMember_lbl0" xml:lang="en-US">ATHAADMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAADMember" xlink:to="athe_ATHAADMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FixturesAndFittingsMember_lbl0" xml:lang="en-US">Fixtures and fittings [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FixturesAndFittingsMember" xlink:to="ifrs-full_FixturesAndFittingsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl0" xml:lang="en-US">United States of America, Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ConsultantAndDirectorExpenses_lbl1" xml:lang="en-US">Consultant And Director Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ConsultantAndDirectorExpenses" xlink:to="athe_ConsultantAndDirectorExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_InterestRateOf000TwoPercentMember_lbl0" xml:lang="en-US">Interest Rate Of000 Two Percent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_InterestRateOf000TwoPercentMember" xlink:to="athe_InterestRateOf000TwoPercentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_DisclosureOfTradeAndOtherReceivableTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Trade And Other Receivable Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfTradeAndOtherReceivableTableTextBlock" xlink:to="athe_DisclosureOfTradeAndOtherReceivableTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_CurrentAbstract_lbl0" xml:lang="en-US">Current Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_CurrentAbstract" xlink:to="athe_CurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Options Outstanding Expiry Date And Exercise Prices Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock" xlink:to="athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl1" xml:lang="en-US">Lease liabilities [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_PercentageOfDefaultVestingConditionsPerYear_lbl1" xml:lang="en-US">Percentage Of Default Vesting Conditions Per Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PercentageOfDefaultVestingConditionsPerYear" xlink:to="athe_PercentageOfDefaultVestingConditionsPerYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl2" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_FinancialAssetsAbstract0_lbl0" xml:lang="en-US">Financial Assets Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FinancialAssetsAbstract0" xlink:to="athe_FinancialAssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_March42024Member_lbl0" xml:lang="en-US">March42024 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_March42024Member" xlink:to="athe_March42024Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOutflowForLeases_lbl0" xml:lang="en-US">Cash outflow for leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock_lbl1" xml:lang="en-US">Disclosure Of Key Management Personnel Compensation Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" xlink:to="athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl0" xml:lang="en-US">Payments for share issue costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_June302025Member_lbl0" xml:lang="en-US">June302025 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_June302025Member" xlink:to="athe_June302025Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold improvements [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseholdImprovementsMember" xlink:to="ifrs-full_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ATHAABMember_lbl0" xml:lang="en-US">ATHAABMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAABMember" xlink:to="athe_ATHAABMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_EstimatedUsefulEconomicLife_lbl1" xml:lang="en-US">Estimated Useful Economic Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_EstimatedUsefulEconomicLife" xlink:to="athe_EstimatedUsefulEconomicLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_IncreaseDecreaseInNumberOfShareOutstanding_lbl2" xml:lang="en-US">Increase Decrease In Number Of Share Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_IncreaseDecreaseInNumberOfShareOutstanding" xlink:to="athe_IncreaseDecreaseInNumberOfShareOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0" xml:lang="en-US">Proportion of ownership interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl4" xml:lang="en-US">Issued capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl0" xml:lang="en-US">Description of accounting policy for government grants [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIssuedCapitalExplanatory_lbl0" xml:lang="en-US">Disclosure of issued capital [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfIssuedCapitalExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl0" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Movements In Options For Fully Paid Ordinary Shares Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock" xlink:to="athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Valuations Of Options Approved And Issued Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock" xlink:to="athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfTradeAndOtherPayableTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Trade And Other Payable Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfTradeAndOtherPayableTableTextBlock" xlink:to="athe_ScheduleOfTradeAndOtherPayableTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for taxes other than income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromInterest_lbl0" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromInterest" xlink:to="ifrs-full_RevenueFromInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCashFlowStatementExplanatory_lbl0" xml:lang="en-US">Disclosure of cash flow statement [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:to="ifrs-full_DisclosureOfCashFlowStatementExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ReclassifyExpiredOptionsFromReservesOne_lbl1" xml:lang="en-US">Reclassify Expired Options From Reserves One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReclassifyExpiredOptionsFromReservesOne" xlink:to="athe_ReclassifyExpiredOptionsFromReservesOne_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_FinancialAssetsAbstract_lbl0" xml:lang="en-US">Financial Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FinancialAssetsAbstract" xlink:to="athe_FinancialAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_PaymentsForRentalSecurityDeposits_lbl1" xml:lang="en-US">Payments For Rental Security Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_PaymentsForRentalSecurityDeposits" xlink:to="athe_PaymentsForRentalSecurityDeposits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl3" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl0" xml:lang="en-US">Other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0" xml:lang="en-US">Short-term deposits, classified as cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantReserve_lbl0" xml:lang="en-US">Warrant reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantReserve" xlink:to="ifrs-full_WarrantReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl0" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl2" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl0" xml:lang="en-US">Additions to right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl1" xml:lang="en-US">Diluted earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_CorporateComplianceExpenses_lbl1" xml:lang="en-US">Corporate Compliance Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_CorporateComplianceExpenses" xlink:to="athe_CorporateComplianceExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilities_lbl0" xml:lang="en-US">Financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_NumberOfOptionsSharesToBeIssued_lbl1" xml:lang="en-US">Number Of Options Shares To Be Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfOptionsSharesToBeIssued" xlink:to="athe_NumberOfOptionsSharesToBeIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherGainsLosses_lbl0" xml:lang="en-US">Other gains (losses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_OtherGainsLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxExpenseIncome_lbl0" xml:lang="en-US">Deferred tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncome" xlink:to="ifrs-full_DeferredTaxExpenseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number of share options expired in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl0" xml:lang="en-US">Key management personnel compensation, share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_FinancialLiabilitiesAbstract0_lbl0" xml:lang="en-US">Financial Liabilities Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_FinancialLiabilitiesAbstract0" xlink:to="athe_FinancialLiabilitiesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_CarryingAmountsMember_lbl0" xml:lang="en-US">Carrying Amounts Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_CarryingAmountsMember" xlink:to="athe_CarryingAmountsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InsuranceExpense_lbl0" xml:lang="en-US">Insurance expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceExpense" xlink:to="ifrs-full_InsuranceExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_LongServiceLeaveAbstract_lbl0" xml:lang="en-US">Long Service Leave Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_LongServiceLeaveAbstract" xlink:to="athe_LongServiceLeaveAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_AccumulatedDeficitDuringDevelopmentStageTextBlock_lbl1" xml:lang="en-US">Accumulated Deficit During Development Stage Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AccumulatedDeficitDuringDevelopmentStageTextBlock" xlink:to="athe_AccumulatedDeficitDuringDevelopmentStageTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl0" xml:lang="en-US">Profit or loss [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_AnnualLeaveAbstract_lbl0" xml:lang="en-US">Annual Leave Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AnnualLeaveAbstract" xlink:to="athe_AnnualLeaveAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_SixToTowelMember_lbl0" xml:lang="en-US">Six To Towel Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_SixToTowelMember" xlink:to="athe_SixToTowelMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ordinarySharesPerShareCents_lbl1" xml:lang="en-US">ordinary Shares Per Share Cents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ordinarySharesPerShareCents" xlink:to="athe_ordinarySharesPerShareCents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl0" xml:lang="en-US">Interest received, classified as operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_EmployeeMember_lbl0" xml:lang="en-US">Employee Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_EmployeeMember" xlink:to="athe_EmployeeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepayments_lbl0" xml:lang="en-US">Current prepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepayments" xlink:to="ifrs-full_CurrentPrepayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_OtherResearchAndDevelopmentExpenses_lbl1" xml:lang="en-US">Other Research And Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OtherResearchAndDevelopmentExpenses" xlink:to="athe_OtherResearchAndDevelopmentExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AuditorsRemunerationForOtherServices_lbl0" xml:lang="en-US">Auditor&apos;s remuneration for other services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemunerationForOtherServices" xlink:to="ifrs-full_AuditorsRemunerationForOtherServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl3" xml:lang="en-US">Profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_CorporateAdvisoryExpenses_lbl1" xml:lang="en-US">Corporate Advisory Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_CorporateAdvisoryExpenses" xlink:to="athe_CorporateAdvisoryExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl1" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl1" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract_lbl0" xml:lang="en-US">Reconciliation of changes in deferred tax liability (asset) [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract" xlink:to="ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxesPaidRefund_lbl0" xml:lang="en-US">Income taxes paid (refund)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefund" xlink:to="ifrs-full_IncomeTaxesPaidRefund_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_TerminationNoticePeriodForResearchAndDevelopmentContracts_lbl1" xml:lang="en-US">Termination Notice Period For Research And Development Contracts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_TerminationNoticePeriodForResearchAndDevelopmentContracts" xlink:to="athe_TerminationNoticePeriodForResearchAndDevelopmentContracts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear_lbl1" xml:lang="en-US">Share Based Payment Number Of Options Options Issued During The Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear" xlink:to="athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ForeignCurrencyRiskMember_lbl0" xml:lang="en-US">Foreign Currency Risk Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ForeignCurrencyRiskMember" xlink:to="athe_ForeignCurrencyRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_NumberOfDirector_lbl1" xml:lang="en-US">Number Of Director</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberOfDirector" xlink:to="athe_NumberOfDirector_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfAuditorRemunerationTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Auditor Remuneration Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfAuditorRemunerationTableTextBlock" xlink:to="athe_ScheduleOfAuditorRemunerationTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl0" xml:lang="en-US">Issue of equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_RiskfreeInterestRate_lbl1" xml:lang="en-US">Riskfree Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_RiskfreeInterestRate" xlink:to="athe_RiskfreeInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl3" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_June302024Member_lbl0" xml:lang="en-US">June302024 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_June302024Member" xlink:to="athe_June302024Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of other provisions, contingent liabilities and contingent assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ResearchAndDevelopmentExpenses1Abstract_lbl0" xml:lang="en-US">Research And Development Expenses1 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ResearchAndDevelopmentExpenses1Abstract" xlink:to="athe_ResearchAndDevelopmentExpenses1Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_NumberofSharesIssuePricePerShare_lbl1" xml:lang="en-US">Numberof Shares Issue Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NumberofSharesIssuePricePerShare" xlink:to="athe_NumberofSharesIssuePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl0" xml:lang="en-US">Profit (loss) before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl0" xml:lang="en-US">Proceeds from issuing other equity instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl1" xml:lang="en-US">Exercise price, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl1"/>
    <loc xlink:type="locator" xlink:label="athe_ScheduleOfReservesOfShareBasedPaymentsAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfReservesOfShareBasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfReservesOfShareBasedPaymentsAbstract_lbl" xml:lang="en-US">Schedule Of Reserves Of Share Based Payments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfReservesOfShareBasedPaymentsAbstract" xlink:to="athe_ScheduleOfReservesOfShareBasedPaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_April222024Member_lbl0" xml:lang="en-US">April222024 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_April222024Member" xlink:to="athe_April222024Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Revenue And Other Income From Continuing Operations Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock" xlink:to="athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_AccruedResearchAndDevelopmentExpenses_lbl1" xml:lang="en-US">Accrued Research And Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AccruedResearchAndDevelopmentExpenses" xlink:to="athe_AccruedResearchAndDevelopmentExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FixedInterestRateMember_lbl0" xml:lang="en-US">Fixed interest rate [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FixedInterestRateMember" xlink:to="ifrs-full_FixedInterestRateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember_lbl2" xml:lang="en-US">Reserve Of Share Based Payments For Options And Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember" xlink:to="athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ATHAAGOneMember_lbl0" xml:lang="en-US">ATHAAGOne Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAAGOneMember" xlink:to="athe_ATHAAGOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl0" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_lbl0" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear_lbl1" xml:lang="en-US">Reserve Of Share Based Payments Expired During The Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear" xlink:to="athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_June302023Member_lbl0" xml:lang="en-US">June302023 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_June302023Member" xlink:to="athe_June302023Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_AccruedProfessionalFees_lbl1" xml:lang="en-US">Accrued Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_AccruedProfessionalFees" xlink:to="athe_AccruedProfessionalFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_February22024Member_lbl0" xml:lang="en-US">February22024 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_February22024Member" xlink:to="athe_February22024Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0" xml:lang="en-US">Disclosure of information about key management personnel [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareOptionsMember_lbl1" xml:lang="en-US">Share options [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOptionsMember" xlink:to="ifrs-full_ShareOptionsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_February32025Member_lbl0" xml:lang="en-US">February32025 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_February32025Member" xlink:to="athe_February32025Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_January302025Member_lbl0" xml:lang="en-US">January302025 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_January302025Member" xlink:to="athe_January302025Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_OfficeRentalExpenses_lbl1" xml:lang="en-US">Office Rental Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_OfficeRentalExpenses" xlink:to="athe_OfficeRentalExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_September212022Member_lbl0" xml:lang="en-US">September212022 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_September212022Member" xlink:to="athe_September212022Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ExpensesRelatingToShorttermLeases_lbl1" xml:lang="en-US">Expenses Relating To Shortterm Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ExpensesRelatingToShorttermLeases" xlink:to="athe_ExpensesRelatingToShorttermLeases_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ATHAADOneMember_lbl0" xml:lang="en-US">ATHAADOne Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ATHAADOneMember" xlink:to="athe_ATHAADOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_NonExecutiveDirectorsMember_lbl0" xml:lang="en-US">Non Executive Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_NonExecutiveDirectorsMember" xlink:to="athe_NonExecutiveDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl2" xml:lang="en-US">Number of share options granted in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_lbl0" xml:lang="en-US">Disclosure of auditors&apos; remuneration [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:to="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_EligibleAmountUnderTaxIncentiveScheme_lbl1" xml:lang="en-US">Eligible Amount Under Tax Incentive Scheme</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_EligibleAmountUnderTaxIncentiveScheme" xlink:to="athe_EligibleAmountUnderTaxIncentiveScheme_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0" xml:lang="en-US">Disclosure of events after reporting period [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Equity attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of financial liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for provisions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl3" xml:lang="en-US">Number of shares issued and fully paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetAssetsLiabilities_lbl0" xml:lang="en-US">Assets (liabilities)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetAssetsLiabilities" xlink:to="ifrs-full_NetAssetsLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Reserve Of Share Based Payments Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock" xlink:to="athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>athe-20250630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 29 01:27:04 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ConsolidatedBalanceSheet" roleURI="http://pranabio.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://pranabio.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ConsolidatedIncomeStatement" roleURI="http://pranabio.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ConsolidatedCashFlow" roleURI="http://pranabio.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ShareholdersEquityType2or3" roleURI="http://pranabio.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_BackgroundandSummaryofMaterialAccountingPolicies" roleURI="http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_InterestandOtherIncomefromContinuingOperations" roleURI="http://pranabio.com/role/InterestandOtherIncomefromContinuingOperations"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ExpensesfromOrdinaryActivities" roleURI="http://pranabio.com/role/ExpensesfromOrdinaryActivities"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_IncomeTax" roleURI="http://pranabio.com/role/IncomeTax"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_TradeandOtherReceivables" roleURI="http://pranabio.com/role/TradeandOtherReceivables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_OtherCurrentAssets" roleURI="http://pranabio.com/role/OtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_TradeandOtherPayables" roleURI="http://pranabio.com/role/TradeandOtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_Provisions" roleURI="http://pranabio.com/role/Provisions"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_CommitmentsandContingencies" roleURI="http://pranabio.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_IssuedCapital" roleURI="http://pranabio.com/role/IssuedCapital"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_Reserves" roleURI="http://pranabio.com/role/Reserves"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_AccumulatedDeficitDuringDevelopmentStage" roleURI="http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStage"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_Leases" roleURI="http://pranabio.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_CashFlowInformation" roleURI="http://pranabio.com/role/CashFlowInformation"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ExpenditureCommitments" roleURI="http://pranabio.com/role/ExpenditureCommitments"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ShareBasedPayments" roleURI="http://pranabio.com/role/ShareBasedPayments"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_SubsequentEvents" roleURI="http://pranabio.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_LossPerShare" roleURI="http://pranabio.com/role/LossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_KeyManagementPersonnelCompensation" roleURI="http://pranabio.com/role/KeyManagementPersonnelCompensation"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_AuditorsRemuneration" roleURI="http://pranabio.com/role/AuditorsRemuneration"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_RelatedPartyTransactions" roleURI="http://pranabio.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_SegmentInformation" roleURI="http://pranabio.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_FinancialInstruments" roleURI="http://pranabio.com/role/FinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ParentEntityFinancialInformation" roleURI="http://pranabio.com/role/ParentEntityFinancialInformation"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_AccountingPoliciesByPolicy" roleURI="http://pranabio.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_BackgroundandSummaryofMaterialAccountingPoliciesTables" roleURI="http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_InterestandOtherIncomefromContinuingOperationsTables" roleURI="http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ExpensesfromOrdinaryActivitiesTables" roleURI="http://pranabio.com/role/ExpensesfromOrdinaryActivitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_IncomeTaxTables" roleURI="http://pranabio.com/role/IncomeTaxTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_TradeandOtherReceivablesTables" roleURI="http://pranabio.com/role/TradeandOtherReceivablesTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_OtherCurrentAssetsTables" roleURI="http://pranabio.com/role/OtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_TradeandOtherPayablesTables" roleURI="http://pranabio.com/role/TradeandOtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ProvisionsTables" roleURI="http://pranabio.com/role/ProvisionsTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_IssuedCapitalTables" roleURI="http://pranabio.com/role/IssuedCapitalTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ReservesTables" roleURI="http://pranabio.com/role/ReservesTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_AccumulatedDeficitDuringDevelopmentStageTables" roleURI="http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStageTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_LeasesTables" roleURI="http://pranabio.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_CashFlowInformationTables" roleURI="http://pranabio.com/role/CashFlowInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ShareBasedPaymentsTables" roleURI="http://pranabio.com/role/ShareBasedPaymentsTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_LossPerShareTables" roleURI="http://pranabio.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_KeyManagementPersonnelCompensationTables" roleURI="http://pranabio.com/role/KeyManagementPersonnelCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_AuditorsRemunerationTables" roleURI="http://pranabio.com/role/AuditorsRemunerationTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_FinancialInstrumentsTables" roleURI="http://pranabio.com/role/FinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ParentEntityFinancialInformationTables" roleURI="http://pranabio.com/role/ParentEntityFinancialInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofEstimatedUsefulLivesTable" roleURI="http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofInterestandOtherIncomefromContinuingOperationsTable" roleURI="http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofExpensesfromOrdinaryActivitiesTable" roleURI="http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofIncomeTaxTable" roleURI="http://pranabio.com/role/ScheduleofIncomeTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofIncomeTaxTable_Parentheticals" roleURI="http://pranabio.com/role/ScheduleofIncomeTaxTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofTradeandOtherReceivablesTable" roleURI="http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofTradeandOtherPayablesTable" roleURI="http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofProvisionsTable" roleURI="http://pranabio.com/role/ScheduleofProvisionsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofMovementsinProvisionsTable" roleURI="http://pranabio.com/role/ScheduleofMovementsinProvisionsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofIssuedCapitalTable" roleURI="http://pranabio.com/role/ScheduleofIssuedCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofIssuedCapitalTable_Parentheticals" roleURI="http://pranabio.com/role/ScheduleofIssuedCapitalTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofMovementsinIssuedSharesTable" roleURI="http://pranabio.com/role/ScheduleofMovementsinIssuedSharesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofShareIssuancesTable" roleURI="http://pranabio.com/role/ScheduleofShareIssuancesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofReservesofShareBasedPaymentsTable" roleURI="http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofReservesofShareBasedPaymentsTable_Parentheticals" roleURI="http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable" roleURI="http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofAccumulatedDeficitDuringDevelopmentStageTable" roleURI="http://pranabio.com/role/ScheduleofAccumulatedDeficitDuringDevelopmentStageTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable" roleURI="http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofProfitorLossShowstheFollowingAmountsRelatingtoLeasesTable" roleURI="http://pranabio.com/role/ScheduleofProfitorLossShowstheFollowingAmountsRelatingtoLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofCashFlowInformationTable" roleURI="http://pranabio.com/role/ScheduleofCashFlowInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofOptionsGrantedTable" roleURI="http://pranabio.com/role/ScheduleofOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofOptionsOutstandingTable" roleURI="http://pranabio.com/role/ScheduleofOptionsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofValuationsofOptionsApprovedandIssuedTable" roleURI="http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofSharesIssuedunderStockOptionPlanTable" roleURI="http://pranabio.com/role/ScheduleofSharesIssuedunderStockOptionPlanTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofEarningLossPerShareTable" roleURI="http://pranabio.com/role/ScheduleofEarningLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofKeyManagementPersonnelCompensationTable" roleURI="http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofAuditandReviewofFinancialStatementsTable" roleURI="http://pranabio.com/role/ScheduleofAuditandReviewofFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable" roleURI="http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable" roleURI="http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable" roleURI="http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ScheduleofIndividualFinancialStatementsfortheParentEntityTable" roleURI="http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_BackgroundandSummaryofMaterialAccountingPoliciesDetails" roleURI="http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_InterestandOtherIncomefromContinuingOperationsDetails" roleURI="http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_IncomeTaxDetails" roleURI="http://pranabio.com/role/IncomeTaxDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_OtherCurrentAssetsDetails" roleURI="http://pranabio.com/role/OtherCurrentAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_IssuedCapitalDetails" roleURI="http://pranabio.com/role/IssuedCapitalDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ReservesDetails" roleURI="http://pranabio.com/role/ReservesDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_LeasesDetails" roleURI="http://pranabio.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ExpenditureCommitmentsDetails" roleURI="http://pranabio.com/role/ExpenditureCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_ShareBasedPaymentsDetails" roleURI="http://pranabio.com/role/ShareBasedPaymentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_SubsequentEventsDetails" roleURI="http://pranabio.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_RelatedPartyTransactionsDetails" roleURI="http://pranabio.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_SegmentInformationDetails" roleURI="http://pranabio.com/role/SegmentInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="athe-20250630.xsd#athe_r_FinancialInstrumentsDetails" roleURI="http://pranabio.com/role/FinancialInstrumentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://pranabio.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_RightofuseAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentProvisions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentTaxLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_CurrentLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_Liabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetAssetsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetAssetsLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_NetAssetsLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_EquityAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_Equity" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_RevenueFromInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IntellectualPropertyExpenses" xlink:href="athe-20250630.xsd#athe_IntellectualPropertyExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="IntellectualPropertyExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherGainsLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherGainsLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherGainsLosses" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForfeitedOptionsFromReserves" xlink:href="athe-20250630.xsd#athe_ForfeitedOptionsFromReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ForfeitedOptionsFromReserves" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherComprehensiveIncome" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromResearchAndDevelopmentTaxRefund" xlink:href="athe-20250630.xsd#athe_ProceedsFromResearchAndDevelopmentTaxRefund"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ProceedsFromResearchAndDevelopmentTaxRefund" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxesPaidRefund" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_IncomeTaxesPaidRefund" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentsForRentalSecurityDeposits" xlink:href="athe-20250630.xsd#athe_PaymentsForRentalSecurityDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="PaymentsForRentalSecurityDeposits" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsForShareIssueCosts" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="StatementsTable" xlink:href="athe-20250630.xsd#athe_StatementsTable"/>
    <loc xlink:type="locator" xlink:label="StatementsLineItems" xlink:href="athe-20250630.xsd#athe_StatementsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="StatementsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_IssuedCapitalMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReservesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_OtherReservesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsTable" xlink:to="StatementsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsLineItems" xlink:to="ifrs-full_Equity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ChangesInEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsLineItems" xlink:to="ifrs-full_ChangesInEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesNetOfCostsValue" xlink:href="athe-20250630.xsd#athe_IssuanceOfSharesNetOfCostsValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInEquityAbstract" xlink:to="IssuanceOfSharesNetOfCostsValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesNetOfCostsShares" xlink:href="athe-20250630.xsd#athe_IssuanceOfSharesNetOfCostsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInEquityAbstract" xlink:to="IssuanceOfSharesNetOfCostsShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInEquityAbstract" xlink:to="IncreaseDecreaseThroughIssuanceOfOptionsToEmployees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInEquityAbstract" xlink:to="ifrs-full_IssueOfEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseThroughIssuanceOfOptionsToConsultants" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInEquityAbstract" xlink:to="IncreaseDecreaseThroughIssuanceOfOptionsToConsultants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" xlink:href="athe-20250630.xsd#athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInEquityAbstract" xlink:to="IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInEquityAbstract" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInEquityAbstract" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInEquityAbstract" xlink:to="IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForfeitedOptionsReversedToProfitOrLoss" xlink:href="athe-20250630.xsd#athe_ForfeitedOptionsReversedToProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInEquityAbstract" xlink:to="ForfeitedOptionsReversedToProfitOrLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInEquityAbstract" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TransactionsWithOwnersInTheirCapacitySharesAsOwners" xlink:href="athe-20250630.xsd#athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInEquityAbstract" xlink:to="TransactionsWithOwnersInTheirCapacitySharesAsOwners" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInEquityAbstract" xlink:to="ifrs-full_ProfitLoss" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsLineItems" xlink:to="ifrs-full_Equity_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/InterestandOtherIncomefromContinuingOperations" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInterestIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInterestIncomeExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:to="ifrs-full_DisclosureOfInterestIncomeExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ExpensesfromOrdinaryActivities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseByNatureAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_DisclosureOfExpensesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/IncomeTax" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/TradeandOtherReceivables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/OtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/TradeandOtherPayables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/Provisions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ProvisionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProvisionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfProvisionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="ifrs-full_DisclosureOfProvisionsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CommitmentsAndContingenciesAbstract" xlink:href="athe-20250630.xsd#athe_CommitmentsAndContingenciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/IssuedCapital" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIssuedCapitalExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_DisclosureOfIssuedCapitalExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/Reserves" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReservesWithinEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStage" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:href="athe-20250630.xsd#athe_AccumulatedDeficitDuringDevelopmentStageAbstract"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDeficitDuringDevelopmentStageTextBlock" xlink:href="athe-20250630.xsd#athe_AccumulatedDeficitDuringDevelopmentStageTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:to="AccumulatedDeficitDuringDevelopmentStageTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/CashFlowInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_DisclosureOfCashFlowStatementExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ExpenditureCommitments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ExpenditureCommitmentsAbstract" xlink:href="athe-20250630.xsd#athe_ExpenditureCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpenditureCommitmentsAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ShareBasedPayments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/LossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/KeyManagementPersonnelCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/AuditorsRemuneration" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemunerationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAuditorsRemunerationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AuditorsRemunerationAbstract" xlink:to="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/SegmentInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/FinancialInstruments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ParentEntityFinancialInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ParentEntityFinancialInformationAbstract" xlink:href="athe-20250630.xsd#athe_ParentEntityFinancialInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInterimFinancialReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInterimFinancialReportingExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ParentEntityFinancialInformationAbstract" xlink:to="ifrs-full_DisclosureOfInterimFinancialReportingExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" xlink:href="athe-20250630.xsd#athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForRecognitionOfOtherIncome" xlink:href="athe-20250630.xsd#athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForRecognitionOfOtherIncome" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock" xlink:href="athe-20250630.xsd#athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock" xlink:href="athe-20250630.xsd#athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:to="ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ExpensesfromOrdinaryActivitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseByNatureAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/IncomeTaxTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfIncomeTaxExplanatoryTableTextBlock" xlink:href="athe-20250630.xsd#athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="DisclosureOfIncomeTaxExplanatoryTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/TradeandOtherReceivablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfTradeAndOtherReceivableTableTextBlock" xlink:href="athe-20250630.xsd#athe_DisclosureOfTradeAndOtherReceivableTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="DisclosureOfTradeAndOtherReceivableTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/OtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/TradeandOtherPayablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfTradeAndOtherPayableTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfTradeAndOtherPayableTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ScheduleOfTradeAndOtherPayableTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ProvisionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ProvisionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProvisionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock" xlink:href="athe-20250630.xsd#athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/IssuedCapitalTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ReservesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReservesWithinEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfReserveOfShareBasedPaymentsTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:to="ScheduleOfReserveOfShareBasedPaymentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:to="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStageTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:href="athe-20250630.xsd#athe_AccumulatedDeficitDuringDevelopmentStageAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:to="ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountsRelatingToLeasesTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ScheduleOfAmountsRelatingToLeasesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases" xlink:href="athe-20250630.xsd#athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/CashFlowInformationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfNumberOfSharesIssuedTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfNumberOfSharesIssuedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ScheduleOfNumberOfSharesIssuedTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/LossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/KeyManagementPersonnelCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" xlink:href="athe-20250630.xsd#athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/AuditorsRemunerationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemunerationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAuditorRemunerationTableTextBlock" xlink:href="athe-20250630.xsd#athe_ScheduleOfAuditorRemunerationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AuditorsRemunerationAbstract" xlink:to="ScheduleOfAuditorRemunerationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ParentEntityFinancialInformationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ParentEntityFinancialInformationAbstract" xlink:href="athe-20250630.xsd#athe_ParentEntityFinancialInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfParentEntityFinancialStatementsExplanatory" xlink:href="athe-20250630.xsd#athe_DisclosureOfParentEntityFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ParentEntityFinancialInformationAbstract" xlink:to="DisclosureOfParentEntityFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfEstimatedUsefulLivesAbstract"/>
    <loc xlink:type="locator" xlink:label="BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:href="athe-20250630.xsd#athe_BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedUsefulLivesAbstract" xlink:to="BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RangesAxis" xlink:href="athe-20250630.xsd#athe_RangesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:to="RangesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RangesDomainDomain" xlink:href="athe-20250630.xsd#athe_RangesDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesAxis" xlink:to="RangesDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangesAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FixturesAndFittingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_FixturesAndFittingsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlantAndEquipmentMember" xlink:href="athe-20250630.xsd#athe_PlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="PlantAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="UsefulLivesOrDepreciationRatePropertyPlantAndEquipments" xlink:href="athe-20250630.xsd#athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="UsefulLivesOrDepreciationRatePropertyPlantAndEquipments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract" xlink:to="ifrs-full_RevenueAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueFromInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_OtherRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentTaxIncentive" xlink:href="athe-20250630.xsd#athe_ResearchAndDevelopmentTaxIncentive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ResearchAndDevelopmentTaxIncentive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAndOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAndOperatingIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_RevenueAndOperatingIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenses1Abstract" xlink:href="athe-20250630.xsd#athe_ResearchAndDevelopmentExpenses1Abstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="ResearchAndDevelopmentExpenses1Abstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpenses1Abstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherResearchAndDevelopmentExpenses" xlink:href="athe-20250630.xsd#athe_OtherResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpenses1Abstract" xlink:to="OtherResearchAndDevelopmentExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GeneralAndAdministrationExpensesAbstract" xlink:href="athe-20250630.xsd#athe_GeneralAndAdministrationExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="GeneralAndAdministrationExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrationExpensesAbstract" xlink:to="ifrs-full_DepreciationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrationExpensesAbstract" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEmployeeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEmployeeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrationExpensesAbstract" xlink:to="ifrs-full_OtherEmployeeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultantAndDirectorExpenses" xlink:href="athe-20250630.xsd#athe_ConsultantAndDirectorExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrationExpensesAbstract" xlink:to="ConsultantAndDirectorExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AuditInternalControlAndOtherAssuranceExpenses" xlink:href="athe-20250630.xsd#athe_AuditInternalControlAndOtherAssuranceExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrationExpensesAbstract" xlink:to="AuditInternalControlAndOtherAssuranceExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateComplianceExpenses" xlink:href="athe-20250630.xsd#athe_CorporateComplianceExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrationExpensesAbstract" xlink:to="CorporateComplianceExpenses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InsuranceExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InsuranceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrationExpensesAbstract" xlink:to="ifrs-full_InsuranceExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeRentalExpenses" xlink:href="athe-20250630.xsd#athe_OfficeRentalExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrationExpensesAbstract" xlink:to="OfficeRentalExpenses" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrationExpensesAbstract" xlink:to="ifrs-full_AdministrativeExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrationExpensesAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateAdvisoryExpenses" xlink:href="athe-20250630.xsd#athe_CorporateAdvisoryExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrationExpensesAbstract" xlink:to="CorporateAdvisoryExpenses" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherGainsAndLossesAbstract" xlink:href="athe-20250630.xsd#athe_OtherGainsAndLossesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesFromOrdinaryActivitiesAbstract" xlink:to="OtherGainsAndLossesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherGainsAndLossesAbstract" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofIncomeTaxTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfIncomeTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_CurrentTaxExpenseIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DeferredTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DeferredTaxExpenseIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxAbstract" xlink:to="ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrimaFaciesTaxOnNetLossBeforeIncomeTax" xlink:href="athe-20250630.xsd#athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract" xlink:to="PrimaFaciesTaxOnNetLossBeforeIncomeTax" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AddTaxEffectOfAbstract" xlink:href="athe-20250630.xsd#athe_AddTaxEffectOfAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxAbstract" xlink:to="AddTaxEffectOfAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AddTaxEffectOfAbstract" xlink:to="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxEffectOfResearchAndDevelopmentExpenditure" xlink:href="athe-20250630.xsd#athe_TaxEffectOfResearchAndDevelopmentExpenditure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AddTaxEffectOfAbstract" xlink:to="TaxEffectOfResearchAndDevelopmentExpenditure" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AddTaxEffectOfAbstract" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxEffectOfDeferredTaxAssetNotRecognized" xlink:href="athe-20250630.xsd#athe_TaxEffectOfDeferredTaxAssetNotRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxAbstract" xlink:to="TaxEffectOfDeferredTaxAssetNotRecognized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DeferredTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxAbstract" xlink:to="ifrs-full_DeferredTaxAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DeferredTaxAssets" xlink:to="ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofIncomeTaxTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfIncomeTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="PrimaFacieTaxOnNetLossBeforeIncomeTax" xlink:href="athe-20250630.xsd#athe_PrimaFacieTaxOnNetLossBeforeIncomeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxAbstract" xlink:to="PrimaFacieTaxOnNetLossBeforeIncomeTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentTaxIncentiveReceivable" xlink:href="athe-20250630.xsd#athe_ResearchAndDevelopmentTaxIncentiveReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ResearchAndDevelopmentTaxIncentiveReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedResearchAndDevelopmentExpenses" xlink:href="athe-20250630.xsd#athe_AccruedResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="AccruedResearchAndDevelopmentExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedProfessionalFees" xlink:href="athe-20250630.xsd#athe_AccruedProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="AccruedProfessionalFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherCurrentAccruedExpenses" xlink:href="athe-20250630.xsd#athe_OtherCurrentAccruedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="OtherCurrentAccruedExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_OtherPayables" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofProvisionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfProvisionsAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfProvisionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ProvisionsScheduleofProvisionsDetailsTable" xlink:href="athe-20250630.xsd#athe_ProvisionsScheduleofProvisionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProvisionsAbstract" xlink:to="ProvisionsScheduleofProvisionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfProvisionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionsScheduleofProvisionsDetailsTable" xlink:to="ifrs-full_ClassesOfProvisionsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfOtherProvisionsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AnnualLeaveMember" xlink:href="athe-20250630.xsd#athe_AnnualLeaveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="AnnualLeaveMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongServiceLeaveMember" xlink:href="athe-20250630.xsd#athe_LongServiceLeaveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="LongServiceLeaveMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionsScheduleofProvisionsDetailsTable" xlink:to="ifrs-full_DisclosureOfOtherProvisionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_CurrentProvisions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_NoncurrentProvisions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofMovementsinProvisionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementsInProvisionsAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfMovementsInProvisionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ProvisionsScheduleofMovementsinProvisionsDetailsTable" xlink:href="athe-20250630.xsd#athe_ProvisionsScheduleofMovementsinProvisionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInProvisionsAbstract" xlink:to="ProvisionsScheduleofMovementsinProvisionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfProvisionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionsScheduleofMovementsinProvisionsDetailsTable" xlink:to="ifrs-full_ClassesOfProvisionsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfOtherProvisionsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AnnualLeaveMember" xlink:href="athe-20250630.xsd#athe_AnnualLeaveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="AnnualLeaveMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongServiceLeaveMember" xlink:href="athe-20250630.xsd#athe_LongServiceLeaveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="LongServiceLeaveMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProvisionsScheduleofMovementsinProvisionsDetailsTable" xlink:to="ifrs-full_DisclosureOfOtherProvisionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Provisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Provisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_Provisions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Provisions_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Provisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_Provisions_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="AnnualLeaveAndLongServiceLeaveCarryingAmount" xlink:href="athe-20250630.xsd#athe_AnnualLeaveAndLongServiceLeaveCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="AnnualLeaveAndLongServiceLeaveCarryingAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofIssuedCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="IssuedCapitalScheduleofIssuedCapitalDetailsTable" xlink:href="athe-20250630.xsd#athe_IssuedCapitalScheduleofIssuedCapitalDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfIssuedCapitalLineItems" xlink:href="athe-20250630.xsd#athe_ScheduleOfIssuedCapitalLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="IssuedCapitalScheduleofIssuedCapitalDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuedCapitalScheduleofIssuedCapitalDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsMember" xlink:href="athe-20250630.xsd#athe_OptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="OptionsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuedCapitalScheduleofIssuedCapitalDetailsTable" xlink:to="ScheduleOfIssuedCapitalLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AIssuedCapitalAbstract" xlink:href="athe-20250630.xsd#athe_AIssuedCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedCapitalLineItems" xlink:to="AIssuedCapitalAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesOfIssuedCapital" xlink:href="athe-20250630.xsd#athe_SharesOfIssuedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AIssuedCapitalAbstract" xlink:to="SharesOfIssuedCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AIssuedCapitalAbstract" xlink:to="ifrs-full_IssuedCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofIssuedCapitalTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable" xlink:href="athe-20250630.xsd#athe_IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfIssuedCapitalLineItems" xlink:href="athe-20250630.xsd#athe_ScheduleOfIssuedCapitalLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsMember" xlink:href="athe-20250630.xsd#athe_OptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="OptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable" xlink:to="ScheduleOfIssuedCapitalLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofMovementsinIssuedSharesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementsInIssuedSharesAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfMovementsInIssuedSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable" xlink:href="athe-20250630.xsd#athe_IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInIssuedSharesAbstract" xlink:to="IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_IssuedCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="MovementDuringTheYearNoOfSharesinShares" xlink:href="athe-20250630.xsd#athe_MovementDuringTheYearNoOfSharesinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="MovementDuringTheYearNoOfSharesinShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValueOfIncreaseDecreaseInSharesOutstanding" xlink:href="athe-20250630.xsd#athe_ValueOfIncreaseDecreaseInSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ValueOfIncreaseDecreaseInSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_IssuedCapital_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofShareIssuancesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareIssuancesAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfShareIssuancesAbstract"/>
    <loc xlink:type="locator" xlink:label="IssuedCapitalScheduleofShareIssuancesDetailsTable" xlink:href="athe-20250630.xsd#athe_IssuedCapitalScheduleofShareIssuancesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfShareIssuancesLineItems" xlink:href="athe-20250630.xsd#athe_ScheduleOfShareIssuancesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareIssuancesAbstract" xlink:to="IssuedCapitalScheduleofShareIssuancesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuedCapitalScheduleofShareIssuancesDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssuanceDateAxis" xlink:href="athe-20250630.xsd#athe_ShareIssuanceDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuedCapitalScheduleofShareIssuancesDetailsTable" xlink:to="ShareIssuanceDateAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssuanceDateDomainDomain" xlink:href="athe-20250630.xsd#athe_ShareIssuanceDateDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="ShareIssuanceDateDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="September212022Member" xlink:href="athe-20250630.xsd#athe_September212022Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="September212022Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="March152023Member" xlink:href="athe-20250630.xsd#athe_March152023Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="March152023Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="June302023Member" xlink:href="athe-20250630.xsd#athe_June302023Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="June302023Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="November292023Member" xlink:href="athe-20250630.xsd#athe_November292023Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="November292023Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV6][yCK1+ZoBXLMR8yo0j2pNSp6VBCvRutHeg5vepaXYeUx1avN23SwC70Kiz1kcIin/IKYUfmlhC+ymiZvK+qrrdga5elfpB06nMQqO23Wb/1Im2VhF6I9XxYBIWZv3XWM6xRn1Vv6IsJcorZPHCirEOzaF5160Xfqi0s7SjYmSCeITg6l8z8qu79jpHBH3/yYSVGWfepq3nbP9ktIWEOrfzo7oXbKwp4zh2r0BYVeaRO2cE1HzR8D6gVSExbCW4JGvvKVamheVoovRoNRutr+o6T3QPULomNDq6CF2atrEfxKhgCwIByEPqAYPbGXbjbVgOZvkYQynN9vHCbmuqxm3MGkD5yJsBTGFOzCZxiH/JnF+VwE2qw==] CSR-->
    <loc xlink:type="locator" xlink:label="January82024Member" xlink:href="athe-20250630.xsd#athe_January82024Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="January82024Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="February22024Member" xlink:href="athe-20250630.xsd#athe_February22024Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="February22024Member" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="March42024Member" xlink:href="athe-20250630.xsd#athe_March42024Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="March42024Member" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="April222024Member" xlink:href="athe-20250630.xsd#athe_April222024Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="April222024Member" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="June302024Member" xlink:href="athe-20250630.xsd#athe_June302024Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="June302024Member" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="July182024Member" xlink:href="athe-20250630.xsd#athe_July182024Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="July182024Member" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="January222025Member" xlink:href="athe-20250630.xsd#athe_January222025Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="January222025Member" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="January302025Member" xlink:href="athe-20250630.xsd#athe_January302025Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="January302025Member" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="February32025Member" xlink:href="athe-20250630.xsd#athe_February32025Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="February32025Member" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="February172025Member" xlink:href="athe-20250630.xsd#athe_February172025Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="February172025Member" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="March142025Member" xlink:href="athe-20250630.xsd#athe_March142025Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="March142025Member" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="April42025Member" xlink:href="athe-20250630.xsd#athe_April42025Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="April42025Member" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="June302025Member" xlink:href="athe-20250630.xsd#athe_June302025Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareIssuanceDateAxis" xlink:to="June302025Member" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuedCapitalScheduleofShareIssuancesDetailsTable" xlink:to="ScheduleOfShareIssuancesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInNumberOfShareOutstanding" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseInNumberOfShareOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareIssuancesLineItems" xlink:to="IncreaseDecreaseInNumberOfShareOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalPreferenceShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalPreferenceShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareIssuancesLineItems" xlink:to="ifrs-full_IssuedCapitalPreferenceShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInNumberOfShareOutstanding_0" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseInNumberOfShareOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareIssuancesLineItems" xlink:to="IncreaseDecreaseInNumberOfShareOutstanding_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalPreferenceShares_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalPreferenceShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareIssuancesLineItems" xlink:to="ifrs-full_IssuedCapitalPreferenceShares_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesIssuedDuringTheYear" xlink:href="athe-20250630.xsd#athe_NumberOfSharesIssuedDuringTheYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareIssuancesLineItems" xlink:to="NumberOfSharesIssuedDuringTheYear" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareIssuancesLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberofSharesIssuePricePerShare" xlink:href="athe-20250630.xsd#athe_NumberofSharesIssuePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareIssuancesLineItems" xlink:to="NumberofSharesIssuePricePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuedCapitalPreferenceShare" xlink:href="athe-20250630.xsd#athe_IssuedCapitalPreferenceShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareIssuancesLineItems" xlink:to="IssuedCapitalPreferenceShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfReservesOfShareBasedPaymentsAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfReservesOfShareBasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ReservesScheduleofReservesofShareBasedPaymentsDetailsTable" xlink:href="athe-20250630.xsd#athe_ReservesScheduleofReservesofShareBasedPaymentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReservesWithinEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReservesOfShareBasedPaymentsAbstract" xlink:to="ReservesScheduleofReservesofShareBasedPaymentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReservesWithinEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReservesWithinEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReservesScheduleofReservesofShareBasedPaymentsDetailsTable" xlink:to="ifrs-full_ReservesWithinEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReservesWithinEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReservesWithinEquityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReservesWithinEquityAxis" xlink:to="ifrs-full_ReservesWithinEquityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember" xlink:href="athe-20250630.xsd#athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReservesWithinEquityAxis" xlink:to="ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReservesScheduleofReservesofShareBasedPaymentsDetailsTable" xlink:to="ifrs-full_DisclosureOfReservesWithinEquityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WarrantReserve" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_WarrantReserve" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfReservesOfShareBasedPaymentsAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfReservesOfShareBasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable" xlink:href="athe-20250630.xsd#athe_ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReservesWithinEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReservesOfShareBasedPaymentsAbstract" xlink:to="ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SegmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable" xlink:to="ifrs-full_DisclosureOfReservesWithinEquityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OptionsForFullyPaidOrdinaryShares1" xlink:href="athe-20250630.xsd#athe_OptionsForFullyPaidOrdinaryShares1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="OptionsForFullyPaidOrdinaryShares1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FreeattachingOptionsForFullyPaidOrdinaryShares" xlink:href="athe-20250630.xsd#athe_FreeattachingOptionsForFullyPaidOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="FreeattachingOptionsForFullyPaidOrdinaryShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesOptionsOutstanding" xlink:href="athe-20250630.xsd#athe_NumberOfSharesOptionsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="NumberOfSharesOptionsOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReserveOfOptionsIssuedDuringTheYear" xlink:href="athe-20250630.xsd#athe_ReserveOfOptionsIssuedDuringTheYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="ReserveOfOptionsIssuedDuringTheYear" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReserveOfShareBasedPaymentsExpiredDuringTheYear" xlink:href="athe-20250630.xsd#athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="ReserveOfShareBasedPaymentsExpiredDuringTheYear" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOptionsForfeitedDuringTheYear" xlink:href="athe-20250630.xsd#athe_NumberOfOptionsForfeitedDuringTheYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="NumberOfOptionsForfeitedDuringTheYear" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReserveOfSharebasedPaymentsForfeitedDuringYear" xlink:href="athe-20250630.xsd#athe_ReserveOfSharebasedPaymentsForfeitedDuringYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="ReserveOfSharebasedPaymentsForfeitedDuringYear" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOptionsOptionsExercisedDuringTheYear" xlink:href="athe-20250630.xsd#athe_NumberOfOptionsOptionsExercisedDuringTheYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="NumberOfOptionsOptionsExercisedDuringTheYear" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsExercisedDuringTheYear" xlink:href="athe-20250630.xsd#athe_OptionsExercisedDuringTheYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="OptionsExercisedDuringTheYear" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOptionsSharesToBeIssued" xlink:href="athe-20250630.xsd#athe_NumberOfOptionsSharesToBeIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="NumberOfOptionsSharesToBeIssued" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesToBeIssued" xlink:href="athe-20250630.xsd#athe_SharesToBeIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="SharesToBeIssued" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentExpenseForOptionsIssuedI" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentExpenseForOptionsIssuedI"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="ShareBasedPaymentExpenseForOptionsIssuedI" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesOptionsOutstanding_0" xlink:href="athe-20250630.xsd#athe_NumberOfSharesOptionsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="NumberOfSharesOptionsOutstanding_0" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract" xlink:to="ifrs-full_ReserveOfSharebasedPayments_0" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofAccumulatedDeficitDuringDevelopmentStageTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:href="athe-20250630.xsd#athe_AccumulatedDeficitDuringDevelopmentStageAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:to="ifrs-full_RetainedEarnings" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:to="ifrs-full_ProfitLoss" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassifyExpiredOptionsFromReservesOne" xlink:href="athe-20250630.xsd#athe_ReclassifyExpiredOptionsFromReservesOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:to="ReclassifyExpiredOptionsFromReservesOne" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassifyForfeitedOptionsFromReserves" xlink:href="athe-20250630.xsd#athe_ReclassifyForfeitedOptionsFromReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:to="ReclassifyForfeitedOptionsFromReserves" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDeficitDuringDevelopmentStageAbstract" xlink:to="ifrs-full_RetainedEarnings_0" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetsAbstract" xlink:href="athe-20250630.xsd#athe_RightOfUseAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="RightOfUseAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RightOfUseAssetsAbstract" xlink:to="ifrs-full_RightofuseAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_LeaseLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofProfitorLossShowstheFollowingAmountsRelatingtoLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract" xlink:to="ifrs-full_InterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpensesRelatingToShorttermLeases" xlink:href="athe-20250630.xsd#athe_ExpensesRelatingToShorttermLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract" xlink:to="ExpensesRelatingToShorttermLeases" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract" xlink:to="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofCashFlowInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashFlowInformationAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashFlowInformationAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashFlowInformationAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_DepreciationRightofuseAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashPaymentsFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCashPaymentsFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_OtherCashPaymentsFromOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignExchangegainLoss" xlink:href="athe-20250630.xsd#athe_ForeignExchangegainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ForeignExchangegainLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FixedAssetWriteOff" xlink:href="athe-20250630.xsd#athe_FixedAssetWriteOff"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="FixedAssetWriteOff" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesInAssetsAndLiabilitiesAbstract" xlink:href="athe-20250630.xsd#athe_ChangesInAssetsAndLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashFlowInformationAbstract" xlink:to="ChangesInAssetsAndLiabilitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInTradeAndOtherReceivables" xlink:href="athe-20250630.xsd#athe_IncreaseDecreaseInTradeAndOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAssetsAndLiabilitiesAbstract" xlink:to="IncreaseDecreaseInTradeAndOtherReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_AdjustmentsForProvisions" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashFlowInformationAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOnHand" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOnHand"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashOnHand" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofOptionsGrantedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:href="athe-20250630.xsd#athe_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsAbstract" xlink:to="ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_ShareOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofOptionsOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsOutstandingAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfOptionsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsOutstandingLineItems" xlink:href="athe-20250630.xsd#athe_ScheduleOfOptionsOutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsOutstandingAbstract" xlink:to="ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_ShareOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsSeriesAxis" xlink:href="athe-20250630.xsd#athe_OptionsSeriesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable" xlink:to="OptionsSeriesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsSeriesDomainDomain" xlink:href="athe-20250630.xsd#athe_OptionsSeriesDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="OptionsSeriesDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ATHAABOneMember" xlink:href="athe-20250630.xsd#athe_ATHAABOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHAABOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHAADOneMember" xlink:href="athe-20250630.xsd#athe_ATHAADOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHAADOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHAAEMember" xlink:href="athe-20250630.xsd#athe_ATHAAEMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHAAEMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHAAFOneMember" xlink:href="athe-20250630.xsd#athe_ATHAAFOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHAAFOneMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHAAGOneMember" xlink:href="athe-20250630.xsd#athe_ATHAAGOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHAAGOneMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHAAHMember" xlink:href="athe-20250630.xsd#athe_ATHAAHMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHAAHMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHAAMember" xlink:href="athe-20250630.xsd#athe_ATHAAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHAAMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHABMember" xlink:href="athe-20250630.xsd#athe_ATHABMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHABMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHACMember" xlink:href="athe-20250630.xsd#athe_ATHACMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHACMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable" xlink:to="ScheduleOfOptionsOutstandingLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsOutstandingLineItems" xlink:to="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpiryDateOfOutstandingShareOptions" xlink:href="athe-20250630.xsd#athe_ExpiryDateOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsOutstandingLineItems" xlink:to="ExpiryDateOfOutstandingShareOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceOfOutstandingShareOption1" xlink:href="athe-20250630.xsd#athe_ExercisePriceOfOutstandingShareOption1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsOutstandingLineItems" xlink:to="ExercisePriceOfOutstandingShareOption1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsOutstandingLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsOutstandingLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfValuationsOfOptionsApprovedAndIssuedAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfValuationsOfOptionsApprovedAndIssuedAbstract" xlink:to="ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OptionsSeriesAxis" xlink:href="athe-20250630.xsd#athe_OptionsSeriesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable" xlink:to="OptionsSeriesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHAABMember" xlink:href="athe-20250630.xsd#athe_ATHAABMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHAABMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHAADMember" xlink:href="athe-20250630.xsd#athe_ATHAADMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHAADMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHAAEMember" xlink:href="athe-20250630.xsd#athe_ATHAAEMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHAAEMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHAAFMember" xlink:href="athe-20250630.xsd#athe_ATHAAFMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHAAFMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHAAGMember" xlink:href="athe-20250630.xsd#athe_ATHAAGMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHAAGMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHAAHMember" xlink:href="athe-20250630.xsd#athe_ATHAAHMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHAAHMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHAAMember" xlink:href="athe-20250630.xsd#athe_ATHAAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHAAMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHABMember" xlink:href="athe-20250630.xsd#athe_ATHABMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHABMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ATHACMember" xlink:href="athe-20250630.xsd#athe_ATHACMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionsSeriesAxis" xlink:to="ATHACMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DateOfGrantOfSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DateOfGrantOfSharebasedPaymentArrangement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePriceAtGrantDate" xlink:href="athe-20250630.xsd#athe_SharePriceAtGrantDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="SharePriceAtGrantDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YearsToExpiry" xlink:href="athe-20250630.xsd#athe_YearsToExpiry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="YearsToExpiry" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RiskfreeInterestRate" xlink:href="athe-20250630.xsd#athe_RiskfreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="RiskfreeInterestRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValuePerOptions" xlink:href="athe-20250630.xsd#athe_FairValuePerOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="FairValuePerOptions" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofSharesIssuedunderStockOptionPlanTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSharesIssuedUnderStockOptionPlanAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfSharesIssuedUnderStockOptionPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfSharesIssuedUnderStockOptionPlanLineItems" xlink:href="athe-20250630.xsd#athe_ScheduleOfSharesIssuedUnderStockOptionPlanLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSharesIssuedUnderStockOptionPlanAbstract" xlink:to="ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PlanAxis" xlink:href="athe-20250630.xsd#athe_PlanAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable" xlink:to="PlanAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AsxPlan2004Member" xlink:href="athe-20250630.xsd#athe_AsxPlan2004Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanAxis" xlink:to="AsxPlan2004Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable" xlink:to="ScheduleOfSharesIssuedUnderStockOptionPlanLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSharesIssuedUnderStockOptionPlanLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSharesIssuedUnderStockOptionPlanLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSharesIssuedUnderStockOptionPlanLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofEarningLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KeyManagementPersonnelCompensationLongtermBenefits" xlink:href="athe-20250630.xsd#athe_KeyManagementPersonnelCompensationLongtermBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="KeyManagementPersonnelCompensationLongtermBenefits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofAuditandReviewofFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAuditAndReviewOfFinancialStatementsAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfAuditAndReviewOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemunerationForAuditServices" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForAuditServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAuditAndReviewOfFinancialStatementsAbstract" xlink:to="ifrs-full_AuditorsRemunerationForAuditServices" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemunerationForOtherServices" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemunerationForOtherServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAuditAndReviewOfFinancialStatementsAbstract" xlink:to="ifrs-full_AuditorsRemunerationForOtherServices" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AuditorsRemuneration" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AuditorsRemuneration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAuditAndReviewOfFinancialStatementsAbstract" xlink:to="ifrs-full_AuditorsRemuneration" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CashAndCashEquivalentMember" xlink:href="athe-20250630.xsd#athe_CashAndCashEquivalentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="CashAndCashEquivalentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradeAndOtherPayablesMember" xlink:href="athe-20250630.xsd#athe_TradeAndOtherPayablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="TradeAndOtherPayablesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable" xlink:to="srt_CurrencyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_USD" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_GBP"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_GBP" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_JPY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_JPY"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_JPY" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsTotalExposure" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsTotalExposure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="FinancialInstrumentsTotalExposure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfInterestRatesAndTheEffectiveWeightedAverageInterestRateForClassesOfFinancialAssetsAndLiabilitiesAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfInterestRatesAndTheEffectiveWeightedAverageInterestRateForClassesOfFinancialAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInterestRatesAndTheEffectiveWeightedAverageInterestRateForClassesOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CashAndCashEquivalentMember" xlink:href="athe-20250630.xsd#athe_CashAndCashEquivalentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="CashAndCashEquivalentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TradeAndOtherReceivablesMember" xlink:href="athe-20250630.xsd#athe_TradeAndOtherReceivablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="TradeAndOtherReceivablesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherCurrentAssetMember" xlink:href="athe-20250630.xsd#athe_OtherCurrentAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="OtherCurrentAssetMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TradeAndOtherPayablesMember" xlink:href="athe-20250630.xsd#athe_TradeAndOtherPayablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="TradeAndOtherPayablesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_LeaseLiabilitiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherCurrentLiabilitieMember" xlink:href="athe-20250630.xsd#athe_OtherCurrentLiabilitieMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="OtherCurrentLiabilitieMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable" xlink:to="ifrs-full_MaturityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInterestRatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInterestRatesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FloatingInterestRateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FloatingInterestRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_FloatingInterestRateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FixedInterestRateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixedInterestRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_FixedInterestRateMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonInterestBearingMember" xlink:href="athe-20250630.xsd#athe_NonInterestBearingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="NonInterestBearingMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRateRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRateRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_InterestRateRiskMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable" xlink:to="FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FinancialAssetsAbstract" xlink:href="athe-20250630.xsd#athe_FinancialAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems" xlink:to="FinancialAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AverageInterestRate" xlink:href="athe-20250630.xsd#athe_AverageInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAbstract" xlink:to="AverageInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialLiabilitiesAbstract" xlink:href="athe-20250630.xsd#athe_FinancialLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems" xlink:to="FinancialLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanysLiquidityReserveOnTheBasisOfExpectedCashFlowsAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfCompanysLiquidityReserveOnTheBasisOfExpectedCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanysLiquidityReserveOnTheBasisOfExpectedCashFlowsAbstract" xlink:to="FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LessThenSixMonthsMember" xlink:href="athe-20250630.xsd#athe_LessThenSixMonthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="LessThenSixMonthsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SixToTowelMember" xlink:href="athe-20250630.xsd#athe_SixToTowelMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="SixToTowelMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GreaterThanTowelMonthsAndLessThanFiveYearsMember" xlink:href="athe-20250630.xsd#athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="GreaterThanTowelMonthsAndLessThanFiveYearsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalContractedCashFlowsMember" xlink:href="athe-20250630.xsd#athe_TotalContractedCashFlowsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="TotalContractedCashFlowsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CarryingAmountsMember" xlink:href="athe-20250630.xsd#athe_CarryingAmountsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="CarryingAmountsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TradeAndOtherPayablesMember" xlink:href="athe-20250630.xsd#athe_TradeAndOtherPayablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="TradeAndOtherPayablesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_LeaseLiabilitiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_TradeAndOtherPayables" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIndividualFinancialStatementsForTheParentEntityAbstract" xlink:href="athe-20250630.xsd#athe_ScheduleOfIndividualFinancialStatementsForTheParentEntityAbstract"/>
    <loc xlink:type="locator" xlink:label="StatementsTable" xlink:href="athe-20250630.xsd#athe_StatementsTable"/>
    <loc xlink:type="locator" xlink:label="StatementsLineItems" xlink:href="athe-20250630.xsd#athe_StatementsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIndividualFinancialStatementsForTheParentEntityAbstract" xlink:to="StatementsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ParentCompanyMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsTable" xlink:to="StatementsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsLineItems" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsLineItems" xlink:to="ifrs-full_CurrentLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsLineItems" xlink:to="ifrs-full_NoncurrentLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsLineItems" xlink:to="ifrs-full_Liabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_ReserveOfSharebasedPayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_Equity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementsLineItems" xlink:to="ifrs-full_IncomeStatementAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable" xlink:href="athe-20250630.xsd#athe_BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TaxRateEffectFromChangesInTaxRate" xlink:href="athe-20250630.xsd#athe_TaxRateEffectFromChangesInTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="TaxRateEffectFromChangesInTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EligibleAmountUnderTheTaxIncentiveScheme" xlink:href="athe-20250630.xsd#athe_EligibleAmountUnderTheTaxIncentiveScheme"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="EligibleAmountUnderTheTaxIncentiveScheme" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_OtherIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ProfitLossBeforeTax1" xlink:href="athe-20250630.xsd#athe_ProfitLossBeforeTax1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ProfitLossBeforeTax1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProfitLossBeforeTax2" xlink:href="athe-20250630.xsd#athe_ProfitLossBeforeTax2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ProfitLossBeforeTax2" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EstimatedUsefulEconomicLife" xlink:href="athe-20250630.xsd#athe_EstimatedUsefulEconomicLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="EstimatedUsefulEconomicLife" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Employeesdescription" xlink:href="athe-20250630.xsd#athe_Employeesdescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="Employeesdescription" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:to="ifrs-full_TaxRateEffectFromChangeInTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TurnoverRevenue" xlink:href="athe-20250630.xsd#athe_TurnoverRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:to="TurnoverRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EligibleAmountUnderTaxIncentiveScheme" xlink:href="athe-20250630.xsd#athe_EligibleAmountUnderTaxIncentiveScheme"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:to="EligibleAmountUnderTaxIncentiveScheme" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MiscellaneousIncomeDisputeWithCatalent" xlink:href="athe-20250630.xsd#athe_MiscellaneousIncomeDisputeWithCatalent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:to="MiscellaneousIncomeDisputeWithCatalent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MiscellaneousIncomeSettlementOfAnInsuranceClaim" xlink:href="athe-20250630.xsd#athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract" xlink:to="MiscellaneousIncomeSettlementOfAnInsuranceClaim" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/IncomeTaxDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxDetailsTable" xlink:href="athe-20250630.xsd#athe_IncomeTaxDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxLineItems" xlink:href="athe-20250630.xsd#athe_IncomeTaxLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="IncomeTaxDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsTable" xlink:to="IncomeTaxLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxLineItems" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxLineItems" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/OtherCurrentAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="TermDeposit" xlink:href="athe-20250630.xsd#athe_TermDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="TermDeposit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaturityDate" xlink:href="athe-20250630.xsd#athe_MaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="MaturityDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/IssuedCapitalDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CapitalCommitments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_CapitalCommitments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_IssuedCapitalOrdinaryShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_ParValuePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ordinarySharesPerShareCents" xlink:href="athe-20250630.xsd#athe_ordinarySharesPerShareCents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ordinarySharesPerShareCents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ReservesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReservesWithinEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ReservesDetailsTable" xlink:href="athe-20250630.xsd#athe_ReservesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReservesWithinEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityAbstract" xlink:to="ReservesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReservesDetailsTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_ShareOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReservesDetailsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FreeAttachingOptionMember" xlink:href="athe-20250630.xsd#athe_FreeAttachingOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="FreeAttachingOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongDatedOptionsMember" xlink:href="athe-20250630.xsd#athe_LongDatedOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="LongDatedOptionsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShortDatedOptionsMember" xlink:href="athe-20250630.xsd#athe_ShortDatedOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ShortDatedOptionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShortFreeAttachingOptionsMember" xlink:href="athe-20250630.xsd#athe_ShortFreeAttachingOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ShortFreeAttachingOptionsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReservesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeeMember" xlink:href="athe-20250630.xsd#athe_EmployeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="EmployeeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DirectorsMember" xlink:href="athe-20250630.xsd#athe_DirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="DirectorsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultantMember" xlink:href="athe-20250630.xsd#athe_ConsultantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ConsultantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChiefExecutiveOfficersMember" xlink:href="athe-20250630.xsd#athe_ChiefExecutiveOfficersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ChiefExecutiveOfficersMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonExecutiveDirectorsMember" xlink:href="athe-20250630.xsd#athe_NonExecutiveDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="NonExecutiveDirectorsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReservesDetailsTable" xlink:to="ifrs-full_DefinedBenefitPlansAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitPlansDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AsxPlan2004Member" xlink:href="athe-20250630.xsd#athe_AsxPlan2004Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="AsxPlan2004Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdsPlanTwoThousandEighteenMember" xlink:href="athe-20250630.xsd#athe_AdsPlanTwoThousandEighteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="AdsPlanTwoThousandEighteenMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReservesDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SubsequentsEventMember" xlink:href="athe-20250630.xsd#athe_SubsequentsEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="SubsequentsEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CreationDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReservesDetailsTable" xlink:to="ifrs-full_CreationDateAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="ifrs-full_DefaultFinancialStatementsDateMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AugustThirtyFirstTwoThousandTwentySixMember" xlink:href="athe-20250630.xsd#athe_AugustThirtyFirstTwoThousandTwentySixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CreationDateAxis" xlink:to="AugustThirtyFirstTwoThousandTwentySixMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReservesWithinEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReservesWithinEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReservesDetailsTable" xlink:to="ifrs-full_ReservesWithinEquityAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReservesWithinEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReservesWithinEquityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReservesWithinEquityAxis" xlink:to="ifrs-full_ReservesWithinEquityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember" xlink:href="athe-20250630.xsd#athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReservesWithinEquityAxis" xlink:to="ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ShortFreeAttachingOptionsMember_0" xlink:href="athe-20250630.xsd#athe_ShortFreeAttachingOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReservesWithinEquityAxis" xlink:to="ShortFreeAttachingOptionsMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReservesDetailsTable" xlink:to="ifrs-full_DisclosureOfReservesWithinEquityLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpiredTerm" xlink:href="athe-20250630.xsd#athe_ExpiredTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ExpiredTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReserveOfOrdinaryShares" xlink:href="athe-20250630.xsd#athe_ReserveOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="ReserveOfOrdinaryShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="athe-20250630.xsd#athe_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_AdditionsToRightofuseAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_CashOutflowForLeases" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShortTermLeaseTerm" xlink:href="athe-20250630.xsd#athe_ShortTermLeaseTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ShortTermLeaseTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ExpenditureCommitmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ExpenditureCommitmentsAbstract" xlink:href="athe-20250630.xsd#athe_ExpenditureCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="TerminationNoticePeriodForResearchAndDevelopmentContracts" xlink:href="athe-20250630.xsd#athe_TerminationNoticePeriodForResearchAndDevelopmentContracts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpenditureCommitmentsAbstract" xlink:to="TerminationNoticePeriodForResearchAndDevelopmentContracts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentTerminationCommitments" xlink:href="athe-20250630.xsd#athe_ResearchAndDevelopmentTerminationCommitments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExpenditureCommitmentsAbstract" xlink:to="ResearchAndDevelopmentTerminationCommitments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsDetailsTable" xlink:href="athe-20250630.xsd#athe_ShareBasedPaymentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ShareBasedPaymentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PlanAxis" xlink:href="athe-20250630.xsd#athe_PlanAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsTable" xlink:to="PlanAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlanDomainDomain" xlink:href="athe-20250630.xsd#athe_PlanDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanAxis" xlink:to="PlanDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AdsPlanTwoThousandEighteenMember" xlink:href="athe-20250630.xsd#athe_AdsPlanTwoThousandEighteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanAxis" xlink:to="AdsPlanTwoThousandEighteenMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfDirector" xlink:href="athe-20250630.xsd#athe_NumberOfDirector"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfDirector" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfKeyManagementPersonnel" xlink:href="athe-20250630.xsd#athe_NumberOfKeyManagementPersonnel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfKeyManagementPersonnel" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfEmployees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfConsultant" xlink:href="athe-20250630.xsd#athe_NumberOfConsultant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="NumberOfConsultant" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareholdersAuthorizedSecurities" xlink:href="athe-20250630.xsd#athe_ShareholdersAuthorizedSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ShareholdersAuthorizedSecurities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfDefaultVestingConditionsPerYear" xlink:href="athe-20250630.xsd#athe_PercentageOfDefaultVestingConditionsPerYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="PercentageOfDefaultVestingConditionsPerYear" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="athe-20250630.xsd#athe_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsMember" xlink:href="athe-20250630.xsd#athe_SubsequentEventsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="SubsequentEventsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ASXEmployeeSharePlanMember" xlink:href="athe-20250630.xsd#athe_ASXEmployeeSharePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ASXEmployeeSharePlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ADSEmployeeSharePlanMember" xlink:href="athe-20250630.xsd#athe_ADSEmployeeSharePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ADSEmployeeSharePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceExpiryTerm" xlink:href="athe-20250630.xsd#athe_ExercisePriceExpiryTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ExercisePriceExpiryTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="athe-20250630.xsd#athe_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/SegmentInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfReportableSegment" xlink:href="athe-20250630.xsd#athe_NumberOfReportableSegment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="NumberOfReportableSegment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://pranabio.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialInstrumentsDetailsTable" xlink:href="athe-20250630.xsd#athe_FinancialInstrumentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="FinancialInstrumentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CashAndCashEquivalentMember" xlink:href="athe-20250630.xsd#athe_CashAndCashEquivalentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="CashAndCashEquivalentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ForeignCurrencyRiskMember" xlink:href="athe-20250630.xsd#athe_ForeignCurrencyRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ForeignCurrencyRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestRateRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRateRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_InterestRateRiskMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="CashAndCashEquivalentMember_0" xlink:href="athe-20250630.xsd#athe_CashAndCashEquivalentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="CashAndCashEquivalentMember_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRate385PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRate385PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="InterestRate385PercentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInterestRatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfInterestRatesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="InterestRateOf000OnePercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000OnePercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="InterestRateOf000OnePercentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRateOf000PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="InterestRateOf000PercentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRate36PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRate36PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="InterestRate36PercentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRate105PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRate105PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="InterestRate105PercentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRateOf15To482PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf15To482PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="InterestRateOf15To482PercentMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRateOf000TwoPercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000TwoPercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="InterestRateOf000TwoPercentMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRateOf000ThreePercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000ThreePercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="InterestRateOf000ThreePercentMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRateOf000FourPercentMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000FourPercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="InterestRateOf000FourPercentMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRateOf000PercentFiveMember" xlink:href="athe-20250630.xsd#athe_InterestRateOf000PercentFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="InterestRateOf000PercentFiveMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRateOf27Member" xlink:href="athe-20250630.xsd#athe_InterestRateOf27Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="InterestRateOf27Member" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRate144PercentMember" xlink:href="athe-20250630.xsd#athe_InterestRate144PercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="InterestRate144PercentMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRate385OnePercentMember" xlink:href="athe-20250630.xsd#athe_InterestRate385OnePercentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="InterestRate385OnePercentMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsDetailsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AverageAnnualMovementForeignExchangeRate" xlink:href="athe-20250630.xsd#athe_AverageAnnualMovementForeignExchangeRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="AverageAnnualMovementForeignExchangeRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar" xlink:href="athe-20250630.xsd#athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_Cash" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfInterestRate" xlink:href="athe-20250630.xsd#athe_PercentageOfInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="PercentageOfInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaturityDate" xlink:href="athe-20250630.xsd#athe_MaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="MaturityDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10.0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ALTERITY THERAPEUTICS LIMITED<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001131343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-49843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">C3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Level 14, 350 Collins Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Melbourne<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">AU<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">3000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing 600 Ordinary Shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATHE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">9,127,370,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">David Stamler<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Level 14, 350 Collins Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Melbourne<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">AU<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">3000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">3 9349 4906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Melbourne, Australia<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Opinion on the Financial Statements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying consolidated statements of financial
position of Alterity Therapeutics Limited and its subsidiaries (the &#8220;Company&#8221;) as of June 30, 2025 and 2024, and the related
consolidated statements of profit or loss and other comprehensive loss, of changes in shareholders&#8217; equity and of cash flows for
each of the three years in the period ended June 30, 2025, including the related notes (collectively referred to as the &#8220;consolidated
financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company as of June 30, 2025 and 2024, and the results of its operations and its cash flows for each of the three years
in the period ended June 30, 2025 in conformity with International Financial Reporting Standards as issued by the International Accounting
Standards Board and Australian equivalents to International Financial Reporting Standards as issued by the Australian Accounting Standards
Board.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 33,158,642<span></span>
</td>
<td class="nump">$ 12,638,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">3,937,607<span></span>
</td>
<td class="nump">4,041,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">8,774,937<span></span>
</td>
<td class="nump">2,356,300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total Current Assets</a></td>
<td class="nump">45,871,186<span></span>
</td>
<td class="nump">19,036,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">3,848<span></span>
</td>
<td class="nump">32,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">151,326<span></span>
</td>
<td class="nump">154,729<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total Non-Current Assets</a></td>
<td class="nump">155,174<span></span>
</td>
<td class="nump">186,883<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total Assets</a></td>
<td class="nump">46,026,360<span></span>
</td>
<td class="nump">19,223,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">2,575,490<span></span>
</td>
<td class="nump">4,619,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions</a></td>
<td class="nump">875,908<span></span>
</td>
<td class="nump">530,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">66,912<span></span>
</td>
<td class="nump">107,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilities', window );">Current tax liabilities</a></td>
<td class="nump">16,280<span></span>
</td>
<td class="nump">15,995<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total Current Liabilities</a></td>
<td class="nump">3,534,729<span></span>
</td>
<td class="nump">5,373,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">88,545<span></span>
</td>
<td class="nump">51,914<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total Non-Current Liabilities</a></td>
<td class="nump">88,545<span></span>
</td>
<td class="nump">51,914<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">3,623,274<span></span>
</td>
<td class="nump">5,425,686<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net Assets</a></td>
<td class="nump">42,403,086<span></span>
</td>
<td class="nump">13,798,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued capital 2025: 9,127,370,686 fully paid ordinary shares Nil options over fully paid ordinary shares 2024: 5,245,115,318 fully paid ordinary shares Nil options over fully paid ordinary shares</a></td>
<td class="nump">262,949,462<span></span>
</td>
<td class="nump">223,152,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">Reserves</a></td>
<td class="nump">5,342,304<span></span>
</td>
<td class="nump">4,806,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Accumulated deficit during the development stage</a></td>
<td class="num">(225,888,680)<span></span>
</td>
<td class="num">(214,161,131)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total Equity</a></td>
<td class="nump">$ 42,403,086<span></span>
</td>
<td class="nump">$ 13,798,057<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets less the amount of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG63<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG63&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from share-based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position (Parentheticals) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Ordinary shares</a></td>
<td class="nump">9,127,370,686<span></span>
</td>
<td class="nump">5,245,115,318<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Profit or Loss and Other Comprehensive Loss - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">$ 446,291<span></span>
</td>
<td class="nump">$ 268,419<span></span>
</td>
<td class="nump">$ 16,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">7,641,516<span></span>
</td>
<td class="nump">4,019,285<span></span>
</td>
<td class="nump">3,916,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IntellectualPropertyExpenses', window );">Intellectual property expenses</a></td>
<td class="num">(127,523)<span></span>
</td>
<td class="num">(214,304)<span></span>
</td>
<td class="num">(285,067)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administration expenses</a></td>
<td class="num">(5,481,399)<span></span>
</td>
<td class="num">(4,762,643)<span></span>
</td>
<td class="num">(5,056,571)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(14,404,282)<span></span>
</td>
<td class="num">(18,644,047)<span></span>
</td>
<td class="num">(13,198,583)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(87,265)<span></span>
</td>
<td class="num">(5,238)<span></span>
</td>
<td class="num">(29,404)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherGainsLosses', window );">Other gains / (losses)</a></td>
<td class="num">(67,111)<span></span>
</td>
<td class="nump">261,152<span></span>
</td>
<td class="nump">917,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ForfeitedOptionsFromReserves', window );">Forfeited options from reserves</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,150<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income tax expense</a></td>
<td class="num">(12,079,773)<span></span>
</td>
<td class="num">(19,077,376)<span></span>
</td>
<td class="num">(13,702,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="num">(68,055)<span></span>
</td>
<td class="num">(46,088)<span></span>
</td>
<td class="num">(104,459)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the year</a></td>
<td class="num">(12,147,828)<span></span>
</td>
<td class="num">(19,123,464)<span></span>
</td>
<td class="num">(13,806,515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the year</a></td>
<td class="num">$ (12,147,828)<span></span>
</td>
<td class="num">$ (19,123,464)<span></span>
</td>
<td class="num">$ (13,806,515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Loss per share (basic - cents per share) (in Dollars per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Loss per share (Diluted - cents per share) (in Dollars per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of ordinary shares used in computing basic net loss per share (in Shares)</a></td>
<td class="nump">6,396,924,117<span></span>
</td>
<td class="nump">3,648,875,564<span></span>
</td>
<td class="nump">2,427,841,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares used in computing diluted net loss per share (in Shares)</a></td>
<td class="nump">6,396,924,117<span></span>
</td>
<td class="nump">3,648,875,564<span></span>
</td>
<td class="nump">2,427,841,917<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ForfeitedOptionsFromReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forfeited options from reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ForfeitedOptionsFromReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_IntellectualPropertyExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the expenses associated to cost and fees of intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_IntellectualPropertyExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Cash Flow Statements - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees', window );">Payments to suppliers and employees</a></td>
<td class="num">$ (17,459,061)<span></span>
</td>
<td class="num">$ (21,393,136)<span></span>
</td>
<td class="num">$ (19,943,617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">446,291<span></span>
</td>
<td class="nump">269,075<span></span>
</td>
<td class="nump">15,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ProceedsFromResearchAndDevelopmentTaxRefund', window );">R&amp;D tax refund</a></td>
<td class="nump">5,629,577<span></span>
</td>
<td class="nump">8,583,477<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(7,217)<span></span>
</td>
<td class="num">(4,565)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefund', window );">Income tax paid</a></td>
<td class="num">(68,055)<span></span>
</td>
<td class="num">(58,023)<span></span>
</td>
<td class="num">(103,453)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(11,451,248)<span></span>
</td>
<td class="num">(12,605,824)<span></span>
</td>
<td class="num">(20,035,837)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PaymentsForRentalSecurityDeposits', window );">Payments for rental security deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(29,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Payments for purchase of plant and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(5,722)<span></span>
</td>
<td class="num">(7,311)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments', window );">Payments for term deposit</a></td>
<td class="num">(7,500,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(7,500,000)<span></span>
</td>
<td class="num">(5,722)<span></span>
</td>
<td class="num">(36,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingOtherEquityInstruments', window );">Proceeds from issue of ordinary shares and other equity securities</a></td>
<td class="nump">42,570,645<span></span>
</td>
<td class="nump">10,144,682<span></span>
</td>
<td class="nump">316,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Payment of share issue costs</a></td>
<td class="num">(2,774,168)<span></span>
</td>
<td class="num">(918,020)<span></span>
</td>
<td class="num">(132,413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Principal elements of lease payments</a></td>
<td class="num">(127,097)<span></span>
</td>
<td class="num">(10,370)<span></span>
</td>
<td class="num">(59,922)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash flows generated from financing activities</a></td>
<td class="nump">39,669,380<span></span>
</td>
<td class="nump">9,216,292<span></span>
</td>
<td class="nump">124,340<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net (decrease)/increase in cash and cash equivalents</a></td>
<td class="nump">20,718,132<span></span>
</td>
<td class="num">(3,395,254)<span></span>
</td>
<td class="num">(19,947,958)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">12,638,885<span></span>
</td>
<td class="nump">15,773,783<span></span>
</td>
<td class="nump">34,806,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Exchange rate adjustments on cash and cash equivalents held in foreign currencies</a></td>
<td class="num">(198,375)<span></span>
</td>
<td class="nump">260,356<span></span>
</td>
<td class="nump">914,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 33,158,642<span></span>
</td>
<td class="nump">$ 12,638,885<span></span>
</td>
<td class="nump">$ 15,773,783<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_PaymentsForRentalSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for rental security deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_PaymentsForRentalSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ProceedsFromResearchAndDevelopmentTaxRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the cash inflow from research and development tax refund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ProceedsFromResearchAndDevelopmentTaxRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payments to suppliers for goods and services and to, and on behalf of, employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingOtherEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingOtherEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity - AUD ($)<br></strong></div></th>
<th class="th"><div>Issued Capital</div></th>
<th class="th"><div>Reserves</div></th>
<th class="th"><div>Accumulated Deficit During Development Stage</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 213,787,061<span></span>
</td>
<td class="nump">$ 3,565,918<span></span>
</td>
<td class="num">$ (181,884,388)<span></span>
</td>
<td class="nump">$ 35,468,591<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2022</a></td>
<td class="nump">2,406,874,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Transactions with owners in their capacity as owners:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuanceOfSharesNetOfCostsValue', window );">Issuance of shares</a></td>
<td class="nump">$ 316,675<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">316,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuanceOfSharesNetOfCostsShares', window );">Issuance of shares (in Shares)</a></td>
<td class="nump">33,023,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees', window );">Non-cash issuance of options to directors and employees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">983,721<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">983,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants', window );">Non-cash issuance of options to consultants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars', window );">Issuance of shares in connection with exercise of options, net of costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Transaction costs from issuance of shares</a></td>
<td class="num">(132,413)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(132,413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement', window );">Expired options</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(560,014)<span></span>
</td>
<td class="nump">560,014<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ForfeitedOptionsReversedToProfitOrLoss', window );">Forfeited options of reversed to profit or loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(17,150)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total transactions with owners in their capacity as owners</a></td>
<td class="nump">$ 184,262<span></span>
</td>
<td class="nump">406,557<span></span>
</td>
<td class="nump">560,014<span></span>
</td>
<td class="nump">1,150,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners', window );">Total transactions with owners in their capacity as owners (in Shares)</a></td>
<td class="nump">33,023,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,806,515)<span></span>
</td>
<td class="num">(13,806,515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,806,515)<span></span>
</td>
<td class="num">(13,806,515)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 213,971,323<span></span>
</td>
<td class="nump">3,972,475<span></span>
</td>
<td class="num">(195,130,889)<span></span>
</td>
<td class="nump">22,812,909<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2023</a></td>
<td class="nump">2,439,897,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Transactions with owners in their capacity as owners:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuanceOfSharesNetOfCostsValue', window );">Issuance of shares</a></td>
<td class="nump">$ 10,050,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,050,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuanceOfSharesNetOfCostsShares', window );">Issuance of shares (in Shares)</a></td>
<td class="nump">2,798,120,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees', window );">Non-cash issuance of options to directors and employees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">881,950<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">881,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Contributions of equity/ Shares to be issued</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars', window );">Issuance of shares in connection with exercise of options, net of costs</a></td>
<td class="nump">$ 49,682<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">49,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Issuance of shares in connection with exercise of options, net of costs (in Shares)</a></td>
<td class="nump">7,097,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Transaction costs from issuance of shares</a></td>
<td class="num">$ (918,020)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(918,020)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement', window );">Expired options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ForfeitedOptionsReversedToProfitOrLoss', window );">Forfeited options of reversed to profit or loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(93,222)<span></span>
</td>
<td class="nump">93,222<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total transactions with owners in their capacity as owners</a></td>
<td class="nump">$ 9,181,662<span></span>
</td>
<td class="nump">833,728<span></span>
</td>
<td class="nump">93,222<span></span>
</td>
<td class="nump">10,108,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners', window );">Total transactions with owners in their capacity as owners (in Shares)</a></td>
<td class="nump">2,805,217,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,123,464)<span></span>
</td>
<td class="num">(19,123,464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,123,464)<span></span>
</td>
<td class="num">(19,123,464)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 223,152,985<span></span>
</td>
<td class="nump">4,806,203<span></span>
</td>
<td class="num">(214,161,131)<span></span>
</td>
<td class="nump">13,798,057<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2024</a></td>
<td class="nump">5,245,115,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Transactions with owners in their capacity as owners:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuanceOfSharesNetOfCostsValue', window );">Issuance of shares</a></td>
<td class="nump">$ 42,547,105<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">42,547,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuanceOfSharesNetOfCostsShares', window );">Issuance of shares (in Shares)</a></td>
<td class="nump">3,875,826,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees', window );">Non-cash issuance of options to directors and employees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">979,920<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">979,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Contributions of equity/ Shares to be issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars', window );">Issuance of shares in connection with exercise of options, net of costs</a></td>
<td class="nump">$ 23,540<span></span>
</td>
<td class="num">(23,540)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Issuance of shares in connection with exercise of options, net of costs (in Shares)</a></td>
<td class="nump">6,428,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Transaction costs from issuance of shares</a></td>
<td class="num">$ (2,774,168)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,774,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement', window );">Expired options</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(326,544)<span></span>
</td>
<td class="nump">326,544<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ForfeitedOptionsReversedToProfitOrLoss', window );">Forfeited options of reversed to profit or loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(93,735)<span></span>
</td>
<td class="nump">93,735<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total transactions with owners in their capacity as owners</a></td>
<td class="nump">$ 39,796,477<span></span>
</td>
<td class="nump">536,101<span></span>
</td>
<td class="nump">420,279<span></span>
</td>
<td class="nump">40,752,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners', window );">Total transactions with owners in their capacity as owners (in Shares)</a></td>
<td class="nump">3,882,255,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,147,828)<span></span>
</td>
<td class="num">(12,147,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,147,828)<span></span>
</td>
<td class="num">(12,147,828)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 262,949,462<span></span>
</td>
<td class="nump">$ 5,342,304<span></span>
</td>
<td class="num">$ (225,888,680)<span></span>
</td>
<td class="nump">$ 42,403,086<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2025</a></td>
<td class="nump">9,127,370,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ForfeitedOptionsReversedToProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forfeited options reversed to profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ForfeitedOptionsReversedToProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the increase in equity through the issue of options to consultants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the increase in equity through the issue of options to employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the increase (decrease) in equity through options expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares in connection with exercise of options, net of costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_IssuanceOfSharesNetOfCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares net of costs, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_IssuanceOfSharesNetOfCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_IssuanceOfSharesNetOfCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares net of costs value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_IssuanceOfSharesNetOfCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total transactions with owners in their capacity as owners (in Shares).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from transactions with owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background and Summary of Material Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Background and Summary of Material Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory', window );">BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Background</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alterity Therapeutics Limited and its controlled subsidiaries, Alterity
Therapeutics Inc. and Alterity Therapeutics UK Limited (referred to collectively as &#8220;Alterity&#8221; or the &#8220;Group&#8221;),
is a development stage enterprise engaged in the research and development of therapeutic drugs designed to treat the underlying cause
of degeneration of the brain focusing on Alzheimer&#8217;s disease, Huntington disease, Parkinson&#8217;s disease and other neurological
disorders. Alterity Therapeutics Limited, the parent entity, was incorporated on November 11, 1997 in Melbourne, Australia and the UK
and U.S. subsidiaries were incorporated in August 2004.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Financial Reporting Framework</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial report of Alterity Therapeutics Limited for the year
ended June 30, 2025 was authorized for issue on August 29, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alterity Therapeutics Limited is a for-profit entity for the purpose
of preparing the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements of the Group comply with International
Financial Reporting Standards (&#8220;IFRS Accounting Standards&#8221;) as issued by the International Accounting Standards Board (IASB)
and Australian equivalents to International Financial Reporting Standards, as issued by the Australian Accounting Standards Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These financial statements have been prepared under the historical
cost convention, as modified by the revaluation of financial liabilities at fair value through profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounting policies are selected and applied in a manner which ensures
that the resulting financial information satisfies the concepts of relevance and reliability, thereby ensuring that the substance of the
underlying transactions or other events is reported.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accounting policies set out below have been applied in preparing
the financial statements for the year ended June 30, 2025 and the comparative information presented in these financial statements for
the years ended June 30, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical accounting estimates, judgments and assumptions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Estimates and judgments are continually evaluated and are based on
historical experience and other factors, including expectations of future events that may have a financial impact on the entity and that
are believed to be reasonable under the circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group makes estimates and assumptions concerning the future. The
resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a
significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are
discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Share-based Payments</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The value attributed to share options and remuneration shares issued
is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models and the resultant
option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options to shares and the
value and volatility of the price of the underlying shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>R&amp;D Tax Incentives</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Australian Government adopted a research and development tax incentive
in July 2011. The provisions provide refundable or non-refundable tax offsets. The research and development tax incentive applies to expenditures
incurred and the use of depreciating assets. A 43.5% refundable tax offset is available to eligible small companies with an annual aggregate
turnover of less than $20 million. Management has assessed these activities and expenditure to determine which are likely to be eligible
under the incentive scheme. For the period to June 30, 2025, the Group has recorded an item in other income of A$5.4 million (2024: A$4.0
million, 2023: A$3.9 million) to recognize the amount which relates to this period (A$3.9 million).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Going Concern Basis</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group is a development stage medical biotechnology company and
as such expects to be utilizing sources of cash funding until its research activities have become marketable. The Group has incurred recurring
losses since inception including a net loss of $12,147,828 in the year ended June 30, 2025 (2024: $19,123,464) and a net operating cash
outflow of $11,451,248 in the year ended June 30, 2025 (2024: $12,605,824). The Group expects to continue incurring losses into the foreseeable
future and will need to raise additional capital to continue the development of its planned research and development programs. The continuing
viability of the Group is subject to its ability to raise additional capital to finance the continuation of its planned research and development
programs, maintaining implemented cost containment and deferment strategies, and successfully commercializing its initiatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group raised new equity funding, net proceeds totaling $39,669,380
(see Note 10), during the financial year to enable progression of its planned research and development programs.</p>

<p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company believes the cash and cash equivalents as of June&#160;30,
2025 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the
date of issuance of these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The inability to raise additional capital, as and when needed on acceptable
terms, or if at all would have a negative impact on the Group&#8217;s financial condition and ability to pursue its business strategies.
If the Group is unable to obtain the required funding to operate and to develop and commercialize its product candidates, it could be
forced to delay, reduce or eliminate some or all of its research and development programs, which would adversely affect its business prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These consolidated financial statements have been prepared assuming
the Group will continue as a going concern which contemplates the continuity of operations, realization of assets and the satisfaction
of liabilities in the ordinary course of business and do not include adjustments that would result if the Group were unable to continue
as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of these consolidated financial statements requires
the Group to make estimates and judgments that affect the reported amounts of assets, liabilities, income and expenses and related disclosures.
On an ongoing basis, the Group evaluates its significant accounting policies and estimates. Estimates are based on historical experience
and on various market-specific and other relevant assumptions that the Group believes to be reasonable under the circumstances, the results
of which form the basis for making judgments about the carrying values of assets and liabilities. Estimates are assessed each period and
updated to reflect current information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Development Stage &#8211; Risks and Uncertainties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a development stage enterprise, the Group&#8217;s prospects are
subject to the risks, expenses and uncertainties frequently encountered by companies which have not yet commercialized any applications
of their technology, particularly in new and evolving markets. Alterity&#8217;s operating results may fluctuate significantly in the future
as a result of a variety of factors, including capital expenditure and other costs relating to establishing, maintaining and expanding
the operations, the number and mix of potential customers, potential pricing of future products by the Group and its competitors, new
technology introduced by the Group and its competitors, delays or expense in obtaining necessary equipment, economic and social conditions
in the biotechnology industry and general economic conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group cannot be certain that it will be able to raise any required
funding or capital, on favorable terms or at all, or that it will be able to establish corporate collaborations on acceptable terms, if
at all. If the Group is unable to obtain such additional funding or capital, it may be required to reduce the scope of its development
plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group&#8217;s experience in exploiting its technology is limited
and it cannot be certain that its operations will be profitable in the short-term, or at all. If the Group fails in its efforts to establish
or expand its business, the results of operations, financial condition and liquidity of the Group could be materially adversely affected.
The Group cannot be certain that it will be able to sell and deliver its technology or to obtain or retain any permits required in the
market in which it operates. Any of these factors could result in the reduction or cessation of the Group&#8217;s operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Material Accounting Policies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounting policies are selected and applied in a manner which ensures
that the resulting financial information satisfies the concepts of relevance and reliability, thereby ensuring that the substance of the
underlying transactions or other events is reported.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following material accounting policies have been adopted in the
preparation and presentation of the financial report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(a) Principles of Consolidation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements are prepared by combining the
financial statements of all the entities that comprise the Group, being Alterity Therapeutics Limited and its subsidiaries as defined
in Accounting Standard IFRS10 (AASB 10): <i>Consolidated Financial Statements</i>. Consistent accounting policies are employed in the
preparation and presentation of the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsidiaries are all those entities (including special purpose entities)
over which the Group has control. The Group controls an entity where the group is exposed to, or has rights to, variable returns from
its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity.
The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether
the Group controls another entity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsidiaries are fully consolidated from the date on which control
is transferred to the Group. They are de-consolidated from the date that control ceases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In preparing the consolidated financial statements, all inter-company
balances and transactions, and unrealized profits/losses arising within the Group are eliminated in full. Investments in subsidiaries
are accounted for at cost in the individual financial statements of Alterity Therapeutics Limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(b) Segment Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating segments are reported in a manner consistent with the internal
reporting provided to the chief operating decision maker (the &#8220;CODM&#8221;). The CODM, who is responsible for allocating resources
and assessing performance of the operating segments, has been identified as the Chief Executive Officer of Alterity Therapeutics Limited.
For the current and previous reporting periods, the Group operated in one segment, being research and development into Parkinsonian and
other neurodegenerative disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(c) Income Tax</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Current tax</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Current tax is calculated by reference to the amount of income taxes
payable or recoverable in respect of the taxable profit or loss for the period. It is calculated using tax rates and tax laws that have
been enacted or substantively enacted by reporting date. Current tax for current and prior periods is recognised as a liability (or asset)
to the extent that it is unpaid (or refundable).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Deferred tax</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax is accounted for using the liability method in respect
of temporary differences arising from differences between the carrying amount of assets and liabilities in the financial statements and
the corresponding tax base of those items.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In principle, deferred tax assets and liabilities are recognised for
all taxable temporary differences. Deferred tax assets are recognised to the extent that it is probable that sufficient taxable amounts
will be available against which deductible temporary differences or unused tax losses and tax offsets can be utilized. However, deferred
tax assets and liabilities are not recognised if the temporary differences giving rise to them arise from the initial recognition of assets
and liabilities (other than as a result of a business combination) which affects neither taxable income nor accounting profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax liabilities are recognised for taxable temporary differences
arising on investments in subsidiaries except where the Group is able to control the reversal of the temporary differences and it is probable
that the temporary differences will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences
associated with these investments are only recognised to the extent that it is probable that there will be sufficient taxable profits
against which to utilize the benefits of the temporary differences and they are expected to reverse in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax assets and liabilities are measured at the tax rates that
are expected to apply to the period(s) when the asset and liability giving rise to them are realized or settled, based on tax rates (and
tax laws) that have been enacted or substantively enacted by reporting date. The measurement of deferred tax liabilities and assets reflects
the tax consequences that would follow from the manner in which the Group expects, at the reporting date, to recover or settle the carrying
amount of its assets and liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax assets and liabilities are offset when there is a legally
enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.
Current tax assets and tax liabilities are offset when the entity has a legally enforceable right to offset and intends either to settle
on a net basis or to realize the asset and settle the liability simultaneously.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Current and deferred tax for the period</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Current and deferred tax is recognised as an expense or income in the
Statement of Profit or Loss and Other Comprehensive Loss except when it relates to items credited or debited directly to equity, in which
case the deferred tax is also recognised directly in equity, or where it arises from the initial accounting for a business combination,
in which case it is taken into account in the determination of goodwill.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group has significant unused tax losses and as such a significant
deferred tax asset; however, the deferred tax asset has not been recognised, as it is not probable that future taxable profit will be
available against which the unused losses and unused tax credits can be utilized, given the nature of the Group&#8217;s business (research
and development) and its history of losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Property and Equipment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment is measured at historical cost less accumulated
depreciation and impairment and consists of laboratory equipment, computer equipment, furniture and fittings and leasehold improvements
attributable to the Group&#8217;s premises at Melbourne, Victoria, Australia and San Francisco, U.S.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Historical cost includes expenditure that is directly attributable
to the acquisition of the item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Subsequent costs are included in the asset&#8217;s carrying amount
or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will
flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate
asset is derecognised when replaced. All other repairs and maintenance are charged to the income statement during the reporting period
in which they are incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Depreciation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation is provided on property and equipment. Depreciation is
calculated on a straight-line method to allocate their cost, net of their residual values, over their estimated useful lives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following estimated useful lives, ranging from 3 to 20 years are
used in the calculation of depreciation:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Class of Fixed Asset</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Depreciation Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fittings</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-33%</span></td><td style="text-align: left"></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left">Computer equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">33%</td><td style="width: 1%; text-align: left"></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Plant and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-33%</span></td><td style="text-align: left"></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">33%</td><td style="text-align: left"></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leasehold improvements are depreciated over the shorter of the lease
term and useful life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The depreciation method, residual values and useful lives are reviewed,
and adjusted if appropriate, at each annual reporting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(e) Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accounting policies for the Group&#8217;s lease recognition are
explained in Note 13.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(f) Investments and other financial assets </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Classification </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group classifies its financial assets in the following measurement
categories:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">those to be measured subsequently at fair value (either through OCI or through profit or loss), and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">those to be measured at amortized cost.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The classification depends on the entity&#8217;s business model for
managing the financial assets and the contractual terms of the cash flow. For assets measured at fair value, gains and losses will either
be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, this will depend on whether
the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through
other comprehensive income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recognition and derecognition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regular way purchases and sales of financial assets are recognised
on trade-date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognised when the rights to
receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the
risks and rewards of ownership.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Measurement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At initial recognition, the Group measures a financial asset at its
fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs that are directly attributable
to the acquisition of the financial asset. Transaction costs of financial assets carried at fair value through profit or loss are expensed
in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assets that are held for collection of contractual cash flows where
those cash flows represent solely payments of principal and interest are measured at amortised cost. Interest income from these financial
assets is included in finance income using the effective interest method. Any gain or loss arising on derecognition is recognised directly
in profit or loss and presented in other gains/(losses) together with foreign exchange gains and losses. Impairment losses are presented
as a separate line item in the consolidated statement of profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Impairment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group assesses on a forward looking basis the expected credit losses
associated with its debt instruments carried at amortized cost and fair value through other comprehensive income. The impairment methodology
applied depends on whether there has been a significant increase in credit risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For trade receivables, the Group applies the simplified approach which
requires expected lifetime losses to be recognised from initial recognition of the receivables, see Note 5 for further details.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(g) Impairment of Assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At each reporting date, the Group reviews the carrying amounts of its
tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If any such indication
exists, the recoverable amount of the asset is estimated to determine the extent of the impairment loss (if any).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where the asset does not generate cash flows that are independent from
other assets, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recoverable amount is the higher of fair value less costs of disposal
and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount
rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of
future cash flows have not been adjusted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the recoverable amount of an asset (or cash-generating unit) is
estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable
amount. An impairment loss is recognised in the consolidated statement of profit or loss and other comprehensive loss immediately.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where an impairment loss subsequently reverses, the carrying amount
of the asset (or cash-generating unit) is reversed to the revised estimate of its recoverable amount, but only to the extent that the
increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for
the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised in the consolidated statement of profit
or loss and other comprehensive loss immediately.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No impairment charges were incurred during the year ended June 30,
2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(h) Intangible Assets - Research and Development </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Expenditure during the research phase of a project is recognised as
an expense when incurred. Where no internally generated intangible assets can be recognised, development expenditure is recognised as
an expense in the period as incurred. Development costs are capitalised if and only if, all of the following are demonstrated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the technical feasibility of completing the intangible asset so that it will be available for use or sale;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the intention to complete the intangible asset and use or sell it;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to use or sell the intangible asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">how the intangible asset will generate probable future economic benefits;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to measure reliably the expenditure attributable to the intangible asset during its development.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Internally-generated intangible assets (capitalised development costs)
are stated at cost less accumulated amortisation and impairment, and are amortised on a straight-line basis over their useful lives over
a maximum of five years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2025, 2024 and 2023, the Group had no capitalized research
and development costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(i) Foreign Currency Transactions and Balances</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Functional and Presentation Currency</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements are presented in Australian dollars
($), which is Alterity Therapeutics Limited&#8217;s functional and presentation currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Foreign currency transactions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All foreign currency transactions during the financial year are brought
to account using the exchange rate in effect at the date of the transaction. Foreign currency monetary items at each reporting date are
translated at the exchange rate existing at each reporting date. Non-monetary assets and liabilities carried at fair value that are denominated
in foreign currencies are translated at the rates prevailing at the date when the fair value was determined.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exchange differences are recognised in profit or loss in the period
in which they arise except for exchange differences on monetary items receivable from or payable to a foreign operation for which settlement
is neither planned or likely to occur, which form part of the net investment in a foreign operation, are recognised in the foreign currency
translation reserve and recognised in profit or loss on disposal of the net investment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Subsidiaries</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The results and financial position of all the Group&#8217;s entities
that have a functional currency difference from the presentation currency are translated into the presentation currency as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet, and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">income and expenses for each income statement are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions), and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all resulting exchange differences are recognised as a separate component of equity.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(j) Employee Benefits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Short-term obligations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Short-term employee benefits are benefits (other than termination benefits)
that are expected to be settled wholly before 12 months after the end of the annual reporting period in which the employees render the
related service, including wages, and salaries. Short-term employee benefits are measured at the (undiscounted) amounts expected to be
paid when the obligation is settled. The Group&#8217;s obligations for short-term employee benefits such as wages and salaries are recognised
as a part of current trade and other payables in the statement of financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group&#8217;s obligations for annual leave are presented as part
of provisions in the Statement of Financial Position. The obligations are presented as current liabilities in the Statement of Financial
Position if the Group does not have an unconditional right to defer settlement for at least twelve months after the reporting period regardless
of when the actual settlement is expected to occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Other long-term obligations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The liability for long service leave is not expected to be settled
wholly within twelve months after the end of the period in which the employees render the related service. The liability is therefore
recognised in the provision for employee benefits and measured as the present value of expected future payments to be made in respect
of services provided by employees up to the end of the reporting period using the projected unit credit method. Consideration is given
to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted
using market yields at the end of the reporting period of high quality corporate bonds with terms and currencies that match, as closely
as possible, the estimated future cash outflows. Re-measurements as a result of experience adjustments and changes in actuarial assumptions
are recognised in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The obligations are presented as current liabilities in the balance
sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless
of when the actual settlement is expected to occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(k) Provisions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Provisions are recognised when the Group has a present obligation,
the future sacrifice of economic benefits is probable, and the amount of the provision can be measured reliably.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amount recognised as a provision is the best estimate of the consideration
required to settle the present obligation at reporting date, taking into account the risks and uncertainties surrounding the obligation.
Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value
of those cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">When some or all of the economic benefits required to settle a provision
are expected to be recovered from a third party, the receivable is recognised as an asset if it is virtually certain that recovery will
be received and the amount of the receivable can be measured reliably.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(l) Cash and Cash Equivalents</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash and cash equivalents include cash on hand, deposits held at call
with banks and other short-term highly liquid investments with original maturities of three months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><b>(m) Interest income</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other income is made up of interest income which is recognised on a
time proportion basis using the effective interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(n) Grants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Grants are recognised when there is reasonable assurance that the grant
will be received and all grant conditions will be complied with.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">When the grant relates to an expense item, it is recognised as income
over the periods necessary to match the grant on a systematic basis to the costs that it is expected to compensate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(o) Goods and Services Tax (&#8220;GST&#8221;)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenues, expenses and assets are recognised net of the amount of GST,
except where the amount of GST incurred is not recoverable from the taxation authority. In these circumstances the GST is recognised as
part of the cost of acquisition of the asset or as part of an item of expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Receivables and payables in the Statement of Financial Position are
shown inclusive of GST. The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables
or payables.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash flows are included in the Cash Flow Statement on a gross basis.
The GST component of cash flows arising from investing and financing activities which is recoverable from, or payable to, the taxation
authority is classified as operating cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(p) Trade and Other Payables</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These amounts represent liabilities for goods and services provided
to the Group prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of
recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months from the reporting
date. They are recognised initially at their fair value and subsequently measured at amortized cost using the effective interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(q) Share-Based Payments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The measurement date is determined for share-based payments issued
to directors, employees and consultants as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Directors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The issuance of share-based payments to directors is subject to approval
by shareholders as per ASX Listing Rule 10.11. The measurement date for share-based payments issued to directors is the grant date, being
the date at which the share-based payments are approved by shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Employees</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The issuance of share-based payments to employees may be subject to
shareholder approval per ASX Listing Rule 7.1 which prohibits the issuance of more than 15% of the Group&#8217;s shares in a 12 month
period without shareholder approval. The measurement date for share-based payments issued to employees is the grant date, being the date
at which a shared understanding of the terms and conditions of the arrangement is reached. However, if an issuance to an employee is subject
to shareholder approval because it exceeds the 15% threshold per ASX Listing Rule 7.1, then the measurement date of these share-based
payments is the date at which the share-based payments are approved by shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Consultants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The issuance of share-based payments to consultants may be subject
to shareholder approval per ASX Listing Rule 7.1 which prohibits the issuance of more than 15% of the Group&#8217;s shares in a 12 month
period without shareholder approval. The measurement date for share-based payments issued to consultants who provide services considered
to be similar to employees is deemed to be the date at which a shared understanding of the terms and conditions of the arrangement is
reached. The measurement date for share-based payments issued to consultants who provide services considered to be differentiated from
those provided by employees is deemed to be the date at which the entity obtains the goods or the counterparty renders the service. If
a service period applies and the work is continually provided over the service period, and if the share price of the Group does not change
significantly during the service period, then the average share price, volatility and risk-free rate over the service period are used
in calculating the value of the share-based payments issued. However, if the underlying share price of the Group does change significantly
during the service period, then the value of share-based payments are calculated at each individual date that goods and services are provided,
using the actual valuation inputs at that date. Shares issued to consultants for services are recorded as non-cash compensation and are
recognised at either the fair value of the services rendered, or if this cannot be reasonably estimated, the fair value of the underlying
equity instruments issued. Equity-based compensation benefits are provided to directors, employees and consultants under the 2004 ASX
Plan (the &#8220;2004 ASX Plan&#8221;) and the 2018 American Depository Share (ADS) Option Plan (the &#8220;2018 ADS Plan&#8221;). Information
relating to this plan is set out in Note 16.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value of options granted under these plans is recognised as
an expense with a corresponding increase in equity. The fair value is measured at grant date and recognised over the period during which
the recipients become unconditionally entitled to the options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value at grant date is independently determined using a Black-Scholes
(for options without market condition) and Barrier Pricing (for options with market conditions) model that takes into account the exercise
price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share,
the expected dividend yield and the risk free interest rate for the term of the option. The expected life used in the model has been adjusted,
based on management&#8217;s best estimate, for the effects of non-transferability, exercise restrictions, and behavioral considerations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value determined at the grant date of the equity-settled share-based
payments is expensed on a straight-line basis over the vesting period, based on the Group&#8217;s estimate of shares that will eventually
vest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(r) Loss Per Share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic loss per share is determined by dividing the net loss after income
tax expense by the weighted average number of ordinary shares outstanding during the financial period. For all periods presented, diluted
loss per share is equivalent to basic loss per share as the potentially dilutive securities are excluded from the computation of diluted
loss per share because the effect is anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(s) Share Capital</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ordinary share capital is recognised as the fair value of the consideration
received by the Group. Any transaction costs arising on the issue of ordinary shares are recognised directly in equity as a reduction
of the share proceeds received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(t) Trade and Other Receivables</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Trade and other receivables are recognised initially at fair value
and subsequently measured at amortized cost using the effective interest rate method less provision for impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(u) Comparative Figures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Comparative figures, are, where appropriate, reclassified to be comparable
with figures presented in the current financial year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(v) New Accounting Standards and Interpretations </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group has adopted all of the new or amended Accounting Standards
and Interpretations issued by the International Accounting Standards Board &#8216;IASB&#8217; and Australian Accounting Standards Board
&#8216;AASB&#8217; that are mandatory for the current reporting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The adoption of these standards has not had any material impact on
the disclosures or amounts reported in these financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2024, IFRS 18, &#8220;Presentation and Disclosure in Financial
Statements&#8221; was issued to achieve comparability of the financial performance of similar entities. The standard, which replaces IAS
1 &#8220;Presentation of Financial Statements&#8221;, impacts the presentation of primary financial statements and notes, including the
statement of earnings where companies will be required to present separate categories of income and expense for operating, investing,
and financing activities with prescribed subtotals for each new category. The standard will also require management-defined performance
measures to be explained and included in a separate note within the consolidated financial statements. The standard is effective for annual
reporting periods beginning on or after January 1, 2027, including interim financial statements, and requires retrospective application.
The Group is currently assessing the impact of the new standard.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no other new accounting standards and interpretations not
yet adopted by the Group for the June 30, 2025 reporting period that are expected to materially impact the Group.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes made to accounting policies by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest and Other Income from Continuing Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract', window );"><strong>Interest and Other Income from Continuing Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterestIncomeExplanatory', window );">INTEREST AND OTHER INCOME FROM CONTINUING OPERATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. INTEREST AND OTHER INCOME FROM CONTINUING OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Interest income</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Interest income</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">446,291</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">268,419</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">16,436</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total interest income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">446,291</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">268,419</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,436</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D Tax Incentive (1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,438,918</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,019,285</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,914,230</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Miscellaneous income (2)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,202,598</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,103</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,641,516</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,019,285</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,916,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total interest and other income from continuing operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,087,807</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,287,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,932,769</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A 43.5% R&amp;D Tax incentive refundable tax offset, is available to eligible small companies with an annual aggregate turnover of less than $20 million. For the years ended June 30, 2025, June 30, 2024 and June 30, 2023, the Group was eligible to receive the refundable tax offset. Management, with input from an independent expert, has applied judgement when assessing activities and expenditures that are likely to be eligible under the incentive scheme and therefore recorded $5,438,918, $4,019,285 and $3,914,230 in other income, respectively.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Miscellaneous income is comprised of other income of $1,975,056 in relation to settlement of a dispute with Catalent, and other income of $227,542 in relation to settlement of an insurance claim in relation to a U.S. employment case.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterestIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of interest income. [Refer: Interest income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterestIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Expenses from Ordinary Activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses from Ordinary Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesExplanatory', window );">EXPENSES FROM ORDINARY ACTIVITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>3. EXPENSES FROM ORDINARY ACTIVITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Research and Development Expenses (1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Employee expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,424,781</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,456,230</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,720,345</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,107,024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,187,817</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,478,238</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">General and Administration Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Depreciation on fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,307</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,344</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,854</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Depreciation on leased assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111,408</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,409</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Employee expenses (non R&amp;D related)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,046,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">515,803</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">926,314</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Consultant and director expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">652,260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">321,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">320,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Audit, internal control and other assurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">460,254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">238,728</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Corporate compliance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">780,320</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">790,350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457,215</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">549,408</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">676,219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">721,732</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Office rental</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,253</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,674</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,634</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other administrative and office expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">520,142</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,028,638</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,032,843</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Share based payment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">979,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">881,950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">966,571</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Corporate advisory expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">355,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204,621</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Other gains and losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Foreign exchange (gain)/loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(259,433</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(261,152</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(917,650</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses mainly consist of expenses paid for contracted research and development activities conducted by third parties on behalf of the Group.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">INCOME TAX</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. INCOME TAX</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>(a) Income tax expense:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Current tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">77,411</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">58,463</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33,808</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustment for current tax of prior periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,356</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,375</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,651</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">(b) Numerical reconciliation of income tax expense to prima facie tax payable:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Prima facie tax on net loss before income tax at 25% (2024: 25%, 2023: 25%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,019,943</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,769,344</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,446,718</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Effect of lower tax rates of tax on overseas income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,745</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,134</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,440</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Add tax effect of:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Under/(Over) provision of income tax in previous year relating to a revision of estimates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,356</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,375</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,651</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenditure (net of tax incentive)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">898,066</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,305,112</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267,940</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">464,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">377,405</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">413,976</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred tax asset not recognised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,749,734</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,156,424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,805,050</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Income tax expense attributable to loss before income tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,055</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,088</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">104,459</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">(c) Potential deferred tax asset as of June 30, 2025, 2024 and 2023 in respect of: tax losses not brought to account is (1)(2):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,885,043</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,758,242</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,056,899</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Temporary differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,798,561</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,660,171</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,675,742</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">As of June 30, 2025, the Group had a potential tax benefit related to gross tax losses carried forward of $187,632,492 (2024: $179,125,289) and a non-refundable R&amp;D tax offset of $2,126,801 (2024: $3,703,478).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unused tax loss amounts are only attributable to the Group&#8217;s operations in Australia, as the subsidiary in the United States has no carryforward tax losses as of June 30, 2025. Tax losses can be carried forward indefinitely subject to continuity of ownership and same business test rules.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and Other Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">TRADE AND OTHER RECEIVABLES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. TRADE AND OTHER RECEIVABLES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued interest income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">157</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">R&amp;D tax incentive receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,928,563</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,019,286</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Goods and services tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,044</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,232</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,937,607</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,041,675</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">R&amp;D tax incentive receivable represents the amount of the financial
year 2025 R&amp;D tax incentive the Group expects to recover. For further details, see Note 2.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherAssetsExplanatory', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6. OTHER CURRENT ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Years Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Prepayments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,233,122</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,315,632</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Term deposit (1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,668</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,774,937</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,356,300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Term deposit of 150-day term and maturity date of October
17, 2025.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other assets. [Refer: Other assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Trade and Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">TRADE AND OTHER PAYABLES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>7. TRADE AND OTHER PAYABLES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Trade creditors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">538,276</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">581,137</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,684,726</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,499,960</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">193,095</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234,899</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued corporate personnel expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">139,240</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166,063</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,457</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,253</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,431</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,575,490</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,619,947</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionsAbstract', window );"><strong>Provisions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionsExplanatory', window );">PROVISIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8. PROVISIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="text-decoration:underline">Current</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Annual leave (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">631,941</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">318,694</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Long service leave (1)(2)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">243,967</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">212,005</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">875,908</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">530,699</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline">Non-Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long service leave (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A provision has been recognised for employee entitlements relating
to long service leave. In calculating the present value of future cash flows in respect of long service leave, the probability of long
service leave being taken is based on historical data. The measurement and recognition criteria relating to employee benefits have been
included in Note 1 to this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(1) Movements in provisions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Movements in each class of provision during the financial year are
set out below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Annual leave</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Carrying amount at start of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">318,694</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">420,380</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">371,877</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Charged/(credited) to profit or loss -additional provisions recognised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409,646</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">179,923</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">272,502</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amounts used during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(97,011</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(280,618</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(232,747</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in foreign exchange</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">612</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(991</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,748</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Carrying amount at end of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">631,941</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">318,694</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">420,380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Long service leave</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Carrying amount at start of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">212,005</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">328,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">298,143</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Charged/(credited) to profit or loss -additional provisions recognised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,901</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,308</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,182</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Amounts used during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(939</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(146,628</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Carrying amount at end of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">243,967</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">212,005</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">328,325</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">875,908</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">530,699</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">748,705</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(2) Amounts not expected to be settled within the next 12 months</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The current provision for long service leave includes all unconditional
entitlements where employees have completed the required period of service and also those where employees are entitled to pro-rata payments
in certain circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The entire amount is presented as current, since the Group does not
have an unconditional right to defer settlement. However, based on past experience, the Group does not expect all employees to take the
full amount of accrued long service leave or require payment within the next 12 months.<b>&#160;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>9. COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There are no contingent liabilities at the date of this report. The
Group is not involved in any legal or arbitration proceedings and, so far as management is aware, no such proceedings are pending or threatened
against the Group.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In respect of expenditure commitments, refer to Note 15.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapitalAbstract', window );"><strong>Issued Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIssuedCapitalExplanatory', window );">ISSUED CAPITAL</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>10. ISSUED CAPITAL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In February 2025, we received commitments for a
capital raising of approximately $40 million by means of a two tranche placement (the <b>Placement</b>) of fully paid ordinary shares.
For every three new shares issued, one free attaching option was issued. The number of securities issued to the Placement participants
on February 17, 2025 (Tranche 1), April 4, 2025 (Tranche 2) and April 23,2025 (Options) pursuant to ASX Listing Rule 7.1, and which are
within the volumes approved by shareholders at the EGM on March 31, 2025, are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,636,363,636 ordinary shares at A$0.011 (1.1 Australian cents) per share (ASX:ATH); and</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,222,300,911 listed Long-Dated Options (each with an exercise price of A$0.028, expiring on February 26, 2027) (ASX: ATHOA).</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">(a) Issued Capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">9,127,370,686 (2024: 5,245,115,318) fully paid ordinary shares</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">10(b)</td><td style="width: 1%; text-align: left"></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">262,949,462</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">223,152,985</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">213,971,323</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Nil (2024: Nil) options for fully paid ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">10(c)</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85"><span style="-sec-ix-hidden: hidden-fact-88">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86"><span style="-sec-ix-hidden: hidden-fact-89">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">262,949,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">223,152,985</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">213,971,323</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(b) Movements in Issued Shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,245,115,318</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">223,152,985</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,439,897,618</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">213,971,323</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,406,874,578</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">213,787,061</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Movement during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,882,255,368</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,796,477</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,805,217,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,181,662</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,023,040</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184,262</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">End of the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,127,370,686</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">262,949,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,245,115,318</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">223,152,985</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,439,897,618</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">213,971,323</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Details of share issuances are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Date</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Details</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Notes</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Number</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Issue<br/> Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%; font-weight: bold; padding-bottom: 1.5pt">Year end June 30, 2022</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 30%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1.5pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">322,857,900</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">16,339,071</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>September 21, 2022</td><td>&#160;</td> <td style="text-align: left">Issue of shares under ATM Facility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,543,840</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0135</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">128,842</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>March 15, 2023</td><td>&#160;</td> <td style="text-align: left">Issue of shares under ATM Facility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">23,479,200</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0080</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">187,834</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">June 30, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; padding-bottom: 1.5pt">Security issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(132,413</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Year end June 30, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">33,023,040</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">184,263</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>November 29,2023</td><td>&#160;</td> <td style="text-align: left">Issue of shares under ATM Facility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">362,462,762</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0035</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,268,620</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>January 8,2024</td><td>&#160;</td> <td style="text-align: left">Issue of shares under ATM Facility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,008,965,805</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0035</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,531,380</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>February 2,2024</td><td>&#160;</td> <td style="text-align: left">Issue of shares under ATM Facility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">571,428,556</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0035</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>March 4, 2024</td><td>&#160;</td> <td style="text-align: left">Issue of shares under ATM Facility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">855,263,158</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0038</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,250,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>April 22, 2024</td><td>&#160;</td> <td style="text-align: left">Issue of shares under options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7,097,419</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0070</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">49,682</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>June 30, 2024</td><td>&#160;</td> <td style="text-align: left">Security issuance costs</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(918,020</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 1.5pt">Year end June 30, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,805,217,700</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">9,181,662</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>July 18,2024</td><td>&#160;</td> <td style="text-align: left">Issue of shares under ATM Facility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">75,220,800</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0054</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">398,645</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>January 22,2025</td><td>&#160;</td> <td style="text-align: left">Issue of shares under options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">95,238</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0100</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">952</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>January 30,2025</td><td>&#160;</td> <td style="text-align: left">Issue of shares under options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,333,333</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">48,873</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>February 3,2025</td><td>&#160;</td> <td style="text-align: left">Issue of shares under ATM Facility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">164,242,200</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0129</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,122,173</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>February 17,2025</td><td>&#160;</td> <td>Issue of Placement shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,165,841,830</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0110</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12,824,260</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>March 14, 2025</td><td>&#160;</td> <td style="text-align: left">Issue of shares under options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">161</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0100</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>April 4, 2025</td><td>&#160;</td> <td>Issue of Placement shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,470,521,806</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0110</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">27,175,740</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">June 30, 2025</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; padding-bottom: 1.5pt">Security issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,774,168</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; font-weight: bold">Year end June 30, 2025</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,882,255,368</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">39,796,477</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(c) Terms and Conditions of Issued Capital</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Ordinary shares</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ordinary shares have the right to receive dividends as declared and,
in the event of a winding up of the Group, to participate in the proceeds from the sale of all surplus assets in proportion to the number
of and amounts paid up on shares held. Ordinary shares entitle their holder to vote, either in person or by proxy, at a meeting of the
Group&#8217;s shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Options</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Option holders do not have the right to receive dividends and are not
entitled to vote at a meeting of the Group&#8217;s shareholders. Options may be exercised at any time from the date they vest to the date
of their expiration. Share options convert into ordinary shares on a one for one basis on the date they are exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Shares Issued after Reporting Date</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No shares have been issued after the reporting date.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityAbstract', window );"><strong>Reserves [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">RESERVES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>11. RESERVES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">(a) Share Based Payments</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">2,683,471,567 (2024: 3,250,009,092, 2023: 170,042,720) options for fully paid ordinary shares</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1.5pt; text-align: center">11(c)</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"></td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5,342,304</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">4,806,203</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3,972,475</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,342,304</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,806,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,972,475</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The share-based payment reserve is used to recognize the fair value
of options issued to directors, executives, employees and consultants but not exercised. Amounts are transferred out of the reserve and
into issued capital when the options are exercised. When options expire, the amount is transferred from reserve to accumulated losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">(b) Warrants/Free-attaching options</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,154,912,180 free-attaching options (2024: 2,868,466,372 free-attaching options, 2023: 674,694,939) for fully paid ordinary shares <sup>(1)</sup></span></td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1.5pt; text-align: center">11(c)</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 8, 2024 a total of 457,142,830 free attaching options with an exercise price of A$0.01, expiring on August 31, 2026 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 8, 2024 a total of 1,371,428,567 free attaching options with an exercise price of A$0.007, expiring on August 31, 2024 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 2, 2024 a total of 190,476,123 free attaching options with an exercise price of A$0.002, expiring on August 31, 2026 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 2, 2024 a total of 571,428,556 free attaching options with an exercise price of A$0.007, expiring on August 31, 2024 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 15, 2024 a total of 285,087,715 free attaching options with an exercise price of A$0.01, expiring on August 31, 2026 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 23, 2025 a total of 1,222,300,911 free attaching options with an exercise price if A$0.028, expiring on February 26, 2027 were issued.</p></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Movements in Options for Fully Paid Ordinary Shares</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="23" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(A$)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(A$)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(A$)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,250,009,092</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,806,203</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">170,042,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,972,475</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">184,692,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,565,918</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Options issued during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,392,300,911</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,092,563,791</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Expired during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,947,759,704</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(326,544</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,150,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(560,014</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Forfeited during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,650,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(93,735</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,500,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(93,222</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,500,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,150</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Options exercised during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,428,732</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,540</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Shares to be issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Share Based Payment expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">979,920</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">881,950</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">983,721</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">End of the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,683,471,567</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,342,304</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,250,009,092</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,806,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">170,042,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,972,475</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Details of option grants are summarized as follows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Year ended June 30, 2023:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 14, 2022, 12,450,000 options expired.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 31, 2023, 700,000 options expired.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 3, 2023, 1,500,000 options were forfeited upon resignation
of an employee.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Year ended June 30, 2024:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 11, 2023, 500,000 options were forfeited upon resignation of an employee.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On December 21, 2023, 8,000,000 options were
issued to the Group&#8217;s employees based in Australia under the 2004 ASX Plan. The options are exercisable at A$0.0105 and expire
on December 19, 2026. The fair value of the options is A$0.005 per option.</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On January 08, 2024, 457,142,830 long dated
options were issued as per the placement. The options are exercisable at A$0.01 and expire on August 31, 2026.</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On January 08, 2024, 1,371,418,567 free attaching short - dated options were issued as per the placement. The options are exercisable at A$0.007 and expire on August 31, 2024.</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On February 02, 2024, 190,476,123 long dated options were issued as per the securities placement plan. The options are exercisable at A$0.002 and expire on August 31, 2026.</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On February 02, 2024, 571,428,556 short - dated options were issued as per the securities placement plan. The options are exercisable at A$0.007 and expire on August 31, 2024.</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On April 15, 2024, 285,087,725 short &#8211; free attaching options were issued as per the securities placement plan. The options are exercisable at A$0.01 and expire on August 31, 2024</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 22, 2024, 7,097,419 options were exercised.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 21, 2024, 5,000,000 options were forfeited upon resignation of an employee.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On June 27, 2024, 26,500,000 options were issued to the Group&#8217;s employees based under the 2004 ASX Plan. The options are exercisable at A$0.004 and expire on March 13, 2029. The fair value of the options is A$0.004 per option.</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On June 27, 2024, 62,500,000 options were issued to the Group&#8217;s employees based under the Company&#8217;s 2018 American Depositary Share (ADS) Option Plan. The options are exercisable at US$0.0031 (A$0.0046) and expire on March 13, 2029. The fair value of the options is A$0.0037 per option.</p></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On June 27, 2024, 120,000,000 options were issued to the Group&#8217;s key management personnel based under the Company&#8217;s 2018 American Depositary Share (ADS) Option Plan. The options are exercisable at US$0.003 (A$0.0044) and expire on March 21, 2029. The fair value of the options is A$0.0037 per option.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Year ended June 30, 2025:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 1, 2024, 12,000,000 options expired.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 31, 2024, 1,935,759,704 options expired.</span></td> </tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 30, 2024, 170,000,000 options were issued to the Group&#8217;s directors as per resolutions passed at the AGM in November 2024. The options are exercisable at A$0.01 and expire on December 30, 2027.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 22, 2025, 95,238 options were exercised.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 30, 2025, 6,333,333 options were exercised.</span></td> <td></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#9679;</td> <td>On January 4, 2022, 14,000,000 options were forfeited upon resignation of two Non-Executive Directors. </td></tr><tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 14, 2025, 161 options were exercised.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 23, 2025, 1,222,300,911 free-attaching options were issued
as per the securities placement plan. The options are exercisable at A$0.028 and expire on February 26, 2027.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 30, 2025, 4,650,000 options were forfeited upon resignation of employees.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Terms and Conditions of Reserves </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Options and warrants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Option holders and warrant holders do not have the right to receive
dividends and are not entitled to vote at a meeting of the Group&#8217;s shareholders. Options and warrants may be exercised at any time
from the date they vest to the date of their expiration. Share options are exercisable into ordinary shares on a one for one basis on
the date they are exercised. Options granted under the 2018 ADS Plan are exercisable into ADRs, being one option for one ADR, which equals
600 ordinary shares, on the date they are exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Expired options are reclassified into accumulated losses. Options forfeited
due to failure of a vesting condition result in a reversal of the accumulated expense through the statement of profit or loss and other
comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In Australia, there is not a set number of authorized shares, shares
are not reserved for the exercise of options, and shares do not have a par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(e) Options and Warrants Issued after Reporting Date</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">15,000,000 options were issued under the 2004 ASX Plan after reporting
date.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReservesWithinEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReservesWithinEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Deficit During Development Stage<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_AccumulatedDeficitDuringDevelopmentStageAbstract', window );"><strong>Accumulated Deficit During Development Stage [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_AccumulatedDeficitDuringDevelopmentStageTextBlock', window );">ACCUMULATED DEFICIT DURING DEVELOPMENT STAGE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. ACCUMULATED DEFICIT DURING DEVELOPMENT STAGE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Balance at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">214,161,131</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">195,130,889</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">181,884,388</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,147,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,123,464</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,806,515</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Reclassify expired options from reserves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(326,544</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(560,014</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Reclassify forfeited options from reserves</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(93,735</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(93,222</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Balance at end of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">225,888,680</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">214,161,131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">195,130,889</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_AccumulatedDeficitDuringDevelopmentStageAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_AccumulatedDeficitDuringDevelopmentStageAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_AccumulatedDeficitDuringDevelopmentStageTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated deficit during development stage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_AccumulatedDeficitDuringDevelopmentStageTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>13. LEASES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amounts recognised in the statement of financial position</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statement of financial position shows the following amounts relating
to leases:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><b><i>Right-of-use assets</i></b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">151,326</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">154,729</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">207,087</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,912</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,177</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,545</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,914</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,207</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">155,457</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">159,045</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">210,384</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additions to the right-of-use assets during the current financial year
were $106,834 (2024:$59,031, 2023:$152,817).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td>
    <td style="width: 96%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amounts recognised in the statement of profit or loss</i></span></td>
    <td style="width: 1%">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statement of profit or loss shows the following amounts relating
to leases:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation of right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">111,408</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">112,185</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">64,409</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,188</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,565</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expenses relating to short-term leases (included in general and administration expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,674</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,634</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expenses relating to variable lease payments not included in lease liabilities (included in general and administration expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The total cash outflow for leases in 2025 was $127,097 (2024: $7,913,
2023: $133,121).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
Group&#8217;s leasing activities and how these are accounted for</i></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leases are recognised as a right-of-use asset and a corresponding liability
at the date at which the leased asset is available for use by the Group. Each lease payment is allocated between the liability and finance
cost. The finance cost is charged to profit or loss over the lease year so as to produce a constant periodic rate of interest on the remaining
balance of the liability for each year. The right-of-use asset is depreciated over the shorter of the asset&#8217;s useful life and the
lease term on a straight-line basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assets and liabilities arising from a lease are initially measured
on a present value basis. Lease liabilities include the net present value of the following lease payments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fixed payments (including in-substance fixed payments), less any lease incentives receivable</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variable lease payments that are based on an index or a rate</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amounts expected to be payable by the lessee under residual value guarantees</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The lease payments are discounted using the interest rate implicit
in the lease, if that rate can be determined, or the Group&#8217;s incremental borrowing rate applied at the commencement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Right-of-use assets are measured at cost comprising the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount of the initial measurement of lease liability</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any lease payments made at or before the commencement date, less any lease incentives received</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any initial direct costs, and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restoration costs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payments associated with short-term leases and leases of low-value
assets are recognised on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months
or less.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory', window );">CASH FLOW INFORMATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>14. CASH FLOW INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">(a) Reconciliation of Net Loss to Net Cash Flows Used In Operations</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(12,147,828</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(19,123,464</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(13,806,515</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Non-cash items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,307</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,344</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,854</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation on leased assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111,408</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,409</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,056</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based payment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">979,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">881,950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">966,571</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Foreign exchange loss/(gain)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(259,433</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(261,152</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(917,650</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Fixed asset write off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,232</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Changes in assets and liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Decrease/(increase) in trade and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,068</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,624,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,940,343</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Decrease/(increase) in other current assets (excepting term deposit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,081,363</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">252,986</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(968,207</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">(Decrease)/increase in trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,044,457</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,102,239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,560,873</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">(Decrease) in other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(99,861</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,935</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Increase/(decrease) in provision for employee entitlements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">345,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(218,006</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78,685</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash flows used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,451,248</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,605,824</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,035,837</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">(b) Reconciliation of Cash and Cash Equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents balance comprises:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">- cash and cash equivalents on hand</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,158,642</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,638,885</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,773,783</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Closing cash and cash equivalents balance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,158,642</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,638,885</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,773,783</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(c) Non-Cash Financing and Investing Activities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no non-cash financing and investing activities during the
years ended June 30, 2025, 2024 and 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section Presentation of a statement of cash flows<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS07_g10-17_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashFlowStatementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Expenditure Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpenditureCommitmentsAbstract', window );"><strong>Expenditure Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsExplanatory', window );">EXPENDITURE COMMITMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>15. EXPENDITURE COMMITMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2025 and 2024, the Group no longer has short term leases
contracted for but not capitalized in the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The majority of our contracts for research and development programs
have a termination notice period of 30 days. As of June 30, 2025, we had research and development termination commitments approximating
A$1.7 million. No liability has been recognised within our financial statements for this period. In addition, we have the ability to scale
down our operations and prioritise our research and development programs to reduce expenditures.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Details in relation to commitments under employee service agreements
with Directors and Key Management Personnel are outlined in Note 21.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ExpenditureCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ExpenditureCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share Based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">SHARE BASED PAYMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>16. SHARE BASED PAYMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the Annual General Meeting held on November 17, 2004, the shareholders
approved the establishment of employee and consultant plans designed to reward directors, employees and consultants for their contributions
to the Group. The plans are to be used as a method of retaining key personnel for the growth and development of the Group. Due to Alterity&#8217;s
U.S. presence, a U.S. plan (the 2018 ADS Plan) and an Australian plan (the 2004 ASX Plan) were developed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2025, equity had been issued to 4 Directors, 1 Key Management
Personnel, 7 employees and 3 consultants under the 2004 ASX Plan and 2018 ADS Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2024, equity had been issued to 3 Directors, 1 Key Management
Personnel, 7 employees and 4 consultants under the 2004 ASX Plan and 2018 ADS Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2023, equity had been issued to 4 Directors, 2 Key Management
Personnel, 9 employees and 3 consultants under the 2004 ASX Plan and 2018 ADS Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the 2004 Annual General Meeting, shareholders authorized the Group
to issue in the aggregate up to 12 million ordinary shares under the two plans. This was increased to 22 million ordinary shares at the
2005 Annual General Meeting and further increased to 30 million ordinary shares at the 2007 Annual General Meeting, 45 million ordinary
shares at the 2008 Annual General Meeting and 60 million ordinary shares at the 2009 Annual General Meeting. At the September 2020 General
Meeting, shareholders authorized the Group to issue up to 157.5 million securities. At the 2020 Annual General Meeting, shareholders authorized
the Group to issue up to 200 million ordinary shares. At the 2022 Annual General Meeting, shareholders authorized the Group to issue up
to 240 million ordinary shares. At the 2024 Annual General Meeting, shareholders authorized the Group to issue up to 450 million ordinary
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Share Plan Committee, a sub-committee of the Remuneration Committee,
administers the two plans and is able to change the terms of the equity issued under them from the default terms<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the 2018 ADS Plan, the exercise price must equal or exceed the
fair value of the ADS on the date the options are awarded. The option expiration date cannot exceed ten years from the date the options
were awarded. The default vesting conditions are 25% per year on the date the options were awarded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the 2004 ASX Plan, the exercise price must be equal or be less
than the market value of the ordinary shares on ASX on the date of grant. The option expiration date cannot exceed ten years from the
date the options were granted. The default vesting conditions are 25% per year on the date the options were granted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Information with respect to the number of options granted under the
2004 ASX Plan and 2018 ADS Plan as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">381,542,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">170,042,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.047</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">184,692,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.05</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issued during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">217,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Exercised during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,333,333</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expired during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,000,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,150,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,650,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.036</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.036</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.02</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Outstanding at year end</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">358,559,387</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.021</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">381,542,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">170,042,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.05</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Vested and Exercisable at year end</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">275,689,612</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.024</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">195,708,100</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.033</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">87,280,755</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.06</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Options outstanding at the end of the year have the following expiry
date and exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><b>Series</b></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>Grant Date</b></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Expiry Date</b></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$A</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%">ATHAAB</td><td style="width: 1%">&#160;</td> <td style="text-align: center; width: 20%; vertical-align: bottom">September 18, 2020</td><td style="width: 1%">&#160;</td> <td style="text-align: center; width: 20%">September 17, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.09</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">35,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">35,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>ATHAAD</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">January 7, 2021</td><td>&#160;</td> <td style="text-align: center">January 6, 2026</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">91,392,720</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">91,392,720</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>ATHAAE</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">November 29, 2021</td><td>&#160;</td> <td style="text-align: center">November 29, 2026</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">14,250,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>ATHAAF</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">July 31, 2021</td><td>&#160;</td> <td style="text-align: center">July 31, 2024</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.07</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12,000,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>ATHAAG</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">November 21, 2021</td><td>&#160;</td> <td style="text-align: center">November 29, 2026</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.02</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11,900,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>ATHAAH</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">December 21, 2023</td><td>&#160;</td> <td style="text-align: center">December 19, 2026</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.001</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8,000,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>ATHAA</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">March 13, 2024</td><td>&#160;</td> <td style="text-align: center">March 13, 2029</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,166,667</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">26,500,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>ATHAB</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">March 13, 2024</td><td>&#160;</td> <td style="text-align: center">March 13, 2029</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.005</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">62,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">62,500,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">ATHAC</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">March 21, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">March 21, 2029</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.003</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-137; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">358,559,387</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">381,542,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="8" style="text-align: left">Weighted average remaining contractual life of options outstanding at end of period.</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.37 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.28 years</span></td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Risk free interest rate </i>&#8211; This is the government bond
rate (having a term that most closely resembles the expected life of the option) in effect at the grant date. The Australian government
bond rate has been used for options which are exercisable for fully paid ordinary shares and the U.S. government bond rate has been used
for options which are exercisable for ADRs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Dividend yield </i>&#8211; Alterity has never declared or paid dividends
on its ordinary shares and does not anticipate paying any dividends in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Expected volatility </i>&#8211; Alterity estimates expected volatility
based on historical volatility over the estimated life of the option and other factors. Historical volatility has been the basis for determining
expected share price volatility as it is assumed that this is indicative of future movements. The life of the options is based on historical
exercise patterns, which may not eventuate in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Expected life </i>&#8211; This is the period of time that the options
granted are expected to remain outstanding. This estimate is based primarily on historical trend of option holders to exercise their option
near the date of expiry. As a result, the expected life is considered to equal the period from grant date to expiry date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Model inputs &#8211;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The model inputs for the valuations of options approved and issued
during the current and previous financial years are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold; vertical-align: bottom"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price <br/> per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share Price <br/> at Grant<br/> Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Expected Share <br/> Price </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Years to<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Dividend<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Risk-free<br/> Interest </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value<br/> per Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom"><b>Series</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>Grant Date</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>A$</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>A$</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Volatility</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Expiry</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Yield</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Rate</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>A$</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 6%; vertical-align: bottom">ATHAAB</td><td style="width: 1%">&#160;</td> <td style="text-align: center; white-space: nowrap; width: 16%; vertical-align: bottom">September 18,2020</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0.09</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0.05</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">98.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">5.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0.43</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0.032</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: bottom">ATHAAD</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">January 7,2021</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.032</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">139.52</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.38</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.028</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">ATHAAE</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">November 29, 2021</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.025</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">138.47</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.021</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: bottom">ATHAAF</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">July 31, 2021</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.07</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.034</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">169.42</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.13</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.027</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">ATHAAG</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">November 29, 2021</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.02</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0238</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">138.47</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.021</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: bottom">ATHAAH</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">December 21, 2023</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0065</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">133.87</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.67</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.005</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">ATHAA</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">March 13, 2024</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">158.31</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.47</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: bottom">ATHAB</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">March 13, 2024</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">158.31</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.47</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">ATHAC</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">March 21, 2024</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.003</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">158.83</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.48</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Information with respect to the number of shares issued under the stock
option plan as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,277,715</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,277,715</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,277,715</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Issued during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">End of the financial year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,277,715</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,277,715</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,277,715</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No shares were granted during the year ended June 30, 2025, 2024 and
2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>17. SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 3, 2025, the Group issued 15,000,000 options with exercise
price of $0.01 and 5 year expiry under the Group&#8217;s ASX Employee Share Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 28, 2025, Alterity Therapeutics announced positive topline
data form the open-label phase 2 clinical trial of ATH434 in Multiple System Atrophy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 15, 2025, the Group issued 11,500,000 options with exercise
price of $0.013 and 5 year expiry under the Group&#8217;s ASX Employee Share Plan, and 314,400,200 options with exercise price of US$0.0086
and 5 year expiry under the Group&#8217;s ADS Employee Share Plan,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No other matter or circumstance has occurred subsequent to year end
that has significantly affected, or may</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">significantly affect, the operations of the Group, the results of those
operations or the state of affairs of the Group or</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">economic entity in subsequent financial years.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">LOSS PER SHARE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>18. LOSS PER SHARE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Basic and diluted loss per share (cents per share)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(0.19</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(0.52</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(0.57</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted average number of ordinary shares on issue used in the calculation of basic and diluted loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,396,924,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,648,875,564</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,427,841,917</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options and warrants in place do not have the effect of diluting
the loss per share. Therefore, they have been excluded from the calculation of diluted loss per share. Please refer to Note 11 and Note
16 for options and warrants on issue which were assessed to be antidilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Key Management Personnel Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract', window );"><strong>Key Management Personnel Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">KEY MANAGEMENT PERSONNEL COMPENSATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><b>19. KEY MANAGEMENT PERSONNEL COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Short-term employee benefits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,522,550</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,551,075</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,727,020</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Post-employment benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,444</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,616</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,215</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Termination benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Share-based payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">802,128</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">520,055</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">764,175</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,343,398</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,113,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,540,854</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Auditors' Remuneration<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationAbstract', window );"><strong>Auditors' Remuneration [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory', window );">AUDITORS' REMUNERATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>20. AUDITORS&#8217; REMUNERATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">- Audit and review of financial statements (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">248,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">248,200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">246,400</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">- Other audit services (2)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">95,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">320,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">343,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">298,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit and review of financial statements consist of fees billed for assurance and related services that generally only the statutory auditor could reasonably provide to a client. </span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included in the balance are amounts related to additional regulatory filings during the 2025 financial year. All services provided are considered audit services for the purpose of SEC classification. </span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PricewaterhouseCoopers was appointed as the Group&#8217;s principal
independent registered public accounting firm on November 30, 2006. Australian law does not require the Group&#8217;s Auditors to be appointed
at the Group&#8217;s annual general meeting of shareholders. There is an annual engagement letter which is signed, subject to the Group&#8217;s
audit committee approval, with PricewaterhouseCoopers for audit and review work. No non-audit services were provided by PricewaterhouseCoopers
during the 2025, 2024 and 2023 financial years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of compensation to the entity's auditors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAuditorsRemunerationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>21. RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity Interests in Subsidiaries</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alterity Therapeutics Limited owns 100% of its subsidiaries, Alterity
Therapeutics Inc. and Alterity Therapeutics UK Ltd.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key Management Personnel Remuneration</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Directors of Alterity during the year:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Geoffrey Kempler, Chairman</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Brian Meltzer, Independent Non-Executive Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Peter Marks, Independent Non-Executive Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Lawrence Gozlan, Non-Executive Director</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Key Management Personnel of the Group during the year:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. David Stamler</span></td>
    <td style="width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Remuneration of all key management personnel of the Group is determined
by the Board of Directors following recommendation by the Remuneration Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group is committed to remunerating senior executives in a manner
that is market competitive and consistent with &#8216;best practice&#8217; including the interests of shareholders. Remuneration packages
are based on fixed and variable components, determined by the executive&#8217;s position, experience and performance, and may be satisfied
via cash or equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please refer to Note 19 for Key Management Personnel Remuneration detail.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>22. SEGMENT INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group&#8217;s Chief Executive Officer (Chief Operating Decision
Maker) examines internal reports to assess the Group&#8217;s performance and determine the allocation of resources. The Group has identified
one reportable segment as a whole and this covers research into Parkinsonian movement disorders, Alzheimer&#8217;s disease, Huntington
disease, and other neurodegenerative disorders.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>23. FINANCIAL INSTRUMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group&#8217;s activities expose it to a variety of financial risks
including market risk, credit risk and liquidity risk. The Group&#8217;s overall risk management program focuses on the unpredictability
of financial markets and seeks to minimize potential adverse effects on the financial performance of the Group. Risk management is carried
out under policies approved by the Board of Directors and overseen by the Audit Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><b>(a)</b></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market Risk</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">(i)</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign Currency Risk</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group engages in international purchase transactions and is exposed
to foreign currency risk arising from various currency exposures, primarily with respect to the Australian dollar. The parent entity also
has exposure to foreign exchange risk in the currency cash reserves it holds to meet its foreign currency payments. The Group does not
make use of derivative financial instruments to hedge foreign exchange risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following financial assets and liabilities are subject to foreign
currency risk, the currency of the original amounts are displayed in brackets, all the amounts in the table below are displayed in A$
at year-end spot rates:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Consolidated Entity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents (USD)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,544,448</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">225,722</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other payables (USD)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(495,145</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(507,820</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade and other payables (&#163;GBP)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,834</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Trade and other payables (JPY)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total exposure</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,050,099</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(288,924</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As shown in the table above, the Group is primarily exposed to changes
in USD/AUD exchange rates. The sensitivity of profit or loss to changes in the exchange rates arises mainly from US-dollar denominated
financial instruments and there is no impact on other components of equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Based on the financial instruments held as of June 30, 2025, had the
Australian dollar weakened/strengthened by 1.77%<br/> (2024: 0.35%, 2023: 3.6%) against the USD with all other variables held constant, the
Group&#8217;s post-tax loss for the year would have been A$18,933 higher/lower (2024: A$1,000 higher/lower).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">(ii)</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest Rate Risk</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interest rate risk is the risk to the Group&#8217;s earnings and equity
arising from movements in interest rates. The Group&#8217;s main interest rate risk arises from cash deposits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group&#8217;s exposure to interest rate risk has not changed since
the prior year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At June 30, 2025, the Group had the following cash accounts:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$2,423,027 in an Australian dollar transaction account at an interest rate of 0.00% as of June 30, 2025;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$40,142 in an Australian dollar transaction account at an interest rate of 0.00% as of June 30, 2025;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$8,027,852 in an Australian dollar cash maximiser account at an interest rate of 3.6%&#160;as of June 30, 2025;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$500,266 in an Australian dollar transaction account at an interest rate of 1.05% as of June 30, 2025;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A$28,125,744 in six Australian dollar term deposit accounts with interest rates within a range of 1.5% to 4.82%</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">as of June 30, 2025;</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.$160,769 (A$246,146) in a U.S. checking account at an interest rate of 0.00% as of June 30, 2025;</span></td> </tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.$29,069 (A$44,381) in U.S. Airwallex accounts at an interest rate of 0.00% as of June 30, 2025;</span></td> </tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.$821,384 (A$1,254,022) in a U.S. checking account at an interest rate of 0.00% as of June 30, 2025;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(A$2,835) in a Visa Credit card account at an interest rate of 0.00% as of June 30, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At June 30, 2024, the Group had the following cash accounts:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$11,529,456 in an Australian dollar cash maximiser account at an interest rate of 2.7%&#160;as of June 30, 2024;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$705,952 in an Australian dollar transaction account at an interest rate of 0.00% as of June 30, 2024;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$182,048 in an Australian dollar transaction account at an interest rate of 0.00% as of June 30, 2024;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.$138,388 (A$207,581) in U.S. checking accounts at an interest rate of 0.00% as of June 30, 2024;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.$12,094 (A$18,141) in U.S. Airwallex accounts at an interest rate of 0.00% as of June 30, 2024</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A$4,293) in a Visa Credit card account at an interest rate of 0.00% as of June 30, 2024.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At June 30, 2023, the Group had the following cash accounts:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$27,457 in an Australian dollar cash maximiser account at an interest rate of 1.44%&#160;as of June 30, 2023;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$61,518 in an Australian dollar transaction account at an interest rate of 0.00% as of June 30, 2023;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$18,864 in an Australian dollar transaction account at an interest rate of 0.00% as of June 30, 2023;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.$10,279,099 (A$15,473,231) in U.S. checking accounts at an interest rate of 0.00% as of June 30, 2023;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$42,713 in a 90 days term deposit at a fixed interest rate of 3.85% which matures on August 28, 2023;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A$150,000 in a 90 days term deposit at a fixed interest rate of 3.85% which matures on September 2, 2023;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The weighted average interest rate is 3.36% for cash and cash equivalents
and 4.75% for other current assets and apart from usual variances in general rates of interest the Group is not exposed to any significant
interest rate risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Receivables and payables are non-interest bearing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group&#8217;s exposure to interest rates and the effective weighted
average interest rate for classes of financial assets and liabilities is set out below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Floating <br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fixed Interest <br/> Maturing in<br/> (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Non-Interest<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Average<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><b>June 30, 2025</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Interest&#160;Rate <br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>1 year<br/> or less</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>1-5 years</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>bearing<br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total<br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Interest Rate</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Financial Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">30,698,409</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,835</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,463,168</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33,158,642</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.130</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,937,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,937,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,531,050</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,765</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,541,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">4.40</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Financial Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,698,409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,528,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,411,540</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,638,064</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,575,490</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,575,490</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(66,912</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(88,545</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(155,457</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Financial Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(66,912</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(88,545</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,575,490</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,730,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Floating <br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fixed Interest <br/> Maturing in<br/> (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Non-Interest<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Average<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><b>June 30, 2024</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Interest&#160;Rate <br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>1 year<br/> or less</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>1-5 years</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>bearing<br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total<br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Interest Rate</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Financial Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,529,456</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(4,293</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,113,722</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12,638,885</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.463</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,041,675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,041,675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,091</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,577</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,668</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3.515</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Financial Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,529,456</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,798</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,165,974</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,721,228</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,619,947</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,619,947</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(107,131</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(51,914</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(159,045</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Financial Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(107,131</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,914</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,719,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,878,992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit Risk</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Credit risk refers to the risk that a counterparty will default on
its contractual obligations resulting in financial loss to the Group. The Group has no significant concentration of credit risk and it
is not the Group&#8217;s policy to hedge credit risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group ensures that surplus cash is invested with financial institutions
of appropriate credit worthiness and limits the amount of credit exposure to any one counter party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There has been no significant change in the Group&#8217;s exposure
to credit risk since the previous year. The carrying amount of the Group&#8217;s financial assets represents the maximum credit exposure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity Risk</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prudent liquidity risk management implies maintaining sufficient cash
and the availability of funding through an adequate amount of committed credit facilities. The Group manages liquidity risk by maintaining
sufficient bank balances to fund its operations and the availability of funding through committed credit facilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Management monitors rolling forecasts of the Group&#8217;s liquidity
reserve on the basis of expected cash flows. See Note 1 (Going Concern Basis) of our accompanying financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturities of Financial Liabilities</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">2025</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than <br/> 6 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">6-12 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Greater than <br/>
12 months <br/>
and less than
    <br/>
5 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> contracted<br/> cash flows</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Carrying<br/> amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Trade and other payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,575,490</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,575,490</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,575,490</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(33,456</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(33,456</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(88,545</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(155,457</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(155,457</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,608,946</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(33,456</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(88,545</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,730,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,730,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">2024</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than<br/> 6 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">6-12 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Greater than<br/>
 12 months <br/>
and less than<br/>

    5 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> contracted<br/> cash flows</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Carrying<br/> amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Trade and other payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(4,619,947</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(4,619,947</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(4,619,947</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(53,566</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(53,565</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,914</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(159,045</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(159,045</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,673,513</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(53,565</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,914</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,778,992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,778,992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital Risk Management</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group&#8217;s objectives when managing capital are to safeguard
the Group&#8217;s ability to continue as a going concern and to maintain an optimal capital structure so as to maximize shareholder value.
In order to maintain or achieve an optimal capital structure, the Group may issue new shares or reduce its capital, subject to the provisions
of the Group&#8217;s constitution. The capital structure of the Group consists of equity attributed to equity holders of the Group, comprising
contributed equity, reserves and accumulated losses disclosed in Notes 10, 11 and 12. By monitoring undiscounted cash flow forecasts and
actual cash flows provided to the Board by the Group&#8217;s Management, the Board monitors the need to raise additional equity from the
equity markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(e)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Estimation</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying amount of financial assets and financial liabilities recorded
in the financial statements represents their respective fair values, determined in accordance with the accounting policies disclosed in
Note 1 to the financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Parent Entity Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ParentEntityFinancialInformationAbstract', window );"><strong>Parent Entity Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterimFinancialReportingExplanatory', window );">PARENT ENTITY FINANCIAL INFORMATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>24. PARENT ENTITY FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The individual financial statements for the parent entity show the
following aggregate amounts:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Statement of financial position</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">44,678,130</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">19,018,719</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">147,018</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,746,459</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,165,737</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,514,494</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,101,935</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,421</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,151,157</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,515,915</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,253,092</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Shareholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Contributed equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">262,948,046</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">223,151,570</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Reserves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,342,304</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,806,203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(227,059,806</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(215,045,128</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41,230,544</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,912,645</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Statement of profit or loss and other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,448,395</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,355,765</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total comprehensive loss for the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(12,448,395</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(19,355,765</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ParentEntityFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ParentEntityFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterimFinancialReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about interim financial reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 34<br> -IssueDate 2024-01-01<br> -Section Content of an interim financial report<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=34&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS34_g5-25_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterimFinancialReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cybersecurity Risk Management and Strategy</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cybersecurity risk management is an integral part
of our risk management framework. Our approach aligns with industry standards, including the National Institute of Standards and Technology
(NIST) Cybersecurity Framework (CSF), to effectively manage cybersecurity threats and incidents, including those related to third-party
applications and services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our framework includes:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Assessing the severity of cybersecurity threats</td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Identifying the sources of cybersecurity threats</td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Implementing countermeasures and mitigation strategies</td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Reporting material cybersecurity threats and incidents to
management</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Processes for Assessing, Identifying, and Managing
Material Risks from Cybersecurity Threats</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">(i)</td><td style="text-align: justify">Integration into Overall Risk Management:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cybersecurity risk management is integrated
into our broader risk management system. Regular risk assessments and business impact analyses are conducted to identify critical
systems, applications, and data, as well as potential disruptions and their consequences. The Information Security Officer (ISO)
conducts these assessments, which inform the development of contingency plans including redundancy, backup and recovery, alternate
site operations, and data restoration.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">(ii)</td><td style="text-align: justify">Engagement &amp; Oversight of Third Parties:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We engage third-party assessors, consultants, auditors,
and experts to strengthen our cybersecurity processes. For example, we utilize third-party services for continuous vulnerability scanning,
perimeter testing, Dynamic Application Security Testing (DAST), and penetration testing to identify and address potential security weaknesses
in our systems. Additionally, we engage expert architects to help design and maintain secure cloud infrastructures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our third-party engagement and oversight process
includes conducting thorough due diligence, performing vendor risk assessments, and maintaining continuous monitoring to ensure that service
providers adhere to our security standards and comply with contractual obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Material Effects of Cybersecurity Threats</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the past year, we did not encounter any cybersecurity
threats that materially affected or are likely to materially affect our business strategy, results of operations, or financial condition.
Nonetheless, we continuously enhance our cybersecurity posture to mitigate potential material impacts. Our risk management program outlines
procedures for regular log reviews, incident detection, and remediation to ensure ongoing protection of our information systems.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cybersecurity Governance</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Board of Directors&#8217; Oversight</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors plays a critical role in
overseeing cybersecurity risks as part of its broader risk oversight responsibilities. The Information Security Officer (ISO) provides
the board with updates on cybersecurity risks and incidents. Significant cybersecurity incidents are reported to the board to ensure appropriate
and timely responses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Management&#8217;s Role in Assessing and Managing Cybersecurity
Risks</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">(i)</td><td style="text-align: justify">Management Positions and Committees:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ISO is responsible for developing and maintaining
our cybersecurity and contingency plans, coordinating risk assessments, and managing incident responses. The ISO has extensive experience
in building secure web applications for healthcare. In addition to the ISO, we engage consultants and DevOps engineers with relevant degrees
and certifications to support our cybersecurity efforts. System Owners are responsible for identifying critical systems, assessing risks,
and implementing appropriate security controls.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">(ii)</td><td style="text-align: justify">Processes for Information and Monitoring:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have established comprehensive processes for
continuous monitoring and information sharing. These include regular reviews of audit logs, system activity analysis, and the deployment
of Security Information and Event Management (SIEM) tools for centralized monitoring. These processes facilitate the timely detection
and response to potential security incidents.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">(iii)</td><td style="text-align: justify">Reporting to the Board:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ISO regularly reports to executive management
and the Board of Directors. These reports include findings from risk assessments, incident reports, and updates on the status of ongoing
security initiatives, ensuring that the board is well-informed about our cybersecurity posture.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cybersecurity risk management is an integral part
of our risk management framework. Our approach aligns with industry standards, including the National Institute of Standards and Technology
(NIST) Cybersecurity Framework (CSF), to effectively manage cybersecurity threats and incidents, including those related to third-party
applications and services.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Cybersecurity risk management is integrated
into our broader risk management system. Regular risk assessments and business impact analyses are conducted to identify critical
systems, applications, and data, as well as potential disruptions and their consequences.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the past year, we did not encounter any cybersecurity
threats that materially affected or are likely to materially affect our business strategy, results of operations, or financial condition.
Nonetheless, we continuously enhance our cybersecurity posture to mitigate potential material impacts. Our risk management program outlines
procedures for regular log reviews, incident detection, and remediation to ensure ongoing protection of our information systems.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ISO is responsible for developing and maintaining
our cybersecurity and contingency plans, coordinating risk assessments, and managing incident responses. The ISO has extensive experience
in building secure web applications for healthcare. In addition to the ISO, we engage consultants and DevOps engineers with relevant degrees
and certifications to support our cybersecurity efforts. System Owners are responsible for identifying critical systems, assessing risks,
and implementing appropriate security controls.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Board of Directors&#8217; Oversight</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors plays a critical role in
overseeing cybersecurity risks as part of its broader risk oversight responsibilities. The Information Security Officer (ISO) provides
the board with updates on cybersecurity risks and incidents. Significant cybersecurity incidents are reported to the board to ensure appropriate
and timely responses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ISO is responsible for developing and maintaining
our cybersecurity and contingency plans, coordinating risk assessments, and managing incident responses. The ISO has extensive experience
in building secure web applications for healthcare. In addition to the ISO, we engage consultants and DevOps engineers with relevant degrees
and certifications to support our cybersecurity efforts. System Owners are responsible for identifying critical systems, assessing risks,
and implementing appropriate security controls.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have established comprehensive processes for
continuous monitoring and information sharing. These include regular reviews of audit logs, system activity analysis, and the deployment
of Security Information and Event Management (SIEM) tools for centralized monitoring. These processes facilitate the timely detection
and response to potential security incidents.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ISO is responsible for developing and maintaining
our cybersecurity and contingency plans, coordinating risk assessments, and managing incident responses. The ISO has extensive experience
in building secure web applications for healthcare. In addition to the ISO, we engage consultants and DevOps engineers with relevant degrees
and certifications to support our cybersecurity efforts. System Owners are responsible for identifying critical systems, assessing risks,
and implementing appropriate security controls.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">The ISO has extensive experience
in building secure web applications for healthcare. In addition to the ISO, we engage consultants and DevOps engineers with relevant degrees
and certifications to support our cybersecurity efforts.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(a) Principles of Consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements are prepared by combining the
financial statements of all the entities that comprise the Group, being Alterity Therapeutics Limited and its subsidiaries as defined
in Accounting Standard IFRS10 (AASB 10): <i>Consolidated Financial Statements</i>. Consistent accounting policies are employed in the
preparation and presentation of the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsidiaries are all those entities (including special purpose entities)
over which the Group has control. The Group controls an entity where the group is exposed to, or has rights to, variable returns from
its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity.
The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether
the Group controls another entity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsidiaries are fully consolidated from the date on which control
is transferred to the Group. They are de-consolidated from the date that control ceases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In preparing the consolidated financial statements, all inter-company
balances and transactions, and unrealized profits/losses arising within the Group are eliminated in full. Investments in subsidiaries
are accounted for at cost in the individual financial statements of Alterity Therapeutics Limited.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(b) Segment Reporting</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating segments are reported in a manner consistent with the internal
reporting provided to the chief operating decision maker (the &#8220;CODM&#8221;). The CODM, who is responsible for allocating resources
and assessing performance of the operating segments, has been identified as the Chief Executive Officer of Alterity Therapeutics Limited.
For the current and previous reporting periods, the Group operated in one segment, being research and development into Parkinsonian and
other neurodegenerative disorders.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income Tax</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(c) Income Tax</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Current tax</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Current tax is calculated by reference to the amount of income taxes
payable or recoverable in respect of the taxable profit or loss for the period. It is calculated using tax rates and tax laws that have
been enacted or substantively enacted by reporting date. Current tax for current and prior periods is recognised as a liability (or asset)
to the extent that it is unpaid (or refundable).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Deferred tax</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax is accounted for using the liability method in respect
of temporary differences arising from differences between the carrying amount of assets and liabilities in the financial statements and
the corresponding tax base of those items.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In principle, deferred tax assets and liabilities are recognised for
all taxable temporary differences. Deferred tax assets are recognised to the extent that it is probable that sufficient taxable amounts
will be available against which deductible temporary differences or unused tax losses and tax offsets can be utilized. However, deferred
tax assets and liabilities are not recognised if the temporary differences giving rise to them arise from the initial recognition of assets
and liabilities (other than as a result of a business combination) which affects neither taxable income nor accounting profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax liabilities are recognised for taxable temporary differences
arising on investments in subsidiaries except where the Group is able to control the reversal of the temporary differences and it is probable
that the temporary differences will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences
associated with these investments are only recognised to the extent that it is probable that there will be sufficient taxable profits
against which to utilize the benefits of the temporary differences and they are expected to reverse in the foreseeable future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax assets and liabilities are measured at the tax rates that
are expected to apply to the period(s) when the asset and liability giving rise to them are realized or settled, based on tax rates (and
tax laws) that have been enacted or substantively enacted by reporting date. The measurement of deferred tax liabilities and assets reflects
the tax consequences that would follow from the manner in which the Group expects, at the reporting date, to recover or settle the carrying
amount of its assets and liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax assets and liabilities are offset when there is a legally
enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.
Current tax assets and tax liabilities are offset when the entity has a legally enforceable right to offset and intends either to settle
on a net basis or to realize the asset and settle the liability simultaneously.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Current and deferred tax for the period</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Current and deferred tax is recognised as an expense or income in the
Statement of Profit or Loss and Other Comprehensive Loss except when it relates to items credited or debited directly to equity, in which
case the deferred tax is also recognised directly in equity, or where it arises from the initial accounting for a business combination,
in which case it is taken into account in the determination of goodwill.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group has significant unused tax losses and as such a significant
deferred tax asset; however, the deferred tax asset has not been recognised, as it is not probable that future taxable profit will be
available against which the unused losses and unused tax credits can be utilized, given the nature of the Group&#8217;s business (research
and development) and its history of losses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Property and Equipment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment is measured at historical cost less accumulated
depreciation and impairment and consists of laboratory equipment, computer equipment, furniture and fittings and leasehold improvements
attributable to the Group&#8217;s premises at Melbourne, Victoria, Australia and San Francisco, U.S.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Historical cost includes expenditure that is directly attributable
to the acquisition of the item.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Subsequent costs are included in the asset&#8217;s carrying amount
or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will
flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate
asset is derecognised when replaced. All other repairs and maintenance are charged to the income statement during the reporting period
in which they are incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Depreciation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation is provided on property and equipment. Depreciation is
calculated on a straight-line method to allocate their cost, net of their residual values, over their estimated useful lives.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following estimated useful lives, ranging from 3 to 20 years are
used in the calculation of depreciation:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Class of Fixed Asset</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Depreciation Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fittings</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-33%</span></td><td style="text-align: left"></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left">Computer equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">33%</td><td style="width: 1%; text-align: left"></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Plant and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-33%</span></td><td style="text-align: left"></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">33%</td><td style="text-align: left"></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leasehold improvements are depreciated over the shorter of the lease
term and useful life.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The depreciation method, residual values and useful lives are reviewed,
and adjusted if appropriate, at each annual reporting period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(e) Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accounting policies for the Group&#8217;s lease recognition are
explained in Note 13.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Investments and other financial assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(f) Investments and other financial assets </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Classification </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group classifies its financial assets in the following measurement
categories:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">those to be measured subsequently at fair value (either through OCI or through profit or loss), and</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">those to be measured at amortized cost.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The classification depends on the entity&#8217;s business model for
managing the financial assets and the contractual terms of the cash flow. For assets measured at fair value, gains and losses will either
be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, this will depend on whether
the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through
other comprehensive income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Recognition and derecognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regular way purchases and sales of financial assets are recognised
on trade-date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognised when the rights to
receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the
risks and rewards of ownership.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Measurement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At initial recognition, the Group measures a financial asset at its
fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs that are directly attributable
to the acquisition of the financial asset. Transaction costs of financial assets carried at fair value through profit or loss are expensed
in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assets that are held for collection of contractual cash flows where
those cash flows represent solely payments of principal and interest are measured at amortised cost. Interest income from these financial
assets is included in finance income using the effective interest method. Any gain or loss arising on derecognition is recognised directly
in profit or loss and presented in other gains/(losses) together with foreign exchange gains and losses. Impairment losses are presented
as a separate line item in the consolidated statement of profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Impairment</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group assesses on a forward looking basis the expected credit losses
associated with its debt instruments carried at amortized cost and fair value through other comprehensive income. The impairment methodology
applied depends on whether there has been a significant increase in credit risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For trade receivables, the Group applies the simplified approach which
requires expected lifetime losses to be recognised from initial recognition of the receivables, see Note 5 for further details.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory', window );">Impairment of Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(g) Impairment of Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At each reporting date, the Group reviews the carrying amounts of its
tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If any such indication
exists, the recoverable amount of the asset is estimated to determine the extent of the impairment loss (if any).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where the asset does not generate cash flows that are independent from
other assets, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recoverable amount is the higher of fair value less costs of disposal
and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount
rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of
future cash flows have not been adjusted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the recoverable amount of an asset (or cash-generating unit) is
estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable
amount. An impairment loss is recognised in the consolidated statement of profit or loss and other comprehensive loss immediately.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where an impairment loss subsequently reverses, the carrying amount
of the asset (or cash-generating unit) is reversed to the revised estimate of its recoverable amount, but only to the extent that the
increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for
the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised in the consolidated statement of profit
or loss and other comprehensive loss immediately.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No impairment charges were incurred during the year ended June 30,
2025.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Intangible Assets - Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(h) Intangible Assets - Research and Development </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Expenditure during the research phase of a project is recognised as
an expense when incurred. Where no internally generated intangible assets can be recognised, development expenditure is recognised as
an expense in the period as incurred. Development costs are capitalised if and only if, all of the following are demonstrated:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the technical feasibility of completing the intangible asset so that it will be available for use or sale;</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the intention to complete the intangible asset and use or sell it;</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to use or sell the intangible asset;</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">how the intangible asset will generate probable future economic benefits;</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to measure reliably the expenditure attributable to the intangible asset during its development.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Internally-generated intangible assets (capitalised development costs)
are stated at cost less accumulated amortisation and impairment, and are amortised on a straight-line basis over their useful lives over
a maximum of five years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2025, 2024 and 2023, the Group had no capitalized research
and development costs.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign Currency Transactions and Balances</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(i) Foreign Currency Transactions and Balances</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Functional and Presentation Currency</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements are presented in Australian dollars
($), which is Alterity Therapeutics Limited&#8217;s functional and presentation currency.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Foreign currency transactions</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All foreign currency transactions during the financial year are brought
to account using the exchange rate in effect at the date of the transaction. Foreign currency monetary items at each reporting date are
translated at the exchange rate existing at each reporting date. Non-monetary assets and liabilities carried at fair value that are denominated
in foreign currencies are translated at the rates prevailing at the date when the fair value was determined.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exchange differences are recognised in profit or loss in the period
in which they arise except for exchange differences on monetary items receivable from or payable to a foreign operation for which settlement
is neither planned or likely to occur, which form part of the net investment in a foreign operation, are recognised in the foreign currency
translation reserve and recognised in profit or loss on disposal of the net investment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Subsidiaries</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The results and financial position of all the Group&#8217;s entities
that have a functional currency difference from the presentation currency are translated into the presentation currency as follows:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet, and</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">income and expenses for each income statement are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions), and</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all resulting exchange differences are recognised as a separate component of equity.</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee Benefits</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(j) Employee Benefits</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Short-term obligations</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Short-term employee benefits are benefits (other than termination benefits)
that are expected to be settled wholly before 12 months after the end of the annual reporting period in which the employees render the
related service, including wages, and salaries. Short-term employee benefits are measured at the (undiscounted) amounts expected to be
paid when the obligation is settled. The Group&#8217;s obligations for short-term employee benefits such as wages and salaries are recognised
as a part of current trade and other payables in the statement of financial position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group&#8217;s obligations for annual leave are presented as part
of provisions in the Statement of Financial Position. The obligations are presented as current liabilities in the Statement of Financial
Position if the Group does not have an unconditional right to defer settlement for at least twelve months after the reporting period regardless
of when the actual settlement is expected to occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Other long-term obligations</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The liability for long service leave is not expected to be settled
wholly within twelve months after the end of the period in which the employees render the related service. The liability is therefore
recognised in the provision for employee benefits and measured as the present value of expected future payments to be made in respect
of services provided by employees up to the end of the reporting period using the projected unit credit method. Consideration is given
to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted
using market yields at the end of the reporting period of high quality corporate bonds with terms and currencies that match, as closely
as possible, the estimated future cash outflows. Re-measurements as a result of experience adjustments and changes in actuarial assumptions
are recognised in profit or loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The obligations are presented as current liabilities in the balance
sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless
of when the actual settlement is expected to occur.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(k) Provisions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Provisions are recognised when the Group has a present obligation,
the future sacrifice of economic benefits is probable, and the amount of the provision can be measured reliably.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amount recognised as a provision is the best estimate of the consideration
required to settle the present obligation at reporting date, taking into account the risks and uncertainties surrounding the obligation.
Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value
of those cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">When some or all of the economic benefits required to settle a provision
are expected to be recovered from a third party, the receivable is recognised as an asset if it is virtually certain that recovery will
be received and the amount of the receivable can be measured reliably.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(l) Cash and Cash Equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash and cash equivalents include cash on hand, deposits held at call
with banks and other short-term highly liquid investments with original maturities of three months or less.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome', window );">Interest income</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><b>(m) Interest income</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other income is made up of interest income which is recognised on a
time proportion basis using the effective interest method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants', window );">Grants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(n) Grants</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Grants are recognised when there is reasonable assurance that the grant
will be received and all grant conditions will be complied with.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">When the grant relates to an expense item, it is recognised as income
over the periods necessary to match the grant on a systematic basis to the costs that it is expected to compensate.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory', window );">Goods and Services Tax (&#8220;GST&#8221;)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(o) Goods and Services Tax (&#8220;GST&#8221;)</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenues, expenses and assets are recognised net of the amount of GST,
except where the amount of GST incurred is not recoverable from the taxation authority. In these circumstances the GST is recognised as
part of the cost of acquisition of the asset or as part of an item of expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Receivables and payables in the Statement of Financial Position are
shown inclusive of GST. The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables
or payables.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash flows are included in the Cash Flow Statement on a gross basis.
The GST component of cash flows arising from investing and financing activities which is recoverable from, or payable to, the taxation
authority is classified as operating cash flows.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory', window );">Trade and Other Payables</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(p) Trade and Other Payables</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These amounts represent liabilities for goods and services provided
to the Group prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of
recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months from the reporting
date. They are recognised initially at their fair value and subsequently measured at amortized cost using the effective interest method.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-Based Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(q) Share-Based Payments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The measurement date is determined for share-based payments issued
to directors, employees and consultants as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Directors</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The issuance of share-based payments to directors is subject to approval
by shareholders as per ASX Listing Rule 10.11. The measurement date for share-based payments issued to directors is the grant date, being
the date at which the share-based payments are approved by shareholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Employees</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The issuance of share-based payments to employees may be subject to
shareholder approval per ASX Listing Rule 7.1 which prohibits the issuance of more than 15% of the Group&#8217;s shares in a 12 month
period without shareholder approval. The measurement date for share-based payments issued to employees is the grant date, being the date
at which a shared understanding of the terms and conditions of the arrangement is reached. However, if an issuance to an employee is subject
to shareholder approval because it exceeds the 15% threshold per ASX Listing Rule 7.1, then the measurement date of these share-based
payments is the date at which the share-based payments are approved by shareholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Consultants</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The issuance of share-based payments to consultants may be subject
to shareholder approval per ASX Listing Rule 7.1 which prohibits the issuance of more than 15% of the Group&#8217;s shares in a 12 month
period without shareholder approval. The measurement date for share-based payments issued to consultants who provide services considered
to be similar to employees is deemed to be the date at which a shared understanding of the terms and conditions of the arrangement is
reached. The measurement date for share-based payments issued to consultants who provide services considered to be differentiated from
those provided by employees is deemed to be the date at which the entity obtains the goods or the counterparty renders the service. If
a service period applies and the work is continually provided over the service period, and if the share price of the Group does not change
significantly during the service period, then the average share price, volatility and risk-free rate over the service period are used
in calculating the value of the share-based payments issued. However, if the underlying share price of the Group does change significantly
during the service period, then the value of share-based payments are calculated at each individual date that goods and services are provided,
using the actual valuation inputs at that date. Shares issued to consultants for services are recorded as non-cash compensation and are
recognised at either the fair value of the services rendered, or if this cannot be reasonably estimated, the fair value of the underlying
equity instruments issued. Equity-based compensation benefits are provided to directors, employees and consultants under the 2004 ASX
Plan (the &#8220;2004 ASX Plan&#8221;) and the 2018 American Depository Share (ADS) Option Plan (the &#8220;2018 ADS Plan&#8221;). Information
relating to this plan is set out in Note 16.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value of options granted under these plans is recognised as
an expense with a corresponding increase in equity. The fair value is measured at grant date and recognised over the period during which
the recipients become unconditionally entitled to the options.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value at grant date is independently determined using a Black-Scholes
(for options without market condition) and Barrier Pricing (for options with market conditions) model that takes into account the exercise
price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share,
the expected dividend yield and the risk free interest rate for the term of the option. The expected life used in the model has been adjusted,
based on management&#8217;s best estimate, for the effects of non-transferability, exercise restrictions, and behavioral considerations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value determined at the grant date of the equity-settled share-based
payments is expensed on a straight-line basis over the vesting period, based on the Group&#8217;s estimate of shares that will eventually
vest.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(r) Loss Per Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic loss per share is determined by dividing the net loss after income
tax expense by the weighted average number of ordinary shares outstanding during the financial period. For all periods presented, diluted
loss per share is equivalent to basic loss per share as the potentially dilutive securities are excluded from the computation of diluted
loss per share because the effect is anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory', window );">Share Capital</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(s) Share Capital</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ordinary share capital is recognised as the fair value of the consideration
received by the Group. Any transaction costs arising on the issue of ordinary shares are recognised directly in equity as a reduction
of the share proceeds received.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory', window );">Trade and Other Receivables</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(t) Trade and Other Receivables</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Trade and other receivables are recognised initially at fair value
and subsequently measured at amortized cost using the effective interest rate method less provision for impairment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock', window );">Comparative Figures</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(u) Comparative Figures</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Comparative figures, are, where appropriate, reclassified to be comparable
with figures presented in the current financial year.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock', window );">New Accounting Standards and Interpretations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(v) New Accounting Standards and Interpretations </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group has adopted all of the new or amended Accounting Standards
and Interpretations issued by the International Accounting Standards Board &#8216;IASB&#8217; and Australian Accounting Standards Board
&#8216;AASB&#8217; that are mandatory for the current reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The adoption of these standards has not had any material impact on
the disclosures or amounts reported in these financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2024, IFRS 18, &#8220;Presentation and Disclosure in Financial
Statements&#8221; was issued to achieve comparability of the financial performance of similar entities. The standard, which replaces IAS
1 &#8220;Presentation of Financial Statements&#8221;, impacts the presentation of primary financial statements and notes, including the
statement of earnings where companies will be required to present separate categories of income and expense for operating, investing,
and financing activities with prescribed subtotals for each new category. The standard will also require management-defined performance
measures to be explained and included in a separate note within the consolidated financial statements. The standard is effective for annual
reporting periods beginning on or after January 1, 2027, including interim financial statements, and requires retrospective application.
The Group is currently assessing the impact of the new standard.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no other new accounting standards and interpretations not
yet adopted by the Group for the June 30, 2025 reporting period that are expected to materially impact the Group.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for basis used for consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for comparative figure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for new accounting standards and interpretations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for recognizing other income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2024-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for taxes other than income tax. [Refer: Tax expense other than income tax expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 46<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_46&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background and Summary of Material Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Background and Summary of Material Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of Estimated Useful Lives</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following estimated useful lives, ranging from 3 to 20 years are
used in the calculation of depreciation:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Class of Fixed Asset</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Depreciation Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fittings</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-33%</span></td><td style="text-align: left"></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left">Computer equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">33%</td><td style="width: 1%; text-align: left"></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Plant and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-33%</span></td><td style="text-align: left"></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">33%</td><td style="text-align: left"></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest and Other Income from Continuing Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract', window );"><strong>Interest and Other Income from Continuing Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock', window );">Schedule of Interest and Other Income from Continuing Operations</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Interest income</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Interest income</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">446,291</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">268,419</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">16,436</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total interest income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">446,291</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">268,419</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,436</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D Tax Incentive (1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,438,918</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,019,285</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,914,230</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Miscellaneous income (2)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,202,598</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,103</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,641,516</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,019,285</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,916,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total interest and other income from continuing operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,087,807</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,287,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,932,769</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A 43.5% R&amp;D Tax incentive refundable tax offset, is available to eligible small companies with an annual aggregate turnover of less than $20 million. For the years ended June 30, 2025, June 30, 2024 and June 30, 2023, the Group was eligible to receive the refundable tax offset. Management, with input from an independent expert, has applied judgement when assessing activities and expenditures that are likely to be eligible under the incentive scheme and therefore recorded $5,438,918, $4,019,285 and $3,914,230 in other income, respectively.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Miscellaneous income is comprised of other income of $1,975,056 in relation to settlement of a dispute with Catalent, and other income of $227,542 in relation to settlement of an insurance claim in relation to a U.S. employment case.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue and other income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Expenses from Ordinary Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses from Ordinary Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Schedule of Expenses from Ordinary Activities</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Research and Development Expenses (1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Employee expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,424,781</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,456,230</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,720,345</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,107,024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,187,817</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,478,238</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">General and Administration Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Depreciation on fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,307</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,344</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,854</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Depreciation on leased assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111,408</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,409</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Employee expenses (non R&amp;D related)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,046,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">515,803</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">926,314</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Consultant and director expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">652,260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">321,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">320,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Audit, internal control and other assurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">460,254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">238,728</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Corporate compliance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">780,320</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">790,350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457,215</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">549,408</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">676,219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">721,732</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Office rental</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,253</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,674</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,634</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other administrative and office expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">520,142</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,028,638</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,032,843</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Share based payment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">979,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">881,950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">966,571</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Corporate advisory expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">355,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204,621</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Other gains and losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Foreign exchange (gain)/loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(259,433</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(261,152</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(917,650</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses mainly consist of expenses paid for contracted research and development activities conducted by third parties on behalf of the Group.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses by nature. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock', window );">Schedule of Income Tax</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>(a) Income tax expense:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Current tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">77,411</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">58,463</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33,808</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustment for current tax of prior periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,356</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,375</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,651</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">(b) Numerical reconciliation of income tax expense to prima facie tax payable:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Prima facie tax on net loss before income tax at 25% (2024: 25%, 2023: 25%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,019,943</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,769,344</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,446,718</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Effect of lower tax rates of tax on overseas income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,745</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,134</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,440</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Add tax effect of:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Under/(Over) provision of income tax in previous year relating to a revision of estimates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,356</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,375</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,651</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development expenditure (net of tax incentive)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">898,066</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,305,112</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267,940</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">464,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">377,405</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">413,976</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred tax asset not recognised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,749,734</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,156,424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,805,050</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Income tax expense attributable to loss before income tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,055</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,088</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">104,459</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">(c) Potential deferred tax asset as of June 30, 2025, 2024 and 2023 in respect of: tax losses not brought to account is (1)(2):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,885,043</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,758,242</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,056,899</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Temporary differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,798,561</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,660,171</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,675,742</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">As of June 30, 2025, the Group had a potential tax benefit related to gross tax losses carried forward of $187,632,492 (2024: $179,125,289) and a non-refundable R&amp;D tax offset of $2,126,801 (2024: $3,703,478).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unused tax loss amounts are only attributable to the Group&#8217;s operations in Australia, as the subsidiary in the United States has no carryforward tax losses as of June 30, 2025. Tax losses can be carried forward indefinitely subject to continuity of ownership and same business test rules.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and Other Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_DisclosureOfTradeAndOtherReceivableTableTextBlock', window );">Schedule of Trade and Other Receivables</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued interest income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">157</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">R&amp;D tax incentive receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,928,563</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,019,286</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Goods and services tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,044</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,232</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,937,607</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,041,675</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_DisclosureOfTradeAndOtherReceivableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of trade and other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_DisclosureOfTradeAndOtherReceivableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory', window );">Schedule of Other Current Assets</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Years Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Prepayments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,233,122</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,315,632</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Term deposit (1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,668</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,774,937</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,356,300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Term deposit of 150-day term and maturity date of October
17, 2025.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of prepayments and other assets. [Refer: Other assets; Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Trade and Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfTradeAndOtherPayableTableTextBlock', window );">Schedule of Trade and Other Payables</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Trade creditors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">538,276</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">581,137</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,684,726</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,499,960</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">193,095</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234,899</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued corporate personnel expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">139,240</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166,063</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,457</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,253</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,431</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,575,490</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,619,947</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfTradeAndOtherPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for trade and other payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfTradeAndOtherPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionsAbstract', window );"><strong>Provisions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory', window );">Schedule of Provisions</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="text-decoration:underline">Current</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Annual leave (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">631,941</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">318,694</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Long service leave (1)(2)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">243,967</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">212,005</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">875,908</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">530,699</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline">Non-Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long service leave (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(1) Movements in provisions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(2) Amounts not expected to be settled within the next 12 months</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock', window );">Schedule of Movements in Provisions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Movements in each class of provision during the financial year are
set out below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Annual leave</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Carrying amount at start of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">318,694</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">420,380</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">371,877</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Charged/(credited) to profit or loss -additional provisions recognised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409,646</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">179,923</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">272,502</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amounts used during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(97,011</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(280,618</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(232,747</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in foreign exchange</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">612</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(991</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,748</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Carrying amount at end of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">631,941</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">318,694</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">420,380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Long service leave</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Carrying amount at start of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">212,005</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">328,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">298,143</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Charged/(credited) to profit or loss -additional provisions recognised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,901</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,308</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,182</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Amounts used during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(939</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(146,628</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Carrying amount at end of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">243,967</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">212,005</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">328,325</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">875,908</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">530,699</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">748,705</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of movements in each class of provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other provisions, contingent liabilities and contingent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS37_g84-92_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapitalAbstract', window );"><strong>Issued Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of Issued Capital</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">(a) Issued Capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">9,127,370,686 (2024: 5,245,115,318) fully paid ordinary shares</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">10(b)</td><td style="width: 1%; text-align: left"></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">262,949,462</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">223,152,985</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">213,971,323</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Nil (2024: Nil) options for fully paid ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">10(c)</td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85"><span style="-sec-ix-hidden: hidden-fact-88">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86"><span style="-sec-ix-hidden: hidden-fact-89">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">262,949,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">223,152,985</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">213,971,323</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock', window );">Schedule of Movements in Issued Shares</a></td>
<td class="text">Movements in Issued Shares<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,245,115,318</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">223,152,985</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,439,897,618</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">213,971,323</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,406,874,578</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">213,787,061</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Movement during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,882,255,368</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,796,477</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,805,217,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,181,662</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,023,040</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184,262</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">End of the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,127,370,686</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">262,949,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,245,115,318</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">223,152,985</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,439,897,618</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">213,971,323</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory', window );">Schedule of Details of Share Issuances</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Details of share issuances are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Date</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Details</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Notes</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Number</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Issue<br/> Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%; font-weight: bold; padding-bottom: 1.5pt">Year end June 30, 2022</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 30%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1.5pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">322,857,900</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">16,339,071</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>September 21, 2022</td><td>&#160;</td> <td style="text-align: left">Issue of shares under ATM Facility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,543,840</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0135</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">128,842</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>March 15, 2023</td><td>&#160;</td> <td style="text-align: left">Issue of shares under ATM Facility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">23,479,200</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0080</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">187,834</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">June 30, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; padding-bottom: 1.5pt">Security issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(132,413</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Year end June 30, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">33,023,040</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">184,263</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>November 29,2023</td><td>&#160;</td> <td style="text-align: left">Issue of shares under ATM Facility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">362,462,762</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0035</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,268,620</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>January 8,2024</td><td>&#160;</td> <td style="text-align: left">Issue of shares under ATM Facility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,008,965,805</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0035</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,531,380</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>February 2,2024</td><td>&#160;</td> <td style="text-align: left">Issue of shares under ATM Facility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">571,428,556</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0035</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>March 4, 2024</td><td>&#160;</td> <td style="text-align: left">Issue of shares under ATM Facility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">855,263,158</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0038</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,250,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>April 22, 2024</td><td>&#160;</td> <td style="text-align: left">Issue of shares under options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7,097,419</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0070</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">49,682</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>June 30, 2024</td><td>&#160;</td> <td style="text-align: left">Security issuance costs</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(918,020</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 1.5pt">Year end June 30, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,805,217,700</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">9,181,662</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>July 18,2024</td><td>&#160;</td> <td style="text-align: left">Issue of shares under ATM Facility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">75,220,800</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0054</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">398,645</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>January 22,2025</td><td>&#160;</td> <td style="text-align: left">Issue of shares under options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">95,238</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0100</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">952</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>January 30,2025</td><td>&#160;</td> <td style="text-align: left">Issue of shares under options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,333,333</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">48,873</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>February 3,2025</td><td>&#160;</td> <td style="text-align: left">Issue of shares under ATM Facility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">164,242,200</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0129</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,122,173</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>February 17,2025</td><td>&#160;</td> <td>Issue of Placement shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,165,841,830</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0110</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12,824,260</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>March 14, 2025</td><td>&#160;</td> <td style="text-align: left">Issue of shares under options exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">161</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0100</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>April 4, 2025</td><td>&#160;</td> <td>Issue of Placement shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,470,521,806</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0110</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">27,175,740</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">June 30, 2025</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: left; padding-bottom: 1.5pt">Security issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,774,168</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; font-weight: bold">Year end June 30, 2025</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,882,255,368</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">39,796,477</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the tabular disclosure of movements in issued shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the range of exercise prices for outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityAbstract', window );"><strong>Reserves [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock', window );">Schedule of Reserves of Share Based Payments</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">(a) Share Based Payments</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">2,683,471,567 (2024: 3,250,009,092, 2023: 170,042,720) options for fully paid ordinary shares</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1.5pt; text-align: center">11(c)</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"></td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5,342,304</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">4,806,203</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3,972,475</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,342,304</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,806,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,972,475</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">(b) Warrants/Free-attaching options</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,154,912,180 free-attaching options (2024: 2,868,466,372 free-attaching options, 2023: 674,694,939) for fully paid ordinary shares <sup>(1)</sup></span></td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1.5pt; text-align: center">11(c)</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 8, 2024 a total of 457,142,830 free attaching options with an exercise price of A$0.01, expiring on August 31, 2026 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 8, 2024 a total of 1,371,428,567 free attaching options with an exercise price of A$0.007, expiring on August 31, 2024 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 2, 2024 a total of 190,476,123 free attaching options with an exercise price of A$0.002, expiring on August 31, 2026 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 2, 2024 a total of 571,428,556 free attaching options with an exercise price of A$0.007, expiring on August 31, 2024 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 15, 2024 a total of 285,087,715 free attaching options with an exercise price of A$0.01, expiring on August 31, 2026 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 23, 2025 a total of 1,222,300,911 free attaching options with an exercise price if A$0.028, expiring on February 26, 2027 were issued.</p></td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock', window );">Schedule of Movements in Options for Fully Paid Ordinary Shares</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Movements in Options for Fully Paid Ordinary Shares</b></span><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="23" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(A$)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(A$)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(A$)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,250,009,092</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,806,203</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">170,042,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,972,475</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">184,692,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,565,918</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Options issued during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,392,300,911</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,092,563,791</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Expired during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,947,759,704</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(326,544</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,150,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(560,014</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Forfeited during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,650,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(93,735</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,500,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(93,222</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,500,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,150</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Options exercised during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,428,732</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,540</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Shares to be issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Share Based Payment expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">979,920</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">881,950</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">983,721</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">End of the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,683,471,567</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,342,304</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,250,009,092</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,806,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">170,042,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,972,475</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of movements in options for fully paid ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of reserve of share based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReservesWithinEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReservesWithinEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Deficit During Development Stage (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_AccumulatedDeficitDuringDevelopmentStageAbstract', window );"><strong>Accumulated Deficit During Development Stage [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock', window );">Schedule of Accumulated Deficit During Development Stage</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Balance at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">214,161,131</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">195,130,889</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">181,884,388</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,147,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,123,464</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,806,515</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Reclassify expired options from reserves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(326,544</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(560,014</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Reclassify forfeited options from reserves</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(93,735</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(93,222</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Balance at end of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">225,888,680</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">214,161,131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">195,130,889</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_AccumulatedDeficitDuringDevelopmentStageAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_AccumulatedDeficitDuringDevelopmentStageAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents tabular disclosure of accumulated deficit during development stage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock', window );">Schedule of Financial Position Shows the Following Amounts Relating to Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statement of financial position shows the following amounts relating
to leases:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><b><i>Right-of-use assets</i></b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">151,326</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">154,729</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">207,087</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,912</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,177</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,545</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,914</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,207</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">155,457</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">159,045</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">210,384</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases', window );">Schedule of Profit or Loss Shows the Following Amounts Relating to Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statement of profit or loss shows the following amounts relating
to leases:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation of right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">111,408</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">112,185</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">64,409</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,188</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,565</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expenses relating to short-term leases (included in general and administration expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,674</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,634</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expenses relating to variable lease payments not included in lease liabilities (included in general and administration expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of amounts recognized in profit or loss relating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of amounts relating to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Schedule of Cash Flow Information</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">(a) Reconciliation of Net Loss to Net Cash Flows Used In Operations</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(12,147,828</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(19,123,464</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(13,806,515</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Non-cash items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,307</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,344</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,854</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation on leased assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111,408</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,409</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,056</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based payment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">979,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">881,950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">966,571</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Foreign exchange loss/(gain)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(259,433</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(261,152</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(917,650</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Fixed asset write off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,232</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Changes in assets and liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Decrease/(increase) in trade and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,068</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,624,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,940,343</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Decrease/(increase) in other current assets (excepting term deposit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,081,363</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">252,986</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(968,207</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">(Decrease)/increase in trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,044,457</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,102,239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,560,873</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">(Decrease) in other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(99,861</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,935</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Increase/(decrease) in provision for employee entitlements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">345,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(218,006</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78,685</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash flows used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,451,248</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,605,824</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,035,837</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">(b) Reconciliation of Cash and Cash Equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents balance comprises:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">- cash and cash equivalents on hand</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,158,642</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,638,885</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,773,783</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Closing cash and cash equivalents balance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,158,642</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,638,885</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,773,783</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share Based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of Options Granted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Information with respect to the number of options granted under the
2004 ASX Plan and 2018 ADS Plan as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">381,542,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">170,042,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.047</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">184,692,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.05</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issued during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">217,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Exercised during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,333,333</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expired during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,000,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,150,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,650,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.036</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.036</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.02</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Outstanding at year end</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">358,559,387</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.021</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">381,542,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">170,042,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.05</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Vested and Exercisable at year end</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">275,689,612</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.024</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">195,708,100</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.033</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">87,280,755</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.06</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock', window );">Schedule of Options Outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Options outstanding at the end of the year have the following expiry
date and exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><b>Series</b></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>Grant Date</b></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Expiry Date</b></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$A</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%">ATHAAB</td><td style="width: 1%">&#160;</td> <td style="text-align: center; width: 20%; vertical-align: bottom">September 18, 2020</td><td style="width: 1%">&#160;</td> <td style="text-align: center; width: 20%">September 17, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.09</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">35,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">35,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>ATHAAD</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">January 7, 2021</td><td>&#160;</td> <td style="text-align: center">January 6, 2026</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">91,392,720</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">91,392,720</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>ATHAAE</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">November 29, 2021</td><td>&#160;</td> <td style="text-align: center">November 29, 2026</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">14,250,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>ATHAAF</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">July 31, 2021</td><td>&#160;</td> <td style="text-align: center">July 31, 2024</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.07</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12,000,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>ATHAAG</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">November 21, 2021</td><td>&#160;</td> <td style="text-align: center">November 29, 2026</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.02</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11,900,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>ATHAAH</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">December 21, 2023</td><td>&#160;</td> <td style="text-align: center">December 19, 2026</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.001</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8,000,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>ATHAA</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">March 13, 2024</td><td>&#160;</td> <td style="text-align: center">March 13, 2029</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,166,667</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">26,500,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>ATHAB</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">March 13, 2024</td><td>&#160;</td> <td style="text-align: center">March 13, 2029</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.005</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">62,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">62,500,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">ATHAC</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">March 21, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">March 21, 2029</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.003</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-137; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">358,559,387</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">381,542,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="8" style="text-align: left">Weighted average remaining contractual life of options outstanding at end of period.</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.37 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.28 years</span></td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock', window );">Schedule of Valuations of Options Approved and Issued</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The model inputs for the valuations of options approved and issued
during the current and previous financial years are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold; vertical-align: bottom"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price <br/> per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share Price <br/> at Grant<br/> Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Expected Share <br/> Price </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Years to<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Dividend<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Risk-free<br/> Interest </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value<br/> per Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom"><b>Series</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>Grant Date</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>A$</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>A$</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Volatility</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Expiry</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Yield</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Rate</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>A$</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 6%; vertical-align: bottom">ATHAAB</td><td style="width: 1%">&#160;</td> <td style="text-align: center; white-space: nowrap; width: 16%; vertical-align: bottom">September 18,2020</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0.09</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0.05</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">98.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">5.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0.43</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0.032</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: bottom">ATHAAD</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">January 7,2021</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.032</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">139.52</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.38</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.028</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">ATHAAE</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">November 29, 2021</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.025</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">138.47</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.021</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: bottom">ATHAAF</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">July 31, 2021</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.07</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.034</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">169.42</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.13</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.027</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">ATHAAG</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">November 29, 2021</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.02</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0238</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">138.47</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.021</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: bottom">ATHAAH</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">December 21, 2023</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0065</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">133.87</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.67</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.005</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">ATHAA</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">March 13, 2024</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">158.31</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.47</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: bottom">ATHAB</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">March 13, 2024</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">158.31</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.47</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: bottom">ATHAC</td><td>&#160;</td> <td style="text-align: center; vertical-align: bottom">March 21, 2024</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.003</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">158.83</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.48</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.004</td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfNumberOfSharesIssuedTableTextBlock', window );">Schedule of Shares Issued under Stock Option Plan</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Information with respect to the number of shares issued under the stock
option plan as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,277,715</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,277,715</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,277,715</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Issued during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">End of the financial year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,277,715</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,277,715</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,277,715</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfNumberOfSharesIssuedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number of shares issued during period under ASX Plan 2004.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfNumberOfSharesIssuedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of options outstanding at the end of the year having expiry dates and exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents tabular disclosure of valuation of options approved and issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Schedule of Earning Loss Per Share</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Basic and diluted loss per share (cents per share)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(0.19</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(0.52</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(0.57</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted average number of ordinary shares on issue used in the calculation of basic and diluted loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,396,924,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,648,875,564</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,427,841,917</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Key Management Personnel Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract', window );"><strong>Key Management Personnel Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock', window );">Schedule of Key Management Personnel Compensation</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Short-term employee benefits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,522,550</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,551,075</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,727,020</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Post-employment benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,444</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,616</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,215</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Termination benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Share-based payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">802,128</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">520,055</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">764,175</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,343,398</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,113,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,540,854</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about key management personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Auditors' Remuneration (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationAbstract', window );"><strong>Auditors' Remuneration [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfAuditorRemunerationTableTextBlock', window );">Schedule of Audit and Review of Financial Statements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">- Audit and review of financial statements (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">248,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">248,200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">246,400</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">- Other audit services (2)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">95,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">320,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">343,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">298,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit and review of financial statements consist of fees billed for assurance and related services that generally only the statutory auditor could reasonably provide to a client. </span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included in the balance are amounts related to additional regulatory filings during the 2025 financial year. All services provided are considered audit services for the purpose of SEC classification. </span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfAuditorRemunerationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of auditor's remuneration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfAuditorRemunerationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory', window );">Schedule of Financial Assets and Liabilities Subject to Foreign Currency Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following financial assets and liabilities are subject to foreign
currency risk, the currency of the original amounts are displayed in brackets, all the amounts in the table below are displayed in A$
at year-end spot rates:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Consolidated Entity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents (USD)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,544,448</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">225,722</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other payables (USD)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(495,145</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(507,820</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade and other payables (&#163;GBP)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,834</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Trade and other payables (JPY)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total exposure</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,050,099</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(288,924</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Schedule of Interest Rates and the Effective Weighted Average Interest Rate for Classes of Financial Assets and Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Group&#8217;s exposure to interest rates and the effective weighted
average interest rate for classes of financial assets and liabilities is set out below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Floating <br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fixed Interest <br/> Maturing in<br/> (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Non-Interest<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Average<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><b>June 30, 2025</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Interest&#160;Rate <br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>1 year<br/> or less</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>1-5 years</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>bearing<br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total<br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Interest Rate</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Financial Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">30,698,409</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,835</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,463,168</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33,158,642</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.130</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,937,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,937,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,531,050</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,765</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,541,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">4.40</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Financial Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,698,409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,528,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,411,540</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,638,064</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,575,490</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,575,490</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(66,912</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(88,545</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(155,457</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Financial Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(66,912</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(88,545</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,575,490</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,730,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Floating <br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fixed Interest <br/> Maturing in<br/> (A$)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Non-Interest<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Average<br/> </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><b>June 30, 2024</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Interest&#160;Rate <br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>1 year<br/> or less</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>1-5 years</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>bearing<br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total<br/> (A$)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Interest Rate</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Financial Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,529,456</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(4,293</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,113,722</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12,638,885</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.463</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,041,675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,041,675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,091</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,577</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,668</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3.515</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Financial Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,529,456</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,798</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,165,974</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,721,228</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,619,947</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,619,947</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(107,131</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(51,914</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(159,045</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Financial Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(107,131</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,914</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,719,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,878,992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Schedule of Company's Liquidity Reserve on the Basis of Expected Cash Flows</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Management monitors rolling forecasts of the Group&#8217;s liquidity
reserve on the basis of expected cash flows. See Note 1 (Going Concern Basis) of our accompanying financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturities of Financial Liabilities</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">2025</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than <br/> 6 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">6-12 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Greater than <br/>
12 months <br/>
and less than
    <br/>
5 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> contracted<br/> cash flows</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Carrying<br/> amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Trade and other payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,575,490</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,575,490</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,575,490</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(33,456</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(33,456</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(88,545</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(155,457</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(155,457</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,608,946</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(33,456</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(88,545</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,730,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,730,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">2024</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than<br/> 6 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">6-12 months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Greater than<br/>
 12 months <br/>
and less than<br/>

    5 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> contracted<br/> cash flows</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Carrying<br/> amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Trade and other payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(4,619,947</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(4,619,947</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(4,619,947</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(53,566</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(53,565</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,914</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(159,045</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(159,045</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,673,513</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(53,565</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,914</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,778,992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,778,992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of risk management strategy related to hedge accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 22A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_22A&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Parent Entity Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ParentEntityFinancialInformationAbstract', window );"><strong>Parent Entity Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_DisclosureOfParentEntityFinancialStatementsExplanatory', window );">Schedule of Individual Financial Statements for the Parent Entity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The individual financial statements for the parent entity show the
following aggregate amounts:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Statement of financial position</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">44,678,130</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">19,018,719</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">147,018</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,746,459</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,165,737</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,514,494</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,101,935</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,421</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,151,157</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,515,915</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,253,092</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Shareholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Contributed equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">262,948,046</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">223,151,570</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Reserves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,342,304</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,806,203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(227,059,806</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(215,045,128</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41,230,544</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,912,645</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Statement of profit or loss and other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,448,395</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,355,765</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total comprehensive loss for the year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(12,448,395</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(19,355,765</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_DisclosureOfParentEntityFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of parent entity financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_DisclosureOfParentEntityFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ParentEntityFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ParentEntityFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background and Summary of Material Accounting Policies (Details) - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Background and Summary of Material Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_TaxRateEffectFromChangesInTaxRate', window );">Tax rate change tax rate, description</a></td>
<td class="text">A 43.5% refundable tax offset is available to eligible small companies with an annual aggregate
turnover of less than $20 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_EligibleAmountUnderTheTaxIncentiveScheme', window );">Other income</a></td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income related to research and development</a></td>
<td class="nump">7,641,516<span></span>
</td>
<td class="nump">4,019,285<span></span>
</td>
<td class="nump">3,916,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ProfitLossBeforeTax1', window );">Operating loss</a></td>
<td class="nump">12,147,828<span></span>
</td>
<td class="nump">19,123,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ProfitLossBeforeTax2', window );">Operating cash outflow</a></td>
<td class="nump">11,451,248<span></span>
</td>
<td class="nump">12,605,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net proceeds</a></td>
<td class="nump">$ 39,669,380<span></span>
</td>
<td class="nump">$ 9,216,292<span></span>
</td>
<td class="nump">$ 124,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_Employeesdescription', window );">Employees,description</a></td>
<td class="text">EmployeesThe issuance of share-based payments to employees may be subject to
shareholder approval per ASX Listing Rule 7.1 which prohibits the issuance of more than 15% of the Group&#8217;s shares in a 12 month
period without shareholder approval. The measurement date for share-based payments issued to employees is the grant date, being the date
at which a shared understanding of the terms and conditions of the arrangement is reached. However, if an issuance to an employee is subject
to shareholder approval because it exceeds the 15% threshold per ASX Listing Rule 7.1, then the measurement date of these share-based
payments is the date at which the share-based payments are approved by shareholders.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Background and Summary of Material Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_EstimatedUsefulEconomicLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Background and Summary of Material Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_EstimatedUsefulEconomicLife', window );">Estimated useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_EligibleAmountUnderTheTaxIncentiveScheme">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Eligible amount under the tax incentive scheme.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_EligibleAmountUnderTheTaxIncentiveScheme</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_Employeesdescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employees, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_Employeesdescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_EstimatedUsefulEconomicLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated useful economic life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_EstimatedUsefulEconomicLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ProfitLossBeforeTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ProfitLossBeforeTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ProfitLossBeforeTax2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit loss before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ProfitLossBeforeTax2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_TaxRateEffectFromChangesInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of tax rate effect from changes in tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_TaxRateEffectFromChangesInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background and Summary of Material Accounting Policies - Schedule of Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments', window );">Estimated useful lives of property and equipment</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments', window );">Estimated useful lives of property and equipment</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_RangesAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member] | Furniture and fittings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments', window );">Estimated useful lives of property and equipment</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_RangesAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member] | Plant and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments', window );">Estimated useful lives of property and equipment</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_RangesAxis=ifrs-full_TopOfRangeMember', window );">Top of range [Member] | Furniture and fittings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments', window );">Estimated useful lives of property and equipment</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_RangesAxis=ifrs-full_TopOfRangeMember', window );">Top of range [Member] | Plant and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments', window );">Estimated useful lives of property and equipment</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on depreciation for fixed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_RangesAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_RangesAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=athe_PlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=athe_PlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_RangesAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_RangesAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest and Other Income from Continuing Operations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract', window );"><strong>Interest and Other Income from Continuing Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectFromChangeInTaxRate', window );">Refundable tax offset rate</a></td>
<td class="nump">43.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_TurnoverRevenue', window );">Annual aggregate turnover</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_EligibleAmountUnderTaxIncentiveScheme', window );">Other income</a></td>
<td class="nump">5,438,918<span></span>
</td>
<td class="nump">$ 4,019,285<span></span>
</td>
<td class="nump">$ 3,914,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_MiscellaneousIncomeDisputeWithCatalent', window );">Miscellaneous income, dispute with catalent</a></td>
<td class="nump">1,975,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim', window );">Miscellaneous income, settlement of an insurance claim</a></td>
<td class="nump">$ 227,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_EligibleAmountUnderTaxIncentiveScheme">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of expenditure eligible for offset under the tax incentive scheme.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_EligibleAmountUnderTaxIncentiveScheme</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_MiscellaneousIncomeDisputeWithCatalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of miscellaneous income, dispute with catalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_MiscellaneousIncomeDisputeWithCatalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of Miscellaneous income, settlement of an insurance claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_TurnoverRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>When ALL data is continuing and no discontinued values are reported, the 'continuing operations' dimension tag need NOT be individually applied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_TurnoverRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from a change in tax rate. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Interest and Other Income from Continuing Operations - Schedule of Interest and Other Income from Continuing Operations (Details) - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Interest income</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 446,291<span></span>
</td>
<td class="nump">$ 268,419<span></span>
</td>
<td class="nump">$ 16,436<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Total interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">446,291<span></span>
</td>
<td class="nump">268,419<span></span>
</td>
<td class="nump">16,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other income</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ResearchAndDevelopmentTaxIncentive', window );">R&amp;D Tax Incentive</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,438,918<span></span>
</td>
<td class="nump">4,019,285<span></span>
</td>
<td class="nump">3,914,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Miscellaneous income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,202,598<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,103<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Total other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,641,516<span></span>
</td>
<td class="nump">4,019,285<span></span>
</td>
<td class="nump">3,916,333<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAndOperatingIncome', window );">Total interest and other income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,087,807<span></span>
</td>
<td class="nump">$ 4,287,704<span></span>
</td>
<td class="nump">$ 3,932,769<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A 43.5% R&amp;D Tax incentive refundable tax offset, is available to eligible small companies with an annual aggregate turnover of less than $20 million. For the years ended June 30, 2025, June 30, 2024 and June 30, 2023, the Group was eligible to receive the refundable tax offset. Management, with input from an independent expert, has applied judgement when assessing activities and expenditures that are likely to be eligible under the incentive scheme and therefore recorded $5,438,918, $4,019,285 and $3,914,230 in other income, respectively.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Miscellaneous income is comprised of other income of $1,975,056 in relation to settlement of a dispute with Catalent, and other income of $227,542 in relation to settlement of an insurance claim in relation to a U.S. employment case.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ResearchAndDevelopmentTaxIncentive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>R&amp;D tax incentive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ResearchAndDevelopmentTaxIncentive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAndOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAndOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Expenses from Ordinary Activities - Schedule of Expenses from Ordinary Activities (Details) - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ResearchAndDevelopmentExpenses1Abstract', window );"><strong>Research and Development Expenses (1)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employee expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2,424,781<span></span>
</td>
<td class="nump">$ 2,456,230<span></span>
</td>
<td class="nump">$ 2,720,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_OtherResearchAndDevelopmentExpenses', window );">Other research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">12,107,024<span></span>
</td>
<td class="nump">16,187,817<span></span>
</td>
<td class="nump">10,478,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_GeneralAndAdministrationExpensesAbstract', window );"><strong>General and Administration Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation on fixed assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28,307<span></span>
</td>
<td class="nump">35,344<span></span>
</td>
<td class="nump">37,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation on leased assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">111,408<span></span>
</td>
<td class="nump">112,185<span></span>
</td>
<td class="nump">64,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEmployeeExpense', window );">Employee expenses (non R&amp;D related)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,046,530<span></span>
</td>
<td class="nump">515,803<span></span>
</td>
<td class="nump">926,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ConsultantAndDirectorExpenses', window );">Consultant and director expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">652,260<span></span>
</td>
<td class="nump">321,000<span></span>
</td>
<td class="nump">320,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_AuditInternalControlAndOtherAssuranceExpenses', window );">Audit, internal control and other assurance expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">460,254<span></span>
</td>
<td class="nump">241,828<span></span>
</td>
<td class="nump">238,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_CorporateComplianceExpenses', window );">Corporate compliance expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">780,320<span></span>
</td>
<td class="nump">790,350<span></span>
</td>
<td class="nump">457,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InsuranceExpense', window );">Insurance expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">549,408<span></span>
</td>
<td class="nump">676,219<span></span>
</td>
<td class="nump">721,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_OfficeRentalExpenses', window );">Office rental</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,253)<span></span>
</td>
<td class="num">(9,674)<span></span>
</td>
<td class="nump">68,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdministrativeExpense', window );">Other administrative and office expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">520,142<span></span>
</td>
<td class="nump">1,028,638<span></span>
</td>
<td class="nump">1,032,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share based payment expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">979,920<span></span>
</td>
<td class="nump">881,950<span></span>
</td>
<td class="nump">966,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_CorporateAdvisoryExpenses', window );">Corporate advisory expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">355,100<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
<td class="nump">204,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_OtherGainsAndLossesAbstract', window );"><strong>Other gains and losses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange (gain)/loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (259,433)<span></span>
</td>
<td class="num">$ (261,152)<span></span>
</td>
<td class="num">$ (917,650)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses mainly consist of expenses paid for contracted research and development activities conducted by third parties on behalf of the Group.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_AuditInternalControlAndOtherAssuranceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of expenses related to audit internal control and other assurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_AuditInternalControlAndOtherAssuranceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ConsultantAndDirectorExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consultant and director expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ConsultantAndDirectorExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_CorporateAdvisoryExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate advisory expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_CorporateAdvisoryExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_CorporateComplianceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of corporate compliance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_CorporateComplianceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_GeneralAndAdministrationExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_GeneralAndAdministrationExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OfficeRentalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Office rental Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OfficeRentalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OtherGainsAndLossesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OtherGainsAndLossesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OtherResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OtherResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ResearchAndDevelopmentExpenses1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ResearchAndDevelopmentExpenses1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity classifies as being administrative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2024-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from purchased insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEmployeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of employee expenses that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEmployeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Details) - AUD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense', window );">Potential tax benefit amount</a></td>
<td class="nump">$ 187,632,492<span></span>
</td>
<td class="nump">$ 179,125,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense', window );">Non-refundable tax</a></td>
<td class="nump">$ 2,126,801<span></span>
</td>
<td class="nump">$ 3,703,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce current tax expense. [Refer: Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 80<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_80_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce deferred tax expense. [Refer: Deferred tax expense (income); Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 80<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_80_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Schedule of Income Tax (Details) - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>(a) Income tax expense:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 77,411<span></span>
</td>
<td class="nump">$ 58,463<span></span>
</td>
<td class="nump">$ 33,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod', window );">Adjustment for current tax of prior periods</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,356)<span></span>
</td>
<td class="num">(12,375)<span></span>
</td>
<td class="nump">70,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>(b) Numerical reconciliation of income tax expense to prima facie tax payable:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax', window );">Prima facie tax on net loss before income tax at 25% (2024: 25%, 2023: 25%)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,019,943)<span></span>
</td>
<td class="num">(4,769,344)<span></span>
</td>
<td class="num">(3,446,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfForeignTaxRates', window );">Effect of lower tax rates of tax on overseas income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,745)<span></span>
</td>
<td class="num">(11,134)<span></span>
</td>
<td class="num">(6,440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_AddTaxEffectOfAbstract', window );"><strong>Add tax effect of:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod', window );">Under/(Over) provision of income tax in previous year relating to a revision of estimates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,356)<span></span>
</td>
<td class="num">(12,375)<span></span>
</td>
<td class="nump">70,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_TaxEffectOfResearchAndDevelopmentExpenditure', window );">Research and development expenditure (net of tax incentive)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">898,066<span></span>
</td>
<td class="nump">1,305,112<span></span>
</td>
<td class="nump">1,267,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">464,299<span></span>
</td>
<td class="nump">377,405<span></span>
</td>
<td class="nump">413,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_TaxEffectOfDeferredTaxAssetNotRecognized', window );">Deferred tax asset not recognised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,749,734<span></span>
</td>
<td class="nump">3,156,424<span></span>
</td>
<td class="nump">1,805,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense attributable to loss before income tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">68,055<span></span>
</td>
<td class="nump">46,088<span></span>
</td>
<td class="nump">104,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">(c) Potential deferred tax asset as of June 30, 2025, 2024 and 2023 in respect of: tax losses not brought to account is:</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">49,885,043<span></span>
</td>
<td class="nump">47,758,242<span></span>
</td>
<td class="nump">44,056,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures', window );">Temporary differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 6,798,561<span></span>
</td>
<td class="nump">$ 6,660,171<span></span>
</td>
<td class="nump">$ 3,675,742<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unused tax loss amounts are only attributable to the Group&#8217;s operations in Australia, as the subsidiary in the United States has no carryforward tax losses as of June 30, 2025. Tax losses can be carried forward indefinitely subject to continuity of ownership and same business test rules.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">As of June 30, 2025, the Group had a potential tax benefit related to gross tax losses carried forward of $187,632,492 (2024: $179,125,289) and a non-refundable R&amp;D tax offset of $2,126,801 (2024: $3,703,478).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_AddTaxEffectOfAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_AddTaxEffectOfAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prima facie tax on net loss before income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_TaxEffectOfDeferredTaxAssetNotRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to deferred tax asset not recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_TaxEffectOfDeferredTaxAssetNotRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_TaxEffectOfResearchAndDevelopmentExpenditure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of research and development expenditure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_TaxEffectOfResearchAndDevelopmentExpenditure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments of tax expense (income) recognised in the period for current tax of prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 80<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_80_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements, for which deferred tax liabilities have not been recognised as a result of satisfying both of the following conditions: (a) the parent, investor, joint venturer or joint operator is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future. [Refer: Total for all associates [member]; Total for all subsidiaries [member]; Temporary differences [member]; Investments in subsidiaries reported in separate financial statements]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Schedule of Income Tax (Parentheticals) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfIncomeTaxAbstract', window );"><strong>Schedule of Income Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PrimaFacieTaxOnNetLossBeforeIncomeTax', window );">Prima facie tax on net loss before income tax</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_PrimaFacieTaxOnNetLossBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prima facie tax on net loss before income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_PrimaFacieTaxOnNetLossBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfIncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfIncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and Other Receivables - Schedule of Trade and Other Receivables (Details) - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivablesAbstract', window );"><strong>Schedule of Trade and Other Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets', window );">Accrued interest income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ResearchAndDevelopmentTaxIncentiveReceivable', window );">R&amp;D tax incentive receivable</a></td>
<td class="nump">3,928,563<span></span>
</td>
<td class="nump">4,019,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxReceivables', window );">Goods and services tax receivable</a></td>
<td class="nump">9,044<span></span>
</td>
<td class="nump">22,232<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Total</a></td>
<td class="nump">$ 3,937,607<span></span>
</td>
<td class="nump">$ 4,041,675<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ResearchAndDevelopmentTaxIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of research and development tax incentive receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ResearchAndDevelopmentTaxIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued income including current contract assets. [Refer: Accrued income including contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax receivables. [Refer: Value added tax receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_TermDeposit', window );">Term deposit</a></td>
<td class="text">150 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_MaturityDate', window );">Maturity Date</a></td>
<td class="text">Oct. 17,  2025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_MaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_MaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_TermDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_TermDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Other Current Assets - Schedule of Other Current Assets (Details) - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Prepayments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,233,122<span></span>
</td>
<td class="nump">$ 2,315,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Term deposit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,815<span></span>
</td>
<td class="nump">40,668<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,774,937<span></span>
</td>
<td class="nump">$ 2,356,300<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Term deposit of 150-day term and maturity date of October
17, 2025.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and Other Payables - Schedule of Trade and Other Payables (Details) - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Schedule of Trade and Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade creditors</a></td>
<td class="nump">$ 538,276<span></span>
</td>
<td class="nump">$ 581,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">1,684,726<span></span>
</td>
<td class="nump">3,499,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_AccruedProfessionalFees', window );">Accrued professional fees</a></td>
<td class="nump">193,095<span></span>
</td>
<td class="nump">234,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued corporate personnel expenses</a></td>
<td class="nump">139,240<span></span>
</td>
<td class="nump">166,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_OtherCurrentAccruedExpenses', window );">Other accrued expenses</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">123,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other payables</a></td>
<td class="nump">19,253<span></span>
</td>
<td class="nump">14,431<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Total</a></td>
<td class="nump">$ 2,575,490<span></span>
</td>
<td class="nump">$ 4,619,947<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_AccruedProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued professional fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_AccruedProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OtherCurrentAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities representing expense that has been earned but is not yet received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OtherCurrentAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Provisions - Schedule of Provisions (Details) - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 875,908<span></span>
</td>
<td class="nump">$ 530,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=athe_AnnualLeaveMember', window );">Annual Leave [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">631,941<span></span>
</td>
<td class="nump">318,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=athe_LongServiceLeaveMember', window );">Long Service Leave [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">243,967<span></span>
</td>
<td class="nump">212,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Non-Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Movements in provisions</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amounts not expected to be settled within the next 12 months</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=athe_AnnualLeaveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=athe_AnnualLeaveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=athe_LongServiceLeaveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=athe_LongServiceLeaveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions - Schedule of Movements in Provisions (Details) - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Movements in Provisions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_AnnualLeaveAndLongServiceLeaveCarryingAmount', window );">Total</a></td>
<td class="nump">$ 875,908<span></span>
</td>
<td class="nump">$ 530,699<span></span>
</td>
<td class="nump">$ 748,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=athe_AnnualLeaveMember', window );">Annual Leave [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Movements in Provisions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Carrying amount at start of year</a></td>
<td class="nump">318,694<span></span>
</td>
<td class="nump">420,380<span></span>
</td>
<td class="nump">371,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Charged/(credited) to profit or loss -additional provisions recognised</a></td>
<td class="nump">409,646<span></span>
</td>
<td class="nump">179,923<span></span>
</td>
<td class="nump">272,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Amounts used during the year</a></td>
<td class="num">(97,011)<span></span>
</td>
<td class="num">(280,618)<span></span>
</td>
<td class="num">(232,747)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets', window );">Change in foreign exchange</a></td>
<td class="nump">612<span></span>
</td>
<td class="num">(991)<span></span>
</td>
<td class="nump">8,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Carrying amount at end of year</a></td>
<td class="nump">631,941<span></span>
</td>
<td class="nump">318,694<span></span>
</td>
<td class="nump">420,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=athe_LongServiceLeaveMember', window );">Long Service Leave [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Movements in Provisions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Carrying amount at start of year</a></td>
<td class="nump">212,005<span></span>
</td>
<td class="nump">328,325<span></span>
</td>
<td class="nump">298,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Charged/(credited) to profit or loss -additional provisions recognised</a></td>
<td class="nump">32,901<span></span>
</td>
<td class="nump">30,308<span></span>
</td>
<td class="nump">30,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Amounts used during the year</a></td>
<td class="num">(939)<span></span>
</td>
<td class="num">(146,628)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Carrying amount at end of year</a></td>
<td class="nump">$ 243,967<span></span>
</td>
<td class="nump">$ 212,005<span></span>
</td>
<td class="nump">$ 328,325<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_AnnualLeaveAndLongServiceLeaveCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual leave and long service leave carrying amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_AnnualLeaveAndLongServiceLeaveCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2024-01-01<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in financial assets resulting from foreign exchange. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph IG20B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2024-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Provisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities of uncertain timing or amount, including provisions for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Provisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=athe_AnnualLeaveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=athe_AnnualLeaveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=athe_LongServiceLeaveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=athe_LongServiceLeaveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapitalAbstract', window );"><strong>Issued Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalCommitments', window );">Commitments for a capital raising | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapitalOrdinaryShares', window );">Ordinary shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,636,363,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Ordinary shares per share | $ / shares</a></td>
<td class="nump">$ 0.011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ordinarySharesPerShareCents', window );">Ordinary shares per share cents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Options shares</a></td>
<td class="nump">1,222,300,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 0.028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ordinarySharesPerShareCents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ordinary shares per share cents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ordinarySharesPerShareCents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of future capital expenditures that the entity is committed to make.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapitalOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapitalOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Issued Capital - Schedule of Issued Capital (Details) - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_AIssuedCapitalAbstract', window );"><strong>(a) Issued Capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued Capital (in Dollars)</a></td>
<td class="nump">$ 262,949,462<span></span>
</td>
<td class="nump">$ 223,152,985<span></span>
</td>
<td class="nump">$ 213,971,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_AIssuedCapitalAbstract', window );"><strong>(a) Issued Capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_SharesOfIssuedCapital', window );">Issued Capital</a></td>
<td class="nump">262,949,462<span></span>
</td>
<td class="nump">223,152,985<span></span>
</td>
<td class="nump">213,971,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued Capital (in Dollars)</a></td>
<td class="nump">$ 262,949,462<span></span>
</td>
<td class="nump">$ 223,152,985<span></span>
</td>
<td class="nump">$ 213,971,323<span></span>
</td>
<td class="nump">$ 213,787,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=athe_OptionsMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_AIssuedCapitalAbstract', window );"><strong>(a) Issued Capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_SharesOfIssuedCapital', window );">Issued Capital</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_AIssuedCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_AIssuedCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_SharesOfIssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_SharesOfIssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=athe_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=athe_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Issued Capital - Schedule of Issued Capital (Parentheticals) (Details) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfIssuedCapitalLineItems', window );"><strong>Schedule of Issued Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of shares issued</a></td>
<td class="nump">9,127,370,686<span></span>
</td>
<td class="nump">5,245,115,318<span></span>
</td>
<td class="nump">2,439,897,618<span></span>
</td>
<td class="nump">2,406,874,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=athe_OptionsMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfIssuedCapitalLineItems', window );"><strong>Schedule of Issued Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfIssuedCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfIssuedCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=athe_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=athe_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital - Schedule of Movements in Issued Shares (Details) - Ordinary Shares [Member] - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Schedule of Movements in Issued Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Beginning of the year, No. of shares</a></td>
<td class="nump">5,245,115,318<span></span>
</td>
<td class="nump">2,439,897,618<span></span>
</td>
<td class="nump">2,406,874,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Beginning of the year</a></td>
<td class="nump">$ 223,152,985<span></span>
</td>
<td class="nump">$ 213,971,323<span></span>
</td>
<td class="nump">$ 213,787,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_MovementDuringTheYearNoOfSharesinShares', window );">Movement during the year, No. of shares</a></td>
<td class="nump">3,882,255,368<span></span>
</td>
<td class="nump">2,805,217,700<span></span>
</td>
<td class="nump">33,023,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ValueOfIncreaseDecreaseInSharesOutstanding', window );">Movement during the year</a></td>
<td class="nump">$ 39,796,477<span></span>
</td>
<td class="nump">$ 9,181,662<span></span>
</td>
<td class="nump">$ 184,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">End of the year, No. of shares</a></td>
<td class="nump">9,127,370,686<span></span>
</td>
<td class="nump">5,245,115,318<span></span>
</td>
<td class="nump">2,439,897,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">End of the year</a></td>
<td class="nump">$ 262,949,462<span></span>
</td>
<td class="nump">$ 223,152,985<span></span>
</td>
<td class="nump">$ 213,971,323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_MovementDuringTheYearNoOfSharesinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares in movement during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_MovementDuringTheYearNoOfSharesinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ValueOfIncreaseDecreaseInSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the value of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ValueOfIncreaseDecreaseInSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital - Schedule of Share Issuances (Details) - Ordinary Shares [Member] - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IncreaseDecreaseInNumberOfShareOutstanding', window );">Number, Beginning (in Shares)</a></td>
<td class="nump">2,805,217,700<span></span>
</td>
<td class="nump">33,023,040<span></span>
</td>
<td class="nump">322,857,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapitalPreferenceShares', window );">Amount, Beginning</a></td>
<td class="nump">$ 9,181,662<span></span>
</td>
<td class="nump">$ 184,263<span></span>
</td>
<td class="nump">$ 16,339,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IncreaseDecreaseInNumberOfShareOutstanding', window );">Number, Ending (in Shares)</a></td>
<td class="nump">3,882,255,368<span></span>
</td>
<td class="nump">2,805,217,700<span></span>
</td>
<td class="nump">33,023,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapitalPreferenceShares', window );">Amount, Ending</a></td>
<td class="nump">$ 39,796,477<span></span>
</td>
<td class="nump">$ 9,181,662<span></span>
</td>
<td class="nump">$ 184,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">September 21, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Issue of shares under ATM Facility<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,543,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberofSharesIssuePricePerShare', window );">Issue Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">March 15, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Issue of shares under ATM Facility<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,479,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberofSharesIssuePricePerShare', window );">Issue Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">June 30, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Security issuance costs<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">November 29, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Issue of shares under ATM Facility<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,462,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberofSharesIssuePricePerShare', window );">Issue Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,268,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">January 8, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Issue of shares under ATM Facility<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,008,965,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberofSharesIssuePricePerShare', window );">Issue Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,531,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">February 2, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Issue of shares under ATM Facility<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,428,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberofSharesIssuePricePerShare', window );">Issue Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">March 4, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Issue of shares under ATM Facility<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">855,263,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberofSharesIssuePricePerShare', window );">Issue Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">April 22, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Issue of shares under options exercised<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,097,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberofSharesIssuePricePerShare', window );">Issue Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">June 30, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Security issuance costs<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (918,020)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">July 18, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">Issue of shares under ATM Facility<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number (in Shares)</a></td>
<td class="nump">75,220,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberofSharesIssuePricePerShare', window );">Issue Price (in Dollars per share)</a></td>
<td class="nump">$ 0.0054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="nump">$ 398,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">January 22, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">Issue of shares under options exercised<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number (in Shares)</a></td>
<td class="nump">95,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberofSharesIssuePricePerShare', window );">Issue Price (in Dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="nump">$ 952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">January 30, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">Issue of shares under options exercised<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number (in Shares)</a></td>
<td class="nump">6,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberofSharesIssuePricePerShare', window );">Issue Price (in Dollars per share)</a></td>
<td class="nump">$ 0.004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="nump">$ 48,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">February 3, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">Issue of shares under ATM Facility<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number (in Shares)</a></td>
<td class="nump">164,242,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberofSharesIssuePricePerShare', window );">Issue Price (in Dollars per share)</a></td>
<td class="nump">$ 0.0129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="nump">$ 2,122,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">February 17, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">Issue of Placement shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number (in Shares)</a></td>
<td class="nump">1,165,841,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberofSharesIssuePricePerShare', window );">Issue Price (in Dollars per share)</a></td>
<td class="nump">$ 0.011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="nump">$ 12,824,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">March 14, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">Issue of shares under options exercised<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number (in Shares)</a></td>
<td class="nump">161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberofSharesIssuePricePerShare', window );">Issue Price (in Dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">April 4, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">Issue of Placement shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number (in Shares)</a></td>
<td class="nump">2,470,521,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberofSharesIssuePricePerShare', window );">Issue Price (in Dollars per share)</a></td>
<td class="nump">$ 0.011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="nump">$ 27,175,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">June 30, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfShareIssuancesLineItems', window );"><strong>Schedule of Share Issuances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesIssuedDuringTheYear', window );">Number of shares issued during the year</a></td>
<td class="text">Security issuance costs<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Number (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IssuedCapitalPreferenceShare', window );">Amount</a></td>
<td class="num">$ (2,774,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_IncreaseDecreaseInNumberOfShareOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in number of share outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_IncreaseDecreaseInNumberOfShareOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_IssuedCapitalPreferenceShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issued capital preference shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_IssuedCapitalPreferenceShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_NumberOfSharesIssuedDuringTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_NumberOfSharesIssuedDuringTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_NumberofSharesIssuePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_NumberofSharesIssuePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfShareIssuancesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfShareIssuancesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapitalPreferenceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital arising from issuing preference shares. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapitalPreferenceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_September212022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_September212022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_March152023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_March152023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_June302023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_June302023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_November292023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_November292023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_January82024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_January82024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_February22024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_February22024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_March42024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_March42024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_April222024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_April222024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_June302024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_June302024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_July182024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_July182024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_January222025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_January222025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_January302025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_January302025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_February32025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_February32025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_February172025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_February172025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_March142025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_March142025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_April42025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_April42025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareIssuanceDateAxis=athe_June302025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareIssuanceDateAxis=athe_June302025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>Options</div>
</th>
<th class="th">
<div>Mar. 14, 2025 </div>
<div>Options</div>
</th>
<th class="th">
<div>Jan. 30, 2025 </div>
<div>Options</div>
</th>
<th class="th">
<div>Jan. 22, 2025 </div>
<div>Options</div>
</th>
<th class="th">
<div>Dec. 30, 2024 </div>
<div>Options </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>Options</div>
</th>
<th class="th">
<div>Aug. 01, 2024 </div>
<div>Options</div>
</th>
<th class="th">
<div>Jun. 27, 2024 </div>
<div>Options </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 21, 2024 </div>
<div>Options</div>
</th>
<th class="th">
<div>Apr. 22, 2024 </div>
<div>Options</div>
</th>
<th class="th">
<div>Apr. 15, 2024 </div>
<div>Options </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 02, 2024 </div>
<div>Options </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 08, 2024 </div>
<div>Options </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 21, 2023 </div>
<div>Options </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 11, 2023 </div>
<div>Options</div>
</th>
<th class="th">
<div>Apr. 03, 2023 </div>
<div>Options</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>Options</div>
</th>
<th class="th">
<div>Dec. 14, 2022 </div>
<div>Options</div>
</th>
<th class="th">
<div>Jan. 04, 2022 </div>
<div>Options</div>
</th>
<th class="th">
<div>Dec. 08, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2025 </div>
<div>Options</div>
</th>
<th class="th">
<div>Apr. 23, 2025 </div>
<div>Options</div>
</th>
<th class="th">
<div>Jun. 27, 2024 </div>
<div>Options </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 23, 2023 </div>
<div>Options </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Option shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457,142,830<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,222,300,911<span></span>
</td>
<td class="nump">62,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Fair value per option (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.007<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Options expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,935,759,704<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Options forfeited</a></td>
<td class="nump">4,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Exercisable per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpiredTerm', window );">Expired term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 30,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 13,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 26,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">6,333,333<span></span>
</td>
<td class="nump">95,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,097,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ReserveOfOrdinaryShares', window );">Reserve of ordinary shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReservesWithinEquityAxis=athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember', window );">Options for Fully Paid Ordinary Shares/Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Option shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,371,428,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Fair value per option (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.002<span></span>
</td>
<td class="nump">$ 0.007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Options expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Exercisable per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpiredTerm', window );">Expired term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReservesWithinEquityAxis=athe_ShortFreeAttachingOptionsMember', window );">Short Free Attaching Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Option shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,087,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=athe_AsxPlan2004Member', window );">2004 ASX Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Fair value per option (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpiredTerm', window );">Expired term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 19,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=athe_AsxPlan2004Member', window );">2004 ASX Plan [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Option shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=athe_AdsPlanTwoThousandEighteenMember', window );">Ads Plan 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Option shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Exercisable per share | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=athe_EmployeeMember', window );">Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Exercisable per share | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=athe_EmployeeMember', window );">Employee [Member] | Options for Fully Paid Ordinary Shares/Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=athe_DirectorsMember', window );">Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Fair value per option (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Exercisable per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=athe_ConsultantMember', window );">Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Exercisable per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=athe_ChiefExecutiveOfficersMember', window );">Chief Executive Office [Memebr]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Fair value per option (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Exercisable per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=athe_NonExecutiveDirectorsMember', window );">Non-Executive Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=athe_FreeAttachingOptionMember', window );">Free Attaching Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Option shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,087,715<span></span>
</td>
<td class="nump">571,428,556<span></span>
</td>
<td class="nump">1,371,418,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,222,300,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=athe_FreeAttachingOptionMember', window );">Free Attaching Option [Member] | August 31 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Option shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,476,123<span></span>
</td>
<td class="nump">457,142,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=athe_LongDatedOptionsMember', window );">Long Dated Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Option shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,476,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=athe_ShortDatedOptionsMember', window );">Short Dated Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Option shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,428,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Exercisable per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpiredTerm', window );">Expired term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=athe_ShortFreeAttachingOptionsMember', window );">Short Free Attaching Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Exercisable per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpiredTerm', window );">Expired term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember', window );">Share Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Reserves [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpiredTerm', window );">Expired term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ExpiredTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expired term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ExpiredTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ReserveOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserve of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ReserveOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReservesWithinEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReservesWithinEquityAxis=athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReservesWithinEquityAxis=athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReservesWithinEquityAxis=athe_ShortFreeAttachingOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReservesWithinEquityAxis=athe_ShortFreeAttachingOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=athe_AsxPlan2004Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=athe_AsxPlan2004Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=athe_SubsequentsEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=athe_SubsequentsEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=athe_AdsPlanTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=athe_AdsPlanTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=athe_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=athe_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=athe_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=athe_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=athe_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=athe_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=athe_ChiefExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=athe_ChiefExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=athe_NonExecutiveDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=athe_NonExecutiveDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=athe_FreeAttachingOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=athe_FreeAttachingOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=athe_AugustThirtyFirstTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=athe_AugustThirtyFirstTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=athe_LongDatedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=athe_LongDatedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=athe_ShortDatedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=athe_ShortDatedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=athe_ShortFreeAttachingOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=athe_ShortFreeAttachingOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_ShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Reserves - Schedule of Reserves of Share Based Payments (Details) - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Schedule of Reserves of Share Based Payments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">Reserve of share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,342,304<span></span>
</td>
<td class="nump">$ 4,806,203<span></span>
</td>
<td class="nump">$ 3,972,475<span></span>
</td>
<td class="nump">$ 3,565,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantReserve', window );">Reserve of Free-attaching options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReservesWithinEquityAxis=athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember', window );">Reserve of Share Based Payments for Warrants/Free-attaching options [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Schedule of Reserves of Share Based Payments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">Reserve of share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,342,304<span></span>
</td>
<td class="nump">4,806,203<span></span>
</td>
<td class="nump">3,972,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantReserve', window );">Reserve of Free-attaching options</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 8, 2024 a total of 457,142,830 free attaching options with an exercise price of A$0.01, expiring on August 31, 2026 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 8, 2024 a total of 1,371,428,567 free attaching options with an exercise price of A$0.007, expiring on August 31, 2024 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 2, 2024 a total of 190,476,123 free attaching options with an exercise price of A$0.002, expiring on August 31, 2026 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 2, 2024 a total of 571,428,556 free attaching options with an exercise price of A$0.007, expiring on August 31, 2024 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 15, 2024 a total of 285,087,715 free attaching options with an exercise price of A$0.01, expiring on August 31, 2026 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 23, 2025 a total of 1,222,300,911 free attaching options with an exercise price if A$0.028, expiring on February 26, 2027 were issued.</p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReservesWithinEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from share-based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReservesWithinEquityAxis=athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReservesWithinEquityAxis=athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Reserves - Schedule of Reserves of Share Based Payments (Parentheticals) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>Options </div>
<div>FreeAttachingOptions</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>Options </div>
<div>FreeAttachingOptions</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>Options </div>
<div>FreeAttachingOptions</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Schedule of Reserves of Share Based Payments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_OptionsForFullyPaidOrdinaryShares1', window );">Options for fully paid ordinary shares | Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,683,471,567<span></span>
</td>
<td class="nump">3,250,009,092<span></span>
</td>
<td class="nump">170,042,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FreeattachingOptionsForFullyPaidOrdinaryShares', window );">Free-attaching options for fully paid ordinary shares | FreeAttachingOptions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,154,912,180<span></span>
</td>
<td class="nump">2,868,466,372<span></span>
</td>
<td class="nump">674,694,939<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 8, 2024 a total of 457,142,830 free attaching options with an exercise price of A$0.01, expiring on August 31, 2026 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 8, 2024 a total of 1,371,428,567 free attaching options with an exercise price of A$0.007, expiring on August 31, 2024 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 2, 2024 a total of 190,476,123 free attaching options with an exercise price of A$0.002, expiring on August 31, 2026 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 2, 2024 a total of 571,428,556 free attaching options with an exercise price of A$0.007, expiring on August 31, 2024 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 15, 2024 a total of 285,087,715 free attaching options with an exercise price of A$0.01, expiring on August 31, 2026 were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 23, 2025 a total of 1,222,300,911 free attaching options with an exercise price if A$0.028, expiring on February 26, 2027 were issued.</p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_FreeattachingOptionsForFullyPaidOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Free-attaching options for fully paid ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_FreeattachingOptionsForFullyPaidOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsForFullyPaidOrdinaryShares1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options for fully paid ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsForFullyPaidOrdinaryShares1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReservesWithinEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves - Schedule of Movements in Options for Fully Paid Ordinary Shares (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>AUD ($) </div>
<div>Options</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>AUD ($) </div>
<div>Options</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>AUD ($) </div>
<div>Options</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract', window );"><strong>Schedule of Movements in Options for Fully Paid Ordinary Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesOptionsOutstanding', window );">Number of Options, Beginning of the year | Options</a></td>
<td class="nump">3,250,009,092<span></span>
</td>
<td class="nump">170,042,720<span></span>
</td>
<td class="nump">184,692,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">Beginning of the year | $</a></td>
<td class="nump">$ 4,806,203<span></span>
</td>
<td class="nump">$ 3,972,475<span></span>
</td>
<td class="nump">$ 3,565,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear', window );">Number of Options , Options issued during the year | Options</a></td>
<td class="nump">1,392,300,911<span></span>
</td>
<td class="nump">3,092,563,791<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ReserveOfOptionsIssuedDuringTheYear', window );">Options issued during the year | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare', window );">Number of Options, Options expired during the year | Options</a></td>
<td class="num">(1,947,759,704)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,150,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear', window );">Expired during the year | $</a></td>
<td class="num">$ (326,544)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (560,014)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfOptionsForfeitedDuringTheYear', window );">Number of Options, Forfeited during the year | Options</a></td>
<td class="num">(4,650,000)<span></span>
</td>
<td class="num">(5,500,000)<span></span>
</td>
<td class="num">(1,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ReserveOfSharebasedPaymentsForfeitedDuringYear', window );">Forfeited during the year | $</a></td>
<td class="num">$ (93,735)<span></span>
</td>
<td class="num">$ (93,222)<span></span>
</td>
<td class="num">$ (17,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfOptionsOptionsExercisedDuringTheYear', window );">Number of Options, Options exercised during the year | Options</a></td>
<td class="num">(6,428,732)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_OptionsExercisedDuringTheYear', window );">Options exercised during the year | $</a></td>
<td class="num">$ (23,540)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfOptionsSharesToBeIssued', window );">Number of Options, Shares to be issued | Options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_SharesToBeIssued', window );">Shares to be issued | $</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ShareBasedPaymentExpenseForOptionsIssuedI', window );">Number of Options, Share Based Payment expense | Options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share Based Payment expense | $</a></td>
<td class="nump">$ 979,920<span></span>
</td>
<td class="nump">$ 881,950<span></span>
</td>
<td class="nump">$ 983,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfSharesOptionsOutstanding', window );">Number of Options, End of the year | Options</a></td>
<td class="nump">2,683,471,567<span></span>
</td>
<td class="nump">3,250,009,092<span></span>
</td>
<td class="nump">170,042,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">End of the year | $</a></td>
<td class="nump">$ 5,342,304<span></span>
</td>
<td class="nump">$ 4,806,203<span></span>
</td>
<td class="nump">$ 3,972,475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_NumberOfOptionsForfeitedDuringTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options, forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_NumberOfOptionsForfeitedDuringTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_NumberOfOptionsOptionsExercisedDuringTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Options, Options exercised during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_NumberOfOptionsOptionsExercisedDuringTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_NumberOfOptionsSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options shares to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_NumberOfOptionsSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_NumberOfSharesOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_NumberOfSharesOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsExercisedDuringTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options exercised during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsExercisedDuringTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ReserveOfOptionsIssuedDuringTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options issued during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ReserveOfOptionsIssuedDuringTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of option reserves share based payment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ReserveOfSharebasedPaymentsForfeitedDuringYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Forfeited options reserves during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ReserveOfSharebasedPaymentsForfeitedDuringYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareBasedPaymentExpenseForOptionsIssuedI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Payment expense for options issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareBasedPaymentExpenseForOptionsIssuedI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Options, Options expired during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Options , Options issued during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_SharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of shares to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_SharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from share-based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Deficit During Development Stage - Schedule of Accumulated Deficit During Development Stage (Details) - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_AccumulatedDeficitDuringDevelopmentStageAbstract', window );"><strong>Accumulated Deficit During Development Stage [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Balance at beginning of year</a></td>
<td class="nump">$ 214,161,131<span></span>
</td>
<td class="nump">$ 195,130,889<span></span>
</td>
<td class="nump">$ 181,884,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the year</a></td>
<td class="nump">12,147,828<span></span>
</td>
<td class="nump">19,123,464<span></span>
</td>
<td class="nump">13,806,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ReclassifyExpiredOptionsFromReservesOne', window );">Reclassify expired options from reserves</a></td>
<td class="num">(326,544)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(560,014)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ReclassifyForfeitedOptionsFromReserves', window );">Reclassify forfeited options from reserves</a></td>
<td class="num">(93,735)<span></span>
</td>
<td class="num">(93,222)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Balance at end of year</a></td>
<td class="nump">$ 225,888,680<span></span>
</td>
<td class="nump">$ 214,161,131<span></span>
</td>
<td class="nump">$ 195,130,889<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_AccumulatedDeficitDuringDevelopmentStageAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_AccumulatedDeficitDuringDevelopmentStageAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ReclassifyExpiredOptionsFromReservesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of Reclassify expired options from reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ReclassifyExpiredOptionsFromReservesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ReclassifyForfeitedOptionsFromReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassify forfeited options from reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ReclassifyForfeitedOptionsFromReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to the right-of-use assets</a></td>
<td class="nump">$ 106,834<span></span>
</td>
<td class="nump">$ 59,031<span></span>
</td>
<td class="nump">$ 152,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Total cash outflow for leases</a></td>
<td class="nump">$ 127,097<span></span>
</td>
<td class="nump">$ 7,913<span></span>
</td>
<td class="nump">$ 133,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ShortTermLeaseTerm', window );">Short term lease term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShortTermLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShortTermLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Financial Position Shows the Following Amounts Relating to Leases (Details) - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_RightOfUseAssetsAbstract', window );"><strong>Right-of-use assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">$ 151,326<span></span>
</td>
<td class="nump">$ 154,729<span></span>
</td>
<td class="nump">$ 207,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current</a></td>
<td class="nump">66,912<span></span>
</td>
<td class="nump">107,131<span></span>
</td>
<td class="nump">107,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current</a></td>
<td class="nump">88,545<span></span>
</td>
<td class="nump">51,914<span></span>
</td>
<td class="nump">103,207<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Total</a></td>
<td class="nump">$ 155,457<span></span>
</td>
<td class="nump">$ 159,045<span></span>
</td>
<td class="nump">$ 210,384<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_RightOfUseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_RightOfUseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Profit or Loss Shows the Following Amounts Relating to Leases (Details) - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract', window );"><strong>Schedule of Amounts Recognized in Profit or Loss Relating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation of right-of-use assets</a></td>
<td class="nump">$ 111,408<span></span>
</td>
<td class="nump">$ 112,185<span></span>
</td>
<td class="nump">$ 64,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="nump">6,188<span></span>
</td>
<td class="nump">7,217<span></span>
</td>
<td class="nump">4,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpensesRelatingToShorttermLeases', window );">Expenses relating to short-term leases (included in general and administration expenses)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(9,674)<span></span>
</td>
<td class="nump">68,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities', window );">Expenses relating to variable lease payments not included in lease liabilities (included in general and administration expenses)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ExpensesRelatingToShorttermLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses relating to short-term leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ExpensesRelatingToShorttermLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to variable lease payments not included in the measurement of lease liabilities. Variable lease payments are the portion of payments made by a lessee to a lessor for the right to use an underlying asset during the lease term that varies because of changes in facts or circumstances occurring after the commencement date, other than the passage of time. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Flow Information - Schedule of Cash Flow Information (Details) - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>(a) Reconciliation of Net Loss to Net Cash Flows Used In Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (12,147,828)<span></span>
</td>
<td class="num">$ (19,123,464)<span></span>
</td>
<td class="num">$ (13,806,515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Non-cash items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation of property and equipment</a></td>
<td class="nump">28,307<span></span>
</td>
<td class="nump">35,344<span></span>
</td>
<td class="nump">37,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation on leased assets</a></td>
<td class="nump">111,408<span></span>
</td>
<td class="nump">112,185<span></span>
</td>
<td class="nump">64,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCashPaymentsFromOperatingActivities', window );">Others</a></td>
<td class="nump">450,056<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payment expenses</a></td>
<td class="nump">979,920<span></span>
</td>
<td class="nump">881,950<span></span>
</td>
<td class="nump">966,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ForeignExchangegainLoss', window );">Foreign exchange loss/(gain)</a></td>
<td class="num">(259,433)<span></span>
</td>
<td class="num">(261,152)<span></span>
</td>
<td class="num">(917,650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FixedAssetWriteOff', window );">Fixed asset write off</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ChangesInAssetsAndLiabilitiesAbstract', window );"><strong>Changes in assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_IncreaseDecreaseInTradeAndOtherReceivables', window );">Decrease/(increase) in trade and other receivables</a></td>
<td class="nump">104,068<span></span>
</td>
<td class="nump">4,624,029<span></span>
</td>
<td class="num">(3,940,343)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets', window );">Decrease/(increase) in other current assets (excepting term deposit)</a></td>
<td class="nump">1,081,363<span></span>
</td>
<td class="nump">252,986<span></span>
</td>
<td class="num">(968,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">(Decrease)/increase in trade and other payables</a></td>
<td class="num">(2,044,457)<span></span>
</td>
<td class="nump">1,102,239<span></span>
</td>
<td class="num">(1,560,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities', window );">(Decrease) in other current liabilities</a></td>
<td class="num">(99,861)<span></span>
</td>
<td class="num">(11,935)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Increase/(decrease) in provision for employee entitlements</a></td>
<td class="nump">345,209<span></span>
</td>
<td class="num">(218,006)<span></span>
</td>
<td class="nump">78,685<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(11,451,248)<span></span>
</td>
<td class="num">(12,605,824)<span></span>
</td>
<td class="num">(20,035,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents balance comprises:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOnHand', window );">- cash and cash equivalents on hand</a></td>
<td class="nump">33,158,642<span></span>
</td>
<td class="nump">12,638,885<span></span>
</td>
<td class="nump">15,773,783<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Closing cash and cash equivalents balance</a></td>
<td class="nump">$ 33,158,642<span></span>
</td>
<td class="nump">$ 12,638,885<span></span>
</td>
<td class="nump">$ 15,773,783<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ChangesInAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ChangesInAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_FixedAssetWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed asset write off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_FixedAssetWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ForeignExchangegainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ForeignExchangegainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_IncreaseDecreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_IncreaseDecreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOnHand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash held by the entity. This does not include demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOnHand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashPaymentsFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for operating activities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashPaymentsFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Expenditure Commitments (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>AUD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpenditureCommitmentsAbstract', window );"><strong>Expenditure Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_TerminationNoticePeriodForResearchAndDevelopmentContracts', window );">Termination notice period for research and development</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ResearchAndDevelopmentTerminationCommitments', window );">Research and development termination</a></td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ExpenditureCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ExpenditureCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ResearchAndDevelopmentTerminationCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research and development contract termination commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ResearchAndDevelopmentTerminationCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_TerminationNoticePeriodForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the termination notice period for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_TerminationNoticePeriodForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2009 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2008 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2007 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2005 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2004 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfDirector', window );">Number of director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfKeyManagementPersonnel', window );">Key management personnel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfConsultant', window );">Number of consultant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares', window );">Number of ordinary shares authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ShareholdersAuthorizedSecurities', window );">Shareholders authorized securities (in Shares)</a></td>
<td class="nump">157.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Issued securities value (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfDefaultVestingConditionsPerYear', window );">Percentage of default vesting conditions per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PlanAxis=athe_AdsPlanTwoThousandEighteenMember', window );">Ads Plan 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Issued securities value (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfDefaultVestingConditionsPerYear', window );">Percentage of default vesting conditions per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_NumberOfConsultant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of consultant of the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_NumberOfConsultant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_NumberOfDirector">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of directors of the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_NumberOfDirector</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_NumberOfKeyManagementPersonnel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of directors by the key management personnel of the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_NumberOfKeyManagementPersonnel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_PercentageOfDefaultVestingConditionsPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents amount of percentage of default vesting conditions per year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_PercentageOfDefaultVestingConditionsPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ShareholdersAuthorizedSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shareholders authorized securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ShareholdersAuthorizedSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of personnel employed by the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issue under options and contracts for the sale of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_PlanAxis=athe_AdsPlanTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_PlanAxis=athe_AdsPlanTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Schedule of Options Granted (Details) - Options [member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>Options </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>Options </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>Options </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share Based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of Options, Beginning of the year | Options</a></td>
<td class="nump">381,542,720<span></span>
</td>
<td class="nump">170,042,720<span></span>
</td>
<td class="nump">184,692,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price, Beginning of the year (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.022<span></span>
</td>
<td class="nump">$ 0.047<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of Options, Issued during the year | Options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">217,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price, Issued during the year (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.004<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of Options, Exercised during the year | Options</a></td>
<td class="num">(6,333,333)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price, Exercised during the year (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.004<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Number of Options, Expired during the year | Options</a></td>
<td class="num">(12,000,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,150,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price, Expired during the year (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of Options, Forfeited during the year | Options</a></td>
<td class="num">(4,650,000)<span></span>
</td>
<td class="num">(5,500,000)<span></span>
</td>
<td class="num">(1,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price, Forfeited during the year (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.036<span></span>
</td>
<td class="nump">$ 0.036<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of Options, Outstanding at year end | Options</a></td>
<td class="nump">358,559,387<span></span>
</td>
<td class="nump">381,542,720<span></span>
</td>
<td class="nump">170,042,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price, Outstanding at year end (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.021<span></span>
</td>
<td class="nump">$ 0.022<span></span>
</td>
<td class="nump">$ 0.047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of Options, Vested and Exercisable at year end | Options</a></td>
<td class="nump">275,689,612<span></span>
</td>
<td class="nump">195,708,100<span></span>
</td>
<td class="nump">87,280,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price, Vested and Exercisable at year end (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.024<span></span>
</td>
<td class="nump">$ 0.033<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Schedule of Options Outstanding (Details) - Options [member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>Options </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>Options</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>Options</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>Options</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfOptionsOutstandingLineItems', window );"><strong>Schedule of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExercisePriceOfOutstandingShareOption1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options | Options</a></td>
<td class="nump">358,559,387<span></span>
</td>
<td class="nump">381,542,720<span></span>
</td>
<td class="nump">170,042,720<span></span>
</td>
<td class="nump">184,692,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Share options, Weighted average remaining contractual life of options outstanding at end of period.</a></td>
<td class="text">2 years 4 months 13 days<span></span>
</td>
<td class="text">3 years 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ShareOptionsMember', window );">ATHAAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfOptionsOutstandingLineItems', window );"><strong>Schedule of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">September 18, 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpiryDateOfOutstandingShareOptions', window );">Expiry Date</a></td>
<td class="text">September 17, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExercisePriceOfOutstandingShareOption1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options | Options</a></td>
<td class="nump">35,000,000<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ShareOptionsMember', window );">ATHAAD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfOptionsOutstandingLineItems', window );"><strong>Schedule of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">January 7, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpiryDateOfOutstandingShareOptions', window );">Expiry Date</a></td>
<td class="text">January 6, 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExercisePriceOfOutstandingShareOption1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options | Options</a></td>
<td class="nump">91,392,720<span></span>
</td>
<td class="nump">91,392,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ShareOptionsMember', window );">ATHAAE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfOptionsOutstandingLineItems', window );"><strong>Schedule of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">November 29, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpiryDateOfOutstandingShareOptions', window );">Expiry Date</a></td>
<td class="text">November 29, 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExercisePriceOfOutstandingShareOption1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options | Options</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">14,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ShareOptionsMember', window );">ATHAAF [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfOptionsOutstandingLineItems', window );"><strong>Schedule of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">July 31, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpiryDateOfOutstandingShareOptions', window );">Expiry Date</a></td>
<td class="text">July 31, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExercisePriceOfOutstandingShareOption1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options | Options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ShareOptionsMember', window );">ATHAAG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfOptionsOutstandingLineItems', window );"><strong>Schedule of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">November 21, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpiryDateOfOutstandingShareOptions', window );">Expiry Date</a></td>
<td class="text">November 29, 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExercisePriceOfOutstandingShareOption1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options | Options</a></td>
<td class="nump">11,500,000<span></span>
</td>
<td class="nump">11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ShareOptionsMember', window );">ATHAAH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfOptionsOutstandingLineItems', window );"><strong>Schedule of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">December 21, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpiryDateOfOutstandingShareOptions', window );">Expiry Date</a></td>
<td class="text">December 19, 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExercisePriceOfOutstandingShareOption1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options | Options</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ShareOptionsMember', window );">ATHAA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfOptionsOutstandingLineItems', window );"><strong>Schedule of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">March 13, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpiryDateOfOutstandingShareOptions', window );">Expiry Date</a></td>
<td class="text">March 13, 2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExercisePriceOfOutstandingShareOption1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options | Options</a></td>
<td class="nump">20,166,667<span></span>
</td>
<td class="nump">26,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ShareOptionsMember', window );">ATHAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfOptionsOutstandingLineItems', window );"><strong>Schedule of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">March 13, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpiryDateOfOutstandingShareOptions', window );">Expiry Date</a></td>
<td class="text">March 13, 2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExercisePriceOfOutstandingShareOption1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options | Options</a></td>
<td class="nump">62,500,000<span></span>
</td>
<td class="nump">62,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ShareOptionsMember', window );">ATHAC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfOptionsOutstandingLineItems', window );"><strong>Schedule of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">March 21, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExpiryDateOfOutstandingShareOptions', window );">Expiry Date</a></td>
<td class="text">March 21, 2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExercisePriceOfOutstandingShareOption1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options | Options</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ExercisePriceOfOutstandingShareOption1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ExercisePriceOfOutstandingShareOption1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ExpiryDateOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents expiry date of options oust standing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ExpiryDateOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfOptionsOutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfOptionsOutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The date on which share-based payment arrangements are granted. [Refer: Types of share-based payment arrangements [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph IG23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DateOfGrantOfSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHAABOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHAABOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHAADOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHAADOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHAAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHAAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHAAFOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHAAFOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHAAGOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHAAGOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHAAHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHAAHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHAAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHAAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Schedule of Valuations of Options Approved and Issued (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_OptionsSeriesAxis=athe_ATHAABMember', window );">ATHAAB[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Schedule of Valuations of Options Approved and Issued [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">September 18,2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price per Share</a></td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_SharePriceAtGrantDate', window );">Share Price at Grant Date</a></td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_YearsToExpiry', window );">Years to Expiry</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_RiskfreeInterestRate', window );">Risk-free Interest Rate</a></td>
<td class="nump">0.43%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected Share Price Volatility</a></td>
<td class="nump">98.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FairValuePerOptions', window );">Fair Value per Options</a></td>
<td class="nump">$ 0.032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_OptionsSeriesAxis=athe_ATHAADMember', window );">ATHAAD[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Schedule of Valuations of Options Approved and Issued [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">January 7,2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price per Share</a></td>
<td class="nump">$ 0.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_SharePriceAtGrantDate', window );">Share Price at Grant Date</a></td>
<td class="nump">$ 0.032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_YearsToExpiry', window );">Years to Expiry</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_RiskfreeInterestRate', window );">Risk-free Interest Rate</a></td>
<td class="nump">0.38%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected Share Price Volatility</a></td>
<td class="nump">139.52%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FairValuePerOptions', window );">Fair Value per Options</a></td>
<td class="nump">$ 0.028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_OptionsSeriesAxis=athe_ATHAAEMember', window );">ATHAAE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Schedule of Valuations of Options Approved and Issued [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">November 29, 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price per Share</a></td>
<td class="nump">$ 0.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_SharePriceAtGrantDate', window );">Share Price at Grant Date</a></td>
<td class="nump">$ 0.025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_YearsToExpiry', window );">Years to Expiry</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_RiskfreeInterestRate', window );">Risk-free Interest Rate</a></td>
<td class="nump">1.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected Share Price Volatility</a></td>
<td class="nump">138.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FairValuePerOptions', window );">Fair Value per Options</a></td>
<td class="nump">$ 0.021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_OptionsSeriesAxis=athe_ATHAAFMember', window );">ATHAAF [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Schedule of Valuations of Options Approved and Issued [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">July 31, 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price per Share</a></td>
<td class="nump">$ 0.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_SharePriceAtGrantDate', window );">Share Price at Grant Date</a></td>
<td class="nump">$ 0.034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_YearsToExpiry', window );">Years to Expiry</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_RiskfreeInterestRate', window );">Risk-free Interest Rate</a></td>
<td class="nump">0.13%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected Share Price Volatility</a></td>
<td class="nump">169.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FairValuePerOptions', window );">Fair Value per Options</a></td>
<td class="nump">$ 0.027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_OptionsSeriesAxis=athe_ATHAAGMember', window );">ATHAAG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Schedule of Valuations of Options Approved and Issued [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">November 29, 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price per Share</a></td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_SharePriceAtGrantDate', window );">Share Price at Grant Date</a></td>
<td class="nump">$ 0.0238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_YearsToExpiry', window );">Years to Expiry</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_RiskfreeInterestRate', window );">Risk-free Interest Rate</a></td>
<td class="nump">1.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected Share Price Volatility</a></td>
<td class="nump">138.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FairValuePerOptions', window );">Fair Value per Options</a></td>
<td class="nump">$ 0.021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_OptionsSeriesAxis=athe_ATHAAHMember', window );">ATHAAH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Schedule of Valuations of Options Approved and Issued [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">December 21, 2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_SharePriceAtGrantDate', window );">Share Price at Grant Date</a></td>
<td class="nump">$ 0.0065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_YearsToExpiry', window );">Years to Expiry</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_RiskfreeInterestRate', window );">Risk-free Interest Rate</a></td>
<td class="nump">3.67%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected Share Price Volatility</a></td>
<td class="nump">133.87%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FairValuePerOptions', window );">Fair Value per Options</a></td>
<td class="nump">$ 0.005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_OptionsSeriesAxis=athe_ATHAAMember', window );">ATHAA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Schedule of Valuations of Options Approved and Issued [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">March 13, 2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price per Share</a></td>
<td class="nump">$ 0.004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_SharePriceAtGrantDate', window );">Share Price at Grant Date</a></td>
<td class="nump">$ 0.004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_YearsToExpiry', window );">Years to Expiry</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_RiskfreeInterestRate', window );">Risk-free Interest Rate</a></td>
<td class="nump">3.47%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected Share Price Volatility</a></td>
<td class="nump">158.31%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FairValuePerOptions', window );">Fair Value per Options</a></td>
<td class="nump">$ 0.004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_OptionsSeriesAxis=athe_ATHABMember', window );">ATHAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Schedule of Valuations of Options Approved and Issued [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">March 13, 2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price per Share</a></td>
<td class="nump">$ 0.004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_SharePriceAtGrantDate', window );">Share Price at Grant Date</a></td>
<td class="nump">$ 0.004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_YearsToExpiry', window );">Years to Expiry</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_RiskfreeInterestRate', window );">Risk-free Interest Rate</a></td>
<td class="nump">3.47%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected Share Price Volatility</a></td>
<td class="nump">158.31%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FairValuePerOptions', window );">Fair Value per Options</a></td>
<td class="nump">$ 0.004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_OptionsSeriesAxis=athe_ATHACMember', window );">ATHAC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Schedule of Valuations of Options Approved and Issued [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement', window );">Grant Date</a></td>
<td class="text">March 21, 2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price per Share</a></td>
<td class="nump">$ 0.003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_SharePriceAtGrantDate', window );">Share Price at Grant Date</a></td>
<td class="nump">$ 0.004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_YearsToExpiry', window );">Years to Expiry</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_RiskfreeInterestRate', window );">Risk-free Interest Rate</a></td>
<td class="nump">3.48%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected Share Price Volatility</a></td>
<td class="nump">158.83%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FairValuePerOptions', window );">Fair Value per Options</a></td>
<td class="nump">$ 0.004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_FairValuePerOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value per option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_FairValuePerOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_RiskfreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of risk-free interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_RiskfreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_SharePriceAtGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price at grant date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_SharePriceAtGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_YearsToExpiry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Years to expiry.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_YearsToExpiry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DateOfGrantOfSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The date on which share-based payment arrangements are granted. [Refer: Types of share-based payment arrangements [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph IG23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DateOfGrantOfSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHAABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHAABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHAADMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHAADMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHAAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHAAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHAAFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHAAFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHAAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHAAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHAAHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHAAHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHAAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHAAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_OptionsSeriesAxis=athe_ATHACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_OptionsSeriesAxis=athe_ATHACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Schedule of Shares Issued under Stock Option Plan (Details) - 2004 ASX Plan [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfSharesIssuedUnderStockOptionPlanLineItems', window );"><strong>Schedule of Shares Issued under Stock Option Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Beginning of the year</a></td>
<td class="nump">13,277,715<span></span>
</td>
<td class="nump">13,277,715<span></span>
</td>
<td class="nump">13,277,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued during the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">End of the financial year</a></td>
<td class="nump">13,277,715<span></span>
</td>
<td class="nump">13,277,715<span></span>
</td>
<td class="nump">13,277,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfSharesIssuedUnderStockOptionPlanLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfSharesIssuedUnderStockOptionPlanLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_PlanAxis=athe_AsxPlan2004Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_PlanAxis=athe_AsxPlan2004Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Events [Member] - $ / shares<br></strong></div></th>
<th class="th"><div>Aug. 15, 2025</div></th>
<th class="th"><div>Jul. 03, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=athe_SubsequentEventsMember', window );">ASX Employee Share Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequents Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="nump">11,500,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Price per share</a></td>
<td class="nump">$ 0.013<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExercisePriceExpiryTerm', window );">Exercise price expiry term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=athe_SubsequentEventsMember', window );">ADS Employee Share Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequents Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="nump">314,400,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Price per share</a></td>
<td class="nump">$ 0.0086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ExercisePriceExpiryTerm', window );">Exercise price expiry term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ExercisePriceExpiryTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price expiry term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ExercisePriceExpiryTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=athe_SubsequentEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=athe_SubsequentEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=athe_ASXEmployeeSharePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=athe_ASXEmployeeSharePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=athe_ADSEmployeeSharePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=athe_ADSEmployeeSharePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Schedule of Earning Loss Per Share (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share (cents per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per share (cents per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of ordinary shares on issue used in the calculation of basic loss per share</a></td>
<td class="nump">6,396,924,117<span></span>
</td>
<td class="nump">3,648,875,564<span></span>
</td>
<td class="nump">2,427,841,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares on issue used in the calculation of diluted loss per share</a></td>
<td class="nump">6,396,924,117<span></span>
</td>
<td class="nump">3,648,875,564<span></span>
</td>
<td class="nump">2,427,841,917<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Key Management Personnel Compensation - Schedule of Key Management Personnel Compensation (Details) - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract', window );"><strong>Key Management Personnel Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employee benefits</a></td>
<td class="nump">$ 1,522,550<span></span>
</td>
<td class="nump">$ 1,551,075<span></span>
</td>
<td class="nump">$ 1,727,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Post-employment benefits</a></td>
<td class="nump">18,720<span></span>
</td>
<td class="nump">38,486<span></span>
</td>
<td class="nump">42,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_KeyManagementPersonnelCompensationLongtermBenefits', window );">Long-term benefits</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(6,616)<span></span>
</td>
<td class="nump">7,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,215<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based payments</a></td>
<td class="nump">802,128<span></span>
</td>
<td class="nump">520,055<span></span>
</td>
<td class="nump">764,175<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">$ 2,343,398<span></span>
</td>
<td class="nump">$ 2,113,215<span></span>
</td>
<td class="nump">$ 2,540,854<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_KeyManagementPersonnelCompensationLongtermBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_KeyManagementPersonnelCompensationLongtermBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Auditors' Remuneration - Schedule of Audit and Review of Financial Statements (Details) - AUD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_ScheduleOfAuditAndReviewOfFinancialStatementsAbstract', window );"><strong>Schedule of Audit and Review of Financial Statements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForAuditServices', window );">- Audit and review of financial statements</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 248,000<span></span>
</td>
<td class="nump">$ 248,200<span></span>
</td>
<td class="nump">$ 246,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForOtherServices', window );">- Other audit services</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">95,500<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemuneration', window );">Total auditors remuneration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="nump">$ 343,700<span></span>
</td>
<td class="nump">$ 298,400<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Audit and review of financial statements consist of fees billed for assurance and related services that generally only the statutory auditor could reasonably provide to a client.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Included in the balance are amounts related to additional regulatory filings during the 2025 financial year. All services provided are considered audit services for the purpose of SEC classification.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_ScheduleOfAuditAndReviewOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_ScheduleOfAuditAndReviewOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemuneration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemuneration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForAuditServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors for auditing services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForAuditServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForOtherServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors for services that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForOtherServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_NumberOfReportableSegment', window );">Reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_NumberOfReportableSegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reportable segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_NumberOfReportableSegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_AverageAnnualMovementForeignExchangeRate', window );">Average annual movement foreign exchange rate</a></td>
<td class="nump">1.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar', window );">Impact of weakened/strengthened of Australian dollar against US Dollar on post-tax loss (in Dollars)</a></td>
<td class="nump">$ 18,933<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_MaturityDate', window );">Maturity date</a></td>
<td class="text">Oct. 17,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_ForeignCurrencyRiskMember', window );">Foreign Currency Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_AverageAnnualMovementForeignExchangeRate', window );">Average annual movement foreign exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest Rate Of 0.00 One Percent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest Rate Of 0.00 Percent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest Rate 1.44 Percent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.44%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="nump">3.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest rate risk [member] | Interest Rate Of 0.00 One Percent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash accounts</a></td>
<td class="nump">$ 2,423,027<span></span>
</td>
<td class="nump">$ 182,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest rate risk [member] | Interest Rate Of 0.00 Percent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash accounts</a></td>
<td class="nump">$ 40,142<span></span>
</td>
<td class="nump">$ 705,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest rate risk [member] | Interest Rate 3.6 Percent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash accounts</a></td>
<td class="nump">$ 8,027,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest rate risk [member] | Interest Rate 1.05 Percent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash accounts</a></td>
<td class="nump">$ 500,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="nump">1.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest rate risk [member] | Interest Rate of 1.5 to 4.82 Percent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash accounts</a></td>
<td class="nump">$ 28,125,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest rate risk [member] | Interest Rate Of 0.00 Two Percent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash accounts</a></td>
<td class="nump">$ 246,146<span></span>
</td>
<td class="nump">$ 207,581<span></span>
</td>
<td class="nump">$ 15,473,231<span></span>
</td>
<td class="nump">$ 160,769<span></span>
</td>
<td class="nump">$ 138,388<span></span>
</td>
<td class="nump">$ 10,279,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest rate risk [member] | Interest Rate Of 0.00 Three Percent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash accounts</a></td>
<td class="nump">$ 44,381<span></span>
</td>
<td class="nump">$ 18,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,069<span></span>
</td>
<td class="nump">$ 12,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest rate risk [member] | Interest Rate Of 0.00 Four Percent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash accounts</a></td>
<td class="nump">$ 1,254,022<span></span>
</td>
<td class="nump">$ 4,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">821,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest rate risk [member] | Interest Rate of 0.00 Percent Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest rate risk [member] | Interest rate of 2.7% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,529,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest rate risk [member] | Interest Rate 3.85 One Percent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_MaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  02,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest rate risk [member] | Bottom of range [member] | Interest Rate of 1.5 to 4.82 Percent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest rate risk [member] | Top of range [member] | Interest Rate of 1.5 to 4.82 Percent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="nump">4.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | Interest Rate 3.85 Percent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_PercentageOfInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_MaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 28,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_AverageAnnualMovementForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the average annual movement foreign exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_AverageAnnualMovementForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_MaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_MaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_PercentageOfInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of interest rate on assets exposed to interest rate risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_PercentageOfInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The hypothetical financial impact of percent change of foreign exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=athe_ForeignCurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=athe_ForeignCurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=athe_CashAndCashEquivalentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=athe_CashAndCashEquivalentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=athe_InterestRateOf000OnePercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=athe_InterestRateOf000OnePercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=athe_InterestRateOf000PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=athe_InterestRateOf000PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=athe_InterestRate144PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=athe_InterestRate144PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=athe_InterestRate36PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=athe_InterestRate36PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=athe_InterestRate105PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=athe_InterestRate105PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=athe_InterestRateOf15To482PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=athe_InterestRateOf15To482PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=athe_InterestRateOf000TwoPercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=athe_InterestRateOf000TwoPercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=athe_InterestRateOf000ThreePercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=athe_InterestRateOf000ThreePercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=athe_InterestRateOf000FourPercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=athe_InterestRateOf000FourPercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=athe_InterestRateOf000PercentFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=athe_InterestRateOf000PercentFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=athe_InterestRateOf27Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=athe_InterestRateOf27Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=athe_InterestRate385OnePercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=athe_InterestRate385OnePercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=athe_InterestRate385PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=athe_InterestRate385PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Financial Assets and Liabilities Subject to Foreign Currency Risk (Details) - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Schedule of Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialInstrumentsTotalExposure', window );">Total exposure</a></td>
<td class="nump">$ 1,050,099<span></span>
</td>
<td class="num">$ (288,924)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalent [Member] | USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Schedule of Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialInstrumentsTotalExposure', window );">Total exposure</a></td>
<td class="nump">1,544,448<span></span>
</td>
<td class="nump">225,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_TradeAndOtherPayablesMember', window );">Trade and Other Payables [Member] | USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Schedule of Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialInstrumentsTotalExposure', window );">Total exposure</a></td>
<td class="num">(495,145)<span></span>
</td>
<td class="num">(507,820)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_TradeAndOtherPayablesMember', window );">Trade and Other Payables [Member] | &#163;GBP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Schedule of Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialInstrumentsTotalExposure', window );">Total exposure</a></td>
<td class="nump">796<span></span>
</td>
<td class="num">(3,834)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_TradeAndOtherPayablesMember', window );">Trade and Other Payables [Member] | JPY [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Schedule of Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialInstrumentsTotalExposure', window );">Total exposure</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (2,992)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_FinancialInstrumentsTotalExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The financial instruments total exposure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_FinancialInstrumentsTotalExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=athe_CashAndCashEquivalentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=athe_TradeAndOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=athe_TradeAndOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Interest Rates and the Effective Weighted Average Interest Rate for Classes of Financial Assets and Liabilities (Details) - AUD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="nump">$ 44,638,064<span></span>
</td>
<td class="nump">$ 16,721,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="num">(2,730,947)<span></span>
</td>
<td class="num">(4,878,992)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember', window );">Floating Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="nump">30,698,409<span></span>
</td>
<td class="nump">11,529,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=athe_NonInterestBearingMember', window );">Non-Interest Bearing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="nump">6,411,540<span></span>
</td>
<td class="nump">5,165,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="num">(2,575,490)<span></span>
</td>
<td class="num">(4,719,947)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">1 year or less [Member] | Fixed Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="nump">7,528,215<span></span>
</td>
<td class="nump">25,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="num">(66,912)<span></span>
</td>
<td class="num">(107,131)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">1-5 years [Member] | Fixed Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="num">(88,545)<span></span>
</td>
<td class="num">(51,914)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="nump">33,158,642<span></span>
</td>
<td class="nump">12,638,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalents [Member] | Floating Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="nump">30,698,409<span></span>
</td>
<td class="nump">11,529,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalents [Member] | Non-Interest Bearing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="nump">$ 2,463,168<span></span>
</td>
<td class="nump">$ 1,113,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalents [Member] | Interest Rate Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_AverageInterestRate', window );">Average Interest Rate</a></td>
<td class="nump">3.13%<span></span>
</td>
<td class="nump">2.463%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalents [Member] | 1 year or less [Member] | Fixed Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="num">$ (2,835)<span></span>
</td>
<td class="num">$ (4,293)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_CashAndCashEquivalentMember', window );">Cash and Cash Equivalents [Member] | 1-5 years [Member] | Fixed Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_TradeAndOtherReceivablesMember', window );">Trade and Other Receivables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="nump">3,937,607<span></span>
</td>
<td class="nump">4,041,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_TradeAndOtherReceivablesMember', window );">Trade and Other Receivables [Member] | Floating Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_TradeAndOtherReceivablesMember', window );">Trade and Other Receivables [Member] | Non-Interest Bearing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="nump">3,937,607<span></span>
</td>
<td class="nump">4,041,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_TradeAndOtherReceivablesMember', window );">Trade and Other Receivables [Member] | 1 year or less [Member] | Fixed Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_TradeAndOtherReceivablesMember', window );">Trade and Other Receivables [Member] | 1-5 years [Member] | Fixed Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_OtherCurrentAssetMember', window );">Other current asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="nump">7,541,815<span></span>
</td>
<td class="nump">40,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_OtherCurrentAssetMember', window );">Other current asset [Member] | Floating Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_OtherCurrentAssetMember', window );">Other current asset [Member] | Non-Interest Bearing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="nump">$ 10,765<span></span>
</td>
<td class="nump">$ 10,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_OtherCurrentAssetMember', window );">Other current asset [Member] | Interest Rate Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_AverageInterestRate', window );">Average Interest Rate</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">3.515%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_OtherCurrentAssetMember', window );">Other current asset [Member] | 1 year or less [Member] | Fixed Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="nump">$ 7,531,050<span></span>
</td>
<td class="nump">$ 30,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_OtherCurrentAssetMember', window );">Other current asset [Member] | 1-5 years [Member] | Fixed Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total Financial Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_TradeAndOtherPayablesMember', window );">Trade and Other Payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="num">(2,575,490)<span></span>
</td>
<td class="num">(4,619,947)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_TradeAndOtherPayablesMember', window );">Trade and Other Payables [Member] | Floating Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_TradeAndOtherPayablesMember', window );">Trade and Other Payables [Member] | Non-Interest Bearing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="num">(2,575,490)<span></span>
</td>
<td class="num">(4,619,947)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_TradeAndOtherPayablesMember', window );">Trade and Other Payables [Member] | 1 year or less [Member] | Fixed Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_TradeAndOtherPayablesMember', window );">Trade and Other Payables [Member] | 1-5 years [Member] | Fixed Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="num">(155,457)<span></span>
</td>
<td class="num">(159,045)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease Liabilities [Member] | Floating Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease Liabilities [Member] | Non-Interest Bearing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease Liabilities [Member] | 1 year or less [Member] | Fixed Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="num">(66,912)<span></span>
</td>
<td class="num">(107,131)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease Liabilities [Member] | 1-5 years [Member] | Fixed Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="num">$ (88,545)<span></span>
</td>
<td class="num">(51,914)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_OtherCurrentLiabilitieMember', window );">Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_OtherCurrentLiabilitieMember', window );">Other Current Liabilities [Member] | Floating Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_OtherCurrentLiabilitieMember', window );">Other Current Liabilities [Member] | Non-Interest Bearing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_OtherCurrentLiabilitieMember', window );">Other Current Liabilities [Member] | 1 year or less [Member] | Fixed Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_OtherCurrentLiabilitieMember', window );">Other Current Liabilities [Member] | 1-5 years [Member] | Fixed Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_athe_FinancialLiabilitiesAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total Financial Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_AverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of average interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_AverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_FinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_FinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_athe_FinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">athe_FinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>athe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=athe_NonInterestBearingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=athe_NonInterestBearingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_CashAndCashEquivalentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_CashAndCashEquivalentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_InterestRateRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_InterestRateRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_TradeAndOtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_TradeAndOtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_OtherCurrentAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_OtherCurrentAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_TradeAndOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_TradeAndOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_OtherCurrentLiabilitieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_OtherCurrentLiabilitieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Company's Liquidity Reserve on the Basis of Expected Cash Flows (Details) - AUD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_LessThenSixMonthsMember', window );">Less than 6 Months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="num">$ (2,608,946)<span></span>
</td>
<td class="num">$ (4,673,513)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_LessThenSixMonthsMember', window );">Less than 6 Months [Member] | Trade And Other Payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="num">(2,575,490)<span></span>
</td>
<td class="num">(4,619,947)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_LessThenSixMonthsMember', window );">Less than 6 Months [Member] | Lease liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="num">(33,456)<span></span>
</td>
<td class="num">(53,566)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_SixToTowelMember', window );">6-12 Months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="num">(33,456)<span></span>
</td>
<td class="num">(53,565)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_SixToTowelMember', window );">6-12 Months [Member] | Trade And Other Payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_SixToTowelMember', window );">6-12 Months [Member] | Lease liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="num">(33,456)<span></span>
</td>
<td class="num">(53,565)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember', window );">Greater than 12 Months and Less Than 5 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="num">(88,545)<span></span>
</td>
<td class="num">(51,914)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember', window );">Greater than 12 Months and Less Than 5 Years [Member] | Trade And Other Payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember', window );">Greater than 12 Months and Less Than 5 Years [Member] | Lease liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="num">(88,545)<span></span>
</td>
<td class="num">(51,914)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_TotalContractedCashFlowsMember', window );">Total Contracted Cash Flows [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="num">(2,730,947)<span></span>
</td>
<td class="num">(4,778,992)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_TotalContractedCashFlowsMember', window );">Total Contracted Cash Flows [Member] | Trade And Other Payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="num">(2,575,490)<span></span>
</td>
<td class="num">(4,619,947)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_TotalContractedCashFlowsMember', window );">Total Contracted Cash Flows [Member] | Lease liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="num">(155,457)<span></span>
</td>
<td class="num">(159,045)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_CarryingAmountsMember', window );">Carrying Amounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="num">(2,730,947)<span></span>
</td>
<td class="num">(4,778,992)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_CarryingAmountsMember', window );">Carrying Amounts [Member] | Trade And Other Payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="num">(2,575,490)<span></span>
</td>
<td class="num">(4,619,947)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=athe_CarryingAmountsMember', window );">Carrying Amounts [Member] | Lease liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="num">$ (155,457)<span></span>
</td>
<td class="num">$ (159,045)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=athe_LessThenSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=athe_LessThenSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_TradeAndOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=athe_TradeAndOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=athe_SixToTowelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=athe_SixToTowelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=athe_TotalContractedCashFlowsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=athe_TotalContractedCashFlowsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=athe_CarryingAmountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=athe_CarryingAmountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Parent Entity Financial Information - Schedule of Individual Financial Statements for the Parent Entity (Details) - Parent [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfFinancialPositionAbstract', window );"><strong>Statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="nump">$ 44,678,130<span></span>
</td>
<td class="nump">$ 19,018,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">68,329<span></span>
</td>
<td class="nump">147,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">44,746,459<span></span>
</td>
<td class="nump">19,165,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(3,514,494)<span></span>
</td>
<td class="num">(5,101,935)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Non-current liabilities</a></td>
<td class="num">(1,421)<span></span>
</td>
<td class="num">(1,151,157)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(3,515,915)<span></span>
</td>
<td class="num">(6,253,092)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Contributed equity</a></td>
<td class="nump">262,948,046<span></span>
</td>
<td class="nump">223,151,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">Reserves</a></td>
<td class="nump">5,342,304<span></span>
</td>
<td class="nump">4,806,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated losses</a></td>
<td class="num">(227,059,806)<span></span>
</td>
<td class="num">(215,045,128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">41,230,544<span></span>
</td>
<td class="nump">12,912,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Statement of profit or loss and other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the year</a></td>
<td class="num">(12,448,395)<span></span>
</td>
<td class="num">(19,355,765)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the year</a></td>
<td class="num">$ (12,448,395)<span></span>
</td>
<td class="num">$ (19,355,765)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from share-based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>353</ContextCount>
  <ElementCount>368</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>109</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Consolidated Statements of Financial Position (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Statements of Financial Position (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Consolidated Statements of Profit or Loss and Other Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Profit or Loss and Other Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Consolidated Cash Flow Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Cash Flow Statements</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Consolidated Statements of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Disclosure - Background and Summary of Material Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPolicies</Role>
      <ShortName>Background and Summary of Material Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Interest and Other Income from Continuing Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/InterestandOtherIncomefromContinuingOperations</Role>
      <ShortName>Interest and Other Income from Continuing Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Expenses from Ordinary Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ExpensesfromOrdinaryActivities</Role>
      <ShortName>Expenses from Ordinary Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Income Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/IncomeTax</Role>
      <ShortName>Income Tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Trade and Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/TradeandOtherReceivables</Role>
      <ShortName>Trade and Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/OtherCurrentAssets</Role>
      <ShortName>Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Trade and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/TradeandOtherPayables</Role>
      <ShortName>Trade and Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Provisions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/Provisions</Role>
      <ShortName>Provisions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Issued Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/IssuedCapital</Role>
      <ShortName>Issued Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/Reserves</Role>
      <ShortName>Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Accumulated Deficit During Development Stage</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStage</Role>
      <ShortName>Accumulated Deficit During Development Stage</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/CashFlowInformation</Role>
      <ShortName>Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Expenditure Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ExpenditureCommitments</Role>
      <ShortName>Expenditure Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995321 - Disclosure - Share Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ShareBasedPayments</Role>
      <ShortName>Share Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995322 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995323 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995324 - Disclosure - Key Management Personnel Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/KeyManagementPersonnelCompensation</Role>
      <ShortName>Key Management Personnel Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995325 - Disclosure - Auditors' Remuneration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/AuditorsRemuneration</Role>
      <ShortName>Auditors' Remuneration</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995326 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995327 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995328 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995329 - Disclosure - Parent Entity Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ParentEntityFinancialInformation</Role>
      <ShortName>Parent Entity Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Background and Summary of Material Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesTables</Role>
      <ShortName>Background and Summary of Material Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Interest and Other Income from Continuing Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsTables</Role>
      <ShortName>Interest and Other Income from Continuing Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/InterestandOtherIncomefromContinuingOperations</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Expenses from Ordinary Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ExpensesfromOrdinaryActivitiesTables</Role>
      <ShortName>Expenses from Ordinary Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/ExpensesfromOrdinaryActivities</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Income Tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/IncomeTaxTables</Role>
      <ShortName>Income Tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/IncomeTax</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Trade and Other Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/TradeandOtherReceivablesTables</Role>
      <ShortName>Trade and Other Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/TradeandOtherReceivables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/OtherCurrentAssets</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Trade and Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/TradeandOtherPayablesTables</Role>
      <ShortName>Trade and Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/TradeandOtherPayables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Provisions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ProvisionsTables</Role>
      <ShortName>Provisions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/Provisions</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Issued Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/IssuedCapitalTables</Role>
      <ShortName>Issued Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/IssuedCapital</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Reserves (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ReservesTables</Role>
      <ShortName>Reserves (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/Reserves</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Accumulated Deficit During Development Stage (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStageTables</Role>
      <ShortName>Accumulated Deficit During Development Stage (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStage</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/Leases</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/CashFlowInformationTables</Role>
      <ShortName>Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/CashFlowInformation</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Share Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/ShareBasedPayments</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/LossPerShare</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Key Management Personnel Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/KeyManagementPersonnelCompensationTables</Role>
      <ShortName>Key Management Personnel Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/KeyManagementPersonnelCompensation</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Auditors' Remuneration (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/AuditorsRemunerationTables</Role>
      <ShortName>Auditors' Remuneration (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/AuditorsRemuneration</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/FinancialInstruments</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Parent Entity Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ParentEntityFinancialInformationTables</Role>
      <ShortName>Parent Entity Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pranabio.com/role/ParentEntityFinancialInformation</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Background and Summary of Material Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails</Role>
      <ShortName>Background and Summary of Material Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Background and Summary of Material Accounting Policies - Schedule of Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable</Role>
      <ShortName>Background and Summary of Material Accounting Policies - Schedule of Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Interest and Other Income from Continuing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsDetails</Role>
      <ShortName>Interest and Other Income from Continuing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Interest and Other Income from Continuing Operations - Schedule of Interest and Other Income from Continuing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable</Role>
      <ShortName>Interest and Other Income from Continuing Operations - Schedule of Interest and Other Income from Continuing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Expenses from Ordinary Activities - Schedule of Expenses from Ordinary Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable</Role>
      <ShortName>Expenses from Ordinary Activities - Schedule of Expenses from Ordinary Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/IncomeTaxDetails</Role>
      <ShortName>Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pranabio.com/role/IncomeTaxTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Income Tax - Schedule of Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofIncomeTaxTable</Role>
      <ShortName>Income Tax - Schedule of Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Income Tax - Schedule of Income Tax (Parentheticals) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofIncomeTaxTable_Parentheticals</Role>
      <ShortName>Income Tax - Schedule of Income Tax (Parentheticals) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Trade and Other Receivables - Schedule of Trade and Other Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable</Role>
      <ShortName>Trade and Other Receivables - Schedule of Trade and Other Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/OtherCurrentAssetsDetails</Role>
      <ShortName>Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pranabio.com/role/OtherCurrentAssetsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Other Current Assets - Schedule of Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable</Role>
      <ShortName>Other Current Assets - Schedule of Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Trade and Other Payables - Schedule of Trade and Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable</Role>
      <ShortName>Trade and Other Payables - Schedule of Trade and Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Provisions - Schedule of Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofProvisionsTable</Role>
      <ShortName>Provisions - Schedule of Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Provisions - Schedule of Movements in Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofMovementsinProvisionsTable</Role>
      <ShortName>Provisions - Schedule of Movements in Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Issued Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/IssuedCapitalDetails</Role>
      <ShortName>Issued Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pranabio.com/role/IssuedCapitalTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Issued Capital - Schedule of Issued Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofIssuedCapitalTable</Role>
      <ShortName>Issued Capital - Schedule of Issued Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Issued Capital - Schedule of Issued Capital (Parentheticals) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofIssuedCapitalTable_Parentheticals</Role>
      <ShortName>Issued Capital - Schedule of Issued Capital (Parentheticals) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Issued Capital - Schedule of Movements in Issued Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofMovementsinIssuedSharesTable</Role>
      <ShortName>Issued Capital - Schedule of Movements in Issued Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Issued Capital - Schedule of Share Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofShareIssuancesTable</Role>
      <ShortName>Issued Capital - Schedule of Share Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ReservesDetails</Role>
      <ShortName>Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pranabio.com/role/ReservesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Reserves - Schedule of Reserves of Share Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable</Role>
      <ShortName>Reserves - Schedule of Reserves of Share Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Reserves - Schedule of Reserves of Share Based Payments (Parentheticals) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable_Parentheticals</Role>
      <ShortName>Reserves - Schedule of Reserves of Share Based Payments (Parentheticals) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Reserves - Schedule of Movements in Options for Fully Paid Ordinary Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable</Role>
      <ShortName>Reserves - Schedule of Movements in Options for Fully Paid Ordinary Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Accumulated Deficit During Development Stage - Schedule of Accumulated Deficit During Development Stage (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofAccumulatedDeficitDuringDevelopmentStageTable</Role>
      <ShortName>Accumulated Deficit During Development Stage - Schedule of Accumulated Deficit During Development Stage (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pranabio.com/role/LeasesTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Leases - Schedule of Financial Position Shows the Following Amounts Relating to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable</Role>
      <ShortName>Leases - Schedule of Financial Position Shows the Following Amounts Relating to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Leases - Schedule of Profit or Loss Shows the Following Amounts Relating to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofProfitorLossShowstheFollowingAmountsRelatingtoLeasesTable</Role>
      <ShortName>Leases - Schedule of Profit or Loss Shows the Following Amounts Relating to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Cash Flow Information - Schedule of Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofCashFlowInformationTable</Role>
      <ShortName>Cash Flow Information - Schedule of Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Expenditure Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ExpenditureCommitmentsDetails</Role>
      <ShortName>Expenditure Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pranabio.com/role/ExpenditureCommitments</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Share Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pranabio.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Share Based Payments - Schedule of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofOptionsGrantedTable</Role>
      <ShortName>Share Based Payments - Schedule of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996051 - Disclosure - Share Based Payments - Schedule of Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofOptionsOutstandingTable</Role>
      <ShortName>Share Based Payments - Schedule of Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996052 - Disclosure - Share Based Payments - Schedule of Valuations of Options Approved and Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable</Role>
      <ShortName>Share Based Payments - Schedule of Valuations of Options Approved and Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996053 - Disclosure - Share Based Payments - Schedule of Shares Issued under Stock Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofSharesIssuedunderStockOptionPlanTable</Role>
      <ShortName>Share Based Payments - Schedule of Shares Issued under Stock Option Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996054 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pranabio.com/role/SubsequentEvents</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Loss Per Share - Schedule of Earning Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofEarningLossPerShareTable</Role>
      <ShortName>Loss Per Share - Schedule of Earning Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996056 - Disclosure - Key Management Personnel Compensation - Schedule of Key Management Personnel Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable</Role>
      <ShortName>Key Management Personnel Compensation - Schedule of Key Management Personnel Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Auditors' Remuneration - Schedule of Audit and Review of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofAuditandReviewofFinancialStatementsTable</Role>
      <ShortName>Auditors' Remuneration - Schedule of Audit and Review of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>996058 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pranabio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>996059 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pranabio.com/role/SegmentInformation</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>996060 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pranabio.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>996061 - Disclosure - Financial Instruments - Schedule of Financial Assets and Liabilities Subject to Foreign Currency Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable</Role>
      <ShortName>Financial Instruments - Schedule of Financial Assets and Liabilities Subject to Foreign Currency Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>996062 - Disclosure - Financial Instruments - Schedule of Interest Rates and the Effective Weighted Average Interest Rate for Classes of Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable</Role>
      <ShortName>Financial Instruments - Schedule of Interest Rates and the Effective Weighted Average Interest Rate for Classes of Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>996063 - Disclosure - Financial Instruments - Schedule of Company's Liquidity Reserve on the Basis of Expected Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable</Role>
      <ShortName>Financial Instruments - Schedule of Company's Liquidity Reserve on the Basis of Expected Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="ea0254438-20f_alterity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>996064 - Disclosure - Parent Entity Financial Information - Schedule of Individual Financial Statements for the Parent Entity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable</Role>
      <ShortName>Parent Entity Financial Information - Schedule of Individual Financial Statements for the Parent Entity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>athe-20250630.xsd</File>
    <File>athe-20250630_cal.xml</File>
    <File>athe-20250630_def.xml</File>
    <File>athe-20250630_lab.xml</File>
    <File>athe-20250630_pre.xml</File>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" isUsgaap="true" original="ea0254438-20f_alterity.htm">ea0254438-20f_alterity.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="43">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
    <BaseTaxonomy items="918">https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>119
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0254438-20f_alterity.htm": {
   "nsprefix": "athe",
   "nsuri": "http://pranabio.com/20250630",
   "dts": {
    "schema": {
     "local": [
      "athe-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd",
      "https://xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "athe-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "athe-20250630_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "athe-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "athe-20250630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0254438-20f_alterity.htm"
     ]
    }
   },
   "keyStandard": 253,
   "keyCustom": 115,
   "axisStandard": 21,
   "axisCustom": 4,
   "memberStandard": 23,
   "memberCustom": 76,
   "hidden": {
    "total": 181,
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 106,
    "http://pranabio.com/20250630": 72,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 353,
   "entityCount": 1,
   "segmentCount": 109,
   "elementCount": 861,
   "unitCount": 8,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 918,
    "http://xbrl.sec.gov/dei/2024": 43,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://pranabio.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentAssets",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://pranabio.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Consolidated Statements of Financial Position (Parentheticals)",
     "shortName": "Consolidated Statements of Financial Position (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://pranabio.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Consolidated Statements of Profit or Loss and Other Comprehensive Loss",
     "shortName": "Consolidated Statements of Profit or Loss and Other Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:RevenueFromInterest",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:IntellectualPropertyExpenses",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://pranabio.com/role/ConsolidatedCashFlow",
     "longName": "995304 - Statement - Consolidated Cash Flow Statements",
     "shortName": "Consolidated Cash Flow Statements",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://pranabio.com/role/ShareholdersEquityType2or3",
     "longName": "995305 - Statement - Consolidated Statements of Changes in Shareholders' Equity",
     "shortName": "Consolidated Statements of Changes in Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "ifrs-full:Equity",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c8",
      "name": "ifrs-full:Equity",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPolicies",
     "longName": "995306 - Disclosure - Background and Summary of Material Accounting Policies",
     "shortName": "Background and Summary of Material Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://pranabio.com/role/InterestandOtherIncomefromContinuingOperations",
     "longName": "995307 - Disclosure - Interest and Other Income from Continuing Operations",
     "shortName": "Interest and Other Income from Continuing Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInterestIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInterestIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://pranabio.com/role/ExpensesfromOrdinaryActivities",
     "longName": "995308 - Disclosure - Expenses from Ordinary Activities",
     "shortName": "Expenses from Ordinary Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfExpensesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfExpensesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://pranabio.com/role/IncomeTax",
     "longName": "995309 - Disclosure - Income Tax",
     "shortName": "Income Tax",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://pranabio.com/role/TradeandOtherReceivables",
     "longName": "995310 - Disclosure - Trade and Other Receivables",
     "shortName": "Trade and Other Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://pranabio.com/role/OtherCurrentAssets",
     "longName": "995311 - Disclosure - Other Current Assets",
     "shortName": "Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://pranabio.com/role/TradeandOtherPayables",
     "longName": "995312 - Disclosure - Trade and Other Payables",
     "shortName": "Trade and Other Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://pranabio.com/role/Provisions",
     "longName": "995313 - Disclosure - Provisions",
     "shortName": "Provisions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfProvisionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfProvisionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://pranabio.com/role/CommitmentsandContingencies",
     "longName": "995314 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://pranabio.com/role/IssuedCapital",
     "longName": "995315 - Disclosure - Issued Capital",
     "shortName": "Issued Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://pranabio.com/role/Reserves",
     "longName": "995316 - Disclosure - Reserves",
     "shortName": "Reserves",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStage",
     "longName": "995317 - Disclosure - Accumulated Deficit During Development Stage",
     "shortName": "Accumulated Deficit During Development Stage",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:AccumulatedDeficitDuringDevelopmentStageTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:AccumulatedDeficitDuringDevelopmentStageTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://pranabio.com/role/Leases",
     "longName": "995318 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://pranabio.com/role/CashFlowInformation",
     "longName": "995319 - Disclosure - Cash Flow Information",
     "shortName": "Cash Flow Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://pranabio.com/role/ExpenditureCommitments",
     "longName": "995320 - Disclosure - Expenditure Commitments",
     "shortName": "Expenditure Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://pranabio.com/role/ShareBasedPayments",
     "longName": "995321 - Disclosure - Share Based Payments",
     "shortName": "Share Based Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://pranabio.com/role/SubsequentEvents",
     "longName": "995322 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://pranabio.com/role/LossPerShare",
     "longName": "995323 - Disclosure - Loss Per Share",
     "shortName": "Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://pranabio.com/role/KeyManagementPersonnelCompensation",
     "longName": "995324 - Disclosure - Key Management Personnel Compensation",
     "shortName": "Key Management Personnel Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://pranabio.com/role/AuditorsRemuneration",
     "longName": "995325 - Disclosure - Auditors' Remuneration",
     "shortName": "Auditors' Remuneration",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://pranabio.com/role/RelatedPartyTransactions",
     "longName": "995326 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://pranabio.com/role/SegmentInformation",
     "longName": "995327 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://pranabio.com/role/FinancialInstruments",
     "longName": "995328 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://pranabio.com/role/ParentEntityFinancialInformation",
     "longName": "995329 - Disclosure - Parent Entity Financial Information",
     "shortName": "Parent Entity Financial Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInterimFinancialReportingExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInterimFinancialReportingExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://pranabio.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Background and Summary of Material Accounting Policies (Tables)",
     "shortName": "Background and Summary of Material Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsTables",
     "longName": "996002 - Disclosure - Interest and Other Income from Continuing Operations (Tables)",
     "shortName": "Interest and Other Income from Continuing Operations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInterestIncomeExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInterestIncomeExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://pranabio.com/role/ExpensesfromOrdinaryActivitiesTables",
     "longName": "996003 - Disclosure - Expenses from Ordinary Activities (Tables)",
     "shortName": "Expenses from Ordinary Activities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfExpensesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfExpensesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://pranabio.com/role/IncomeTaxTables",
     "longName": "996004 - Disclosure - Income Tax (Tables)",
     "shortName": "Income Tax (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:DisclosureOfIncomeTaxExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:DisclosureOfIncomeTaxExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://pranabio.com/role/TradeandOtherReceivablesTables",
     "longName": "996005 - Disclosure - Trade and Other Receivables (Tables)",
     "shortName": "Trade and Other Receivables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:DisclosureOfTradeAndOtherReceivableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:DisclosureOfTradeAndOtherReceivableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://pranabio.com/role/OtherCurrentAssetsTables",
     "longName": "996006 - Disclosure - Other Current Assets (Tables)",
     "shortName": "Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://pranabio.com/role/TradeandOtherPayablesTables",
     "longName": "996007 - Disclosure - Trade and Other Payables (Tables)",
     "shortName": "Trade and Other Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:ScheduleOfTradeAndOtherPayableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:ScheduleOfTradeAndOtherPayableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://pranabio.com/role/ProvisionsTables",
     "longName": "996008 - Disclosure - Provisions (Tables)",
     "shortName": "Provisions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://pranabio.com/role/IssuedCapitalTables",
     "longName": "996009 - Disclosure - Issued Capital (Tables)",
     "shortName": "Issued Capital (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://pranabio.com/role/ReservesTables",
     "longName": "996010 - Disclosure - Reserves (Tables)",
     "shortName": "Reserves (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:ScheduleOfReserveOfShareBasedPaymentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:ScheduleOfReserveOfShareBasedPaymentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStageTables",
     "longName": "996011 - Disclosure - Accumulated Deficit During Development Stage (Tables)",
     "shortName": "Accumulated Deficit During Development Stage (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "athe:AccumulatedDeficitDuringDevelopmentStageTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "athe:AccumulatedDeficitDuringDevelopmentStageTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://pranabio.com/role/LeasesTables",
     "longName": "996012 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:ScheduleOfAmountsRelatingToLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:ScheduleOfAmountsRelatingToLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://pranabio.com/role/CashFlowInformationTables",
     "longName": "996013 - Disclosure - Cash Flow Information (Tables)",
     "shortName": "Cash Flow Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://pranabio.com/role/ShareBasedPaymentsTables",
     "longName": "996014 - Disclosure - Share Based Payments (Tables)",
     "shortName": "Share Based Payments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://pranabio.com/role/LossPerShareTables",
     "longName": "996015 - Disclosure - Loss Per Share (Tables)",
     "shortName": "Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://pranabio.com/role/KeyManagementPersonnelCompensationTables",
     "longName": "996016 - Disclosure - Key Management Personnel Compensation (Tables)",
     "shortName": "Key Management Personnel Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://pranabio.com/role/AuditorsRemunerationTables",
     "longName": "996017 - Disclosure - Auditors' Remuneration (Tables)",
     "shortName": "Auditors' Remuneration (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:ScheduleOfAuditorRemunerationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:ScheduleOfAuditorRemunerationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://pranabio.com/role/FinancialInstrumentsTables",
     "longName": "996018 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://pranabio.com/role/ParentEntityFinancialInformationTables",
     "longName": "996019 - Disclosure - Parent Entity Financial Information (Tables)",
     "shortName": "Parent Entity Financial Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Tables",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:DisclosureOfParentEntityFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInterimFinancialReportingExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:DisclosureOfParentEntityFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInterimFinancialReportingExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails",
     "longName": "996020 - Disclosure - Background and Summary of Material Accounting Policies (Details)",
     "shortName": "Background and Summary of Material Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:TaxRateEffectFromChangesInTaxRate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:TaxRateEffectFromChangesInTaxRate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable",
     "longName": "996021 - Disclosure - Background and Summary of Material Accounting Policies - Schedule of Estimated Useful Lives (Details)",
     "shortName": "Background and Summary of Material Accounting Policies - Schedule of Estimated Useful Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c33",
      "name": "athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c33",
      "name": "athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsDetails",
     "longName": "996022 - Disclosure - Interest and Other Income from Continuing Operations (Details)",
     "shortName": "Interest and Other Income from Continuing Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:TaxRateEffectFromChangeInTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "athe:ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock",
       "ifrs-full:DisclosureOfInterestIncomeExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:TaxRateEffectFromChangeInTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "athe:ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock",
       "ifrs-full:DisclosureOfInterestIncomeExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable",
     "longName": "996023 - Disclosure - Interest and Other Income from Continuing Operations - Schedule of Interest and Other Income from Continuing Operations (Details)",
     "shortName": "Interest and Other Income from Continuing Operations - Schedule of Interest and Other Income from Continuing Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:RevenueFromInterest",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:OtherRevenue",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock",
       "ifrs-full:DisclosureOfInterestIncomeExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable",
     "longName": "996024 - Disclosure - Expenses from Ordinary Activities - Schedule of Expenses from Ordinary Activities (Details)",
     "shortName": "Expenses from Ordinary Activities - Schedule of Expenses from Ordinary Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "ifrs-full:DisclosureOfExpensesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "ifrs-full:DisclosureOfExpensesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://pranabio.com/role/IncomeTaxDetails",
     "longName": "996025 - Disclosure - Income Tax (Details)",
     "shortName": "Income Tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "link:footnote",
       "p",
       "td",
       "tr",
       "table",
       "athe:DisclosureOfIncomeTaxExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "link:footnote",
       "p",
       "td",
       "tr",
       "table",
       "athe:DisclosureOfIncomeTaxExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://pranabio.com/role/ScheduleofIncomeTaxTable",
     "longName": "996026 - Disclosure - Income Tax - Schedule of Income Tax (Details)",
     "shortName": "Income Tax - Schedule of Income Tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:DisclosureOfIncomeTaxExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:DisclosureOfIncomeTaxExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://pranabio.com/role/ScheduleofIncomeTaxTable_Parentheticals",
     "longName": "996027 - Disclosure - Income Tax - Schedule of Income Tax (Parentheticals) (Details)",
     "shortName": "Income Tax - Schedule of Income Tax (Parentheticals) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:PrimaFacieTaxOnNetLossBeforeIncomeTax",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:DisclosureOfIncomeTaxExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:PrimaFacieTaxOnNetLossBeforeIncomeTax",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:DisclosureOfIncomeTaxExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable",
     "longName": "996028 - Disclosure - Trade and Other Receivables - Schedule of Trade and Other Receivables (Details)",
     "shortName": "Trade and Other Receivables - Schedule of Trade and Other Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:CurrentAccruedIncomeIncludingCurrentContractAssets",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:DisclosureOfTradeAndOtherReceivableTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:CurrentAccruedIncomeIncludingCurrentContractAssets",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:DisclosureOfTradeAndOtherReceivableTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://pranabio.com/role/OtherCurrentAssetsDetails",
     "longName": "996029 - Disclosure - Other Current Assets (Details)",
     "shortName": "Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:TermDeposit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "link:footnote",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:TermDeposit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "link:footnote",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable",
     "longName": "996030 - Disclosure - Other Current Assets - Schedule of Other Current Assets (Details)",
     "shortName": "Other Current Assets - Schedule of Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentPrepayments",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentPrepayments",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable",
     "longName": "996031 - Disclosure - Trade and Other Payables - Schedule of Trade and Other Payables (Details)",
     "shortName": "Trade and Other Payables - Schedule of Trade and Other Payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:ScheduleOfTradeAndOtherPayableTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:ScheduleOfTradeAndOtherPayableTableTextBlock",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://pranabio.com/role/ScheduleofProvisionsTable",
     "longName": "996032 - Disclosure - Provisions - Schedule of Provisions (Details)",
     "shortName": "Provisions - Schedule of Provisions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentProvisions",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c37",
      "name": "ifrs-full:CurrentProvisions",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://pranabio.com/role/ScheduleofMovementsinProvisionsTable",
     "longName": "996033 - Disclosure - Provisions - Schedule of Movements in Provisions (Details)",
     "shortName": "Provisions - Schedule of Movements in Provisions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:AnnualLeaveAndLongServiceLeaveCarryingAmount",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:AnnualLeaveAndLongServiceLeaveCarryingAmount",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock",
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://pranabio.com/role/IssuedCapitalDetails",
     "longName": "996034 - Disclosure - Issued Capital (Details)",
     "shortName": "Issued Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c51",
      "name": "ifrs-full:CapitalCommitments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c51",
      "name": "ifrs-full:CapitalCommitments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://pranabio.com/role/ScheduleofIssuedCapitalTable",
     "longName": "996035 - Disclosure - Issued Capital - Schedule of Issued Capital (Details)",
     "shortName": "Issued Capital - Schedule of Issued Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:IssuedCapital",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:IssuedCapital",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://pranabio.com/role/ScheduleofIssuedCapitalTable_Parentheticals",
     "longName": "996036 - Disclosure - Issued Capital - Schedule of Issued Capital (Parentheticals) (Details)",
     "shortName": "Issued Capital - Schedule of Issued Capital (Parentheticals) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c52",
      "name": "ifrs-full:NumberOfSharesIssuedAndFullyPaid",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R71": {
     "role": "http://pranabio.com/role/ScheduleofMovementsinIssuedSharesTable",
     "longName": "996037 - Disclosure - Issued Capital - Schedule of Movements in Issued Shares (Details)",
     "shortName": "Issued Capital - Schedule of Movements in Issued Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c53",
      "name": "ifrs-full:NumberOfSharesIssuedAndFullyPaid",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c59",
      "name": "athe:MovementDuringTheYearNoOfSharesinShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://pranabio.com/role/ScheduleofShareIssuancesTable",
     "longName": "996038 - Disclosure - Issued Capital - Schedule of Share Issuances (Details)",
     "shortName": "Issued Capital - Schedule of Share Issuances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c53",
      "name": "athe:IncreaseDecreaseInNumberOfShareOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c58",
      "name": "athe:IncreaseDecreaseInNumberOfShareOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://pranabio.com/role/ReservesDetails",
     "longName": "996039 - Disclosure - Reserves (Details)",
     "shortName": "Reserves (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c121",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "Options",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c121",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "Options",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable",
     "longName": "996040 - Disclosure - Reserves - Schedule of Reserves of Share Based Payments (Details)",
     "shortName": "Reserves - Schedule of Reserves of Share Based Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ReserveOfSharebasedPayments",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:ScheduleOfReserveOfShareBasedPaymentsTableTextBlock",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c132",
      "name": "ifrs-full:ReserveOfSharebasedPayments",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:ScheduleOfReserveOfShareBasedPaymentsTableTextBlock",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable_Parentheticals",
     "longName": "996041 - Disclosure - Reserves - Schedule of Reserves of Share Based Payments (Parentheticals) (Details)",
     "shortName": "Reserves - Schedule of Reserves of Share Based Payments (Parentheticals) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:OptionsForFullyPaidOrdinaryShares1",
      "unitRef": "Options",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:ScheduleOfReserveOfShareBasedPaymentsTableTextBlock",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:OptionsForFullyPaidOrdinaryShares1",
      "unitRef": "Options",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:ScheduleOfReserveOfShareBasedPaymentsTableTextBlock",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable",
     "longName": "996042 - Disclosure - Reserves - Schedule of Movements in Options for Fully Paid Ordinary Shares (Details)",
     "shortName": "Reserves - Schedule of Movements in Options for Fully Paid Ordinary Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "athe:NumberOfSharesOptionsOutstanding",
      "unitRef": "Options",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "athe:NumberOfSharesOptionsOutstanding",
      "unitRef": "Options",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://pranabio.com/role/ScheduleofAccumulatedDeficitDuringDevelopmentStageTable",
     "longName": "996043 - Disclosure - Accumulated Deficit During Development Stage - Schedule of Accumulated Deficit During Development Stage (Details)",
     "shortName": "Accumulated Deficit During Development Stage - Schedule of Accumulated Deficit During Development Stage (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "ifrs-full:RetainedEarnings",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock",
       "athe:AccumulatedDeficitDuringDevelopmentStageTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:RetainedEarnings",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock",
       "athe:AccumulatedDeficitDuringDevelopmentStageTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://pranabio.com/role/LeasesDetails",
     "longName": "996044 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AdditionsToRightofuseAssets",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AdditionsToRightofuseAssets",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable",
     "longName": "996045 - Disclosure - Leases - Schedule of Financial Position Shows the Following Amounts Relating to Leases (Details)",
     "shortName": "Leases - Schedule of Financial Position Shows the Following Amounts Relating to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:ScheduleOfAmountsRelatingToLeasesTableTextBlock",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://pranabio.com/role/ScheduleofProfitorLossShowstheFollowingAmountsRelatingtoLeasesTable",
     "longName": "996046 - Disclosure - Leases - Schedule of Profit or Loss Shows the Following Amounts Relating to Leases (Details)",
     "shortName": "Leases - Schedule of Profit or Loss Shows the Following Amounts Relating to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DepreciationRightofuseAssets",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "ifrs-full:DisclosureOfExpensesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:InterestExpense",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://pranabio.com/role/ScheduleofCashFlowInformationTable",
     "longName": "996047 - Disclosure - Cash Flow Information - Schedule of Cash Flow Information (Details)",
     "shortName": "Cash Flow Information - Schedule of Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AdjustmentsForDepreciationExpense",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://pranabio.com/role/ExpenditureCommitmentsDetails",
     "longName": "996048 - Disclosure - Expenditure Commitments (Details)",
     "shortName": "Expenditure Commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:TerminationNoticePeriodForResearchAndDevelopmentContracts",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfCommitmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:TerminationNoticePeriodForResearchAndDevelopmentContracts",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfCommitmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://pranabio.com/role/ShareBasedPaymentsDetails",
     "longName": "996049 - Disclosure - Share Based Payments (Details)",
     "shortName": "Share Based Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "athe:NumberOfDirector",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "athe:NumberOfDirector",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://pranabio.com/role/ScheduleofOptionsGrantedTable",
     "longName": "996050 - Disclosure - Share Based Payments - Schedule of Options Granted (Details)",
     "shortName": "Share Based Payments - Schedule of Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c143",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "Options",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c145",
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
      "unitRef": "audPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://pranabio.com/role/ScheduleofOptionsOutstandingTable",
     "longName": "996051 - Disclosure - Share Based Payments - Schedule of Options Outstanding (Details)",
     "shortName": "Share Based Payments - Schedule of Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c149",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "Options",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c146",
      "name": "ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "athe:ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable",
     "longName": "996052 - Disclosure - Share Based Payments - Schedule of Valuations of Options Approved and Issued (Details)",
     "shortName": "Share Based Payments - Schedule of Valuations of Options Approved and Issued (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c177",
      "name": "ifrs-full:DateOfGrantOfSharebasedPaymentArrangement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c177",
      "name": "ifrs-full:DateOfGrantOfSharebasedPaymentArrangement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://pranabio.com/role/ScheduleofSharesIssuedunderStockOptionPlanTable",
     "longName": "996053 - Disclosure - Share Based Payments - Schedule of Shares Issued under Stock Option Plan (Details)",
     "shortName": "Share Based Payments - Schedule of Shares Issued under Stock Option Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c186",
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:ScheduleOfNumberOfSharesIssuedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R88": {
     "role": "http://pranabio.com/role/SubsequentEventsDetails",
     "longName": "996054 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c194",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c194",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://pranabio.com/role/ScheduleofEarningLossPerShareTable",
     "longName": "996055 - Disclosure - Loss Per Share - Schedule of Earning Loss Per Share (Details)",
     "shortName": "Loss Per Share - Schedule of Earning Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:BasicEarningsLossPerShare",
      "unitRef": "audPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "ifrs-full:DilutedEarningsLossPerShare",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R90": {
     "role": "http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable",
     "longName": "996056 - Disclosure - Key Management Personnel Compensation - Schedule of Key Management Personnel Compensation (Details)",
     "shortName": "Key Management Personnel Compensation - Schedule of Key Management Personnel Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://pranabio.com/role/ScheduleofAuditandReviewofFinancialStatementsTable",
     "longName": "996057 - Disclosure - Auditors' Remuneration - Schedule of Audit and Review of Financial Statements (Details)",
     "shortName": "Auditors' Remuneration - Schedule of Audit and Review of Financial Statements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AuditorsRemunerationForAuditServices",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:ScheduleOfAuditorRemunerationTableTextBlock",
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AuditorsRemunerationForAuditServices",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:ScheduleOfAuditorRemunerationTableTextBlock",
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://pranabio.com/role/RelatedPartyTransactionsDetails",
     "longName": "996058 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://pranabio.com/role/SegmentInformationDetails",
     "longName": "996059 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:NumberOfReportableSegment",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:NumberOfReportableSegment",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://pranabio.com/role/FinancialInstrumentsDetails",
     "longName": "996060 - Disclosure - Financial Instruments (Details)",
     "shortName": "Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "athe:AverageAnnualMovementForeignExchangeRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "athe:AverageAnnualMovementForeignExchangeRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable",
     "longName": "996061 - Disclosure - Financial Instruments - Schedule of Financial Assets and Liabilities Subject to Foreign Currency Risk (Details)",
     "shortName": "Financial Instruments - Schedule of Financial Assets and Liabilities Subject to Foreign Currency Risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "athe:FinancialInstrumentsTotalExposure",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "athe:FinancialInstrumentsTotalExposure",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable",
     "longName": "996062 - Disclosure - Financial Instruments - Schedule of Interest Rates and the Effective Weighted Average Interest Rate for Classes of Financial Assets and Liabilities (Details)",
     "shortName": "Financial Instruments - Schedule of Interest Rates and the Effective Weighted Average Interest Rate for Classes of Financial Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable",
     "longName": "996063 - Disclosure - Financial Instruments - Schedule of Company's Liquidity Reserve on the Basis of Expected Cash Flows (Details)",
     "shortName": "Financial Instruments - Schedule of Company's Liquidity Reserve on the Basis of Expected Cash Flows (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c329",
      "name": "ifrs-full:TradeAndOtherPayables",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c329",
      "name": "ifrs-full:TradeAndOtherPayables",
      "unitRef": "aud",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable",
     "longName": "996064 - Disclosure - Parent Entity Financial Information - Schedule of Individual Financial Statements for the Parent Entity (Details)",
     "shortName": "Parent Entity Financial Information - Schedule of Individual Financial Statements for the Parent Entity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c349",
      "name": "ifrs-full:CurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:DisclosureOfParentEntityFinancialStatementsExplanatory",
       "ifrs-full:DisclosureOfInterimFinancialReportingExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c349",
      "name": "ifrs-full:CurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "athe:DisclosureOfParentEntityFinancialStatementsExplanatory",
       "ifrs-full:DisclosureOfInterimFinancialReportingExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0254438-20f_alterity.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "athe_ADSEmployeeSharePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ADSEmployeeSharePlanMember",
     "presentation": [
      "http://pranabio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADS Employee Share Plan [Member]",
        "label": "ADSEmployee Share Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_AIssuedCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "AIssuedCapitalAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIssuedCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(a) Issued Capital",
        "label": "AIssued Capital Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ASXEmployeeSharePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ASXEmployeeSharePlanMember",
     "presentation": [
      "http://pranabio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASX Employee Share Plan [Member]",
        "label": "ASXEmployee Share Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ATHAABMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ATHAABMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATHAAB[Member]",
        "label": "ATHAABMember"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ATHAABOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ATHAABOneMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATHAAB [Member]",
        "label": "ATHAABOne Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ATHAADMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ATHAADMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATHAAD[Member]",
        "label": "ATHAADMember"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ATHAADOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ATHAADOneMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATHAAD [Member]",
        "label": "ATHAADOne Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ATHAAEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ATHAAEMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable",
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATHAAE [Member]",
        "label": "ATHAAEMember"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ATHAAFMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ATHAAFMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATHAAF [Member]",
        "label": "ATHAAFMember"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ATHAAFOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ATHAAFOneMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATHAAF [Member]",
        "label": "ATHAAFOne Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ATHAAGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ATHAAGMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATHAAG [Member]",
        "label": "ATHAAGMember"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ATHAAGOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ATHAAGOneMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATHAAG [Member]",
        "label": "ATHAAGOne Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ATHAAHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ATHAAHMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable",
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATHAAH [Member]",
        "label": "ATHAAHMember"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ATHAAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ATHAAMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable",
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATHAA [Member]",
        "label": "ATHAAMember"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ATHABMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ATHABMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable",
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATHAB [Member]",
        "label": "ATHABMember"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ATHACMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ATHACMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable",
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATHAC [Member]",
        "label": "ATHACMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_AccruedProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "AccruedProfessionalFees",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "documentation": "The amount of current accrued professional fees.",
        "label": "Accrued Professional Fees"
       }
      }
     },
     "auth_ref": []
    },
    "athe_AccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses",
        "documentation": "The amount of current accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "athe_AccumulatedDeficitDuringDevelopmentStageAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "AccumulatedDeficitDuringDevelopmentStageAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit During Development Stage [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_AccumulatedDeficitDuringDevelopmentStageTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "AccumulatedDeficitDuringDevelopmentStageTextBlock",
     "presentation": [
      "http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCUMULATED DEFICIT DURING DEVELOPMENT STAGE",
        "documentation": "Accumulated deficit during development stage.",
        "label": "Accumulated Deficit During Development Stage Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "athe_AddTaxEffectOfAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "AddTaxEffectOfAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Add tax effect of:",
        "label": "Add Tax Effect Of Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "ifrs-full_AdditionalProvisionsOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionalProvisionsOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinProvisionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amounts used during the year",
        "label": "Additional provisions, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additional other provisions made. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsToRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions to the right-of-use assets",
        "label": "Additions to right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedIncomeStatement",
      "http://pranabio.com/role/ScheduleofEarningLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares used in computing diluted net loss per share (in Shares)",
        "verboseLabel": "Weighted average number of ordinary shares on issue used in the calculation of diluted loss per share",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForCurrentTaxOfPriorPeriod",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment for current tax of prior periods",
        "verboseLabel": "Under/(Over) provision of income tax in previous year relating to a revision of estimates",
        "label": "Adjustments for current tax of prior periods"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments of tax expense (income) recognised in the period for current tax of prior periods."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease/(increase) in other current assets (excepting term deposit)",
        "label": "Adjustments for decrease (increase) in other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation of property and equipment",
        "label": "Adjustments for depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Decrease) in other current liabilities",
        "label": "Adjustments for increase (decrease) in other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Decrease)/increase in trade and other payables",
        "label": "Adjustments for increase (decrease) in trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "ifrs-full_AdjustmentsForProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForProvisions",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase/(decrease) in provision for employee entitlements",
        "label": "Adjustments for provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash items",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable",
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payment expenses",
        "verboseLabel": "Share-based payment expenses",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ifrs-full_AdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other administrative and office expenses",
        "label": "Administrative expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity classifies as being administrative."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r59",
      "r176"
     ]
    },
    "athe_AdsPlanTwoThousandEighteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "AdsPlanTwoThousandEighteenMember",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails",
      "http://pranabio.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ads Plan 2018 [Member]",
        "label": "Ads Plan Two Thousand Eighteen Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r253",
      "r269",
      "r304"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r256",
      "r272",
      "r307"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r257",
      "r273",
      "r299",
      "r308",
      "r312",
      "r320"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "athe_AnnualLeaveAndLongServiceLeaveCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "AnnualLeaveAndLongServiceLeaveCarryingAmount",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinProvisionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "documentation": "Annual leave and long service leave carrying amount.",
        "label": "Annual Leave And Long Service Leave Carrying Amount"
       }
      }
     },
     "auth_ref": []
    },
    "athe_AnnualLeaveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "AnnualLeaveMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinProvisionsTable",
      "http://pranabio.com/role/ScheduleofProvisionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Leave [Member]",
        "documentation": "This member stand for annual leave.",
        "label": "Annual Leave Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "athe_April222024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "April222024Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 22, 2024 [Member]",
        "label": "April222024 Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_April42025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "April42025Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 4, 2025 [Member]",
        "label": "April42025 Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NetAssetsLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "terseLabel": "Total assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r103",
      "r104",
      "r105",
      "r164",
      "r166"
     ]
    },
    "athe_AsxPlan2004Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "AsxPlan2004Member",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails",
      "http://pranabio.com/role/ScheduleofSharesIssuedunderStockOptionPlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2004 ASX Plan [Member]",
        "verboseLabel": "Asx Plan 2004 [Member]",
        "documentation": "Represents information regarding Australian plan.",
        "label": "Asx Plan2004 Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_AuditInternalControlAndOtherAssuranceExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "AuditInternalControlAndOtherAssuranceExpenses",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Audit, internal control and other assurance expenses",
        "documentation": "Represents the amount of expenses related to audit internal control and other assurance.",
        "label": "Audit Internal Control And Other Assurance Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r227",
      "r249"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r227",
      "r249"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r227",
      "r249"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AuditorsRemuneration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AuditorsRemuneration",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofAuditandReviewofFinancialStatementsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofAuditandReviewofFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total auditors remuneration",
        "label": "Auditor's remuneration"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "ifrs-full_AuditorsRemunerationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AuditorsRemunerationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditors' Remuneration [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AuditorsRemunerationForAuditServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AuditorsRemunerationForAuditServices",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofAuditandReviewofFinancialStatementsTable": {
       "parentTag": "ifrs-full_AuditorsRemuneration",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofAuditandReviewofFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "- Audit and review of financial statements",
        "label": "Auditor's remuneration for audit services"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors for auditing services."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "ifrs-full_AuditorsRemunerationForOtherServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AuditorsRemunerationForOtherServices",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofAuditandReviewofFinancialStatementsTable": {
       "parentTag": "ifrs-full_AuditorsRemuneration",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofAuditandReviewofFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "- Other audit services",
        "label": "Auditor's remuneration for other services"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors for services that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "athe_AugustThirtyFirstTwoThousandTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "AugustThirtyFirstTwoThousandTwentySixMember",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 31 2026 [Member]",
        "label": "August Thirty First Two Thousand Twenty Six Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_AverageAnnualMovementForeignExchangeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "AverageAnnualMovementForeignExchangeRate",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average annual movement foreign exchange rate",
        "documentation": "Represents the average annual movement foreign exchange rate.",
        "label": "Average Annual Movement Foreign Exchange Rate"
       }
      }
     },
     "auth_ref": []
    },
    "athe_AverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "AverageInterestRate",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average Interest Rate",
        "documentation": "Percentage of average interest rate.",
        "label": "Average Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "athe_BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "BackgroundandSummaryofMaterialAccountingPoliciesDetailsTable",
     "presentation": [
      "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Background and Summary of Material Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "BackgroundandSummaryofMaterialAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Background and Summary of Material Accounting Policies - Schedule of Estimated Useful Lives (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedIncomeStatement",
      "http://pranabio.com/role/ScheduleofEarningLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share (basic - cents per share) (in Dollars per share)",
        "verboseLabel": "Basic loss per share (cents per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails",
      "http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of Range [Member]",
        "verboseLabel": "Bottom of range [member]",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r106",
      "r122",
      "r139",
      "r197",
      "r198",
      "r376"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r227",
      "r249"
     ]
    },
    "ifrs-full_CapitalCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CapitalCommitments",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/IssuedCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments for a capital raising",
        "label": "Capital commitments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of future capital expenditures that the entity is committed to make."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "athe_CarryingAmountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "CarryingAmountsMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Amounts [Member]",
        "label": "Carrying Amounts Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash accounts",
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "athe_CashAndCashEquivalentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "CashAndCashEquivalentMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails",
      "http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable",
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalent [Member]",
        "verboseLabel": "Cash and Cash Equivalents [Member]",
        "label": "Cash And Cash Equivalent Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r81",
      "r99"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(b) Reconciliation of Cash and Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents balance comprises:",
        "label": "Cash and cash equivalents [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Closing cash and cash equivalents balance",
        "label": "Cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for term deposit",
        "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails",
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows generated from financing activities",
        "terseLabel": "Net proceeds",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r83"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Financing Activities",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows used in investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r83"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Investing Activities",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow",
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows used in operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r83"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow",
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Operating Activities",
        "verboseLabel": "(a) Reconciliation of Net Loss to Net Cash Flows Used In Operations",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashOnHand": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashOnHand",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable": {
       "parentTag": "ifrs-full_CashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "- cash and cash equivalents on hand",
        "label": "Cash on hand"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash held by the entity. This does not include demand deposits."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "ifrs-full_CashOutflowForLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashOutflowForLeases",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash outflow for leases",
        "label": "Cash outflow for leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails",
      "http://pranabio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesDomain",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "athe_ChangesInAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ChangesInAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities",
        "label": "Changes In Assets And Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ChangesInEquityAbstract",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions with owners in their capacity as owners:",
        "label": "Changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ChiefExecutiveOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ChiefExecutiveOfficersMember",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Office [Memebr]",
        "label": "Chief Executive Officers Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails",
      "http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r156",
      "r157",
      "r171",
      "r172"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsDomain",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails",
      "http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r129",
      "r156",
      "r157",
      "r171",
      "r172"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable",
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r152",
      "r153",
      "r154"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable",
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r150",
      "r152",
      "r153",
      "r154"
     ]
    },
    "ifrs-full_ClassesOfOtherProvisionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfOtherProvisionsDomain",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinProvisionsTable",
      "http://pranabio.com/role/ScheduleofProvisionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of other provisions [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfProvisionsAxis",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinProvisionsTable",
      "http://pranabio.com/role/ScheduleofProvisionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of other provisions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIssuedCapitalTable",
      "http://pranabio.com/role/ScheduleofIssuedCapitalTable_Parentheticals",
      "http://pranabio.com/role/ScheduleofMovementsinIssuedSharesTable",
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIssuedCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "athe_CommitmentsAndContingenciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "CommitmentsAndContingenciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedIncomeStatement",
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable",
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss for the year",
        "terseLabel": "Total comprehensive loss for the year",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r33",
      "r89",
      "r91",
      "r97",
      "r196"
     ]
    },
    "ifrs-full_ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeContinuingAndDiscontinuedOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest and Other Income from Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment [Member]",
        "label": "Computer equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ConsultantAndDirectorExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ConsultantAndDirectorExpenses",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consultant and director expenses",
        "documentation": "Amount of consultant and director expenses.",
        "label": "Consultant And Director Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ConsultantMember",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consultant [Member]",
        "label": "Consultant Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "athe_CorporateAdvisoryExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "CorporateAdvisoryExpenses",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate advisory expenses",
        "documentation": "Corporate advisory expenses.",
        "label": "Corporate Advisory Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "athe_CorporateComplianceExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "CorporateComplianceExpenses",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate compliance expenses",
        "documentation": "Represents the amount of corporate compliance expenses.",
        "label": "Corporate Compliance Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CreationDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CreationDateAxis",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Creation date [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ]
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued corporate personnel expenses",
        "label": "Current accrued expenses and other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAccruedIncomeIncludingCurrentContractAssets",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest income",
        "label": "Current accrued income including current contract assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current accrued income including current contract assets. [Refer: Accrued income including contract assets]"
       }
      }
     },
     "auth_ref": [
      "r359",
      "r362"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "terseLabel": "Current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r93",
      "r196"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Assets [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable": {
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Current",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "terseLabel": "Current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r95",
      "r196"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentPrepayments",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments",
        "label": "Current prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current prepayments. [Refer: Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_CurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ScheduleofProvisionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "verboseLabel": "Current",
        "label": "Current provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax",
        "label": "Current tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "ifrs-full_CurrentTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax liabilities",
        "label": "Current tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ifrs-full_CurrentValueAddedTaxReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentValueAddedTaxReceivables",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goods and services tax receivable",
        "label": "Current value added tax receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]"
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]",
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r331"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board of Directors Oversight [Text Block]",
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r331"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]",
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r237",
      "r333"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r237",
      "r333"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r237",
      "r333"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]",
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r230",
      "r326"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes Integrated [Flag]",
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r327"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes Integrated [Text Block]",
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r327"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r325"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r325"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r325"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Third Party Engaged [Flag]",
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r328"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r330"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r234",
      "r330"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]",
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r331"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]",
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r238",
      "r334"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Role of Management [Text Block]",
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r236",
      "r332"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]",
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r233",
      "r329"
     ]
    },
    "ifrs-full_DateOfGrantOfSharebasedPaymentArrangement": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DateOfGrantOfSharebasedPaymentArrangement",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable",
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant Date",
        "label": "Date of grant of share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The date on which share-based payment arrangements are granted. [Refer: Types of share-based payment arrangements [domain]]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202"
     ]
    },
    "ifrs-full_DefaultFinancialStatementsDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DefaultFinancialStatementsDateMember",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Default financial statements date [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Creation date' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ]
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(c) Potential deferred tax asset as of June 30, 2025, 2024 and 2023 in respect of: tax losses not brought to account is:",
        "label": "Deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r17",
      "r43"
     ]
    },
    "ifrs-full_DeferredTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxExpenseIncome",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax",
        "label": "Deferred tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ifrs-full_DefinedBenefitPlansAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DefinedBenefitPlansAxis",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plans [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_DefinedBenefitPlansDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DefinedBenefitPlansDomain",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plans [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r276"
     ]
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation on fixed assets",
        "label": "Depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationRightofuseAssets",
     "calculation": {
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable",
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable",
      "http://pranabio.com/role/ScheduleofProfitorLossShowstheFollowingAmountsRelatingtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation on leased assets",
        "verboseLabel": "Depreciation of right-of-use assets",
        "label": "Depreciation, right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "athe_DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "documentation": "The description of the entity's accounting policy for basis used for consolidation.",
        "label": "Description Of Accounting Policy For Basis Of Consolidation Explanatory Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "athe_DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comparative Figures",
        "documentation": "The description of the entity's accounting policy for comparative figure.",
        "label": "Description Of Accounting Policy For Comparative Figures Explanatory Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Per Share",
        "label": "Description of accounting policy for earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefits",
        "label": "Description of accounting policy for employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments and other financial assets",
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Transactions and Balances",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForGovernmentGrants",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants",
        "label": "Description of accounting policy for government grants [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]"
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Assets",
        "label": "Description of accounting policy for impairment of assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of assets."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax",
        "label": "Description of accounting policy for income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income tax."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital",
        "label": "Description of accounting policy for issued capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Description of accounting policy for leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "athe_DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Standards and Interpretations",
        "documentation": "The description of the entity's accounting policy for new accounting standards and interpretations.",
        "label": "Description Of Accounting Policy For New Accounting Standards And Interpretations Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Description of accounting policy for property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "label": "Description of accounting policy for provisions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "athe_DescriptionOfAccountingPolicyForRecognitionOfOtherIncome": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfOtherIncome",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "documentation": "The description of the entity's accounting policy for recognizing other income.",
        "label": "Description Of Accounting Policy For Recognition Of Other Income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets - Research and Development",
        "label": "Description of accounting policy for research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Description of accounting policy for segment reporting [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payments",
        "label": "Description of accounting policy for share-based payment transactions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]"
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goods and Services Tax (\u201cGST\u201d)",
        "label": "Description of accounting policy for taxes other than income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for taxes other than income tax. [Refer: Tax expense other than income tax expense]"
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and Other Payables",
        "label": "Description of accounting policy for trade and other payables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and Other Receivables",
        "label": "Description of accounting policy for trade and other receivables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for trade and other receivables. [Refer: Trade and other receivables]"
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
     "presentation": [
      "http://pranabio.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Share Price Volatility",
        "label": "Expected volatility, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedIncomeStatement",
      "http://pranabio.com/role/ScheduleofEarningLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share (Diluted - cents per share) (in Dollars per share)",
        "verboseLabel": "Diluted loss per share (cents per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64"
     ]
    },
    "athe_DirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "DirectorsMember",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors [Member]",
        "documentation": "This member stands for directors.",
        "label": "Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Key Management Personnel Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases",
     "presentation": [
      "http://pranabio.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Profit or Loss Shows the Following Amounts Relating to Leases",
        "documentation": "Schedule of amounts recognized in profit or loss relating leases.",
        "label": "Disclosure Of Amounts Recognized In Profit Or Loss Relating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAuditorsRemunerationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAuditorsRemunerationExplanatory",
     "presentation": [
      "http://pranabio.com/role/AuditorsRemuneration"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AUDITORS' REMUNERATION",
        "label": "Disclosure of auditors' remuneration [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of compensation to the entity's auditors."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://pranabio.com/role/CashFlowInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash Flow Information",
        "label": "Disclosure of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_DisclosureOfCashFlowStatementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCashFlowStatementExplanatory",
     "presentation": [
      "http://pranabio.com/role/CashFlowInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOW INFORMATION",
        "label": "Disclosure of cash flow statement [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for a statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesLineItems",
     "presentation": [
      "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Background and Summary of Material Accounting Policies [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory",
     "presentation": [
      "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES",
        "label": "Disclosure of changes in accounting policies [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of changes made to accounting policies by the entity."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://pranabio.com/role/IssuedCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Issued Capital",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]"
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinIssuedSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Movements in Issued Shares [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://pranabio.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Disclosure of commitments and contingent liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_DisclosureOfCommitmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCommitmentsExplanatory",
     "presentation": [
      "http://pranabio.com/role/ExpenditureCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EXPENDITURE COMMITMENTS",
        "label": "Disclosure of commitments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Interest Rates and the Effective Weighted Average Interest Rate for Classes of Financial Assets and Liabilities",
        "label": "Disclosure of detailed information about financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r147",
      "r152",
      "r158"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Useful Lives",
        "label": "Disclosure of detailed information about property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://pranabio.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOSS PER SHARE",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://pranabio.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT INFORMATION",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://pranabio.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "presentation": [
      "http://pranabio.com/role/ExpensesfromOrdinaryActivitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Expenses from Ordinary Activities",
        "label": "Disclosure of expenses by nature [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_DisclosureOfExpensesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfExpensesExplanatory",
     "presentation": [
      "http://pranabio.com/role/ExpensesfromOrdinaryActivities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EXPENSES FROM ORDINARY ACTIVITIES",
        "label": "Disclosure of expenses [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of expenses."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsLineItems",
     "presentation": [
      "http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Assets and Liabilities [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://pranabio.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INSTRUMENTS",
        "label": "Disclosure of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails",
      "http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company's Liquidity Reserve on the Basis of Expected Cash Flows",
        "label": "Disclosure of financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://pranabio.com/role/IncomeTax"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAX",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "athe_DisclosureOfIncomeTaxExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "DisclosureOfIncomeTaxExplanatoryTableTextBlock",
     "presentation": [
      "http://pranabio.com/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Tax",
        "documentation": "Tabular disclosure for income taxes.",
        "label": "Disclosure Of Income Tax Explanatory Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
     "presentation": [
      "http://pranabio.com/role/KeyManagementPersonnelCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "KEY MANAGEMENT PERSONNEL COMPENSATION",
        "label": "Disclosure of information about key management personnel [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_DisclosureOfInterestIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInterestIncomeExplanatory",
     "presentation": [
      "http://pranabio.com/role/InterestandOtherIncomefromContinuingOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTEREST AND OTHER INCOME FROM CONTINUING OPERATIONS",
        "label": "Disclosure of interest income [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of interest income. [Refer: Interest income]"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_DisclosureOfInterimFinancialReportingExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInterimFinancialReportingExplanatory",
     "presentation": [
      "http://pranabio.com/role/ParentEntityFinancialInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PARENT ENTITY FINANCIAL INFORMATION",
        "label": "Disclosure of information about interim financial reporting [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about interim financial reporting."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ifrs-full_DisclosureOfIssuedCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIssuedCapitalExplanatory",
     "presentation": [
      "http://pranabio.com/role/IssuedCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ISSUED CAPITAL",
        "label": "Disclosure of issued capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "athe_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "DisclosureOfKeyManagementPersonnelCompensationTableTextBlock",
     "presentation": [
      "http://pranabio.com/role/KeyManagementPersonnelCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Key Management Personnel Compensation",
        "documentation": "Tabular disclosure of information about key management personnel.",
        "label": "Disclosure Of Key Management Personnel Compensation Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://pranabio.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Disclosure of leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119"
     ]
    },
    "athe_DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock",
     "presentation": [
      "http://pranabio.com/role/ProvisionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movements in Provisions",
        "documentation": "Tabular disclosure of movements in each class of provision.",
        "label": "Disclosure Of Movements Of Each Class Of Provision Explanatory Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://pranabio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequents Events [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "athe_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options Granted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "presentation": [
      "http://pranabio.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Options Granted",
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOtherAssetsExplanatory",
     "presentation": [
      "http://pranabio.com/role/OtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER CURRENT ASSETS",
        "label": "Disclosure of other assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other assets. [Refer: Other assets]"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
     "presentation": [
      "http://pranabio.com/role/ProvisionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Provisions",
        "label": "Disclosure of other provisions, contingent liabilities and contingent assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for other provisions, contingent liabilities and contingent assets."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_DisclosureOfOtherProvisionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsLineItems",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinProvisionsTable",
      "http://pranabio.com/role/ScheduleofProvisionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [line items]",
        "terseLabel": "Movements in Provisions [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "athe_DisclosureOfParentEntityFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "DisclosureOfParentEntityFinancialStatementsExplanatory",
     "presentation": [
      "http://pranabio.com/role/ParentEntityFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Individual Financial Statements for the Parent Entity",
        "documentation": "The entire disclosure of parent entity financial statements.",
        "label": "Disclosure Of Parent Entity Financial Statements Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
     "presentation": [
      "http://pranabio.com/role/OtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Current Assets",
        "label": "Disclosure of prepayments and other assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of prepayments and other assets. [Refer: Other assets; Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Useful Lives [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfProvisionsExplanatory",
     "presentation": [
      "http://pranabio.com/role/Provisions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROVISIONS",
        "label": "Disclosure of provisions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "presentation": [
      "http://pranabio.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
     "presentation": [
      "http://pranabio.com/role/IssuedCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Details of Share Issuances",
        "label": "Disclosure of range of exercise prices of outstanding share options [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the range of exercise prices for outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://pranabio.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Disclosure of related party [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ifrs-full_DisclosureOfReservesWithinEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReservesWithinEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserves [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReservesWithinEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReservesWithinEquityLineItems",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails",
      "http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable",
      "http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reserves of Share Based Payments [Line Items]",
        "terseLabel": "Reserves [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Liabilities Subject to Foreign Currency Risk",
        "label": "Disclosure of risk management strategy related to hedge accounting [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of risk management strategy related to hedge accounting."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r174"
     ]
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://pranabio.com/role/Reserves"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESERVES",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://pranabio.com/role/ShareBasedPayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE BASED PAYMENTS",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsGrantedTable",
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable",
      "http://pranabio.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payments [Line Items]",
        "terseLabel": "Schedule of Valuations of Options Approved and Issued [Line Items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://pranabio.com/role/TradeandOtherPayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRADE AND OTHER PAYABLES",
        "label": "Disclosure of trade and other payables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "athe_DisclosureOfTradeAndOtherReceivableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "DisclosureOfTradeAndOtherReceivableTableTextBlock",
     "presentation": [
      "http://pranabio.com/role/TradeandOtherReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade and Other Receivables",
        "documentation": "Schedule of trade and other receivables.",
        "label": "Disclosure Of Trade And Other Receivable Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory",
     "presentation": [
      "http://pranabio.com/role/TradeandOtherReceivables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRADE AND OTHER RECEIVABLES",
        "label": "Disclosure of trade and other receivables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "presentation": [
      "http://pranabio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisposalsAndRetirementsRightofuseAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisposalsAndRetirementsRightofuseAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Amounts Recognized in Profit or Loss Relating Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r276"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r227",
      "r249"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r227",
      "r249",
      "r300"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r227",
      "r249",
      "r300"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://pranabio.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earning Loss Per Share",
        "label": "Earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange rate adjustments on cash and cash equivalents held in foreign currencies",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "athe_EligibleAmountUnderTaxIncentiveScheme": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "EligibleAmountUnderTaxIncentiveScheme",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "documentation": "Represents the amount of expenditure eligible for offset under the tax incentive scheme.",
        "label": "Eligible Amount Under Tax Incentive Scheme"
       }
      }
     },
     "auth_ref": []
    },
    "athe_EligibleAmountUnderTheTaxIncentiveScheme": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "EligibleAmountUnderTheTaxIncentiveScheme",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "documentation": "Eligible amount under the tax incentive scheme.",
        "label": "Eligible Amount Under The Tax Incentive Scheme"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee expenses",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r36",
      "r175"
     ]
    },
    "athe_EmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "EmployeeMember",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee [Member]",
        "label": "Employee Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "auth_ref": []
    },
    "athe_Employeesdescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "Employeesdescription",
     "presentation": [
      "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees,description",
        "documentation": "Employees, description.",
        "label": "Employeesdescription"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable",
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "terseLabel": "Total equity",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r23",
      "r88",
      "r90",
      "r103",
      "r104",
      "r105"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit during the development stage",
        "label": "Equity attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r253",
      "r269",
      "r304"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r239",
      "r250",
      "r266",
      "r301"
     ]
    },
    "athe_EstimatedUsefulEconomicLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "EstimatedUsefulEconomicLife",
     "presentation": [
      "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life",
        "documentation": "Estimated useful economic life.",
        "label": "Estimated Useful Economic Life"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "athe_ExercisePriceExpiryTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ExercisePriceExpiryTerm",
     "presentation": [
      "http://pranabio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price expiry term",
        "documentation": "Exercise price expiry term.",
        "label": "Exercise Price Expiry Term"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ExercisePriceOfOutstandingShareOption1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ExercisePriceOfOutstandingShareOption1",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price (in Dollars per share)",
        "documentation": "Exercise Price.",
        "label": "Exercise Price Of Outstanding Share Option1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExercisePriceShareOptionsGranted2019",
     "presentation": [
      "http://pranabio.com/role/IssuedCapitalDetails",
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price per Share",
        "verboseLabel": "Exercise price",
        "label": "Exercise price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "presentation": [
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend Yield",
        "label": "Expected dividend as percentage, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "athe_ExpenditureCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ExpenditureCommitmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenditure Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseByNatureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseByNatureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses from Ordinary Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Payment expense",
        "label": "Expense from share-based payment transactions with employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofProfitorLossShowstheFollowingAmountsRelatingtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses relating to variable lease payments not included in lease liabilities (included in general and administration expenses)",
        "label": "Expense relating to variable lease payments not included in measurement of lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to variable lease payments not included in the measurement of lease liabilities. Variable lease payments are the portion of payments made by a lessee to a lessor for the right to use an underlying asset during the lease term that varies because of changes in facts or circumstances occurring after the commencement date, other than the passage of time. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "athe_ExpensesRelatingToShorttermLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ExpensesRelatingToShorttermLeases",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofProfitorLossShowstheFollowingAmountsRelatingtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses relating to short-term leases (included in general and administration expenses)",
        "documentation": "Expenses relating to short-term leases.",
        "label": "Expenses Relating To Shortterm Leases"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ExpiredTerm": {
     "xbrltype": "dateItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ExpiredTerm",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired term",
        "documentation": "Expired term.",
        "label": "Expired Term"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ExpiryDateOfOutstandingShareOptions": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ExpiryDateOfOutstandingShareOptions",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiry Date",
        "documentation": "Represents expiry date of options oust standing.",
        "label": "Expiry Date Of Outstanding Share Options"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "athe_FairValuePerOptions": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "FairValuePerOptions",
     "presentation": [
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value per Options",
        "documentation": "Fair value per option.",
        "label": "Fair Value Per Options"
       }
      }
     },
     "auth_ref": []
    },
    "athe_February172025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "February172025Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "February 17, 2025 [Member]",
        "label": "February172025 Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_February22024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "February22024Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "February 2, 2024 [Member]",
        "label": "February22024 Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_February32025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "February32025Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "February 3, 2025 [Member]",
        "label": "February32025 Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Financial Assets",
        "label": "Financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r146",
      "r150",
      "r151",
      "r153",
      "r204"
     ]
    },
    "athe_FinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "FinancialAssetsAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Assets",
        "label": "Financial Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_FinancialInstrumentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "FinancialInstrumentsDetailsTable",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "FinancialInstrumentsScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments - Schedule of Company's Liquidity Reserve on the Basis of Expected Cash Flows (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "FinancialInstrumentsScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments - Schedule of Financial Assets and Liabilities Subject to Foreign Currency Risk (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsLineItems",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments - Schedule of Interest Rates and the Effective Weighted Average Interest Rate for Classes of Financial Assets and Liabilities (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "FinancialInstrumentsScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments - Schedule of Interest Rates and the Effective Weighted Average Interest Rate for Classes of Financial Assets and Liabilities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_FinancialInstrumentsTotalExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "FinancialInstrumentsTotalExposure",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total exposure",
        "documentation": "The financial instruments total exposure.",
        "label": "Financial Instruments Total Exposure"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Financial Liabilities",
        "label": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "athe_FinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "FinancialLiabilitiesAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Liabilities",
        "label": "Financial Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_FixedAssetWriteOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "FixedAssetWriteOff",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed asset write off",
        "documentation": "The amount of fixed asset write off.",
        "label": "Fixed Asset Write Off"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FixedInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FixedInterestRateMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Interest Rate [Member]",
        "label": "Fixed interest rate [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "ifrs-full_FixturesAndFittingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FixturesAndFittingsMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fittings [Member]",
        "label": "Fixtures and fittings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "ifrs-full_FloatingInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FloatingInterestRateMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Floating Interest Rate [Member]",
        "label": "Floating interest rate [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a non-fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "athe_ForeignCurrencyRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ForeignCurrencyRiskMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Risk [Member]",
        "label": "Foreign Currency Risk Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ForeignExchangegainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ForeignExchangegainLoss",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange loss/(gain)",
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]",
        "label": "Foreign Exchangegain Loss"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ForfeitedOptionsFromReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ForfeitedOptionsFromReserves",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited options from reserves",
        "documentation": "Forfeited options from reserves.",
        "label": "Forfeited Options From Reserves"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ForfeitedOptionsReversedToProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ForfeitedOptionsReversedToProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited options of reversed to profit or loss",
        "documentation": "Forfeited options reversed to profit or loss.",
        "label": "Forfeited Options Reversed To Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r257",
      "r273",
      "r308"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r257",
      "r273",
      "r308"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r257",
      "r273",
      "r308"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r257",
      "r273",
      "r308"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r257",
      "r273",
      "r308"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r260"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "athe_FreeAttachingOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "FreeAttachingOptionMember",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Free Attaching Option [Member]",
        "label": "Free Attaching Option Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_FreeattachingOptionsForFullyPaidOrdinaryShares": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "FreeattachingOptionsForFullyPaidOrdinaryShares",
     "presentation": [
      "http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Free-attaching options for fully paid ordinary shares",
        "documentation": "Free-attaching options for fully paid ordinary shares.",
        "label": "Freeattaching Options For Fully Paid Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "currency_GBP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "GBP",
     "presentation": [
      "http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u00a3GBP [Member]",
        "label": "United Kingdom, Pounds"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange (gain)/loss",
        "label": "Foreign exchange gain (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r50"
     ]
    },
    "athe_GeneralAndAdministrationExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "GeneralAndAdministrationExpensesAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administration Expenses",
        "label": "General And Administration Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administration expenses",
        "label": "General and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "athe_GreaterThanTowelMonthsAndLessThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "GreaterThanTowelMonthsAndLessThanFiveYearsMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Greater than 12 Months and Less Than 5 Years [Member]",
        "label": "Greater Than Towel Months And Less Than Five Years Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r227",
      "r249"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of profit or loss and other comprehensive loss",
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_IncomeTaxDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "IncomeTaxDetailsTable",
     "presentation": [
      "http://pranabio.com/role/IncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedIncomeStatement",
      "http://pranabio.com/role/ScheduleofIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "terseLabel": "Income tax expense attributable to loss before income tax",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r34",
      "r39",
      "r40",
      "r41",
      "r60",
      "r102",
      "r163"
     ]
    },
    "athe_IncomeTaxLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "IncomeTaxLineItems",
     "presentation": [
      "http://pranabio.com/role/IncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxesPaidRefund": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidRefund",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax paid",
        "label": "Income taxes paid (refund)"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease)/increase in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares in connection with exercise of options, net of costs (in Shares)",
        "label": "Increase (decrease) in number of ordinary shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "athe_IncreaseDecreaseInNumberOfShareOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "IncreaseDecreaseInNumberOfShareOutstanding",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number, Beginning (in Shares)",
        "periodEndLabel": "Number, Ending (in Shares)",
        "documentation": "Increase decrease in number of share outstanding.",
        "label": "Increase Decrease In Number Of Share Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfSharesOutstanding",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number (in Shares)",
        "label": "Increase (decrease) in number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]"
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "athe_IncreaseDecreaseInTradeAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "IncreaseDecreaseInTradeAndOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease/(increase) in trade and other receivables",
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]",
        "label": "Increase Decrease In Trade And Other Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughForeignExchangeFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinProvisionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in foreign exchange",
        "label": "Increase (decrease) through foreign exchange, financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in financial assets resulting from foreign exchange. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r208"
     ]
    },
    "athe_IncreaseDecreaseThroughIssuanceOfOptionsToConsultants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "IncreaseDecreaseThroughIssuanceOfOptionsToConsultants",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash issuance of options to consultants",
        "documentation": "Represents the increase in equity through the issue of options to consultants.",
        "label": "Increase Decrease Through Issuance Of Options To Consultants"
       }
      }
     },
     "auth_ref": []
    },
    "athe_IncreaseDecreaseThroughIssuanceOfOptionsToEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "IncreaseDecreaseThroughIssuanceOfOptionsToEmployees",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash issuance of options to directors and employees",
        "documentation": "Represents the increase in equity through the issue of options to employees.",
        "label": "Increase Decrease Through Issuance Of Options To Employees"
       }
      }
     },
     "auth_ref": []
    },
    "athe_IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired options",
        "documentation": "Represents the increase (decrease) in equity through options expired.",
        "label": "Increase Decrease Through Options Expired In Share Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs from issuance of shares",
        "label": "Increase (decrease) through share-based payment transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransactionsWithOwners",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total transactions with owners in their capacity as owners",
        "label": "Increase (decrease) through transactions with owners, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from transactions with owners."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinProvisionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charged/(credited) to profit or loss -additional provisions recognised",
        "label": "Increase (decrease) through transfers and other changes, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r257",
      "r273",
      "r299",
      "r308",
      "r312",
      "r320"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r324"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r324"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r324"
     ]
    },
    "ifrs-full_InsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InsuranceExpense",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance expenses",
        "label": "Insurance expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from purchased insurance."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "athe_IntellectualPropertyExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "IntellectualPropertyExpenses",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intellectual property expenses",
        "documentation": "Represents the expenses associated to cost and fees of intellectual property.",
        "label": "Intellectual Property Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofProfitorLossShowstheFollowingAmountsRelatingtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from interest."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r162",
      "r168"
     ]
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "label": "Interest paid, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "athe_InterestRate105PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "InterestRate105PercentMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate 1.05 Percent [Member]",
        "label": "Interest Rate105 Percent Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_InterestRate144PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "InterestRate144PercentMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate 1.44 Percent [Member]",
        "label": "Interest Rate144 Percent Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_InterestRate36PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "InterestRate36PercentMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate 3.6 Percent [Member]",
        "label": "Interest Rate36 Percent Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_InterestRate385OnePercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "InterestRate385OnePercentMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate 3.85 One Percent [Member]",
        "label": "Interest Rate385 One Percent Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_InterestRate385PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "InterestRate385PercentMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate 3.85 Percent [Member]",
        "label": "Interest Rate385 Percent Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_InterestRateOf000FourPercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "InterestRateOf000FourPercentMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Of 0.00 Four Percent [Member]",
        "label": "Interest Rate Of000 Four Percent Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_InterestRateOf000OnePercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "InterestRateOf000OnePercentMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Of 0.00 One Percent [Member]",
        "label": "Interest Rate Of000 One Percent Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_InterestRateOf000PercentFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "InterestRateOf000PercentFiveMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate of 0.00 Percent Five [Member]",
        "label": "Interest Rate Of000 Percent Five Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_InterestRateOf000PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "InterestRateOf000PercentMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Of 0.00 Percent [Member]",
        "verboseLabel": "Interest Rate of 0.05 Percent [Member]",
        "label": "Interest Rate Of000 Percent Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_InterestRateOf000ThreePercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "InterestRateOf000ThreePercentMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Of 0.00 Three Percent [Member]",
        "label": "Interest Rate Of000 Three Percent Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_InterestRateOf000TwoPercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "InterestRateOf000TwoPercentMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Of 0.00 Two Percent [Member]",
        "label": "Interest Rate Of000 Two Percent Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_InterestRateOf15To482PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "InterestRateOf15To482PercentMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate of 1.5 to 4.82 Percent [Member]",
        "label": "Interest Rate Of15 To482 Percent Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_InterestRateOf27Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "InterestRateOf27Member",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate of 2.7% [Member]",
        "label": "Interest Rate Of27 Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestRateRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestRateRiskMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails",
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Risk [Member]",
        "verboseLabel": "Term Deposit [Member]",
        "netLabel": "Interest rate risk [member]",
        "label": "Interest rate risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r159"
     ]
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest received",
        "label": "Interest received, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "athe_IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares in connection with exercise of options, net of costs",
        "documentation": "Issuance of shares in connection with exercise of options, net of costs",
        "label": "Issuance Of Shares In Connection With Exercise Of Options Net Of Costsin Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "athe_IssuanceOfSharesNetOfCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "IssuanceOfSharesNetOfCostsShares",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares (in Shares)",
        "documentation": "Issuance of shares net of costs, shares.",
        "label": "Issuance Of Shares Net Of Costs Shares"
       }
      }
     },
     "auth_ref": []
    },
    "athe_IssuanceOfSharesNetOfCostsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "IssuanceOfSharesNetOfCostsValue",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares",
        "documentation": "Issuance of shares net of costs value.",
        "label": "Issuance Of Shares Net Of Costs Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions of equity/ Shares to be issued",
        "label": "Issue of equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable",
      "http://pranabio.com/role/ScheduleofIssuedCapitalTable",
      "http://pranabio.com/role/ScheduleofMovementsinIssuedSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning of the year",
        "periodEndLabel": "End of the year",
        "terseLabel": "Issued capital 2025: 9,127,370,686 fully paid ordinary shares Nil options over fully paid ordinary shares 2024: 5,245,115,318 fully paid ordinary shares Nil options over fully paid ordinary shares",
        "verboseLabel": "Issued Capital (in Dollars)",
        "netLabel": "Contributed equity",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "ifrs-full_IssuedCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued Capital",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_IssuedCapitalOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapitalOrdinaryShares",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/IssuedCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "label": "Issued capital, ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "athe_IssuedCapitalPreferenceShare": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "IssuedCapitalPreferenceShare",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount",
        "documentation": "Issued capital preference shares.",
        "label": "Issued Capital Preference Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapitalPreferenceShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapitalPreferenceShares",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Amount, Beginning",
        "periodEndLabel": "Amount, Ending",
        "label": "Issued capital, preference shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital arising from issuing preference shares. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "athe_IssuedCapitalScheduleofIssuedCapitalDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "IssuedCapitalScheduleofIssuedCapitalDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIssuedCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued Capital - Schedule of Issued Capital (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "IssuedCapitalScheduleofIssuedCapitalParentheticalsDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIssuedCapitalTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued Capital - Schedule of Issued Capital (Parentheticals) (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "IssuedCapitalScheduleofMovementsinIssuedSharesDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinIssuedSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued Capital - Schedule of Movements in Issued Shares (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_IssuedCapitalScheduleofShareIssuancesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "IssuedCapitalScheduleofShareIssuancesDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued Capital - Schedule of Share Issuances (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_JPY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "JPY",
     "presentation": [
      "http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JPY [Member]",
        "label": "Japan, Yen"
       }
      }
     },
     "auth_ref": []
    },
    "athe_January222025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "January222025Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 22, 2025 [Member]",
        "label": "January222025 Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_January302025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "January302025Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 30, 2025 [Member]",
        "label": "January302025 Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_January82024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "January82024Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 8, 2024 [Member]",
        "label": "January82024 Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_July182024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "July182024Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July 18, 2024 [Member]",
        "label": "July182024 Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_June302023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "June302023Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 30, 2023 [Member]",
        "label": "June302023 Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_June302024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "June302024Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 30, 2024 [Member]",
        "label": "June302024 Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_June302025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "June302025Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 30, 2025 [Member]",
        "label": "June302025 Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensation",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Key management personnel compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "athe_KeyManagementPersonnelCompensationLongtermBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "KeyManagementPersonnelCompensationLongtermBenefits",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term benefits",
        "documentation": "The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]",
        "label": "Key Management Personnel Compensation Longterm Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Post-employment benefits",
        "label": "Key management personnel compensation, post-employment benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments",
        "label": "Key management personnel compensation, share-based payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term employee benefits",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationTerminationBenefits",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofKeyManagementPersonnelCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination benefits",
        "label": "Key management personnel compensation, termination benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1-5 years [Member]",
        "label": "Later than one year and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r209"
     ]
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ifrs-full_LeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilitiesAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilitiesMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable",
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Liabilities [Member]",
        "verboseLabel": "Lease liabilities [Member]",
        "label": "Lease liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194"
     ]
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements [Member]",
        "label": "Leasehold improvements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "athe_LeasesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "LeasesDetailsTable",
     "presentation": [
      "http://pranabio.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "athe_LessThenSixMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "LessThenSixMonthsMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 6 Months [Member]",
        "label": "Less Then Six Months Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NetAssetsLiabilities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "terseLabel": "Total liabilities",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r103",
      "r104",
      "r105",
      "r164",
      "r167"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "athe_LongDatedOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "LongDatedOptionsMember",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long Dated Options [Member]",
        "label": "Long Dated Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_LongServiceLeaveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "LongServiceLeaveMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinProvisionsTable",
      "http://pranabio.com/role/ScheduleofProvisionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long Service Leave [Member]",
        "documentation": "This member stand for Long service leave.",
        "label": "Long Service Leave Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax [Abstract]",
        "terseLabel": "(a) Income tax expense:"
       }
      }
     },
     "auth_ref": []
    },
    "athe_March142025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "March142025Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 14, 2025 [Member]",
        "label": "March142025 Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_March152023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "March152023Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 15, 2023 [Member]",
        "label": "March152023 Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_March42024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "March42024Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 4, 2024 [Member]",
        "label": "March42024 Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r108",
      "r116",
      "r117",
      "r120",
      "r121",
      "r122",
      "r128",
      "r145",
      "r155",
      "r188",
      "r206"
     ]
    },
    "athe_MaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "MaturityDate",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails",
      "http://pranabio.com/role/OtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity Date",
        "verboseLabel": "Maturity date",
        "documentation": "Maturity date.",
        "label": "Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityDomain",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r108",
      "r116",
      "r117",
      "r120",
      "r121",
      "r122",
      "r128",
      "r145",
      "r188",
      "r206",
      "r207"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_MiscellaneousIncomeDisputeWithCatalent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "MiscellaneousIncomeDisputeWithCatalent",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Miscellaneous income, dispute with catalent",
        "documentation": "Represents the amount of miscellaneous income, dispute with catalent.",
        "label": "Miscellaneous Income Dispute With Catalent"
       }
      }
     },
     "auth_ref": []
    },
    "athe_MiscellaneousIncomeSettlementOfAnInsuranceClaim": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "MiscellaneousIncomeSettlementOfAnInsuranceClaim",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Miscellaneous income, settlement of an insurance claim",
        "documentation": "Represents the amount of Miscellaneous income, settlement of an insurance claim.",
        "label": "Miscellaneous Income Settlement Of An Insurance Claim"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MiscellaneousOtherOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MiscellaneousOtherOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other operating expenses",
        "label": "Miscellaneous other operating expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "ifrs-full_MiscellaneousOtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MiscellaneousOtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable": {
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Miscellaneous income",
        "label": "Miscellaneous other operating income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "athe_MovementDuringTheYearNoOfSharesinShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "MovementDuringTheYearNoOfSharesinShares",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinIssuedSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement during the year, No. of shares",
        "documentation": "Number of shares in movement during the year.",
        "label": "Movement During The Year No Of Sharesin Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "ifrs-full_NetAssetsLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NetAssetsLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Assets",
        "label": "Assets (liabilities)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets less the amount of liabilities."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r357"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "athe_NonExecutiveDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "NonExecutiveDirectorsMember",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Executive Directors [Member]",
        "label": "Non Executive Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "athe_NonInterestBearingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "NonInterestBearingMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Interest Bearing [Member]",
        "label": "Non Interest Bearing Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r257",
      "r273",
      "r299",
      "r308"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails",
      "http://pranabio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Non-Current Assets",
        "terseLabel": "Non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r94",
      "r196"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Assets",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable": {
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Non-current",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Non-Current Liabilities",
        "terseLabel": "Non-current liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r96",
      "r196"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Liabilities",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentProvisions",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofProvisionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current",
        "label": "Non-current provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1 year or less [Member]",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r116",
      "r117",
      "r128",
      "r206",
      "r209"
     ]
    },
    "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotesAndOtherExplanatoryInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Background and Summary of Material Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_November292023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "November292023Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 29, 2023 [Member]",
        "label": "November292023 Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_NumberOfConsultant": {
     "xbrltype": "integerItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "NumberOfConsultant",
     "presentation": [
      "http://pranabio.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of consultant",
        "documentation": "Represents number of consultant of the entity at a date.",
        "label": "Number Of Consultant"
       }
      }
     },
     "auth_ref": []
    },
    "athe_NumberOfDirector": {
     "xbrltype": "integerItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "NumberOfDirector",
     "presentation": [
      "http://pranabio.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of director",
        "documentation": "Represents number of directors of the entity at a date.",
        "label": "Number Of Director"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfEmployees",
     "presentation": [
      "http://pranabio.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees",
        "label": "Number of employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of personnel employed by the entity at a date."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "athe_NumberOfKeyManagementPersonnel": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "NumberOfKeyManagementPersonnel",
     "presentation": [
      "http://pranabio.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Key management personnel",
        "documentation": "Represents number of directors by the key management personnel of the entity at a date.",
        "label": "Number Of Key Management Personnel"
       }
      }
     },
     "auth_ref": []
    },
    "athe_NumberOfOptionsForfeitedDuringTheYear": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "NumberOfOptionsForfeitedDuringTheYear",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Forfeited during the year",
        "documentation": "Number of options, forfeited during the year.",
        "label": "Number Of Options Forfeited During The Year"
       }
      }
     },
     "auth_ref": []
    },
    "athe_NumberOfOptionsOptionsExercisedDuringTheYear": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "NumberOfOptionsOptionsExercisedDuringTheYear",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Options exercised during the year",
        "documentation": "Number of Options, Options exercised during the year.",
        "label": "Number Of Options Options Exercised During The Year"
       }
      }
     },
     "auth_ref": []
    },
    "athe_NumberOfOptionsSharesToBeIssued": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "NumberOfOptionsSharesToBeIssued",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Shares to be issued",
        "documentation": "Number of options shares to be issued.",
        "label": "Number Of Options Shares To Be Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails",
      "http://pranabio.com/role/ScheduleofOptionsGrantedTable",
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options, Beginning of the year",
        "periodEndLabel": "Number of Options, Outstanding at year end",
        "terseLabel": "Share options",
        "verboseLabel": "Option shares",
        "label": "Number of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r136",
      "r139"
     ]
    },
    "athe_NumberOfReportableSegment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "NumberOfReportableSegment",
     "presentation": [
      "http://pranabio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable segment",
        "documentation": "Number of reportable segments.",
        "label": "Number Of Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Vested and Exercisable at year end",
        "label": "Number of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails",
      "http://pranabio.com/role/ScheduleofOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Exercised during the year",
        "terseLabel": "Options exercised",
        "label": "Number of share options exercised in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails",
      "http://pranabio.com/role/ScheduleofOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Expired during the year",
        "terseLabel": "Options expired",
        "label": "Number of share options expired in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options expired in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails",
      "http://pranabio.com/role/ScheduleofOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Forfeited during the year",
        "terseLabel": "Options forfeited",
        "label": "Number of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://pranabio.com/role/IssuedCapitalDetails",
      "http://pranabio.com/role/ScheduleofOptionsGrantedTable",
      "http://pranabio.com/role/ScheduleofSharesIssuedunderStockOptionPlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Issued during the year",
        "verboseLabel": "Issued during the year",
        "netLabel": "Options shares",
        "label": "Number of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://pranabio.com/role/ShareBasedPaymentsDetails",
      "http://pranabio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued securities value (in Shares)",
        "verboseLabel": "Number of shares issued",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedAndFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssuedAndFullyPaid",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://pranabio.com/role/ScheduleofIssuedCapitalTable_Parentheticals",
      "http://pranabio.com/role/ScheduleofMovementsinIssuedSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning of the year, No. of shares",
        "periodEndLabel": "End of the year, No. of shares",
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Number of shares issued",
        "label": "Number of shares issued and fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has been received."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "athe_NumberOfSharesIssuedDuringTheYear": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "NumberOfSharesIssuedDuringTheYear",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued during the year",
        "documentation": "Number of shares issued during the year.",
        "label": "Number Of Shares Issued During The Year"
       }
      }
     },
     "auth_ref": []
    },
    "athe_NumberOfSharesOptionsOutstanding": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "NumberOfSharesOptionsOutstanding",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options, Beginning of the year",
        "periodEndLabel": "Number of Options, End of the year",
        "documentation": "The number of shares options outstanding in a share-based payment arrangement.",
        "label": "Number Of Shares Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://pranabio.com/role/ScheduleofSharesIssuedunderStockOptionPlanTable",
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Beginning of the year",
        "verboseLabel": "End of the financial year"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "athe_NumberofSharesIssuePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "NumberofSharesIssuePricePerShare",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue Price (in Dollars per share)",
        "documentation": "Number of shares issued price per share.",
        "label": "Numberof Shares Issue Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "athe_OfficeRentalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "OfficeRentalExpenses",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office rental",
        "documentation": "Office rental Expenses.",
        "label": "Office Rental Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "athe_OptionsExercisedDuringTheYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "OptionsExercisedDuringTheYear",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercised during the year",
        "documentation": "Options exercised during the year.",
        "label": "Options Exercised During The Year"
       }
      }
     },
     "auth_ref": []
    },
    "athe_OptionsForFullyPaidOrdinaryShares1": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "OptionsForFullyPaidOrdinaryShares1",
     "presentation": [
      "http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options for fully paid ordinary shares",
        "documentation": "Options for fully paid ordinary shares.",
        "label": "Options For Fully Paid Ordinary Shares1"
       }
      }
     },
     "auth_ref": []
    },
    "athe_OptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "OptionsMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIssuedCapitalTable",
      "http://pranabio.com/role/ScheduleofIssuedCapitalTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options [Member]",
        "label": "Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_OptionsSeriesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "OptionsSeriesAxis",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable",
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Series [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Options Series Axis"
       }
      }
     },
     "auth_ref": []
    },
    "athe_OptionsSeriesDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "OptionsSeriesDomainDomain",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OptionsSeriesDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIssuedCapitalTable",
      "http://pranabio.com/role/ScheduleofIssuedCapitalTable_Parentheticals",
      "http://pranabio.com/role/ScheduleofMovementsinIssuedSharesTable",
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares [Member]",
        "verboseLabel": "Ordinary shares [member]",
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCashPaymentsFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCashPaymentsFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other cash payments from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for operating activities that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss",
        "label": "Other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r32",
      "r35",
      "r98"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_OtherCurrentAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "OtherCurrentAccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "documentation": "The amount of liabilities representing expense that has been earned but is not yet received.",
        "label": "Other Current Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "athe_OtherCurrentAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "OtherCurrentAssetMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Assets [Member]",
        "verboseLabel": "Other current asset [Member]",
        "label": "Other Current Asset Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Other current assets",
        "label": "Other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "athe_OtherCurrentLiabilitieMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "OtherCurrentLiabilitieMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Liabilities [Member]",
        "label": "Other Current Liabilitie Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "ifrs-full_OtherEmployeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherEmployeeExpense",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee expenses (non R&amp;D related)",
        "label": "Other employee expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of employee expenses that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "athe_OtherGainsAndLossesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "OtherGainsAndLossesAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other gains and losses",
        "label": "Other Gains And Losses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other gains / (losses)",
        "label": "Other gains (losses)"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355"
     ]
    },
    "ifrs-full_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable": {
       "parentTag": "ifrs-full_RevenueAndOperatingIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails",
      "http://pranabio.com/role/ConsolidatedIncomeStatement",
      "http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "terseLabel": "Other income",
        "verboseLabel": "Other income related to research and development",
        "label": "Other income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r175",
      "r176"
     ]
    },
    "ifrs-full_OtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherPayables",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables",
        "label": "Other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "athe_OtherResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "OtherResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other research and development expenses",
        "documentation": "Other research and development expenses.",
        "label": "Other Research And Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherReservesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherReservesMember",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves",
        "label": "Other reserves [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_OtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherRevenue",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable": {
       "parentTag": "ifrs-full_RevenueAndOperatingIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total interest income",
        "label": "Other revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r244",
      "r255",
      "r271",
      "r306"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r258",
      "r274",
      "r309"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r258",
      "r274",
      "r309"
     ]
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://pranabio.com/role/IssuedCapitalDetails",
      "http://pranabio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares per share",
        "verboseLabel": "Price per share",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "srt_ParentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ParentCompanyMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parent [Member]",
        "label": "Parent Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ParentEntityFinancialInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ParentEntityFinancialInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Financial Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "athe_PaymentsForRentalSecurityDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "PaymentsForRentalSecurityDeposits",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for rental security deposits",
        "documentation": "Payments for rental security deposits.",
        "label": "Payments For Rental Security Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsForShareIssueCosts",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of share issue costs",
        "label": "Payments for share issue costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Principal elements of lease payments",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments to suppliers and employees",
        "label": "Payments to suppliers for goods and services and to and on behalf of employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payments to suppliers for goods and services and to, and on behalf of, employees."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "athe_PercentageOfDefaultVestingConditionsPerYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "PercentageOfDefaultVestingConditionsPerYear",
     "presentation": [
      "http://pranabio.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of default vesting conditions per year",
        "documentation": "This element represents amount of percentage of default vesting conditions per year.",
        "label": "Percentage Of Default Vesting Conditions Per Year"
       }
      }
     },
     "auth_ref": []
    },
    "athe_PercentageOfInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "PercentageOfInterestRate",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "documentation": "The percentage of interest rate on assets exposed to interest rate risk.",
        "label": "Percentage Of Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "athe_PlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "PlanAxis",
     "presentation": [
      "http://pranabio.com/role/ScheduleofSharesIssuedunderStockOptionPlanTable",
      "http://pranabio.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Plan Axis"
       }
      }
     },
     "auth_ref": []
    },
    "athe_PlanDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "PlanDomainDomain",
     "presentation": [
      "http://pranabio.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PlanDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_PlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "PlantAndEquipmentMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plant and equipment [Member]",
        "documentation": "This member stands for a class of property, plant and equipment representing plant and equipment.",
        "label": "Plant And Equipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_PrimaFacieTaxOnNetLossBeforeIncomeTax": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "PrimaFacieTaxOnNetLossBeforeIncomeTax",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIncomeTaxTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prima facie tax on net loss before income tax",
        "documentation": "Prima facie tax on net loss before income tax.",
        "label": "Prima Facie Tax On Net Loss Before Income Tax"
       }
      }
     },
     "auth_ref": []
    },
    "athe_PrimaFaciesTaxOnNetLossBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "PrimaFaciesTaxOnNetLossBeforeIncomeTax",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prima facie tax on net loss before income tax at 25% (2024: 25%, 2023: 25%)",
        "documentation": "Prima facie tax on net loss before income tax.",
        "label": "Prima Facies Tax On Net Loss Before Income Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromIssuingOtherEquityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingOtherEquityInstruments",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issue of ordinary shares and other equity securities",
        "label": "Proceeds from issuing other equity instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "athe_ProceedsFromResearchAndDevelopmentTaxRefund": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ProceedsFromResearchAndDevelopmentTaxRefund",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D tax refund",
        "documentation": "Represent the cash inflow from research and development tax refund.",
        "label": "Proceeds From Research And Development Tax Refund"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedIncomeStatement",
      "http://pranabio.com/role/ScheduleofAccumulatedDeficitDuringDevelopmentStageTable",
      "http://pranabio.com/role/ScheduleofCashFlowInformationTable",
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable",
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss for the year",
        "terseLabel": "Net loss",
        "verboseLabel": "Loss for the year",
        "negatedLabel": "Net loss for the year",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r31",
      "r75",
      "r89",
      "r91",
      "r164",
      "r165",
      "r196",
      "r199"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax expense",
        "label": "Profit (loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r142",
      "r175",
      "r176",
      "r210",
      "r211"
     ]
    },
    "athe_ProfitLossBeforeTax1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ProfitLossBeforeTax1",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss",
        "documentation": "The profit (loss) before tax expense or income.",
        "label": "Profit Loss Before Tax1"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ProfitLossBeforeTax2": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ProfitLossBeforeTax2",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash outflow",
        "documentation": "Profit loss before tax.",
        "label": "Profit Loss Before Tax2"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r46"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://pranabio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ownership interest in subsidiary",
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r92"
     ]
    },
    "ifrs-full_Provisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Provisions",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinProvisionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Carrying amount at start of year",
        "periodEndLabel": "Carrying amount at end of year",
        "label": "Provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities of uncertain timing or amount, including provisions for employee benefits."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_ProvisionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProvisionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ProvisionsScheduleofMovementsinProvisionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ProvisionsScheduleofMovementsinProvisionsDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinProvisionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions - Schedule of Movements in Provisions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ProvisionsScheduleofProvisionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ProvisionsScheduleofProvisionsDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofProvisionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions - Schedule of Provisions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for purchase of plant and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r106",
      "r122",
      "r139",
      "r197",
      "r198",
      "r376"
     ]
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r106",
      "r122",
      "r139",
      "r197",
      "r198",
      "r376"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_RangesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "RangesAxis",
     "presentation": [
      "http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges [Axis]",
        "label": "Ranges Axis"
       }
      }
     },
     "auth_ref": []
    },
    "athe_RangesDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "RangesDomainDomain",
     "presentation": [
      "http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RangesDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ReclassifyExpiredOptionsFromReservesOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ReclassifyExpiredOptionsFromReservesOne",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofAccumulatedDeficitDuringDevelopmentStageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reclassify expired options from reserves",
        "documentation": "The amount of Reclassify expired options from reserves.",
        "label": "Reclassify Expired Options From Reserves One"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ReclassifyForfeitedOptionsFromReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ReclassifyForfeitedOptionsFromReserves",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofAccumulatedDeficitDuringDevelopmentStageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassify forfeited options from reserves",
        "documentation": "Reclassify forfeited options from reserves.",
        "label": "Reclassify Forfeited Options From Reserves"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(b) Numerical reconciliation of income tax expense to prima facie tax payable:",
        "label": "Reconciliation of changes in deferred tax liability (asset) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r239",
      "r250",
      "r266",
      "r301"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://pranabio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "athe_ResearchAndDevelopmentExpenses1Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ResearchAndDevelopmentExpenses1Abstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofExpensesfromOrdinaryActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses (1)",
        "label": "Research And Development Expenses1 Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ResearchAndDevelopmentTaxIncentive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ResearchAndDevelopmentTaxIncentive",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable": {
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D Tax Incentive",
        "documentation": "R&amp;D tax incentive.",
        "label": "Research And Development Tax Incentive"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ResearchAndDevelopmentTaxIncentiveReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ResearchAndDevelopmentTaxIncentiveReceivable",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D tax incentive receivable",
        "documentation": "The amount of research and development tax incentive receivable.",
        "label": "Research And Development Tax Incentive Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ResearchAndDevelopmentTerminationCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ResearchAndDevelopmentTerminationCommitments",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ExpenditureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development termination",
        "documentation": "Represents the amount of research and development contract termination commitments.",
        "label": "Research And Development Termination Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ReserveOfOptionsIssuedDuringTheYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ReserveOfOptionsIssuedDuringTheYear",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options issued during the year",
        "documentation": "Options issued during the year.",
        "label": "Reserve Of Options Issued During The Year"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ReserveOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ReserveOfOrdinaryShares",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve of ordinary shares (in Shares)",
        "documentation": "Reserve of ordinary shares.",
        "label": "Reserve Of Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ReserveOfShareBasedPaymentsExpiredDuringTheYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ReserveOfShareBasedPaymentsExpiredDuringTheYear",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired during the year",
        "documentation": "Represents amount of option reserves share based payment expense.",
        "label": "Reserve Of Share Based Payments Expired During The Year"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails",
      "http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve of Share Based Payments for Options [Member]",
        "verboseLabel": "Reserve of Share Based Payments for Warrants/Free-attaching options [Member]",
        "netLabel": "Options for Fully Paid Ordinary Shares/Warrants [Member]",
        "label": "Reserve Of Share Based Payments For Options And Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPayments",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      },
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable",
      "http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable",
      "http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning of the year",
        "periodEndLabel": "End of the year",
        "terseLabel": "Reserves",
        "verboseLabel": "Reserve of share-based payments",
        "label": "Reserve of share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "athe_ReserveOfSharebasedPaymentsForfeitedDuringYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ReserveOfSharebasedPaymentsForfeitedDuringYear",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited during the year",
        "documentation": "Amount of Forfeited options reserves during the year.",
        "label": "Reserve Of Sharebased Payments Forfeited During Year"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ReservesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ReservesDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserves (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ReservesScheduleofReservesofShareBasedPaymentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ReservesScheduleofReservesofShareBasedPaymentsDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserves - Schedule of Reserves of Share Based Payments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ReservesScheduleofReservesofShareBasedPaymentsParentheticalsDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserves - Schedule of Reserves of Share Based Payments (Parentheticals) (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReservesWithinEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReservesWithinEquityAxis",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails",
      "http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserves within equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ifrs-full_ReservesWithinEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReservesWithinEquityDomain",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails",
      "http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserves within equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Reserves within equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r240",
      "r251",
      "r267",
      "r302"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r252",
      "r268",
      "r303"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r259",
      "r275",
      "r310"
     ]
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofAccumulatedDeficitDuringDevelopmentStageTable",
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Balance at beginning of year",
        "negatedPeriodEndLabel": "Balance at end of year",
        "terseLabel": "Accumulated losses",
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit During Development Stage",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r177"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Revenue [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueAndOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueAndOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total interest and other income from continuing operations",
        "label": "Revenue and other operating income"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "ifrs-full_RevenueFromInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromInterest",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable": {
       "parentTag": "ifrs-full_OtherRevenue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedIncomeStatement",
      "http://pranabio.com/role/ScheduleofInterestandOtherIncomefromContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r161",
      "r168",
      "r357"
     ]
    },
    "athe_RightOfUseAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "RightOfUseAssetsAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Right Of Use Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ScheduleofFinancialPositionShowstheFollowingAmountsRelatingtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r115"
     ]
    },
    "athe_RiskfreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "RiskfreeInterestRate",
     "presentation": [
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free Interest Rate",
        "documentation": "Percentage of risk-free interest rate.",
        "label": "Riskfree Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "athe_ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock",
     "presentation": [
      "http://pranabio.com/role/AccumulatedDeficitDuringDevelopmentStageTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accumulated Deficit During Development Stage",
        "documentation": "Represents tabular disclosure of accumulated deficit during development stage.",
        "label": "Schedule Of Accumulated Deficit During Development Stage Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfAmountsRelatingToLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfAmountsRelatingToLeasesTableTextBlock",
     "presentation": [
      "http://pranabio.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Position Shows the Following Amounts Relating to Leases",
        "documentation": "Schedule of amounts relating to leases.",
        "label": "Schedule Of Amounts Relating To Leases Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfAuditAndReviewOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfAuditAndReviewOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Audit and Review of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfAuditorRemunerationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfAuditorRemunerationTableTextBlock",
     "presentation": [
      "http://pranabio.com/role/AuditorsRemunerationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Audit and Review of Financial Statements",
        "documentation": "Tabular disclosure of auditor's remuneration.",
        "label": "Schedule Of Auditor Remuneration Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfCashFlowInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash Flow Information Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfCompanysLiquidityReserveOnTheBasisOfExpectedCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfCompanysLiquidityReserveOnTheBasisOfExpectedCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Companys Liquidity Reserve On The Basis Of Expected Cash Flows Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfEstimatedUsefulLivesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfEstimatedUsefulLivesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Useful Lives Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfExpensesFromOrdinaryActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfExpensesFromOrdinaryActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Expenses From Ordinary Activities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfIncomeTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfIncomeTaxAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfIndividualFinancialStatementsForTheParentEntityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfIndividualFinancialStatementsForTheParentEntityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Individual Financial Statements For The Parent Entity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfInterestAndOtherIncomeFromContinuingOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Interest And Other Income From Continuing Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfInterestRatesAndTheEffectiveWeightedAverageInterestRateForClassesOfFinancialAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfInterestRatesAndTheEffectiveWeightedAverageInterestRateForClassesOfFinancialAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Interest Rates And The Effective Weighted Average Interest Rate For Classes Of Financial Assets And Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfIssuedCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfIssuedCapitalLineItems",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIssuedCapitalTable",
      "http://pranabio.com/role/ScheduleofIssuedCapitalTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Issued Capital [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfMovementsInIssuedSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfMovementsInIssuedSharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Movements In Issued Shares Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Movements in Options for Fully Paid Ordinary Shares [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock",
     "presentation": [
      "http://pranabio.com/role/ReservesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movements in Options for Fully Paid Ordinary Shares",
        "documentation": "Tabular disclosure of movements in options for fully paid ordinary shares.",
        "label": "Schedule Of Movements In Options For Fully Paid Ordinary Shares Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfMovementsInProvisionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfMovementsInProvisionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Movements In Provisions Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfNumberOfSharesIssuedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfNumberOfSharesIssuedTableTextBlock",
     "presentation": [
      "http://pranabio.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Shares Issued under Stock Option Plan",
        "documentation": "Tabular disclosure of number of shares issued during period under ASX Plan 2004.",
        "label": "Schedule Of Number Of Shares Issued Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfOptionsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfOptionsOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Options Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock",
     "presentation": [
      "http://pranabio.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Options Outstanding",
        "documentation": "Tabular disclosure of options outstanding at the end of the year having expiry dates and exercise price.",
        "label": "Schedule Of Options Outstanding Expiry Date And Exercise Prices Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfOptionsOutstandingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfOptionsOutstandingLineItems",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options Outstanding [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfProvisionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfProvisionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Provisions Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock",
     "presentation": [
      "http://pranabio.com/role/IssuedCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movements in Issued Shares",
        "documentation": "Represents the tabular disclosure of movements in issued shares.",
        "label": "Schedule Of Reconciliation Of Number Of Shares Outstanding Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfReserveOfShareBasedPaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfReserveOfShareBasedPaymentsTableTextBlock",
     "presentation": [
      "http://pranabio.com/role/ReservesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reserves of Share Based Payments",
        "documentation": "Tabular disclosure of components of reserve of share based payments.",
        "label": "Schedule Of Reserve Of Share Based Payments Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfReservesOfShareBasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfReservesOfShareBasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Reserves Of Share Based Payments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock",
     "presentation": [
      "http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Interest and Other Income from Continuing Operations",
        "documentation": "Tabular disclosure of revenue and other income from continuing operations.",
        "label": "Schedule Of Revenue And Other Income From Continuing Operations Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfShareIssuancesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfShareIssuancesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Issuances Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfShareIssuancesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfShareIssuancesLineItems",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Issuances [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfSharesIssuedUnderStockOptionPlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfSharesIssuedUnderStockOptionPlanAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Shares Issued Under Stock Option Plan Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfSharesIssuedUnderStockOptionPlanLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfSharesIssuedUnderStockOptionPlanLineItems",
     "presentation": [
      "http://pranabio.com/role/ScheduleofSharesIssuedunderStockOptionPlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Shares Issued under Stock Option Plan [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfTradeAndOtherPayableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfTradeAndOtherPayableTableTextBlock",
     "presentation": [
      "http://pranabio.com/role/TradeandOtherPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade and Other Payables",
        "documentation": "Tabular disclosure for trade and other payable.",
        "label": "Schedule Of Trade And Other Payable Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfValuationsOfOptionsApprovedAndIssuedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Valuations Of Options Approved And Issued Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock",
     "presentation": [
      "http://pranabio.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuations of Options Approved and Issued",
        "documentation": "Represents tabular disclosure of valuation of options approved and issued.",
        "label": "Schedule Of Valuations Of Options Approved And Issued Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ifrs-full_SegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SegmentsAxis",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable_Parentheticals"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r107",
      "r164",
      "r187",
      "r200"
     ]
    },
    "ifrs-full_SegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SegmentsDomain",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable_Parentheticals"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r107",
      "r169",
      "r187",
      "r200"
     ]
    },
    "athe_SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of weakened/strengthened of Australian dollar against US Dollar on post-tax loss (in Dollars)",
        "documentation": "The hypothetical financial impact of percent change of foreign exchange rate.",
        "label": "Sensitivity Analysis Of Post Tax Profit Impact Of Percent Change In Australian Dollar Against Us Dollar"
       }
      }
     },
     "auth_ref": []
    },
    "athe_September212022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "September212022Member",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "September 21, 2022 [Member]",
        "label": "September212022 Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ShareBasedPaymentExpenseForOptionsIssuedI": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ShareBasedPaymentExpenseForOptionsIssuedI",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Share Based Payment expense",
        "documentation": "Share Based Payment expense for options issued.",
        "label": "Share Based Payment Expense For Options Issued I"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Options expired during the year",
        "documentation": "Number of Options, Options expired during the year.",
        "label": "Share Based Payment Number Of Options Options Expired During The Yearin Dollars Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options , Options issued during the year",
        "documentation": "Number of Options , Options issued during the year.",
        "label": "Share Based Payment Number Of Options Options Issued During The Year"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ShareBasedPaymentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ShareBasedPaymentsDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ShareBasedPaymentsScheduleofOptionsGrantedDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payments - Schedule of Options Granted (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ShareBasedPaymentsScheduleofOptionsOutstandingDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payments - Schedule of Options Outstanding (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ShareBasedPaymentsScheduleofSharesIssuedunderStockOptionPlanDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofSharesIssuedunderStockOptionPlanTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payments - Schedule of Shares Issued under Stock Option Plan (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ShareBasedPaymentsScheduleofValuationsofOptionsApprovedandIssuedDetailsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payments - Schedule of Valuations of Options Approved and Issued (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ShareIssuanceDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ShareIssuanceDateAxis",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Issuance Date [Axis]",
        "documentation": "The information related to share issuance date.",
        "label": "Share Issuance Date Axis"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ShareIssuanceDateDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ShareIssuanceDateDomainDomain",
     "presentation": [
      "http://pranabio.com/role/ScheduleofShareIssuancesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareIssuanceDateDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareOptionsMember",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails",
      "http://pranabio.com/role/ScheduleofOptionsGrantedTable",
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options [member]",
        "verboseLabel": "Share Options [Member]",
        "label": "Share options [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share options."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "athe_SharePriceAtGrantDate": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "SharePriceAtGrantDate",
     "presentation": [
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Price at Grant Date",
        "documentation": "Share price at grant date.",
        "label": "Share Price At Grant Date"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ShareholdersAuthorizedSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ShareholdersAuthorizedSecurities",
     "presentation": [
      "http://pranabio.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders authorized securities (in Shares)",
        "documentation": "Number of shareholders authorized securities.",
        "label": "Shareholders Authorized Securities"
       }
      }
     },
     "auth_ref": []
    },
    "athe_SharesOfIssuedCapital": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "SharesOfIssuedCapital",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIssuedCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued Capital",
        "documentation": "Number of shares issued in capital.",
        "label": "Shares Of Issued Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares",
     "presentation": [
      "http://pranabio.com/role/ShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of ordinary shares authorized (in Shares)",
        "label": "Number of shares reserved for issue under options and contracts for sale of shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares reserved for issue under options and contracts for the sale of shares."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "athe_SharesToBeIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "SharesToBeIssued",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinOptionsforFullyPaidOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares to be issued",
        "documentation": "Represent the amount of shares to be issued.",
        "label": "Shares To Be Issued"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ShortDatedOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ShortDatedOptionsMember",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Dated Options [Member]",
        "label": "Short Dated Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ShortFreeAttachingOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ShortFreeAttachingOptionsMember",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Free Attaching Options [Member]",
        "label": "Short Free Attaching Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ShortTermLeaseTerm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ShortTermLeaseTerm",
     "presentation": [
      "http://pranabio.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term lease term",
        "documentation": "Short term lease term.",
        "label": "Short Term Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term deposit",
        "label": "Short-term deposits, classified as cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "athe_SixToTowelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "SixToTowelMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6-12 Months [Member]",
        "label": "Six To Towel Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 equity",
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Assets and Liabilities Subject to Foreign Currency Risk [Abstract]",
        "terseLabel": "Statement of financial position"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_StatementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "StatementsLineItems",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable",
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_StatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "StatementsTable",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIndividualFinancialStatementsfortheParentEntityTable",
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statements Table"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r254",
      "r270",
      "r305"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)"
       }
      }
     },
     "auth_ref": []
    },
    "athe_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://pranabio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_SubsequentEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "SubsequentEventsMember",
     "presentation": [
      "http://pranabio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Member]",
        "label": "Subsequent Events Member"
       }
      }
     },
     "auth_ref": []
    },
    "athe_SubsequentsEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "SubsequentsEventMember",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequents Event Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/IncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential tax benefit amount",
        "label": "Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce current tax expense. [Refer: Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]"
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/IncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable tax",
        "label": "Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce deferred tax expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce deferred tax expense. [Refer: Deferred tax expense (income); Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]"
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "athe_TaxEffectOfDeferredTaxAssetNotRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "TaxEffectOfDeferredTaxAssetNotRecognized",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset not recognised",
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to deferred tax asset not recognized.",
        "label": "Tax Effect Of Deferred Tax Asset Not Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectOfForeignTaxRates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxEffectOfForeignTaxRates",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of lower tax rates of tax on overseas income",
        "label": "Tax effect of foreign tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "athe_TaxEffectOfResearchAndDevelopmentExpenditure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "TaxEffectOfResearchAndDevelopmentExpenditure",
     "crdr": "debit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenditure (net of tax incentive)",
        "documentation": "The amount of research and development expenditure.",
        "label": "Tax Effect Of Research And Development Expenditure"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxRateEffectFromChangeInTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxRateEffectFromChangeInTaxRate",
     "presentation": [
      "http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refundable tax offset rate",
        "label": "Tax rate effect from change in tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from a change in tax rate. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "athe_TaxRateEffectFromChangesInTaxRate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "TaxRateEffectFromChangesInTaxRate",
     "presentation": [
      "http://pranabio.com/role/BackgroundandSummaryofMaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax rate change tax rate, description",
        "documentation": "Description of tax rate effect from changes in tax rate.",
        "label": "Tax Rate Effect From Changes In Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures",
     "presentation": [
      "http://pranabio.com/role/ScheduleofIncomeTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary differences",
        "label": "Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements, for which deferred tax liabilities have not been recognised as a result of satisfying both of the following conditions: (a) the parent, investor, joint venturer or joint operator is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future. [Refer: Total for all associates [member]; Total for all subsidiaries [member]; Temporary differences [member]; Investments in subsidiaries reported in separate financial statements]"
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "athe_TermDeposit": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "TermDeposit",
     "presentation": [
      "http://pranabio.com/role/OtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term deposit",
        "documentation": "Term deposit.",
        "label": "Term Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "athe_TerminationNoticePeriodForResearchAndDevelopmentContracts": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "TerminationNoticePeriodForResearchAndDevelopmentContracts",
     "presentation": [
      "http://pranabio.com/role/ExpenditureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination notice period for research and development",
        "documentation": "Represents the termination notice period for research and development contracts.",
        "label": "Termination Notice Period For Research And Development Contracts"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails",
      "http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of range [Member]",
        "verboseLabel": "Top of range [member]",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r106",
      "r122",
      "r139",
      "r197",
      "r198",
      "r376"
     ]
    },
    "athe_TotalContractedCashFlowsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "TotalContractedCashFlowsMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Contracted Cash Flows [Member]",
        "label": "Total Contracted Cash Flows Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Trade and other payables",
        "label": "Trade and other current payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Trade and Other Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pranabio.com/role/ScheduleofTradeandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade creditors",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r362"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://pranabio.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pranabio.com/role/ConsolidatedBalanceSheet",
      "http://pranabio.com/role/ScheduleofTradeandOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Trade and other receivables",
        "label": "Trade and other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r22"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Trade and Other Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total",
        "label": "Trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and Other Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_TradeAndOtherPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "TradeAndOtherPayablesMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable",
      "http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable",
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and Other Payables [Member]",
        "verboseLabel": "Trade And Other Payables [Member]",
        "label": "Trade And Other Payables Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and Other Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "athe_TradeAndOtherReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "TradeAndOtherReceivablesMember",
     "presentation": [
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and Other Receivables [Member]",
        "label": "Trade And Other Receivables Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "athe_TransactionsWithOwnersInTheirCapacitySharesAsOwners": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "TransactionsWithOwnersInTheirCapacitySharesAsOwners",
     "presentation": [
      "http://pranabio.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total transactions with owners in their capacity as owners (in Shares)",
        "documentation": "Total transactions with owners in their capacity as owners (in Shares).",
        "label": "Transactions With Owners In Their Capacity Shares As Owners"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "athe_TurnoverRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "TurnoverRevenue",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/InterestandOtherIncomefromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual aggregate turnover",
        "documentation": "When ALL data is continuing and no discontinued values are reported, the 'continuing operations' dimension tag need NOT be individually applied.",
        "label": "Turnover Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsAxis",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsDomain",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_TypesOfInterestRatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfInterestRatesAxis",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails",
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of interest rates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "ifrs-full_TypesOfInterestRatesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfInterestRatesDomain",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails",
      "http://pranabio.com/role/ScheduleofInterestRatesandtheEffectiveWeightedAverageInterestRateforClassesofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of interest rates [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails",
      "http://pranabio.com/role/ScheduleofCompanysLiquidityReserveontheBasisofExpectedCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r127",
      "r143",
      "r148",
      "r149",
      "r173"
     ]
    },
    "ifrs-full_TypesOfRisksDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfRisksDomain",
     "presentation": [
      "http://pranabio.com/role/FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of risks [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r127",
      "r143",
      "r148",
      "r149",
      "r173"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails",
      "http://pranabio.com/role/ScheduleofOptionsGrantedTable",
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsDomain",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "USD",
     "presentation": [
      "http://pranabio.com/role/ScheduleofFinancialAssetsandLiabilitiesSubjecttoForeignCurrencyRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "USD [Member]",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "athe_UsefulLivesOrDepreciationRatePropertyPlantAndEquipments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "UsefulLivesOrDepreciationRatePropertyPlantAndEquipments",
     "presentation": [
      "http://pranabio.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives of property and equipment",
        "documentation": "The interest rate on depreciation for fixed assets.",
        "label": "Useful Lives Or Depreciation Rate Property Plant And Equipments"
       }
      }
     },
     "auth_ref": []
    },
    "athe_ValueOfIncreaseDecreaseInSharesOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ValueOfIncreaseDecreaseInSharesOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofMovementsinIssuedSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement during the year",
        "documentation": "The increase (decrease) in the value of shares outstanding.",
        "label": "Value Of Increase Decrease In Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ifrs-full_WarrantReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WarrantReserve",
     "crdr": "credit",
     "presentation": [
      "http://pranabio.com/role/ScheduleofReservesofShareBasedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve of Free-attaching options",
        "label": "Warrant reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]"
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails",
      "http://pranabio.com/role/ScheduleofOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Vested and Exercisable at year end (in Dollars per share)",
        "verboseLabel": "Exercisable per share",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised during the year (in Dollars per share)",
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Expired during the year (in Dollars per share)",
        "label": "Weighted average exercise price of share options expired in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Forfeited during the year (in Dollars per share)",
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Issued during the year (in Dollars per share)",
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://pranabio.com/role/ReservesDetails",
      "http://pranabio.com/role/ScheduleofOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Beginning of the year (in Dollars per share)",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding at year end (in Dollars per share)",
        "terseLabel": "Fair value per option (in Dollars per share)",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r131",
      "r136"
     ]
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://pranabio.com/role/ScheduleofOptionsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options, Weighted average remaining contractual life of options outstanding at end of period.",
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://pranabio.com/role/ConsolidatedIncomeStatement",
      "http://pranabio.com/role/ScheduleofEarningLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares used in computing basic net loss per share (in Shares)",
        "verboseLabel": "Weighted average number of ordinary shares on issue used in the calculation of basic loss per share",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "athe_YearsToExpiry": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "YearsToExpiry",
     "presentation": [
      "http://pranabio.com/role/ScheduleofValuationsofOptionsApprovedandIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Years to Expiry",
        "documentation": "Years to expiry.",
        "label": "Years To Expiry"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "athe_ordinarySharesPerShareCents": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://pranabio.com/20250630",
     "localname": "ordinarySharesPerShareCents",
     "presentation": [
      "http://pranabio.com/role/IssuedCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares per share cents",
        "documentation": "ordinary shares per share cents",
        "label": "ordinary Shares Per Share Cents"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_l&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2024-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2024-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "20",
   "IssueDate": "2024-01-01",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2024-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2024-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_vi&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2024-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "34",
   "IssueDate": "2024-01-01",
   "Section": "Content of an interim financial report",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=34&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS34_g5-25_TI",
   "URIDate": "2024-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2024-01-01",
   "Paragraph": "84",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_84_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2024-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS37_g84-92_TI",
   "URIDate": "2024-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "46",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_46&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "Presentation of a statement of cash flows",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS07_g10-17_TI",
   "URIDate": "2024-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "29",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "49",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2024-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2024-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2024-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "22A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_22A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2024-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2024-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2024-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2024-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2024-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2025-01-01",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "A19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_A19_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "80",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_80_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "80",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_80_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "80",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_80_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI",
   "URIDate": "2024-03-27"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG63&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_IG23&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG20B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG20B&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "5",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2024-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>120
<FILENAME>0001213900-25-082027-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-082027-xbrl.zip
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M1^@?[CBQBZ8@_N3. 5ZX'EA56!#FW#&,*'!:]*CUZJ"5TP]@>+,J2=F]'Z.
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MB#V"-3M8, ><283Z21 LKUSHYQX9M4Q<0SH&9M(A=^HG&2$EFS=KWR$ '(;
MH1#6WB4&QG"S>)='2:W87LD(J4=#9Y0=<H>(M8*#R\.G7EQQ8_.9!!:++._R
M+_H%@CMNS..*&Z<PLWF["M^XBC #/YQ%=Y@(HQ\%071'!GAG3AV_,<MJ3/X9
M1X7H;\E$?B!187=5)<^'7J:2+\_;=71*#L5A6!P"QEFA<3(X3H['B:-F)-6_
MUIO0$#P: OL8@VAS>D;CASL:%8Z?%(1#[ 06V?N88Z<9/(7!(TMB(!D;TN(F
M)B-W6"K.>E >")+,"(V -W@/2;3PJTN:B%7\Y#?_.%)CGM5/:2&2F+R4UC+G
MCDO_FX_2'JP[L]WL&2E"MB=*?SA!28.I=<2=C@KE5?&&R_;866.--.M)<Y#$
M+("+&!0&$N5*:W=.1T;OEDED6FBN.22I(=LO;I"D,6PKR746"Q3= AK!G5[P
MJ:1M7E_O8W7$OY:F'P!K ,7AD&-@?I'9-66S;:ISDXS37DM"'Z!A''DW:==>
M!:[2##:K:[(=.N(.RPQ&0W9,FDF< 7 8@FQD.!1#8R/7? 91:&M)RNC5/)\\
MK/HF8B,@\V!:%X5DS>-2A<DB:&7%36PN76JQ2IALVA27?ZS1PF:2-<PI)A&T
M:6T3N6^8DZP\' SSF#6FF_G]%LTO1NR;:W +P5WAB'M(.@%H?52,J^OVSD>F
MF<\J]U>T$+//4@3EL_$UB&8QV/ ]2;$;F;JL@9'.'6K)'Y=LE'W=9R:%EI:T
ME'9F\J=:_)N3C<[5RJDOR#8HDI2JG,F6YQ5WJM47)R9LIE7-J^0T])4L-A>0
ME U8FA:R[?@;>'$<]2,$X#1,PV2]Y37$-T97R9L1-1H(W%&8>"#(;I:S2%^Z
MN!:P.1DX>AV8P7-R? X%V RLNIFQKLG*1T< &2.GDPF@*8# 5]*Q,[(@=FZ)
MX3,%Q:)$Z78#EP@':X:122ZM']NVWA)XQ1W7F0S257HM!I\-47IYO>+ R5EP
M,A[*-9B#7,:'T9AOK$?C"V^R$7/#);Z WQ)(;/-EYK<842?5$Q=#G&;@\F(:
M Y;>=BL'Z@,(:D^17G&G@R:#+T/T$W96F'+O3(=80G0@,EQYFB^*;'W/WKA?
MUE.1/KR%?N(&@ITEF<6DLXL)@=4:;P-21NLL=Q9IDDFXJM!R<.+M*U58=&"5
M*3<W_IJ!U(L\-H4[H9]V&?>TN+*$3OK9\]09B>*?A%PN)/4SXO_?A/3+WCU^
MZRX6D'"=?4P_A6&4<I(/S5_(5SA?D(GGA.X<X(7K@94H[^[N7MZ/4? R0M.]
M=JMUL =#>C7KD=F-R;R9NQ>1Q\@IJM!_[>;U=NFGW?WV[L'^RWOL[^R]WP0%
M97KLXMHH\GJ;H)BX>,S()7@W)GV-"=WVH1@!)N59\\5*4]==L#I[((CQBLPN
M_;197_@QVJ,T*-7V+N'H8%^.1U>3_1NO@!B,CF(''[%_^;&Q1/(*5!1'ZU:-
MI8!1O($82*V""%8TRC(P91T#[^4TNMW#T#,!42U._R@U7*M1;^GONI,Z[9(:
M:;MIU7KCKD0)>'Z=AO/B](_-&::5<3+>N&%2MRKF6NW[ -9MGU1)V\_J2MH'
M07J/0@&\V\GMD8$P!WMG3.QAUR/SC [<=SNT/?B6?(/A])R8*705V''<K-2[
M'6(\DW^GI18 P<@?L7I^@K+E-X1!0(VLO"S!2=J-$_KK&8J21=X().0+1ITA
MSO*$DK&:[PL[I9S2?4E.:1L[84,."G-/.@RR',5]8:9D&_O"$+'IT,ARG-K(
M*0^NN(K)6%HGDK*1)P$Z,TFM@B#/0[LY5 ,UF)(% L5\*I;S*H2Z7H9ES)93
MC-C(HP2AR53,XWD'@JAR&UDUPJN7:6%49&Z6?6FTM(W=L!%^D_$@"/VQD7\5
M3!,V><=N&[E4H-0/\;4S\:#JS=S)O9EM9+H6;H.UJNC%^UG@Q6MC'QAC-MI'
M,>^D3NX=-1!Y1]G8"75@U]MEL>LZ0GED=MO87]TV#JJWC9W2;:.-O?AD/!M,
M1=DEVB <99=H _X2S<9.?1@C>MVMO"0BHAF5+XEL[*)-65!H--K)+O)F9  6
MLH+DF^U]>WK!%*ATRIP!ZF@:D/H=?PY#2,O31G,2]K!JC%0A5W9>=.;"D*F6
M"%O%H J<W-+L^/[(O4\5+5G)K.%&@DO.2/Z\@S4<5 $IQM6G*+0.O@"3RG;I
MA"'1H!? O07V\" ")55E%U$X'9*U$7K ,C:DR*2\=$I)H^WA1()+/JL_AZ0=
M\LFB#2 /20[_FIJM@\EG##*+U!HNI,BD8ZH[<\,IV>N%=F\HS&#6&'&MY^=)
M@$FEBZO;(&MD(P.F8H;C??_Y^1!@,I*'E1-&B:Z69-K/SXP TP8SQ8(I+T4F
MU<\<ZP?/SX4 TZ83Q2:9".&9"^;P^5D18%()AAZX!0'9BA%S^@I%!$N\S#?.
M96;F40AB%RU%[$S< &OX27\;NP&]("0_@#&,-^=2"5LY$",T 828G]]9H6B>
M7^C]2'X]!/R',*S$+3O-(SWC >"O"O,'0F0G?@TF2>A;+.LZ7*A$G]_1DJZ\
MIL[$P1!X"8+QL@<6-'6HU?+7@Y<-@OQ2/K_2^01B>GJ,8TRON8#-3.N@2Q6S
MO&+Z[XJ:3J^Z-F/Y\7G+("I.E<Y#TK,N!CV0_G\T(PU-9VN2F9(81:?S11 M
M@=VZ;1-VY*(W)M8E_TV"V WMGOF;,62J#<[#+LT;PA(,?(7Q[/0>( _B-=GU
MN(1A+R(L(+M[ZS'XDW:>6!09)6)_0(+^/.3<@CH(T:,+^J?5??<(["FT5M6$
MN28+.")41E&:@WG $D';W$&&',B&SZB0RX..Q<%=2*J?TPM;B+KNPO7(>IXY
M3.'T1PL6JDU0RX^O31^  /?Q21!Y-WD'^#%Z&^<?G[@'ZH-6S((>P!Z";/P,
MZ'L8-+4XH745!=!;D@&67=U374X^^?E-)AG!;ARA95K.JNYY9(ZD8T?7SC7P
MHFD:ZC>8% ( MJ&/I-CEQ]DZDLQ!A.*^!7TX3<CTW.YA5(N?S;OM$[A;?QU2
MGT<7^?2R@;DF+1!(8S?Q%O;@IJR9>;;1Q3!,@%GP#8LIMZKS'H<1E>)?Q<47
M8E8*0]B^+JF)6#'G"H2(.>&O^I:H/0!O&1FKN3<#;>0)6R)%#&@[F:^%UW#0
MKP(&!I-3UYLQW\Y"J-/63(6-^3!P3Z5V0.C! +JI%O^4S,< Y9O9:A)XJ[KH
MX4SHG5)S'U?9^Y/6=H@I;)/ D3J!-S;WR@/X,)A)M9X:M+2'-N3!+"*C_+[6
MJ/B^EJW=80199:T6U?B*&MMY?:<G6\53G+R5M T;.F)S\&8&/!_JQ8[\ECTR
M_FA2H.SD] I!S^YQ\A!&C.:.27R8S1VT 7[]VEQ>Y>WO! .\AH:M87)XJ_KA
M0?CU@R%+65[,5VY?']2!*S^5+'1D,9I($')4V!G8P/Z&R%714<Q!MQ?-77J7
M1O];Y--G7Y[8&9I')#>Q3USO9DJ(A?2MI6$RGQ/S,YI<DDY U%VO?*!&DQ.O
MWP$1I-_),A)FB1B?V"W,C]_.2$WD)6-P7NZ2'\BE8F@4J@Q0#RP0\-+M(8WT
MS#VX:%PQRS_X+8',NBW9790=\NV)9\FFP&L'$8[<^_.0,DB:LOD2U "]?(IE
M!VBJV$2+/=%,T"ODOO;/H'4A&4E$H6X!VVK<\KM>NJBRJX70#>C9.8J"_""Q
M0\PM1,%M ?OU^%#*'RTB@I&^?[L(X):PKT*MF.B3"=E=I:Z*6\"D$*Z)*#O^
M+<3$+-H"'N68%8R23?+<[;L>2V1_/P@_@9@>,)S0_/=@=2ED,=>&#*B.2 KA
MR@KEG[Y#;7%/U&)#JM4+5'I@ A"BN^9[%LOR*8K7!U+;T1%J%HSFA<&T>#[K
MU0RF(LQ5:^RM;T,?0>)IBNKXL05>BPO9X0;9&9%&_1]NO,KZX*%VNQE^13Z)
MM#X]9@:87G2Z0?]Q',M_,,<<8I6N9U9=GAXAK;\%LE6AEDMTG7ASO<=??[/U
M_*(&ZGJLK^XC8;B=O:!GP#3/!TTS4\Y,T7416M+L?^SBR>+%O18;R@"B53:+
MPLLIQ<^V#HW:V)77@ZG/1KGV@[W25WIPXZ-[(2Q5T(NN1](3\!F(H4=0;[-L
M%9S(%:*$<$&E%%,7;UGWF'"AF@1Y_=3[8C0#?Q 3ZE.4WQW"T)JH0E.D\H'
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M\V0Q+PR<VFW7-OPK3,JC)W8/;QOT JHZ*1=M8T,,4)HTOC?,[R[3P ,BOTM
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M51!Q%*XN_"R["U-!DX:216%NNIZP!S&GUO BQJ6,(Z:A2J10^]B>62'$I(N
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M)%L<(TEX@B0%-LOK.7(#PR67Z2Y&>@.%VI G9*FGY\:XGZKP<>V';>.&/;^
M>(]F6AO G(*.)C"1-XH'P3F\4<A$BB[J+O!4,%DR-(#:E$T#&L,\L=D@+-[4
M1F.R*:>(DG)I'!+V+?&[]TA":&>[G^?7/O#&AC+%Z3;6\O^#1%NDQH%V]Q]0
M2P,$%     @ ]:T<6QSNR(K35@  MH(% !4   !A=&AE+3(P,C4P-C,P7V1E
M9BYX;6SM?5F3VSBR[OOY%3Z^+_=&A\=VV;U-3-\3JLU=,V6KIJK<GCDW3G2P
M)$ABFR+57%2E_O47X")QP9( L9#5>IGVV"(R\260R$PD,O_V7T_KX,46Q8D?
MA3^]?/N7-R]?H' 6S?UP^=/+SW>O)G=G5U<O_^O_OGCQ'W_[SU>O7GQ (8J]
M%,U?/.Q>G$7KS=W,?W$?>V&RB.+UB_^=KO_/BU<O5FFZ^>OKUX^/CW^9X=\D
M,S]&293%,Y20OWCQZA4>L!KR+$9DP+^^N(S]%Y-L^>+DQQ=OWO[UY/N_OGG_
MXO/]V8N3-R??%I_\Q]\"/_SZX"7H!>8[3'YZ6:/T]! '?XGBY>N3-V_>O:Y^
M^++XY5^?R%\T?O_X+O_UVQ]__/%U_J_[GR8^[8=XV+>O__7Q^FZV0FOOE1\F
MJ1?."('$_VN2_^5U-//2'$DA7R^8OR#_[U7ULU?DKUZ]/7GU[NU?GI+YGD7\
MFWFZ)U,?X-O7Q3^^)'B]>/&W. K0+5J\R*?XUW2W03^]3/SU)B"<YW^WBM'B
MIY=>NB+43KY]\]V[-X36_R)_\VO\ZUD4)E'@SXF03KV S/ENA5#Z\@49^O/M
MU9Z-#5X'WH,?$1F_)O_XFOGMZ_]KEKE?;[P8A?@WJ3_S@J0/K^VA3+!^A??<
M&MVE^,]K3$N6W?;GKTW(_LQ+5I=!]"C+W/X[PI4>MNY66"2K*)ACQ77Q>^:G
MNWL\R$D4OX,PQ_DZ9U$3DZ?>[.LRCK)P[H7SNVR]]N)=M/B((8E]+YC,9OB?
M4JQG;S!0,Q^!UJCTF,6$M,SG*L14$%%Z\RG^F[A8=(LX6F-I8Z(9ICO=D-,!
M:T#0;"1'U"F<BZ<-"A.4$&+3&!]W&,C)+/6W?@H4A6 $?8N]0.7>>X)!6OU8
MEYK"A_L<51*Z13/D;[V' (81\UM=S.4#GV4Q4="3)$$IB"W*5QKW26/2-]Y.
M#:W]ASI7_4T<;?T$NCUKO]:WFK'-N/93<DHE>*K%/E]BDQ.XZWB?:SOUKI(D
M(^?6QD^] +3K&A]H7$NW*$'Q%@;-_K<:Z>,3)5MG 3G&S]$"'RGI>19CQ,_1
M%@71AL@!6QU+!.$//):^Q7:-L D- J_\I<[-5MD]5R%QC?(S#+3"*9_I4I?Y
MF37WTRQ&M8T$/NVZ7VK;<KE-=HIE,,>*#\P5Y2N-B_\N>TC0[QD>]F(+YJC]
MC<X5=1TER0V*\UF#%G7]]]I$]0^T^X@I+7-7 P^?1&&( A(+P/80>)D#1M&U
MZB<97KA1G-RB=1:6UB1(8=&^TZ><;E&N"[%WB1T0$D'Q9F#+F?FM+LSNT)((
M1E)W4;[2N!\OL8V-3WHON J3-,[ 6H+ZG3XY%N&!"VR)I+L:*2G@A&-HV[U=
M'_%TE_]I!SS#65^[=)WOP3:VXLBZMI6<QPN?EM*XVM84WQ6&SP(TCLYUMO>6
M99!N?J)/C["<93AO@A'TL=IUH.%,,K\U$K"HW&A%$%N?:]LQ!]<:SECG&ZT[
MH>[!2NP&RF>ZY%CYLW!N6E]HLQ^!CBN<4<D1M?H0N:,+9[7Q>WWW"ETG%\X2
M^V/--PP-SQ+.'_-;70NR[M=)2++[E4;C7.S/P3D%CZ5/WC1?3V(_L[_6N7=I
MC@R<2<[76F/, E=&XL"#C:0SXC-;H7D6H&AQD:3^FNCGSPE:9,&U7QTK( 4
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M5:!@T&YZ0$G3B6>G*)H&5L(#1D8>^3-O(NX@0+,T\X(J?[2JL]Z4#>.=.'>
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M:NBP^!!M41P2:_D#MG>&LO]IC#VG(Z*+NKC7J#F#X=Y[0DF^'N]77CCH>QD
MJ\\J)@(1#:0SJJ&%,Y@JZWT9?48F!$@NXL:JAE(#VJ4(ZKGG0UPY8(:';J&8
MD%&UBC@Q66.AD"&\G>[!X_-2.) WUF_9,5=#%SS.JTNK,OBL3!AA(>JWO%"J
M!</%=8\R#;P^G\-'IH?96VYT57OD@P1DR%MO?XLN_646-Y@RD>DJ17#H2\
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M;U+$FTL.(< =2H\+R3TOY,AL]KD_1>DC0F&M(D1N[V-6G1UQ&ED>OB(V(RG
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M6ASSYBUI.MSB62K'U[/2V3W$ _">I;?HK9]\7<0(76$2,4K26^CQ2OWPN1E
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M[86( JU5<S6WYO[6GV=>L)_2H7G&(HHQLS=>7/6<VFGL,%$<J'M:C LTEN%
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MD*YZ@*T@(VF9SGL&A6V_&9]0W [>A]H1-JQ]7S]A\TQA)VI;S)"I-\&&-#<
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M%"^QS#_$T6.Z*N_(-$B"/N[PW5LN*I44]'F[A^NRN&PHK@/\YGAC.I%;2%2
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MPE'LA<%_?W;RY?%G" >KT/6"A__^[,/B:+(XG\T^^[__@]!__/7_'!VA]SC
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M&43J1/ S-;48G>5G&D?&?P4>'RNO0Q8Y<AYN-EY"P\;I:^+TZ=(##NB#::4
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M.+/E8Z0),OO&7I8L*/2$-@?BXI%3Z6,T[Z!5@=&HB:7"+IW+LFRI+,CVBSD
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M5)QT^VA'^=G);R$AYD:RBRX^]$B;TNJZ:B_9!5Z3$NOH:Q"D D&O:F^/%8>
MZ+O R&.+/B*S*-990 P0'"=W9"^U$@S=)L!X6 ]$25>\LY<U0/0NNX4WFY'-
MH%2YD<S\B?>Y!+UVDEUDNFI8;5"C/JWJR !H\D_&HI5X$JJ#HS6I7IZG#&KT
MN&A%S90#FSZE-PGHTBH1_7 L,('$QM4C]2GJ54^_=:(\'&A?V?D*?Z_2_;5T
M9P:3A\G2! 7=L^8H;8^JCL8.E[CQR'Q%09:1^RH,4O0NLJ-D&,2A[[GT(J@(
M.QOHB ]U;6 W$HT/6="5SU'^O7TW0(=\"I> :+(](A+L) MNYP(>6B-).!JE
M<OZF'UE^MB^3BQ=,M:N99RI,8U^#Q!)$0 +L@ 4B!\HF%09'J1<O04T(V<JM
MTB'11E(5T7S[E5L(MSA*]O3)&HVZHOE66?$;8\B"*1@\&JH;5R QD$64?<^N
MK7#^L75P=4JU64Q!-&O]N*A&XG%S<5#-@>V4?FE0 <4[T<^.PO41^3#S8MLN
M_0+(K1'.Q)M>CYN1RJ6O\=V--[:=C8U#"?3 K_S2,EX$DFL4WP FUV<#R[9U
MF^@1D&!%\<#T"&]A$S0>2'5+M7%A(9YRGPO;M.?BH9G!R[+6R.:3'+5H@.V@
M[ /KM@\H,"YB&C,[@-*72A?)I8874I-]^**YW*/6^3QYQ%%[L1M;D]#X-B*S
M %J@Q#?T:Y0=(I'/T_2VL-0AU#JB1+/N$2*1=6BKW!LTO@U< ;2(2@KR\635
M<I"J!B>:ZM#>!Y5]@$>0Y&[PLKE^/("IMG2>+2[AQN@V#P!U4CIL?\(#[BJV
M"2>^)+E@XLRU!Y)*=ZO-<Z68"MN.=_GC9=7[SCUB6G?!2Y\SNZ<_S"V/-4-$
M0(*=V@8@/>KVR AP)K4_=LQY<)M0KJ"!D"AN11"R[%=- ^4/( "=)QUEW_1N
M)=F;SV-7'];.YE$G JI5R#ZRC!B^E!K)Z=JS&0 821)Y][O$N??Q,IQ_"@A7
MY^LT+,DT6$2D6 60@# H;F2UVFUV:6(!%Z^]E9<@=Q?1+/VT1(2+G[ ?LBM/
M%"?. [9NF\BC@0O*+@[U >H=85:PPY>$XCQXV]S-+F=L.U#D4 )@+_\S\H)5
MN,&V4U> PFMFJ^#/KP]RF._NO>,%,<U.:MIM6QW8BBW;I$+HJ7V@WZ'7Z'.?
M??N%?3,6DA['/]N<I%XX]F48K;%'5':6 )UB\0['.'IJ0@<(P19V8#RCN8@:
M*)=#WB0OTX:H4%"4M;*6^5Q&,D5,=>>\]=WVZ65 N-E&^!$'L?>$9TS'&KX/
MXA!@9U."R!'?"56_1U3=C$37" 3+NQ,"IMUGPSIS8F^5)Z&F^BQ/1&T,8# %
M%J(C06)$.<B+LD3H\WO:'AVA%7LB6]8KDBAC9 >&G?*OXU#,GX&C-Z2\-D**
M>$X;UH I@:K@F@*SG?UT2+D<]ZK0X>_H"Q";&D)$@_F (0$UDDHBZT%/35A*
M:-6)@F8.*S&3;$4A==#%TQ>YM.0UQA]"1#U"F!KEZEB7YD["_-&M'(>YI'15
M?76RNIM!46X\C%PO<*)]5C09[6@%.*(HJ%F[HYD,46IV!#AIH91\E@X[ EM#
MB MAQ<,*Y^S<#8'T"$NH=HLR#) 7QSM<R)3Z:E>.OZ*>7/K8F+2YYQ@L?PQA
M]KMGFK :3=BUJV[$5%AZ:"JBZ1#ZQ\WVR+%K("G(-)ZY=O)R^*U%2B5U$F9
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M 5UF9(.@_Z$#/SF^493KT&8%[QJ$0N^FLAY800#D,(=]:LJ$ 5I1]4Y!SW[
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M%-\ (*KK][[\ZV-V=X]]&\9)*@3ZR0B7 T"@%<-'EUI@'="/C\JO.6M@I"M
M#!I5^ MXIF?9= ]Y%08/=,'Q\0[8,QK=FK9BU$F$G!SDLU1#\Q2S<0-%7Z*%
M6:+)F@,:(TLREA>P'T>H=WG4V7B4H$4I@.K*E]9Q/1!25)4MQ"S]MSDR]DWC
M;>*(8-ZF;:2618M04<3F$?N05H>E7UJZ9QX$(NJV-(]-/9+45(^SDYWKD6_C
M.[S9!3AB ]KV&7;19$-G*] 'H'CRX6*VG-\M_N1LP_@OZ&YZ_>%F>M=P EKW
M $KB ?;WR3"GYYNM;(CJ"+U"+;K[,Q[IK$"<A*N.]<$>6MWA)P]_HK^[)%MF
ML/(<'RT2)VG6;K47:R$M7$ZHA1RO>A35YF#[,HS8KQ<X>J*Y-(QI3"EBK.S\
M,I2!51Y+K$8%5M<%5F,.5FV9 "IH:!0=EF50CTT>&(,5VQX+5NO$C FK-<I
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M&)<8T;L3^WNR4'IUF,&SZY'9[])[IM[HF/1[Z24TW":^QA3.QA $4V#EX1)
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MZ!LFZ+>VG8L=?"]7-7]^>ID$\7U$.SM5E#.OG>&L@6T*H."8[$MT"LG9>+I
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MY(>$OG8VBSIH_,&OWL5X \@ @)9]C>[3S]&6?C\2@'4(M(XLT;3U][XE^8I
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MX2>;RU[$>I&P3[6%/8T3;T-CC3_$>+WSIROZ[M=;77EKR8U T-YP[6L!*0
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MAL#%B7F%*BNVBGM*@B6]_-JY D_9D\;-&+?$:H-;\&OSZ #0EOZQ"JXG&L#
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M,S+A).UQGWX'%*\!X#+PD,:WV6'IATZSD1>LO*V/8[J/UOJR9T$>!BP%O@_
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M)<N72TRWO1O29M3JS=KQO"9VC5RAL '3%F:&CD%;=E3J\4KGJD:,0G>#!QJ
M-HD\49T%ZAMV0^4/L*U@W%A0EVFQ^2NRJE\QL8J";8#:[C8.$F-S\X:( I-K
MYDWYFM"GV[57WZZM;]5=*( W:"%W]!Y'\Y;"=?B4NL&\8& EV=VS28>!%H6J
MRK/H$'F!G"8=@R*5AH!0I\HQTUCPIOJBXKVOA 0ZWK/!813.\3!^<9;G(:OG
M9NL8P*%AX! >R2- FY!N^S]FZ3Y6:2..\6_7]H?%"QC^  NT T>K]0)+S53[
MM?+6IMRIR5U-E3@H0(Q]GY>8;&QJC3^.9R_3%7<91J;#/;V4J5GG\WKGP*$
MN@[NZL3<^;.+% FO6P-68[DZEA14>8\LPXE#*K1;HD(#\G'BK1Q?W7+O.80Y
MR/4C= C%5^_]BS'Y1X8!BI)B[.#UP)"OG"[2+YCI,!C<9;H?P;XN0:8.T&NG
MG.S+M&<1QL<"<@5H= %<EK^J-@#_P,4U@^WZ"3M(,GI0DJ=+PMH00'R\9WDY
M@, G>@FN:6=CICU2/CID3K2X@'( D;@'<V&.(C+ S/_<-NWP(ALI_R7D4DGX
MWS5YW4>\?/U:&V^PS5O0JS$8*9.FLT^GR5Z+[E["YMPM\:X]N8.%NA'VQ;&M
MWK_NB1SJQ:31V$F-Q#[9A-@8-D<U@7%.YB)VZ)MR=SC&T1..?_221R^P\@)(
M0(+IBUV8%"@P-VN /K$6HF= 5@RQ;O'6#:\.!NC=V.:=ENHP_TVF&,^<&+NW
MSI[9MLH;:H_NC09[:Y/9A;WZ_EK\NE"$K&.4]SRJ#;<_-,J0\W[\'>8TS%L_
M=@_#8HIL1LX(*9/8Y3N!/H9MOP=,X"-Q-^=,*.J>/OO!!C/GO1^*Y*$5NH)/
M?^PJ7L&_/Z@T>D5,+LE7N8/JOC+H)(KH.ZATPS%K5"N09-0?*D\7L$A8!T44
MR1'K VW33I!3Z64\1K@Z/.JJ7Y%GO;RAM353KJRLA.9[,F""765=K]FU6?^I
M,GTBQVI31]=5>EY@->MT7 J['P[J;ED]GO8)TZO:24L<;>))X)Z'@<L2OG2L
M(KN6NCZUQE.E#$*VRO*!3'GKEGQOB,%6?C_&:KJ4LY6YP)&G\9X>;FWPJ3-(
M!  XSO>\2S#SBKA3%H6N%4]9*]M+M_:>[Y(X<0@V@X=#& 10]T8O([3)[&\;
M5#H>4Y!6?V"H6 @B[O:,86V/H'MM)NK)1C2K@!X)MQH/?Z.+:Y40'N<*K8LQ
MAS@Y_>#X.X<-6X!ZLJ4O_C#-XY!>%P^J/I4'-'#^'YQH??5:CE0%>SX8RU62
MA2^\$*6K"S I-:PE%W.IZ@]@./,>T.GAQ[[2?%E'EF-M_4O3?RB?55J-3.G!
MYL#0^]SB,\YIQ/B+6X##Y6-:WJ3T;J%$^BB-=DT7V"YP<;1(PM5OZ2ID) RY
MDRH-9M#0&XAD_3TTBSG.]!P;![&!,GV8EG)_,4Y-'5!)[9[*TM V0.M18MF0
M'SA#ZIYQY/LU9DZJTR8;.M@)[3%$%O05/!1B*,W((;)J%3G9)^3?QB]).\BP
ME%6+2TSWJ_IUD=[>8>W&EU5+*&S@<3W,#$6OYFH713A8[7^9^/YY^G/A*Q4
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MQU<4,6\H6VFY/)(_,XH49*/S]E%].I4 ^,!3+:$;WO/11XQ-$ '*\:5Q2U\
MP2^_K_3@AGBYU+(_/%R&$2*H>EL<F4&)^;B#(+N:TJQML_434R?5FJKJS_OM
M]G"3%?EUS?3,K#YP3=,M0S;*^VZ8?H,QL0'FPH'LV%!,B&(L]AJ%P1!WW"2B
M38G.X!G"<^JJ7-?P.+Z@XK]7Y=<]0$Q?;\2SH7]&P!0_6L2J1B"Y' +NN)(/
M O<E%R-[6+669Q5"Z:%(8@UQ3N53:@NI.3^'M]&=M,41R(3"#WNR$^>;0H[]
M%B3K\=7"40RA>TS9WE)U*+^!(_DM_*EDZBI7:S;;ZINX5]_PE(>B?,M. UH+
M0Q0 ]+SPJMF]6G3O_N@?R8W^(42,KG@11*PNO_2P5]?]4UWM'Y^NFF8/V3W7
M&WG W5=]FEQL\I-:73S^AV-HLU_SX<6?V3<&-AJVDOJL0LRP\EE,"8I^ FO3
M*P+QD^W\>-]O%5#U"4PS]0R.'+$$1EQ=@+X@YRIG* W$5Z6!];NJ:W@3PH]3
M5\0;=1.]M2P.M1ZH^/+RCH,IG(E=&=.YG?[":.EV2]?M/MNR^YE=[FTP,WDD
M_PY>(VN::ETHA(UUU8A<<L"C$F'%_:= Z>#?PGLV^"BWR#?$)H0SOCMVQ-/D
MJCR'6&4.FPB5+I1'M#N6OM(6DC2;MBG*BVJ[S6JGB-78W<. 1_VNN_')-_8!
M)GGI->[/^W=<>^0)TNP[J*;.4_#'7 @G8SK^@NFGYK<'6!:#+N1WA@4 7]9C
MTH)RM/,B^6GLG!7W6LT4D/#2X?H= I1-D(_&"0RU"O3;_#S;%2W<!/#JI6R:
M?)(^\5#P%/!.[.I3O<R-@R$6%SE6F?AI3W^FA=-U /,,HC5D;<Q8#$=M!-!F
M7!E0W-+RQ .EG_DUR,T>@"<GXG/4VT=5&=5L)=>AIG\D?W%]%?Q;(N&BJE4&
MABJJA^F!FBX.8Y7-E6CR6(F?LW9?,Q%<2-PGF\U5M>$!+(C[7)^KP7&3D-3W
MWL]%LV;Z=5;2:M^(',R+HMGM6PHZU7G6<M_JY)2&9WU8F:[Z#M*78&2APJ[E
MV)C*2QSUIM@F,"W]P6R9W1UMVRW?UE">_:J4 (3GVZQPQMLY9?NS5;9-]PE1
MYQZB8\17(%NQ>%Z8F'T<B9%WF*/)=[),DA3XL>Q._2^:U5\KI<85I?^I\77H
MCN*OS@[#4:+OPCHXL%%Q%=I(0DTI3F$01EB:<I?U5NR(O=F[$34@P0%R",E:
MDHVO002YF>09(G)Q(/TAJF:B8 PG24)A.#81@L"2@B+,*8,AY0@//C41NUHZ
M4R /!RX0YZ,B8N=@2<S.!Z?\?&Q+KK&K2?51'B*69W 6AZ^FSM2YZ8*=/%<3
MEJ"\1#KE%<&:U"K%:&J=3T486J<*[UH)[[IS2,F!%BQ$+\TA648P#%//D-,3
M:L]]=4:%F2EZ&RI-L:W(@_0_Y\M0,1R4A>1EYP3BU2?*&T)4RQU]]#F&>]G4
M71?V)'L<H8!@R<.@PRD)!\5H%Y;T-?'E,/&\4^\H88/V/:&PQ.(DSBF> #OP
M]'0Q,77NAD,RP>9<CD75Y[AU_44V O_[^P=>:7HGX@=(U@<0X&\P%_D!0;KX
MA:-H5/KRXMG$3&WU^G=<FTTDM4-R'/\]OC[A)LTAH1 O4DOH>K-A<[B%)MM0
ME(IH2VK>F%PN 3K?-GV#\VX:DU\_LU3M27IU>A%,TJ07JCH'LQ2<. ]*.+&Y
M''@2\A#G$E.0'RBR B_ON:@(*,OF3:LFN"VRAV++X^Q!K19F)=A/,NZ.[:NL
M)4\9U RF@,Q8EVS//>Q;=@V1LFK9GFME'#[VP\C#"U.F(;XEOWM$@/^<\I#"
MTU_'EX%$$8R?-KN 8OB1_-J2L;4-A^6&:_2.KH6#FSWK&D\(B.HHP<RYXM#(
MODQBHC.BU3Q(F"&D2%:D?S'UQ;^N-Q=TD^VW[5]I ^?:>04HA'">LS8^1>/^
MB1UP5'I[Z][@WA^=NT&%L5Q\AKR([X"G2GZ(Z^C8)K\)'#'%/)6;N */J0X'
ME^!0?H/*<)#(SX$5&@%W(6+.ATWJHOD'YFYU4.R5WC**R;&GWG/V.5L7@*EX
M77ZE+60UGU' 0^@@TIVG*'0F&^C-$2>9I" :E=<$>.!#:,CQJ*IF%)FFN.*9
MDUI'Z:?6)!4<HN1\A'I$%^8/PA%95VM*\PX%PE2LV.1NZ69?.KTCG=^9O[9Y
M$F]1]FF\3A44Q%WSD?&4T GD6P0[D74HTMT4VG)C$W(^T_GE-TC+EOL/Y*3>
M?9597@=C(YI4V:3C(#W]V\"<RB?W><@EH)]_^#>6.?T8=G]"8O<MY44BBLU!
MYD!:@&ZN2Z\2V*OS_6 JBS0$_H,AHDB2#:E-8A6&4MA/< Y@DR:\32QV$Z+L
M)L$X3>%,^HO'>1]V8.E.F?U[]KS[X\40-QY5/"%*+**)(QYG0X7FUN.)Q)V0
M7OVN1_[O45E0+[,I],\0[)AY"Q(QK9^+DG<ZKYZ?"P'F,SD%PBEMQOBVSM8M
M1RF6'X*,-O4E3(5Q"D=BA>YA)Y;0V8'?!71-B-M1_KE@N Z&V (T6:45Q0<$
MM53-+ H03S;G08=+0;USD. 1@@O'#H?S!A2*0DF)VB>W-G._T"8[/5(BV@WC
MI>3C&?L$G, "MT2GL#"U)7(XR0=]DJ/8<I^85YUL;;BB4LR+2@N;1G= MG%L
M0X@,OBV:?VQJ2F,<.3<#)P[X9-Y#UZ&O!E</M5!C2L9)<O+;2U7DXX6H]\_[
M+4 N7=!-L2YD6J&F'-T!Y^,J_>F*IK4$:-9_#KRI\#VU^W3ULX%/8IZPQS+(
M$/YI.(ZABVHS5]6J5=$546ME>A'(OOAW7Y'&*$.#*/(8.GT2CN=3ZDM5F^0^
M+UJ(Z7C>EQR/];B*SYD8[M^S7=7\$23;#XMZ,D\@V"?1.&:E5X;[*7:UA:_*
M8##CR8HX3P7VQI3_? 9Y%L:Q7,=<,;9<F&-6AI&&,C1![&A=5+FL);JZ^S_D
MAHU)V,Q_Q-6WIS#$LQ)BN8E[A9N),GTEJ569#TK@'75,V%*0LE;FI.<J/1U>
M6^0I>Y'!R*I.5\/MD710VG$AM\@1#/0LGJ/%@KNJ;B42?,';CO>"1M7T5P2O
M.1R\A^1)8\D]0%PJ,[GB629'\1GQD>FQ-QUSQ@#"7E7R-2!]&=+$:C';+6A5
M1/+"NPXF\1/!O*//]866^ZZ^@0B1 Z?V>05)*'M>,D7JU$>MAEI\2"L=(4,-
M>6C NON:JC_!/K>0.^4(%GD7R9&,Q[U3!E4QV.KF$YR[/.!],JYFLA-C+L+B
M$";6(^A83N'*$T!WQ5KKU)W5;E>S6SQG<Y_R^@@:&5_4IW1%-),?XRM@"1@?
MQ[#&LQKF\CF]>D#+IN#U?PZK,ML>FH+-^*9J( )#Q!]>/>^R=<M^*>S_Y[S4
MX%6YVC=L+S,E2**AKZ#Z8-/^THA_^N)<G@X[V/QML<ZV>@%4_B$MWT<6>^05
M.&4!QT$Q2#RG[??BFKFBOJMX$.P>8U5)IAA^KNI!<,&5TX#-E4H^ KD9^H+Y
M_5(- B]P58M86DVI3^,2AF8YGJ$+J\KT8W?E$^+A."Q87R)L>$%(7Z?D2'A!
M',WNY:Z96>A(:F'T2R0"*&FI:R0F)NM89B(=_=QVMFI_JK.RO? $&XAC7@#O
M9"UYA/;HT)E6"NR2L=.)M>F>JFU.ZV:U;Y^JNO@7S67V>!$-X"Q'(%DWA$JH
M+Y ]2P'Z[.(),B2Y1UC8#C>#TAQ3<:J@LI/HB?F<ME%BEX*=7JQ-$H%9.<S*
M[ ,6O<B5. +PP%0N!I?RCFT^'O3-(S/@!_=UP%KR*'@1H<)_Q&3Q>.(6)MMI
M2W_OLI?BY69#X8UX 05K:K \O*X <^%KU8(SX[&$(S B,X4C%-5#OU!>;%05
MI ?:?@/H(N$NZA-<WP@3\%MN]&E%2FR^7W? \MEZ#<-S][1(U7S>;]MBMRT
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MPT7[$(!$B[']/GT\2#=1,^YC1$/:0YL75HAX<_%VUD<4COMI-&V'[\E*7/*
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MV?$O0?.A@K!<2]F1O L;T4XBG!3>#AXPG[U&A/Z+1OBA__ID=4$X*$EZ<)J
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M(P&K7JB>.!<I5FW)3S?B$O\4O\0_+6N)FT$3+N+2P'UQ1\+Z\/>?SF[</"W
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MRLZBT%R5YU594HZ^R<$WY1.I>SI]I2VH;DW;%#+,W_FF5V-K5NFKDO3C$_A
M]];4WZ'L(_!/^1F9?(&B49V,28;43\=YA+!AR(5F_X$HA9=LR[.C-;^CU< #
M\70\G1Q^H'W');E9_:0YS$ 1[$@(V\"6TE.US6G=K/8MNTN+?]'\CJ[W=1?&
M9\V?TOJ1OB/I>^+"-OBILB@1,6Q(=4T!@$0V I  Q%JV>@XW69$KS ]_>LM@
M%+W.)N$#$1BI1TL9);DD=ZE/(METM\_@6&J7"B]<J,% A()*>/LA@H;UX$-R
MK3NH<3C1O;1C@;=]_/''Z;AMK),3L T3KFU,C*D_!"E/YXVX8?SU!0?"WXV0
MP.3L5;,T6#F<?CJVA5Y3<4"4VFN3Z<QB'!Y5K0-VN$$GDX-U3"+:D-4<GB5\
M3_TUV^[%S'C.5I_#)4-9AC$L-G'R$:0D1:*<&@1>3RJZQQ+5DUZ4\<0:8IS*
MIP2ZVOJ0__W\\  PYUQ//'#41;:LA/L<[(!URQ]D_2]O:;-CNDDQ7G/6C")]
M; *#DWX@T@T/)B/M]]H7R*_]_D7"8#H5C_3U<%J^)T.X@'5ZIKE)5$F3JI8*
MJZB2>N5]<A$^ I%#*.A#KM4K#5\,0ZXP3;>1I-K?8?%,2HZD%ZHI8JE9<;*J
M+EU]CT*K[[$D _%QS''8CT_!<51\/;M[U(J(.ZIFN#PG<8@RNPSC^)'4?WG7
MLD<0?/QZ(\!HFJM29%"%7N5=3QYO(?I"%*+,35L.YF&81+NT8EF#&B1S4U.U
M(U0"G BKF^QLV_4C:9F&F4SH621D:0SQ86]</ OUXW,.M#7?\<I[,1?*VC%(
MP@*H@:E$ %4+#:[K:86E1L2E]LO)@D/M8012-.0%W="ZICG[%5_,7ZL6X%H?
M2S#GQT5"JB&X142DG+%12#\,JK1B:36D-HU)* '?PBX#ZKZ_BI%>>EO&$'%L
M(-;E+;Y'T$Z+PQ7H(SQYR8RA9>7^J:[VCT^R3.+EJ]!U.GV[CV*W6\P59I-"
M;WI+6C%@5YZ2RB'?:4\;(YH?J>K&#%;8)7P$5_'!O>2TQK N3F^]%?UFHP99
M-/J-A52W]SZ630F5$Z6T-_<**,3[>&F$?1_51S^<LJEFV$A*>R_IZO+_9DI.
M6[0<MONJ9&?8,\>(7CU4^_86$J^J#5OR8O]^*4IZQ2;O/!Z'3Y!_:D.S+=.-
M33(8G-0P^OMJ\YZ-WSU,V(196_C& GS!1_,I_%HY@OW)8FE^HH <OF6OJ57^
M7)0%J,.RGC /" Z9%F1_GH(S'*$O<6,^&5+OVU@JC0T]C3V)=WK S"BLSA)Z
MYU06W4(8ZB7BD2L*?I&V7!<_YAEQ_=Q-&=RJA4C\\(?IL2$__,%3RP\U.F1$
MC3<XQ$IY4O/LT&+<OY+ :E54-9M>43F?\V,S^EI[+G*#'QL!(/[8$%A!BA,I
MC3&K>YF$EAMT 9 06U"2AU?V30V@F.T! FE:=B. @5GE8DZSW^;R"Q;%:2<_
M\H[ F"TW[U+UH64=MR=B65B/.EX@R?SEG9E1%5PJ,G&#C,!>^LB/Z75XAT/#
M;TQ<' U;W%.)%\]L.Y,]'KON40Q/AS0(+@L=4\&?^,F;$V4[%(9=[/A-!PF&
M:+RD)L20J$JE)YS1#! 0_+H1:]^7=Y4]%E#4T46&P78_O;@H <HU.U*G9]5O
M[+W8XX>*LV[C(FP-<4P(7XI3F+FL=^E]G>54N6]OL@.<QR>+.&IA<,TIOI/C
M+\DM?B1_YKU7X[B>_'S0;PDMU\*U!L2%J%Y'6IX)KD@=5-@EY249,?F;J=,O
M12,@@R8'I*BNBWVB6*F+B3AQ,B6QJ*3)\99N>=6"^^JO[':'7<SSE%1<VM>J
MO2K7VWT.SZ6?V5\8%2(P:IS.Y)*L"L^MY8>@6NZ+_!39<@=I%WP$8*J%_!Q<
MQ<_]!V%9;,?98/A7\:FY:%]!WT=6R5XIH;L$2C8TD*9=-NQ7N;*(?X\:O?Q3
M(DU>^]AON$SO--X9ZOWW$$VZQ]@8#J#/]N>I,A,P%G3P!,([+P8X8424:;:.
M84+J+(&_T$.?>')#ZP9@&K: :<\.,KZ*[FG]7)3\QS-:TDWACJ1A@Y'G/KMG
MIX8#K+=NO'>D[4<D#W)(_!MB%B?LU\ 13$U9X*SE"4D7LGZN#7A;M>%P2ZAE
MS?JY&OO*)*0W^\X) 8;=F DD385.LMJ!IDMS*$G'_7\S X,G#9T.5V/6_")B
MB/OA=/P;-2*/'9 )8);H8CPC]9P%8+%,3V9F0N<Q>]ZL*<UY8)BSJM,MW>Q+
MI^M2#4%@##<F*T0FBX%PT^/C"39$.IE9Z:-ANTQQ>'XP)9#IAGN.+D)%W(HS
M%O)^B7'),039;]YX5@PVVYQK0A4L;J[*WE@P\U[PCX5P$7@G%''R=_TAK;\?
M86E9)%$RM!SM8?8D/,MULU4WL>O-9;9^.M]F3:,9LXZ$W^BEROX!XQ/^ ?A7
M]XE(8 Z,%_H)^&2^RT_&_/3P^A*:CRLB$S'U%>*AT-[<./IX2/I.XDS/:1P[
M$E_J>MTF6<TIY, >%+CJBE^9Y:VPKG4G2?:[/,"!9+?B_;XNV<ZN;YF^5[J-
M5:H9D>TPHP9&4S:6O)6D9 P=Q&_^Q^^9;&=$K_['[PGKZ EA18U@-:DRS8$Q
M7$BC1C1U^_>;#/R28*/*RH-?$*(ID6W)KS^;!TQ"YCLFK_/;2U^2<]T* W16
M974N"D6TE%[7=_N'M?J7A@$$>#)LKS:0.3('AXE_AG3?(55-]"\-0)@@E*+[
MV%(AF8[AF[XLOI-0D,N?^8%6C?)EI=#IJ@U;%Q)>M1'*G<R*).MLN]Y+G_##
ML :]67Q^"87+3-S5*&8E+7D G[VOSJA0-[TP6@VYK\@9E<HVIH5T-&OS@6PE
M*R%? 6Q^]9E=I6'<?-YL 6K#:,H&3ZTD::K:'-.5R@L>!-;/,ESY1L* ._',
M)\)JQ1/#H3O1^ILV*SQ[583@+-:J$%.2!_]% C-\=D,MX-PS42@*3GR$)%NA
M#P\6!=/+? **M^P,-EM9)1Z\.=H "TCIC2+0V P3V(*6?Z8>A,*',:,2CWP>
MRY(\2T);C*'2OILF, A-<,= NOT&(-SF@K8%8=H2'8FWJOA?7"D*V9Q'+#@*
M3B0_]!PD&,><E]1T^IC#2=['/&G5,7UBL <4:-%CVCBH3H<I!%N%-HU;.-D:
M'2H;I' /TR[/:/N-4CTEJ:XV!>3FQN*DB00/CI(FOL%-4?4PY?5!?&:0 L0_
MQ!-_%@FQ=CK.V0_<4TLFY<'\YZS<LS/J/]@#\T?_@UUON02T"G/FQJYV$8>*
M[]Q7(E#_-;)UG:^Q,52% LOC>TW"YA6E5&C6CHKW"\"MB.&!?:_-Y66RQQ]4
MEEH-*TOY]Q5T(*M1W:WQ!L,HKV6EPMAC 7H3 X.:8'M7Y0M[K@S ]H)/<"<V
M8:$&T[ );1#>2T$I]!!OWUYS&)C:U_*5,4-F<%I2M:PQ,U7YOLM;]>3%(45D
MN,AQA63XR4\M#G78KM?UGN8=.)O,=HY/+U9(&YD8J*_VW2>4^W*/T;3+J?0[
M-MXL+J;.6 [ALDTI81V%>!>J;(TE]#F<<%AK9O/TN P;9<A32TQ\!XY]6[SV
M3-?4S(\@!%O/FVF$/ZN+F (;BGAARPIZ/&>C'YWTPUM#M/$\7L<M%8LS[ AF
MIW1DW_V?R^?=MCI0$:( 4&<!GW;?0]9NX'4IC<=R<O^VDQ+3U1T@.K5VH5]_
MD2[+(4Z)!RL>TQQE)\EC7_+Q(!7$GAXN>;WY]#\GQ(H2:+\$LY&=!F,?^$A-
MQ6ZFZ2NU,/!B!>"T#JD..U3"G+;!71=EB @\_#$UW7?(GY-+QCPSZ H[#1VL
M2.[Q&-KZS$JN5EBM6--I8:DX4I1.##-T)\8L9L384"?Q%:'&B,]*AV]P<YO1
MTOMR9.Y"]JBIV+<2D,&:/=ZU'SQ4;H<X$^G3Q!UD&+>(G][DQ]5@V\CK3=\]
MUH2ET7&CM%;+L8.RQ'TTV9=^F OI8B!6^[QH^<HHLRT\+5ESK7;AO@8H(&5K
M<\+#PR!$C4+D,-ISOANIJ[J!&LL\A6;S^3>=8RBEWSA:TRK/>5&Z6[JFQ8OW
M]E?*\0OT(QETY%;%NN^*?L,'2//:C?W\2&@TZ:*?S+*]3-?8T*)5B;V^)&<M
M_JL?1Q4Q;T@WDLIZ'F0\HP6&19%L#3V:RK'D=<QU\&.FV[ C ?X#H/]L1]'(
MJN5#$&EPLL+%QW^@_4@+?DL%20^_K2*YES /V%IO4&(EL7D5-3B!^=H\T];F
MJJXAFAM^="('JA>6&IO(P3L4*CD\Q+H+<^F9OL^)]@T\@,'C^6.Q+9V(YTFC
MK<UWH@)M& :Z]FEGL84^V;/;G0%9C#/NT."0)E!O/P?F<##U2>]8FTRK+YL-
MK7N/M$CF$":"#GYGBM15>==6#:T_@\3H[Y01IOL ]GOH./;$+8LY+$]Z$LC"
M:Z.0:+N-1I2J6^/'B/NF[S+BV,E,;0.KGG=[]B#K*BSYO2ZJN5ZYRD2?P6&\
MG1(']WUDIS,A\%T(P7YLJ_VM:)^NOY5L2UZ5]T^TJ-D*R=9%*X_M52/^Z+'U
M=$,1&(N(]J#^\.&(&D]!.ZT:V031=SR# 8;",YN)R6\_O;"DF;]CO=H&13G?
MC?477 NUAQ['711B0-H$OT!LU%%5 6/BSV95!%QH2-H1]0!/)H;$5Z>RHYA%
M'3@N8+$I:+YJ'.78[:A+T@)E*[#QCJR[44G6! K98RV3V3RQKXTC69PJE.+/
M^^WA8TR24]<..P-C/&/C4K63E!KHY2P.Z.5L04 O9P&@ES%):1T<]JKG+\KI
MXN*RJ@4/-U0VZ*@"Z;&U_P!A]N,EBAL)U_Q7@)=E*^/3?[*-]T,(#%1ONX#5
M;YN\L07<%":N9*@9S7DM)S"#,B5CLJ.A%IW)#GHOMD2:@\2P0\'+FV1NA![T
M0!BQ)P :ZU@/TB\0AC3& W]PTN=V[(5XDDQ*-W7QG'W.H$XIU'TOO]+V2]4T
M9Y2]=6B7:.(N-L%Z$]&=EY2X+GDI*!B"B#%4:@/[*QY01QR59C31!.:DLS]=
MOM)Z7324S8X'7A3U 5 I7#)2S0EO+QQL!P[7@2</!PF& +RDIN/X((-\F([G
MXOJH5+A,8+1% R5GOH<:0P!!RE.]UF3=^,W &A7 YX0(1G%MR/;H()VC^1OL
M]E"9\A67YQUTR?4FE&C 6O.C7[3GI2.QTPWL!)A/.P^=J=:UP!&-P44=/Q9P
M$%&]<*@8&3%]"J&M8$1<.14].=-53,-7,P4O#S-,LWG&3&98\K!I>VZ[37+G
M"T[_CTWPM\,UH$#?:^4QH;A:TP V9TL?:WA/?MYFCQ/P[?NQ2#<8Z4<CO\)X
M6-4)YE&OB_$8_B7?4+IUH$L7O2K9A;=_GA6JV:?0%OTH3N\7NBDE0'/8I!+%
M- QD[=4SN-Z:OK2YR-2;?N_)@8@:"=#MQ5C+*A<VD73/]3>!=8FC*D7>4L"\
MWR5GF<9\K$"XP;P=T00VXM*:D9V^::>+U^?R1P;1<Q+C\,WZ:4]F=M3/UFX?
MKJO'LO@7Q#D+-,SK&JQM:G^*W>DZRH85$?O#3(TI"UX"*.EU+>R3W4DG1D9[
MK<[FA7&V'<G55$^VRVWQ",5ZQ!1_*7,H)@>6U*L2DC>+%PJ']+,S257UEV(F
M? 3N$P [1#<($:-@/M1B*34-GY-8A)T: D]'R +L_!KWE4*,<6Y8=RJ(&DUW
M_S!EI!L1SP0R@WQ#LK-9B *SH^80T$6$M9LJH".+1H*(JS.BP7XQNJD]LJB/
MGH4.<?ML&PN+(]O#HZI7>M//5<VCI< :/ +X\=?6F C#]MVGA0C<]KUIFP+U
MQN?",\3AGNJF0[K";W)"PQZ0UDKDI&"XOO1.="&8!8#$I5KZ'EBY)$LAH8OF
M+_2@V9IHW51E22$O!0XNCI'WI2H?&4'/9[2D3.MSWL-LI(&I3HU%],&(&HVH
MX1 7V'3:C04REWW)#K-5\PI/--92"^7\9/,--:]$M5Q /)DQ;]-39*<LU=OC
M"VT:=@B4=\7KSU79/C5^UQLTAQ.[)*P#$3WPP1L=1!B\]A*K6RNC%)N Q?L.
MXC#IXX$=D#]!$6LX-:E=.P$&-(P#G'HVVN\>JY?_P8;_'Q"Z##^ ZO(C5UN.
M^FB: _F8*3I4"*\[Y1U10[[CIJA^5/+KRL"=7Y);)6J)1#A7PBQ=5$[2 /](
M0V(Y54K2&*!.0[!95+FYX]GD<-2<BO_)0%/U\)X;=B0RQ9,QD/OAG?:20203
MZ7N). 5$HXB'&-/Z$:0\<3[8+;P!JLV^H7X$8=[N?;5YSUJ:L,$H^VD\=?OF
ML!.8VIATPX9[RAKV(G-Z(/3D,$N!$:=S1HX,QZ,W-W.<BV<KW(*;FGL\DQQ.
MGQ,Q/^'[EIW:['5>7KX*V(_'K"C!:^$Z'&5SHK?G3AZ\:DEV HP#T4LH2E$R
MFH\,(_ZZG)T!*Y,&+#=NCZR91-;9=KV7OK>\V.ZA-\WJDOV[(6Q]BO:X>]'+
M"_LVBV!?2NC7GQF]3Q]_'TY*TQKB/VV-61L[QD%7TD!T'8*K VP2?ILA9-<@
MM:<H+ZKM-JN;&UI[=3T;\ED?EZI\8F/(M%%N%-MH\G-@U!MKB3@!\"?BFVGP
M/;E0$"N832Q>9HM\Q:Y:-J%@&4ZM,I'7*A?)+=U5=0M/PCOZZ(,O[/=@WX7(
M/GBU%5Q4&+LD0&_:*"SY&'^AY3[@5JY%(^SGECYACP]Y0-*Q];ARIG_G^VS;
M^:#NVJRE"@B6G6 W&6RBR[(MVL-L3_"\KR3<J$=/-LI3JT;6O*S]V-P3"U>K
M&)Z(\?%3G4ZV6JS.T_G,3IH_=1&1/W6QB/RI"U_^U$5B?;8_N3X7K^V^YA[R
MST4+#[. 7TQUX":6C>RR&%1!)SGV<SM ?8I[46A#Z\/??[F[</'\EY+CF_,M
MR.&F5L^T+M;9.Z7G(_E\M*D/?#@&2:G.A'.FZN^WK3!Q73"-?\VNVE#"=M^)
M!]6H;HLHX. ER#A+(LA/:8<8EDW[\.'#_;=*EFF95BR.=26L+Y&=%Q#M$"3-
M]'_$,2-=)I$>,N[PD\7E$@T#\$41F[X@2C_:HA)I)U-O"'0F_U)NP,B"@<YB
M@1@'7J!8H+-28.+GB#(O[=N&G;<YTQP$2,D%V][@7M'A2V;DY'66OGY\A=\"
M7^#[:PCOXDO6PWN:',$FS_/D:.8G3\,=XV'V1[YM)7P9HXF:^C6*=FVGPJY:
M^RA.H Z&DK2KIA!KJ!:0[BVES2UM=NQ7Q7B]S$A[5\,3B.+N/D"T+Y!?^YVZ
MS)BM:!X-=/^3\CW5NT$O'GA!-QE3HO\J/.%,I<[%C%D;'W+=L'ZB'(3(44@_
M#'?)C!'LTL.BQ1-LG,.3F978F3WRP@YN PEY8EX@LL*.7G%+J[#SZ</'_W3%
M81MN<*KNY1V'76//=>[5)I6\TROM3B]*\<?WHJC93KK\,DNQH\3+Y+OSTWYM
M?%?A8=T[$A*$U]?=5/4SF_)9E=5Y=P1>UW?[A[7ZEW8>LB[7C!,-,&7.G22_
MS(-%NV\3_O'^7H)+2O_^X)J"GMT47)<6^JUU8@X';[3O(M%DSYAQ8I-\3'UP
MVWS'R6>J!V)8@8L(,]#*2VWRP)P?P\#S?3MLX/GQC.TQ.09)J6,HH((BNP\V
MV^H;VU\]LH&K5#C<P="8GVY;-! (/P'V"])-*@J$1SB?;HX1,2XUT6GPP#0F
M3F6(UZXXC[N)077Z^K1<"^.!_N=5XXZH[PJGP.X3NC$O[$C6T L=S<A-D'U'
MAAB0,%SBS_N2_O !8CY"E4U4.^P+9CQC8SO824I]P?!S]JG:YE?/4']2!$*$
M$DAE%U)H?99DR;/3XS'G^1B0-.SC+*;*S"+"/LZ\Q64P&'C9M,4SH%+^TE F
MVDM&1O5<K+\4&S?LDNI"1!^B.A'HA6K(\E!C\#Q(>;(L0&?M7V'@Z"T;+J.3
MB:%T58X!C'7G$>([+9Y8B\]\&I^21DY!1E55B]134:;RJ=@I+_]5R9[_39$7
MF3O#MQ^ I\RH(4BAHA_ .-B-@F\'C";8H29-XU?J&UY7NWW6Q.F(N0$#[X+!
M<V/Y8!?X?(ZF!5T=5USXT7;>#@J[XN]%9S$)+UV)'3&A['R!X !+X">V&-SO
MQ2@HA,=N,/+(1UM6=:^)K'#LJ%D,32UU;=L/UN#D@[,8;+JE5=B-(#-\+OH9
ME+SBM:%O@;5Q5>;P'\@8?\FV<&"+,EBJ?(K*8(;(QG/^D[L^ME);W^3R$V]%
M6G#SQ./)^0^T_Q!Y$)7$J*@PP]8$E1\C@ -#Q,_H> PGXYOC)#^M6## ZG]6
M)H.K4KIOV7'UF1%WN,F*?%A;?'JT7#<ZO()4Z!RD[? O$/@$4=]0Q5T68SP^
M!9.,E]/I.(^Q6OZ:;?>9</*K6+_5CIN=<K;JY];WZ4?5(RS5P#RD,ESQ!V]U
M3&>*9U7,Y3!"I.T@MIJ]'N(#TW7AC\/2Y4"+BDF?0K-'MK$,2U^+)H36E;W2
MAL_ZGMU7797-DX&EP? 2**UE'V":!Z]/RGYOURT7^5((,VG>VR&6^:EU4IE5
M_9FQ21F+@FE#0K#(H B6B=LEXZ00M5@4Z):?M]6W+N]W\O.-*_,\RJ)18RS7
MU.4C-_R,"S,K8?%M"79VD)@G2NMCQ,LBU,UUZ73U]-T[=)E.H68C$#4$86.@
MJ<R1-!IWY"3>I P,<X2H38['PP,]LQ-@2,!+:+JGAA:R<0NA[-L[&=MY07>0
MH>#,%>Y"5^!U*;H2U9>HSHC/A2!AAD0B69'8B-BA./4N/CWV&^;T@T4\7SL$
MNE.%W./@*?FIM]]'42Q+[E4+:)UPZD($*>2K,S5H6^WD[0DIZZ=2_&OY$6YB
MS/O/J&HUOR6HY%B&S7L$3!-'4C>=J$=?/>]J^L1F4[Q0\4;Q(TBM]0[&NP 1
M3LI"B5UD?KJ3/Q'NGJJZA?(8ZGK0\6-']FB7:/@8[WE1D5R.,H;H'3L"L&4V
MA6R['*<S+I%LC\S8/*(V=$R2[*A4-':>T32^Z"OA9&Q>4!);/_T3IE';4]:T
M=3,YI1I_V1S%N^ J.H%DDE[E?^.Z=BM?W*ZE(5MQ[8TU0];+AG.V'_$VNA9G
M9#<BL>[9G!L PA<PN2?1N&T/K%;[SF])XXYEV#R->YHXDFY33R#!M2,"P;5H
M+OWQ&Z3RQ("@O\9G\,&^%F8S%".=TCX76RSZ>8SD\-(J8Z7C(SKIOEOE$D3C
MOHJM4=-U(6U%:E_!&J22"DZ*[+((LB!ME2]1J>)2%JJ *ATA'/^+<7&+-UO6
MZZVEQ@6:[\M)D\O=%6!".HS/>E?![0%&D6T!!>#"")^R"^G[+ 3>TTF+8:@/
MTIT8-U@Z<D8P_GYWE;5D 1I4L$F!?>F[:4WFU1U5M9#A>M692#;.PV4+E!-7
M13]6Y(S*<#?T^@4.HHP=$,6$U+H2M\_^E!4E/Q+=FT#8HZ'*D[P,:/,6?0^,
M)^\Q01LDIG<E;6A=0UCBJSSW_ X U9['=RE/SQOA GB+'>-E)\7UA/01GMS
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MLN#W]RNTWB^[,:'1Z4,3,^]%]26WW:WJUUV2['FQX6"3J"I:+++,H]3E7[\
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MV-W0,Z#WGK#1=QZ]%6?.QO5=!C_K%YM#:$S(NN"8EN!U8E4C^T] ]EZ1>HH
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M1Q9%DB%.P5^]@]Z#Z:+Q#)CH"^BCLFVD*%-P5__H]T"))O7V(N42C#'RF#3
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MV(I9N&S81V^XJ$:R]%'K:4I3Z3CS\(S03>VLB=<M/:P09+GPBN[:H\ISDP]
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M#J"0MQI(KYZU) >JU]EL\>-L=C+W"4\_"?!6_V:,V&J<"ZOW3PK(F0:"SR:
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M$>M]Z=!_<9=I=9#OI#^F?URL66%=M* J^H3N]64HD>L#$I+W!**Z)'BK%[7
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M@"EW=W73<4'"S1G9LDH;N4A7Z??((<DV_*>1J_+1L%*.KJTXK4HYD\T/JWR
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M- 4\Z$./3\\_^S]'WWY*TN2D',-/!RP0OQ7G:OBW9P.PI))@#$\&0^6GHW0
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M?KG'3HYZ],4UF&@;G]+TJYANA;92'A?H2O/F@>T #KII& 32 G\2ZQE<9<*
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M.="-_^'TE\XYZK3.DEY]P63S<<F;@W9S]Z3C]]K''> ^&X)9!<KH+L>5K.[
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M5PJ_Z,,CQV.-[3,.IGX0YZD?A,!+N<+!8""N!P4MI5_F$5I,FUYW"(^>:DC
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MTL(57R:"4$NI.'I!FH>UH)G-[#W1?!<+7O%U J[[@%VR@>)*EZ9'%3)!,J/
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MNVBZ@8E$2PFU X6/F84HJ[?:5#H*=*T9!O[0.Z#]_S/BOU0S AC)<_P:@]]
M!B\="B(M50X"XP1S-DX&&=H>IZD3GC"'X$YYJM]"BF,&H)=<4"=,A>#@35I1
MK4+=3KQJ&3N@84B7V_(E9:#,IR.\L.G&U=9)][Z><U^@2P1<WO3_.>L&5@)]
M.@)(6ER/)C%CPQF:O X.8@*.'.WF50+3#(=4HNP.37%FI;#K8%]$&DG!-['Q
M5X1XL;,>7;E%66EN1G0V>4X/E!M5XV9&)U#I>M=ULJK*PPJ#4Z5H<Y3TUK5Y
M!K''.4<.NNE!F Q%Y[X/#8FRZ^:]GOE]WK2@"C!(1:A[%:'NG]9:QFCF/,5K
MP3Q%5!6:3M/G'I5:(2YM+(TIJNRNGETD[?D5V2F;;,/C'N,!#BHH3.1\PL+&
MSO0GJ0XSST^S*C0-D&2C +=I@CG-(QQ<7Z;4?L)YX]GGW%03L[.NB9E7$W.P
MKHE9:3JGYE#&BB*HJ A\38Z<&J^V@ACJ2:'#))BZ4&<&]VH$(M#INVX9]U3I
M*=XT7MJI26RY,\*-F8]RF#.,3]@\O!  GZ:=LZ;"[]P)U9]ZM:X</^36^W'S
M5!2Q:"XLB()CG-0*0%M\\)Q?MIV? B)&<7V5<(*N0@V62G2=9(6:&,E3D )D
MDC68/>"FS5Y%<7\+DB $(0DQ$YHAB#967ER*!91E,"A-.FU0@A,X1L S)TO/
MI04-Z&W5/L:FB*PQ.KN)W\;67!"? =^0>Z*0%Q1(5(^/1Q"+=1VN@RYG 8@S
ME0^R:,()AUIP'I&:8I!\X=1M_G6FF$A6A>PVF:'&L3A\+RY&T8;.[*_0] 59
MR<D)A.=E;WFH0BICC9$ ]:$1O(.XYE\2"NSU"E,CI^)<76/$G,DL"-.)R1 E
M4X],OQ@3$3%O>'7X"EJK:6[S^+?/:3(@KD\TM]XT)DD[<W#,<1H5\XU>MWF+
MFGP)&R\1>#?"5(%[<H*[6A5N:Y?R8J9(0VHA>4BZZ40U]2;:S>)9E ZQB>P(
M*GDNMST-X209'$=C%>*/@\O;E1!26[U6O<78G$'NKH%IIO(0?>^6S^J.@(6!
M26,"\XQQ1*C.D"+[<N.<5'U7]D1#O>#4:#U0?LK-'#DNPQ1SNCN-W%;JANIX
M:IOX:G"-]C%6MOA&ME2+&"IL23$!IY+?LYO*\[^M7XS^OI2Y,^BDG?[=@&0)
M^Q7C.',- U$I=M+%/@W]A13;]RK^%6DU NYL"3F2[&_B_ENU0*TQGBA8E UM
MN)$^!KA9LMCDN3ND8O6?'FKN5T';>10/T03OUPR7S(R,;'PE!Q=%YXTM].@3
ME6O=Q";"B7>P7NOW,HMRA *DTTC+(J<HU$AY>%U+0 O)&>_C+!"W&=55*BR@
MC%9A^ M#*FAZAN9#AO+3G./8(/DT+] OMU,#N7S:JP(V?>!6#XSFZ.7EO#HK
M2686IQ#<4)(O&G38Z%3<$F(H^%3/0J6:7C$>'&[WJ%XMP,'#[A4V1=TB.HTN
M1X5FY$Q@)46P5XP.MCQQ@?V(P4,P+:5+XBKOJ(\ 5^L=I@G!5W,\+DHPE*6!
M.[0-08=,ED5E,SAT.*5INI<)Q;\J R1\/4"B3[$:"H: YDARD&644*]OCB>#
MU5C26BPG6&YQC2MV6Z'<W(29HJ6YO:4-TXKDYSUB".?/I 4RF>6<*8J46@GB
MR9UJ$G^L0.&%&MZ!2JB;]KT.CX1"#,4HJ1_L.!P&5RE&#&4VA'XO0W]90/!T
M2, >!^QSI;Y6@T9FZU1>H3]152CA\D+LOTD046LY>0.91$C+A%!I)'M)S613
M.E4S#IG'+% &T@NPT0GU<DXFB3/=H@FGEO5/AE&R&QHJ,3/I7T6R'J>.F50/
M7$5*CK2P*!=/SVE& IPM5M5=$LFLM>E88B*IGZIX'FI%ZZI+#; A[CNC?C@$
M3]CCT4"9V5Z\:1P61QF7B6P'L:2%JIR"6PMSAX.PL#HR=X$ >0*LOD*&]-@X
M_$\@3W.<.>99@4QB$>.:AZXQZH+9$>OPRQ'L.M ]AO,+QV,B+FF9#<-Z 8;?
MJ9B4DR!'KJQ9(?BN,8D'%5;J!!RY:)RU6OS5E1N&01ITA8@P*^BJ8FG [= 1
M^?[F'5N5<Z.V$/%O]9/D>&N@1:A>\"9QFI>2>W7%MC>&#<$=(M%)6HHL@$%
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M972,92\Q.J.\W5%G/"N-C57VRLQ$2<<^<)LZ'9N)BA+0AN47UU:.9Q-\$;=
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MU^6"[LM9#>;\$6VC47FD;+DM#Q)$A$O@HMPJ_Y6@!BMX"(#EF&Y^<W1YG?%
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M)O&IYINGIM>A+)YLRS&C2&<1N9-RGNY O_*\I93:%!BR&RFW,:B#+NC)9(-
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M$+,OA!!G7.]EE#@53,QFXA$S 5[CR>HD$,82EUQ;9)?5$C<>(APUOA@#G?F
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M\*[(^OLK?OMW%;_+*W[//NN*WS.E/7Q]AHZRXOS3%O<.;D+]@PNQPT+$,V?
M3EIX-;>7GFS" Z237HYH@=4#ZT7=3%"1%'YVKGNRDT<83/E*JMK6[%F[C3EK
MQ)G2L]XYCL+[S(P*Z/?PB9G,9T**U;IJ+M#S8-+2WG.G2Q(=A'<3(JY@I4!<
MPBK>:H]-,HPJ&*@YIR&/ 7"?VB/H6?FF99>,L(W[YRL:W .J^^[M!;>0&NGJ
MGMVQALJZG?N?.2V'<V+*."VX':GL.>$>8L8DBADISO! <A]5F$@#<8*+Y8BV
MUR>X1FU ?BG017W2;<+?),J2MG2#[$QH8NJ"EQ1'II(K(G8BL$]BXA,^ ^[V
M][4VSLV%.(EQE5)3QD!16;_"5Q,7^)SRAO2@PG!#5 =*YC;C)_*9)E*7'>6:
MI$I%GZ_6I[DI4]UK6JE=I>&W]VWU*M,(:[ZAEY#RE:2O9N 6OZ5["Y9Q<@51
MA)RO")H@7:7G3;*M$(!BUG0EC9H.J)# M;1TLI8FT7 CQ"N(O31/,UY#25A#
MZ7 -Z3(F4$F@+P\R/KGS@UV XQY=03_'*"M(.8[6FC2CFUIJ&(V)G:-[_):N
MD"$=CXQ.V\R43(0K RZ>[8$&X1"5SE/GQ^Y!J(C2$ MC%:A:X7'2P1*Z8-49
MKFK1*9ID:"-OZ1CS">?.G:=9>.V.Z5+\-J153[D#&F*0W+'3T5#V#RVIJG+U
MEL'SE,SB=A*/&@I^7]D<[*>O^)#)V_08OLF<[7\,U'JII)M&,#9/5]COF/X2
MI3ZHQOACB4-7WK?4S)^CVD^3*A7F#/H(U!M*6Y')[<Y@Q['EW6]F]@F8] 6T
MXYS0]5U-Z2.WP/QMC7>5H%98J,*8&^T-CR8ZG8#!(DE F L>!?^&>#6@I<28
M4.L1RL71> S>,^8$WKUV)_Y:J::?:];0YQ'CVA_!<SG?Y&;)C1Z-R!M>I=V7
M]LI7Q&I-IW)+0E& EA@X!&EP4"MHP@UM5/ <E=3*@7,N5Y;$'+26^8(V2P^2
M-'4C1UG:_*38,=X9^Y;SO"9J"3XB!12!I>O[[:G#T"8*J?;@_,Q*)#\8=M0-
M6^2)$M+0($3>9Y34Y'B*NN@8Q:@?8Z"?*<]:O.3EA3_K(;@9/*Q^.RW<9+9#
MGY49,G[84'FX;^K@!+S94,^Y&Q*WIG/GL+LQ.55WPX812_8UY64\-93;U V5
M67Q6/!!X!==CJ:T[@0/-3!-[R&$>D^#D>B(%M.WD'K(G\R74NJK4I->>F+9,
MZQ$1:2P]Y'@]^KLFL\*VQ5FJ.ZY_X;KF158YGQ06B ;FO]P](?$[5)4SHJ1L
MX"*MYBSOY/,FLN!A&JUM'R?=T@/^;9,R$D(=*&=""!R]2/]:?@>%]/*L^>O7
MY7?*3D/)?MEP$Q4=*A3ZEN:\+I%A=N=C45F<YQ08[NI[*NRG)-IG% [)"KFE
MT_5FHH:&=D<B(50GR_JGH5HH(6/>E303K1Z5!IFVFVZYOH56+#?5LJQ2.GB%
M$&F>SIT=1AW*UZF;EGTEH9&F]D 7S(8^0:[\T2-53;/8X<F;Y:WS&=M,;-,*
M/7/4NQB5A96G@_*D^%;3LS:K1D6Z=)V1I+6+J\7+.7&OAD5T2]?)VT;[Z16%
MN19Q.-1&%MRB0%NX7!< Q/%AB*KO^'@WATR4?0HX*<T]XHJT7Q]_"W1>7_KM
M"Q"I\<]^UJ-:PPA/B$)8!49&T_>=^TT)R8[\"?C7>$@??E$CIV)_LK2[J)&O
M*26M=9KCK'*C]IN<"1@+>4 3(")WH,\I#K:[24+7+CG_&=P$3B1!F8=3J9XC
MP9Z39>M.'71GE!WY3')BNK<%=H:QV^$!O.."_*_GHZ$&8QD5- TSP/1G6U1-
M[XEW=WSXLWAS]U.)P?P0K9JRX+Y_G+TG&V@:F5A.LX6=+!0,)+EY])Y1>P5-
MS6#<1#2)[#G8C]R97*XXFSG8_MQ5['R$68/$Z'!R&$O; ?.QX)E7JIW.KRF[
MAF3"$GO&2&Z57'Z"VQ6B-*FQ/B\>8]SLS ZR3 -#>$LMQ>N)9(:A0?03&P@[
M*'DR2*?NIK\0*-FM0UYFVRH9"A1-Q?[:V1$HNF^6L$4)FC>?IB'1 L9[>VR*
M (O(2U3,?L[KCL\:QM"PMR>//TKO?-:-V0_V[C #6S$#C^XP X.E=P5+8C[-
M9>FKW62\H./9KHJEN_M/T98ESU2!7GZ_$0V<'MJ_24RJ)V<OW4)R:BZF@;02
M* ,ZZ!R>HA8<8JX')OS#TD,E&>';!8T(99/WZ26?O#!G^RZ-!5]?[PKX%5@Z
MY*')0>GDYNP!&&^7+C0O%H66;MQ3K''BLF8(2#VX=)#X !Z637QU3ID8)#Q)
M%_(EQ$#[H-^=K-JJ->R"6C3G<*<+YVX%SK7@L;\C&\RT@^Y5A#J]PKGHKDVQ
MP8I;3Z+HH R437CV]_AYPL!G8(XX*&!V-FLSL9>5,T3DE8X$F_^8;$?[V/;\
MNH[GK4QG'PKD3"X!<@;2?F)FA<\M66WBBE\KS=\HSR@QHG&/KJW'Z+H&V-,T
MO>7-]-,HS#F2[74=N>*;]/3H35VTNZ7NB>CW.E[QQG=&E%*,&WM8HPW]L>+0
M&OWF0:]K?UKX;.6@N37.I4YFOJ_2W3G9';(2*68#+%!#C.;++WMR#"I$U6D4
MZL$MX$R4GEPYP0Y2YX:)K2]K&N,B(*<Q_95< ,[J,P5+9UWS$!Q\L_OXIL?[
MC7U9JH'R\%3<0TKMM21ID>BRRU*@&I=>7[F'$'RK953BR4;(US&G+S'Y3AW)
M409=$@',><U?VS*AB5GJFNFC&)R/K!^+<W3@+DIJ\0J$G+Z3:OJJ"@!00@T(
M]C4U=^P%-;O0<4PKCW@P+U9KY\]WD[U=T2NNX0+56*Q0.5LU('+6;W_A>Q93
M04L'6)ALNZE+3-Z&X3=+-[3H[Q!CFF]Z$<8>=-51P7NUSJF#01>B9'UT!MIB
M6:FA5A\1-Z\:1LMI8)_PJLDYD1D &[T+$CMO)@9(*>[Z7Y?,;]RZ>.)EK^^\
M+A?5171+G7<1UX8 .;7G+.&AXJ_BWN\F?)4.9"+.&TWO,;W(*5RH8G&?]]?%
MV@<S!)^D)X/W>E8N-JB::3'MT1Y]X?&>IDHJ]YPR.:.ASRFB8HAWLYJ)OE42
M6=)NE9DYL1KD7.&ED[%CF:5-30 _SU;MSR3*T=.S=QN2#* ^WUQA&3-G7*JO
M9U6^6%#>CCJD&;OF9WR65_IY>._SAE&/3(N/)UD3E([XI:G.X(8+'/PFLG'S
M=NI^BVXS[=4OE0S7,%K$IWHR8H>0!.D)"31R%YQA@O"259.]H5R9X-7%JQ*%
M3_6T>)E)JYM1!"+F%-7:_4F#(P_NH'O^0-1!&=M$F11WY+F1>+27(>5F5XLJ
M-[KKX15 N-O'=7]@AH5[X,@CSTY=&)UTTKC=VXTGPRD%>S*-*K;$R!A)_X?,
M((M'L":46%7/5:ELICAU_$;RFXO#45&?8 G+^76<S#=K0)\59"/0#NE&1]8F
M3 %!IZ.MFR4^QVGQ?[7@_TX%_T>T NF<^YPDT?^L;*C9DI.H=DBW(QW3>[.R
M>?7+\??W%?%!G>@NZ$XB.\M;QVVWD@P43;YG N&' 0M0>&1J\O0(<]'N3/^9
M(Y7A;$QOH5ZOA,'C.4.PS +FU$?"&,E6"#HAJ $N4O>%*D=NQ4W(JZ,,28BE
M>U;@&I8<PY%SCDWYQM-8O?3)F:;=];!*.ZRE%#:A\]KVR ,1R"!,$OR"J86+
M0%F+K3)2+AA>*YNO'2N/U3@K.<2.F )YF3AC?%+08M%ASU)G5V>5XF/X9F+4
M9V'R@>GVX(A0FC?9HJ(^$145I<#QA9D"Y%[YG&*:0>"4#:#;#$Z)EN^V<?$+
MAR64R[9MJ%>1>L2+6C@S $D;IA>8XF#G8&]_"Z&'&U;%*?0ZOLFIE4IK<4C3
MTQ+F9=V[=_U-!S$4M4:W'@%I[T&X@4C%[U]WJ'#-]9ZO;BB+,1I3(J4:\U$E
MY&I1NY-O(1@LOPAHX%PHL-U/!>V12[ E>M]*395<@9IJDE4JY (&G%+X+_L.
M1"1'.#5J.:!:"1%.J/<3(?<3RRB5;F>4^M">B.O,)$RB'J]2O-J_*UYM+5X]
MOBM>W1BX=INR%*$-BM.BINC/HHGD:""Q(-5Q8E-B1%*I1$4^KP834\TKA.(^
M:0 \LB1M K4L/$*$+-BJ@3\9P',V[9&8[%C(/9*W]K(FI+C%1:@-AM$2_I(K
M<^8MAK'T7\OONLT,,G?.2B5UZ<;&@ZP6!8..N/>,J3WQZ(BU*JXFT=-VY3 X
MY[A+X@Y^=N=-_:_)[RE[B3T&DF%DJ V2%/C/G(\)+T]?<FH O+Z(4+EK_#-Q
MD,#)8S;[OI-3I*GCQRG>Y5YOFCADAY<5?D&D0I!&TIB;!F4P#%\.<GUZ<_UD
M-E.7+XN>L$/.%L_#<=HW[TK^,5$''?X:+UN!E"B:FSD$E;>5I#2()'GCQK_5
MJN9@%^8+-QTEH0EIA4,>F#,Z"$R4A8_=2>\@)\*%^*5/P+^0XYBC,Y'E$SPI
MGOC;^V&<9/"Y64J&/P QO5 TIQLHM.V=+T<0G(Q0GY4%?E4"S<WGIZC5*$:7
M-":9S=#%%9(LD$$G@(!\H*R3$828;-S1ACRL%_^;R$*HR@ 3NN4E+V,*M.]I
M??\AAV8R9)8<\V<J423^/4$6*2U\2'+."]+UR[<1<OIJ.BXY:D5(9!1N%BAV
MK=T][DP9.[F2M[JN@B7=NO3O5=Y0N+35F4>9:VO_@<^NG[ @EF8<,LU,YU'R
M&HDW*K(MTU#RX2)/D*WT27408O(II+)_BZ"J2%EV++GHW$_#N<^13Q38*%"'
M_L)0RD)@M>[]",9)PHBM,\)KG)-Q8&3:^3SE$78!^^])]*B[Z??OI*O>\R=G
M/@+2R[? Q3!F-R,,BEIZ28"ZL9PCD"J+99;.-KW*/T\WB(=(,!DT]W[I!X78
M531\"B?C_AYW?E)0O[VV'<JX(9AWRZX]P;&@YM69N'E;S@I1;;N?!<RTQ?>+
M9\0.<SWTC]BO,\4#=TA0 P ?$<[_U9P>ZL^C$ZQ8!,_+@\ (1D2LBD7M/07.
MHB^I8=0Y)S6+;2\@B]9<H 7+/+*P;UVV34R:(/.X)3U.E8&4:DM(PH?L L>L
M[(.C'\S34;\*,+GTO'&.[X(G#QD%90F)WION) /".8[%)"("GMC8/:9>CY@,
MQ&2BA^BQ+WXG:.?S_OZHYT%!B8)@(Z )&0>2_A:S2PV*$RT P:E5IOR)A \W
MHTU@1$85P,'\)1/L[=QM@(*U]WTBGHZ(H3O@ B^M]U-$(SZVEB)_.3Y*_W2P
M]QC%*O:6@A^#>?C?;HWN\(9_Y:Q[7E3IWW?3%\T[]_\(SR:$N?8??ZMD]CF)
M:%2<\U=%;:"VD$"$<MA6_^';Y+DPM/#POVF+G><Z$L<2:[BA_[XF3_2'S0IN
MFW[@+;F)NW+1:R*9>[+[9 PD>;K[S:.;+F(Q'^^3+#UJ6'3R15G_ZJPJ$JQ9
M^MRMRII)'U'W*?(3< ^MM965\^]#TS;*/ 1,Z61&@4UF"IM)S80(TW:,S')>
MUZ"X=QX&M\Z2XS^P<X7M6S$;S$244IP<!?<<$"@]N"WN;MT-"9\\-A&3<S^Z
MNZR[/_WY<G#)O<-'#][>Q^W8\UE!? 4-$SO%N[7R@9Y.Y:0Y^8VL3X)KT#<S
MS1S$A5QY]>(=Y=7C$XQ;/21W8R1-,36[9DJL@$(>'8%THI -(F1#UU1@3Y_(
M,Q'OP;PDY7,B,:WRCBAZ9H6SLB5*=M_7++OJ?BO-WEV@;$>^97": =S43N1T
MLF2<Q2(02(E9S>O"Q9IX\S@5(RVP.2FSOZ4\TQJMV6C.&NH&XL]Q+\Q@P7?,
M6NWU(,8+#@\T8@'B4UCPZWX)3N0"ATO)JP^B[SJWN]/Y28=SMV'8@I('2]'I
M=3%G?DY&[44Q:S<H?3*1,[92? 8EY@S*SYD4S1?I<VU+HU,M\ZM %\&;D,QR
MV_W[J!HKJX%,V0_%JEQ;[-I/37U*Q\T;X"/[(GE%I@*QSA&JIJ^YCJE^;OKF
M:'@PZ72+)64_%/>ET_CATT<XC7D5GS1L 7T%531]0E*;<JKV71+-:X<7P;,M
M"N *RUKKJU1N1::[Z:*T'?%!,_GO=M,W2,B,T0:JWT"\,CU\LH-K8WO]!&OV
M.@JU-U?\]9"30 O8U!'SA@NJS\@X-[79#.-(4KRUOWSI@8.S-D?%G.7>L%09
M UW7;F/.Y=A*UKZ5AD1PX,9(?WY0!+>&8_ON6;/A$!^###Y/!'.=4 Z1=^"D
M<($,.L1I1?Z,MQ<?>PV"X&Q\Z'TO\#3_E'#/U3#M<*;UF.K\K[3.SV B]Y#4
MS7^X7*)MBPE*7H(D#[M[9!Y?Y?/\/\[%%".7#=YO!#^B<.-*\"--@;VHFK8P
M1%*)HHHZ(9U" 4 9JF14S$*?\D40O0N"( *ATT2"=[,@PD=Z"%A-X;)IG)\-
MO#S&25%Y3)8_KQK26T:JW#G=5<I'AJ>248_69V"VNS/TWHH-MQ4GOKUDPTGK
MI.3.(/(+*560;%V$@Y0+>VLFB=--%\"\P\BL(3,+E\ O:)'YDH&"*D7*8)F?
M-5PYB%:,Z-*XI3D3MT\.1H$8J3_LWY<>#!'$J#SGO6&I1;B5 9['O*<NPCIW
M,[0^O>AB=33.B&@O,F&9.].-C Q"7<A+*^)7'%,D+4].I"O:?*4MI-V>4,U(
M"17""*04JR#?H)JCS+=S[<YSE@)GVW*N)>9H[QP7Z]Z;J8=J+5YB?]0*475V
M@;(<TR[GD4&AO-)DQ9%'^=][=021MK<P'G^Y1MN17L%V3(!5/H'#<!6<S,$=
M3F8K3N;)'4[FTWLWD=T0]:QUX5:8EN63?^.XQ,GVU_([.DTMBTA&V?!!THA[
M^&P21TXUF*YZD/*CDQ2G6']I<L77)NZ].;KOGF27$AATA!,UL]3/AL&<W/AG
M<.ZZH4*VD.WJ#Q?.(5J5.=__%8%S7HWN[HYZ'X)+2SA!F]$'$3EVC58VF(]"
MVXD6Q1)Q/Z>>D 4BZR=O:\]C%PSN^F?*Z'LUMU-K;K\#EDFZX/LF:1;H\")J
M'$$?JW:R>Y11/Q.]U)'OS$#O.I?!I)4EC;N?D +NW$'9JJA'QEUDK8@!$:W@
M._)5JXODZ=Z?<7UZBAW&0,^UYQZO%4) [K:93B3FOH+9K1@A1 ]XX;YR@O1Y
M.5> )*9R09B%&@TU\L==%VY;#+CR"C*.I)O,+$X]1S^0N:2B:\\2HGG9:AV+
M;RR9.2UQNO6=#%V//+A&U"5$K2;LA!A@EL\P#.!9PTQJ9AJ@V(D*KM54(*8>
M%NU+A=%P04*!.5M2O(1D$UP4B7%K,%.+BSM>[7[Y4&(P1GHD;B7<GC!_JSE]
M/>\;,:;[&:W\O[/YO#QB"P848ZNY48J 8H;H3EBDM25"DS:C2---TTF.XB9Z
MN^"&BJZ4FDJW_2<,9?)S0;0Z'?3 &[1ON*\=7701G@T..)+3VXSFT*,4"[J+
M!-EPI0#\)T;+-!TP7FE;_[#" 2X'4A.RZ))06_L;.#XBSV,X8$DT8-!2. $]
M"=H)Q:[;9KQ%&":&2:W090<^^4T[\_$:QU-AS[AU5B[!$M9[,&1>FTX6%@%(
MR JY.'BAU%MZ+/QGP[1([@.5N] 75*D-8*$7;OP7;>$L:&@BZ?-W)1<IOBRV
MWZV6X7#=EA4%9XB1.!L3IT 2"=K^U;251Z91150#M[%_\ZSDN)6R(;Z<W!'K
M;124_5*7SK^F$&OGK2?MI:LC]'HK[=/I>"X2G@N_B\-QKJEF 1Y((VI4EI/V
M)7(U"(E ++$@XVFU4W310GMDS,^P]4D\Q__6MN:X&99<B'1^6E;N<JC%R&_R
M!:RL?2'R$<Q;H0588F=ZWOEI0>A4R>4,R32A),$?Y!V*DC__[$OGLV;A8GDW
MGV1FX:/DM5Y;E%!'2N^XZD"<@B^K!.WAPF_-Z0'QZI*X7X?'NK#+E(6TF':D
M!"G>BG\.Q7VIGT#9%5N VAXK(%1X!?[@"I:Q8\;92<\\8ZB;Y$]);#U02OLB
MG&WPY]$2H'#9F)-!5^B78RR""=Q*D*L6D!_@^A[C1ADNGKT](-,W23O,JN[#
M\?#R%YP(BQO-RFX*K.PANJ8]['U<M=)6G?I'E)"%N+.!E$H\0)K\;0%<4\<J
M8Y)S*7UA92M,F7[C9G1!,,154?2,%2(>E0ND -=P.WPB6]L7N4B]*+YTR:7M
MTN^LAC0NK"!8F>TXWPM1;WV2Y.[\XXPD5@?-CIN3T#_LW%4D]W.<JNX17NT>
M[6;IX>YK--0WSM*?Y2KN) 1V4XSPXTTXZ,@3_=U?4)-@T"T]($!;\GA9J#,K
MQ)S<<V?\G/5LRY/3OE,L;CZ_J-+3BT6;_P:S+X*\FAKQ*D>D*RPZPPADB5S%
M?<'Y"S/W@<QB^$A:C#IKW,ES#C_B'+A8?4Q#[JO9 I;J+7\KF'>Y]PB(X6UI
MB6/<J>=WZ^Y\24]P"LYP,Q9E %LPZS05L=KF(J_Z4CD^G+.;5T47#DND7/KK
M !]^TNHPV?O >GZYP;\UIG[@6E%R(?1 8#MN'Q*P%9JNWHS7(2Q[E,_QC?#B
MFOS\^.L#VW9'O!P3Z@T,DSM(\R2VUTHYK*L^YE(87XDY<;OR'0I2_6E'[QWD
M=/B?V*+$D_#RIR.51?# (6VL2>SIT)"H-VUHBHKQ-+,"]B%Z>W<O=&.)1(/M
MY/$--NXM'RD0_#$R2=#N1<V:KJEGF;;2.'<O"5TW#+'G:E;+^2/J_<H\QL0%
MVI3#I:R6_&YQ4>=,5!/1)>!^.N[4[],6@CWU^&GTR@"A3?K%BX2>D"FH"/OG
M@3,_--7"(,]#XUG0VJ!K*H\4I?<:;L'@8X2JLLVF HX])>$ZXAPF"R4HEMMH
M@9",F1!_"2NRN[[@>]I6\'/9#IYKDR>%Q^VV+P27W.K\&=2L/3R$V_C*5P*V
M[)G#.I]+E\[8F]BQ[D1"!_4O=?F/C3.3F;8]J$O1\797 5*WW]Z.],+<-PL0
MS#J3<>^7?]S/O%\6P=AC5Z4+N7(X*@DY*NXWS?J46,V# @V<_68U0Z1> WKG
M//]9R8!YF6^A2BW:V>8$M.=#Q\Z,"HX;2LYZ'VZ+*^4&QO<N*79@1ZHW<+,X
M14-$++E?@Y*&D-LN[%LP%YB[UHB:@^Q7D+N)!T*2J)[QCRR;N6'H3W#&65$,
MU'Y&'0"LNX8P2T>K]X]./%X^$4!B9Y7O^0(H9D?J8Y(.2-P:5]VWF%&8@#SN
MY;#VLPA_0^_&9KDME.K=[U@S@Q31,60B3.5(<<3V .=Q=8)*3L7:7?#SL/-7
M@14\N(,5;(45?','*[AQ.;\8QDQ6'&U**D#DY?ZN3;KO9GT'O)O0XJ9O1'/G
M,XC;IO;9A][M?3NR7$'YN/_;5U^E73O_VU?.CIX4_V=O;W_WW^N3K_1)G)O0
MG[JM\F1__>[;]+3 F>ELWN-'ZW=??7W]R51*+=^T+W?#J;._;RHT0.P_'2*2
M@X8Y=Q#F U"^)YA34CKF\+!AFX1R%OWOSLU3XK2\2)E:M% *7Q\X4@TEBQD%
MO6!IEK@0OMU0#/;-'M=>S)6T1YSU#^#_.-^SHA;M=%TTP*3?H_#Z\2-&I+ R
M$KW K\4%M4/0XS),)WZW3&)A+E QVRQQX!-!:>D;Q4PI);TW'(O[MMF3^HAQ
M%\DR^YX>4DJC^#*F*/F"BA);-,C<P)CI4GB*#$$W9QAK0J_.4E*V.05M^BYP
M8-+O)<L=+(3_E(?+<X2$BS&P.K,,&W*_,,IQ V[.*?VDRU&WQQ7.Q)^OW2NE
M3P[24W?OCE(/!&+1:0OWW/H"YN7] Y%=2Q?Y!;@):-&9UKPLB7O/.TFX"*V)
MNX!;VP(A-T.0*6*Y%_(J9NOUKX2S=;Q/:WX*KD1\XQQTJ;F>-PG=HNO#RT8W
MF[N'F[6-$"DOJTVYD$Z=JO(BJ^X5\@7Q6_:21.:6(2G$K(%G$]2^Y+;=KBI,
MGW3)]/"!3T+Q4U2")>&S;_8>?1LVMQ]B#2GP!N'!:12^X7>6]/>MV&&A4VJ:
M_":1C@(0PKHPJ'CG[!?EJ83=@\IB@8='0>EL;2E2#,,>V7$#T+05KVT9Q>1P
MP3$9H>8@/ZD%8OMM\R3TW)3+FS6"&D.%!YE-@\"A+5ZPJE >W8&P9H/?4?.-
M5!1(QX[[^2UK-(\GAN56+(^8R94+\J9!B/;8X:J KK([>N?.Y*XN8FK=PQJ,
M!R[NY@H[U<S8C9CHASDG-1_)K&+X9SC.,&-:RX&S)=9RG[KO<;MDV.4_Z !X
MR52@S/H[ZB@^#/P'U MPZ-?N:UJ[_/,_@S6&GS>")9C,@W]Y?)!,O\4\[S^E
MRJ,91L7F\"O^A=_Q!4E8HC6!VG7T5=.KOJJA<CB>>E7FW&.C34[=Q^O<2-&Y
MX:]P'QF0GZBM_$5KFJ+YG<,P^.RYK\:-:<;8G9Q<(=LFA) A\HB)?T2:F1M(
MODAL].\-]#(N/@?(:$BZ(O$.='D34859%%C$*29Y4D!Y&HS_IAOV]8[*VZ^.
M#S,/,; 7PS[7:K6;KK_G-;JK$[8*$PQILOU#1I((&&"4@R(D]4[U/G_,+3Z5
M$%D1?OPLK_QSQD\O2V9(D4;/3GC'92F ,=($84/BSS]<4Z7I(K;.&C$Q8<WD
MXW9P#^>]I7SH\W?I'("KGK,9>MM%$H(IT1Q.7ZH1/7B4V8-4AW0++9SPO?QR
M3)/-W(2FD,60$6?G>8.:BQR%BX"%F3S%A136\SEB'+AI&"R<K(NR5]7@.*7.
MH"TNO9\;)14]@!''E9P6IM-[4Z^*7O0#0&%47(O YA>P9U_Z+4*5DZ3LN<(=
M=05OXPT$K6+Z_?,L'3 0CG:XFTT]7#@VGMQUO>ZY9'K/R5;R#_)+[9_AE^R*
MV\]RL'*EP;.E&HZ43C/R.&!DK1&(SQ#O]HT+*[K,@Y>712'D(^3L$F_/+SO+
M#2UG3VM$(_69B[D^O$O(;TW(/[U+R']2+1.;%(UD&>*T_<W6GZ\K!ZS_[U5L
MMV9.T>UX+A5K,MM(2Y%4?3)-+QN;R"W**O3)+/VU!MHTMVH8F:I3U8MF1<(Q
MZ:(!J](.!$+<3Q(>[P@79D4L*;[11^'R[DRO1(ICHNW'&.W:T"5#U4GE1CS<
ME#2-^NB<:#:]ZJ!T14\AHO2T,6L5O>MY(4&]I[1#=;MI1VPO<#^4C)DD0R"$
MQ;F'T>BQ5 ,E?=SF5015>!U\+@%,$K[;>1,E#>\]VDM7+#[^Y!'^U9^C6W"1
ME]6%3=M2NTT_/R723Q[L:Q<0O&XXSQ76.R+3;00F<:F =5VTQ=$P+<!JC$1<
M0A^(RL$\>:(9/;\IOFB!QBL-K_C^#R>H8:BYH_9T=\D1TC:OFKH431%R"_N^
M*-)[1Z^>WS<A=DG*.V7+#:(@ZT3P87SV34U6HU@,C13+YFC0/F'U:<YVD^>#
MS@]\FJP?;2^^4<>@'O=L:6"N@\!7XUZQ1;O:S%D,6T$"OP7LZ<*ZP2)]I=K'
MZ$"I0/S']L1= 9Q[Q#RGA/S$%2Q78MO'G<ZA+VY55I!FJ?ERA$$IUWF@)U'-
M,O=HI -3"=^$% LH?"R1Y(%\6BTB1)XFY ^P;"WZB]>N 6$.:XB#I23=4AR#
M5XA,]=0 FP>C@B"3IBLS2%JQGA"+Z#'&6S:,!AK<*892A^]D^@-,AHDG'PWM
M2#P8)K53RLD.>JZD(X9;@\I:^-8UV_NMA5&N>Y[%E[T\_O-%@@AV;$DCA:<\
M(1I(*[<2= (AW>O)?E0]0FCI1)XA:F(#),SVK_F<9^@20^<K2KO2:@<^<!J1
MW..RR;H0U3?[2WR+93[G&@*-MTH:4"=N)W R_V[S0OO>46P.ZUH\J0Q=T&RA
M?ZGY?^'2_$Q%]N38?90X\WH7'-[[Q?WEYV/Y\3XYA6Y-M&X#.#NU<C&Z^\IR
M U%W5B L>Z6>X.UFR(1R&*NH_U_#=!9TX,X3?L0$"1MVQ90&@+)E/A479 _^
M"#Y12-B9C9*[_UQ@G./&5N-&X^]E9QC[DWOUWY[LWT_/3QN"JP-I7L @4D=/
MT_7$D4P;F&?1VKDM:XGI%70]\7+!"9>^M(S.4/N#@YM6[C?0/<8JVTU?"XU4
MN-S4K@V8$,@63O&^8C7I_B$J$$0)J+YM.O6=,VT9??C-G[E+"A('P6Q(<").
M /OHY+;?6_]M;W?OX+X8A =[X>OIMJ^S8\_(BCY]=. V;?'K]1\-GWJI'H;5
MZ=M;PD)2^MS$DNP/6WHIR<RKZ*4OZ[ )] F _U4U,TAMKM9&._18IYT-V!3K
MOMP095ZN7?@2;\_]9&-@@\H[SWDB.7(CZ\LM;RL"(FPUP[QV]K[YYKZL=:3Q
MH4J)+\R)0H> $VYK'@OWS6'8>/=R[ZEX;T=8YIPIQA$%TANTKNF+A$#5!;A%
MS>#HB/\F?9QR.,UH$UV:D!^ ?68Y@U%X?M(VFW47V/T\4J7+5^BJ)L)_?MEO
M_$"YQW*_V"=Z-]H0;A">J7T) ]M-;=ZD*G_%TR)_D,L1'Z2V55Z=OCH*IP=/
M?>MWW4M/%YAO39 D)D$2" HGUGV:=WZ+I':+H)4S!WS#<__[S(HD5-)-7U8D
M#N!],LHN,;+?6_#$N T14R.Z&_IB#1P]3@($:W1PG.?5K^[SP,6!X$5^I&!(
M*H3T>Z^ @#]$&)$8#B(\EZ6+R?(VR2>@(9/O+R@0*3=1Y>F,8C=[ 3=\O7 >
M+$)-9#?]N3C)68V;FI@ 0Q5 P^/]*![,DJD#<"RK.R-\$R""OS'VC,]"SS@0
MB9)/3?/4.ZI+)BY:,I 4?UE[]V/ZG'8[#]W*91T>AB^1BQCT%1_$V4IB\V)^
MTH3C-^]CJ[J:!.@+[9?V?=&7%Y5OO3FX.BURTHS29K1EKX$'^?=W$++4-(0;
MUEA]]<G?OMH;(K?W]_;^_)'!X[ZFU:USK&3\\MVW7[GG:?7F9V E 7.HU*;<
MY;[Z+OEKOQ@\'<_+U]]-_>5 R@M/'S]YZEZ^7^!3WZF_ST(D^]\.\#78I(%D
M)^8XE=5_7%%SDF)MWL1RV8'KX5@8NH;Z[8GHMWL*4SS9UWV+_V!";@R<]D><
M?D^^]$CG_W*8W+W#PY]&9+=O)1-SY#.LN0OQ0S7GB*HYZ3.NYKR1(^!YJ.;$
M2R2J)@T62WJW6+[4Q7(H_(\P#,\$?_LO]>N.R:_C%03_)R@7S=&RB97PT@/C
MI8/S>\.K^6F7"?_W\OKM'WO!^..%TG\*8$$@VG3E9C4Z6C[(?DS:C>/#.QOQ
M":9\0+>^\Q'QNFZ8GSS\-IWD6S^,W8QD H$\A:Z>A!P'^-?;R*&_.XD^FU46
M."/3_\)O&2R:*=CZI8LF^=P7S4?$\3VZP_%MP_$]V+O#\=U@8_W[DA(#5-_!
M#:/Z;EI8_.HU/88X056DE%H7Z[UM0_450T&DP_29Q\I-N%QO(K")X)R\J-$8
M^'? M19_S81O2V! [9\%)^ZZ@"3:K%"2;RY-EU4E^"ITS_9-NO_(],[* TB^
M;F'+]+0F^$H1/$8[*Y,86V>3?/L'.XR_&P+Z+"TM5Z$^ @HQ2[1+>ZH%71ZA
MD&94_WW%GBL9/N5HO=!X!!4B/"4RR#BY&G+-/=&P=KT1U5H2J-:H0NLN)'SK
M8V6]H "Q#:UHF-C-(\XNTE<_OTSO_>/XU=<_'_P_]S\/SID;VJ1OJ;M-E^4)
M]>)L> TUE(/>0 LH&8YU,509LO)8U'=&<^J+\J!*+\*FZ$\9AN?WC,<KCD&.
M#(X;!^'Q%;6VMG0AFE8MYJ?0\ZI/W"LM-KXCE\-VKO>7;>IV<PT];9-#,LN,
M-OMI4:T-B>@&A%O(V>,5;0N/<L1B%.-J'@J VOG+0UO4.VQ9PN#[/C #019D
MYQ]I11HX^  $IPBI!/U5SCYL U8J6R1!PH<G0VR8L?SU:AY+XBDOMMA)T1-,
MGL27G]("ANU^K,:(RFNV-*;"A \&SWG:,&12K\@G0*HGP"%Q7>AE"0RHFR]+
M'SX@Z9?H@L+B91$"4A5A%$)F%4>T$\CM*,\?7U\"<^%"5C(HE&=N(8T?!'B<
MCL-&EF_A2GLMT1)C"U2(XIZ54U\W) !_GVA*%?LN-=H3ADJ4'BI!<#<BO,5'
M/(NNYRMG?OXRKP.],U>0>4%,W-< $>@E=)"B$J1RZ+O_PX$B# MCO9CUIG<#
MQ3?'LP._XRR5,VZBGLPC%'3Q*)I<EE5.4_<C45P\/\4!=N^G%S_>1] H2Q/\
M#N^8';_^]Z:%X.%I42=1_7&XU!9$Y'HMC-:?M96)$T:#GO,/M37HRV\(>@5J
MZAT*K+AH38A+T\)/+A7W=G=2K2J&>L=M 7+4&OC3[Y4F#]\[9GCF!]0I%*R%
MAO,54PS\T>;9,YJ/<+R"AD\BO/30 SD8<,:'C@#W,7XM<5&.W4ZG$+Q77Z-
M?R8C"]4LEN%X>Q0=;XD' "N^."BWB0%7!502DVTCT* V@)*A(A JK%&DCZ5(
M5,54N.\#[FC\=Z+O($[DM6I)6/D/]FB$HOF9;XN&/Z-@F^C$')UU'E$18:R
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M+ /Q.>X\WU>Z8#]&%SJ=]55AV02Y:-D@=9!R*%,)NV\UNU7 *Q>,%FTZII8
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MC,@#RK:1%[Q277V'VP+R)T;>=)1H2=F,)-MW[A7$_WDXG8;!O>OXR2W6,6?
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M^@W&TKP?,[&\:/4&5L<>*C]CF6Y@CDF]2_9S]:U!OT58M;U>H_TC9Y74E[Q
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M&[WX1_A#6^N-Z3;.5&],Z<VA:NSED>2[F6&$2!1LM)JG;ZA%C'FM904@%OG
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M.O42F80%FV)(+"U$G!+(]2\ZC8$)!Y"/>CT"W\-UF!;&P44F0I69[_"M@@+
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MJ-CA&<*P9+3L2!N +5)4'8'.E?P#U4#D#5$,"Q/<$)\%8Q%ACK##93#PKPA
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M9,[#X-J-R C!VO[F1-,PT+I>OKCC6Q:A3DA/,OOLW@A'F[\*JP9&=TQQ#3@
M])W?4IB^^4?L5L,VOGT7-T%YA'YX@R3&Z(4@UZA$7I* 2B1F1:)&+BXZ/92#
MS'[OBW@>,1D0?782DL7@ZS%7_5E<Z!6-52P0J$07/2WZ/,#(@YK>P!M&/<NN
M8?!>@%O#$XBW$++;\;-<NJ2K*WD-0EC="QB4M"*2YHVX)N5)LV&=-'MJ6NKU
M3B?-OD18*'(9H.ET,GKD(\J+/<R'*K&?0>?O72,#(W,2)K;,C!'%)(33;R*4
MA)]+4I&5!VLO>XT))W;&T(TF,S20+R+0EF:1._'&"@T.6< Q)B9H[S$82V<\
M)U,D09K$F:CY+1J]@CR+!+'"@69/9,\['2?:W,FRSZ59CB6+;<,XHWP$R)_;
MT"$(QNT0Z[1<O#"4O5!,'/)PD0A:8W&31B^?A@JL15)CRQR*;%@5CP8M$@B,
MAHCRX?3 <!QA#=F)45,@KZ?T!-.3"<(#1'U%F*+,)Y=3/]R%S]KSXW2$CAN1
MPVH=^EB:@C+R H/.DUS"H^!?JY262*(4MY'LY%]8#-FR+U'\11J) %@Y:\(#
M%2Z.H8T/IH4.I1JHA55\X.#'B:#L%3HBLT#R4ACF>XT<RY1WE9D43J0@*PF-
M-7#1')!FYH<>:\!!!KO4ZC) P4PR+.P$Z4\2-Y,CNVW.G>/Y."9+<M2,7#D]
MVA03UW=@=Q%1'A4^XE!<1#6D>$[FT!S*@V/*R"B 7"(-0H)-Y21-SI<); (9
MH:3!M7,71B2:7/*=C">F,@,LJ8$G44Y2H"KA8,$<CL55 ^;-O0 SA+=<MA=C
MR84<GV0QEL9>D@.S%.')LQ"SAQZ%26PRZ&+4H6PXEO=.&8(LX'QBAN0@1\7,
M.@WSO0H@4<9B08BV!F\3,F8<(8F"BB/IC+IL0"B^J>OR.16"[WSC9,"A,;@:
M3E9QMY6D>F?0&'8+"9,5?F>K6?N=3_7L+G;:[SS'D!L#8CR"167)A4AF']_=
MK)HY;<Q_I9,;-E]H[X4!((HLERYB$0B&[OXB5URTPI%TZ\5X=S@6>,N1Y\K\
M"QL73)X0[WKF+;#K(JWLM;H?N.-B1&DBR:MQ-(.EO!KR/PG[;"YN1016G?"1
MR?[3<:"8O3)XL;$7C=,IGM3@\ARN7S)UOF:@U;R^!,XC@-4%_(XL(>8E8"^"
MP7@X;ZGV2/8D]",L3"=,7%@:CZ]T8]?'!(A@*KMU,[! 3E7P,X6;LG14!BVD
M6'<=VCCRXJ\$1.ZD3&R?7>1D;2WRZFP,)S&CO5+M&),29= O.L2+YF\'(,8"
MPI" /XS':4Q)&?#2[O=>87Y R!\B<CWE/?Q)W),R -!^3VXYU! :,%?5M0K@
M2J*SE50#7#,P30/AE1@YFBETB3!PEO>>8.^PL('QX-EASR5ZX4NWC#.,_E$8
M3>'+F=$DU#'RZ)$?@>)P+*007OQM*,A;Z$,N $G4QL3]('[,DY)I2WU[L_V;
M@O-<P%\4R<VO8"AOPY SC^+>5MS6@F4@6/VL\CR4NS-459EB1$*J\%]W(;["
M]U2-3$9!PW?68'X9@UDP>^V[JM$^.I<W%%_(%H%/$:68/#_<O:1FG-",1<T#
MN@NPK#<"I$Z[0S=*ZB9,K8R3[H0<E)O+% VRM"([A2BDE(4E(K0Z__R17 I9
MHR5O3K!"A?=(S/A^?.Z+8,I@ER2K\2CCG! U*811EYNL.+TR?X0925G#8U<;
M(J=4%'MIX-Z$$*#1)A)X9<8=EC[D9B8A_.C?^>II+H'QLO854:] !Z5@B@ K
M,^:;)HF.1FBRG#52N- 8[L62]Q4'**@$)@V#VGIHM(37*F)2:EU9N,#B99<+
M*2&JR] !D1,01R9;&/2GJ%56EV0\=$-EN[*A8I^ "#X=546"BG.I9[,$$GQ6
M]8/?)?M'T+B@+Y8H29O+"-WWV4<4@+<$1$A AM[$R*^\&J]$FY,_%I_S;;,N
M7$SG(4/OWINYY2<JB%13><X*8:P@N21F<!Z=BD2)<>VZ6H4DX_7G228LO0XI
MD[>^Q4U\BH74DG>N,CTJT)B"HP81NA.XF.:@O^I!1WSKS6;$!HQ%A9'';BT^
MD9$ZY<%.R2AUQR\-NCJY03](%6GK4HT0^X>9^9"_S0H7:8QI@OQ$2DL,L?W0
M;L6J7E(P$M!>36@TUWIQ$YH:VLR6*8K?E=+)C.(D/QNVK!.M8BTKCA+L-.#G
M8*:&TK5JFK2KV9:A5=5#)L'%X @.'WB1RY><A3TC9(?V9.+2GL7\IF@BLY@O
MF;T:ZAZD8C%XEL\A'5\U)*X0N#H'$M8\?>&I;O 4GSHWP19,X"S8^VU'WH5L
M=OSB? -C)YH=*_+3G\."E%/JP((CH9MR><F5,,JPP"F&U;;>(\##29=T?AT^
MVVE3QN1!2Z8=#4X]C RL&BD K'-W9*QBYW5>[U"S)1>=9U6166^+*O7DICG%
M5$6!!H6R>%(Z00XJ7M0D"HY'S%Y?(V=7?I9GY2CQHL53GFLJN9ZC,*)4FKB<
ME-&S@7%/@&FB#-(^0[3/H==KX/6Y9/.MP]"L%&2S*Z65"-/YKU>.4FI?L+MH
MS+@4T\Q%X*.&G*5]%H#CS3>2I(-<CP76-/K;6SB^9C3"S$\ J8./LP")SX1>
MC:%BTCO!1J>?L6FMT<P@H[$UZ><\NOY+ 9<?W@3>7W@GY,F^-S$_3J:(8X)+
MCF#$SV?DUBDC'=9EI$O+2#MU&>DC#J#"U8R=NYK99OG2Y9>+]V:O8;Z^_'QQ
M_N7CYRO+N+KX</GQL_G^[,/9VXOW%Q^^F&<?7IL7[S^]^_C/BXNKE:5.NWMD
MTVQ/KA+L]A<)G,]:9@S^@PA?,%[7SO#7X G[(34=Z=6&+ZM!%5];7UKU5=X*
M\A]8Z+.=OK![314M,K]SY08>:%WF/1S=E1U&6I-,)I3W%4#Z<06 ])43?%6Y
MDXJPT>K\S+L2HQ)78I,;#,__95ML%>[30\,L<ULV;1MN*AGYAD?Y*>3FNJ7&
MX"G(:/]Q?GYQ\>;-4E/<:?ZXR6F\=2$&B]RY^:EA_HZ%WVZTRB0_#M*Y^6/5
MNM)O;FRTG<%&!7M^ZW@1]C$(3^95Z$2$5Z1.EB>IC 9&O[FQOG;NO(EYUL!&
M]>D2#5@7*6[S:]SKK#N>C2Z?YUZ;%]_<<4K1^T<L.G3+&2XWLLTW./9WSCWW
MYKQJF&_#OWPGV*T%[?2>84'EMMN=7?<)TTFXZ]X[T=?X;W$Z^_7$?FF>M"!T
MP?_8K47K#?=MT;:][5Y%%([">KI^\A?8"K&B.[J@?7O7%O00J%H_IDD<IA%>
M))R+=IHK1&!,\.(=0TD^6-ZHBB]QL#!(9A93Z2A\G'>MHZS-1%EJ5!OVI!^(
MN)[N0>]V//947_OA>>U#M+8<QWJ3CL(M7MC,S-\<+XA-/E;:.WFF]+K/X:JO
M8V>_TX&O9%W/1J,Y.'_C %MP/D"4$8C%[>SDXG;:>[FXV_4J'CPX<RGH->[Z
MR@_1PDFY.JV?/R!4)MTHR_.WP(LI(\<"/W85E+MZZ'MW.N(;^(1*+29>@H[0
MU$L2UV4EH95Y .(])YA%L92QEQ^LY%M/D7SNXDPM %]F4/WY)]\)JEZ9*LGJ
M]\!#776CUNK,OFW2.+-#L&B=J_)"(H4A$IOG;SYBZ4^[";^=):R&&=IN7!((
MP;?MOOD!02?EEQ]Y,.=DNTDY=JJ68\FICP##SFP6(LS*=TATL(9$JS@-^9^-
MS'X]ZTTEN/KOHX:I+C;4K<;H5ZJHPMI5(661HC=$L_-BBMZ,L7XK$ZL]'/;!
M%KC)/=+/YSYFZ//T!LPQ2+_9,469++\*'[\DI<QKBJC3!K72B!+$F0A7<#S+
M?BG*"0,7W]@5??-_=X(4-0)4P&Z8* HA 0+E"51OS'5(56JQCBX%.M4P])\0
MQ)4$-G/,63P?WU([>"R0.K"-/XAQ4%H;IN(?4'A6"@LBA\OUFRXB1ZT'-7!\
M"(/3;,9R17"P'V<P?,=\)VJX3SZ<7;T^^^^?/W[Z\M)BD6C;P)9B^0@_%SNC
M:1%HVQ1$36T!,P0=T.]KSM)XY(78^VX9JM)$H>J*/PD,%!TOC7L_L(S.G.9.
MX\M@@H^9FV>3.P38G0M=<[C3X4L:P5D-WQ* POBS5Q%UN\/SWH.L'-_XS75\
MA$9)S/=A@, '?P0>=4PE<TLXQ3 #_.EO[C=O"@)*)OGUAY6;X-A>-:[&$EX%
MWA&/>=5(="7/?ALY\*#7WJQAGLUF#>,J'#?,3Z@)#?D4^NG5O1>,<";:KP\
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M^S/7K:2C.\W2=+2D=<)*A'#J+LU,;A<MK-/I6:WAPG&S/W!GK=[ ZMC#_9V
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MG*T^_1?!.O._5H3JO&/2J!#5><=FNHNHSNN;TTK@F[>U<!LSW57!*^_PC*N
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M$O1AS8I,>,*9#V87JW11*9R9"[H\CLUWWE20L2TL&IS"L\B]\T+PO]0"&KB
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M"QTDG+K.N M"1J)=2NQA1M@I/<*6.5RF7-SG#;98B-_3P4T@*F6B_HPXASM
M\&!:P#N4YHHQ-:/(45 F"+S1E6*<I+SF"FJN6H0U""I504DXL;EA62-:+X(O
M(J^#WF'.)MZRQ1CXE!W-+['BB H);!")I%3CNB>/!S']J25$OM96-6726[:V
M.J^(O1$1$,]!F#.EWD&P>[ 5]+;W@JW-?<VO([2V!T%O<Q^L)_C,[FXC5(_R
MN;V_'6P?[ 6[VSTLD(O<SFP!$_J-&%7K',W6G,%:-)^5:&XM6S1/]'VF+Q^L
MI"HSN =SY7>W,3R'_]^0.M,/S;V34-GW_[39V3R0[!'5T7)N'48P+8@@RN_N
M:;0@B63+BW<W[_GB;LN+C]20WRMPISU")*+>!T-70I"5@U%[98!?;!L*CN)2
M$?\\<>5DI."1_\ETXX 5[.[NW/QM^,[[<'8=#;_Y7^'R^EB,.K@R;FG]T);6
MVYND\J*]G=U;WW(6CL(L_'?X(^\YN,M2'&:S',E!S]$!O8!]NN][25!ZP<'>
M7=[^^?0][+T!H>4+O=UP%KAO1]L'O;&=S3?,<@?&0*?R"4U3QP80-U9HR[EJ
MHZH^@^;HFR(Q=S69/7;>;/VU1K^_1N]M/RRF9/O1]'FM/:NK7?>[P?Y>#XR%
MG3MJUZT6[?JW,"GQ ;ND6^&_-[RX=Q=]_OL9OK+UG9\(9-KKTBL/2/QK;]4\
M(P0490,' 1'N8 YV@_V[WC$RIOW=ED')>_9Q4%N;'=U1,D^MS]C= E-N9Q\9
MOM#SFR)>ENE%][>"G9UM'%!],!W?;.FVCHLW!JPMO-Q'*@;CN<7A4$BC1ESR
MC+^EA2#FRK5F>$::8>=)+;V]I1IZ<^V\G27;>1AHU>]U+:%/L#CI+-1WY,+F
M"&?% D)".Z=QONTXST:LOK_UC/_(T2;RT&N%+9SRRB+KYK8*'A86R%VI-252
MC*H\C9F208K"^[]^6CN$STA)[+Y&);'U.,[@@4Y.WNP+[@7=_9W@8'=_P:/^
M,9Q,P\G=/1^GGP_[R6"T@;_:W>\M^.*S2SC8D6G0( /P_RLN?G9[!9V5R&3]
MH43BT3\?_M=%\;.CC>P['TP;;?V8-O+;ZFG6"NJY**B]%5=03ZJ?)']^2ZP*
M?+#6,'&KDGA_[G\-$U! DQ!.O4YR!$31@JUNL7LB'4&DNB2.=,MNSFKI(-CN
M[@0[^]LWA,,,C;K9/9@(>*![O;UGHUB>DG5FD1JPWKH&;&X-V-ZZ!NP1*=ZX
M+HEXZ[\P(?I79"!?W7J<D\3_G%ZQ6NZAD4A=KO ND+YN^$O?<'P(3T[@-?C+
M45\B\UT95QJNG!GJ=V<]B=S./+Q_]C_R6]WN@G\]@4D,$=S%9)_8]H6?]K9_
M=/9.GN>U/._HC)Z'*MF='%A[[N3@R>5T1"EX_ 8RS7/J&PF\< Z<W#9DG B^
M(.12XT5XZWFAG\ V%"K90.U-G^[X'V1<<"T,LX@78*#B]#IH3I_S #!*^UR<
M;*;&*I/N+D5ZP6S),HJFH'8\V[2T^G2A%J2[J#7/6CI?= =1^2)&]XBNY!H!
M"-3U@U8I+(O+- -;AL9)G_7L YOCA*5G#EP_O+C 4JY"@=:9:VN@5=&(*\[_
M/'@899:7L(?(N(C[26JS<-MQF^X..>\%T;0@-7!2<'L73)1<$U+#%2(ABR"[
M)R$N7SOCMDEMVPB%5Y_5V]9I];;GVESO_)O6M./W$P+Q@,;/E9 ^79H&U*;A
M;V,<>A@X";+B;MRY*'<1*FTKNF+]&FYZ=^6,=?08*(8&-C1VWQ%SSZN>QHC-
M["R=I(4RW;&H_7M+KZWZWXE#U!)75.&60ZN$6Y[E(6-0I?N /T=C!-63C^TI
M[_=*O_[*@.BB/2(V0*T&_QLTC7WIUS[@ 9AF7$W996EM\U[J']:&<EF9L>?L
MWRI>\>>-NP I\4V+%DO)2;<K7:AN:R!BM-RPS9Q$_MI;O]@KKRK^R#8]C-.\
MS)1[ >(MJ=MFM3]0&FA)NP*Z##7!_ISF,_!^-A,:$\D=Q%S'/[-*C+ONF'8_
MC*XS;=602=Q\SR.>WAM>?REWL]R(!7&A\Q% X!VN U*#(/H2WDP2:62WG'<2
MB78+%@NN"?+J/.(XS;EST7B.+4$*A@R/ <X>FQT%PHV2#R/\7]/#VV5+<5&;
MS0=+GPF^X>$'G@">5,6CQQN3"?(1, !&$=(.$AEJQJV.&*_H7"$6)FEV(!K/
M67Z$/W+J8Z2&O #>)!PI+<)S-F5JS0$6SEN6#ZE?$>8PYDX4R D3E\2Z1L7@
MD<0G$L)&"NQRA;6',1UJ$8TTJR>E ^&WIH@0KC.UQ3'!;S[P+5^C/< 0#<%P
MAY=JA,UIJ7H !#B]QD6.TE'>'(,;63=/(U'T6HX%084-C/I&H0GFH:R;PE/U
M8! XR^U4J.&$Q\Q^HW18$LB66B4TNFD.$1ALAZ3BZ((:AK%PU1O)B#/2)KL=
ML=9JMUW+8F@A-Z!**=8PP3RA":QNIL(6FC@,:540(MD5=7A#CD/!/==N7MU3
M 5[M25A*@[EID.2_.2TR:Z\T/,YS3K?9T5S02:1'X+OX#JM3AU$&6X"NW1 9
M$<_U_2,C9@%M-Q&:B[:H%/WL7Z;7R!<58$<4>8E^B+/87C@NY(7J^S3269,Q
M>I04#\Q9<-RUPTN%QNL"RVD%KWGQA =;D. -17[S'#RGGQM*M2J$HR/2%/*.
M5/,!=@TUQ[,TVXGV6YMPSEMG-@$]; @#JU6Y,D0OR%'7C39*[K8AAJ&I.0@3
M1/!3J]7<=,2T-0>H,6P'=.QM)P4(>?0=.Y(4E[E8K.[BBR,M-R#Z<MV>_G0T
M=E2DTQ?(\OB^XYXBV,"%IGI%ICT2-H=,^$91!-9ZN.), H=GST/&8+AWI/=M
M;^>-#O4J#F-3X)V^WI 8D9:SVS3HW&T1+*!L!7&JZ0('TS(7# Z0*R&ONRRS
M48PW3K6;Z(UGYE7YCTZHA7MYXB!:_4<W*#/??VSUP)(TV7 2LXS,=]PY79@7
MN*Y<4&G\J7M,8#=IHD"T/3!;+YR62)((CVG?">N*T06#Y<<$B:.SSJ1+UW:O
MIV^Z$]V&^10)%,$"/4Q'M$+=@_U=MO#1S,4#+6X(?H!^P"60[L_8W-1],^5N
MVH9$(TZ3F(;M'&/+(2B-DV[R=N&0:^9 5BS8="".0-1#Z1GB$@U9QQH[=U#L
M%&%V]3?>Z%^_HPW"L8O:<S50,K-HW>[F&^I=A,DY6>$BQ80Z/'U YU3JA+@P
M""]*4%7#.-1-P66UFD.JN/L>]47 E_U&@:*.?Y[Z3A\4<[_;L-DXC+**71&X
MVD/,"=)JFLU8KM;(L0*Q N3H3#K5:@V/.DNZW<[9]+:<)KYN'&6@HREJ0<VE
MY MH@$C3%9C\,(RQJ:SH;_4=>=5S__?.6>=/70[J!4P8+.,U+:V*3#&#(X*Q
MYPOK\^[5M+5.Y,U-Y.VO$WE/WJOI]_:;R80Z)9KAACJ]N]V--24^MPEL>TS4
MK\5$34S3,S'-9L*@A>.NPQ\S$ V0F;&*JG=SS86LY)VX4[/S ,J".4:?'AC^
MG?P5=+2,.8WSE.:"F7(\DIR*?T<ZYNBJ4'TQ4G/&*ZU-A?;6-ZT:=5]H_+CG
MEB&3\\@J%3>2&FO I['IB1]>A5%L5#FFZ5QG+Y]GKZQP0*=A3-;#P2A3;>'@
M^X9-_47"IK>'3+T;0Z:5$UT/F;;&_.I"OUC(U+L]9.H^6!_ZFI7\HS%3[P=B
MIOX#Q4R[^YZ9IK%DUD%3.F,%F ,VXD%>0(NYV7!-//>O[X):+"RH!%)U<5 E
M:'I+D*6.+U@T"'27<*@YA"WA4#T!ZFU(RGW +H-T>F]+?GKZFK@M#EIQIL^;
MD6B$ U-X!#]UUU">#EW2'6U/=,7ED&"?WQ(%YS#C'"F@L8BW9@.K")G5DW,\
M(L]$6NG:P[FX'I%\@?6D3A\O,(9*G,IZ:_/&!I_PFF/S%Q_;XH$#=P25 +6.
MF7H+QTPEWLS$%QP6#O/[+8R3PI0832V\.\8GW30.$_;.X=ZCJ="ISG6DI![!
MK1\=EG%]VDT<T7/BB!MSXXC^C\81 ]VON"7DS ?)FW.UM"N"%;T+%A5R(9KQ
MPCP'CU33XH!?D>1C6$+\6=03/PGO K( Z#C"GVC_)59!+#'8L1+L%MV$9(0-
M2*)!61CJ'Q$S:[=;(+('MY$B3><>64RO4SAL5OU=1DT\+TIDY&:+AQO+&3\E
MQ%.UHAO<AS,\F4B_3W*48+JEY6%J0*B$T;S670JQ98(!Q*XUA*LAQJ8*/IS5
M"<4X6;%BB!B/)7&A^++<> (19;$F(+\_ 7DS.K1L+NLED%E7&R(]+J7T,UC2
MW8=?43RLSY0,?3FSW7Y5LVV0X:[\&5F"UN%>!,]4;I8PWS_H&6K$!/\A=@>[
M4/R#MJWX)_;"^-]O^W]Z]WJ6:"T2:Y%8B\0=1.*A)>)1&H'T]ELZ0]2[!1[@
M:/4D\ -_\0]P/[2C7.%QY(C$0($#D@AEI':#GDF?C*U]Y/3'@M]GTNSC3W?M
M\[%YMSX?SZI+21=I\]:K_U2KO[\=[!Z\TM7_8=[\6S7BKQPR7#(+_<9RV? ;
M6]*^#YL-/_.)2/E[74.UL5Z89R8G=QS"([0UN?4,'^O@^I)WY^UNL+6UA?]_
M^QK=L]/&$G9H+:SKI7B*F_68,&NC/QM@W+)/)]A).PO>*4L\G7"=/)?;Y&TO
MV%GTEGTE*]+=0HJ^9[ DW>[+NV<_8N)PZ<?8<HZLI79]CN<)R7-9D3OV.7O(
M1G /$/03&%(]W+>D7=O:V0]V=@Z"K?TE=V9=SMXM;UWFAS=?];K<$'A\DG6Y
M8T/9Q^WX>5=M4&,A>'QMT-O;"7;W#Y;?*W+!W5W J7\<J3_8"?8V]X/N,PF.
M/9=UV=\+>ON;P=ZR^SHON"R[]U,&2VDM^K@032ZL=RF9Z>TCY.PE&/)?"'\;
M1XGZZ1>G)/[(\E.=<A4-X:(-<^XRB %HK'HAEO:"$YCO)(G&,S2MJKQMNK1Q
M=>E-CRQR%LN2$NI6Q?3*5/(9)45(E1^$_H?MQ]H6;YK&T7#&)62R>%SYSLU+
M_:/**GXQ]?M8=)@7/OR 3_5!L 91S*U$HX2^+/7=^@&(E):O![ZA"?"':5YP
ME9GZ/E4)%MN'>9X.HU#Z_N3E$$O$QB5R;X[46+'AS*#K:99BU3G\(N<" 5V>
M2G6G>I+XL<MH@%5V#C>;W+!)6-B?/#T/2T883L >L$S6<%BB<D*\H-1B%$LU
M3%% H.'+6.R %1:MNZ$7.N+J42H*&%5V -9#KQ4Q5L)2T0IRA>VOU$Q:2NVH
M'@\QT.EH9KH0*+,_H6]GY.X+E6*TOF4)R/7YAW^10OOM=:']W$+[@W6A_:,S
M9C/+E_;E$V%':COXCAUO=(#'%OV*7T*W+@,76Z'&+1-#'U6C.QW[_1C9E4!U
M@6K/PJDJP6O+_8](*&.JBTQ)&+6)SOUQ&L?I=;XN![E_.<AM"K(-]W9]"7M"
MKU>H+Z]ANUIP>C_[\\9P).5V5-TXJ]OT<W" B[UT8?CC[?.>%SAH'4C;5= R
M.)TU9V"LYX!DO3M (N^Q%*]D?1E[*RM*.H/_J37'$A?X48"H>[MO?OJEV>:F
M/JTG@LUA6YZY0WGVH+^MG7DYL*5"YWZI=6-=<D3G&067#KK!5CO(\BEBO+_8
M;@@'C[43SR6UU]V\'S3P7O+^!.O\;)(K=TBA/H+$F\9EW4?;B3LB,)87V'Y$
M@9<NTUO=U[;(!S#EWE8OV-QOF 5/(N\?U""CJ[;'=^W>(VB>_6>R%[ 3O5ZP
M!4)_L#P85)MNT4T17X_84PK]&:GY3V$VO/2[6[0/!\O?AV=CUO0V@^XNMM:\
M(_3E7@+_Z*N\Y)3LPF/9O0-2[M&DO==]M'UX+NZ4]%?K/8I-\[<RGOFTQEN;
MRU_C9Z/9YX8(GD34Q;#<?[1M>"ZBOGP_JAF!FU-MW[X'MWSIAE69$Y%<=+$6
M^/I-^[F,M]\XW;NG'^:]^VY/TC&_;B_8;E>:]UJ*Y0:!;U_>ER%Z]_[^2LE>
M+SB *_L (Z!-;/8/2=]2\&Z/@^HZJ[>6#Y&CNHQM?]!FTZ65S[!K<+#P(]8(
M%G>#[=Y^L+?5\P0S5$^N<T_CNZSHBC):GA%,H;9\>P=P!@^"_69;8N_N"X<,
MHD=9QS\*KZ*1?U:$DQ@A<-0*SQ^7&1&;=H,M>&EWO]D/>LX+O9M?R'2IW*QX
M5;?NG$CXF4M68'I(DC\-(],VI](_T;MEORSM<&[;W(S:@2P:'ED%M# &41"#
M- YDX>:^@!'W2L7^ZI[T3:VR9C\J\.XA7_#5@C!]:OI^&<;C"EAQ=;7QY]3%
MH#(D=(#4[@.8-USIB(2BW@Q7*@$)C)(Y*\0<\['"[XN('<(?"P$YY=(?K+>U
MI__\U^B70X%[DL3VAP4VL.M*9^Z7*4J?TV0C1!PJS#B[@D.QPA?Y'TK:8 RC
MD=-SG$''&O&;^,R130A]#PU W&WN2@H?C-"G"(L2/COC+X'F(A V=RAQGH7=
MI;M[/^>$LP;_(Y>>L_A3I$R; RN1I+0F(& %$:#;;@34&])V=<OI4[G36SO,
M!B%V*/WR/58S$DR069#-WHN_B$A(^[4%M>V1AMAA81B'?"975W3[_C"=&@[P
MNH#-6P^\]DS;EJI>V]K<.[1ZKT6K824 MY[!FSVU[S4MZ^89PWCQ<KD!UQ,<
M?Z=2 *^[T^GQJM%[L3%0DI1,Y XRCT?O0YI-X!D;'U[LU7QH"@(NL%%"0M40
MJ#&HY&=U!?2DV;\%^[IB\V<TZTZQ><QVI[O9V:+.%AYI/"/ )#9VZ7ZU2W>F
MEXXZ[5+C"PS7$ R\0%M]D$<%U7%>7U]W0H$O%PYZN3-,)R]>#<YSI2X2:7U3
M6WNRNM.X-$U+X+R:PB)N:N^V8,I[!_MO>^]N5 A/OH8WXKL7'T$%[GT#+/P^
M^.XBG<Y%C6X[[],!I4%+)8Q;7DAHUW$XB>+97VZ;%WTVC_ZC>!E^^N7/^9_]
M7U4Z'F=@$_P=;1TDQ)62PY9(G(QS=_/-7<.IE6D_X P6&?TS&>KA91AABVK_
M&8_QDXH'8&TFZL''V!+?_:'G\3]^_$*6O)!@''=0ISS4H[GBZK8)5X+ 2R^W
MHO^$?C3Z[Y_"_]W<V\%1AK^LAOK4G<T?Z#3(+Z["+ IQZODDC..-(8R=S#@T
M0-%4FZ\MW23 OT'(HO'LT49W5*FI#?U3=8'ME^"CQJ+J#[7A?JJ&U++K.,O2
M1*5E'H.'>!UF:)T?IA,L 0ZE^7-UQD\DQ,L*&Q5.U\JEN!>-"2U2:[NSKK6=
M5VN[N[FNM;VW\N_M593_ ]QW#=4V3SN=G!]_\O<JZF3PB_^I_[<OI][9;_W3
MX]^^?#PZ/CWS^Y^/_-/CC_WSXR/_:__T_%_^^6G_\UG_\/SDR^>SY?C*_%_4
M"77:('W!W!PDJ*WR_OJ*O<'@Q-#=L[Y(/X7_3J47M63N'O42? XQA$I.+W=6
MPO^6I-=D0908W$Y]_(E;I&/Z+9YYDY0"WK!1.V_\]K3WBXWC86@E@IEB@.10
M.B5*H]0OUPDLSV4TQ3G/DZ 7-^MVZ?C;UT]I=H%-VB^QD^U_A9/ISV U=B1F
MRWTBSW1WZ.[6K]XXBOFWG\*9W]/Y?9"2 MN07TLBULH1BI4BII5M<--V][K!
M]OZV_T6+$4-1 MOLDY+$V);\>S0)"P7&[&YGRXJ?97KT:L_H^%]X4#MZ4+=/
M;I%A;^WN!IM;V\'!UM[-P_:JP][N;+8-N_Z,1PN[/<:I:IX6_Y\I!X@1CK7"
MN<<^? CG[FA8_SHMXQ'Q&5$6>Q2-QXHP#E>T)AY!U%ZN"D7',QM)/^O54HO<
M^51'EQPMAW<IX8=V@OV=KH8#(70HX]5HOR8#_/WU980U$]OZH_+E@/[15'M;
M.YVMK7GW+GPI',&#,"Z@B(%J-()?YRKWY!;[/2%*%\JO,)47J,"$F!MRW2ZZ
MUF+9$'@QOP/\Y.A#?9YE/((#2I TB]/BL]K3/)HRKA518[4\"CX<C50@>* )
MDF_Q"! ]U ;:N@3/R[=K/9@A*.0;C2H3@%:23J)$R8SY3$;%C+!=64BKC%@N
MF,#OG;,.W/C8\ARYV*+<'Z4)=<F>J##A_3\ZR_F*"%M?_MO9^T/_$$0$F<(^
MRXO]C\6H$\AFTW=@([MZ'[WEVT]WTX8U?^=@[>_<[.^\?];^SJEPUWT-,^1X
MPO;OX="![ZYH\.],83_$N)$(]:<A2DLTU=2'1#@8AT/*.*.F[$^S*";MKE6D
M^7-%\Y .F)CH:ZR2"\S")B-,LP[1O!P1;F(8YI?T)'U/@-/%BDG3"DYI:PIG
M:SS^ #E:W))=?Q9\,T/VB._Z.RC93V$27O  OX+F2Y-$(<)B4H*YJN.\CQ#[
M;%4?6YNKI#ZV]Z??'UA['#YK[7&" 5^X#^GR.R90&Y.4'J9EDJOXU<5.ZDF%
M14*D\B0ZX* 1)G_QRRFL)"@&U3!F92F?2:IB=YVJF)NJZ*Y3%?>_%;I/FZK8
MKZ<J/IQ\[G\^/.E_]$X^?_AR^JF/^8B7D([8ZJW2_?KZTA$?3&V+ WLD%G"R
M .V?3Q*\.D*+>7Y%E^Z94N2@#\$TQEN"+&%;%62PMKE#>DX ^B0M5,XQFB+%
M/_HG\$F_N_^H%O&#1+P^$A>[4P:TNH'3/Y2)1D7)51I?"> UF349Z=$^\$)R
MK9SJ"?IL<0DW;($E03Z2YE^$#(^A^'[N8T@MB[C( V5K4.91HG**&UG1 HGC
M:I"7)S!'T54TPFJZ(P0*10,&!G^E5@0K+3O<,@#]?RX/1 ?<'\EJY'J_W;QG
MQX.O80590@XV* MLMS NJ6F!"K.$) V=^3+'#U8%!K7U*"5Q!0TOL05X-37(
MJ+T\35HKA3D.X:$IF"M%=SB_O>/W09)E)/HQOO23N([B&.'Q(P6B/*&V$U(=
M]#X-.?!<[2RAOS"@X$0YA='@O926,+F0/N8J4!PH%W)RB'<JT03X4,L!"4RY
M)A7=)C;(0DN0P'G%+_),X #G4Q@8_$8WD^"J$)14#H%P0Q%4W9Z,S9>,7,OD
MN,8+-'NF8G4%+U_"<7U@NVUK;;>]Y+!J"UC@U9EE2P=8_DC>8F_[:5W,@[J+
M>?[;L??EPX?C4P+!?3PY.S_Y_.N+<#&W5TY556-%#ZX[7H#?^06!!W3'?I1Z
MO2.T>N+'S@H]!BK!:<MVIL!*X0Y:Q]^'I+=7UQ;^TF)IDG&,>6]E^#NP:)/R
M[63Q10DL#_I8Y0 4.[9T4]QM!I%4Q/!(E36;FU)=3'P;L\D@C7W,A?4V?_[Z
M_IS^U?V9\%><3R.>MNX!NFF\[",RA)-P0F7YK4UH/-V$ADQ!BS!PYS!O$/WS
MWV00AEL$_#Z,'+Q8<,WG_ME1_Q_^83B-"M@@V(UO:H7+B[_@:=4--PC M]DC
M*2 ,QD ABD\#.-*$PCVM*S1?3D_[GSM:2'Y(4'U'4#TSQ 7%]/CQY/2![8)U
ML=F]79C'NN:_QF'"KK*- :W]E&=^KG;7Y^J^F(G'JR+!J^7UN?SGU)X5+JIH
M"A>LIOJ8PW^(MR%^!*]0H7R#&U2CHYI!T-RQ2#N^ &[I4I;K/[#W/R&I%(A?
MA*<#R6KPHM4/J!D"7\X/O?=E'"L8K80/VR"Q9&>620$O;%@>SJNKUO/];0[O
MP6P._\=L#L_:'-AREY 3E'+!1 KXA=,TCPJ_CRUT"61&=",4B0V3;[A)*%'_
M2K-O\DH&NK9](/ 1X(:XYMP?\7-!  +F#LR]_M%IWO&_9A'2#:7:W]BFU=D-
M?!7"C_ 9BRI&0)Q*YA4B<?5']1FPQ I<FB&MG$\!;5ES/T_)^/+D-6>5U^PV
M22/?5@M4_-V-<9IM=.%KH!]!OG.X<8IW- K=:HQ)";;N-HPDO;9#R6$DMP^E
MN]D^EJ5X)@O'Q6[".2V"1MI;HY'FHI%Z:S32_=%(>VN#ZV:#Z^C)#:XSV [4
M;:^Z</>E.3+K4OE;SM7QDY^KHRA>!P4>BQVF_92L"ZQN.27SF9D>ZY1@Y4.2
MJUR7$YV@O[(^,DNZ?O9:[Y^].R3_MZM51X^>_.]NUK/__:.C$\24OSR$^79W
MK9_NF^E_-.N8NA](#&JMEY[Y@5J7;#S[O-DG-4FS,!F5$XJO]G$]8K[_^WF>
M#J/P51K-?T@)L\,RD2:^:2S?[09^]^!@#\.[7V'Y0N]K,4/V PY2.Y_$1M#P
M20YYIPD*'!<WAQIX,DPG4T3QXS?;@N+T?)>VFE@6W&!KEW$J&&SUYC_A?906
M:GB9I'%Z,=-!]1\$KCB/(0PU4W42/;\0:42YWS_\[&_N;^X>'&SN[KQ84(J>
MOZF#_UIFV*A"BIBH(&.%2U7Z>5-BKZ4$ 10*.0O,Z1/XT_0:B6&((2"+KJ)8
M7;!&"4&:BA+9"J94OL]B<Y@F>1$57+8Q2HE9I? 1-A^-9U3@,M5+C50GO-(O
M5HXPL?B5%JA!V;"ZTO.[R=!-L_0JRBE%*LFLRO;C+T8.E__,MK5"*9,5FYKU
MXV(Y$L? ;W!)&/X:TRA$"'"J[\S:&P,0"Y( *CW0@ /;8VM$I!C^A4J(>V.B
ME$X/5ZIM_+Z9#%5N.)0<5.=EOHA'Y0K4,[7HP34"<0_C ,:>H2:F9&2:F1(2
M9._0)#L^$6\IM](KGG&7*(49Z0#S;''*J4B<IQZ1TV&%/TL\0-1@I;WO0GV1
M/%@DZ5%6PGK3Y2!;8K:0.A'A\SG)"C99EE[3C.W,3+&0=+**6 '$?+4$L.A#
M-2UT(AM;GB%?$C+480NV9*8Y1"RM"&YS^7)51)];QZ!0''^':9DDZ"<6EQ56
M%'@?M)4](1<9F4\)-IK2S77D^'BU<X>',U9ACFUW0'@Q,SSSP<I7R2C,J+5/
M0!*-I6](_36!&5P:=1+C%\=1/I0V?!M8B#8(8^YV<PFO% 0!>&/1D%G*Y7U>
M;Q_^-LOQVN/,/ATX/.ZBN?2!CVSS(JQ\ QEW]UE_"G7&0.F)FZ*W@5X@<\P"
MK-B;DO(8J0F!,\=T<]I/T-T),TQ(8Q"]:67--!&;'+/PX@+,N9#;S_!BTEHA
MG0=I(UXL:24Y9(>\.17/3 5W$.<"ZDDQ,:"E6.UU>=G"<2'7!"Z.J"1LZ"*,
M9K5G$<,8J8JP,(K_.M7[V7B:!T^[@$DLI\;U49HCXD[@?+"F <1+VD_YO<X6
M56UBT7>.0;GWV(OH?6<;_[.+_]G#_^P'WOO. 2F6]QT3NGLF%"S[:]##7-##
MUAKT<.^TT_9*%: ^*C'7XX%,A:+@4 S<YX!X6# 3HH5P27Q6<\-34HA/Q>!X
MT\,GL&J^Y%)U6D6?G9;0,Q00YB_L/8BE'<:@'D9H+.3#,L\%:LEDUV1BPYW.
M]PSUG^76QMI6&8(9( VC':Z )TPS;Z]4%><2SOO38YQT12*?]_21:S&?@Y]C
M @O^)9PP<+DOD/8X'(!= BX&-M*5%1K*"GG8%)(8>RD8X')HLG'LU'Z.4!HI
M]#K.%#Y7 L^$("<_G B ^6/P=>QO.=+D%H7IF2 T%_!][)Y X;AHZ&5ES($X
MMV<ON@H9N0_<B9QZGHZS=&*'A1IBFJ7C"".$(\T3$FC7@?R3'!Z)(Q^72"$R
M4!BVH(>F:-TJ."R6M3CP)"Y 09XA3 ^I3*;AC$,*!:K'9(-IEO$7VFFP_/?L
MG3GK=HC\'0YQK']*G\W]_@686S--; SN141>*7([>^Y.!$P)(LWC4PZAE.PM
M3=,"4<N@A)TW%N%W6$<P^F(NU16'SX2K6(&CKTJ^3IG$Q,-BV#_P 1QN+Y "
M:*;[B.:7TMX"LX6S%^ONH%Q_D(WO#V%-\LA2IIR'WQ0V_^)@7?=@;V=UPR(<
M/W4$)PZOB>5+R_TPRH;E!/LL#%7NZ</"47:F/(>S1W<X$HKAP0QQ/:G@V?KA
MH0ZZ:3<?#7>)7%@"'_B@,Q*3#  A3<L"#0JB"V&I3/%8$[?[%4@^O;AVZ,Y!
M<+';6Z9)B%V]@@//%;5E+BZUZ>%\>3'A"#P)\59^^^0T'LL.M5?7 "TYJ]%A
M*;DL(_!P\ZH" Y= >J$HJ,H-=R41C .)\ALDJ8N]<B2XU"(V,R,LE^$5ZW6L
M)(+'JR(G=4Y49W[_3[W=71^N@EC"\_C VC45UL9,JI.,61I-Y<4WO9:B_.[[
M/#V!:$QK%@HU%$\HE!?D]K:4QTG\C/-<<>PWSB!2;EVJ*'.6DWFJ>.+80Y=&
MJP-OGCY1%([31TB6M?T _99>8[ SH%B0%$'157^B;TU=#H6CL0T :!NU*N%H
M.MU;&=Q)("!$,)?C!'FUND%W9]OL#P%2L#3'QNE;M=([R@5@K8_.XF3JBBBY
MG!6EG$G;R'4I&>4HQBX%6/4>H!VC;R:D0W#),OTKBM-,LRA_7!CLDKJ22\,*
M!6N;HR>F9<2VN$@'N V80T'2-2,H=%8FL&RHRLE?$8M#&W!RABC$"$XAYE[K
MY[D@PU4^.-+A]%#;B7R%1"E)3 %3Z_A&,7F:/\T1XJIY1R8N<[]AAQ 1ZHC"
MP6 #1=_0J*7#2 )@YL5-9VAFU'?#3(][<>"'P6Y2=(KDC5YJ.E[Q.<SU09SC
MY0H30Z"-L>H(0#)'N1V:(]DX=G:_X7%B>QH1U2FXCG>N4UQH9YNS%8U_5--H
M']^=)!FK=3WZ%GU\4,?FN^_T+E.R#6SSC!2$[L5B:/3TFC66RF3N%'+H47Z#
M:T>U+CLZPV-?^%+91T6#'-[PN,SS)GV]HM>XG.ZZN/KMXAH6=(WC0:/5XX/
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M#;U&NF2+Y8*5E^+ 84Q-E^KTB+65%"$DZ4U,E89_$49X \!O=6&EM&U&X77
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MX);/TTLFIDI+7D-A$\*85H9'-J&YTSTN6+%^"6Y7:>O<Y5'Z[J(;@WF6JI_
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M8>Y'4NYR0I:\Y. S)8SOLF["V^O0-BHR:VW=MW]!E2*&>\?RI91*; )Y=CH
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M=.>K$]3GI.V!/RAR-SUZ\8.P\'L.;G^/%CZ,YM]E(18?[6M=SNV'7,[%S]
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M?W0DH8SYY#)R2Q$]ACQYG^?Z8&TLK9AAG8$S!&4::T"B4@GB&E@*=&)@!=.
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M@>E@TZBAX3"^,8X?!+8@/#I#_S(#TN'(HDC'1^KW@7]*/_[2NW\0G<\3YK!
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MTA\R_PH;S2A)@9BU^*7F-E^:7VG5<>WT"BD>W)W[BF )$?6Y\LQ!.(<S#/N
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MM&S.O)OG%G?96K-20=3C5J-C=-I-HYD8YSO ,]\I!I?%F3<KZQS$G;:XV];
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MY WFUPW+D5P/=@#VLCT=$M7@<X/ #($[1], 9(B\F'2UQ^:,\[6IBA%@PT&
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M?VC)B$HTOL>Q9UM(,6KN2(1/B\7Q8!<Q"09/%W*']U RAXVL:)#G<D('LEB
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M2F[/@C__$<Z)XH<V=!G'\7YD#B-'0''70N</YQ6B!8#GA=I#%"1P?E*96S*
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MB_S ?\!';7QUXWO!"??H3>TYZV.U_B01JC5H'ONG[4^ 64?,BX^".I'71=]
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M3O7C9F7.22MC1@[GU&C@K,PYZ=1:U7A9/KA8'@)C?5Y,I]1OG+A:03PPSX:
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MK-1R1VJ'>%]O76Y-K=!NH]$N^7]H:\XL8\T-)Y<XN0/;9XI0QCX;3BXY.NS
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M-6 .OH348L(A*3(M;F&Q2M3.LBPJ:?LD)7'_$4G<*X;5,@N!7#?VPO,)]UT
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MR/;,;72I1?8\(:P+9Y#^&J/X*GN>]@B:RIB_5M0<Q4#4G/RP>]/H.AECM5N
MUIDY/^&6QMXA\_V02T#7!\M[%!\3E$S)CYWP','%PE&[E)G@:SCA]XDXH3@'
M&,]\K[ [ Y=UF,NV!2/"!QS8[!/1ALH"9)[+8;SC)VHZBVBK@8L&+J)OB:J^
M,/ T":E==$^XB9P:L\M0,MDVFXP*BM"9+L%?IZKPQ](BD[;M8."J@:OH6U(3
MG!>^,V&#M1=+'^SO()ZK[LR2[.6@HK,"SX6C?8&C]1'$%QDR?A21;?2[9!KT
MP'$#Q]&WQ.H/BUUMUYH3(Y[, @-O!WS ,&IO(.J27[%>[!'Y]FP.,C!(LB3C
M//K=F/?.=O%=-G)S0WBFV0[!7C!@2T)%2P-4]':H:%D8H*('J.@!*KI+4-'M
ML4HYT&7N. ::WOM.07.QE]-T-*9="B-=-]6XLN;/HBL[A26PB/LRB!1Y'&XE
M\5?G<3%W)DXX8HU'235OL<],@+G N9G:U":PISS'AH6FDP".._%)ZPQH#U [
M/@WQD4=8"W@-QK)IK'OB/3ZBY"8Q:@Q\=S9\F@$B2$@;!4=Q1R1&#EM:^$Y,
MY3C$V6A,4]QZ%P:3NR\F-TDYD/!!% YG(?>(IZ+FLW0YS,O@M T<Q()/<:P[
MEO:/UI0D#T$N4^LV6\SF!\OM(3@P\%F"SR+9-'6 /ZBJ"X88TL FB;>@,>FQ
M0DS"'SOC//NUA.KSX;?8H X"CU42/#OA0T:!.\FQT[^B^O:>3TFH?Y0P&Q/%
M(MLJ"4@525S2BE5\Z8*+,^YV\\V^'?V5K,U*!NA@+3G=^<G9'_CLNZAB&?^2
MKB+#YC*)>X0'/ 0;99*D]C"@M1#DETFO:)_>6$DD@NRY0EAJ]PE.\39"!-@R
M8DA7FYEY@NZL<L9]'-_^C?OT^?H?W-773]<W7\9W5]=?&QPI5!NW83NUQNX4
M_[C\S](!SL=;LXUD".,U(!D,2 9-4F] ,AB0##J-9+#U(A3=>RXZ>:^?6WT6
M4\;Y'%LG' ()N1-GOD)P^&J''$()878<_X[:BD,='W#?T2:[<KGKA4UMV=V(
M^YVEXJ%/YW!P'7B@%" K?:D/A%BPNT>S5LL-1<5"1B[9D6FB]<Z+BLX;4DTX
MCI->D+E6AU!5,AN(9VSRHB3SBI;?Q?D*R%RKI:DRF1$*6.8-0>-5L2;6R4E#
M+;.Y0FHO#9/Y'^SX_)1.+:9=S9=CK992@#@4 BT:)[0?AX%!?5K,(7KUU^'-
M%KX'MB_K"+/_LW06CP<>-E03&!F;'TGL]I/G)S=;!KG%D,!3-'BYP&B"+B+=
MU 1G;H2"\M&YK/*R4A?/XC 4K(D0W0@%%: @F.SJ_A!!]@D?E)9#;JKMM6TM
MUF'@1$,M#IS8Q8MS6!1$0RN.@MA%ZAT6TM#0"T,:MFS7Y$J/:ZQR[:^8(,O'
M,&249_[D>X\L!NG^&,=P"L6.S3@Z5U2!%]3\0;Z=Q_*1^@M#)->$(>J6?KY]
ML'S[E+;%1K@2$>!6;^]=VC(C6R0[C*YAL?MF'IV;NLF;DM#9^[8G[Z B!4T!
M1RR*O*GVDX(->@=5*2@"#VH:K^IUY[L>(@8!^[;A2R!/)@^6^\,F"9Q?CW]8
MCMLVEE_C^1E2/\4V=,GV@QLI']DV,>B@FKPB;V*,Y9_I80E7%7RT&<+A'#--
MY$6URI3HPQ*N*NIH,X130(J(.J]5DL.ELR?[-%\^$;P8B@CU[#L$<VK6&5-1
MZ:^5JW9NZ:U<+V0?XCK_ YGG>C8KII8Q>B, .]<=5U]'*S>86_I(A L!%;4R
M$<4ZF%09%M,O1_/"GB"0B?WK,>DDA;^=D'EX/FEN G8C'<T)5*^^N9]$H%RQ
MO46[O7+O<(-C=TIB03>KW143-!CHA.,0M#<3)FZ%C#I.:- D(*14-^C9,P.R
M&B4+V)3&T;G,FXK RTH-/^8PJ?%,243E3S3HE^G!8_!=[07%R<%VFZF]\ (G
M/.@$@T83YQ%71'_2D#4E0HF<@HG%A[Q@B+RL56&'7HJJMJDJ"@*&"B3>-#H;
M\F^Q=+ >47-%F"B0X!K8.97*/SKM%A]'U#KY-9)Q6<860S1LV])JL5@ZS2,Y
MRNX;VVY)-L%X'2\H"J^H-1BE]U*M G&WTU1&=0&D!=Y_.P;9?ME601*KFL ;
M>L\,M)7TVK3+]A>4.*#42FJVSZL-EV0 %=2;R1M:E=11[](,^R8NJ4#B3;E*
M 5)G!EE)6D]J&;:T;A83)Q$+_'H\3<J5A>\].0'R'ADX\;B8>R^(;NJ&3C@G
MD  ;S68EFEO9-_(;6HN><[DG[=F/_!;1LJ#ZUX_.944%RSM?^>\Z^@)DZ]V1
M[4TR9I]9 =%G@#TL&KP@Y#NEA0]OHQ.N=^>V+V.Q[%4SC\YU@]<*5,I6NFE#
M4]VPF'Z;!]A93AKK9@0J8!G0@:1>5*:;&'O6>R'5HD\3 2J1&F?$6P!+>W>E
M<[ZJ$05B92NJR$M*?@;L#6F;%JV$5@Y2)-@$FJ#RAI3?Z#0<9%/31!L_2 R&
M"KP@PT'*^='0L@<Y6!/#8OK;HG]\GP5+1&"(,.="_I* S^L@J8?%#'Y.M\^A
M4XOI9O(W%CC$J[%7 H>+1NZR<08VSF3M'%&'Q;0F@YISFD\I<V5R&:B]!X(A
MWG/3?*=E+M6US*_=OP&1"L7P1 39D'E1-7A-R2\Y?VL1\YWG)._SG!3JY8)$
M-]J*M[[6<]+V>4[8OJ'RNB[SNI%?&]%R7+RR:3!8E*]O,1U2\1_G'AEXM5W1
M,W/R=0NFVHH^X?$7DT[:H.T/INU+'Y8^J/R#J?S2AV7L3^]O&7S<Q2F(O]V?
M'T].. 08I9#IC@MBG60^741-?[(#D@<=)_*@;0TL:61:IF]SS_@?UX/_9ZBI
ML]2FG'A3J^0N-UWZ;,#CZ(7,U;!3<S4XG!=!_JN09^"(@=4PG(WAUBV.PBDT
M:UH>9DWOF#4M#K.FAUG3PZSI+LV:+C(1>A<]&YMUY3T^.K3<+GO E2GJ2@,S
MP0I-P%;/N,M_?KO\>G%U]_WF$D[T"[ Q.;LNZ^ QF9&74IR1RE3XU6QI5-!S
MS_UA^]R#%="9>UQB\MT(#Q&M,]#"6*-]OPR1 \$173@AL.I_::46F<A,U3MH
MFR :Z!9T=NPT#O1^M/[M^4[X@H3RECX7;34@._7M "R0"?6[I_:3/?<(7C<6
MK?_PK<=@]& ]V9S%T:'=--<,I'% ARW@G=ZTP&# A+V-70+OP/Z96B^I[O&[
MU>._DJ=_(P__Y/DW;(5C=WJQ6M_':!=IN]L$CU98-Y,X>%EPQF7P"@_F&W#$
M=#L9DMN>K.XK3B+WO9_@,:!M-QK_I;AG?ZH6[ZG/WGN"5@D1$CLFV@['1,(Z
MM[/-<AKNT9G/X2]G8)RO9D63RW)OVVYRX"1.AL2J16"EK+M N H^$3#V.,-I
M2.C?X'L8O9_H7.'H+:%'ESZ:>L_TP5X\/8D<R (>!"R,>@%_F\NS^$3?GBZ!
M1PG")+P<!&YP1F]7\TY-6EDT\M0+.[2<.0'*\>TYY3_859(%ER#%$^TD@>T_
MX:VT?O@V/8H1&>)Y04;N>CXEY?]GOW!?0-/\H-.<X98%GNO:<S+[TUN&.$"4
MR#JXA38GB7OT.[;9;[ME"YL-:D_'<)_^2*K7#23$L>\C^M"ZPCV="'_@4_X0
MRRCOHD]/J7.CB1&?A=2Y=L;=_FT,BOS#^!9LLF_C?W5?EX=$*HQ==PD2Y7?;
M!1DPY[[8-G&?'\ AP83O5^_)?KP'QA=UE.$"4_,!'L>#-X<K$8R(<'X"/L;?
M@/MMW<^=X($P/&B ^,:04#/(F.4\M%!ZP)&!;VYC;2)^%V7(L^5/V=!JN$%\
M_-U@[<N1V+,=IF =,"%0?HW@,;$9<L:A0J;OP?L&O[NW:1TX3NOE'NWP@2I4
M'Z^_B_O^$R[L(KZE["W<#]][#C<%('PS\;*+)7G%> Y*#.0L,<'U]\'H^]GM
M&<A*D*+@B?+P7OH#6!9WC%^7!-'@QA>WW#?XT0EYB94RVY,?%11N?/M/]E$2
M#&$+LJ>=-8LR+0',-Q"5-Z4JSPF")66#IJ/V1+6#/ ,NOIY%XCDSKK@ 49/6
MW^+1^695\TK&\^TN%K3'2GG$NJ/@TB4P/3:7GE9(H_BAS>]D)<>C[5Q&M[G@
M#N2C\PS3*2T36J7_QUC@%%PQN(^;X>>4W*)6Q,9=9EY40A#TZ#8KE6]SA;1.
MG=NL9AY/T=M<=[&U;K/6Y&VNE4VK>IOUNK>Y+OU+WV8C4_B_]MLL5[[-%?)^
M=6ZS64LWUUULG=LL(_Q78[>Y5KJUXFV6$6*KUFVN2_^RMUF6WH)N#A/+SW3L
M^)3KQEE+<(%\$G"-/1GTH<B-CV*PUH\?OOW#"L%W6N0* 5%.];:=:B49DCCZ
M 4;B?' I$>@%E_(=C^9Z07R\L3N-PY$X@0'.GL4'LH-R ?M5DAD0IBKC!K*P
M'.?Y4\>U_!=*K"1GA,\>]2C1N70"[MG"H!%%'\F7D**L]8 X8,5*)8AC$:8;
M =.IVZ()>(-F2Y\ /I6AEMX#:JG)&'A1:N$5U;=>T1RJ&#V@BH8SK?*I,MJ@
MBK&+AW((8_: ,#BCK1*[F%L(<\8QJ7]K+T(:JP,K3H@^-BHN^+E8\!>1\XI0
M-<URFUC(.%['K3U9^NG.Y3Q:DK(O_6P'GP7Q0V,R$>*45(ZCJC02:W%D9.M0
M%B/L."U,'!,;NHMS6I(^4G7C(4F?41Y]ZHGW.M11T )7JE&GAFE5BGODPU%'
M)!,)"XOOSMK#&/\G!*"&/$W?AC:)P@?+^]-)](,HE']C/RY=E@Q-?'QD31\=
MUPE"/-B4&4BK#N&/^SF)_K.!6.0SMO\81 ]F+C7SI&-[\I&;^=XC^<34GEG@
MB="O_79_?M;EY-'WA*N4<(QH<LC^:?L3S!XO?,R0/BZ#$/</-P7Q^'Y.;'HE
M1C/+\;DGK&6,J(3/\:C3,45_ __B+5AF&D[1P@21/:6)'?H+3#D[[,#(=R:6
MB[4DT7MLEZ-%GRM"KSUY1-(HJ4='9Q$5D\*]I!EUNHP<H9\*.TO%]2(X_%CM
M!?[_]>R"KN#O= $?X_?#9_X%VXEO\JFTR^E5R$BRC7O\"Z:X"%FV4CM%DSYP
M8<)AW\Z%]_:*$>'O6 0'JMVB-("'_VF':89<-\> 7/B6)-7@DS]\RPUK,>4H
M^P#(@YM@2J$[+"G78LF((@>ISVZWP+-D';@RU('OJ .7ACKPH0Y\J /O4AUX
M>ZRRLP:+.XYKUO:^,=!/[.56K),;JIZ3J%:M6X+77'D]=3C'[O0?!',+]O@$
MCM0/^Y+98=_0# O8(EE ;4OAGH0.: /'<N52.P=)3XHSP81;V).08U5B+EDR
MJ=1F-@8S+U8.VB@G%8259#.X3MXS8NZT82:3?D.X_O,YZUNDB'YE7\&T^P2O
M_B( G1;][3V09AH^X%.$7^+/!0L+F^IP23_?'Q5J75\UKF_I-,U 9"O1^ KK
MA46Y8+Y*\?;S>U=S4. BJ?HO8HU?IOH"RS?I%N[RWQ>IM.8IA=5[!1MJ-YZX
MK06YT[M57L%NMV%-%-W*5N+(>[DD64 8T2+:%37-<]376.<P'=A1]FIAZY%A
M\-N]_^LYQ\P#^H_(2*#_(J8"=SS^2S$8X%=!G)@O* D&YAB88V".@S-'NVA?
MS/"6C%^J8Q-_L,%S(*TK+&2-,=3US4<6_B\[,67B3Q4'CV%?,7\ICQ*#D> &
M"A>OEV$0@EL&%$AZEIE%@?'ODO%HK-DW1%Y5)%Z7-G.>6TE9FDA=IKY<DOJ[
M?/RTBY\XGRMW5X "W&IS&]H/EL)FI*G5HW/A3,BH57NUAU9K $1C5P:;$72!
M%][:E5'Z?V5T<F64_ D/K^;0:HW::.S*8*F:H?":^<:NC%H^\=RU*V.2*Y./
M 5B8M(<8O4L+P!)0:"D[L26@U.+S2O6*\TH[A?':'AUWWS&]"0F7O$V_TRS(
M[IM46/:I6&LIZKP@"/B_KDX%+T/D]G1_(=*7%V*J2(28D#^BZU#4+RPJC*Z)
MBN)+-WLRE;F82HFX>-]:9?=D-?1.&A:'\4:;$HC2T;G&R[*,_^OBF/$2]&U/
M$A:D>@59*+\668A]Q#V5A=A W->E2_U=NMRZ!FI2ORP<_RUH%[+-IG0+'553
MW=;NDG*1ZNF/ G2MH#W4H_,S(3]^UGE1H/17BJE=6WJ>T# Z+C0PH(^327HJ
M-(S]!!G;DB@D)B]NPCMUVTFL-8/HD^?/;"?<KMV+UY-U;#+*WNV'F)1-"0.$
MO>*U@K+@#4UT[X9;7/"X*X@AFN>0M6'84<DKW7C\O>DKK0E'YRJO%O0)ABN]
MYYA_:U=:$X<K7>U*-VZP-WZE$=YWN-)==17:N](T>-W2^,C:8;YA=.VPF&$Q
M!UE,K_S_1+T60MP1W _;G;YV[6-VH191PXIWU>!5U>1E(S^2_=9LPS)GV,LB
M8(W5S>=''(>C[U[#BJ:5:U@9SO"5M;UH>M&VE^'HN]<\HQGEFF>&,]Q^AKWL
M)]"*]A,,'GR/O;%A,<-B7K4'CS"@.$C1G48M^ 2G:G#F:]>9(QT;RA+HV'JC
MJ[QFF+R6,?#D_V?OW9M3-Y:]X?_]*71\3DXE[\:VKEQ6\KB*Y4OBQ,OVL;UV
M=LY33Z5D&(SV HE(PC;Y]&_W2("  83094:H:F=M&R.IU?V;GKY-=V5L\.#J
MQY;[[L9&(\@ JMMKW2O1I^_J9[RX,078,FH-N5E3TDP"'J"$Q5S<02XPQAFB
M2O3I!P(R7MSZ\7FS45.;<JUA9.0K'HB LRP(SFYM!S'ZC"IWII[&&6TNN])(
M/Y4FMK/NV-,'SZ:9[-YQ.!@;U>F3[AA';JT&:6AI]N32]$G;[BYV''[&5WR&
M)WP>.)UOT3;#!@[C2N%-0W(D9S&I28=0V-UH7RZI;[X%0PV"GL'X33HJ8A(,
M@$!O:G%N1:F["L?I 2IMQ_IJ#[>SZ I)U-8NQF/7.>?Q>MKE0F*NI&39 '"Z
MI*5(F[^8FC#;]H>9OWDPOLKAJ..CB*^,&]ZNVB;&/)27<]2#Q LVMUUMJMWL
MJ77JAL5!((PV$I%P1\R#N#5$!-OR6BKXA-]_M0]CF7'3R3V/-TVIBWL\/1(O
M0,_J!*M^=WS>?OZEW?Z\3"^[O=OF[N@S(TQ%&VR=SMMDCV/SIM6I'["<[WM4
MP6R>.;+HT=1!L\]&U"K-&IW$NC+#*^77COUZU,68NQ$;$OW1=VHLO%.#OI.Q
M_SOEW*7/4';WET-^+?C&;)8I.WJ^3>KYMO+KD<@-YXNJ26FTL"(T=M.(4C!^
M84CGS=UU0:QORMFP/NY&%6Q#P9YSR<J);U.UR785+:U=I:D<G_]JVF.<T1FH
M7V6=^HW_5K&I3[1I--4YR75*<GT?DE-MI6 DB)QFMA,TP_Q&JKU6"F!C46J]
MJ1^?MY2:%K/G,']<-#C1T4:*?$S;@PA4]U5^JKN>FNH&A^#.>0ML9[65E_*N
M[Z>\&ZM$<Z2^&SRI[\"03[?-8@%L+$Q]@U6NR)FT3<Z'BTT^U'<+3&P%U&;B
M[E;[VM77^2GG5EK*N85V]7@PD30E+\7<VDLQM]1%@G5NE')=YD@IMP*;.MW^
MA;DW *RGT@ P'^DKG&A!?<_&H-D;L3_GIB?KC,ZB"?6D$;4'\]*5<_J3Z4J&
MY<V/$5O7>-*7C9C]5OA3/%R<5F[A<<?XC8KXXZ+.B?IN43ZV<E7?4>7\2W[*
MV4A).:LR6/Z7I+.@G+7LE;.QCW)6925"M,*=<D[0YC(KY0R,"28Y[-LZMW ^
M%J2=51F\@::X$89Z@POE#/9L>FS,QK3.3WDW4U/>8%E_,=U.7U*T_3WZ>)J[
MN9_FKB]1W.)';2<XRIB=VFYD,8"G #X6IK:;6--6@TVD5J_S&<K9R,6&S(G>
M!J-:K:?DG"0PJC_GII8;2EIJ69%S5\MSXA.I947A5BTW5([4LA):T]M/&_*G
M4%0>U+("UG1=%3?6T=#X4,N*GB(?LZK87E/6CFK]8IG"W4Y;L)3^3D?0MJE3
M/;6]8&:BJUN2;AES(O8;)]M ZDNON78#2?::61S>3E 2VS!XVHQ"'X&#W@;"
M''M?%&!ANR!&_-7X=2N5_&;RJW.R_[9RD.!N[E)\:1>Y[>9*1CJ/RV_OP=-]
M\:H[&N$QO)XYM :33]MZ$-#O>M;?)&A9<'S^[/CFX*<S?&"E;?AN1J^J,F?-
MZ,61'R?>FJKDT(\\=2]N=MRX><S2O $%TTY DAFT I)<,C0M&[NVH"SP#<?F
M0!I8/8)=7AQV'YBP!\P(M)73/2TR"C"+MD5U\5ZJ=J/;A2,1(Y!$I?^I.W:Q
M$<[6KDN/4TY?S!E]"WQ>B]>@Q5(4E^KQN7JJ-99]-=J(QUNS/919&HU"I:&!
MECA5FRE*(] )6;:PFCXMI09,/UGGCY;W3>JYA$@6"I]XON1BXR<@'Y[65!7E
M1^FY;WD2_ _;1+TZ(  ; R^@XNSN$?WR]WWSC>H64)KN$+X'2F;HP*TZ \<C
M@PFH*8\,@2O!/<C'B'10BTWU%'X8Z*H?@ R)]'KP]VG'JE?:-P2[49T")41J
MCSV0^, "B,Z).4)B LK[IB>]$&)+8P\> 0";J<'WOM7I2]C*A40:!.,W$&(3
ML&HM4(PN0 =/0@8Q -H!"\GX>OITNOSVC <>Q7M@^_+1.\VFD58JL+BTWJPN
M[A,3BPRZ"VAH#T#(EC^A[VT38 CN^@-X2V1>P,1N>+EW!%:"Y7M,KG8=^,%V
M0- V;)W6"'DY,B<42/9D?@^$1-"A#&%$ AZ._;%+TN/@3]:,B=9YFG>]FF+]
MS1F8OC5 QC&Y"2L/S"(?[DY6+SFBP4\)F E+T7=<M#2B=T18!DLKO MK;5&F
M._ [X!TTIN-ZI](OS-O-$(T7PZ-A[2-HNP27-U6[1S,BJ4"#UG#16\ =+!^5
MANEYH &[@5+P0TUB@7[NP%??*(F!,$%CO-&(KA>L\]47H)<R.'$T[U!G^D"B
M#0()EM[0G%"$ 4IMV")\,L.2</BA[%BGE0-3CG(+[C?E]8QO1U2'HMGH1K2O
M[X3F8]0^/ WN.\71G.,@8: .K( E%/IN:$Z&(.L[ W L/+S[3"Q BC75BD<V
MMAU$XFB#0;@PZ#=X*K4!++A3C =^C;%/ "5@/WB@$]R >/(7VKJ1U^^YSC"R
M700DT'Y/=/= L=!=&<T0RP8X4&\ #VV M(+#&_O*C-WN9ZZ?PZ=-'_<?)R?2
M-6K83](#6#4_PCW_&A.[@P:48OPH_=,<C/%GZ>0DO)1V/0TNCAQ."6@X\9T1
M?%E%[R7\9.K3U/&S&/W#EM[?1O-L$(L-K#!1E"R9016U$:]/HFR8,@#P/1G!
MJ[==\\7J_"C=@3T8,.G.06YH6O2JL^EEE%%4SE,6K6/9BTO,;R<O!'>53Z X
MD/M1>NL,>I&U429%1+\@9/;#H_3BB\R%FA;ZCL\C&$OMGBOHS72M_/1RWKY]
MOGJ\>?Y#>O[EZK']</7U^>;B2;J]^7+S?'4Y;=N:$RW3E\_UH7?WSU=/TO.]
M='%_]W1_>W/9AA>7KF_NVG<7-^U;Z>D9/OAR=??\)(6[P1%H\8AAW,6FIZ"$
MOQ_;8'1[P:[_CJH8=D/2_2&;]V%L@^D^(/CWU+#LY:$@]$/*.Z5^*CW]TGZ\
MDCZWGX!K#^T_ DY]'ZK]XEY_:>NAWNB?EY:'7A)8(YOSW!Y8 @/3-F'?G9QT
MY#_Q3G^JJ;0+!K*_.%TR .-H!); %%-IFS(K!M+>;9=Q>Z2L]&8MF-NCD0MV
M9+=M=V_ \B3=]=V6FVHZ[$-C=1CE']K*:):\S<B+!N/,D$)JCEN4QJ/NV$6W
M!R_JC%T7_4O\Z\@E;Y8SACN"\V1W+-B*:72"VG&F%_9LKCHR[Q[,979J7'/_
MP^G=G$O#9%J4$;9-!L-=HDHO9DQ>\+:?01_A* / 3Z,U3L%O05M:CCFQ5U?O
MN2\;\"'2.5LJ\5O_036V[P2O6^(7G<8,2_^B&#,_P9AY\*8WT\ YUZ^<FA*[
M-BTW"$S,=?@][ZW161; VEK5!$W4ESS%G=/VJ?92CX^;-61G"1_T[_\K-F>9
M8%FENGKY).A,]*9K7NN?L]#_7G1Q\2Y!.;;X[_$'!AO%?XW'W49&5-IA\>6S
M.F^RNJ&&[GQ]0VO_5$<)]"V?T'@!P4S%NVN.YB&%341L/IK12.LPBJHOS1=(
M9[Q \K[DS21]R1L).GC..;=P$B-:C_-SD)'<>0Z=JAIB=N//C?E!C!091YG>
M]BFK$<([,KI.&;W]\&7Y&*WOB/)+XG5<BP+[OC>-<LPM(@;N9Z(X42.R&(U=
MLBB#QO%YJWFZ;Q_^[_CA_WJENZ44D,*:QE*>G<! 6^14\_C<B#!JJWXM#5AW
M5\D!/J?AFK8'ZQ_W5/.5I:'C(K4%VJ(T*$U12U#<8L0( T;34-%C5!MO9JPF
MHQK6MQ\[+!5O=SCLB?$H&HX"&&\Z*K!VH]."D?3:]I:*&0T[66]1;S2C\YN.
MTDBMAY*F1J>C[-N:--UF TV^#%U-V&$CBYS<82FG8+5J>MS%S#G;N+%!-7"X
M%*UU:B1AZ7?9<W.]RMK/HL2>WG$L2LYQQ(=YB(/-DS1.R0$_*:[&O6T].J!$
M:PK,J%P-MU;0"CL)O_+HR+.C/9??R*1&6E,Y5%U.>612NM!L\672Z8JH X@:
M2=MUIF#2Z4$;.%7$-G M+DTZ74.3KGFJ)VG569Q)U]K7I--U44VZ/159%B:=
M;@AGTB58C?N:=#IX$<JIED1W\<*H/$TZ/9QNLF\#_5P"</F-46NF-?1>U9LI
MCE%+%73-!%/),C766AP/)MN!D_D::X8<Q-\$M'$7V<:-L6: TZ#46Z>Z4/&W
MIKROL6:H@AIK^RJR+(PU0Q/-6$NR&O<UU@R:/%"2I%QX852>QIH1E&*I^VZ1
MG,3?\IOVV$QM^(&1]LCR=*&I\&72&<+.3ESDY [:, V3+AB;KB;*2PC(MSQL
MNI:( 3ADYGXV75T6U:;;4Y-E8=/5%>%LNJ1:; ^;KJX*&(!;9%2>-EU=$R@
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M[$[CDK_&EDM8(Y+"_6K:XV5*[1&LZ-5OF[8]!FB$2UT:$D(I @'3'C1]9P"
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M'6%6(.@3 9_VK ^,>0,%;V#N!AH'2'-LS#75(N*>RF[V>O/8N./1S$4-_@;
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M=1*F] ZV9L -OT^-XS=,Y\/;@UN,50,V,/0!+%[+!HL(5_00JR'P\J[E4>N
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M-^TX&S5WIV6M1T.PNG'D,)V*"*Q_"VRU^8YAS8T1?$R?=($V)K$9:?/4ZHZ
MQ'D@\ G$Y)/725B-].S\@B_6GI4(KS.\&G(JAA=*8AZ)GW,;'9QPGP<045.
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M-TF9B N7="U?>K2\;\O$+*,D=5#L?[N0>A>HEUS2(ZX'8I3\/@D^\ONF+YF
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M..\ DR="I#MP!B1%^OYG!Y]S@4$6UY8^XW4_X(7.V)7,#@@2%BA5_W,5[_D
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MN!2T1\<_@8]L<#_^S['5<[V3WG@P^!2,!+_O!2,1;NBTN;;=O8:_31Y,<*3
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M[WBOW%F$U0&D3/:%E5#R/(!L!95CD%[U::8SGB=9N1#)$'4 N8)<$%5Y#IP
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MYQ9X0WKE+2"@!$XIB-<G*E-)'D!N(5H%,Y=E52F?):P.(+N0'ZPJCX$35!]
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MN76!HZ:"X.=P36Y=X"BN(. Z')-;%SBJ+ B8RF]RZP)'N0_6Q!4XJGR0)J7
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M    96$P,C4T-#,X,#%E>#$R+3)?86QT97)I='DN:'1M[5I=;]LV%'TWX/]
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MAVT!!7)+6$36$<WOMXSG(JZ-9RE^Z*L E>K[DMS4K^3[=W3]*O\?4$L#!!0
M   ( /:M'%MG+K@R'P(  (D%   >    96$P,C4T-#,X,#%E>#$U+3%?86QT
M97)I='DN:'1MW51;:^) %'X7_ \''Y8M&(VQ5JM9P4ML QI%4Y8^CG%B!I*9
M,#-BW5^_9QQ;E@IE%WS:/,SE7+_O&W+\YW@Q'U8K_G,PFN(.YO/C,)X'0[]I
M=_0V+VY_O)R^PB9^G0<_:JG@N@\MM]00LX(JB.@1UJ(@O&X-==A0R=(:)F+J
MZCU/TS?MD)SM>1\DVV=Z  61>\8=+<H^N!_7K=!:%&BI#?W9,HK_;.RDI&#Y
MJ?]UZP&<8Q7[12U2K#0>!F\9VS)=K;0ZC9;?'"-34QZWU1=0$\HUE;;BW]#^
MQ*K4U[P,GF]\J\K!=>M_;7,N9\2[QEP;3I;1)D !ES,(HVFP"G#!ZSIX"C=Q
ML ZFL'H9S\,)C":3Y4L4A]%3M3(+UXO_09+:\">%C$JZ/4$BN$+0H 7HC +C
MB9"ED$0SP0']DJ88R!/C.D>LZ9XI;0.JE8TFFA980 '&SX0L8./TX'LD5 /:
M[;;C>;V';JMNS_>]QYY[.7=:;K=]!X3O;-K,:9NT2U;WOM=ZN .1PBA'19D^
M08R(24D/FB4*YJQ@FNY,@#C(:D52!*UA1XQQ=-@?E ;OL0Z>ZW600XYP^?Z=
M9,HXX0DC.:@/^'4X9BS)@)0E)5)9MDQ9;)[KS!HWE/_F[]E435A)EM C\I&9
M."@Z$:*D4OGC-399T'R+.G%:1W',Z^6,6,\GK6Z&R:X-K\/XY0]D?$=-*<=:
MKU1HFE%J9ZL9P;\!4$L#!!0    ( /:M'%L2]Y"._     @"   >    96$P
M,C4T-#,X,#%E>#$U+3)?86QT97)I='DN:'1MK5*Q:L,P$-T#^8?#0Z<T3@I=
M8M608$,*;AL2+1GE^FP?D<^N)-/T[ROC%D*Z9*B6!W?OO;O'26SE2Q9/)V*;
MKA./,#PAGV66QB(<T7?#G[;8O"5'.,ACECX%9<MN!<M%YT!2@Q9>\1/V;:-X
M-A9F<$!#9>"%7KK[U3D\NWNEJ>(5&*IJ%\%HE;>ZN,$O@D:9BKQZ$<3IN::<
M'"P?YP\BW%V-NB#><6Z[Z"_EUA074SW5&\J:+'2J0O!H\*,G@X5/8F#=6V=\
M0,60D'W7K>T-PGZD-,C.@N(":F6GDQR1@=CY*K6LM/X"C:6#7"L^S?]QW:O\
MX7#)\;3##_@&4$L#!!0    ( /:M'%NFQ' T"V ! #R% 0 -    :6UA9V5?
M,# Q+FIP9Z2X>SS3[_\_OE*I),FIB%5")51..6VODI"DDO-A+TG,8LEI&*N<
M":\HBB)G<E@8<QB+.51R'!N3PS8YCTT.SYCMM]?[\_E^?W]\OG_\;K_O<[?K
M=MNNZWH^KNO^N.[WQ^-QC3_"GP(=N7G#_ 9HUZY=H+\%'Q!_#&3\[Z__J^=?
M(_^W-G;QOX#$]^\ZL+M4:-=IT&[Q74+BN_CM(# (M&OO?TT _?>S:[?0GKW[
MA/<?."@BF%![!+1[EY#0[CU">_?NV2,8#1>,@_:([SUZZM+5?1)WW81/^TE>
M?OXJ=[_BM:I6J7L#[#.:#YZ^.'!06N;8<5DE996SY\YK:>OH7M'3-[YN<L/4
MS/RF]7T;6SM[!T?WAQZ//+W@WOX!@4'!J)#0R*CHF-BX^(34M-=OTC/>OLO,
MRR\H+"HN*?U478.KK</7-S2VD=H[.KN^?OL^2!X:IE!'1FET!G/ZU\SLW/P"
M9_7WVOK&)O!GZU]<NT!"_QOZ_Q&7N #7[CU[A/8(_XMKU^[@?R>([]E[ZM*^
MHU?O"KOY29R^_'R_Y+57N56M!Q0U[[&E'CP=."A]1HNNQ/D7VG^0_7\#]N+_
M%[+_#>S_Q44#'1+:)3@\(7$0%,0C<2VW'\_Q]@,IS,E#J.*VC42ZU6Y@:_N+
M3&-.+/KZQ"D.S1D^*4)0XD 6VX-S#E?@4%@RZ5I?Q]WY:XNWAVH-OE;Z6 [W
MO-9Y&B_10-BI:1&%/_D64J&2HF5YV:#,16+;[CY;.)X5,,NI6 NR<F<S#-(_
MJZJTJU*'<-L65@>5 _76Y>K7IE].E+6U$/B@O2W'#- W7@-0,PMBHFY?"8H/
MNIL\_F#8T.3)EG(D?5!#6TLD?%I4D:2O],G)5-_I8U42Y92B@:X0$SD*HX.3
ME#GJ^9"HNJV^N/)*TP]^@:4+LE(I<<K5+]J@QTATSZ&*M13@YD<\#G>?0K=P
ML3Q3E[ @TAVV+O-,Z&#W1CO@%%:1<PCCAKZ'XVA_!B*5*^C;*S'9YVJ'M521
M,1 Y ,/ 2DTLWNE^6.;F+IW!,6T5*1S_SA#UWG2*Z;8,F367"M'#(/N>O8+C
M]3_&,EQZZEXA*EV!LB7P(:Y3J?E4M]7AA2U(8JDSJO "[D_O.QD:^FJ>,TTS
M),>7K'TLT "FT^.1;I03"ZZ*;5O9#WAVT,")/=3V#Z9==9/B6GTRB[+3F6\^
M#P=H),AZ/M>RDO&*]]KJ+/3;FUQ8@-9F^Y1WK*N^BYR_X13BD\XP0]2S5Y8J
MV,9M6W8) >$:;2I+$]JXH0M<&R5*:>G/<<1=[QJXC/[SADR+W%^U/VB'7P.U
M3BBZ=+P4X0GI[9Q0)>#&R2"!I27N0TX,<F%NZI$E"YDJ<6H$*[J/$RE#7R9.
M*^2"R6SLNEGME5,Z6_C10".H]0NJVD;2Y675K^_RQ_&4LGCV)FE2!&7GS!&+
MTU+56PH4D_(.C:FMC&XAA!GLP*Q=+AN,FR\]?,>ZM^J%"X> ]:\,IQXSQ-&J
MS>3J/NY../M?K>5</\8W)XKJ:)1<P?B@V^DJ7;NM2^-:E.>(+(82(PVE1(<W
M$WS6_!G(X_8C\F K'\>QM@S\W?+4"'HQKC;G(55<>-N1<%EL%#_5KG!\F"MK
M*.6N&Z,],YA<D^_L[-KG65*4%(()=Q/];O[$8<HBZ3;P[<C?:4JDKK,/:9)"
MI&6HK]4>!Q3Q_F @5A25TP:1&<#!1!>#'?M><HT8/<*P(1;7A*[Q$G(QVM"(
M;LL>;]_*AV2QJS66YF6W*&KW%NWK!RM&$(T!^K;Y$T#&1@/@/S5OJ(%@I!SF
M6K)YA<P#A54#N'$$G4<L<I&W69XAKWU09[LXY3E881?$U;)3M)8O+"ME_VS^
M 5>F/YW<@ )[CPUUK$16UG92U#Y6$3/:%90XZC4&\Q1760XF$C<.F9C9M$EG
M=%)OLJG)!(LB>%Z;$]P',J&1G[%]^]B*#3GB*W'WBO:*&)!_GTW)KT0EDLAS
M>!U:;P,#><2;%KTV(4?50)O3)UE.6>/7'#3<!K23+.X0R*P#R3VRR_<S)QZ*
M7_C[!"P6XP,5\J9Y9)>5 '9=CAZ]#?25 T :B;>_CIT3%XB-EX"WG&373B;6
MBE18D/1],]1P.J'J24CY:6JC:T79E_Z^(^]ISE:(O5W6]!7:;SHTT=#$ASXI
M2@.V'?33RS ?O3)_Y3Q#F_&.4;E7"V@C"XZ5L7F(F6^/M46M;@]@<QP)^)A[
M#\A:%4%3.4":MXCHS$YJA'!=EG)FRXGA4WM9Z9-WZCBF<3[:62)R1OHK)K&F
MY/4PGQMRVT9RVT>W9F^$ZQ]O%RO6\KNH@?0Y8Q0%!45(C8[,T8+>T7,+'%'!
M'34 \WJ*&9%('K/DJ%%R_ I=8([?]GYO5.O-"@[T,&K2O*K6_&/^M&YF^[,P
M-<F(>N8D=RWOV<&S_]4N<J\RC,!M6^C0HH;@#=7C@49@,_.7FI9-=ZBU3I82
M-R,?BG]ELO3?[%00W]IUI_3\5GJ8Y$#UIW+YH!SR'ZHPY_C*:?:TJ+L?0]6!
M#Z*KL!_@LJ7):K4^=\:(B0'W&V.<+#X^<#G-&"^,A34+]9)Q#AHK4Z<17E]7
MH'U_^"#HX#/#8F9P>T/$$:X6E1".S!,3'Y\/SCY&OA!@2Y1UMJ/%)G =<@%3
M*Z>DZV.N609FR,"QL*R&P<&%^[4Q2.4)>-"-":'*B!%IS&%#\W+ @*D1%1MI
M:$Y/.D6P*6^E+^XX==F&$E\LKZ6(3WK1-B,+!PAZ\LNY1KWY=,LPTY8!PE4W
M>M*-7A]]BWK%%EQ]5>KB A0,B)"@$FC%,I1BI_0];P4%2LL7:EW_N+/#;>7!
M=0,U3\M&?%-MJD%B6):\]>WJEKITE4-I8YVW?^VURG#B_8 *3[U8JHO_-+XH
M&_V+EXMA-*T<1> CU)J:A[0>L;FIW=@>-+7LD*R!]IOL#R(FA;3.WSC;4\LK
MCE-"F>#:S;:<I>T=YWD^Z$CRJ]RY;V5 OET=6RQN98UX\)N?CW]8L5?C1JX;
MW-\'CEV@_'/5KQB..(.7Z"J;VQ.E/Y.I?AHYICD579B3,$,-!$N@G.ZP[]:F
MM$,4.!I1M<W@]G2JW65:F0-M;M.V++#DY]C5,,]P?_F$G_O+U14;OZ7X.<E:
M+<&WC;Q"'S<JOYGJ3H(:-U</L0*;#W>U1YS\/$ P\2]W0<C@&SN;"D<6;"EV
M-*;KXE;S#_VW,>=8OQH3OXYD^J:FRXMBEVK9^B))^[866^\@]#-BL6B[4B?O
M1EY^Z:)^TG(NTT567J@].+-C>'VZHJP[I&!LC/9%(VH GG=LANR.JX?I/#/L
M@2(UGI%I65G&G-T R8,1_H@WT4VG)E16!A / ::D+;&$=:R4]Z6.O]LF256H
ML/9&2#ZR5/K2SYVRI7]BFI-87>2)PYS9&"ZJY51&VV:JMVV$+$>J*WHE4/+%
M?7)E+<+(X-:01OX@UN&Z[(>6[*U,>##>%GE!A]:37ESXE;%BU9!DF&^VD]D"
M1JE:9&K$4%ZAK-JEMX+CM,:%7(?<LCH^>P5%*,62*)D5<0/:8=/5+8/3G]F=
M*0\RT;VORJ5S7\; E5)=%Z?ZVE(.H0\#;E.3T:YB HU\1LL5F!:-_9PPL @O
M'?]V 9]95%7R8VE%)[]\(4,WLY!;ON2ZL'SOV,N_A<AEHFC3?&*\$CMUG ]J
MWY*7!1\Q?^#VWMV\OCG'*F;NMKOT;. X;B#DFO'9L?J/UXXMVPF?R/!D> S=
M8+9CW!3V5[WR@=VJ4Y"0,74FVM7'VHMLX*D_KBK6DQVB":&AK4_S?[SN%PZ!
M"0.1&XQ^@@2##SH.YUUB=^!<#[,S7AIZTD4^F+;Q3F(D@>51K@1=!"D#6VS$
MDYHL946O31HWQV"6%H_C>HQMF[8?IB?YP46;6].A!-7OCX!3[,HP,?#\RE2/
MO"*0'XP)8S:]]4D7M6JW7K@[TA&RL6,KGYG8<2;4)Z%@][3)$7S*=Y,O7X2S
MO"9K^:!6(UBGG>O>^N%U[.'%('%OQ3MI'9 3PSAY#<NA-83E93[(H5];U)8W
M82 G'V9>0PEHP.*Z2_.RE9O,_H*GFI$5.S"UQ.B ;ETB&Q_#-6>(JH-/:+PH
MX+CFYBW25)YCU=66 WN@CHW]!.N=) P<RP<]6'"4[RBG;#V^UTP[X/D9\7;*
M9Z+"DRU#MXE-T9Z,VYB0PL$D4&]\G5P\4^&XBINKZVJGFH>6<?!L2WV?F\LB
M(F=5&L."'EEXC=L\FE1U^[:MB99/_VW;D$8*]D&6+?H#J2['%K=6N(H41]:O
MGIV9_%*XH]A&[(9KEE^IJ[==AAW&HRX9JF,K/;_G%N>S<*KW)%Z&9&1PG;HL
MW>>:8MVO%1:3<7^(>XEIH!&KZWJA!K KX#YH8-?F)#U@=TSC[52GDESE7:'5
M<_Z3AG=<G#">HC<G$/NWQ21X5#[H(%>%OB(%D.Z3(8K02*X2IFS$!:CLIF_&
MJW.-2O&Q@2([FNW!LH=+Y7-&:Q-]#O^^.<1L"=-]E3#BW.V;9BIQ<2E08[1L
MJA-+;^ JEJ!T)IBD3?WW6P2*:%C)>4BN/WL#'.WO?%SZU\.?O+WX1&-5(C*=
MZ"6RD>IA6)P(=<]Y!M&)M,=Q9*)6L.7:62S$G?"+0%:[>>%\!D19-[9])1<>
M>6][WTOTM:WT7.5BI6B"IE8&7@VAA'T_]2S4LRTE09HH=<'0ZM.(?471ASP4
MWIJ]\>$I7L-O!UM,,X8'>I0?FZZM#5/$^(1(%GVCV-5!%;__V*]0-E@OJ-(!
ML3:B&&[Q@TJ;OB-</WQ\T5MSK( J$=L4%A9FK+[]SB,-8E(@SL28M>H],%_L
M,UXSVF?U:W+^KV,M\ASI%$:%NI'GM<9MWP]*$\4/,A1N]3^:-1NJ7$NZ!E5G
M7"G8Z<QU#]S'R#JSNMG9(Z<JWTB'R'4':T2QLK>8[7:Z*K:<*YJHLEOX0>W\
MHZ@<>XN U,ZA_?<ZY?PD':]/(0F#1SM7'_<\F=X,V-6*MN&T8PZU'$<; REJ
MD=ZO4"*MD+.<UYD/?E9D>1^@5TAOVB-.!7&^IQ.]I1^)X0SO73#@=MX0P7&1
M8JQ)CR)4Y5A;A#(06++PM*.1:4^-.#KI#98B0)%N*I%H$Z9DVNV& 2[4,R0P
MI& 4>,0RM/$(=R_2253(S7/N4%I=^,<4YH_"DF3!281+# UA5&:GD34I6W5
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M2=\AMN_(;KJPUP>5=B9>#WAG(FEJEHLCX7(<:8NO.-5]U?4<>5P%HV_?C54
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M>M_RR>HX'U30+_QFGH@'1UUO,6BFHE7+N^C8_18EA>FE=/L5@DO)XC^CW-M
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MW@8N'[3%4DEN#^[V2]E>&D N#/YG>A ?]"U7T-[+M"V:5K,#:PF9X9WIW>5
MM575."H5*MV;AY%:M"[OJ>@X4WK>I?S%LJK\]%Q_G\++5L<OG[:D0C+:'M5
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MRN7J<L]<37EM:+I3?K)]M[CKAUL?\Q+.@OZ["?5"SM*,5F)Q<_GDRMH;5C*
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M&>J/]/1!Y_T4IU@SN\WD3^C?=W8$^>NA$=2!;1H[QIPEC8U;,522BH!@NGW
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M7"<(7W]QC<$2:%A^%\>.%$0\R#N)/HEGK[3GR,#0VFS7"@92'%76D2-G".?
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MN\TTW8[=M4E(E+A4+_V>^F$N2X8]_5OJNW>^FO= J?W+;/R7>AF\P]5@7/)
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M4Z5M)&8:4(O:](?QRU)(5Y%_6!+O%O4C-^2-W;FI5:D\?ML:R*__B30<^;T
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M5N'[6'IW3J0>[?RJN]ST8>?Y5[1@!_\CUR)JKWYUDXBKD+$]G6)^:'GP05J
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M_X^FB]]G;=L&._I#F3HJ74*5W ,H989ZFA/\3GZM_DQ27?WM18WKV)/?4V2
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M-"NVGPO#)@6C=][P<-9IV+E<KE,XJ/[G;Y._,V=AH[]:$-16$+ 'Z?8V_.Z
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MF]#C3=A,)X5[(^47-F3A^5M \=%X,K@%['^1;OS&8W7;C>>;<F::3&[_VU
ML)5-BB-RGU):/<+EX%.U5(X DDIB, F ,JCC?1P7@K7(L)J9UNNLGP8!;V=:
M;H:D(?^3CQ#;#-WGT!QE(7UO J@*?MP")Y!\L0*,=RR(:B-?WZPX76.MK#5^
M5K<%Z36G:<X,C]2BXN-AC$N]7Q2L&.GEA06< -R'+,LQ?[[*PX4F4["VH$S=
ML@=? :)K8TVNN_<X&;IO.*PN[4QD@<L1]?Q91UV7\[>]*M%RO5P#'_Y.T(^8
MCFYZ9$LNF(+O8\W=M!V)-  KY"F7G$+U57=T9[Z^T"2E-<>7!WFH-T'Q-2IR
M_ALJDY0Q^SW3H]YSVAFU[)_A0'4=[Q J_.]5,1#TX><8?[CZQDAYYN1(/^LY
M:FQD91F4[$;FR._8V_]L /+^9:_!FEO@)<-!;!#!KP3\;W/Z?RRY_^D*EH7^
M<8T@G/7^NMQ1S3KQZW('F,R>VBC\?S-T_\E_EH-V2_:U#Q9D0Z'+\(W3+E'T
M=0MN[P/X+Y-+8!OU?J'_(CE0+^@.@O2*_W5%@E!)YA^BM*;P TI!#OPOA?7?
MG?5_LDV_#2S!&L'X[&2*\W=)<+;YZ\O=UP_<U!MS ^2IE)T3AO7Q)%1OM+QT
M<_+82(<T=MVQFC*!H7DV]"\$T%/G[?OMGNA$&:DF&>FHGR"'_Q]L5B!0GX>)
M0(C,)N#S@+V^<)HN0Z$$TQ6NG738C3Q5?FS1J[:A\KZEQAN1N53?_5;G)1M?
MU=0U?#Q^PN@Y&*>]9@/7=QH\'1TG% L@CDL]>K+$#)6-V@$P8E&98Y^&ZW\&
M]DWR'>9 T82)ZB?U(ALV)=L_Y-7T'S/40OK?K2X'MKHTV_J_)L?V>K5EB#M^
MEK]I-,Y1P("9OH/]ZCM06_SM9_48GIO:XA]3-+0F@/S/RPN.?U_8^FU3184>
MGDZI0(%6J4H Z4_\_Z.>C-RJ6S8'> 7C/E,W8G(*^#[_'Y90_@]+")[.64%R
MY?X",6N+WWK*IA4WCN'O4@2S 'JG7&'7P/%LEF'#Z\9<&10* _?#QX0@@H*"
M#K9OVWTV5T=3;<!\5M;Z8/5[!96#U4>%YA&+/&%^C N"+W(=+-NUB]HY:KM-
MLHNB?_\S\=3U:+$S0MW4F'>&2>[+X"1SP<K&$@$'>X4[#BRHS$CV^&"[1>WK
MJ/03XT0]G;7:\I>1//KZ\<*"8C^V<=*G@A**\VP6^JFEX32/-[C_UJU7RIHZ
M/4,?7[5NNW#4Q>S:>8^9K.40SCGNUFUQP 3CP>YPH2E$3/#O<[_K+VW;LS&R
M#%;6=I ^HA.X%@"=&4DF5?O<N;'$E6)XTDSOZR!WSDM'/1IQT,_LT-R'N3'/
M@=L--IFJZ%\84XPK1X6+Q>=WX=X'_:94%*HA/P779-;3>J.O8Z.8,K2EVXJ^
MH=^8(RE-4M3WZ$/5<5.6AECG*7>MTY&KMZ/+EKP;$]W*%!]=[+L[^M?U%%!\
M0%MBON0>H#Z%23+)TE,G;%K@ZLZ+:D4J[X^&3US<;V;0XEPA7^>9T''5S^3$
MW"C60=?)0,W[U6");8%-N?GR#?@[ Y_5TN>/@DQ4XQL<XWQ]5F]B>A=*GB3#
MM3N\'G1Z!W6:;G7(W16KHI76-M!E1LM+J*#.V]TOVG6S,#63;8!O/\?]30!Y
M,<$ M9@8(@:_$6G*U39]J\E6__62"<8W0$\ R1SBZB+QK;JX \Z8>G*+9/]/
M SWF;Z=$M3KW8'6&<7+SC6*514!:EX<D4,N@TVX\IT'W-@\U$UE*E47N6-.^
M"G3V8:8<@167@]Y1%%*4^$2E/A9.?4*2;'(LY!H3+(9P\BAV42Q.W@TS__8S
M1L:ABIF<P/3@6#!;"-0 _-L6J9%G^L&M=#DMAQ97I]#1,F7^P*!'5U?G]\1+
M<<S-PK=G6%YIJ=?,-\@[E[;5VHX@XG4,^WCC,LW$*JM<I29=^O&"H8%_AVV[
MQ7;-Z_/&_>U756W@4Y>YEUB]8DWR=^9-,(TW]GQ:D?2C9BC97^E=H%M9Y1^M
M+8H+G;$Y\;C$_VFZ^6 Q@O-4 (F["VP70(Q)-!A?EK #% _L%, WY2_DJBM_
MCP!">\\ 7:EF*> "@(YV&W.D11BC8V \A9#&1"RYU']N$9IK[(W77H1\U$XR
MI>LEK.%%ZFYKO,R*(>L^I\Z7JUQ )V6\G_$_.V-A5Y_15X ; '5A]'4G/YP\
M4^.Y'_-&=V?$4KR14B]CR?ZS@215!KK;@G;B&?-3"O5=+>4NBPF,0?<"^KUV
MB9L[ \:8@V;HCJ==W[6!J3BIM9?>S7?)FC]*J2-#C,<-F,6GCNV>E>B;)UR^
MX+:U#14Y-$L/'K:_@1M^ZDNC&5@*K959M%^9.YNO?!83KV\W[\B]*)EPKTX!
M"M^Y/&?/:(C E*R6!IEH/)WM+Y=.+7P=]73"O,K.O^AL--%E;Y&.@W:Z?G4!
MKP&T4W_7%^4_ZBO*L8:23-B.SN8$:)D"S8QV^T'B(2>U!>TE&&##9L_YG' *
M6 RH+5;.,C%0"\K3DK\7A)QA<MQPW1%""\UTE.96%Z E4-9?B=Y1UU@P-!)G
MH/G<9;SE=HEQ?J?1TT9H"A=MP&+?F8T\V%G>3NNQZ3^%P?*T/C8\5&]QJ%:V
M:HSC6'D/+)7G.R\2KSN7+:D7)L60U9M[7B=CO!RW9%R8<':Z)LU12_NAT.9F
MF7JY>B&^,_G/CNF-0HFIX ] KM#;*YYW[TRXA*K:M0]VG9.0EE"Q:0RR+K9)
MFK$\8KY_HZEWUJ\C7,GG[H?J0&C5O3^:Q Y8DR_E=0 ?^@L.=^68OXJUC\L1
M<M">4W5O] \X<M)85P 9E/7<*@??2KZ1.V%8NJ)!X>]JYZBZ<;=7 DORI>6\
M+ Z=1UKXG M!6031W[6H(*:^-.F'O@]-J;D2.M@WG4(^YW@\*@[Q^WL);O 3
M[^2M3#)WCRE_ERA3@?6@GVO&,<)ZAC>935%B<R4':@FBW'-!JG/2H%ZTI/5W
MY4R]UIJV+/=+W=@S[M_@C+:  VS'QOK4,':T)G (ND"$QO]9:\*\Q!R\Y6*4
MA5.4*3^&+BY?129EX*47EUS/<'8!"/[>DT75,6^U@')MZRE) )?P3)BYSY<.
M(#OPT)4EX89V76K+(2>?Q]/!SVURE84<QR^OB)"DC*]6+70+:S\:DKTA9C=?
M8N\I/:@T9UU&-!O*7*O?%I1K36[2R0PRN3AONCW%_HK*'X\CU:S$)>-*U[ W
MH'MDEAL;KE_T,?OTM,"J+"K'W))C;!DEQ<QD,7F$EKU8]4;@2<#4&YC<1@*]
MFD82 8)G/@P;N,+;>O<+(&U23(UQTU3^[P%8RK9Y:Z3KO%'D,]$K)VHY5C^Z
M-W!)("\8\YX8(,(*)GR-_L08R G=;]$&M,BY:LS[82V_([:[<Z$,KOP!IDG1
M_K3RV?>14SE'%KYK9$KO22\O[ZNXX6EU5=YY"@X<(MS&6E?,I?GC:_2Z1K&[
MZF'2%4W"C(_$O[XQEMJ?M!@"[7SQ7EA+XDLSFL,(&GFJH\K=;1;&>.#O$L^R
M+_C&CB*Q3QJ[D$ I1DUO#+MO(,<\V]X&^X/KH_Z]-HIS 5-/(\88V K%*3#"
M8@W<.2: "DP$*/FP[C+0=$H V1FP%.]XJ9X_5N-:RGDS832W/'TP7/W\K6[&
M5T98309ALFB#8Z'IT+]25S2,9(/.>P.:D1EF%)_"WV7,44=%U+>KPK> =MN"
MV95&I\#\)W\?P9[S"=*X[<68I%@ QYA"]#LX#2:ZZ)YZ:)2)IK"_AS@07JR;
M7>KJTIP^-J'X3<_&9<R]!E=.@XY;L%R8,^V$N_C]7'5F:>M82COISG QGJG0
MT=^#+QS'G$(0$/SARD%TJ:5#5[=-_<":I28/;MJR/S"@=-QK=53C7@/RGCJ>
MFHH7,[#>GUV*C03ZF!9T:&(!8ZTHVL"L=*Z'"J++^!P!*DZ%=O:.\@=H/;7U
ML=R3><8^!4X_2#+8@(HSQ'$R[%ZM*,YB)Q%]).!/SIXE(V%\Z[$6":XX(,6D
M4W,?@C)D#XK$:%X5E6G+/<S\])I&B*]"U7G(,2KBT7D8'ZM,J\3V8MHBNB9;
MSH3OT\@4R\8;?AU9Z;EY]H\A,2_4:F,2V[U61HDHN:2=:A,<\/+ER0]''TQ+
M1-D/EWM\&GLS.F9QH3Y,0D9IX[5= >Q%J.8X@67)A,4;6$_UZ-&1<;9G&0Z)
MSS$IG7HN!16D9SUYOCBEH;S/H7(V=,3P:A+<.J/;;M@[\6)M[O#PE%[3PX-J
MPAK8'K ^B@B5U\>(;8M:9X%*S43QJ?6.G2TR@*D#@Q33A"KU#<%$:T*10()/
MPY G@^V2(Q^)VEY7/U3FP?ID4=K@BJF]QYH;H6]>Q&U5OF&@Q4RDGFYD5@&E
MU)36DTWN]%/$/?-90U\INXV4YB=55:.>80V'F^0*9S.0T%!"+!**1<C5)QFH
M%CD7?+9T43SCL_?-1WXZ%09V0 Q?QE\7=-1W2+[$^_KPQ%7-^_HPD!EWSHUY
M9S)^MI]A-'_*!%,G T#M&?PG5%6\<(I0(D("\"2/+:;<17L6:!!#CONM'W4;
M;\XZ(CM%4/4[-?;IDJ4%$EVD<^AG5NWK]*R@^X_R]FBO_1@:,+>:71BP]N^U
M#.SV)FA9GHRR#@.;>0_OWG7M)7G_=4*-Z5_4 2-I2T_H?<TL2^?R!9,"N@PB
MOLY1/Y)<0.(>TA7'?&?WMA59,WX,7;\Z7'&E.FM*-^/XF "R2P )A(W"Z#Y)
MH;WQ<!$C/8QGIY'NL*.C=%C\LVKFCISPD' :D!L5=@%:YCN&KD*Q#9L"0XHQ
M$<[TX87%6U][+S_0OT#9!VSE_][,,<0:(7:/_6@YR1P<L_S93&T^U^:0V8B/
M_HF&;OV!$P.F:?AD>IL#[L\ R%SCSY0R(*W-Q>HAELU=KP_RM=YP2#..>#@)
M+5O5_!)"H\1S(_.Y9VN8IO<(=GUX/V0"H>:K;I+8;;G\%C6 0!V';_=GBRSN
M2)=[Q^"EQSX*NW6Q6JE(?;RAJ:7AKWSSYOR R!]#(\T(E!ZI!G5MS<J">-P,
MQ(+RHHU@]P@=R>DJ-.XH6!47X*"MN+V,-1]H"F!:PVE*@+5O(-:=.J'0GJLT
M:' I@XEBF\81K_4M6*5MDV;[1=2]*6@OZ<Z;F.PL4O^*"&7&GQ[+1#(N"2!?
M/G0%X/HY]/JXA5JHL&_NCI&F,P7N?CB5&(?^12,E/P_98>YV+Z,L]JY)^%T#
MVWR@_C2I'WLL4&12(7=L[;N^2T'RLV&2,F: __LB(XV,W\]7YSJ-M.A@KV2L
M3!4F,!W-^>\IM".FL=- <05PKF/=L?'&ZY!G/17^%K2DD-8(2W)<Z.+5Y:6+
MM34K-?.ED:4V)2TD/*C59AFLU_F8TDN#?'TNX@W02L2B #W.V5F*-&T NR5@
MBB"*=0%T&"'M\.VA 3C*Z3I&&V!J5SG2I/#<WP:5M;\V#^E7Y8$I=4KM4CWO
MNN?Z1OI";3^';!Q:N[[D/>98VZB;3Y?:O*LDD[!N,SO)LZE*2WGI <;6&'\U
MRFB]+2MJ9'$/%?.S"?5B%)-XVLX]V#?[[*#!N7"::I2C8T/,A=3Q=@?/#G;4
M]]MHY03%?LNX4F%GI'K-M!V#)$RBOH15Z74H$/W8O1U)FK3>>UA#.G(OH++>
M+J^A5_G5(HBV)#L*_&9H3G:L&_CV&2VL;NHZ%'K:J/7EUY8G^ZLOLXFC"@\^
M&+G5@GKSO)E0!W&_,!X4;+MK"'>,C !['YIFHBY+H2T3IP?0IZ+"II;N\56Q
MYDW,\N$\FME"DWH1)LUVY(J%F<%OH:>:C;Y^=7(N+Z\R??/92 5<X?'04_#H
M",W;_-WOO>ARGJT.^)H;.32\,-=V,-.4$5?LP['H+!P#[J#&>F-7I9K.!>K]
M-6(Q4*NY8]+OJOJ9-5&C27>3GZB'$E]%M5E\$A'P[JHU6F!F=A(AF,2V7%U"
M&U^]7\>3T3T5&,N5H]^J9GR;/)9XGNE F((*^TO'QQ4-=.R +6(6=2P.(VWK
MP_,8S8O]_GK'SX44(&3UQEDQ#//[CW72DL74XDRI7@IPV]SF<.).((1CT,,Y
MCNMJD05.>98#Y"Z/(Y_+5\MMR2UZC 6&\111'C/OSC0L;&:*=V5U?BH_5*Z;
M0T1)9M4]GSJ?Y1R(B'-9[A_J:7LK]-#LTU3$M\T;R?'R+:3RJ!21:QB1R0P-
M3*=[HX1OF_R'^BJWZ@*'X):4)Y.[)C*+@=Y[;H&$FQE:RL_3NH6D,5\U-&KQ
M951^K::?J7A<$>+A"CD]V#XKR&]B=-6H!S^F_'8V.F"M)4K-+F21,\ W\8<#
MODN_W>YIJ5_C_,Y/=>S4BJ*LS*FDK7+Q72U5!I(//WSXTM+("ZP&O6?@"OQ
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M\SS*D]8*"E^DNI!',9ZLB0&L<]&L^&SNE@9+4W=>;I,SY_2L2Q0E45L8_7J
MJT /HKY9$A'.P*O-.>X].ABPM,>C^[U#7;#&_NQGH_Z6='A\6&-F6\^6I7P
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M#=IW<T]!NC?>L;7L8I!_",;9:U>R;KYB8DZ$35?CO5R5'-F+>V\Z73WZ5=+
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M0PEQCA"'/2VGW>=7*TZ<@%'9%TG?RLLBM/N16]V(TU/ (&$T3EM\)=9Q4!E
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M$3H$X/I.?5@! LA'\O'GE(<-V$?ZV7?#.7H.:XNF]:,&;9RNW!U9C3_N">_
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MUDME7-PJ?/V4YF%6MXN6O$^'A.Y7'E35A^"SIO%_O'XJN7D?WHB@QCF&(L)
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MEMW<&8E9'OEJ**#H *MQ^I8Y4KGZT'93JSUU\M6$HLS;QUF\WVD24SD(J-<
M<W>"[(P\^8Z8/?*T>()(@$J\TH^>)J^*9-G7'\Y\-RJ'\%]+FK2P,O=I"!$2
M'K@SLE6B!!35QYB'%D]WR0Z)$3FSC''U0^?<H^\D5MHGV.3ISEUJ?J28'W&G
MDIG9R>9&!]%2*H6E^)0QV[O7'X0E:.O9<G;*O8)"E-H9P.VJS5/FLQ-MC>\M
M<\4_B^K7O2$I,R7+2FL<J$WN.74:X=M-3D[/3-C8^>Q89UE/A'1BD8*E>W-+
M(YF9UJ/<9II7,E6)-4,R18'S-^R?O_]PU]*4 O]H]M8'S>ZU*])UO%OP34J0
MHDZ 0&#'N1C( .?&FV0]C0 .7YSCRX7FT'88M!8*F;1%%;?9Z51@WWFM,,:6
MUR!9/._=JU>Y9[>5K1V/VFQICU&Y(;-Z]R?6[^M[?1&KFVXY9YYN&/TF5CGD
MN]4"(_3&!0?NPQ(6U8>+4@-3)\#ND ^ZA';M"1*6*4<3W<[LN'E^C[$XQ1.>
M(B6IMSCV3;KW/4^VC:83 [-!K5W"=#)4I9S[:F.BOW>2@6J$#J]UB5FF_&07
MJUVNY]O^P._1-PS004\(N>F",>6);:Z5EA(#Q?B1P$:S)#O-@8[&H>6A B>E
M5TS/+75MPI3='+]4I2B5&%_<1<9;S9Z@!EU.*EG!G:NMHJ@\*G:T;J5)]\F[
M)K33^##6ZKJ9ZX73O_L59,Y:(\XN6:F$N:V5[^2\90:X?G:Z)_*,^Q(P9Y?J
MN,+R8RF(=FVYEN%B>QBTF_2BAA_!,O;EITMX27#O20#9NIN]W?/^$4+\)OZ#
MH<^'_H+\Y:_H0KW-O*]BE!E]'!3(NCDL=[XO:<MJ!I8\?C?=F+P"O.N_=45D
M0N?[2%AG O+EC-2$T:*/R\#<A_H7^C]\FWV(31J^EWLT62G'PC4TPK&<7MU!
M!5GV_'M;_$F1->X6%IY(ESL?JI[.LHOBWF]\K/[+Z3@ZM[A=E6\\4YX_X8LG
MH=+F^<"CKY<2Q5EO4VH#I RANJAQF2:H5*US5J-J6(A/I$L15YFEVE &G\4K
MPZF2MN=O;U]$.<BYV;/&MC6.?EH82TS@?%(8\TPTKMSP%'="^>J/H:Z@T1+=
MI)M:FD:2!@%O2BU+I5K<NMIF3_B$]H13H*38]E[V9?V@$*0(GT>R,AT2*\3[
MOJGVQ5K%N<$:]&_ZKY^7%^2)QIP8WG9TF4\TH;U02'H>0O$2.D-^$U 13;G6
M<<_?T79R&3ZN+3I::P+[D5U>.#"UA_"*[<!,9#?9&_KZA*LEZ(W4U%VT-PH2
M?N[R'".;X#"\G61]<S"'4-=TW X3%^*H'IY!GJL=R%R30^8+6CLQ?/8P_) _
M7U[L+#4Y.5N<IY0Z5:5GV)XO.5JSQM 69$CN[; N6IZU&F3<\8OILNR[0&ZN
MW]>JS9AYG2 [7CM\%QMB\MZ(CV>B];[MY6XE-@'/!35CKDQ%7CWI@FY>W8+.
M[M\ZE164"Z6>.8O&81/:25+#>3=<)"N\"#ZWFMZN.+<\"E[RL9;\6JG\OL'@
M1?[Y#ZT6(R=<5:WRN1+/&Y>]VO;FN2O&%2W1BO+&K4KWEY'X @KC0Z8\K%<R
M@-2Y</LFV0LK[?L7ARO.(\5&).\I#]I[EQ,.TKU.><B4E.O)/M )E9;*F/K$
M6U) 3'EXIZ:Z*:&=:U,O$BDXW>PO,C!56STU/B'3XQ<WV!Y#NE5E,G.A;C+N
M^[E.0^O._1[JSD3F2Y/6EG!SW*#?]MY6F^]KX\J>MRCS=B$^"E<ZLL AVK(V
MMAUW?F34M"[;2[N'_0I6=++'I?J/C!HHFV.;=FFX%[FZLW(:%=A)Y.=ON7:U
M)1+1/A&5:#73:237_SUY9CF\]%[B[^OY(S]G9B0N?"WE>[B"/QO0UR[%5O#D
MR9U%OGO=J)C"&^8%O,;5V;:NQ5+O"XV,61>+C=\]*^"6ZBLV+LYC.=%J\7*E
MLTXNXGUBT8B&2*&QI93%K4*>(->,&X//WNDJ9HDLF_N\>-L7E*L]!$[A5W/G
MF:94XK?:'Q:G#;MGNJ2VM"MXFW4?N_&%=3X^.-+HCJ7(FTQKULNB5VM'T=Y+
MLYM[T,,M=&LS@PF@Q5+YNG,WOEC'K6+B2F1 P3*?!:&&#EF#UB&F)E\S#UW.
M0GL-8[_G%6B[.!I\C3[NF? 31DZQ1?M'^8+&P'IBOF%&I'TP1,'F] F>+QSB
M^B5$KR_>A2IJ^IV%$PG&SU[F.ILQ!1;;,;WA0YQ/:273A+QY'.ZIUQ28U4B+
M,[%93*N]U94R340JBUHI\P46BY]0-_-/PW6KWTY\VWOK1A?CU%S06II_&/'%
M!PA,_9!!#G[M4/H[EC7J(Z+2)$'S2@6 ;9^MAG[*"VK/%Q]1AI\%'ML--;._
M<5A6Q]67S?2\79XH/_SZ_H6<? CS0?S/BN) .]N%-%TU%Q]NFF#7 :,KG/P9
MSZ"-(3_\\8(.&4 O/CV E7[?,,2P9ZNIEDY*=WMP[#X#FS8]P R9T9U1ZZ6J
M4Y>2[?=ZZ43%S,@;^\VPCK ?8!I\<?UFSP_^/]Z^!!S*_FU[>GI*A2:)":&2
M9'_(OLP\Y8DD)F1?II)L(2$C8Z:2?:N$(J82DIBREC 82Y(FZV0=,[)O,]:;
MV;[;L_W?]WUZO_=_'-]WO,?1T5$TO^6\SNN\SDOW_?M]"I@D??7(N<W%0=P#
MUQXF\2#J+!ZDG&,"L)UXD-W?.1&E/,C13(8V#[+#4)@'2<"^9\OC:(.X-R$<
M<?\Z*OO@,H*K9M)3XK^QLQV&7-_G3L13<$=2-_@SPI_Q(!$3/$@KUA?O.6;\
MBQWA',F0(]$U19:V&:Q>)*Y]G9A9XD$2,9L3C7(BB)-=6+ =H?&!GV/&(7XP
MAX_3C$,^5UR=RO4S8_ @AY:ZYY \")\9LY<'Z5H(G/NIK=EANRZKCJ.6QCT_
M]#%@27XB^7%XN'H "FQF2>_ #FAA0X-ZFPB<F,2Q+]W>/!F?$U'"QU;WKR.#
MDR"_[A"4MFT-02=TK!!7+1R(X0'7PV&HK J+8-4R!"-H;DV>4(\A$/M/=#\9
M0[J.!*]2D[CXQ[KYZ_'3B 70V=$+Z60@!#8KV<45TQZY@IL]V1'(@[Q8QI'>
MX2[P('_.[4ED)]N^=.?GNAWWI;+;U,F4XS4<)^S5PAZN(PI0)TQM6Y?V6H^=
M1F@:AE=:A1;,;"0S"?$@YH@WN#_Q*$-Q37*XDB06'P_2D;=Y^D<#_RG0+M[$
MMASC09X.4GD0P5 4#V) 6B.V@0YS^^9!\="RZNX5,+"=_WFYT%EI'L3XCP@K
MPT W"I(C^AJWG@=9]B)NQ3'N=.#6I9+='N*^^OGS(%'5!!XD^R*+.@8.$+%Y
M;CQ?/_;21C)K"@>\,FA:D5X#;2O3ANG!UH]>A?(@.>:;+[??%8T'?>\/<#!Y
M^PDQJ0U.3;KBP(.0?^$L+(*?KT_%K6^=0ZB%FW"6B6P;"4HWCFJZF;E->,:\
M]#<$-U%[Q)^[QU$5--R@H=]-XT3P('^R9]MS<$V&4O_"X;''/W!8([SD06I3
M>)"XG,\H2QXD'!Q(!"7Z@^7]:!=A!W*X$8$XMI8[GKT$'>9!E%798G:;#YUU
M+<' E8+S-%F.JVY. 78$<81XQ+\5.L,D<"4GWA.Y$NID;FCT BXMG2M0N/ET
MG1G;Q*PM>;=32[X1W2GS-CUYVR<W1EJ!>ZYW0[\JS+/$U4RV9S0&91S5<R6]
M4<O[MXVHNQF1B<5^*H?YW@OP;8G&SK#7F #V'8&,BL$S+'B0;W86C&78'FPK
MOK1-'XVOKVCTWCB:2?-!J"PU56F^S@PVLW_@H'KR;(M%)W^H(X<'Z5LV[7G:
M?<1HZ#] E,6#C)_L0(,+E"PX$V4!ALVGW8EBESKFN\R#%,1S*_C_Y#.8J,]6
MDU8DQ0+)VZ(7J2L3?(BBHSQ(,(@/#\+2 X@_0N,?F(G 27)@2*M[J:L*G[@\
MR/I^$*('^#\@PGO.HQ:@K$D<\Y,V],\_ !]^-"YR,S\/Z'%;J5L1?U ;W[/H
M]^YUSX9[Z"913J[\:U OO[\&/9O_BNO&@R39-5$9\ZK?]+F)^B,>?Q*P<U-:
M_BMO>A;]-W:U8T-M-W^4]1Q6P'[(@S#TB.S;JU@3EO3:M\WDBTS2)P,.Z=:/
M#$YK=(W$[T\;*S<S9@34B(^QJO=X;6F:1M^_*"_[Y3EULL2KR.<JL2:Q<!S_
MN[P\@?;I;\K+B0XD=X '<:39<7?26+O 3;:^[T+.9K(,8F#U6G:W$H4MPCW:
MP_TV1)<,9,?"'TAJ>ZNFTB%XSW=52T%K.)6A;;+1K>4\B'>['@_R.5^1!YF(
M8*W]/$TH18*)@E#@WF>3OU;GOQKET$!.QZEG@["$0[DJM<J@1 1PZT%%3;$
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MNN,O/JY(/R(D@*9[) OQINC%ZIHMM22Y#E#Q]8@:'T:S^7*4[I%_CE=2;VZ
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M)1(PW 6SBCS6D8/*?J%P<:8CM_7.AAG3V"V:1'^3O8_N<Y&)=GST6=*N,:A
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M.0,G?]_\2<<GK?GP]Z'!@AL.E]$4[JY6UC$TDFX7C9'PHKL8-<+WX,\ Y47
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M$S+K5JXR :=25M_)YA#9<ET4$_\*C);^E,WHMIWONIH9G/2E:^VP@5K5P(W
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M WIUEI_6RI>:GWH2*IZV+%IBZ@<Q=G-Q&:[D0;9YZ5F\]7_&;<=+&$#IJ+W
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M98(5^*O#6/[(@XXC]W<GRA7F0]G;<$[3V 8<J8('N43>.'P/1PMFZO]Q'_T
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M-AP@P!+G8024*C!))BJ$Y!MWB@Q*14X 6N@B\N AU,>XIJ=KG*K#K!OWLUJ
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MN )1$T)#?GS0T1Y1?_C%'<K-9"-%4P-LP^["!^?TZ)?IO^Z/7$DL2!?KC)#
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MYSTO@#@R:T&1]U)-Z%%O7T3FY#+[;8LI#\KNY>MP4=S#<0>*U'7O>8_-N3F
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M+3(P,C4P-C,P+GAS9%!+ 0(4 Q0    ( /6M'%N[#O_Q*0\  ./!   5
M          "  >DB  !A=&AE+3(P,C4P-C,P7V-A;"YX;6Q02P$"% ,4
M" #UK1Q;'.[(BM-6  "V@@4 %0              @ %%,@  871H92TR,#(U
M,#8S,%]D968N>&UL4$L! A0#%     @ ]:T<6R\#?8'XU   N7,* !4
M         ( !2XD  &%T:&4M,C R-3 V,S!?;&%B+GAM;%!+ 0(4 Q0    (
M /6M'%OEKX*G"%H  )_F!0 5              "  79> 0!A=&AE+3(P,C4P
M-C,P7W!R92YX;6Q02P$"% ,4    " #VK1Q; :A&5 4< P"IPAX &@
M        @ &QN $ 96$P,C4T-#,X+3(P9E]A;'1E<FET>2YH=&U02P$"% ,4
M    " #VK1Q;;E?R*IT'   _)P  '@              @ 'NU 0 96$P,C4T
M-#,X,#%E>#$R+3%?86QT97)I='DN:'1M4$L! A0#%     @ ]JT<6[G<J/>H
M!P  @B<  !X              ( !Q]P$ &5A,#(U-#0S.# Q97@Q,BTR7V%L
M=&5R:71Y+FAT;5!+ 0(4 Q0    ( /:M'%O?4LS#1P0  "D0   >
M      "  :OD! !E83 R-30T,S@P,65X,3,M,5]A;'1E<FET>2YH=&U02P$"
M% ,4    " #VK1Q;4WQ L24$  #1#P  '@              @ $NZ00 96$P
M,C4T-#,X,#%E>#$S+3)?86QT97)I='DN:'1M4$L! A0#%     @ ]JT<6V<N
MN#(? @  B04  !X              ( !C^T$ &5A,#(U-#0S.# Q97@Q-2TQ
M7V%L=&5R:71Y+FAT;5!+ 0(4 Q0    ( /:M'%L2]Y"._     @"   >
M          "  >KO! !E83 R-30T,S@P,65X,34M,E]A;'1E<FET>2YH=&U0
M2P$"% ,4    " #VK1Q;IL1P- M@ 0 \A0$ #0              @ $B\00
C:6UA9V5?,# Q+FIP9U!+!08     #0 - )8#  !8408    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>ea0254438-20f_alterity_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:athe="http://pranabio.com/20250630"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="athe-20250630.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:RangesAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:RangesAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:RangesAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">athe:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:RangesAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">athe:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:AnnualLeaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:AnnualLeaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:LongServiceLeaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:LongServiceLeaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:AnnualLeaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:AnnualLeaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:AnnualLeaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:AnnualLeaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:AnnualLeaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:LongServiceLeaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:LongServiceLeaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:LongServiceLeaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:LongServiceLeaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">athe:LongServiceLeaveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">athe:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">athe:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">athe:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:September212022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:March152023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:June302023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:November292023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:January82024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:February22024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:March42024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:April222024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:June302024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:July182024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:January222025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:January302025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:February32025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:February172025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:March142025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:April42025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:ShareIssuanceDateAxis">athe:June302025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">athe:AugustThirtyFirstTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:FreeAttachingOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-08</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2024-01-08</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-08</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">athe:AugustThirtyFirstTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:FreeAttachingOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:FreeAttachingOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:FreeAttachingOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-15</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2024-04-15</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:FreeAttachingOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-23</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2023-04-23</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2023-09-11</startDate>
            <endDate>2023-09-11</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2023-12-21</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-21</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-21</startDate>
            <endDate>2023-12-21</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:FreeAttachingOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-08</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-08</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:LongDatedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ChiefExecutiveOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-02</startDate>
            <endDate>2024-02-02</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:ShortDatedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:ShortDatedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-02</startDate>
            <endDate>2024-02-02</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ShortFreeAttachingOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-15</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:ShortFreeAttachingOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-15</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">athe:ShortFreeAttachingOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-15</startDate>
            <endDate>2024-04-15</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2024-04-22</startDate>
            <endDate>2024-04-22</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-21</startDate>
            <endDate>2024-05-21</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-27</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2024-06-27</startDate>
            <endDate>2024-06-27</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-27</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2024-06-27</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">athe:AdsPlanTwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-27</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ChiefExecutiveOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-27</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-27</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-27</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-01</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2024-08-31</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2024-12-30</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2024-12-30</startDate>
            <endDate>2024-12-30</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2025-01-22</startDate>
            <endDate>2025-01-22</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2025-01-30</startDate>
            <endDate>2025-01-30</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:NonExecutiveDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-04</startDate>
            <endDate>2022-01-04</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2025-03-14</startDate>
            <endDate>2025-03-14</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2025-04-23</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2021-12-08</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2021-12-08</startDate>
            <endDate>2021-12-08</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">athe:SubsequentsEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-01</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">athe:ReserveOfShareBasedPaymentsForOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2004-06-30</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2005-06-30</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2007-06-30</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2008-06-30</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <instant>2009-06-30</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:PlanAxis">athe:AdsPlanTwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:PlanAxis">athe:AdsPlanTwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAABOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAABOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAABOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAADOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAADOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAADOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAFOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAFOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAFOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAGOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAGOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAGOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHACMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHACMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHACMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAADMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHAAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:OptionsSeriesAxis">athe:ATHACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:PlanAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:PlanAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:PlanAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:PlanAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:PlanAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="athe:PlanAxis">athe:AsxPlan2004Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ASXEmployeeSharePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">athe:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-03</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ASXEmployeeSharePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">athe:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-03</startDate>
            <endDate>2025-07-03</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ASXEmployeeSharePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">athe:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-15</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ASXEmployeeSharePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">athe:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-15</startDate>
            <endDate>2025-08-15</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ADSEmployeeSharePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">athe:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-15</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">athe:ADSEmployeeSharePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">athe:SubsequentEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-15</startDate>
            <endDate>2025-08-15</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:ForeignCurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:ForeignCurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000OnePercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000OnePercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRate36PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRate36PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRate105PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRate105PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf15To482PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf15To482PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf15To482PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000TwoPercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000TwoPercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000ThreePercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000ThreePercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000FourPercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000FourPercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000PercentFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000PercentFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf27Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf27Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000OnePercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000OnePercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000TwoPercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000TwoPercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000ThreePercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000ThreePercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000FourPercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000FourPercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRate144PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRate144PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000OnePercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000OnePercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000TwoPercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRateOf000TwoPercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:InterestRate385PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:InterestRate385PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRate385OnePercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:InterestRate385OnePercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:CashAndCashEquivalentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentLiabilitieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentLiabilitieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentLiabilitieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentLiabilitieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">athe:NonInterestBearingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:OtherCurrentLiabilitieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:LessThenSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:SixToTowelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:GreaterThanTowelMonthsAndLessThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:TotalContractedCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CarryingAmountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:LessThenSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:SixToTowelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:GreaterThanTowelMonthsAndLessThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:TotalContractedCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CarryingAmountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:LessThenSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:SixToTowelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:GreaterThanTowelMonthsAndLessThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:TotalContractedCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CarryingAmountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:LessThenSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:SixToTowelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:GreaterThanTowelMonthsAndLessThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:TotalContractedCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">athe:TradeAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CarryingAmountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:LessThenSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:SixToTowelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:GreaterThanTowelMonthsAndLessThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:TotalContractedCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CarryingAmountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:LessThenSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:SixToTowelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:GreaterThanTowelMonthsAndLessThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:TotalContractedCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">athe:CarryingAmountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001131343</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="aud">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="audPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:AUD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Options">
        <measure>athe:Options</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="FreeAttachingOptions">
        <measure>athe:FreeAttachingOptions</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-23370">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0" id="ixv-23371">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-23372">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-23373">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-23374">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-23375">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-23376">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0" id="ixv-23377">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-23378">000-49843</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-102">ALTERITY THERAPEUTICS LIMITED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-110">C3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-23379">Level 14, 350 Collins Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-23380">Melbourne</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-23381">3000</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-23382">AU</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-23383">David Stamler</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-23384">Level 14, 350 Collins Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-23385">Melbourne</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-23386">3000</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-23387">AU</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c1" id="ixv-23388">+61</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-23389">3 9349 4906</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-159">American Depositary Shares, each representing 600 Ordinary Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-164">ATHE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-23390">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-23391"
      unitRef="shares">9127370686</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-23392">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-23393">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-23394">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-23395">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-23396">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-23397">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-23398">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-23399">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c0" id="ixv-23400">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c0" id="ixv-23401">false</dei:EntityShellCompany>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c0" id="ixv-23402">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c0" id="ixv-10728">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Cybersecurity Risk Management and Strategy&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Cybersecurity risk management is an integral part
of our risk management framework. Our approach aligns with industry standards, including the National Institute of Standards and Technology
(NIST) Cybersecurity Framework (CSF), to effectively manage cybersecurity threats and incidents, including those related to third-party
applications and services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Our framework includes:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Assessing the severity of cybersecurity threats&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Identifying the sources of cybersecurity threats&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Implementing countermeasures and mitigation strategies&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Reporting material cybersecurity threats and incidents to
management&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Processes for Assessing, Identifying, and Managing
Material Risks from Cybersecurity Threats&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(i)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Integration into Overall Risk Management:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Cybersecurity risk management is integrated
into our broader risk management system. Regular risk assessments and business impact analyses are conducted to identify critical
systems, applications, and data, as well as potential disruptions and their consequences. The Information Security Officer (ISO)
conducts these assessments, which inform the development of contingency plans including redundancy, backup and recovery, alternate
site operations, and data restoration.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(ii)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Engagement &amp;amp; Oversight of Third Parties:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We engage third-party assessors, consultants, auditors,
and experts to strengthen our cybersecurity processes. For example, we utilize third-party services for continuous vulnerability scanning,
perimeter testing, Dynamic Application Security Testing (DAST), and penetration testing to identify and address potential security weaknesses
in our systems. Additionally, we engage expert architects to help design and maintain secure cloud infrastructures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Our third-party engagement and oversight process
includes conducting thorough due diligence, performing vendor risk assessments, and maintaining continuous monitoring to ensure that service
providers adhere to our security standards and comply with contractual obligations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Material Effects of Cybersecurity Threats&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In the past year, we did not encounter any cybersecurity
threats that materially affected or are likely to materially affect our business strategy, results of operations, or financial condition.
Nonetheless, we continuously enhance our cybersecurity posture to mitigate potential material impacts. Our risk management program outlines
procedures for regular log reviews, incident detection, and remediation to ensure ongoing protection of our information systems.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Cybersecurity Governance&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Board of Directors&#x2019; Oversight&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Our Board of Directors plays a critical role in
overseeing cybersecurity risks as part of its broader risk oversight responsibilities. The Information Security Officer (ISO) provides
the board with updates on cybersecurity risks and incidents. Significant cybersecurity incidents are reported to the board to ensure appropriate
and timely responses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Management&#x2019;s Role in Assessing and Managing Cybersecurity
Risks&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(i)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Management Positions and Committees:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The ISO is responsible for developing and maintaining
our cybersecurity and contingency plans, coordinating risk assessments, and managing incident responses. The ISO has extensive experience
in building secure web applications for healthcare. In addition to the ISO, we engage consultants and DevOps engineers with relevant degrees
and certifications to support our cybersecurity efforts. System Owners are responsible for identifying critical systems, assessing risks,
and implementing appropriate security controls.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(ii)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Processes for Information and Monitoring:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We have established comprehensive processes for
continuous monitoring and information sharing. These include regular reviews of audit logs, system activity analysis, and the deployment
of Security Information and Event Management (SIEM) tools for centralized monitoring. These processes facilitate the timely detection
and response to potential security incidents.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(iii)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Reporting to the Board:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The ISO regularly reports to executive management
and the Board of Directors. These reports include findings from risk assessments, incident reports, and updates on the status of ongoing
security initiatives, ensuring that the board is well-informed about our cybersecurity posture.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c0" id="ixv-10734">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Cybersecurity risk management is an integral part
of our risk management framework. Our approach aligns with industry standards, including the National Institute of Standards and Technology
(NIST) Cybersecurity Framework (CSF), to effectively manage cybersecurity threats and incidents, including those related to third-party
applications and services.&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c0" id="ixv-23403">Cybersecurity risk management is integrated
into our broader risk management system. Regular risk assessments and business impact analyses are conducted to identify critical
systems, applications, and data, as well as potential disruptions and their consequences.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c0" id="ixv-23404">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c0" id="ixv-23405">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c0" id="ixv-23406">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="c0" id="ixv-10834">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In the past year, we did not encounter any cybersecurity
threats that materially affected or are likely to materially affect our business strategy, results of operations, or financial condition.
Nonetheless, we continuously enhance our cybersecurity posture to mitigate potential material impacts. Our risk management program outlines
procedures for regular log reviews, incident detection, and remediation to ensure ongoing protection of our information systems.&lt;/p&gt;</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c0" id="ixv-23407">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c0" id="ixv-10845">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Board of Directors&#x2019; Oversight&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Our Board of Directors plays a critical role in
overseeing cybersecurity risks as part of its broader risk oversight responsibilities. The Information Security Officer (ISO) provides
the board with updates on cybersecurity risks and incidents. Significant cybersecurity incidents are reported to the board to ensure appropriate
and timely responses.&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c0" id="ixv-10871">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The ISO is responsible for developing and maintaining
our cybersecurity and contingency plans, coordinating risk assessments, and managing incident responses. The ISO has extensive experience
in building secure web applications for healthcare. In addition to the ISO, we engage consultants and DevOps engineers with relevant degrees
and certifications to support our cybersecurity efforts. System Owners are responsible for identifying critical systems, assessing risks,
and implementing appropriate security controls.&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c0" id="ixv-10872">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The ISO is responsible for developing and maintaining
our cybersecurity and contingency plans, coordinating risk assessments, and managing incident responses. The ISO has extensive experience
in building secure web applications for healthcare. In addition to the ISO, we engage consultants and DevOps engineers with relevant degrees
and certifications to support our cybersecurity efforts. System Owners are responsible for identifying critical systems, assessing risks,
and implementing appropriate security controls.&lt;/p&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c0" id="ixv-10873">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The ISO is responsible for developing and maintaining
our cybersecurity and contingency plans, coordinating risk assessments, and managing incident responses. The ISO has extensive experience
in building secure web applications for healthcare. In addition to the ISO, we engage consultants and DevOps engineers with relevant degrees
and certifications to support our cybersecurity efforts. System Owners are responsible for identifying critical systems, assessing risks,
and implementing appropriate security controls.&lt;/p&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c0" id="ixv-23408">The ISO has extensive experience
in building secure web applications for healthcare. In addition to the ISO, we engage consultants and DevOps engineers with relevant degrees
and certifications to support our cybersecurity efforts.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c0" id="ixv-23409">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c0" id="ixv-10888">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;We have established comprehensive processes for
continuous monitoring and information sharing. These include regular reviews of audit logs, system activity analysis, and the deployment
of Security Information and Event Management (SIEM) tools for centralized monitoring. These processes facilitate the timely detection
and response to potential security incidents.&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <dei:AuditorFirmId contextRef="c0" id="ixv-23410">1379</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="c0" id="ixv-11172">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Opinion on the Financial Statements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We have audited the accompanying consolidated statements of financial
position of Alterity Therapeutics Limited and its subsidiaries (the &#x201c;Company&#x201d;) as of June 30, 2025 and 2024, and the related
consolidated statements of profit or loss and other comprehensive loss, of changes in shareholders&#x2019; equity and of cash flows for
each of the three years in the period ended June 30, 2025, including the related notes (collectively referred to as the &#x201c;consolidated
financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company as of June 30, 2025 and 2024, and the results of its operations and its cash flows for each of the three years
in the period ended June 30, 2025 in conformity with International Financial Reporting Standards as issued by the International Accounting
Standards Board and Australian equivalents to International Financial Reporting Standards as issued by the Australian Accounting Standards
Board.&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="c0" id="ixv-23411">PricewaterhouseCoopers</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-23412">Melbourne, Australia</dei:AuditorLocation>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="0" id="ixv-23413" unitRef="aud">33158642</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="0" id="ixv-23414" unitRef="aud">12638885</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c2" decimals="0" id="ixv-23415" unitRef="aud">3937607</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c3" decimals="0" id="ixv-23416" unitRef="aud">4041675</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:OtherCurrentAssets contextRef="c2" decimals="0" id="ixv-23417" unitRef="aud">8774937</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c3" decimals="0" id="ixv-23418" unitRef="aud">2356300</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c2" decimals="0" id="ixv-23419" unitRef="aud">45871186</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c3" decimals="0" id="ixv-23420" unitRef="aud">19036860</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c2" decimals="0" id="ixv-23421" unitRef="aud">3848</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c3" decimals="0" id="ixv-23422" unitRef="aud">32154</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="c2" decimals="0" id="ixv-23423" unitRef="aud">151326</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c3" decimals="0" id="ixv-23424" unitRef="aud">154729</ifrs-full:RightofuseAssets>
    <ifrs-full:NoncurrentAssets contextRef="c2" decimals="0" id="ixv-23425" unitRef="aud">155174</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c3" decimals="0" id="ixv-23426" unitRef="aud">186883</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c2" decimals="0" id="ixv-23427" unitRef="aud">46026360</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c3" decimals="0" id="ixv-23428" unitRef="aud">19223743</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c2" decimals="0" id="ixv-23429" unitRef="aud">2575490</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c3" decimals="0" id="ixv-23430" unitRef="aud">4619947</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentProvisions contextRef="c2" decimals="0" id="ixv-23431" unitRef="aud">875908</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions contextRef="c3" decimals="0" id="ixv-23432" unitRef="aud">530699</ifrs-full:CurrentProvisions>
    <ifrs-full:OtherCurrentLiabilities contextRef="c2" decimals="0" id="ixv-23433" unitRef="aud">139</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c3" decimals="0" id="ixv-23434" unitRef="aud">100000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c2" decimals="0" id="ixv-23435" unitRef="aud">66912</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c3" decimals="0" id="ixv-23436" unitRef="aud">107131</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentTaxLiabilities contextRef="c2" decimals="0" id="ixv-23437" unitRef="aud">16280</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentTaxLiabilities contextRef="c3" decimals="0" id="ixv-23438" unitRef="aud">15995</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c2" decimals="0" id="ixv-23439" unitRef="aud">3534729</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c3" decimals="0" id="ixv-23440" unitRef="aud">5373772</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c2" decimals="0" id="ixv-23441" unitRef="aud">88545</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c3" decimals="0" id="ixv-23442" unitRef="aud">51914</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c2" decimals="0" id="ixv-23443" unitRef="aud">88545</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c3" decimals="0" id="ixv-23444" unitRef="aud">51914</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities contextRef="c2" decimals="0" id="ixv-23445" unitRef="aud">3623274</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c3" decimals="0" id="ixv-23446" unitRef="aud">5425686</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c2" decimals="0" id="ixv-23447" unitRef="aud">42403086</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c3" decimals="0" id="ixv-23448" unitRef="aud">13798057</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:IssuedCapital contextRef="c2" decimals="0" id="ixv-23449" unitRef="aud">262949462</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c3" decimals="0" id="ixv-23450" unitRef="aud">223152985</ifrs-full:IssuedCapital>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c2" decimals="0" id="ixv-23451" unitRef="aud">5342304</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c3" decimals="0" id="ixv-23452" unitRef="aud">4806203</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c2" decimals="0" id="ixv-23453" unitRef="aud">-225888680</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c3" decimals="0" id="ixv-23454" unitRef="aud">-214161131</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:Equity contextRef="c2" decimals="0" id="ixv-23455" unitRef="aud">42403086</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="0" id="ixv-23456" unitRef="aud">13798057</ifrs-full:Equity>
    <ifrs-full:RevenueFromInterest contextRef="c0" decimals="0" id="ixv-23457" unitRef="aud">446291</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="c4" decimals="0" id="ixv-23458" unitRef="aud">268419</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="c5" decimals="0" id="ixv-23459" unitRef="aud">16436</ifrs-full:RevenueFromInterest>
    <ifrs-full:OtherIncome contextRef="c0" decimals="0" id="ixv-23460" unitRef="aud">7641516</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c4" decimals="0" id="ixv-23461" unitRef="aud">4019285</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c5" decimals="0" id="ixv-23462" unitRef="aud">3916333</ifrs-full:OtherIncome>
    <athe:IntellectualPropertyExpenses contextRef="c0" decimals="0" id="ixv-23463" unitRef="aud">127523</athe:IntellectualPropertyExpenses>
    <athe:IntellectualPropertyExpenses contextRef="c4" decimals="0" id="ixv-23464" unitRef="aud">214304</athe:IntellectualPropertyExpenses>
    <athe:IntellectualPropertyExpenses contextRef="c5" decimals="0" id="ixv-23465" unitRef="aud">285067</athe:IntellectualPropertyExpenses>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-23466" unitRef="aud">5481399</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c4" decimals="0" id="ixv-23467" unitRef="aud">4762643</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c5" decimals="0" id="ixv-23468" unitRef="aud">5056571</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-23469" unitRef="aud">14404282</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c4" decimals="0" id="ixv-23470" unitRef="aud">18644047</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" id="ixv-23471" unitRef="aud">13198583</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c0" decimals="0" id="ixv-23472" unitRef="aud">87265</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c4" decimals="0" id="ixv-23473" unitRef="aud">5238</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c5" decimals="0" id="ixv-23474" unitRef="aud">29404</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:OtherGainsLosses contextRef="c0" decimals="0" id="ixv-23475" unitRef="aud">-67111</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c4" decimals="0" id="ixv-23476" unitRef="aud">261152</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c5" decimals="0" id="ixv-23477" unitRef="aud">917650</ifrs-full:OtherGainsLosses>
    <athe:ForfeitedOptionsFromReserves contextRef="c5" decimals="0" id="ixv-23478" unitRef="aud">17150</athe:ForfeitedOptionsFromReserves>
    <ifrs-full:ProfitLossBeforeTax contextRef="c0" decimals="0" id="ixv-23479" unitRef="aud">-12079773</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c4" decimals="0" id="ixv-23480" unitRef="aud">-19077376</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c5" decimals="0" id="ixv-23481" unitRef="aud">-13702056</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c0" decimals="0" id="ixv-23482" unitRef="aud">68055</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c4" decimals="0" id="ixv-23483" unitRef="aud">46088</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c5" decimals="0" id="ixv-23484" unitRef="aud">104459</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="0" id="ixv-23485" unitRef="aud">-12147828</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="0" id="ixv-23486" unitRef="aud">-19123464</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="0" id="ixv-23487" unitRef="aud">-13806515</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c0" decimals="0" id="ixv-23488" unitRef="aud">-12147828</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c4" decimals="0" id="ixv-23489" unitRef="aud">-19123464</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c5" decimals="0" id="ixv-23490" unitRef="aud">-13806515</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-23491"
      unitRef="audPershares">-0.19</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-23492"
      unitRef="audPershares">-0.19</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c4"
      decimals="2"
      id="ixv-23493"
      unitRef="audPershares">-0.52</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c4"
      decimals="2"
      id="ixv-23494"
      unitRef="audPershares">-0.52</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c5"
      decimals="2"
      id="ixv-23495"
      unitRef="audPershares">-0.57</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c5"
      decimals="2"
      id="ixv-23496"
      unitRef="audPershares">-0.57</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c0"
      decimals="0"
      id="ixv-23497"
      unitRef="shares">6396924117</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c0"
      decimals="0"
      id="ixv-23498"
      unitRef="shares">6396924117</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c4"
      decimals="0"
      id="ixv-23499"
      unitRef="shares">3648875564</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c4"
      decimals="0"
      id="ixv-23500"
      unitRef="shares">3648875564</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c5"
      decimals="0"
      id="ixv-23501"
      unitRef="shares">2427841917</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c5"
      decimals="0"
      id="ixv-23502"
      unitRef="shares">2427841917</ifrs-full:WeightedAverageShares>
    <ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees contextRef="c0" decimals="0" id="ixv-23503" unitRef="aud">17459061</ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees>
    <ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees contextRef="c4" decimals="0" id="ixv-23504" unitRef="aud">21393136</ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees>
    <ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees contextRef="c5" decimals="0" id="ixv-23505" unitRef="aud">19943617</ifrs-full:PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c0" decimals="0" id="ixv-23506" unitRef="aud">446291</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c4" decimals="0" id="ixv-23507" unitRef="aud">269075</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c5" decimals="0" id="ixv-23508" unitRef="aud">15798</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <athe:ProceedsFromResearchAndDevelopmentTaxRefund contextRef="c0" decimals="0" id="ixv-23509" unitRef="aud">5629577</athe:ProceedsFromResearchAndDevelopmentTaxRefund>
    <athe:ProceedsFromResearchAndDevelopmentTaxRefund contextRef="c4" decimals="0" id="ixv-23510" unitRef="aud">8583477</athe:ProceedsFromResearchAndDevelopmentTaxRefund>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c4" decimals="0" id="ixv-23511" unitRef="aud">7217</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c5" decimals="0" id="ixv-23512" unitRef="aud">4565</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="c0" decimals="0" id="ixv-23513" unitRef="aud">68055</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="c4" decimals="0" id="ixv-23514" unitRef="aud">58023</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="c5" decimals="0" id="ixv-23515" unitRef="aud">103453</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-23516" unitRef="aud">-11451248</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c4" decimals="0" id="ixv-23517" unitRef="aud">-12605824</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c5" decimals="0" id="ixv-23518" unitRef="aud">-20035837</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <athe:PaymentsForRentalSecurityDeposits contextRef="c5" decimals="0" id="ixv-23519" unitRef="aud">29150</athe:PaymentsForRentalSecurityDeposits>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c4" decimals="0" id="ixv-23520" unitRef="aud">5722</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c5" decimals="0" id="ixv-23521" unitRef="aud">7311</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="c0" decimals="0" id="ixv-23522" unitRef="aud">-7500000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c0" decimals="0" id="ixv-23523" unitRef="aud">-7500000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c4" decimals="0" id="ixv-23524" unitRef="aud">-5722</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c5" decimals="0" id="ixv-23525" unitRef="aud">-36461</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingOtherEquityInstruments contextRef="c0" decimals="0" id="ixv-23526" unitRef="aud">42570645</ifrs-full:ProceedsFromIssuingOtherEquityInstruments>
    <ifrs-full:ProceedsFromIssuingOtherEquityInstruments contextRef="c4" decimals="0" id="ixv-23527" unitRef="aud">10144682</ifrs-full:ProceedsFromIssuingOtherEquityInstruments>
    <ifrs-full:ProceedsFromIssuingOtherEquityInstruments contextRef="c5" decimals="0" id="ixv-23528" unitRef="aud">316675</ifrs-full:ProceedsFromIssuingOtherEquityInstruments>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c0" decimals="0" id="ixv-23529" unitRef="aud">2774168</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c4" decimals="0" id="ixv-23530" unitRef="aud">918020</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c5" decimals="0" id="ixv-23531" unitRef="aud">132413</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c0" decimals="0" id="ixv-23532" unitRef="aud">127097</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c4" decimals="0" id="ixv-23533" unitRef="aud">10370</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c5" decimals="0" id="ixv-23534" unitRef="aud">59922</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-23535" unitRef="aud">39669380</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c4" decimals="0" id="ixv-23536" unitRef="aud">9216292</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c5" decimals="0" id="ixv-23537" unitRef="aud">124340</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c0" decimals="0" id="ixv-23538" unitRef="aud">20718132</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c4" decimals="0" id="ixv-23539" unitRef="aud">-3395254</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c5" decimals="0" id="ixv-23540" unitRef="aud">-19947958</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="0" id="ixv-23541" unitRef="aud">12638885</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c6" decimals="0" id="ixv-23542" unitRef="aud">15773783</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c7" decimals="0" id="ixv-23543" unitRef="aud">34806799</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c0" decimals="0" id="ixv-23544" unitRef="aud">-198375</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c4" decimals="0" id="ixv-23545" unitRef="aud">260356</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c5" decimals="0" id="ixv-23546" unitRef="aud">914942</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="0" id="ixv-23547" unitRef="aud">33158642</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c3" decimals="0" id="ixv-23548" unitRef="aud">12638885</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c6" decimals="0" id="ixv-23549" unitRef="aud">15773783</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c8"
      decimals="0"
      id="ixv-23550"
      unitRef="shares">2406874578</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c8" decimals="0" id="ixv-23551" unitRef="aud">213787061</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c9" decimals="0" id="ixv-23552" unitRef="aud">3565918</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c10" decimals="0" id="ixv-23553" unitRef="aud">-181884388</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c7" decimals="0" id="ixv-23554" unitRef="aud">35468591</ifrs-full:Equity>
    <athe:IssuanceOfSharesNetOfCostsShares
      contextRef="c11"
      decimals="0"
      id="ixv-23555"
      unitRef="shares">33023040</athe:IssuanceOfSharesNetOfCostsShares>
    <athe:IssuanceOfSharesNetOfCostsValue contextRef="c11" decimals="0" id="ixv-23556" unitRef="aud">316675</athe:IssuanceOfSharesNetOfCostsValue>
    <athe:IssuanceOfSharesNetOfCostsValue contextRef="c5" decimals="0" id="ixv-23557" unitRef="aud">316675</athe:IssuanceOfSharesNetOfCostsValue>
    <athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees contextRef="c12" decimals="0" id="ixv-23558" unitRef="aud">983721</athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees>
    <athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees contextRef="c5" decimals="0" id="ixv-23559" unitRef="aud">983721</athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c11" decimals="0" id="ixv-23560" unitRef="aud">-132413</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c5" decimals="0" id="ixv-23561" unitRef="aud">-132413</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement contextRef="c12" decimals="0" id="ixv-23562" unitRef="aud">-560014</athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement>
    <athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement contextRef="c13" decimals="0" id="ixv-23563" unitRef="aud">560014</athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement>
    <athe:ForfeitedOptionsReversedToProfitOrLoss contextRef="c12" decimals="0" id="ixv-23564" unitRef="aud">-17150</athe:ForfeitedOptionsReversedToProfitOrLoss>
    <athe:ForfeitedOptionsReversedToProfitOrLoss contextRef="c5" decimals="0" id="ixv-23565" unitRef="aud">-17150</athe:ForfeitedOptionsReversedToProfitOrLoss>
    <athe:TransactionsWithOwnersInTheirCapacitySharesAsOwners
      contextRef="c11"
      decimals="0"
      id="ixv-23566"
      unitRef="shares">33023040</athe:TransactionsWithOwnersInTheirCapacitySharesAsOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c11" decimals="0" id="ixv-23567" unitRef="aud">184262</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c12" decimals="0" id="ixv-23568" unitRef="aud">406557</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c13" decimals="0" id="ixv-23569" unitRef="aud">560014</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c5" decimals="0" id="ixv-23570" unitRef="aud">1150833</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:ProfitLoss contextRef="c13" decimals="0" id="ixv-23571" unitRef="aud">-13806515</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="0" id="ixv-23572" unitRef="aud">-13806515</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c13" decimals="0" id="ixv-23573" unitRef="aud">-13806515</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c5" decimals="0" id="ixv-23574" unitRef="aud">-13806515</ifrs-full:ComprehensiveIncome>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c14"
      decimals="0"
      id="ixv-23575"
      unitRef="shares">2439897618</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c14" decimals="0" id="ixv-23576" unitRef="aud">213971323</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c15" decimals="0" id="ixv-23577" unitRef="aud">3972475</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c16" decimals="0" id="ixv-23578" unitRef="aud">-195130889</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c6" decimals="0" id="ixv-23579" unitRef="aud">22812909</ifrs-full:Equity>
    <athe:IssuanceOfSharesNetOfCostsShares
      contextRef="c17"
      decimals="0"
      id="ixv-23580"
      unitRef="shares">2798120281</athe:IssuanceOfSharesNetOfCostsShares>
    <athe:IssuanceOfSharesNetOfCostsValue contextRef="c17" decimals="0" id="ixv-23581" unitRef="aud">10050000</athe:IssuanceOfSharesNetOfCostsValue>
    <athe:IssuanceOfSharesNetOfCostsValue contextRef="c4" decimals="0" id="ixv-23582" unitRef="aud">10050000</athe:IssuanceOfSharesNetOfCostsValue>
    <athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees contextRef="c18" decimals="0" id="ixv-23583" unitRef="aud">881950</athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees>
    <athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees contextRef="c4" decimals="0" id="ixv-23584" unitRef="aud">881950</athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees>
    <ifrs-full:IssueOfEquity contextRef="c18" decimals="0" id="ixv-23585" unitRef="aud">45000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c4" decimals="0" id="ixv-23586" unitRef="aud">45000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c17"
      decimals="0"
      id="ixv-23587"
      unitRef="shares">7097419</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars contextRef="c17" decimals="0" id="ixv-23588" unitRef="aud">49682</athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars>
    <athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars contextRef="c4" decimals="0" id="ixv-23589" unitRef="aud">49682</athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c17" decimals="0" id="ixv-23590" unitRef="aud">-918020</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c4" decimals="0" id="ixv-23591" unitRef="aud">-918020</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <athe:ForfeitedOptionsReversedToProfitOrLoss contextRef="c18" decimals="0" id="ixv-23592" unitRef="aud">-93222</athe:ForfeitedOptionsReversedToProfitOrLoss>
    <athe:ForfeitedOptionsReversedToProfitOrLoss contextRef="c19" decimals="0" id="ixv-23593" unitRef="aud">93222</athe:ForfeitedOptionsReversedToProfitOrLoss>
    <athe:TransactionsWithOwnersInTheirCapacitySharesAsOwners
      contextRef="c17"
      decimals="0"
      id="ixv-23594"
      unitRef="shares">2805217700</athe:TransactionsWithOwnersInTheirCapacitySharesAsOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c17" decimals="0" id="ixv-23595" unitRef="aud">9181662</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c18" decimals="0" id="ixv-23596" unitRef="aud">833728</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c19" decimals="0" id="ixv-23597" unitRef="aud">93222</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c4" decimals="0" id="ixv-23598" unitRef="aud">10108612</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:ProfitLoss contextRef="c19" decimals="0" id="ixv-23599" unitRef="aud">-19123464</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="0" id="ixv-23600" unitRef="aud">-19123464</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c19" decimals="0" id="ixv-23601" unitRef="aud">-19123464</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c4" decimals="0" id="ixv-23602" unitRef="aud">-19123464</ifrs-full:ComprehensiveIncome>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c20"
      decimals="0"
      id="ixv-23603"
      unitRef="shares">5245115318</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c20" decimals="0" id="ixv-23604" unitRef="aud">223152985</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c21" decimals="0" id="ixv-23605" unitRef="aud">4806203</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c22" decimals="0" id="ixv-23606" unitRef="aud">-214161131</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c3" decimals="0" id="ixv-23607" unitRef="aud">13798057</ifrs-full:Equity>
    <athe:IssuanceOfSharesNetOfCostsShares
      contextRef="c23"
      decimals="0"
      id="ixv-23608"
      unitRef="shares">3875826636</athe:IssuanceOfSharesNetOfCostsShares>
    <athe:IssuanceOfSharesNetOfCostsValue contextRef="c23" decimals="0" id="ixv-23609" unitRef="aud">42547105</athe:IssuanceOfSharesNetOfCostsValue>
    <athe:IssuanceOfSharesNetOfCostsValue contextRef="c0" decimals="0" id="ixv-23610" unitRef="aud">42547105</athe:IssuanceOfSharesNetOfCostsValue>
    <athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees contextRef="c24" decimals="0" id="ixv-23611" unitRef="aud">979920</athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees>
    <athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees contextRef="c0" decimals="0" id="ixv-23612" unitRef="aud">979920</athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c23"
      decimals="0"
      id="ixv-23613"
      unitRef="shares">6428732</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars contextRef="c23" decimals="0" id="ixv-23614" unitRef="aud">23540</athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars>
    <athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars contextRef="c24" decimals="0" id="ixv-23615" unitRef="aud">-23540</athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c23" decimals="0" id="ixv-23616" unitRef="aud">-2774168</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c0" decimals="0" id="ixv-23617" unitRef="aud">-2774168</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement contextRef="c24" decimals="0" id="ixv-23618" unitRef="aud">-326544</athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement>
    <athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement contextRef="c25" decimals="0" id="ixv-23619" unitRef="aud">326544</athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement>
    <athe:ForfeitedOptionsReversedToProfitOrLoss contextRef="c24" decimals="0" id="ixv-23620" unitRef="aud">-93735</athe:ForfeitedOptionsReversedToProfitOrLoss>
    <athe:ForfeitedOptionsReversedToProfitOrLoss contextRef="c25" decimals="0" id="ixv-23621" unitRef="aud">93735</athe:ForfeitedOptionsReversedToProfitOrLoss>
    <athe:TransactionsWithOwnersInTheirCapacitySharesAsOwners
      contextRef="c23"
      decimals="0"
      id="ixv-23622"
      unitRef="shares">3882255368</athe:TransactionsWithOwnersInTheirCapacitySharesAsOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c23" decimals="0" id="ixv-23623" unitRef="aud">39796477</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c24" decimals="0" id="ixv-23624" unitRef="aud">536101</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c25" decimals="0" id="ixv-23625" unitRef="aud">420279</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c0" decimals="0" id="ixv-23626" unitRef="aud">40752857</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:ProfitLoss contextRef="c25" decimals="0" id="ixv-23627" unitRef="aud">-12147828</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="0" id="ixv-23628" unitRef="aud">-12147828</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c25" decimals="0" id="ixv-23629" unitRef="aud">-12147828</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c0" decimals="0" id="ixv-23630" unitRef="aud">-12147828</ifrs-full:ComprehensiveIncome>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c26"
      decimals="0"
      id="ixv-23631"
      unitRef="shares">9127370686</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c26" decimals="0" id="ixv-23632" unitRef="aud">262949462</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c27" decimals="0" id="ixv-23633" unitRef="aud">5342304</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c28" decimals="0" id="ixv-23634" unitRef="aud">-225888680</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c2" decimals="0" id="ixv-23635" unitRef="aud">42403086</ifrs-full:Equity>
    <ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory contextRef="c0" id="ixv-14020">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;1. BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Background&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Alterity Therapeutics Limited and its controlled subsidiaries, Alterity
Therapeutics Inc. and Alterity Therapeutics UK Limited (referred to collectively as &#x201c;Alterity&#x201d; or the &#x201c;Group&#x201d;),
is a development stage enterprise engaged in the research and development of therapeutic drugs designed to treat the underlying cause
of degeneration of the brain focusing on Alzheimer&#x2019;s disease, Huntington disease, Parkinson&#x2019;s disease and other neurological
disorders. Alterity Therapeutics Limited, the parent entity, was incorporated on November 11, 1997 in Melbourne, Australia and the UK
and U.S. subsidiaries were incorporated in August 2004.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Financial Reporting Framework&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The financial report of Alterity Therapeutics Limited for the year
ended June 30, 2025 was authorized for issue on August 29, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Alterity Therapeutics Limited is a for-profit entity for the purpose
of preparing the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The consolidated financial statements of the Group comply with International
Financial Reporting Standards (&#x201c;IFRS Accounting Standards&#x201d;) as issued by the International Accounting Standards Board (IASB)
and Australian equivalents to International Financial Reporting Standards, as issued by the Australian Accounting Standards Board.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;These financial statements have been prepared under the historical
cost convention, as modified by the revaluation of financial liabilities at fair value through profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Accounting policies are selected and applied in a manner which ensures
that the resulting financial information satisfies the concepts of relevance and reliability, thereby ensuring that the substance of the
underlying transactions or other events is reported.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The accounting policies set out below have been applied in preparing
the financial statements for the year ended June 30, 2025 and the comparative information presented in these financial statements for
the years ended June 30, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Critical accounting estimates, judgments and assumptions&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Estimates and judgments are continually evaluated and are based on
historical experience and other factors, including expectations of future events that may have a financial impact on the entity and that
are believed to be reasonable under the circumstances.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group makes estimates and assumptions concerning the future. The
resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a
significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are
discussed below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Share-based Payments&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The value attributed to share options and remuneration shares issued
is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models and the resultant
option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options to shares and the
value and volatility of the price of the underlying shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;R&amp;amp;D Tax Incentives&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Australian Government adopted a research and development tax incentive
in July 2011. The provisions provide refundable or non-refundable tax offsets. The research and development tax incentive applies to expenditures
incurred and the use of depreciating assets. A 43.5% refundable tax offset is available to eligible small companies with an annual aggregate
turnover of less than $20 million. Management has assessed these activities and expenditure to determine which are likely to be eligible
under the incentive scheme. For the period to June 30, 2025, the Group has recorded an item in other income of A$5.4 million (2024: A$4.0
million, 2023: A$3.9 million) to recognize the amount which relates to this period (A$3.9 million).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Going Concern Basis&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group is a development stage medical biotechnology company and
as such expects to be utilizing sources of cash funding until its research activities have become marketable. The Group has incurred recurring
losses since inception including a net loss of $12,147,828 in the year ended June 30, 2025 (2024: $19,123,464) and a net operating cash
outflow of $11,451,248 in the year ended June 30, 2025 (2024: $12,605,824). The Group expects to continue incurring losses into the foreseeable
future and will need to raise additional capital to continue the development of its planned research and development programs. The continuing
viability of the Group is subject to its ability to raise additional capital to finance the continuation of its planned research and development
programs, maintaining implemented cost containment and deferment strategies, and successfully commercializing its initiatives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group raised new equity funding, net proceeds totaling $39,669,380
(see Note 10), during the financial year to enable progression of its planned research and development programs.&lt;/p&gt;

&lt;p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company believes the cash and cash equivalents as of June&#160;30,
2025 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the
date of issuance of these consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The inability to raise additional capital, as and when needed on acceptable
terms, or if at all would have a negative impact on the Group&#x2019;s financial condition and ability to pursue its business strategies.
If the Group is unable to obtain the required funding to operate and to develop and commercialize its product candidates, it could be
forced to delay, reduce or eliminate some or all of its research and development programs, which would adversely affect its business prospects.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;These consolidated financial statements have been prepared assuming
the Group will continue as a going concern which contemplates the continuity of operations, realization of assets and the satisfaction
of liabilities in the ordinary course of business and do not include adjustments that would result if the Group were unable to continue
as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The preparation of these consolidated financial statements requires
the Group to make estimates and judgments that affect the reported amounts of assets, liabilities, income and expenses and related disclosures.
On an ongoing basis, the Group evaluates its significant accounting policies and estimates. Estimates are based on historical experience
and on various market-specific and other relevant assumptions that the Group believes to be reasonable under the circumstances, the results
of which form the basis for making judgments about the carrying values of assets and liabilities. Estimates are assessed each period and
updated to reflect current information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Development Stage &#x2013; Risks and Uncertainties&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As a development stage enterprise, the Group&#x2019;s prospects are
subject to the risks, expenses and uncertainties frequently encountered by companies which have not yet commercialized any applications
of their technology, particularly in new and evolving markets. Alterity&#x2019;s operating results may fluctuate significantly in the future
as a result of a variety of factors, including capital expenditure and other costs relating to establishing, maintaining and expanding
the operations, the number and mix of potential customers, potential pricing of future products by the Group and its competitors, new
technology introduced by the Group and its competitors, delays or expense in obtaining necessary equipment, economic and social conditions
in the biotechnology industry and general economic conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group cannot be certain that it will be able to raise any required
funding or capital, on favorable terms or at all, or that it will be able to establish corporate collaborations on acceptable terms, if
at all. If the Group is unable to obtain such additional funding or capital, it may be required to reduce the scope of its development
plans.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group&#x2019;s experience in exploiting its technology is limited
and it cannot be certain that its operations will be profitable in the short-term, or at all. If the Group fails in its efforts to establish
or expand its business, the results of operations, financial condition and liquidity of the Group could be materially adversely affected.
The Group cannot be certain that it will be able to sell and deliver its technology or to obtain or retain any permits required in the
market in which it operates. Any of these factors could result in the reduction or cessation of the Group&#x2019;s operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Material Accounting Policies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Accounting policies are selected and applied in a manner which ensures
that the resulting financial information satisfies the concepts of relevance and reliability, thereby ensuring that the substance of the
underlying transactions or other events is reported.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following material accounting policies have been adopted in the
preparation and presentation of the financial report.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(a) Principles of Consolidation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The consolidated financial statements are prepared by combining the
financial statements of all the entities that comprise the Group, being Alterity Therapeutics Limited and its subsidiaries as defined
in Accounting Standard IFRS10 (AASB 10): &lt;i&gt;Consolidated Financial Statements&lt;/i&gt;. Consistent accounting policies are employed in the
preparation and presentation of the consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Subsidiaries are all those entities (including special purpose entities)
over which the Group has control. The Group controls an entity where the group is exposed to, or has rights to, variable returns from
its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity.
The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether
the Group controls another entity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Subsidiaries are fully consolidated from the date on which control
is transferred to the Group. They are de-consolidated from the date that control ceases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In preparing the consolidated financial statements, all inter-company
balances and transactions, and unrealized profits/losses arising within the Group are eliminated in full. Investments in subsidiaries
are accounted for at cost in the individual financial statements of Alterity Therapeutics Limited.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(b) Segment Reporting&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Operating segments are reported in a manner consistent with the internal
reporting provided to the chief operating decision maker (the &#x201c;CODM&#x201d;). The CODM, who is responsible for allocating resources
and assessing performance of the operating segments, has been identified as the Chief Executive Officer of Alterity Therapeutics Limited.
For the current and previous reporting periods, the Group operated in one segment, being research and development into Parkinsonian and
other neurodegenerative disorders.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(c) Income Tax&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Current tax&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Current tax is calculated by reference to the amount of income taxes
payable or recoverable in respect of the taxable profit or loss for the period. It is calculated using tax rates and tax laws that have
been enacted or substantively enacted by reporting date. Current tax for current and prior periods is recognised as a liability (or asset)
to the extent that it is unpaid (or refundable).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Deferred tax&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Deferred tax is accounted for using the liability method in respect
of temporary differences arising from differences between the carrying amount of assets and liabilities in the financial statements and
the corresponding tax base of those items.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In principle, deferred tax assets and liabilities are recognised for
all taxable temporary differences. Deferred tax assets are recognised to the extent that it is probable that sufficient taxable amounts
will be available against which deductible temporary differences or unused tax losses and tax offsets can be utilized. However, deferred
tax assets and liabilities are not recognised if the temporary differences giving rise to them arise from the initial recognition of assets
and liabilities (other than as a result of a business combination) which affects neither taxable income nor accounting profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Deferred tax liabilities are recognised for taxable temporary differences
arising on investments in subsidiaries except where the Group is able to control the reversal of the temporary differences and it is probable
that the temporary differences will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences
associated with these investments are only recognised to the extent that it is probable that there will be sufficient taxable profits
against which to utilize the benefits of the temporary differences and they are expected to reverse in the foreseeable future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Deferred tax assets and liabilities are measured at the tax rates that
are expected to apply to the period(s) when the asset and liability giving rise to them are realized or settled, based on tax rates (and
tax laws) that have been enacted or substantively enacted by reporting date. The measurement of deferred tax liabilities and assets reflects
the tax consequences that would follow from the manner in which the Group expects, at the reporting date, to recover or settle the carrying
amount of its assets and liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Deferred tax assets and liabilities are offset when there is a legally
enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.
Current tax assets and tax liabilities are offset when the entity has a legally enforceable right to offset and intends either to settle
on a net basis or to realize the asset and settle the liability simultaneously.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Current and deferred tax for the period&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Current and deferred tax is recognised as an expense or income in the
Statement of Profit or Loss and Other Comprehensive Loss except when it relates to items credited or debited directly to equity, in which
case the deferred tax is also recognised directly in equity, or where it arises from the initial accounting for a business combination,
in which case it is taken into account in the determination of goodwill.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group has significant unused tax losses and as such a significant
deferred tax asset; however, the deferred tax asset has not been recognised, as it is not probable that future taxable profit will be
available against which the unused losses and unused tax credits can be utilized, given the nature of the Group&#x2019;s business (research
and development) and its history of losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(d) Property and Equipment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Property and equipment is measured at historical cost less accumulated
depreciation and impairment and consists of laboratory equipment, computer equipment, furniture and fittings and leasehold improvements
attributable to the Group&#x2019;s premises at Melbourne, Victoria, Australia and San Francisco, U.S.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Historical cost includes expenditure that is directly attributable
to the acquisition of the item.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;Subsequent costs are included in the asset&#x2019;s carrying amount
or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will
flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate
asset is derecognised when replaced. All other repairs and maintenance are charged to the income statement during the reporting period
in which they are incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Depreciation is provided on property and equipment. Depreciation is
calculated on a straight-line method to allocate their cost, net of their residual values, over their estimated useful lives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following estimated useful lives, ranging from 3 to 20 years are
used in the calculation of depreciation:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Class of Fixed Asset&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Depreciation Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fittings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5-33%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;33%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Plant and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10-33%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;33%&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Leasehold improvements are depreciated over the shorter of the lease
term and useful life.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The depreciation method, residual values and useful lives are reviewed,
and adjusted if appropriate, at each annual reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(e) Leases&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The accounting policies for the Group&#x2019;s lease recognition are
explained in Note 13.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(f) Investments and other financial assets &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Classification &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group classifies its financial assets in the following measurement
categories:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;those to be measured subsequently at fair value (either through OCI or through profit or loss), and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;those to be measured at amortized cost.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The classification depends on the entity&#x2019;s business model for
managing the financial assets and the contractual terms of the cash flow. For assets measured at fair value, gains and losses will either
be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, this will depend on whether
the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through
other comprehensive income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Recognition and derecognition&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Regular way purchases and sales of financial assets are recognised
on trade-date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognised when the rights to
receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the
risks and rewards of ownership.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Measurement&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At initial recognition, the Group measures a financial asset at its
fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs that are directly attributable
to the acquisition of the financial asset. Transaction costs of financial assets carried at fair value through profit or loss are expensed
in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Assets that are held for collection of contractual cash flows where
those cash flows represent solely payments of principal and interest are measured at amortised cost. Interest income from these financial
assets is included in finance income using the effective interest method. Any gain or loss arising on derecognition is recognised directly
in profit or loss and presented in other gains/(losses) together with foreign exchange gains and losses. Impairment losses are presented
as a separate line item in the consolidated statement of profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Impairment&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group assesses on a forward looking basis the expected credit losses
associated with its debt instruments carried at amortized cost and fair value through other comprehensive income. The impairment methodology
applied depends on whether there has been a significant increase in credit risk.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;For trade receivables, the Group applies the simplified approach which
requires expected lifetime losses to be recognised from initial recognition of the receivables, see Note 5 for further details.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(g) Impairment of Assets&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At each reporting date, the Group reviews the carrying amounts of its
tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If any such indication
exists, the recoverable amount of the asset is estimated to determine the extent of the impairment loss (if any).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Where the asset does not generate cash flows that are independent from
other assets, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Recoverable amount is the higher of fair value less costs of disposal
and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount
rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of
future cash flows have not been adjusted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;If the recoverable amount of an asset (or cash-generating unit) is
estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable
amount. An impairment loss is recognised in the consolidated statement of profit or loss and other comprehensive loss immediately.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Where an impairment loss subsequently reverses, the carrying amount
of the asset (or cash-generating unit) is reversed to the revised estimate of its recoverable amount, but only to the extent that the
increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for
the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised in the consolidated statement of profit
or loss and other comprehensive loss immediately.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;No impairment charges were incurred during the year ended June 30,
2025.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(h) Intangible Assets - Research and Development &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Expenditure during the research phase of a project is recognised as
an expense when incurred. Where no internally generated intangible assets can be recognised, development expenditure is recognised as
an expense in the period as incurred. Development costs are capitalised if and only if, all of the following are demonstrated:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the technical feasibility of completing the intangible asset so that it will be available for use or sale;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the intention to complete the intangible asset and use or sell it;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the ability to use or sell the intangible asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;how the intangible asset will generate probable future economic benefits;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the ability to measure reliably the expenditure attributable to the intangible asset during its development.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Internally-generated intangible assets (capitalised development costs)
are stated at cost less accumulated amortisation and impairment, and are amortised on a straight-line basis over their useful lives over
a maximum of five years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of June 30, 2025, 2024 and 2023, the Group had no capitalized research
and development costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(i) Foreign Currency Transactions and Balances&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Functional and Presentation Currency&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The consolidated financial statements are presented in Australian dollars
($), which is Alterity Therapeutics Limited&#x2019;s functional and presentation currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Foreign currency transactions&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;All foreign currency transactions during the financial year are brought
to account using the exchange rate in effect at the date of the transaction. Foreign currency monetary items at each reporting date are
translated at the exchange rate existing at each reporting date. Non-monetary assets and liabilities carried at fair value that are denominated
in foreign currencies are translated at the rates prevailing at the date when the fair value was determined.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Exchange differences are recognised in profit or loss in the period
in which they arise except for exchange differences on monetary items receivable from or payable to a foreign operation for which settlement
is neither planned or likely to occur, which form part of the net investment in a foreign operation, are recognised in the foreign currency
translation reserve and recognised in profit or loss on disposal of the net investment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Subsidiaries&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The results and financial position of all the Group&#x2019;s entities
that have a functional currency difference from the presentation currency are translated into the presentation currency as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet, and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;income and expenses for each income statement are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions), and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;all resulting exchange differences are recognised as a separate component of equity.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(j) Employee Benefits&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Short-term obligations&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Short-term employee benefits are benefits (other than termination benefits)
that are expected to be settled wholly before 12 months after the end of the annual reporting period in which the employees render the
related service, including wages, and salaries. Short-term employee benefits are measured at the (undiscounted) amounts expected to be
paid when the obligation is settled. The Group&#x2019;s obligations for short-term employee benefits such as wages and salaries are recognised
as a part of current trade and other payables in the statement of financial position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group&#x2019;s obligations for annual leave are presented as part
of provisions in the Statement of Financial Position. The obligations are presented as current liabilities in the Statement of Financial
Position if the Group does not have an unconditional right to defer settlement for at least twelve months after the reporting period regardless
of when the actual settlement is expected to occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Other long-term obligations&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The liability for long service leave is not expected to be settled
wholly within twelve months after the end of the period in which the employees render the related service. The liability is therefore
recognised in the provision for employee benefits and measured as the present value of expected future payments to be made in respect
of services provided by employees up to the end of the reporting period using the projected unit credit method. Consideration is given
to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted
using market yields at the end of the reporting period of high quality corporate bonds with terms and currencies that match, as closely
as possible, the estimated future cash outflows. Re-measurements as a result of experience adjustments and changes in actuarial assumptions
are recognised in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The obligations are presented as current liabilities in the balance
sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless
of when the actual settlement is expected to occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(k) Provisions&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Provisions are recognised when the Group has a present obligation,
the future sacrifice of economic benefits is probable, and the amount of the provision can be measured reliably.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The amount recognised as a provision is the best estimate of the consideration
required to settle the present obligation at reporting date, taking into account the risks and uncertainties surrounding the obligation.
Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value
of those cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;When some or all of the economic benefits required to settle a provision
are expected to be recovered from a third party, the receivable is recognised as an asset if it is virtually certain that recovery will
be received and the amount of the receivable can be measured reliably.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(l) Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Cash and cash equivalents include cash on hand, deposits held at call
with banks and other short-term highly liquid investments with original maturities of three months or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&lt;b&gt;(m) Interest income&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Other income is made up of interest income which is recognised on a
time proportion basis using the effective interest method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(n) Grants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Grants are recognised when there is reasonable assurance that the grant
will be received and all grant conditions will be complied with.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;When the grant relates to an expense item, it is recognised as income
over the periods necessary to match the grant on a systematic basis to the costs that it is expected to compensate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(o) Goods and Services Tax (&#x201c;GST&#x201d;)&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Revenues, expenses and assets are recognised net of the amount of GST,
except where the amount of GST incurred is not recoverable from the taxation authority. In these circumstances the GST is recognised as
part of the cost of acquisition of the asset or as part of an item of expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Receivables and payables in the Statement of Financial Position are
shown inclusive of GST. The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables
or payables.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Cash flows are included in the Cash Flow Statement on a gross basis.
The GST component of cash flows arising from investing and financing activities which is recoverable from, or payable to, the taxation
authority is classified as operating cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(p) Trade and Other Payables&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;These amounts represent liabilities for goods and services provided
to the Group prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of
recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months from the reporting
date. They are recognised initially at their fair value and subsequently measured at amortized cost using the effective interest method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(q) Share-Based Payments&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The measurement date is determined for share-based payments issued
to directors, employees and consultants as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Directors&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The issuance of share-based payments to directors is subject to approval
by shareholders as per ASX Listing Rule 10.11. The measurement date for share-based payments issued to directors is the grant date, being
the date at which the share-based payments are approved by shareholders.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Employees&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The issuance of share-based payments to employees may be subject to
shareholder approval per ASX Listing Rule 7.1 which prohibits the issuance of more than 15% of the Group&#x2019;s shares in a 12 month
period without shareholder approval. The measurement date for share-based payments issued to employees is the grant date, being the date
at which a shared understanding of the terms and conditions of the arrangement is reached. However, if an issuance to an employee is subject
to shareholder approval because it exceeds the 15% threshold per ASX Listing Rule 7.1, then the measurement date of these share-based
payments is the date at which the share-based payments are approved by shareholders.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Consultants&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The issuance of share-based payments to consultants may be subject
to shareholder approval per ASX Listing Rule 7.1 which prohibits the issuance of more than 15% of the Group&#x2019;s shares in a 12 month
period without shareholder approval. The measurement date for share-based payments issued to consultants who provide services considered
to be similar to employees is deemed to be the date at which a shared understanding of the terms and conditions of the arrangement is
reached. The measurement date for share-based payments issued to consultants who provide services considered to be differentiated from
those provided by employees is deemed to be the date at which the entity obtains the goods or the counterparty renders the service. If
a service period applies and the work is continually provided over the service period, and if the share price of the Group does not change
significantly during the service period, then the average share price, volatility and risk-free rate over the service period are used
in calculating the value of the share-based payments issued. However, if the underlying share price of the Group does change significantly
during the service period, then the value of share-based payments are calculated at each individual date that goods and services are provided,
using the actual valuation inputs at that date. Shares issued to consultants for services are recorded as non-cash compensation and are
recognised at either the fair value of the services rendered, or if this cannot be reasonably estimated, the fair value of the underlying
equity instruments issued. Equity-based compensation benefits are provided to directors, employees and consultants under the 2004 ASX
Plan (the &#x201c;2004 ASX Plan&#x201d;) and the 2018 American Depository Share (ADS) Option Plan (the &#x201c;2018 ADS Plan&#x201d;). Information
relating to this plan is set out in Note 16.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The fair value of options granted under these plans is recognised as
an expense with a corresponding increase in equity. The fair value is measured at grant date and recognised over the period during which
the recipients become unconditionally entitled to the options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The fair value at grant date is independently determined using a Black-Scholes
(for options without market condition) and Barrier Pricing (for options with market conditions) model that takes into account the exercise
price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share,
the expected dividend yield and the risk free interest rate for the term of the option. The expected life used in the model has been adjusted,
based on management&#x2019;s best estimate, for the effects of non-transferability, exercise restrictions, and behavioral considerations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The fair value determined at the grant date of the equity-settled share-based
payments is expensed on a straight-line basis over the vesting period, based on the Group&#x2019;s estimate of shares that will eventually
vest.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(r) Loss Per Share&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basic loss per share is determined by dividing the net loss after income
tax expense by the weighted average number of ordinary shares outstanding during the financial period. For all periods presented, diluted
loss per share is equivalent to basic loss per share as the potentially dilutive securities are excluded from the computation of diluted
loss per share because the effect is anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(s) Share Capital&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Ordinary share capital is recognised as the fair value of the consideration
received by the Group. Any transaction costs arising on the issue of ordinary shares are recognised directly in equity as a reduction
of the share proceeds received.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(t) Trade and Other Receivables&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Trade and other receivables are recognised initially at fair value
and subsequently measured at amortized cost using the effective interest rate method less provision for impairment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(u) Comparative Figures&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Comparative figures, are, where appropriate, reclassified to be comparable
with figures presented in the current financial year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(v) New Accounting Standards and Interpretations &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group has adopted all of the new or amended Accounting Standards
and Interpretations issued by the International Accounting Standards Board &#x2018;IASB&#x2019; and Australian Accounting Standards Board
&#x2018;AASB&#x2019; that are mandatory for the current reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The adoption of these standards has not had any material impact on
the disclosures or amounts reported in these financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In April 2024, IFRS 18, &#x201c;Presentation and Disclosure in Financial
Statements&#x201d; was issued to achieve comparability of the financial performance of similar entities. The standard, which replaces IAS
1 &#x201c;Presentation of Financial Statements&#x201d;, impacts the presentation of primary financial statements and notes, including the
statement of earnings where companies will be required to present separate categories of income and expense for operating, investing,
and financing activities with prescribed subtotals for each new category. The standard will also require management-defined performance
measures to be explained and included in a separate note within the consolidated financial statements. The standard is effective for annual
reporting periods beginning on or after January 1, 2027, including interim financial statements, and requires retrospective application.
The Group is currently assessing the impact of the new standard.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;There were no other new accounting standards and interpretations not
yet adopted by the Group for the June 30, 2025 reporting period that are expected to materially impact the Group.&lt;/p&gt;</ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory>
    <athe:TaxRateEffectFromChangesInTaxRate contextRef="c0" id="ixv-23636">A 43.5% refundable tax offset is available to eligible small companies with an annual aggregate
turnover of less than $20 million.</athe:TaxRateEffectFromChangesInTaxRate>
    <athe:EligibleAmountUnderTheTaxIncentiveScheme contextRef="c0" decimals="-5" id="ixv-23637" unitRef="aud">5400000</athe:EligibleAmountUnderTheTaxIncentiveScheme>
    <athe:EligibleAmountUnderTheTaxIncentiveScheme contextRef="c4" decimals="-5" id="ixv-23638" unitRef="aud">4000000</athe:EligibleAmountUnderTheTaxIncentiveScheme>
    <athe:EligibleAmountUnderTheTaxIncentiveScheme contextRef="c5" decimals="-5" id="ixv-23639" unitRef="aud">3900000</athe:EligibleAmountUnderTheTaxIncentiveScheme>
    <ifrs-full:OtherIncome contextRef="c5" decimals="-5" id="ixv-23640" unitRef="aud">3900000</ifrs-full:OtherIncome>
    <athe:ProfitLossBeforeTax1 contextRef="c0" decimals="0" id="ixv-23641" unitRef="aud">12147828</athe:ProfitLossBeforeTax1>
    <athe:ProfitLossBeforeTax1 contextRef="c4" decimals="0" id="ixv-23642" unitRef="aud">19123464</athe:ProfitLossBeforeTax1>
    <athe:ProfitLossBeforeTax2 contextRef="c0" decimals="0" id="ixv-23643" unitRef="aud">11451248</athe:ProfitLossBeforeTax2>
    <athe:ProfitLossBeforeTax2 contextRef="c4" decimals="0" id="ixv-23644" unitRef="aud">12605824</athe:ProfitLossBeforeTax2>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-23645" unitRef="aud">39669380</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <athe:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock contextRef="c0" id="ixv-14198">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(a) Principles of Consolidation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The consolidated financial statements are prepared by combining the
financial statements of all the entities that comprise the Group, being Alterity Therapeutics Limited and its subsidiaries as defined
in Accounting Standard IFRS10 (AASB 10): &lt;i&gt;Consolidated Financial Statements&lt;/i&gt;. Consistent accounting policies are employed in the
preparation and presentation of the consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Subsidiaries are all those entities (including special purpose entities)
over which the Group has control. The Group controls an entity where the group is exposed to, or has rights to, variable returns from
its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity.
The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether
the Group controls another entity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Subsidiaries are fully consolidated from the date on which control
is transferred to the Group. They are de-consolidated from the date that control ceases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In preparing the consolidated financial statements, all inter-company
balances and transactions, and unrealized profits/losses arising within the Group are eliminated in full. Investments in subsidiaries
are accounted for at cost in the individual financial statements of Alterity Therapeutics Limited.&lt;/p&gt;</athe:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory contextRef="c0" id="ixv-14215">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(b) Segment Reporting&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Operating segments are reported in a manner consistent with the internal
reporting provided to the chief operating decision maker (the &#x201c;CODM&#x201d;). The CODM, who is responsible for allocating resources
and assessing performance of the operating segments, has been identified as the Chief Executive Officer of Alterity Therapeutics Limited.
For the current and previous reporting periods, the Group operated in one segment, being research and development into Parkinsonian and
other neurodegenerative disorders.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="c0" id="ixv-14223">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(c) Income Tax&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Current tax&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Current tax is calculated by reference to the amount of income taxes
payable or recoverable in respect of the taxable profit or loss for the period. It is calculated using tax rates and tax laws that have
been enacted or substantively enacted by reporting date. Current tax for current and prior periods is recognised as a liability (or asset)
to the extent that it is unpaid (or refundable).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Deferred tax&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Deferred tax is accounted for using the liability method in respect
of temporary differences arising from differences between the carrying amount of assets and liabilities in the financial statements and
the corresponding tax base of those items.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In principle, deferred tax assets and liabilities are recognised for
all taxable temporary differences. Deferred tax assets are recognised to the extent that it is probable that sufficient taxable amounts
will be available against which deductible temporary differences or unused tax losses and tax offsets can be utilized. However, deferred
tax assets and liabilities are not recognised if the temporary differences giving rise to them arise from the initial recognition of assets
and liabilities (other than as a result of a business combination) which affects neither taxable income nor accounting profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Deferred tax liabilities are recognised for taxable temporary differences
arising on investments in subsidiaries except where the Group is able to control the reversal of the temporary differences and it is probable
that the temporary differences will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences
associated with these investments are only recognised to the extent that it is probable that there will be sufficient taxable profits
against which to utilize the benefits of the temporary differences and they are expected to reverse in the foreseeable future.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Deferred tax assets and liabilities are measured at the tax rates that
are expected to apply to the period(s) when the asset and liability giving rise to them are realized or settled, based on tax rates (and
tax laws) that have been enacted or substantively enacted by reporting date. The measurement of deferred tax liabilities and assets reflects
the tax consequences that would follow from the manner in which the Group expects, at the reporting date, to recover or settle the carrying
amount of its assets and liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Deferred tax assets and liabilities are offset when there is a legally
enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.
Current tax assets and tax liabilities are offset when the entity has a legally enforceable right to offset and intends either to settle
on a net basis or to realize the asset and settle the liability simultaneously.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Current and deferred tax for the period&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Current and deferred tax is recognised as an expense or income in the
Statement of Profit or Loss and Other Comprehensive Loss except when it relates to items credited or debited directly to equity, in which
case the deferred tax is also recognised directly in equity, or where it arises from the initial accounting for a business combination,
in which case it is taken into account in the determination of goodwill.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group has significant unused tax losses and as such a significant
deferred tax asset; however, the deferred tax asset has not been recognised, as it is not probable that future taxable profit will be
available against which the unused losses and unused tax credits can be utilized, given the nature of the Group&#x2019;s business (research
and development) and its history of losses.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c0" id="ixv-14301">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(d) Property and Equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Property and equipment is measured at historical cost less accumulated
depreciation and impairment and consists of laboratory equipment, computer equipment, furniture and fittings and leasehold improvements
attributable to the Group&#x2019;s premises at Melbourne, Victoria, Australia and San Francisco, U.S.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Historical cost includes expenditure that is directly attributable
to the acquisition of the item.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;Subsequent costs are included in the asset&#x2019;s carrying amount
or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will
flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate
asset is derecognised when replaced. All other repairs and maintenance are charged to the income statement during the reporting period
in which they are incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Depreciation is provided on property and equipment. Depreciation is
calculated on a straight-line method to allocate their cost, net of their residual values, over their estimated useful lives.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following estimated useful lives, ranging from 3 to 20 years are
used in the calculation of depreciation:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Class of Fixed Asset&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Depreciation Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fittings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5-33%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;33%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Plant and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10-33%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;33%&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Leasehold improvements are depreciated over the shorter of the lease
term and useful life.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The depreciation method, residual values and useful lives are reviewed,
and adjusted if appropriate, at each annual reporting period.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="c0" id="ixv-14355">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following estimated useful lives, ranging from 3 to 20 years are
used in the calculation of depreciation:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Class of Fixed Asset&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Depreciation Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fittings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5-33%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;33%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Plant and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10-33%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;33%&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <athe:EstimatedUsefulEconomicLife contextRef="c29" id="ixv-23646">P3Y</athe:EstimatedUsefulEconomicLife>
    <athe:EstimatedUsefulEconomicLife contextRef="c30" id="ixv-23647">P20Y</athe:EstimatedUsefulEconomicLife>
    <athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments contextRef="c31" decimals="2" id="ixv-23648" unitRef="pure">0.05</athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments>
    <athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments contextRef="c32" decimals="2" id="ixv-23649" unitRef="pure">0.33</athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments>
    <athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments contextRef="c33" decimals="2" id="ixv-23650" unitRef="pure">0.33</athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments>
    <athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments contextRef="c34" decimals="2" id="ixv-23651" unitRef="pure">0.10</athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments>
    <athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments contextRef="c35" decimals="2" id="ixv-23652" unitRef="pure">0.33</athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments>
    <athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments contextRef="c36" decimals="2" id="ixv-23653" unitRef="pure">0.33</athe:UsefulLivesOrDepreciationRatePropertyPlantAndEquipments>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="c0" id="ixv-14405">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(e) Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The accounting policies for the Group&#x2019;s lease recognition are
explained in Note 13.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="c0" id="ixv-14413">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(f) Investments and other financial assets &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Classification &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group classifies its financial assets in the following measurement
categories:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;those to be measured subsequently at fair value (either through OCI or through profit or loss), and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;those to be measured at amortized cost.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The classification depends on the entity&#x2019;s business model for
managing the financial assets and the contractual terms of the cash flow. For assets measured at fair value, gains and losses will either
be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, this will depend on whether
the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through
other comprehensive income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Recognition and derecognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Regular way purchases and sales of financial assets are recognised
on trade-date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognised when the rights to
receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the
risks and rewards of ownership.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Measurement&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At initial recognition, the Group measures a financial asset at its
fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs that are directly attributable
to the acquisition of the financial asset. Transaction costs of financial assets carried at fair value through profit or loss are expensed
in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Assets that are held for collection of contractual cash flows where
those cash flows represent solely payments of principal and interest are measured at amortised cost. Interest income from these financial
assets is included in finance income using the effective interest method. Any gain or loss arising on derecognition is recognised directly
in profit or loss and presented in other gains/(losses) together with foreign exchange gains and losses. Impairment losses are presented
as a separate line item in the consolidated statement of profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Impairment&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group assesses on a forward looking basis the expected credit losses
associated with its debt instruments carried at amortized cost and fair value through other comprehensive income. The impairment methodology
applied depends on whether there has been a significant increase in credit risk.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;For trade receivables, the Group applies the simplified approach which
requires expected lifetime losses to be recognised from initial recognition of the receivables, see Note 5 for further details.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory contextRef="c0" id="ixv-14511">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(g) Impairment of Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At each reporting date, the Group reviews the carrying amounts of its
tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If any such indication
exists, the recoverable amount of the asset is estimated to determine the extent of the impairment loss (if any).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Where the asset does not generate cash flows that are independent from
other assets, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Recoverable amount is the higher of fair value less costs of disposal
and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount
rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of
future cash flows have not been adjusted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;If the recoverable amount of an asset (or cash-generating unit) is
estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable
amount. An impairment loss is recognised in the consolidated statement of profit or loss and other comprehensive loss immediately.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Where an impairment loss subsequently reverses, the carrying amount
of the asset (or cash-generating unit) is reversed to the revised estimate of its recoverable amount, but only to the extent that the
increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for
the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised in the consolidated statement of profit
or loss and other comprehensive loss immediately.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;No impairment charges were incurred during the year ended June 30,
2025.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="c0" id="ixv-14565">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(h) Intangible Assets - Research and Development &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Expenditure during the research phase of a project is recognised as
an expense when incurred. Where no internally generated intangible assets can be recognised, development expenditure is recognised as
an expense in the period as incurred. Development costs are capitalised if and only if, all of the following are demonstrated:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the technical feasibility of completing the intangible asset so that it will be available for use or sale;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the intention to complete the intangible asset and use or sell it;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the ability to use or sell the intangible asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;how the intangible asset will generate probable future economic benefits;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the ability to measure reliably the expenditure attributable to the intangible asset during its development.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Internally-generated intangible assets (capitalised development costs)
are stated at cost less accumulated amortisation and impairment, and are amortised on a straight-line basis over their useful lives over
a maximum of five years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of June 30, 2025, 2024 and 2023, the Group had no capitalized research
and development costs.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c0" id="ixv-14634">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(i) Foreign Currency Transactions and Balances&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Functional and Presentation Currency&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The consolidated financial statements are presented in Australian dollars
($), which is Alterity Therapeutics Limited&#x2019;s functional and presentation currency.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Foreign currency transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;All foreign currency transactions during the financial year are brought
to account using the exchange rate in effect at the date of the transaction. Foreign currency monetary items at each reporting date are
translated at the exchange rate existing at each reporting date. Non-monetary assets and liabilities carried at fair value that are denominated
in foreign currencies are translated at the rates prevailing at the date when the fair value was determined.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Exchange differences are recognised in profit or loss in the period
in which they arise except for exchange differences on monetary items receivable from or payable to a foreign operation for which settlement
is neither planned or likely to occur, which form part of the net investment in a foreign operation, are recognised in the foreign currency
translation reserve and recognised in profit or loss on disposal of the net investment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The results and financial position of all the Group&#x2019;s entities
that have a functional currency difference from the presentation currency are translated into the presentation currency as follows:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet, and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;income and expenses for each income statement are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions), and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;all resulting exchange differences are recognised as a separate component of equity.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="c0" id="ixv-14727">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(j) Employee Benefits&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Short-term obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Short-term employee benefits are benefits (other than termination benefits)
that are expected to be settled wholly before 12 months after the end of the annual reporting period in which the employees render the
related service, including wages, and salaries. Short-term employee benefits are measured at the (undiscounted) amounts expected to be
paid when the obligation is settled. The Group&#x2019;s obligations for short-term employee benefits such as wages and salaries are recognised
as a part of current trade and other payables in the statement of financial position.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group&#x2019;s obligations for annual leave are presented as part
of provisions in the Statement of Financial Position. The obligations are presented as current liabilities in the Statement of Financial
Position if the Group does not have an unconditional right to defer settlement for at least twelve months after the reporting period regardless
of when the actual settlement is expected to occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Other long-term obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The liability for long service leave is not expected to be settled
wholly within twelve months after the end of the period in which the employees render the related service. The liability is therefore
recognised in the provision for employee benefits and measured as the present value of expected future payments to be made in respect
of services provided by employees up to the end of the reporting period using the projected unit credit method. Consideration is given
to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted
using market yields at the end of the reporting period of high quality corporate bonds with terms and currencies that match, as closely
as possible, the estimated future cash outflows. Re-measurements as a result of experience adjustments and changes in actuarial assumptions
are recognised in profit or loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The obligations are presented as current liabilities in the balance
sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless
of when the actual settlement is expected to occur.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="c0" id="ixv-14784">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(k) Provisions&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Provisions are recognised when the Group has a present obligation,
the future sacrifice of economic benefits is probable, and the amount of the provision can be measured reliably.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The amount recognised as a provision is the best estimate of the consideration
required to settle the present obligation at reporting date, taking into account the risks and uncertainties surrounding the obligation.
Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value
of those cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;When some or all of the economic benefits required to settle a provision
are expected to be recovered from a third party, the receivable is recognised as an asset if it is virtually certain that recovery will
be received and the amount of the receivable can be measured reliably.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents contextRef="c0" id="ixv-14797">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(l) Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Cash and cash equivalents include cash on hand, deposits held at call
with banks and other short-term highly liquid investments with original maturities of three months or less.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents>
    <athe:DescriptionOfAccountingPolicyForRecognitionOfOtherIncome contextRef="c0" id="ixv-14804">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&lt;b&gt;(m) Interest income&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Other income is made up of interest income which is recognised on a
time proportion basis using the effective interest method.&lt;/p&gt;</athe:DescriptionOfAccountingPolicyForRecognitionOfOtherIncome>
    <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants contextRef="c0" id="ixv-14811">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(n) Grants&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Grants are recognised when there is reasonable assurance that the grant
will be received and all grant conditions will be complied with.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;When the grant relates to an expense item, it is recognised as income
over the periods necessary to match the grant on a systematic basis to the costs that it is expected to compensate.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
    <ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory contextRef="c0" id="ixv-14821">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(o) Goods and Services Tax (&#x201c;GST&#x201d;)&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Revenues, expenses and assets are recognised net of the amount of GST,
except where the amount of GST incurred is not recoverable from the taxation authority. In these circumstances the GST is recognised as
part of the cost of acquisition of the asset or as part of an item of expense.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Receivables and payables in the Statement of Financial Position are
shown inclusive of GST. The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables
or payables.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Cash flows are included in the Cash Flow Statement on a gross basis.
The GST component of cash flows arising from investing and financing activities which is recoverable from, or payable to, the taxation
authority is classified as operating cash flows.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory contextRef="c0" id="ixv-14865">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(p) Trade and Other Payables&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;These amounts represent liabilities for goods and services provided
to the Group prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of
recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months from the reporting
date. They are recognised initially at their fair value and subsequently measured at amortized cost using the effective interest method.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="c0" id="ixv-14872">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(q) Share-Based Payments&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The measurement date is determined for share-based payments issued
to directors, employees and consultants as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Directors&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The issuance of share-based payments to directors is subject to approval
by shareholders as per ASX Listing Rule 10.11. The measurement date for share-based payments issued to directors is the grant date, being
the date at which the share-based payments are approved by shareholders.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Employees&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The issuance of share-based payments to employees may be subject to
shareholder approval per ASX Listing Rule 7.1 which prohibits the issuance of more than 15% of the Group&#x2019;s shares in a 12 month
period without shareholder approval. The measurement date for share-based payments issued to employees is the grant date, being the date
at which a shared understanding of the terms and conditions of the arrangement is reached. However, if an issuance to an employee is subject
to shareholder approval because it exceeds the 15% threshold per ASX Listing Rule 7.1, then the measurement date of these share-based
payments is the date at which the share-based payments are approved by shareholders.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Consultants&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The issuance of share-based payments to consultants may be subject
to shareholder approval per ASX Listing Rule 7.1 which prohibits the issuance of more than 15% of the Group&#x2019;s shares in a 12 month
period without shareholder approval. The measurement date for share-based payments issued to consultants who provide services considered
to be similar to employees is deemed to be the date at which a shared understanding of the terms and conditions of the arrangement is
reached. The measurement date for share-based payments issued to consultants who provide services considered to be differentiated from
those provided by employees is deemed to be the date at which the entity obtains the goods or the counterparty renders the service. If
a service period applies and the work is continually provided over the service period, and if the share price of the Group does not change
significantly during the service period, then the average share price, volatility and risk-free rate over the service period are used
in calculating the value of the share-based payments issued. However, if the underlying share price of the Group does change significantly
during the service period, then the value of share-based payments are calculated at each individual date that goods and services are provided,
using the actual valuation inputs at that date. Shares issued to consultants for services are recorded as non-cash compensation and are
recognised at either the fair value of the services rendered, or if this cannot be reasonably estimated, the fair value of the underlying
equity instruments issued. Equity-based compensation benefits are provided to directors, employees and consultants under the 2004 ASX
Plan (the &#x201c;2004 ASX Plan&#x201d;) and the 2018 American Depository Share (ADS) Option Plan (the &#x201c;2018 ADS Plan&#x201d;). Information
relating to this plan is set out in Note 16.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The fair value of options granted under these plans is recognised as
an expense with a corresponding increase in equity. The fair value is measured at grant date and recognised over the period during which
the recipients become unconditionally entitled to the options.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The fair value at grant date is independently determined using a Black-Scholes
(for options without market condition) and Barrier Pricing (for options with market conditions) model that takes into account the exercise
price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share,
the expected dividend yield and the risk free interest rate for the term of the option. The expected life used in the model has been adjusted,
based on management&#x2019;s best estimate, for the effects of non-transferability, exercise restrictions, and behavioral considerations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The fair value determined at the grant date of the equity-settled share-based
payments is expensed on a straight-line basis over the vesting period, based on the Group&#x2019;s estimate of shares that will eventually
vest.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <athe:Employeesdescription contextRef="c0" id="ixv-14887">EmployeesThe issuance of share-based payments to employees may be subject to
shareholder approval per ASX Listing Rule 7.1 which prohibits the issuance of more than 15% of the Group&#x2019;s shares in a 12 month
period without shareholder approval. The measurement date for share-based payments issued to employees is the grant date, being the date
at which a shared understanding of the terms and conditions of the arrangement is reached. However, if an issuance to an employee is subject
to shareholder approval because it exceeds the 15% threshold per ASX Listing Rule 7.1, then the measurement date of these share-based
payments is the date at which the share-based payments are approved by shareholders.</athe:Employeesdescription>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="c0" id="ixv-14948">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(r) Loss Per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basic loss per share is determined by dividing the net loss after income
tax expense by the weighted average number of ordinary shares outstanding during the financial period. For all periods presented, diluted
loss per share is equivalent to basic loss per share as the potentially dilutive securities are excluded from the computation of diluted
loss per share because the effect is anti-dilutive.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory contextRef="c0" id="ixv-14955">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(s) Share Capital&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Ordinary share capital is recognised as the fair value of the consideration
received by the Group. Any transaction costs arising on the issue of ordinary shares are recognised directly in equity as a reduction
of the share proceeds received.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory contextRef="c0" id="ixv-14962">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(t) Trade and Other Receivables&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Trade and other receivables are recognised initially at fair value
and subsequently measured at amortized cost using the effective interest rate method less provision for impairment.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory>
    <athe:DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock contextRef="c0" id="ixv-14969">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(u) Comparative Figures&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Comparative figures, are, where appropriate, reclassified to be comparable
with figures presented in the current financial year.&lt;/p&gt;</athe:DescriptionOfAccountingPolicyForComparativeFiguresExplanatoryPolicyTextBlock>
    <athe:DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock contextRef="c0" id="ixv-14976">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(v) New Accounting Standards and Interpretations &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group has adopted all of the new or amended Accounting Standards
and Interpretations issued by the International Accounting Standards Board &#x2018;IASB&#x2019; and Australian Accounting Standards Board
&#x2018;AASB&#x2019; that are mandatory for the current reporting period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The adoption of these standards has not had any material impact on
the disclosures or amounts reported in these financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In April 2024, IFRS 18, &#x201c;Presentation and Disclosure in Financial
Statements&#x201d; was issued to achieve comparability of the financial performance of similar entities. The standard, which replaces IAS
1 &#x201c;Presentation of Financial Statements&#x201d;, impacts the presentation of primary financial statements and notes, including the
statement of earnings where companies will be required to present separate categories of income and expense for operating, investing,
and financing activities with prescribed subtotals for each new category. The standard will also require management-defined performance
measures to be explained and included in a separate note within the consolidated financial statements. The standard is effective for annual
reporting periods beginning on or after January 1, 2027, including interim financial statements, and requires retrospective application.
The Group is currently assessing the impact of the new standard.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;There were no other new accounting standards and interpretations not
yet adopted by the Group for the June 30, 2025 reporting period that are expected to materially impact the Group.&lt;/p&gt;</athe:DescriptionOfAccountingPolicyForNewAccountingStandardsAndInterpretationsPolicyTextBlock>
    <ifrs-full:DisclosureOfInterestIncomeExplanatory contextRef="c0" id="ixv-15015">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;2. INTEREST AND OTHER INCOME FROM CONTINUING OPERATIONS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Interest income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;Interest income&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;446,291&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;268,419&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;16,436&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total interest income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;446,291&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;268,419&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,436&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Other income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D Tax Incentive (1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,438,918&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,019,285&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,914,230&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Miscellaneous income (2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,202,598&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,103&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total other income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,641,516&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,019,285&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,916,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total interest and other income from continuing operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,087,807&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,287,704&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,932,769&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A 43.5% R&amp;amp;D Tax incentive refundable tax offset, is available to eligible small companies with an annual aggregate turnover of less than $20 million. For the years ended June 30, 2025, June 30, 2024 and June 30, 2023, the Group was eligible to receive the refundable tax offset. Management, with input from an independent expert, has applied judgement when assessing activities and expenditures that are likely to be eligible under the incentive scheme and therefore recorded $5,438,918, $4,019,285 and $3,914,230 in other income, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Miscellaneous income is comprised of other income of $1,975,056 in relation to settlement of a dispute with Catalent, and other income of $227,542 in relation to settlement of an insurance claim in relation to a U.S. employment case.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfInterestIncomeExplanatory>
    <athe:ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock contextRef="c0" id="ixv-15019">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Interest income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;Interest income&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;446,291&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;268,419&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;16,436&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total interest income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;446,291&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;268,419&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,436&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Other income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D Tax Incentive (1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,438,918&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,019,285&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,914,230&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Miscellaneous income (2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,202,598&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,103&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total other income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,641,516&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,019,285&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,916,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total interest and other income from continuing operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,087,807&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,287,704&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,932,769&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A 43.5% R&amp;amp;D Tax incentive refundable tax offset, is available to eligible small companies with an annual aggregate turnover of less than $20 million. For the years ended June 30, 2025, June 30, 2024 and June 30, 2023, the Group was eligible to receive the refundable tax offset. Management, with input from an independent expert, has applied judgement when assessing activities and expenditures that are likely to be eligible under the incentive scheme and therefore recorded $5,438,918, $4,019,285 and $3,914,230 in other income, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Miscellaneous income is comprised of other income of $1,975,056 in relation to settlement of a dispute with Catalent, and other income of $227,542 in relation to settlement of an insurance claim in relation to a U.S. employment case.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</athe:ScheduleOfRevenueAndOtherIncomeFromContinuingOperationsTableTextBlock>
    <ifrs-full:RevenueFromInterest contextRef="c0" decimals="0" id="ixv-23654" unitRef="aud">446291</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="c4" decimals="0" id="ixv-23655" unitRef="aud">268419</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="c5" decimals="0" id="ixv-23656" unitRef="aud">16436</ifrs-full:RevenueFromInterest>
    <ifrs-full:OtherRevenue contextRef="c0" decimals="0" id="ixv-23657" unitRef="aud">446291</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c4" decimals="0" id="ixv-23658" unitRef="aud">268419</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c5" decimals="0" id="ixv-23659" unitRef="aud">16436</ifrs-full:OtherRevenue>
    <athe:ResearchAndDevelopmentTaxIncentive contextRef="c0" decimals="0" id="ix_0_fact" unitRef="aud">5438918</athe:ResearchAndDevelopmentTaxIncentive>
    <athe:ResearchAndDevelopmentTaxIncentive contextRef="c4" decimals="0" id="ix_1_fact" unitRef="aud">4019285</athe:ResearchAndDevelopmentTaxIncentive>
    <athe:ResearchAndDevelopmentTaxIncentive contextRef="c5" decimals="0" id="ix_2_fact" unitRef="aud">3914230</athe:ResearchAndDevelopmentTaxIncentive>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c0" decimals="0" id="ix_3_fact" unitRef="aud">2202598</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c5" decimals="0" id="ix_4_fact" unitRef="aud">2103</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:OtherIncome contextRef="c0" decimals="0" id="ixv-23665" unitRef="aud">7641516</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c4" decimals="0" id="ixv-23666" unitRef="aud">4019285</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c5" decimals="0" id="ixv-23667" unitRef="aud">3916333</ifrs-full:OtherIncome>
    <ifrs-full:RevenueAndOperatingIncome contextRef="c0" decimals="0" id="ixv-23668" unitRef="aud">8087807</ifrs-full:RevenueAndOperatingIncome>
    <ifrs-full:RevenueAndOperatingIncome contextRef="c4" decimals="0" id="ixv-23669" unitRef="aud">4287704</ifrs-full:RevenueAndOperatingIncome>
    <ifrs-full:RevenueAndOperatingIncome contextRef="c5" decimals="0" id="ixv-23670" unitRef="aud">3932769</ifrs-full:RevenueAndOperatingIncome>
    <ifrs-full:TaxRateEffectFromChangeInTaxRate contextRef="c0" decimals="3" id="ixv-23671" unitRef="pure">0.435</ifrs-full:TaxRateEffectFromChangeInTaxRate>
    <athe:TurnoverRevenue contextRef="c0" decimals="-6" id="ixv-23672" unitRef="usd">20000000</athe:TurnoverRevenue>
    <athe:EligibleAmountUnderTaxIncentiveScheme contextRef="c0" decimals="0" id="ixv-23673" unitRef="usd">5438918</athe:EligibleAmountUnderTaxIncentiveScheme>
    <athe:EligibleAmountUnderTaxIncentiveScheme contextRef="c4" decimals="0" id="ixv-23674" unitRef="usd">4019285</athe:EligibleAmountUnderTaxIncentiveScheme>
    <athe:EligibleAmountUnderTaxIncentiveScheme contextRef="c5" decimals="0" id="ixv-23675" unitRef="usd">3914230</athe:EligibleAmountUnderTaxIncentiveScheme>
    <athe:MiscellaneousIncomeDisputeWithCatalent contextRef="c0" decimals="0" id="ixv-23677" unitRef="usd">1975056</athe:MiscellaneousIncomeDisputeWithCatalent>
    <athe:MiscellaneousIncomeSettlementOfAnInsuranceClaim contextRef="c0" decimals="0" id="ixv-23678" unitRef="usd">227542</athe:MiscellaneousIncomeSettlementOfAnInsuranceClaim>
    <ifrs-full:DisclosureOfExpensesExplanatory contextRef="c0" id="ixv-15227">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;3. EXPENSES FROM ORDINARY ACTIVITIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Research and Development Expenses (1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Employee expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,424,781&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,456,230&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,720,345&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Other research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,107,024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,187,817&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,478,238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;General and Administration Expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Depreciation on fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,307&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,344&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Depreciation on leased assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111,408&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112,185&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Employee expenses (non R&amp;amp;D related)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,046,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;515,803&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;926,314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Consultant and director expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;652,260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;321,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;320,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Audit, internal control and other assurance expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;460,254&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;238,728&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Corporate compliance expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;780,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;790,350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;457,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Insurance expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;549,408&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;676,219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;721,732&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Office rental&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,253&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,674&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Other administrative and office expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;520,142&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,028,638&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,032,843&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Share based payment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;979,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;881,950&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;966,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Corporate advisory expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;355,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;204,621&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Other gains and losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Foreign exchange (gain)/loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(259,433&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(261,152&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(917,650&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenses mainly consist of expenses paid for contracted research and development activities conducted by third parties on behalf of the Group.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfExpensesExplanatory>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory contextRef="c0" id="ixv-15231">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Research and Development Expenses (1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Employee expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,424,781&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,456,230&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,720,345&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Other research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,107,024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,187,817&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,478,238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;General and Administration Expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Depreciation on fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,307&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,344&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Depreciation on leased assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111,408&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112,185&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Employee expenses (non R&amp;amp;D related)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,046,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;515,803&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;926,314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Consultant and director expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;652,260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;321,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;320,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Audit, internal control and other assurance expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;460,254&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;238,728&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Corporate compliance expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;780,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;790,350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;457,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Insurance expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;549,408&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;676,219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;721,732&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Office rental&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,253&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,674&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Other administrative and office expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;520,142&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,028,638&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,032,843&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Share based payment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;979,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;881,950&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;966,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Corporate advisory expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;355,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;204,621&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Other gains and losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Foreign exchange (gain)/loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(259,433&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(261,152&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(917,650&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenses mainly consist of expenses paid for contracted research and development activities conducted by third parties on behalf of the Group.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c0" decimals="0" id="ix_5_fact" unitRef="aud">2424781</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c4" decimals="0" id="ix_6_fact" unitRef="aud">2456230</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c5" decimals="0" id="ix_7_fact" unitRef="aud">2720345</ifrs-full:EmployeeBenefitsExpense>
    <athe:OtherResearchAndDevelopmentExpenses contextRef="c0" decimals="0" id="ix_8_fact" unitRef="aud">12107024</athe:OtherResearchAndDevelopmentExpenses>
    <athe:OtherResearchAndDevelopmentExpenses contextRef="c4" decimals="0" id="ix_9_fact" unitRef="aud">16187817</athe:OtherResearchAndDevelopmentExpenses>
    <athe:OtherResearchAndDevelopmentExpenses contextRef="c5" decimals="0" id="ix_10_fact" unitRef="aud">10478238</athe:OtherResearchAndDevelopmentExpenses>
    <ifrs-full:DepreciationExpense contextRef="c0" decimals="0" id="ixv-23685" unitRef="aud">28307</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c4" decimals="0" id="ixv-23686" unitRef="aud">35344</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c5" decimals="0" id="ixv-23687" unitRef="aud">37854</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c0" decimals="0" id="ixv-23688" unitRef="aud">111408</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c4" decimals="0" id="ixv-23689" unitRef="aud">112185</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c5" decimals="0" id="ixv-23690" unitRef="aud">64409</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:OtherEmployeeExpense contextRef="c0" decimals="0" id="ixv-23691" unitRef="aud">1046530</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c4" decimals="0" id="ixv-23692" unitRef="aud">515803</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c5" decimals="0" id="ixv-23693" unitRef="aud">926314</ifrs-full:OtherEmployeeExpense>
    <athe:ConsultantAndDirectorExpenses contextRef="c0" decimals="0" id="ixv-23694" unitRef="aud">652260</athe:ConsultantAndDirectorExpenses>
    <athe:ConsultantAndDirectorExpenses contextRef="c4" decimals="0" id="ixv-23695" unitRef="aud">321000</athe:ConsultantAndDirectorExpenses>
    <athe:ConsultantAndDirectorExpenses contextRef="c5" decimals="0" id="ixv-23696" unitRef="aud">320500</athe:ConsultantAndDirectorExpenses>
    <athe:AuditInternalControlAndOtherAssuranceExpenses contextRef="c0" decimals="0" id="ixv-23697" unitRef="aud">460254</athe:AuditInternalControlAndOtherAssuranceExpenses>
    <athe:AuditInternalControlAndOtherAssuranceExpenses contextRef="c4" decimals="0" id="ixv-23698" unitRef="aud">241828</athe:AuditInternalControlAndOtherAssuranceExpenses>
    <athe:AuditInternalControlAndOtherAssuranceExpenses contextRef="c5" decimals="0" id="ixv-23699" unitRef="aud">238728</athe:AuditInternalControlAndOtherAssuranceExpenses>
    <athe:CorporateComplianceExpenses contextRef="c0" decimals="0" id="ixv-23700" unitRef="aud">780320</athe:CorporateComplianceExpenses>
    <athe:CorporateComplianceExpenses contextRef="c4" decimals="0" id="ixv-23701" unitRef="aud">790350</athe:CorporateComplianceExpenses>
    <athe:CorporateComplianceExpenses contextRef="c5" decimals="0" id="ixv-23702" unitRef="aud">457215</athe:CorporateComplianceExpenses>
    <ifrs-full:InsuranceExpense contextRef="c0" decimals="0" id="ixv-23703" unitRef="aud">549408</ifrs-full:InsuranceExpense>
    <ifrs-full:InsuranceExpense contextRef="c4" decimals="0" id="ixv-23704" unitRef="aud">676219</ifrs-full:InsuranceExpense>
    <ifrs-full:InsuranceExpense contextRef="c5" decimals="0" id="ixv-23705" unitRef="aud">721732</ifrs-full:InsuranceExpense>
    <athe:OfficeRentalExpenses contextRef="c0" decimals="0" id="ixv-23706" unitRef="aud">-2253</athe:OfficeRentalExpenses>
    <athe:OfficeRentalExpenses contextRef="c4" decimals="0" id="ixv-23707" unitRef="aud">-9674</athe:OfficeRentalExpenses>
    <athe:OfficeRentalExpenses contextRef="c5" decimals="0" id="ixv-23708" unitRef="aud">68634</athe:OfficeRentalExpenses>
    <ifrs-full:AdministrativeExpense contextRef="c0" decimals="0" id="ixv-23709" unitRef="aud">520142</ifrs-full:AdministrativeExpense>
    <ifrs-full:AdministrativeExpense contextRef="c4" decimals="0" id="ixv-23710" unitRef="aud">1028638</ifrs-full:AdministrativeExpense>
    <ifrs-full:AdministrativeExpense contextRef="c5" decimals="0" id="ixv-23711" unitRef="aud">1032843</ifrs-full:AdministrativeExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="0" id="ixv-23712" unitRef="aud">979920</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c4" decimals="0" id="ixv-23713" unitRef="aud">881950</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c5" decimals="0" id="ixv-23714" unitRef="aud">966571</ifrs-full:AdjustmentsForSharebasedPayments>
    <athe:CorporateAdvisoryExpenses contextRef="c0" decimals="0" id="ixv-23715" unitRef="aud">355100</athe:CorporateAdvisoryExpenses>
    <athe:CorporateAdvisoryExpenses contextRef="c4" decimals="0" id="ixv-23716" unitRef="aud">169000</athe:CorporateAdvisoryExpenses>
    <athe:CorporateAdvisoryExpenses contextRef="c5" decimals="0" id="ixv-23717" unitRef="aud">204621</athe:CorporateAdvisoryExpenses>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c0" decimals="0" id="ixv-23718" unitRef="aud">-259433</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c4" decimals="0" id="ixv-23719" unitRef="aud">-261152</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c5" decimals="0" id="ixv-23720" unitRef="aud">-917650</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c0" id="ixv-15560">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;4. INCOME TAX&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;(a) Income tax expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Current tax&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;77,411&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;58,463&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33,808&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Adjustment for current tax of prior periods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,356&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,375&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Deferred tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;(b) Numerical reconciliation of income tax expense to prima facie tax payable:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Prima facie tax on net loss before income tax at 25% (2024: 25%, 2023: 25%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,019,943&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,769,344&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,446,718&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Effect of lower tax rates of tax on overseas income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,745&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,134&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,440&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Add tax effect of:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Under/(Over) provision of income tax in previous year relating to a revision of estimates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,356&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,375&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenditure (net of tax incentive)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;898,066&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,305,112&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,267,940&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;464,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;377,405&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;413,976&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Deferred tax asset not recognised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,749,734&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,156,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,805,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Income tax expense attributable to loss before income tax&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46,088&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;104,459&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;(c) Potential deferred tax asset as of June 30, 2025, 2024 and 2023 in respect of: tax losses not brought to account is (1)(2):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,885,043&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,758,242&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,056,899&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Temporary differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,798,561&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,660,171&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,675,742&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;As of June 30, 2025, the Group had a potential tax benefit related to gross tax losses carried forward of $187,632,492 (2024: $179,125,289) and a non-refundable R&amp;amp;D tax offset of $2,126,801 (2024: $3,703,478).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unused tax loss amounts are only attributable to the Group&#x2019;s operations in Australia, as the subsidiary in the United States has no carryforward tax losses as of June 30, 2025. Tax losses can be carried forward indefinitely subject to continuity of ownership and same business test rules.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <athe:DisclosureOfIncomeTaxExplanatoryTableTextBlock contextRef="c0" id="ixv-15564">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;(a) Income tax expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Current tax&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;77,411&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;58,463&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33,808&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Adjustment for current tax of prior periods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,356&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,375&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Deferred tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;(b) Numerical reconciliation of income tax expense to prima facie tax payable:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Prima facie tax on net loss before income tax at 25% (2024: 25%, 2023: 25%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,019,943&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,769,344&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,446,718&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Effect of lower tax rates of tax on overseas income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,745&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,134&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,440&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Add tax effect of:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Under/(Over) provision of income tax in previous year relating to a revision of estimates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,356&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,375&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Research and development expenditure (net of tax incentive)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;898,066&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,305,112&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,267,940&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;464,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;377,405&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;413,976&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Deferred tax asset not recognised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,749,734&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,156,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,805,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Income tax expense attributable to loss before income tax&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46,088&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;104,459&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;(c) Potential deferred tax asset as of June 30, 2025, 2024 and 2023 in respect of: tax losses not brought to account is (1)(2):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,885,043&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,758,242&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,056,899&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Temporary differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,798,561&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,660,171&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,675,742&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;As of June 30, 2025, the Group had a potential tax benefit related to gross tax losses carried forward of $187,632,492 (2024: $179,125,289) and a non-refundable R&amp;amp;D tax offset of $2,126,801 (2024: $3,703,478).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unused tax loss amounts are only attributable to the Group&#x2019;s operations in Australia, as the subsidiary in the United States has no carryforward tax losses as of June 30, 2025. Tax losses can be carried forward indefinitely subject to continuity of ownership and same business test rules.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</athe:DisclosureOfIncomeTaxExplanatoryTableTextBlock>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c0" decimals="0" id="ixv-23721" unitRef="aud">77411</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c4" decimals="0" id="ixv-23722" unitRef="aud">58463</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c5" decimals="0" id="ixv-23723" unitRef="aud">33808</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="c0" decimals="0" id="ixv-23724" unitRef="aud">-9356</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="c4" decimals="0" id="ixv-23725" unitRef="aud">-12375</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="c5" decimals="0" id="ixv-23726" unitRef="aud">70651</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <athe:PrimaFacieTaxOnNetLossBeforeIncomeTax contextRef="c0" decimals="2" id="ixv-23727" unitRef="pure">0.25</athe:PrimaFacieTaxOnNetLossBeforeIncomeTax>
    <athe:PrimaFacieTaxOnNetLossBeforeIncomeTax contextRef="c4" decimals="2" id="ixv-23728" unitRef="pure">0.25</athe:PrimaFacieTaxOnNetLossBeforeIncomeTax>
    <athe:PrimaFacieTaxOnNetLossBeforeIncomeTax contextRef="c5" decimals="2" id="ixv-23729" unitRef="pure">0.25</athe:PrimaFacieTaxOnNetLossBeforeIncomeTax>
    <athe:PrimaFaciesTaxOnNetLossBeforeIncomeTax contextRef="c0" decimals="0" id="ixv-23730" unitRef="aud">3019943</athe:PrimaFaciesTaxOnNetLossBeforeIncomeTax>
    <athe:PrimaFaciesTaxOnNetLossBeforeIncomeTax contextRef="c4" decimals="0" id="ixv-23731" unitRef="aud">4769344</athe:PrimaFaciesTaxOnNetLossBeforeIncomeTax>
    <athe:PrimaFaciesTaxOnNetLossBeforeIncomeTax contextRef="c5" decimals="0" id="ixv-23732" unitRef="aud">3446718</athe:PrimaFaciesTaxOnNetLossBeforeIncomeTax>
    <ifrs-full:TaxEffectOfForeignTaxRates contextRef="c0" decimals="0" id="ixv-23733" unitRef="aud">-14745</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates contextRef="c4" decimals="0" id="ixv-23734" unitRef="aud">-11134</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates contextRef="c5" decimals="0" id="ixv-23735" unitRef="aud">-6440</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="c0" decimals="0" id="ixv-23736" unitRef="aud">-9356</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="c4" decimals="0" id="ixv-23737" unitRef="aud">-12375</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="c5" decimals="0" id="ixv-23738" unitRef="aud">70651</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <athe:TaxEffectOfResearchAndDevelopmentExpenditure contextRef="c0" decimals="0" id="ixv-23739" unitRef="aud">-898066</athe:TaxEffectOfResearchAndDevelopmentExpenditure>
    <athe:TaxEffectOfResearchAndDevelopmentExpenditure contextRef="c4" decimals="0" id="ixv-23740" unitRef="aud">-1305112</athe:TaxEffectOfResearchAndDevelopmentExpenditure>
    <athe:TaxEffectOfResearchAndDevelopmentExpenditure contextRef="c5" decimals="0" id="ixv-23741" unitRef="aud">-1267940</athe:TaxEffectOfResearchAndDevelopmentExpenditure>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c0" decimals="0" id="ixv-23742" unitRef="aud">464299</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c4" decimals="0" id="ixv-23743" unitRef="aud">377405</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c5" decimals="0" id="ixv-23744" unitRef="aud">413976</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <athe:TaxEffectOfDeferredTaxAssetNotRecognized contextRef="c0" decimals="0" id="ixv-23745" unitRef="aud">1749734</athe:TaxEffectOfDeferredTaxAssetNotRecognized>
    <athe:TaxEffectOfDeferredTaxAssetNotRecognized contextRef="c4" decimals="0" id="ixv-23746" unitRef="aud">3156424</athe:TaxEffectOfDeferredTaxAssetNotRecognized>
    <athe:TaxEffectOfDeferredTaxAssetNotRecognized contextRef="c5" decimals="0" id="ixv-23747" unitRef="aud">1805050</athe:TaxEffectOfDeferredTaxAssetNotRecognized>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c0" decimals="0" id="ixv-23748" unitRef="aud">68055</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c4" decimals="0" id="ixv-23749" unitRef="aud">46088</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c5" decimals="0" id="ixv-23750" unitRef="aud">104459</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:DeferredTaxAssets contextRef="c2" decimals="0" id="ix_11_fact" unitRef="aud">49885043</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c3" decimals="0" id="ix_12_fact" unitRef="aud">47758242</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c6" decimals="0" id="ix_13_fact" unitRef="aud">44056899</ifrs-full:DeferredTaxAssets>
    <ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures contextRef="c2" decimals="0" id="ix_14_fact" unitRef="aud">6798561</ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures>
    <ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures contextRef="c3" decimals="0" id="ix_15_fact" unitRef="aud">6660171</ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures>
    <ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures contextRef="c6" decimals="0" id="ix_16_fact" unitRef="aud">3675742</ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense contextRef="c0" decimals="0" id="ixv-23758" unitRef="aud">187632492</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense contextRef="c4" decimals="0" id="ixv-23759" unitRef="aud">179125289</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense contextRef="c0" decimals="0" id="ixv-23760" unitRef="aud">2126801</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense contextRef="c4" decimals="0" id="ixv-23761" unitRef="aud">3703478</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="c0" id="ixv-15900">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;5. TRADE AND OTHER RECEIVABLES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued interest income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;157&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D tax incentive receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,928,563&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,019,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Goods and services tax receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,937,607&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,041,675&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;R&amp;amp;D tax incentive receivable represents the amount of the financial
year 2025 R&amp;amp;D tax incentive the Group expects to recover. For further details, see Note 2.&lt;/p&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <athe:DisclosureOfTradeAndOtherReceivableTableTextBlock contextRef="c0" id="ixv-15904">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued interest income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;157&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D tax incentive receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,928,563&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,019,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Goods and services tax receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,937,607&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,041,675&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</athe:DisclosureOfTradeAndOtherReceivableTableTextBlock>
    <ifrs-full:CurrentAccruedIncomeIncludingCurrentContractAssets contextRef="c3" decimals="0" id="ixv-23762" unitRef="aud">157</ifrs-full:CurrentAccruedIncomeIncludingCurrentContractAssets>
    <athe:ResearchAndDevelopmentTaxIncentiveReceivable contextRef="c2" decimals="0" id="ixv-23763" unitRef="aud">3928563</athe:ResearchAndDevelopmentTaxIncentiveReceivable>
    <athe:ResearchAndDevelopmentTaxIncentiveReceivable contextRef="c3" decimals="0" id="ixv-23764" unitRef="aud">4019286</athe:ResearchAndDevelopmentTaxIncentiveReceivable>
    <ifrs-full:CurrentValueAddedTaxReceivables contextRef="c2" decimals="0" id="ixv-23765" unitRef="aud">9044</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:CurrentValueAddedTaxReceivables contextRef="c3" decimals="0" id="ixv-23766" unitRef="aud">22232</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c2" decimals="0" id="ixv-23767" unitRef="aud">3937607</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c3" decimals="0" id="ixv-23768" unitRef="aud">4041675</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:DisclosureOfOtherAssetsExplanatory contextRef="c0" id="ixv-15983">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;6. OTHER CURRENT ASSETS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Prepayments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,233,122&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,315,632&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Term deposit (1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41,815&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40,668&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,774,937&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,356,300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Term deposit of 150-day term and maturity date of October
17, 2025.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfOtherAssetsExplanatory>
    <ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory contextRef="c0" id="ixv-15987">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Prepayments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,233,122&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,315,632&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Term deposit (1)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41,815&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40,668&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,774,937&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,356,300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Term deposit of 150-day term and maturity date of October
17, 2025.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory>
    <ifrs-full:CurrentPrepayments contextRef="c2" decimals="0" id="ixv-23769" unitRef="aud">1233122</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments contextRef="c3" decimals="0" id="ixv-23770" unitRef="aud">2315632</ifrs-full:CurrentPrepayments>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c2" decimals="0" id="ix_17_fact" unitRef="aud">7500000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c2" decimals="0" id="ixv-23772" unitRef="aud">41815</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c3" decimals="0" id="ixv-23773" unitRef="aud">40668</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c2" decimals="0" id="ixv-23774" unitRef="aud">8774937</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c3" decimals="0" id="ixv-23775" unitRef="aud">2356300</ifrs-full:OtherCurrentAssets>
    <athe:TermDeposit contextRef="c0" id="ixv-23777">P150D</athe:TermDeposit>
    <athe:MaturityDate contextRef="c0" id="ixv-23778">2025-10-17</athe:MaturityDate>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="c0" id="ixv-16059">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;7. TRADE AND OTHER PAYABLES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Trade creditors&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;538,276&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;581,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,684,726&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,499,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;193,095&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;234,899&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued corporate personnel expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139,240&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,253&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,431&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,575,490&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,619,947&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <athe:ScheduleOfTradeAndOtherPayableTableTextBlock contextRef="c0" id="ixv-16063">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Trade creditors&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;538,276&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;581,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,684,726&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,499,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;193,095&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;234,899&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued corporate personnel expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139,240&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,253&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,431&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,575,490&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,619,947&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</athe:ScheduleOfTradeAndOtherPayableTableTextBlock>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c2" decimals="0" id="ixv-23779" unitRef="aud">538276</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c3" decimals="0" id="ixv-23780" unitRef="aud">581137</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <athe:AccruedResearchAndDevelopmentExpenses contextRef="c2" decimals="0" id="ixv-23781" unitRef="aud">1684726</athe:AccruedResearchAndDevelopmentExpenses>
    <athe:AccruedResearchAndDevelopmentExpenses contextRef="c3" decimals="0" id="ixv-23782" unitRef="aud">3499960</athe:AccruedResearchAndDevelopmentExpenses>
    <athe:AccruedProfessionalFees contextRef="c2" decimals="0" id="ixv-23783" unitRef="aud">193095</athe:AccruedProfessionalFees>
    <athe:AccruedProfessionalFees contextRef="c3" decimals="0" id="ixv-23784" unitRef="aud">234899</athe:AccruedProfessionalFees>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c2" decimals="0" id="ixv-23785" unitRef="aud">139240</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c3" decimals="0" id="ixv-23786" unitRef="aud">166063</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <athe:OtherCurrentAccruedExpenses contextRef="c2" decimals="0" id="ixv-23787" unitRef="aud">900</athe:OtherCurrentAccruedExpenses>
    <athe:OtherCurrentAccruedExpenses contextRef="c3" decimals="0" id="ixv-23788" unitRef="aud">123457</athe:OtherCurrentAccruedExpenses>
    <ifrs-full:OtherPayables contextRef="c2" decimals="0" id="ixv-23789" unitRef="aud">19253</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables contextRef="c3" decimals="0" id="ixv-23790" unitRef="aud">14431</ifrs-full:OtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c2" decimals="0" id="ixv-23791" unitRef="aud">2575490</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c3" decimals="0" id="ixv-23792" unitRef="aud">4619947</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:DisclosureOfProvisionsExplanatory contextRef="c0" id="ixv-16182">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;8. PROVISIONS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="text-decoration:underline"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Annual leave (1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;631,941&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;318,694&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Long service leave (1)(2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;243,967&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;212,005&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;875,908&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;530,699&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline"&gt;Non-Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long service leave (2)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;A provision has been recognised for employee entitlements relating
to long service leave. In calculating the present value of future cash flows in respect of long service leave, the probability of long
service leave being taken is based on historical data. The measurement and recognition criteria relating to employee benefits have been
included in Note 1 to this report.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(1) Movements in provisions&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Movements in each class of provision during the financial year are
set out below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Annual leave&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Carrying amount at start of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;318,694&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;420,380&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;371,877&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Charged/(credited) to profit or loss -additional provisions recognised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;409,646&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;179,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;272,502&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Amounts used during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(97,011&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(280,618&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(232,747&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in foreign exchange&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;612&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(991&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,748&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Carrying amount at end of year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;631,941&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;318,694&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;420,380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Long service leave&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Carrying amount at start of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;212,005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;328,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;298,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Charged/(credited) to profit or loss -additional provisions recognised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,901&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amounts used during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(939&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(146,628&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Carrying amount at end of year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;243,967&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;212,005&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;328,325&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;875,908&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;530,699&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;748,705&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(2) Amounts not expected to be settled within the next 12 months&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The current provision for long service leave includes all unconditional
entitlements where employees have completed the required period of service and also those where employees are entitled to pro-rata payments
in certain circumstances.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The entire amount is presented as current, since the Group does not
have an unconditional right to defer settlement. However, based on past experience, the Group does not expect all employees to take the
full amount of accrued long service leave or require payment within the next 12 months.&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</ifrs-full:DisclosureOfProvisionsExplanatory>
    <ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory contextRef="c0" id="ixv-16186">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="text-decoration:underline"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Annual leave (1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;631,941&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;318,694&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Long service leave (1)(2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;243,967&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;212,005&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;875,908&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;530,699&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-decoration: underline"&gt;Non-Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long service leave (2)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(1) Movements in provisions&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(2) Amounts not expected to be settled within the next 12 months&lt;/b&gt;&lt;/p&gt;</ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory>
    <ifrs-full:CurrentProvisions contextRef="c37" decimals="0" id="ix_18_fact" unitRef="aud">631941</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions contextRef="c38" decimals="0" id="ix_19_fact" unitRef="aud">318694</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions contextRef="c39" decimals="0" id="ix_20_fact" unitRef="aud">243967</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions contextRef="c40" decimals="0" id="ix_21_fact" unitRef="aud">212005</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions contextRef="c2" decimals="0" id="ixv-23797" unitRef="aud">875908</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions contextRef="c3" decimals="0" id="ixv-23798" unitRef="aud">530699</ifrs-full:CurrentProvisions>
    <athe:DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock contextRef="c0" id="ixv-16297">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Movements in each class of provision during the financial year are
set out below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Annual leave&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Carrying amount at start of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;318,694&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;420,380&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;371,877&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Charged/(credited) to profit or loss -additional provisions recognised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;409,646&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;179,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;272,502&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Amounts used during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(97,011&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(280,618&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(232,747&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in foreign exchange&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;612&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(991&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,748&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Carrying amount at end of year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;631,941&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;318,694&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;420,380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Long service leave&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Carrying amount at start of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;212,005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;328,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;298,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Charged/(credited) to profit or loss -additional provisions recognised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,901&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amounts used during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(939&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(146,628&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Carrying amount at end of year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;243,967&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;212,005&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;328,325&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;875,908&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;530,699&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;748,705&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</athe:DisclosureOfMovementsOfEachClassOfProvisionExplanatoryTableTextBlock>
    <ifrs-full:Provisions contextRef="c38" decimals="0" id="ixv-23800" unitRef="aud">318694</ifrs-full:Provisions>
    <ifrs-full:Provisions contextRef="c41" decimals="0" id="ixv-23801" unitRef="aud">420380</ifrs-full:Provisions>
    <ifrs-full:Provisions contextRef="c42" decimals="0" id="ixv-23802" unitRef="aud">371877</ifrs-full:Provisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c43" decimals="0" id="ixv-23803" unitRef="aud">409646</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c44" decimals="0" id="ixv-23804" unitRef="aud">179923</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c45" decimals="0" id="ixv-23805" unitRef="aud">272502</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="c43" decimals="0" id="ixv-23806" unitRef="aud">97011</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="c44" decimals="0" id="ixv-23807" unitRef="aud">280618</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="c45" decimals="0" id="ixv-23808" unitRef="aud">232747</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets contextRef="c43" decimals="0" id="ixv-23809" unitRef="aud">612</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets contextRef="c44" decimals="0" id="ixv-23810" unitRef="aud">-991</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets contextRef="c45" decimals="0" id="ixv-23811" unitRef="aud">8748</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:Provisions contextRef="c37" decimals="0" id="ixv-23812" unitRef="aud">631941</ifrs-full:Provisions>
    <ifrs-full:Provisions contextRef="c38" decimals="0" id="ixv-23813" unitRef="aud">318694</ifrs-full:Provisions>
    <ifrs-full:Provisions contextRef="c41" decimals="0" id="ixv-23814" unitRef="aud">420380</ifrs-full:Provisions>
    <ifrs-full:Provisions contextRef="c40" decimals="0" id="ixv-23815" unitRef="aud">212005</ifrs-full:Provisions>
    <ifrs-full:Provisions contextRef="c46" decimals="0" id="ixv-23816" unitRef="aud">328325</ifrs-full:Provisions>
    <ifrs-full:Provisions contextRef="c47" decimals="0" id="ixv-23817" unitRef="aud">298143</ifrs-full:Provisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c48" decimals="0" id="ixv-23818" unitRef="aud">32901</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c49" decimals="0" id="ixv-23819" unitRef="aud">30308</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c50" decimals="0" id="ixv-23820" unitRef="aud">30182</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="c48" decimals="0" id="ixv-23821" unitRef="aud">939</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="c49" decimals="0" id="ixv-23822" unitRef="aud">146628</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:Provisions contextRef="c39" decimals="0" id="ixv-23823" unitRef="aud">243967</ifrs-full:Provisions>
    <ifrs-full:Provisions contextRef="c40" decimals="0" id="ixv-23824" unitRef="aud">212005</ifrs-full:Provisions>
    <ifrs-full:Provisions contextRef="c46" decimals="0" id="ixv-23825" unitRef="aud">328325</ifrs-full:Provisions>
    <athe:AnnualLeaveAndLongServiceLeaveCarryingAmount contextRef="c0" decimals="0" id="ixv-23826" unitRef="aud">875908</athe:AnnualLeaveAndLongServiceLeaveCarryingAmount>
    <athe:AnnualLeaveAndLongServiceLeaveCarryingAmount contextRef="c4" decimals="0" id="ixv-23827" unitRef="aud">530699</athe:AnnualLeaveAndLongServiceLeaveCarryingAmount>
    <athe:AnnualLeaveAndLongServiceLeaveCarryingAmount contextRef="c5" decimals="0" id="ixv-23828" unitRef="aud">748705</athe:AnnualLeaveAndLongServiceLeaveCarryingAmount>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="c0" id="ixv-16554">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;b&gt;9. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;There are no contingent liabilities at the date of this report. The
Group is not involved in any legal or arbitration proceedings and, so far as management is aware, no such proceedings are pending or threatened
against the Group.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In respect of expenditure commitments, refer to Note 15.&lt;/p&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <ifrs-full:DisclosureOfIssuedCapitalExplanatory contextRef="c0" id="ixv-16564">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;b&gt;10. ISSUED CAPITAL&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;In February 2025, we received commitments for a
capital raising of approximately $40 million by means of a two tranche placement (the &lt;b&gt;Placement&lt;/b&gt;) of fully paid ordinary shares.
For every three new shares issued, one free attaching option was issued. The number of securities issued to the Placement participants
on February 17, 2025 (Tranche 1), April 4, 2025 (Tranche 2) and April 23,2025 (Options) pursuant to ASX Listing Rule 7.1, and which are
within the volumes approved by shareholders at the EGM on March 31, 2025, are:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,636,363,636 ordinary shares at A$0.011 (1.1 Australian cents) per share (ASX:ATH); and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,222,300,911 listed Long-Dated Options (each with an exercise price of A$0.028, expiring on February 26, 2027) (ASX: ATHOA).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;(a) Issued Capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;9,127,370,686 (2024: 5,245,115,318) fully paid ordinary shares&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;10(b)&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;262,949,462&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;223,152,985&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;213,971,323&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Nil (2024: Nil) options for fully paid ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;10(c)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;262,949,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;223,152,985&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;213,971,323&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(b) Movements in Issued Shares&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;No. of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;No. of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;No. of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,245,115,318&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;223,152,985&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,439,897,618&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;213,971,323&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,406,874,578&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;213,787,061&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Movement during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,882,255,368&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,796,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,805,217,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,181,662&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,023,040&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184,262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;End of the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,127,370,686&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;262,949,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,245,115,318&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;223,152,985&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,439,897,618&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;213,971,323&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Details of share issuances are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom"&gt;Date&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;Details&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold"&gt;Notes&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold"&gt;Number&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold"&gt;Issue&lt;br/&gt; Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold"&gt;$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 25%; font-weight: bold; padding-bottom: 1.5pt"&gt;Year end June 30, 2022&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 30%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1.5pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;322,857,900&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;16,339,071&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;September 21, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under ATM Facility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,543,840&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;March 15, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under ATM Facility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,479,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187,834&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 1.5pt"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Security issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(132,413&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Year end June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;33,023,040&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;184,263&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;November 29,2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under ATM Facility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;362,462,762&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,268,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;January 8,2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under ATM Facility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,008,965,805&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,531,380&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;February 2,2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under ATM Facility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;571,428,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;March 4, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under ATM Facility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;855,263,158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0038&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;April 22, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,097,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0070&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,682&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;June 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Security issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(918,020&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Year end June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,805,217,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;9,181,662&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;July 18,2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under ATM Facility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,220,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;January 22,2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95,238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;January 30,2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,333,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,873&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;February 3,2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under ATM Facility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;164,242,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,122,173&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;February 17,2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;Issue of Placement shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,165,841,830&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,824,260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;March 14, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;April 4, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;Issue of Placement shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,470,521,806&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,175,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 1.5pt"&gt;June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Security issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,774,168&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;Year end June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,882,255,368&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;39,796,477&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(c) Terms and Conditions of Issued Capital&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Ordinary shares&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Ordinary shares have the right to receive dividends as declared and,
in the event of a winding up of the Group, to participate in the proceeds from the sale of all surplus assets in proportion to the number
of and amounts paid up on shares held. Ordinary shares entitle their holder to vote, either in person or by proxy, at a meeting of the
Group&#x2019;s shareholders.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Options&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Option holders do not have the right to receive dividends and are not
entitled to vote at a meeting of the Group&#x2019;s shareholders. Options may be exercised at any time from the date they vest to the date
of their expiration. Share options convert into ordinary shares on a one for one basis on the date they are exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(d) Shares Issued after Reporting Date&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-variant: small-caps"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;No shares have been issued after the reporting date.&lt;/p&gt;</ifrs-full:DisclosureOfIssuedCapitalExplanatory>
    <ifrs-full:CapitalCommitments contextRef="c51" decimals="-6" id="ixv-23830" unitRef="usd">40000000</ifrs-full:CapitalCommitments>
    <ifrs-full:IssuedCapitalOrdinaryShares contextRef="c2" decimals="0" id="ixv-23831" unitRef="usd">3636363636</ifrs-full:IssuedCapitalOrdinaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c2"
      decimals="3"
      id="ixv-23832"
      unitRef="audPershares">0.011</ifrs-full:ParValuePerShare>
    <athe:ordinarySharesPerShareCents contextRef="c2" decimals="1" id="ixv-23833" unitRef="pure">1.1</athe:ordinarySharesPerShareCents>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c0" decimals="0" id="ixv-23834" unitRef="pure">1222300911</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c0"
      decimals="3"
      id="ixv-23835"
      unitRef="audPershares">0.028</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c0" id="ixv-16587">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;(a) Issued Capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;9,127,370,686 (2024: 5,245,115,318) fully paid ordinary shares&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;10(b)&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;262,949,462&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;223,152,985&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;213,971,323&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Nil (2024: Nil) options for fully paid ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;10(c)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;262,949,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;223,152,985&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;213,971,323&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c52"
      decimals="INF"
      id="ixv-23836"
      unitRef="shares">9127370686</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c53"
      decimals="INF"
      id="ixv-23837"
      unitRef="shares">5245115318</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <athe:SharesOfIssuedCapital
      contextRef="c52"
      decimals="INF"
      id="ixv-23838"
      unitRef="shares">262949462</athe:SharesOfIssuedCapital>
    <athe:SharesOfIssuedCapital
      contextRef="c53"
      decimals="INF"
      id="ixv-23839"
      unitRef="shares">223152985</athe:SharesOfIssuedCapital>
    <athe:SharesOfIssuedCapital
      contextRef="c54"
      decimals="INF"
      id="ixv-23840"
      unitRef="shares">213971323</athe:SharesOfIssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c2" decimals="INF" id="ixv-23841" unitRef="aud">262949462</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c3" decimals="INF" id="ixv-23842" unitRef="aud">223152985</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c6" decimals="INF" id="ixv-23843" unitRef="aud">213971323</ifrs-full:IssuedCapital>
    <athe:ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock contextRef="c0" id="ixv-23844">Movements in Issued Shares&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;No. of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;No. of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;No. of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,245,115,318&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;223,152,985&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,439,897,618&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;213,971,323&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,406,874,578&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;213,787,061&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Movement during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,882,255,368&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,796,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,805,217,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,181,662&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,023,040&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184,262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;End of the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,127,370,686&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;262,949,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,245,115,318&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;223,152,985&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,439,897,618&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;213,971,323&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</athe:ScheduleOfReconciliationOfNumberOfSharesOutstandingTableTextBlock>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c53"
      decimals="INF"
      id="ixv-23845"
      unitRef="shares">5245115318</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:IssuedCapital contextRef="c53" decimals="0" id="ixv-23846" unitRef="aud">223152985</ifrs-full:IssuedCapital>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c54"
      decimals="INF"
      id="ixv-23847"
      unitRef="shares">2439897618</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:IssuedCapital contextRef="c54" decimals="0" id="ixv-23848" unitRef="aud">213971323</ifrs-full:IssuedCapital>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c58"
      decimals="INF"
      id="ixv-23849"
      unitRef="shares">2406874578</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:IssuedCapital contextRef="c58" decimals="0" id="ixv-23850" unitRef="aud">213787061</ifrs-full:IssuedCapital>
    <athe:MovementDuringTheYearNoOfSharesinShares
      contextRef="c59"
      decimals="INF"
      id="ixv-23851"
      unitRef="shares">3882255368</athe:MovementDuringTheYearNoOfSharesinShares>
    <athe:ValueOfIncreaseDecreaseInSharesOutstanding contextRef="c59" decimals="0" id="ixv-23852" unitRef="aud">39796477</athe:ValueOfIncreaseDecreaseInSharesOutstanding>
    <athe:MovementDuringTheYearNoOfSharesinShares
      contextRef="c60"
      decimals="INF"
      id="ixv-23853"
      unitRef="shares">2805217700</athe:MovementDuringTheYearNoOfSharesinShares>
    <athe:ValueOfIncreaseDecreaseInSharesOutstanding contextRef="c60" decimals="0" id="ixv-23854" unitRef="aud">9181662</athe:ValueOfIncreaseDecreaseInSharesOutstanding>
    <athe:MovementDuringTheYearNoOfSharesinShares
      contextRef="c61"
      decimals="INF"
      id="ixv-23855"
      unitRef="shares">33023040</athe:MovementDuringTheYearNoOfSharesinShares>
    <athe:ValueOfIncreaseDecreaseInSharesOutstanding contextRef="c61" decimals="0" id="ixv-23856" unitRef="aud">184262</athe:ValueOfIncreaseDecreaseInSharesOutstanding>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c52"
      decimals="INF"
      id="ixv-23857"
      unitRef="shares">9127370686</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:IssuedCapital contextRef="c52" decimals="0" id="ixv-23858" unitRef="aud">262949462</ifrs-full:IssuedCapital>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c53"
      decimals="INF"
      id="ixv-23859"
      unitRef="shares">5245115318</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:IssuedCapital contextRef="c53" decimals="0" id="ixv-23860" unitRef="aud">223152985</ifrs-full:IssuedCapital>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c54"
      decimals="INF"
      id="ixv-23861"
      unitRef="shares">2439897618</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:IssuedCapital contextRef="c54" decimals="0" id="ixv-23862" unitRef="aud">213971323</ifrs-full:IssuedCapital>
    <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory contextRef="c0" id="ixv-16923">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Details of share issuances are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom"&gt;Date&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;Details&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold"&gt;Notes&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold"&gt;Number&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold"&gt;Issue&lt;br/&gt; Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold"&gt;$&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 25%; font-weight: bold; padding-bottom: 1.5pt"&gt;Year end June 30, 2022&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 30%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1.5pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;322,857,900&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;16,339,071&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;September 21, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under ATM Facility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,543,840&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;March 15, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under ATM Facility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,479,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187,834&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 1.5pt"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Security issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(132,413&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Year end June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;33,023,040&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;184,263&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;November 29,2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under ATM Facility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;362,462,762&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,268,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;January 8,2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under ATM Facility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,008,965,805&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,531,380&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;February 2,2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under ATM Facility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;571,428,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;March 4, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under ATM Facility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;855,263,158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0038&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;April 22, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,097,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0070&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,682&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;June 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Security issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(918,020&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Year end June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,805,217,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;9,181,662&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;July 18,2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under ATM Facility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,220,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;January 22,2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95,238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;January 30,2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,333,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,873&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;February 3,2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under ATM Facility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;164,242,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,122,173&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;February 17,2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;Issue of Placement shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,165,841,830&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,824,260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;March 14, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Issue of shares under options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;April 4, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;Issue of Placement shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,470,521,806&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,175,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 1.5pt"&gt;June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Security issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,774,168&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;Year end June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,882,255,368&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;39,796,477&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
    <athe:IncreaseDecreaseInNumberOfShareOutstanding
      contextRef="c58"
      decimals="INF"
      id="ixv-23863"
      unitRef="shares">322857900</athe:IncreaseDecreaseInNumberOfShareOutstanding>
    <ifrs-full:IssuedCapitalPreferenceShares contextRef="c58" decimals="0" id="ixv-23864" unitRef="aud">16339071</ifrs-full:IssuedCapitalPreferenceShares>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c62" id="ixv-23865">Issue of shares under ATM Facility</athe:NumberOfSharesIssuedDuringTheYear>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c62"
      decimals="INF"
      id="ixv-23866"
      unitRef="shares">9543840</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <athe:NumberofSharesIssuePricePerShare
      contextRef="c62"
      decimals="4"
      id="ixv-23867"
      unitRef="audPershares">0.0135</athe:NumberofSharesIssuePricePerShare>
    <athe:IssuedCapitalPreferenceShare contextRef="c62" decimals="0" id="ixv-23868" unitRef="aud">128842</athe:IssuedCapitalPreferenceShare>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c63" id="ixv-23869">Issue of shares under ATM Facility</athe:NumberOfSharesIssuedDuringTheYear>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c63"
      decimals="INF"
      id="ixv-23870"
      unitRef="shares">23479200</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <athe:NumberofSharesIssuePricePerShare
      contextRef="c63"
      decimals="4"
      id="ixv-23871"
      unitRef="audPershares">0.008</athe:NumberofSharesIssuePricePerShare>
    <athe:IssuedCapitalPreferenceShare contextRef="c63" decimals="0" id="ixv-23872" unitRef="aud">187834</athe:IssuedCapitalPreferenceShare>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c64" id="ixv-23873">Security issuance costs</athe:NumberOfSharesIssuedDuringTheYear>
    <athe:IssuedCapitalPreferenceShare contextRef="c64" decimals="0" id="ixv-23874" unitRef="aud">132413</athe:IssuedCapitalPreferenceShare>
    <athe:IncreaseDecreaseInNumberOfShareOutstanding
      contextRef="c54"
      decimals="INF"
      id="ixv-23875"
      unitRef="shares">33023040</athe:IncreaseDecreaseInNumberOfShareOutstanding>
    <ifrs-full:IssuedCapitalPreferenceShares contextRef="c54" decimals="0" id="ixv-23876" unitRef="aud">184263</ifrs-full:IssuedCapitalPreferenceShares>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c65" id="ixv-23877">Issue of shares under ATM Facility</athe:NumberOfSharesIssuedDuringTheYear>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c65"
      decimals="INF"
      id="ixv-23878"
      unitRef="shares">362462762</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <athe:NumberofSharesIssuePricePerShare
      contextRef="c65"
      decimals="4"
      id="ixv-23879"
      unitRef="audPershares">0.0035</athe:NumberofSharesIssuePricePerShare>
    <athe:IssuedCapitalPreferenceShare contextRef="c65" decimals="0" id="ixv-23880" unitRef="aud">1268620</athe:IssuedCapitalPreferenceShare>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c66" id="ixv-23881">Issue of shares under ATM Facility</athe:NumberOfSharesIssuedDuringTheYear>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c66"
      decimals="INF"
      id="ixv-23882"
      unitRef="shares">1008965805</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <athe:NumberofSharesIssuePricePerShare
      contextRef="c66"
      decimals="4"
      id="ixv-23883"
      unitRef="audPershares">0.0035</athe:NumberofSharesIssuePricePerShare>
    <athe:IssuedCapitalPreferenceShare contextRef="c66" decimals="0" id="ixv-23884" unitRef="aud">3531380</athe:IssuedCapitalPreferenceShare>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c67" id="ixv-23885">Issue of shares under ATM Facility</athe:NumberOfSharesIssuedDuringTheYear>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c67"
      decimals="INF"
      id="ixv-23886"
      unitRef="shares">571428556</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <athe:NumberofSharesIssuePricePerShare
      contextRef="c67"
      decimals="4"
      id="ixv-23887"
      unitRef="audPershares">0.0035</athe:NumberofSharesIssuePricePerShare>
    <athe:IssuedCapitalPreferenceShare contextRef="c67" decimals="0" id="ixv-23888" unitRef="aud">2000000</athe:IssuedCapitalPreferenceShare>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c68" id="ixv-23889">Issue of shares under ATM Facility</athe:NumberOfSharesIssuedDuringTheYear>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c68"
      decimals="INF"
      id="ixv-23890"
      unitRef="shares">855263158</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <athe:NumberofSharesIssuePricePerShare
      contextRef="c68"
      decimals="4"
      id="ixv-23891"
      unitRef="audPershares">0.0038</athe:NumberofSharesIssuePricePerShare>
    <athe:IssuedCapitalPreferenceShare contextRef="c68" decimals="0" id="ixv-23892" unitRef="aud">3250000</athe:IssuedCapitalPreferenceShare>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c69" id="ixv-23893">Issue of shares under options exercised</athe:NumberOfSharesIssuedDuringTheYear>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c69"
      decimals="INF"
      id="ixv-23894"
      unitRef="shares">7097419</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <athe:NumberofSharesIssuePricePerShare
      contextRef="c69"
      decimals="4"
      id="ixv-23895"
      unitRef="audPershares">0.007</athe:NumberofSharesIssuePricePerShare>
    <athe:IssuedCapitalPreferenceShare contextRef="c69" decimals="0" id="ixv-23896" unitRef="aud">49682</athe:IssuedCapitalPreferenceShare>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c70" id="ixv-23897">Security issuance costs</athe:NumberOfSharesIssuedDuringTheYear>
    <athe:IssuedCapitalPreferenceShare contextRef="c70" decimals="0" id="ixv-23898" unitRef="aud">-918020</athe:IssuedCapitalPreferenceShare>
    <athe:IncreaseDecreaseInNumberOfShareOutstanding
      contextRef="c53"
      decimals="INF"
      id="ixv-23899"
      unitRef="shares">2805217700</athe:IncreaseDecreaseInNumberOfShareOutstanding>
    <ifrs-full:IssuedCapitalPreferenceShares contextRef="c53" decimals="0" id="ixv-23900" unitRef="aud">9181662</ifrs-full:IssuedCapitalPreferenceShares>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c71" id="ixv-23901">Issue of shares under ATM Facility</athe:NumberOfSharesIssuedDuringTheYear>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c71"
      decimals="INF"
      id="ixv-23902"
      unitRef="shares">75220800</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <athe:NumberofSharesIssuePricePerShare
      contextRef="c71"
      decimals="4"
      id="ixv-23903"
      unitRef="audPershares">0.0054</athe:NumberofSharesIssuePricePerShare>
    <athe:IssuedCapitalPreferenceShare contextRef="c71" decimals="0" id="ixv-23904" unitRef="aud">398645</athe:IssuedCapitalPreferenceShare>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c72" id="ixv-23905">Issue of shares under options exercised</athe:NumberOfSharesIssuedDuringTheYear>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c72"
      decimals="INF"
      id="ixv-23906"
      unitRef="shares">95238</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <athe:NumberofSharesIssuePricePerShare
      contextRef="c72"
      decimals="4"
      id="ixv-23907"
      unitRef="audPershares">0.01</athe:NumberofSharesIssuePricePerShare>
    <athe:IssuedCapitalPreferenceShare contextRef="c72" decimals="0" id="ixv-23908" unitRef="aud">952</athe:IssuedCapitalPreferenceShare>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c73" id="ixv-23909">Issue of shares under options exercised</athe:NumberOfSharesIssuedDuringTheYear>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c73"
      decimals="INF"
      id="ixv-23910"
      unitRef="shares">6333333</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <athe:NumberofSharesIssuePricePerShare
      contextRef="c73"
      decimals="3"
      id="ixv-23911"
      unitRef="audPershares">0.004</athe:NumberofSharesIssuePricePerShare>
    <athe:IssuedCapitalPreferenceShare contextRef="c73" decimals="0" id="ixv-23912" unitRef="aud">48873</athe:IssuedCapitalPreferenceShare>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c74" id="ixv-23913">Issue of shares under ATM Facility</athe:NumberOfSharesIssuedDuringTheYear>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c74"
      decimals="INF"
      id="ixv-23914"
      unitRef="shares">164242200</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <athe:NumberofSharesIssuePricePerShare
      contextRef="c74"
      decimals="4"
      id="ixv-23915"
      unitRef="audPershares">0.0129</athe:NumberofSharesIssuePricePerShare>
    <athe:IssuedCapitalPreferenceShare contextRef="c74" decimals="0" id="ixv-23916" unitRef="aud">2122173</athe:IssuedCapitalPreferenceShare>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c75" id="ixv-23917">Issue of Placement shares</athe:NumberOfSharesIssuedDuringTheYear>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c75"
      decimals="INF"
      id="ixv-23918"
      unitRef="shares">1165841830</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <athe:NumberofSharesIssuePricePerShare
      contextRef="c75"
      decimals="4"
      id="ixv-23919"
      unitRef="audPershares">0.011</athe:NumberofSharesIssuePricePerShare>
    <athe:IssuedCapitalPreferenceShare contextRef="c75" decimals="0" id="ixv-23920" unitRef="aud">12824260</athe:IssuedCapitalPreferenceShare>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c76" id="ixv-23921">Issue of shares under options exercised</athe:NumberOfSharesIssuedDuringTheYear>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c76"
      decimals="INF"
      id="ixv-23922"
      unitRef="shares">161</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <athe:NumberofSharesIssuePricePerShare
      contextRef="c76"
      decimals="4"
      id="ixv-23923"
      unitRef="audPershares">0.01</athe:NumberofSharesIssuePricePerShare>
    <athe:IssuedCapitalPreferenceShare contextRef="c76" decimals="0" id="ixv-23924" unitRef="aud">2</athe:IssuedCapitalPreferenceShare>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c77" id="ixv-23925">Issue of Placement shares</athe:NumberOfSharesIssuedDuringTheYear>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c77"
      decimals="INF"
      id="ixv-23926"
      unitRef="shares">2470521806</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <athe:NumberofSharesIssuePricePerShare
      contextRef="c77"
      decimals="4"
      id="ixv-23927"
      unitRef="audPershares">0.011</athe:NumberofSharesIssuePricePerShare>
    <athe:IssuedCapitalPreferenceShare contextRef="c77" decimals="0" id="ixv-23928" unitRef="aud">27175740</athe:IssuedCapitalPreferenceShare>
    <athe:NumberOfSharesIssuedDuringTheYear contextRef="c78" id="ixv-23929">Security issuance costs</athe:NumberOfSharesIssuedDuringTheYear>
    <athe:IssuedCapitalPreferenceShare contextRef="c78" decimals="0" id="ixv-23930" unitRef="aud">-2774168</athe:IssuedCapitalPreferenceShare>
    <athe:IncreaseDecreaseInNumberOfShareOutstanding
      contextRef="c52"
      decimals="INF"
      id="ixv-23931"
      unitRef="shares">3882255368</athe:IncreaseDecreaseInNumberOfShareOutstanding>
    <ifrs-full:IssuedCapitalPreferenceShares contextRef="c52" decimals="0" id="ixv-23932" unitRef="aud">39796477</ifrs-full:IssuedCapitalPreferenceShares>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c0" id="ixv-17422">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;b&gt;11. RESERVES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;(a) Share Based Payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;2,683,471,567 (2024: 3,250,009,092, 2023: 170,042,720) options for fully paid ordinary shares&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1.5pt; text-align: center"&gt;11(c)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;5,342,304&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;4,806,203&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;3,972,475&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,342,304&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,806,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,972,475&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The share-based payment reserve is used to recognize the fair value
of options issued to directors, executives, employees and consultants but not exercised. Amounts are transferred out of the reserve and
into issued capital when the options are exercised. When options expire, the amount is transferred from reserve to accumulated losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;(b) Warrants/Free-attaching options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,154,912,180 free-attaching options (2024: 2,868,466,372 free-attaching options, 2023: 674,694,939) for fully paid ordinary shares &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1.5pt; text-align: center"&gt;11(c)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On January 8, 2024 a total of 457,142,830 free attaching options with an exercise price of A$0.01, expiring on August 31, 2026 were issued.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On January 8, 2024 a total of 1,371,428,567 free attaching options with an exercise price of A$0.007, expiring on August 31, 2024 were issued.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On February 2, 2024 a total of 190,476,123 free attaching options with an exercise price of A$0.002, expiring on August 31, 2026 were issued.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On February 2, 2024 a total of 571,428,556 free attaching options with an exercise price of A$0.007, expiring on August 31, 2024 were issued.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On April 15, 2024 a total of 285,087,715 free attaching options with an exercise price of A$0.01, expiring on August 31, 2026 were issued.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On April 23, 2025 a total of 1,222,300,911 free attaching options with an exercise price if A$0.028, expiring on February 26, 2027 were issued.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(c)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Movements in Options for Fully Paid Ordinary Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="23" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Years Ended June 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(A$)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(A$)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(A$)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,250,009,092&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,806,203&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;170,042,720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,972,475&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;184,692,720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,565,918&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Options issued during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,392,300,911&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,092,563,791&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Expired during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,947,759,704&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(326,544&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(560,014&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,650,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(93,735&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(93,222&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(17,150&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Options exercised during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,428,732&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(23,540&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Shares to be issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Share Based Payment expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;979,920&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;881,950&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;983,721&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;End of the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,683,471,567&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,342,304&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,250,009,092&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,806,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;170,042,720&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,972,475&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Details of option grants are summarized as follows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Year ended June 30, 2023:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On December 14, 2022, 12,450,000 options expired.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January 31, 2023, 700,000 options expired.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On April 3, 2023, 1,500,000 options were forfeited upon resignation
of an employee.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Year ended June 30, 2024:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On September 11, 2023, 500,000 options were forfeited upon resignation of an employee.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;On December 21, 2023, 8,000,000 options were
issued to the Group&#x2019;s employees based in Australia under the 2004 ASX Plan. The options are exercisable at A$0.0105 and expire
on December 19, 2026. The fair value of the options is A$0.005 per option.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;On January 08, 2024, 457,142,830 long dated
options were issued as per the placement. The options are exercisable at A$0.01 and expire on August 31, 2026.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;On January 08, 2024, 1,371,418,567 free attaching short - dated options were issued as per the placement. The options are exercisable at A$0.007 and expire on August 31, 2024.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;On February 02, 2024, 190,476,123 long dated options were issued as per the securities placement plan. The options are exercisable at A$0.002 and expire on August 31, 2026.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;On February 02, 2024, 571,428,556 short - dated options were issued as per the securities placement plan. The options are exercisable at A$0.007 and expire on August 31, 2024.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;On April 15, 2024, 285,087,725 short &#x2013; free attaching options were issued as per the securities placement plan. The options are exercisable at A$0.01 and expire on August 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 22, 2024, 7,097,419 options were exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On May 21, 2024, 5,000,000 options were forfeited upon resignation of an employee.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;On June 27, 2024, 26,500,000 options were issued to the Group&#x2019;s employees based under the 2004 ASX Plan. The options are exercisable at A$0.004 and expire on March 13, 2029. The fair value of the options is A$0.004 per option.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;On June 27, 2024, 62,500,000 options were issued to the Group&#x2019;s employees based under the Company&#x2019;s 2018 American Depositary Share (ADS) Option Plan. The options are exercisable at US$0.0031 (A$0.0046) and expire on March 13, 2029. The fair value of the options is A$0.0037 per option.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;On June 27, 2024, 120,000,000 options were issued to the Group&#x2019;s key management personnel based under the Company&#x2019;s 2018 American Depositary Share (ADS) Option Plan. The options are exercisable at US$0.003 (A$0.0044) and expire on March 21, 2029. The fair value of the options is A$0.0037 per option.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Year ended June 30, 2025:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 1, 2024, 12,000,000 options expired.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 31, 2024, 1,935,759,704 options expired.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On December 30, 2024, 170,000,000 options were issued to the Group&#x2019;s directors as per resolutions passed at the AGM in November 2024. The options are exercisable at A$0.01 and expire on December 30, 2027.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January 22, 2025, 95,238 options were exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January 30, 2025, 6,333,333 options were exercised.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#x25cf;&lt;/td&gt; &lt;td&gt;On January 4, 2022, 14,000,000 options were forfeited upon resignation of two Non-Executive Directors. &lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 14, 2025, 161 options were exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On April 23, 2025, 1,222,300,911 free-attaching options were issued
as per the securities placement plan. The options are exercisable at A$0.028 and expire on February 26, 2027.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 30, 2025, 4,650,000 options were forfeited upon resignation of employees.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(d) Terms and Conditions of Reserves &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Options and warrants&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Option holders and warrant holders do not have the right to receive
dividends and are not entitled to vote at a meeting of the Group&#x2019;s shareholders. Options and warrants may be exercised at any time
from the date they vest to the date of their expiration. Share options are exercisable into ordinary shares on a one for one basis on
the date they are exercised. Options granted under the 2018 ADS Plan are exercisable into ADRs, being one option for one ADR, which equals
600 ordinary shares, on the date they are exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Expired options are reclassified into accumulated losses. Options forfeited
due to failure of a vesting condition result in a reversal of the accumulated expense through the statement of profit or loss and other
comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In Australia, there is not a set number of authorized shares, shares
are not reserved for the exercise of options, and shares do not have a par value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(e) Options and Warrants Issued after Reporting Date&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;15,000,000 options were issued under the 2004 ASX Plan after reporting
date.&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <athe:ScheduleOfReserveOfShareBasedPaymentsTableTextBlock contextRef="c0" id="ixv-17427">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;(a) Share Based Payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;2,683,471,567 (2024: 3,250,009,092, 2023: 170,042,720) options for fully paid ordinary shares&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1.5pt; text-align: center"&gt;11(c)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;5,342,304&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;4,806,203&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;3,972,475&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,342,304&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,806,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,972,475&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;(b) Warrants/Free-attaching options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,154,912,180 free-attaching options (2024: 2,868,466,372 free-attaching options, 2023: 674,694,939) for fully paid ordinary shares &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1.5pt; text-align: center"&gt;11(c)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On January 8, 2024 a total of 457,142,830 free attaching options with an exercise price of A$0.01, expiring on August 31, 2026 were issued.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On January 8, 2024 a total of 1,371,428,567 free attaching options with an exercise price of A$0.007, expiring on August 31, 2024 were issued.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On February 2, 2024 a total of 190,476,123 free attaching options with an exercise price of A$0.002, expiring on August 31, 2026 were issued.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On February 2, 2024 a total of 571,428,556 free attaching options with an exercise price of A$0.007, expiring on August 31, 2024 were issued.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On April 15, 2024 a total of 285,087,715 free attaching options with an exercise price of A$0.01, expiring on August 31, 2026 were issued.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On April 23, 2025 a total of 1,222,300,911 free attaching options with an exercise price if A$0.028, expiring on February 26, 2027 were issued.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</athe:ScheduleOfReserveOfShareBasedPaymentsTableTextBlock>
    <athe:OptionsForFullyPaidOrdinaryShares1
      contextRef="c0"
      decimals="INF"
      id="ixv-23933"
      unitRef="Options">2683471567</athe:OptionsForFullyPaidOrdinaryShares1>
    <athe:OptionsForFullyPaidOrdinaryShares1
      contextRef="c4"
      decimals="INF"
      id="ixv-23934"
      unitRef="Options">3250009092</athe:OptionsForFullyPaidOrdinaryShares1>
    <athe:OptionsForFullyPaidOrdinaryShares1
      contextRef="c5"
      decimals="INF"
      id="ixv-23935"
      unitRef="Options">170042720</athe:OptionsForFullyPaidOrdinaryShares1>
    <ifrs-full:ReserveOfSharebasedPayments
      contextRef="c132"
      decimals="INF"
      id="ixv-23936"
      unitRef="aud">5342304</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments
      contextRef="c133"
      decimals="INF"
      id="ixv-23937"
      unitRef="aud">4806203</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments
      contextRef="c134"
      decimals="INF"
      id="ixv-23938"
      unitRef="aud">3972475</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c2" decimals="INF" id="ixv-23939" unitRef="aud">5342304</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c3" decimals="INF" id="ixv-23940" unitRef="aud">4806203</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c6" decimals="INF" id="ixv-23941" unitRef="aud">3972475</ifrs-full:ReserveOfSharebasedPayments>
    <athe:FreeattachingOptionsForFullyPaidOrdinaryShares
      contextRef="c0"
      decimals="INF"
      id="ix_22_fact"
      unitRef="FreeAttachingOptions">2154912180</athe:FreeattachingOptionsForFullyPaidOrdinaryShares>
    <athe:FreeattachingOptionsForFullyPaidOrdinaryShares
      contextRef="c4"
      decimals="INF"
      id="ix_23_fact"
      unitRef="FreeAttachingOptions">2868466372</athe:FreeattachingOptionsForFullyPaidOrdinaryShares>
    <athe:FreeattachingOptionsForFullyPaidOrdinaryShares
      contextRef="c5"
      decimals="INF"
      id="ix_24_fact"
      unitRef="FreeAttachingOptions">674694939</athe:FreeattachingOptionsForFullyPaidOrdinaryShares>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c79"
      decimals="0"
      id="ixv-23945"
      unitRef="Options">457142830</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c80"
      decimals="2"
      id="ixv-23946"
      unitRef="audPershares">0.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c81"
      decimals="0"
      id="ixv-23947"
      unitRef="Options">1371428567</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c81"
      decimals="3"
      id="ixv-23948"
      unitRef="audPershares">0.007</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c82"
      decimals="0"
      id="ixv-23949"
      unitRef="Options">190476123</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c83"
      decimals="3"
      id="ixv-23950"
      unitRef="audPershares">0.002</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c84"
      decimals="0"
      id="ixv-23951"
      unitRef="Options">571428556</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c85"
      decimals="3"
      id="ixv-23952"
      unitRef="audPershares">0.007</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c86"
      decimals="0"
      id="ixv-23953"
      unitRef="Options">285087715</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c87"
      decimals="2"
      id="ixv-23954"
      unitRef="audPershares">0.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c88"
      decimals="0"
      id="ixv-23955"
      unitRef="Options">1222300911</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c89"
      decimals="3"
      id="ixv-23956"
      unitRef="audPershares">0.028</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <athe:ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock contextRef="c0" id="ixv-17712">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Movements in Options for Fully Paid Ordinary Shares&lt;/b&gt;&lt;/span&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="23" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Years Ended June 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(A$)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(A$)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(A$)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,250,009,092&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,806,203&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;170,042,720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,972,475&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;184,692,720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,565,918&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Options issued during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,392,300,911&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,092,563,791&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Expired during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,947,759,704&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(326,544&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(560,014&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,650,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(93,735&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(93,222&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(17,150&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Options exercised during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,428,732&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(23,540&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Shares to be issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Share Based Payment expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;979,920&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;881,950&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;983,721&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;End of the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,683,471,567&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,342,304&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,250,009,092&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,806,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;170,042,720&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,972,475&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</athe:ScheduleOfMovementsInOptionsForFullyPaidOrdinarySharesTableTextBlock>
    <athe:NumberOfSharesOptionsOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-23957"
      unitRef="Options">3250009092</athe:NumberOfSharesOptionsOutstanding>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c3" decimals="INF" id="ixv-23958" unitRef="aud">4806203</ifrs-full:ReserveOfSharebasedPayments>
    <athe:NumberOfSharesOptionsOutstanding
      contextRef="c6"
      decimals="INF"
      id="ixv-23959"
      unitRef="Options">170042720</athe:NumberOfSharesOptionsOutstanding>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c6" decimals="INF" id="ixv-23960" unitRef="aud">3972475</ifrs-full:ReserveOfSharebasedPayments>
    <athe:NumberOfSharesOptionsOutstanding
      contextRef="c7"
      decimals="INF"
      id="ixv-23961"
      unitRef="Options">184692720</athe:NumberOfSharesOptionsOutstanding>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c7" decimals="INF" id="ixv-23962" unitRef="aud">3565918</ifrs-full:ReserveOfSharebasedPayments>
    <athe:ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear
      contextRef="c0"
      decimals="INF"
      id="ixv-23963"
      unitRef="Options">1392300911</athe:ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear>
    <athe:ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear
      contextRef="c4"
      decimals="INF"
      id="ixv-23964"
      unitRef="Options">3092563791</athe:ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear>
    <athe:ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare
      contextRef="c0"
      decimals="INF"
      id="ixv-23965"
      unitRef="Options">-1947759704</athe:ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare>
    <athe:ReserveOfShareBasedPaymentsExpiredDuringTheYear contextRef="c0" decimals="INF" id="ixv-23966" unitRef="aud">-326544</athe:ReserveOfShareBasedPaymentsExpiredDuringTheYear>
    <athe:ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare
      contextRef="c5"
      decimals="INF"
      id="ixv-23967"
      unitRef="Options">-13150000</athe:ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare>
    <athe:ReserveOfShareBasedPaymentsExpiredDuringTheYear contextRef="c5" decimals="INF" id="ixv-23968" unitRef="aud">-560014</athe:ReserveOfShareBasedPaymentsExpiredDuringTheYear>
    <athe:NumberOfOptionsForfeitedDuringTheYear
      contextRef="c0"
      decimals="INF"
      id="ixv-23969"
      unitRef="Options">-4650000</athe:NumberOfOptionsForfeitedDuringTheYear>
    <athe:ReserveOfSharebasedPaymentsForfeitedDuringYear contextRef="c0" decimals="INF" id="ixv-23970" unitRef="aud">-93735</athe:ReserveOfSharebasedPaymentsForfeitedDuringYear>
    <athe:NumberOfOptionsForfeitedDuringTheYear
      contextRef="c4"
      decimals="INF"
      id="ixv-23971"
      unitRef="Options">-5500000</athe:NumberOfOptionsForfeitedDuringTheYear>
    <athe:ReserveOfSharebasedPaymentsForfeitedDuringYear contextRef="c4" decimals="INF" id="ixv-23972" unitRef="aud">-93222</athe:ReserveOfSharebasedPaymentsForfeitedDuringYear>
    <athe:NumberOfOptionsForfeitedDuringTheYear
      contextRef="c5"
      decimals="INF"
      id="ixv-23973"
      unitRef="Options">-1500000</athe:NumberOfOptionsForfeitedDuringTheYear>
    <athe:ReserveOfSharebasedPaymentsForfeitedDuringYear contextRef="c5" decimals="INF" id="ixv-23974" unitRef="aud">-17150</athe:ReserveOfSharebasedPaymentsForfeitedDuringYear>
    <athe:NumberOfOptionsOptionsExercisedDuringTheYear
      contextRef="c0"
      decimals="INF"
      id="ixv-23975"
      unitRef="Options">-6428732</athe:NumberOfOptionsOptionsExercisedDuringTheYear>
    <athe:OptionsExercisedDuringTheYear contextRef="c0" decimals="INF" id="ixv-23976" unitRef="aud">-23540</athe:OptionsExercisedDuringTheYear>
    <athe:SharesToBeIssued contextRef="c4" decimals="INF" id="ixv-23977" unitRef="aud">45000</athe:SharesToBeIssued>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c0" decimals="INF" id="ixv-23978" unitRef="aud">979920</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c4" decimals="INF" id="ixv-23979" unitRef="aud">881950</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c5" decimals="INF" id="ixv-23980" unitRef="aud">983721</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <athe:NumberOfSharesOptionsOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-23981"
      unitRef="Options">2683471567</athe:NumberOfSharesOptionsOutstanding>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c2" decimals="INF" id="ixv-23982" unitRef="aud">5342304</ifrs-full:ReserveOfSharebasedPayments>
    <athe:NumberOfSharesOptionsOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-23983"
      unitRef="Options">3250009092</athe:NumberOfSharesOptionsOutstanding>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c3" decimals="INF" id="ixv-23984" unitRef="aud">4806203</ifrs-full:ReserveOfSharebasedPayments>
    <athe:NumberOfSharesOptionsOutstanding
      contextRef="c6"
      decimals="INF"
      id="ixv-23985"
      unitRef="Options">170042720</athe:NumberOfSharesOptionsOutstanding>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c6" decimals="INF" id="ixv-23986" unitRef="aud">3972475</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="c90"
      decimals="0"
      id="ixv-23987"
      unitRef="Options">12450000</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="c91"
      decimals="0"
      id="ixv-23988"
      unitRef="Options">700000</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c92"
      decimals="0"
      id="ixv-23989"
      unitRef="Options">1500000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c93"
      decimals="0"
      id="ixv-23990"
      unitRef="Options">500000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c94"
      decimals="0"
      id="ixv-23991"
      unitRef="Options">8000000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c95"
      decimals="4"
      id="ixv-23992"
      unitRef="audPershares">0.0105</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <athe:ExpiredTerm contextRef="c96" id="ixv-23993">2026-12-19</athe:ExpiredTerm>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c94"
      decimals="3"
      id="ixv-23994"
      unitRef="audPershares">0.005</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c80"
      decimals="0"
      id="ixv-23995"
      unitRef="Options">457142830</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c80"
      decimals="2"
      id="ixv-23996"
      unitRef="audPershares">0.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <athe:ExpiredTerm contextRef="c97" id="ixv-23997">2026-08-31</athe:ExpiredTerm>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c98"
      decimals="0"
      id="ixv-23998"
      unitRef="Options">1371418567</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c99"
      decimals="3"
      id="ixv-23999"
      unitRef="audPershares">0.007</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <athe:ExpiredTerm contextRef="c100" id="ixv-24000">2024-08-31</athe:ExpiredTerm>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c101"
      decimals="0"
      id="ixv-24001"
      unitRef="Options">190476123</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c102"
      decimals="3"
      id="ixv-24002"
      unitRef="audPershares">0.002</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <athe:ExpiredTerm contextRef="c103" id="ixv-24003">2026-08-31</athe:ExpiredTerm>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c104"
      decimals="0"
      id="ixv-24004"
      unitRef="Options">571428556</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c104"
      decimals="3"
      id="ixv-24005"
      unitRef="audPershares">0.007</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <athe:ExpiredTerm contextRef="c105" id="ixv-24006">2024-08-31</athe:ExpiredTerm>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c106"
      decimals="0"
      id="ixv-24007"
      unitRef="Options">285087725</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c107"
      decimals="2"
      id="ixv-24008"
      unitRef="audPershares">0.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <athe:ExpiredTerm contextRef="c108" id="ixv-24009">2024-08-31</athe:ExpiredTerm>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c109"
      decimals="0"
      id="ixv-24010"
      unitRef="Options">7097419</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c110"
      decimals="0"
      id="ixv-24011"
      unitRef="Options">5000000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c111"
      decimals="0"
      id="ixv-24012"
      unitRef="Options">26500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c111"
      decimals="3"
      id="ixv-24013"
      unitRef="audPershares">0.004</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <athe:ExpiredTerm contextRef="c112" id="ixv-24014">2029-03-13</athe:ExpiredTerm>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c113"
      decimals="3"
      id="ixv-24015"
      unitRef="audPershares">0.004</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c114"
      decimals="0"
      id="ixv-24016"
      unitRef="Options">62500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c115"
      decimals="4"
      id="ixv-24017"
      unitRef="usdPershares">0.0031</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c115"
      decimals="4"
      id="ixv-24018"
      unitRef="audPershares">0.0046</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c116"
      decimals="4"
      id="ixv-24019"
      unitRef="audPershares">0.0037</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c115"
      decimals="0"
      id="ixv-24020"
      unitRef="Options">120000000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c117"
      decimals="3"
      id="ixv-24021"
      unitRef="usdPershares">0.003</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c117"
      decimals="4"
      id="ixv-24022"
      unitRef="audPershares">0.0044</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c118"
      decimals="4"
      id="ixv-24023"
      unitRef="audPershares">0.0037</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="c119"
      decimals="0"
      id="ixv-24024"
      unitRef="Options">12000000</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="c120"
      decimals="0"
      id="ixv-24025"
      unitRef="Options">1935759704</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c121"
      decimals="0"
      id="ixv-24026"
      unitRef="Options">170000000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c121"
      decimals="2"
      id="ixv-24027"
      unitRef="audPershares">0.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <athe:ExpiredTerm contextRef="c122" id="ixv-24028">2027-12-30</athe:ExpiredTerm>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c123"
      decimals="0"
      id="ixv-24029"
      unitRef="Options">95238</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c124"
      decimals="0"
      id="ixv-24030"
      unitRef="Options">6333333</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c125"
      decimals="0"
      id="ixv-24031"
      unitRef="Options">14000000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c126"
      decimals="0"
      id="ixv-24032"
      unitRef="Options">161</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c127"
      decimals="0"
      id="ixv-24033"
      unitRef="Options">1222300911</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c128"
      decimals="3"
      id="ixv-24034"
      unitRef="audPershares">0.028</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <athe:ExpiredTerm contextRef="c129" id="ixv-24035">2027-02-26</athe:ExpiredTerm>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c130"
      decimals="0"
      id="ixv-24036"
      unitRef="Options">4650000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <athe:ReserveOfOrdinaryShares
      contextRef="c0"
      decimals="0"
      id="ixv-24037"
      unitRef="shares">600</athe:ReserveOfOrdinaryShares>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c131"
      decimals="0"
      id="ixv-24038"
      unitRef="Options">15000000</ifrs-full:NumberOfOutstandingShareOptions>
    <athe:AccumulatedDeficitDuringDevelopmentStageTextBlock contextRef="c0" id="ixv-18283">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;12. ACCUMULATED DEFICIT DURING DEVELOPMENT STAGE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Balance at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;214,161,131&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;195,130,889&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;181,884,388&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net loss for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,147,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,123,464&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,806,515&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Reclassify expired options from reserves&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(326,544&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(560,014&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Reclassify forfeited options from reserves&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(93,735&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(93,222&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Balance at end of year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;225,888,680&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;214,161,131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;195,130,889&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</athe:AccumulatedDeficitDuringDevelopmentStageTextBlock>
    <athe:ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock contextRef="c0" id="ixv-18287">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Balance at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;214,161,131&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;195,130,889&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;181,884,388&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net loss for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,147,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,123,464&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,806,515&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Reclassify expired options from reserves&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(326,544&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(560,014&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Reclassify forfeited options from reserves&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(93,735&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(93,222&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Balance at end of year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;225,888,680&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;214,161,131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;195,130,889&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</athe:ScheduleOfAccumulatedDeficitDuringDevelopmentStageTableTextBlock>
    <ifrs-full:RetainedEarnings contextRef="c3" decimals="0" id="ixv-24039" unitRef="aud">-214161131</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c6" decimals="0" id="ixv-24040" unitRef="aud">-195130889</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c7" decimals="0" id="ixv-24041" unitRef="aud">-181884388</ifrs-full:RetainedEarnings>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="0" id="ixv-24042" unitRef="aud">-12147828</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="0" id="ixv-24043" unitRef="aud">-19123464</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="0" id="ixv-24044" unitRef="aud">-13806515</ifrs-full:ProfitLoss>
    <athe:ReclassifyExpiredOptionsFromReservesOne contextRef="c0" decimals="0" id="ixv-24045" unitRef="aud">326544</athe:ReclassifyExpiredOptionsFromReservesOne>
    <athe:ReclassifyExpiredOptionsFromReservesOne contextRef="c5" decimals="0" id="ixv-24046" unitRef="aud">560014</athe:ReclassifyExpiredOptionsFromReservesOne>
    <athe:ReclassifyForfeitedOptionsFromReserves contextRef="c0" decimals="0" id="ixv-24047" unitRef="aud">-93735</athe:ReclassifyForfeitedOptionsFromReserves>
    <athe:ReclassifyForfeitedOptionsFromReserves contextRef="c4" decimals="0" id="ixv-24048" unitRef="aud">-93222</athe:ReclassifyForfeitedOptionsFromReserves>
    <ifrs-full:RetainedEarnings contextRef="c2" decimals="0" id="ixv-24049" unitRef="aud">-225888680</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c3" decimals="0" id="ixv-24050" unitRef="aud">-214161131</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c6" decimals="0" id="ixv-24051" unitRef="aud">-195130889</ifrs-full:RetainedEarnings>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="c0" id="ixv-18414">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;b&gt;13. LEASES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Amounts recognised in the statement of financial position&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The statement of financial position shows the following amounts relating
to leases:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&lt;i&gt;Right-of-use assets&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;151,326&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;154,729&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;207,087&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,912&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107,177&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Non-current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;88,545&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51,914&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103,207&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;155,457&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;159,045&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;210,384&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Additions to the right-of-use assets during the current financial year
were $106,834 (2024:$59,031, 2023:$152,817).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 96%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Amounts recognised in the statement of profit or loss&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The statement of profit or loss shows the following amounts relating
to leases:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Depreciation of right-of-use assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;111,408&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;112,185&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;64,409&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,188&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expenses relating to short-term leases (included in general and administration expenses)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,674&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expenses relating to variable lease payments not included in lease liabilities (included in general and administration expenses)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The total cash outflow for leases in 2025 was $127,097 (2024: $7,913,
2023: $133,121).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(iii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;The
Group&#x2019;s leasing activities and how these are accounted for&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Leases are recognised as a right-of-use asset and a corresponding liability
at the date at which the leased asset is available for use by the Group. Each lease payment is allocated between the liability and finance
cost. The finance cost is charged to profit or loss over the lease year so as to produce a constant periodic rate of interest on the remaining
balance of the liability for each year. The right-of-use asset is depreciated over the shorter of the asset&#x2019;s useful life and the
lease term on a straight-line basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Assets and liabilities arising from a lease are initially measured
on a present value basis. Lease liabilities include the net present value of the following lease payments:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;fixed payments (including in-substance fixed payments), less any lease incentives receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;variable lease payments that are based on an index or a rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;amounts expected to be payable by the lessee under residual value guarantees&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The lease payments are discounted using the interest rate implicit
in the lease, if that rate can be determined, or the Group&#x2019;s incremental borrowing rate applied at the commencement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Right-of-use assets are measured at cost comprising the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the amount of the initial measurement of lease liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;any lease payments made at or before the commencement date, less any lease incentives received&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;any initial direct costs, and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;restoration costs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Payments associated with short-term leases and leases of low-value
assets are recognised on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months
or less.&lt;/p&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <athe:ScheduleOfAmountsRelatingToLeasesTableTextBlock contextRef="c0" id="ixv-18427">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The statement of financial position shows the following amounts relating
to leases:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&lt;i&gt;Right-of-use assets&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;151,326&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;154,729&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;207,087&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,912&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107,177&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Non-current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;88,545&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51,914&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;103,207&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;155,457&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;159,045&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;210,384&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</athe:ScheduleOfAmountsRelatingToLeasesTableTextBlock>
    <ifrs-full:RightofuseAssets contextRef="c2" decimals="0" id="ixv-24052" unitRef="aud">151326</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c3" decimals="0" id="ixv-24053" unitRef="aud">154729</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c6" decimals="0" id="ixv-24054" unitRef="aud">207087</ifrs-full:RightofuseAssets>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c2" decimals="0" id="ixv-24055" unitRef="aud">66912</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c3" decimals="0" id="ixv-24056" unitRef="aud">107131</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c6" decimals="0" id="ixv-24057" unitRef="aud">107177</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c2" decimals="0" id="ixv-24058" unitRef="aud">88545</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c3" decimals="0" id="ixv-24059" unitRef="aud">51914</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c6" decimals="0" id="ixv-24060" unitRef="aud">103207</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c2" decimals="0" id="ixv-24061" unitRef="aud">155457</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c3" decimals="0" id="ixv-24062" unitRef="aud">159045</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c6" decimals="0" id="ixv-24063" unitRef="aud">210384</ifrs-full:LeaseLiabilities>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c0" decimals="0" id="ixv-24064" unitRef="aud">106834</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c4" decimals="0" id="ixv-24065" unitRef="aud">59031</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c5" decimals="0" id="ixv-24066" unitRef="aud">152817</ifrs-full:AdditionsToRightofuseAssets>
    <athe:DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases contextRef="c0" id="ixv-18546">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The statement of profit or loss shows the following amounts relating
to leases:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Depreciation of right-of-use assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;111,408&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;112,185&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;64,409&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,188&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expenses relating to short-term leases (included in general and administration expenses)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(9,674&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expenses relating to variable lease payments not included in lease liabilities (included in general and administration expenses)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</athe:DisclosureOfAmountsRecognizedInProfitOrLossRelatingLeases>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c0" decimals="0" id="ixv-24067" unitRef="aud">111408</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c4" decimals="0" id="ixv-24068" unitRef="aud">112185</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c5" decimals="0" id="ixv-24069" unitRef="aud">64409</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:InterestExpense contextRef="c0" decimals="0" id="ixv-24070" unitRef="aud">6188</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="c4" decimals="0" id="ixv-24071" unitRef="aud">7217</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="c5" decimals="0" id="ixv-24072" unitRef="aud">4565</ifrs-full:InterestExpense>
    <athe:ExpensesRelatingToShorttermLeases contextRef="c4" decimals="0" id="ixv-24073" unitRef="aud">-9674</athe:ExpensesRelatingToShorttermLeases>
    <athe:ExpensesRelatingToShorttermLeases contextRef="c5" decimals="0" id="ixv-24074" unitRef="aud">68634</athe:ExpensesRelatingToShorttermLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c0" decimals="0" id="ixv-24075" unitRef="aud">127097</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c4" decimals="0" id="ixv-24076" unitRef="aud">7913</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c5" decimals="0" id="ixv-24077" unitRef="aud">133121</ifrs-full:CashOutflowForLeases>
    <athe:ShortTermLeaseTerm contextRef="c0" id="ixv-24078">12 months</athe:ShortTermLeaseTerm>
    <ifrs-full:DisclosureOfCashFlowStatementExplanatory contextRef="c0" id="ixv-18757">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;14. CASH FLOW INFORMATION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;(a) Reconciliation of Net Loss to Net Cash Flows Used In Operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(12,147,828&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(19,123,464&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(13,806,515&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Non-cash items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Depreciation of property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,307&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,344&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Depreciation on leased assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111,408&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112,185&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;450,056&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;979,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;881,950&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;966,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Foreign exchange loss/(gain)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(259,433&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(261,152&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(917,650&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Fixed asset write off&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Changes in assets and liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Decrease/(increase) in trade and other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104,068&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,624,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,940,343&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Decrease/(increase) in other current assets (excepting term deposit)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,081,363&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;252,986&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(968,207&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;(Decrease)/increase in trade and other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,044,457&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,102,239&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,560,873&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;(Decrease) in other current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(99,861&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,935&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Increase/(decrease) in provision for employee entitlements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;345,209&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(218,006&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78,685&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Net cash flows used in operating activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(11,451,248&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12,605,824&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(20,035,837&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;(b) Reconciliation of Cash and Cash Equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Cash and cash equivalents balance comprises:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;- cash and cash equivalents on hand&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33,158,642&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,638,885&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,773,783&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Closing cash and cash equivalents balance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33,158,642&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,638,885&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,773,783&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(c) Non-Cash Financing and Investing Activities&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;There were no non-cash financing and investing activities during the
years ended June 30, 2025, 2024 and 2023.&lt;/p&gt;</ifrs-full:DisclosureOfCashFlowStatementExplanatory>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="c0" id="ixv-18761">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;(a) Reconciliation of Net Loss to Net Cash Flows Used In Operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(12,147,828&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(19,123,464&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(13,806,515&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Non-cash items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Depreciation of property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,307&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,344&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Depreciation on leased assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111,408&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112,185&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;450,056&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;979,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;881,950&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;966,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Foreign exchange loss/(gain)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(259,433&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(261,152&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(917,650&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Fixed asset write off&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Changes in assets and liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Decrease/(increase) in trade and other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104,068&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,624,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,940,343&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Decrease/(increase) in other current assets (excepting term deposit)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,081,363&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;252,986&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(968,207&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;(Decrease)/increase in trade and other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,044,457&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,102,239&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,560,873&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;(Decrease) in other current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(99,861&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,935&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Increase/(decrease) in provision for employee entitlements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;345,209&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(218,006&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78,685&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Net cash flows used in operating activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(11,451,248&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12,605,824&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(20,035,837&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;(b) Reconciliation of Cash and Cash Equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Cash and cash equivalents balance comprises:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;- cash and cash equivalents on hand&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33,158,642&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,638,885&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,773,783&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Closing cash and cash equivalents balance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33,158,642&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,638,885&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,773,783&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="0" id="ixv-24079" unitRef="aud">-12147828</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="0" id="ixv-24080" unitRef="aud">-19123464</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c5" decimals="0" id="ixv-24081" unitRef="aud">-13806515</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c0" decimals="0" id="ixv-24082" unitRef="aud">28307</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c4" decimals="0" id="ixv-24083" unitRef="aud">35344</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c5" decimals="0" id="ixv-24084" unitRef="aud">37854</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c0" decimals="0" id="ixv-24085" unitRef="aud">111408</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c4" decimals="0" id="ixv-24086" unitRef="aud">112185</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c5" decimals="0" id="ixv-24087" unitRef="aud">64409</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:OtherCashPaymentsFromOperatingActivities contextRef="c0" decimals="0" id="ixv-24088" unitRef="aud">450056</ifrs-full:OtherCashPaymentsFromOperatingActivities>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="0" id="ixv-24089" unitRef="aud">979920</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c4" decimals="0" id="ixv-24090" unitRef="aud">881950</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c5" decimals="0" id="ixv-24091" unitRef="aud">966571</ifrs-full:AdjustmentsForSharebasedPayments>
    <athe:ForeignExchangegainLoss contextRef="c0" decimals="0" id="ixv-24092" unitRef="aud">-259433</athe:ForeignExchangegainLoss>
    <athe:ForeignExchangegainLoss contextRef="c4" decimals="0" id="ixv-24093" unitRef="aud">-261152</athe:ForeignExchangegainLoss>
    <athe:ForeignExchangegainLoss contextRef="c5" decimals="0" id="ixv-24094" unitRef="aud">-917650</athe:ForeignExchangegainLoss>
    <athe:FixedAssetWriteOff contextRef="c5" decimals="0" id="ixv-24095" unitRef="aud">10232</athe:FixedAssetWriteOff>
    <athe:IncreaseDecreaseInTradeAndOtherReceivables contextRef="c0" decimals="0" id="ixv-24096" unitRef="aud">104068</athe:IncreaseDecreaseInTradeAndOtherReceivables>
    <athe:IncreaseDecreaseInTradeAndOtherReceivables contextRef="c4" decimals="0" id="ixv-24097" unitRef="aud">4624029</athe:IncreaseDecreaseInTradeAndOtherReceivables>
    <athe:IncreaseDecreaseInTradeAndOtherReceivables contextRef="c5" decimals="0" id="ixv-24098" unitRef="aud">-3940343</athe:IncreaseDecreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="c0" decimals="0" id="ixv-24099" unitRef="aud">1081363</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="c4" decimals="0" id="ixv-24100" unitRef="aud">252986</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="c5" decimals="0" id="ixv-24101" unitRef="aud">-968207</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c0" decimals="0" id="ixv-24102" unitRef="aud">-2044457</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c4" decimals="0" id="ixv-24103" unitRef="aud">1102239</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c5" decimals="0" id="ixv-24104" unitRef="aud">-1560873</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities contextRef="c0" decimals="0" id="ixv-24105" unitRef="aud">-99861</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities contextRef="c4" decimals="0" id="ixv-24106" unitRef="aud">-11935</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
    <ifrs-full:AdjustmentsForProvisions contextRef="c0" decimals="0" id="ixv-24107" unitRef="aud">345209</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions contextRef="c4" decimals="0" id="ixv-24108" unitRef="aud">-218006</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions contextRef="c5" decimals="0" id="ixv-24109" unitRef="aud">78685</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-24110" unitRef="aud">-11451248</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c4" decimals="0" id="ixv-24111" unitRef="aud">-12605824</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c5" decimals="0" id="ixv-24112" unitRef="aud">-20035837</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashOnHand contextRef="c2" decimals="0" id="ixv-24113" unitRef="aud">33158642</ifrs-full:CashOnHand>
    <ifrs-full:CashOnHand contextRef="c3" decimals="0" id="ixv-24114" unitRef="aud">12638885</ifrs-full:CashOnHand>
    <ifrs-full:CashOnHand contextRef="c6" decimals="0" id="ixv-24115" unitRef="aud">15773783</ifrs-full:CashOnHand>
    <ifrs-full:CashEquivalents contextRef="c2" decimals="0" id="ixv-24116" unitRef="aud">33158642</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents contextRef="c3" decimals="0" id="ixv-24117" unitRef="aud">12638885</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents contextRef="c6" decimals="0" id="ixv-24118" unitRef="aud">15773783</ifrs-full:CashEquivalents>
    <ifrs-full:DisclosureOfCommitmentsExplanatory contextRef="c0" id="ixv-19174">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;b&gt;15. EXPENDITURE COMMITMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of June 30, 2025 and 2024, the Group no longer has short term leases
contracted for but not capitalized in the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The majority of our contracts for research and development programs
have a termination notice period of 30 days. As of June 30, 2025, we had research and development termination commitments approximating
A$1.7 million. No liability has been recognised within our financial statements for this period. In addition, we have the ability to scale
down our operations and prioritise our research and development programs to reduce expenditures.&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Details in relation to commitments under employee service agreements
with Directors and Key Management Personnel are outlined in Note 21.&lt;/p&gt;</ifrs-full:DisclosureOfCommitmentsExplanatory>
    <athe:TerminationNoticePeriodForResearchAndDevelopmentContracts contextRef="c0" id="ixv-24119">P30D</athe:TerminationNoticePeriodForResearchAndDevelopmentContracts>
    <athe:ResearchAndDevelopmentTerminationCommitments contextRef="c2" decimals="-5" id="ixv-24120" unitRef="aud">1700000</athe:ResearchAndDevelopmentTerminationCommitments>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c0" id="ixv-19187">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;b&gt;16. SHARE BASED PAYMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At the Annual General Meeting held on November 17, 2004, the shareholders
approved the establishment of employee and consultant plans designed to reward directors, employees and consultants for their contributions
to the Group. The plans are to be used as a method of retaining key personnel for the growth and development of the Group. Due to Alterity&#x2019;s
U.S. presence, a U.S. plan (the 2018 ADS Plan) and an Australian plan (the 2004 ASX Plan) were developed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of June 30, 2025, equity had been issued to 4 Directors, 1 Key Management
Personnel, 7 employees and 3 consultants under the 2004 ASX Plan and 2018 ADS Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of June 30, 2024, equity had been issued to 3 Directors, 1 Key Management
Personnel, 7 employees and 4 consultants under the 2004 ASX Plan and 2018 ADS Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of June 30, 2023, equity had been issued to 4 Directors, 2 Key Management
Personnel, 9 employees and 3 consultants under the 2004 ASX Plan and 2018 ADS Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At the 2004 Annual General Meeting, shareholders authorized the Group
to issue in the aggregate up to 12 million ordinary shares under the two plans. This was increased to 22 million ordinary shares at the
2005 Annual General Meeting and further increased to 30 million ordinary shares at the 2007 Annual General Meeting, 45 million ordinary
shares at the 2008 Annual General Meeting and 60 million ordinary shares at the 2009 Annual General Meeting. At the September 2020 General
Meeting, shareholders authorized the Group to issue up to 157.5 million securities. At the 2020 Annual General Meeting, shareholders authorized
the Group to issue up to 200 million ordinary shares. At the 2022 Annual General Meeting, shareholders authorized the Group to issue up
to 240 million ordinary shares. At the 2024 Annual General Meeting, shareholders authorized the Group to issue up to 450 million ordinary
shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Share Plan Committee, a sub-committee of the Remuneration Committee,
administers the two plans and is able to change the terms of the equity issued under them from the default terms&lt;b&gt;.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Under the 2018 ADS Plan, the exercise price must equal or exceed the
fair value of the ADS on the date the options are awarded. The option expiration date cannot exceed ten years from the date the options
were awarded. The default vesting conditions are 25% per year on the date the options were awarded.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Under the 2004 ASX Plan, the exercise price must be equal or be less
than the market value of the ordinary shares on ASX on the date of grant. The option expiration date cannot exceed ten years from the
date the options were granted. The default vesting conditions are 25% per year on the date the options were granted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Information with respect to the number of options granted under the
2004 ASX Plan and 2018 ADS Plan as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;381,542,720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.022&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;170,042,720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;184,692,720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Issued during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;217,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Exercised during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,333,333&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expired during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Forfeited during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,650,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.036&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.036&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.02&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding at year end&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;358,559,387&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;381,542,720&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;170,042,720&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.05&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Vested and Exercisable at year end&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;275,689,612&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;195,708,100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.033&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;87,280,755&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.06&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Options outstanding at the end of the year have the following expiry
date and exercise prices:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Series&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Grant Date&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Expiry Date&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;$A&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 22%"&gt;ATHAAB&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; width: 20%; vertical-align: bottom"&gt;September 18, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; width: 20%"&gt;September 17, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.09&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;ATHAAD&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;January 7, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;January 6, 2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,392,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,392,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;ATHAAE&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;November 29, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;November 29, 2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;ATHAAF&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;July 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;July 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;ATHAAG&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;November 21, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;November 29, 2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.02&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,900,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;ATHAAH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;December 21, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;December 19, 2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;ATHAA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;March 13, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;March 13, 2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,166,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;ATHAB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;March 13, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;March 13, 2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;ATHAC&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;March 21, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;March 21, 2029&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.003&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-137; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;358,559,387&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;381,542,720&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td colspan="8" style="text-align: left"&gt;Weighted average remaining contractual life of options outstanding at end of period.&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.37 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.28 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Risk free interest rate &lt;/i&gt;&#x2013; This is the government bond
rate (having a term that most closely resembles the expected life of the option) in effect at the grant date. The Australian government
bond rate has been used for options which are exercisable for fully paid ordinary shares and the U.S. government bond rate has been used
for options which are exercisable for ADRs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Dividend yield &lt;/i&gt;&#x2013; Alterity has never declared or paid dividends
on its ordinary shares and does not anticipate paying any dividends in the foreseeable future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Expected volatility &lt;/i&gt;&#x2013; Alterity estimates expected volatility
based on historical volatility over the estimated life of the option and other factors. Historical volatility has been the basis for determining
expected share price volatility as it is assumed that this is indicative of future movements. The life of the options is based on historical
exercise patterns, which may not eventuate in the future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Expected life &lt;/i&gt;&#x2013; This is the period of time that the options
granted are expected to remain outstanding. This estimate is based primarily on historical trend of option holders to exercise their option
near the date of expiry. As a result, the expected life is considered to equal the period from grant date to expiry date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Model inputs &#x2013;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The model inputs for the valuations of options approved and issued
during the current and previous financial years are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold; vertical-align: bottom"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price &lt;br/&gt; per Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share Price &lt;br/&gt; at Grant&lt;br/&gt; Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Expected Share &lt;br/&gt; Price &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Years to&lt;br/&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Dividend&lt;br/&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Risk-free&lt;br/&gt; Interest &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;br/&gt; per Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom"&gt;&lt;b&gt;Series&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Grant Date&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Volatility&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Expiry&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Yield&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Rate&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; width: 6%; vertical-align: bottom"&gt;ATHAAB&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; white-space: nowrap; width: 16%; vertical-align: bottom"&gt;September 18,2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0.09&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;98.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0.43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0.032&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; vertical-align: bottom"&gt;ATHAAD&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;January 7,2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.032&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139.52&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.38&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; vertical-align: bottom"&gt;ATHAAE&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;November 29, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;138.47&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; vertical-align: bottom"&gt;ATHAAF&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;July 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.034&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169.42&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; vertical-align: bottom"&gt;ATHAAG&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;November 29, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.02&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;138.47&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; vertical-align: bottom"&gt;ATHAAH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;December 21, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133.87&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.67&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; vertical-align: bottom"&gt;ATHAA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;March 13, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158.31&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.47&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; vertical-align: bottom"&gt;ATHAB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;March 13, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158.31&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.47&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; vertical-align: bottom"&gt;ATHAC&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;March 21, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.003&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158.83&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.48&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Information with respect to the number of shares issued under the stock
option plan as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,277,715&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,277,715&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,277,715&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Issued during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;End of the financial year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,277,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,277,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,277,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;No shares were granted during the year ended June 30, 2025, 2024 and
2023.&lt;/p&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <athe:NumberOfDirector contextRef="c2" decimals="0" id="ixv-24121" unitRef="pure">4</athe:NumberOfDirector>
    <athe:NumberOfKeyManagementPersonnel contextRef="c2" decimals="0" id="ixv-24122" unitRef="pure">1</athe:NumberOfKeyManagementPersonnel>
    <ifrs-full:NumberOfEmployees contextRef="c2" decimals="0" id="ixv-24123" unitRef="pure">7</ifrs-full:NumberOfEmployees>
    <athe:NumberOfConsultant contextRef="c2" decimals="0" id="ixv-24124" unitRef="pure">3</athe:NumberOfConsultant>
    <athe:NumberOfDirector contextRef="c3" decimals="0" id="ixv-24125" unitRef="pure">3</athe:NumberOfDirector>
    <athe:NumberOfKeyManagementPersonnel contextRef="c3" decimals="0" id="ixv-24126" unitRef="pure">1</athe:NumberOfKeyManagementPersonnel>
    <ifrs-full:NumberOfEmployees contextRef="c3" decimals="0" id="ixv-24127" unitRef="pure">7</ifrs-full:NumberOfEmployees>
    <athe:NumberOfConsultant contextRef="c3" decimals="0" id="ixv-24128" unitRef="pure">4</athe:NumberOfConsultant>
    <athe:NumberOfDirector contextRef="c6" decimals="0" id="ixv-24129" unitRef="pure">4</athe:NumberOfDirector>
    <athe:NumberOfKeyManagementPersonnel contextRef="c6" decimals="0" id="ixv-24130" unitRef="pure">2</athe:NumberOfKeyManagementPersonnel>
    <ifrs-full:NumberOfEmployees contextRef="c6" decimals="0" id="ixv-24131" unitRef="pure">9</ifrs-full:NumberOfEmployees>
    <athe:NumberOfConsultant contextRef="c6" decimals="0" id="ixv-24132" unitRef="pure">3</athe:NumberOfConsultant>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
      contextRef="c135"
      decimals="-6"
      id="ixv-24133"
      unitRef="shares">12000000</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
      contextRef="c136"
      decimals="-6"
      id="ixv-24134"
      unitRef="shares">22000000</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
      contextRef="c137"
      decimals="-6"
      id="ixv-24135"
      unitRef="shares">30000000</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
      contextRef="c138"
      decimals="-6"
      id="ixv-24136"
      unitRef="shares">45000000</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
      contextRef="c139"
      decimals="-6"
      id="ixv-24137"
      unitRef="shares">60000000</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <athe:ShareholdersAuthorizedSecurities
      contextRef="c140"
      decimals="-5"
      id="ixv-24138"
      unitRef="shares">157500000</athe:ShareholdersAuthorizedSecurities>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c141"
      decimals="-6"
      id="ixv-24139"
      unitRef="shares">200000000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c7"
      decimals="-6"
      id="ixv-24140"
      unitRef="shares">240000000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c3"
      decimals="-6"
      id="ixv-24141"
      unitRef="shares">450000000</ifrs-full:NumberOfSharesIssued>
    <athe:PercentageOfDefaultVestingConditionsPerYear
      contextRef="c142"
      decimals="2"
      id="ixv-24142"
      unitRef="pure">0.25</athe:PercentageOfDefaultVestingConditionsPerYear>
    <athe:PercentageOfDefaultVestingConditionsPerYear contextRef="c0" decimals="2" id="ixv-24143" unitRef="pure">0.25</athe:PercentageOfDefaultVestingConditionsPerYear>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="c0" id="ixv-19241">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Information with respect to the number of options granted under the
2004 ASX Plan and 2018 ADS Plan as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;381,542,720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.022&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;170,042,720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;184,692,720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Issued during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;217,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Exercised during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,333,333&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expired during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Forfeited during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,650,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.036&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.036&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.02&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding at year end&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;358,559,387&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;381,542,720&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;170,042,720&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.05&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Vested and Exercisable at year end&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;275,689,612&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;195,708,100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.033&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;87,280,755&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.06&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c143"
      decimals="0"
      id="ixv-24144"
      unitRef="Options">381542720</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c143"
      decimals="3"
      id="ixv-24145"
      unitRef="audPershares">0.022</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c144"
      decimals="0"
      id="ixv-24146"
      unitRef="Options">170042720</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c144"
      decimals="3"
      id="ixv-24147"
      unitRef="audPershares">0.047</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c145"
      decimals="0"
      id="ixv-24148"
      unitRef="Options">184692720</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c145"
      decimals="2"
      id="ixv-24149"
      unitRef="audPershares">0.05</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c147"
      decimals="0"
      id="ixv-24150"
      unitRef="Options">217000000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c147"
      decimals="3"
      id="ixv-24151"
      unitRef="audPershares">0.004</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c146"
      decimals="0"
      id="ixv-24152"
      unitRef="Options">6333333</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c146"
      decimals="3"
      id="ixv-24153"
      unitRef="audPershares">0.004</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="c146"
      decimals="0"
      id="ixv-24154"
      unitRef="Options">12000000</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="c146"
      decimals="2"
      id="ixv-24155"
      unitRef="audPershares">0.07</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="c148"
      decimals="0"
      id="ixv-24156"
      unitRef="Options">13150000</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="c148"
      decimals="2"
      id="ixv-24157"
      unitRef="audPershares">0.11</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c146"
      decimals="0"
      id="ixv-24158"
      unitRef="Options">4650000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c146"
      decimals="3"
      id="ixv-24159"
      unitRef="audPershares">0.036</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c147"
      decimals="0"
      id="ixv-24160"
      unitRef="Options">5500000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c147"
      decimals="3"
      id="ixv-24161"
      unitRef="audPershares">0.036</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c148"
      decimals="0"
      id="ixv-24162"
      unitRef="Options">1500000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c148"
      decimals="2"
      id="ixv-24163"
      unitRef="audPershares">0.02</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c149"
      decimals="0"
      id="ixv-24164"
      unitRef="Options">358559387</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c149"
      decimals="3"
      id="ixv-24165"
      unitRef="audPershares">0.021</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c143"
      decimals="0"
      id="ixv-24166"
      unitRef="Options">381542720</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c143"
      decimals="3"
      id="ixv-24167"
      unitRef="audPershares">0.022</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c144"
      decimals="0"
      id="ixv-24168"
      unitRef="Options">170042720</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c144"
      decimals="2"
      id="ixv-24169"
      unitRef="audPershares">0.05</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c149"
      decimals="0"
      id="ixv-24170"
      unitRef="Options">275689612</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c149"
      decimals="3"
      id="ixv-24171"
      unitRef="audPershares">0.024</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c143"
      decimals="0"
      id="ixv-24172"
      unitRef="Options">195708100</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c143"
      decimals="3"
      id="ixv-24173"
      unitRef="audPershares">0.033</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c144"
      decimals="0"
      id="ixv-24174"
      unitRef="Options">87280755</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c144"
      decimals="2"
      id="ixv-24175"
      unitRef="audPershares">0.06</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <athe:ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock contextRef="c0" id="ixv-19537">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Options outstanding at the end of the year have the following expiry
date and exercise prices:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Series&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Grant Date&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Expiry Date&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;$A&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 22%"&gt;ATHAAB&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; width: 20%; vertical-align: bottom"&gt;September 18, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; width: 20%"&gt;September 17, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.09&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;ATHAAD&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;January 7, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;January 6, 2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,392,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,392,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;ATHAAE&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;November 29, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;November 29, 2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;ATHAAF&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;July 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;July 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;ATHAAG&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;November 21, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;November 29, 2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.02&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,900,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;ATHAAH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;December 21, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;December 19, 2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;ATHAA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;March 13, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;March 13, 2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,166,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;ATHAB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;March 13, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;March 13, 2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;ATHAC&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;March 21, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;March 21, 2029&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.003&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-137; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;358,559,387&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;381,542,720&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td colspan="8" style="text-align: left"&gt;Weighted average remaining contractual life of options outstanding at end of period.&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.37 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.28 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</athe:ScheduleOfOptionsOutstandingExpiryDateAndExercisePricesTableTextBlock>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c150" id="ixv-24176">September 18, 2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <athe:ExpiryDateOfOutstandingShareOptions contextRef="c150" id="ixv-24177">September 17, 2025</athe:ExpiryDateOfOutstandingShareOptions>
    <athe:ExercisePriceOfOutstandingShareOption1
      contextRef="c151"
      decimals="2"
      id="ixv-24178"
      unitRef="audPershares">0.09</athe:ExercisePriceOfOutstandingShareOption1>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c151"
      decimals="0"
      id="ixv-24179"
      unitRef="Options">35000000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c152"
      decimals="INF"
      id="ixv-24180"
      unitRef="Options">35000000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c153" id="ixv-24181">January 7, 2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <athe:ExpiryDateOfOutstandingShareOptions contextRef="c153" id="ixv-24182">January 6, 2026</athe:ExpiryDateOfOutstandingShareOptions>
    <athe:ExercisePriceOfOutstandingShareOption1
      contextRef="c154"
      decimals="2"
      id="ixv-24183"
      unitRef="audPershares">0.03</athe:ExercisePriceOfOutstandingShareOption1>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c154"
      decimals="0"
      id="ixv-24184"
      unitRef="Options">91392720</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c155"
      decimals="INF"
      id="ixv-24185"
      unitRef="Options">91392720</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c156" id="ixv-24186">November 29, 2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <athe:ExpiryDateOfOutstandingShareOptions contextRef="c156" id="ixv-24187">November 29, 2026</athe:ExpiryDateOfOutstandingShareOptions>
    <athe:ExercisePriceOfOutstandingShareOption1
      contextRef="c157"
      decimals="2"
      id="ixv-24188"
      unitRef="audPershares">0.04</athe:ExercisePriceOfOutstandingShareOption1>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c157"
      decimals="0"
      id="ixv-24189"
      unitRef="Options">10000000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c158"
      decimals="INF"
      id="ixv-24190"
      unitRef="Options">14250000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c159" id="ixv-24191">July 31, 2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <athe:ExpiryDateOfOutstandingShareOptions contextRef="c159" id="ixv-24192">July 31, 2024</athe:ExpiryDateOfOutstandingShareOptions>
    <athe:ExercisePriceOfOutstandingShareOption1
      contextRef="c160"
      decimals="2"
      id="ixv-24193"
      unitRef="audPershares">0.07</athe:ExercisePriceOfOutstandingShareOption1>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c161"
      decimals="INF"
      id="ixv-24194"
      unitRef="Options">12000000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c162" id="ixv-24195">November 21, 2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <athe:ExpiryDateOfOutstandingShareOptions contextRef="c162" id="ixv-24196">November 29, 2026</athe:ExpiryDateOfOutstandingShareOptions>
    <athe:ExercisePriceOfOutstandingShareOption1
      contextRef="c163"
      decimals="2"
      id="ixv-24197"
      unitRef="audPershares">0.02</athe:ExercisePriceOfOutstandingShareOption1>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c163"
      decimals="0"
      id="ixv-24198"
      unitRef="Options">11500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c164"
      decimals="INF"
      id="ixv-24199"
      unitRef="Options">11900000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c165" id="ixv-24200">December 21, 2023</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <athe:ExpiryDateOfOutstandingShareOptions contextRef="c165" id="ixv-24201">December 19, 2026</athe:ExpiryDateOfOutstandingShareOptions>
    <athe:ExercisePriceOfOutstandingShareOption1
      contextRef="c166"
      decimals="3"
      id="ixv-24202"
      unitRef="audPershares">0.001</athe:ExercisePriceOfOutstandingShareOption1>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c166"
      decimals="0"
      id="ixv-24203"
      unitRef="Options">8000000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c167"
      decimals="INF"
      id="ixv-24204"
      unitRef="Options">8000000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c168" id="ixv-24205">March 13, 2024</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <athe:ExpiryDateOfOutstandingShareOptions contextRef="c168" id="ixv-24206">March 13, 2029</athe:ExpiryDateOfOutstandingShareOptions>
    <athe:ExercisePriceOfOutstandingShareOption1
      contextRef="c169"
      decimals="3"
      id="ixv-24207"
      unitRef="audPershares">0.004</athe:ExercisePriceOfOutstandingShareOption1>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c169"
      decimals="0"
      id="ixv-24208"
      unitRef="Options">20166667</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c170"
      decimals="INF"
      id="ixv-24209"
      unitRef="Options">26500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c171" id="ixv-24210">March 13, 2024</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <athe:ExpiryDateOfOutstandingShareOptions contextRef="c171" id="ixv-24211">March 13, 2029</athe:ExpiryDateOfOutstandingShareOptions>
    <athe:ExercisePriceOfOutstandingShareOption1
      contextRef="c172"
      decimals="3"
      id="ixv-24212"
      unitRef="audPershares">0.005</athe:ExercisePriceOfOutstandingShareOption1>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c172"
      decimals="0"
      id="ixv-24213"
      unitRef="Options">62500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c173"
      decimals="INF"
      id="ixv-24214"
      unitRef="Options">62500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c174" id="ixv-24215">March 21, 2024</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <athe:ExpiryDateOfOutstandingShareOptions contextRef="c174" id="ixv-24216">March 21, 2029</athe:ExpiryDateOfOutstandingShareOptions>
    <athe:ExercisePriceOfOutstandingShareOption1
      contextRef="c175"
      decimals="3"
      id="ixv-24217"
      unitRef="audPershares">0.003</athe:ExercisePriceOfOutstandingShareOption1>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c175"
      decimals="0"
      id="ixv-24218"
      unitRef="Options">120000000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c176"
      decimals="INF"
      id="ixv-24219"
      unitRef="Options">120000000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c149"
      decimals="0"
      id="ixv-24220"
      unitRef="Options">358559387</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c143"
      decimals="INF"
      id="ixv-24221"
      unitRef="Options">381542720</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c146" id="ixv-24222">P2Y4M13D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c147" id="ixv-24223">P3Y3M10D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <athe:ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock contextRef="c0" id="ixv-19822">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The model inputs for the valuations of options approved and issued
during the current and previous financial years are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left; font-weight: bold; vertical-align: bottom"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercise Price &lt;br/&gt; per Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share Price &lt;br/&gt; at Grant&lt;br/&gt; Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Expected Share &lt;br/&gt; Price &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Years to&lt;br/&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Dividend&lt;br/&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Risk-free&lt;br/&gt; Interest &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;br/&gt; per Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom"&gt;&lt;b&gt;Series&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Grant Date&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Volatility&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Expiry&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Yield&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Rate&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;A$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; width: 6%; vertical-align: bottom"&gt;ATHAAB&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; white-space: nowrap; width: 16%; vertical-align: bottom"&gt;September 18,2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0.09&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;98.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0.43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0.032&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; vertical-align: bottom"&gt;ATHAAD&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;January 7,2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.032&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139.52&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.38&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; vertical-align: bottom"&gt;ATHAAE&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;November 29, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;138.47&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; vertical-align: bottom"&gt;ATHAAF&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;July 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.034&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169.42&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; vertical-align: bottom"&gt;ATHAAG&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;November 29, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.02&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;138.47&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; vertical-align: bottom"&gt;ATHAAH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;December 21, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133.87&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.67&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; vertical-align: bottom"&gt;ATHAA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;March 13, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158.31&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.47&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; vertical-align: bottom"&gt;ATHAB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;March 13, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158.31&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.47&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; vertical-align: bottom"&gt;ATHAC&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: bottom"&gt;March 21, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.003&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158.83&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.48&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</athe:ScheduleOfValuationsOfOptionsApprovedAndIssuedTableTextBlock>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c177" id="ixv-24224">September 18,2020</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c177"
      decimals="2"
      id="ixv-24225"
      unitRef="audPershares">0.09</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <athe:SharePriceAtGrantDate
      contextRef="c177"
      decimals="2"
      id="ixv-24226"
      unitRef="audPershares">0.05</athe:SharePriceAtGrantDate>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c177"
      decimals="4"
      id="ixv-24227"
      unitRef="pure">0.98</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <athe:YearsToExpiry contextRef="c177" id="ixv-24228">P5Y</athe:YearsToExpiry>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c177"
      decimals="2"
      id="ixv-24229"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <athe:RiskfreeInterestRate
      contextRef="c177"
      decimals="4"
      id="ixv-24230"
      unitRef="pure">0.0043</athe:RiskfreeInterestRate>
    <athe:FairValuePerOptions
      contextRef="c177"
      decimals="3"
      id="ixv-24231"
      unitRef="audPershares">0.032</athe:FairValuePerOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c178" id="ixv-24232">January 7,2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c178"
      decimals="2"
      id="ixv-24233"
      unitRef="audPershares">0.03</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <athe:SharePriceAtGrantDate
      contextRef="c178"
      decimals="3"
      id="ixv-24234"
      unitRef="audPershares">0.032</athe:SharePriceAtGrantDate>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c178"
      decimals="4"
      id="ixv-24235"
      unitRef="pure">1.3952</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <athe:YearsToExpiry contextRef="c178" id="ixv-24236">P5Y</athe:YearsToExpiry>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c178"
      decimals="2"
      id="ixv-24237"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <athe:RiskfreeInterestRate
      contextRef="c178"
      decimals="4"
      id="ixv-24238"
      unitRef="pure">0.0038</athe:RiskfreeInterestRate>
    <athe:FairValuePerOptions
      contextRef="c178"
      decimals="3"
      id="ixv-24239"
      unitRef="audPershares">0.028</athe:FairValuePerOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c179" id="ixv-24240">November 29, 2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c179"
      decimals="2"
      id="ixv-24241"
      unitRef="audPershares">0.04</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <athe:SharePriceAtGrantDate
      contextRef="c179"
      decimals="3"
      id="ixv-24242"
      unitRef="audPershares">0.025</athe:SharePriceAtGrantDate>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c179"
      decimals="4"
      id="ixv-24243"
      unitRef="pure">1.3847</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <athe:YearsToExpiry contextRef="c179" id="ixv-24244">P5Y</athe:YearsToExpiry>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c179"
      decimals="2"
      id="ixv-24245"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <athe:RiskfreeInterestRate
      contextRef="c179"
      decimals="4"
      id="ixv-24246"
      unitRef="pure">0.0135</athe:RiskfreeInterestRate>
    <athe:FairValuePerOptions
      contextRef="c179"
      decimals="3"
      id="ixv-24247"
      unitRef="audPershares">0.021</athe:FairValuePerOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c180" id="ixv-24248">July 31, 2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c180"
      decimals="2"
      id="ixv-24249"
      unitRef="audPershares">0.07</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <athe:SharePriceAtGrantDate
      contextRef="c180"
      decimals="3"
      id="ixv-24250"
      unitRef="audPershares">0.034</athe:SharePriceAtGrantDate>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c180"
      decimals="4"
      id="ixv-24251"
      unitRef="pure">1.6942</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <athe:YearsToExpiry contextRef="c180" id="ixv-24252">P5Y</athe:YearsToExpiry>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c180"
      decimals="2"
      id="ixv-24253"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <athe:RiskfreeInterestRate
      contextRef="c180"
      decimals="4"
      id="ixv-24254"
      unitRef="pure">0.0013</athe:RiskfreeInterestRate>
    <athe:FairValuePerOptions
      contextRef="c180"
      decimals="3"
      id="ixv-24255"
      unitRef="audPershares">0.027</athe:FairValuePerOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c181" id="ixv-24256">November 29, 2021</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c181"
      decimals="2"
      id="ixv-24257"
      unitRef="audPershares">0.02</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <athe:SharePriceAtGrantDate
      contextRef="c181"
      decimals="4"
      id="ixv-24258"
      unitRef="audPershares">0.0238</athe:SharePriceAtGrantDate>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c181"
      decimals="4"
      id="ixv-24259"
      unitRef="pure">1.3847</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <athe:YearsToExpiry contextRef="c181" id="ixv-24260">P5Y</athe:YearsToExpiry>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c181"
      decimals="2"
      id="ixv-24261"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <athe:RiskfreeInterestRate
      contextRef="c181"
      decimals="4"
      id="ixv-24262"
      unitRef="pure">0.0135</athe:RiskfreeInterestRate>
    <athe:FairValuePerOptions
      contextRef="c181"
      decimals="3"
      id="ixv-24263"
      unitRef="audPershares">0.021</athe:FairValuePerOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c182" id="ixv-24264">December 21, 2023</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c182"
      decimals="2"
      id="ixv-24265"
      unitRef="audPershares">0.01</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <athe:SharePriceAtGrantDate
      contextRef="c182"
      decimals="4"
      id="ixv-24266"
      unitRef="audPershares">0.0065</athe:SharePriceAtGrantDate>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c182"
      decimals="4"
      id="ixv-24267"
      unitRef="pure">1.3387</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <athe:YearsToExpiry contextRef="c182" id="ixv-24268">P3Y</athe:YearsToExpiry>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c182"
      decimals="2"
      id="ixv-24269"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <athe:RiskfreeInterestRate
      contextRef="c182"
      decimals="4"
      id="ixv-24270"
      unitRef="pure">0.0367</athe:RiskfreeInterestRate>
    <athe:FairValuePerOptions
      contextRef="c182"
      decimals="3"
      id="ixv-24271"
      unitRef="audPershares">0.005</athe:FairValuePerOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c183" id="ixv-24272">March 13, 2024</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c183"
      decimals="3"
      id="ixv-24273"
      unitRef="audPershares">0.004</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <athe:SharePriceAtGrantDate
      contextRef="c183"
      decimals="3"
      id="ixv-24274"
      unitRef="audPershares">0.004</athe:SharePriceAtGrantDate>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c183"
      decimals="4"
      id="ixv-24275"
      unitRef="pure">1.5831</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <athe:YearsToExpiry contextRef="c183" id="ixv-24276">P5Y</athe:YearsToExpiry>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c183"
      decimals="2"
      id="ixv-24277"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <athe:RiskfreeInterestRate
      contextRef="c183"
      decimals="4"
      id="ixv-24278"
      unitRef="pure">0.0347</athe:RiskfreeInterestRate>
    <athe:FairValuePerOptions
      contextRef="c183"
      decimals="3"
      id="ixv-24279"
      unitRef="audPershares">0.004</athe:FairValuePerOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c184" id="ixv-24280">March 13, 2024</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c184"
      decimals="3"
      id="ixv-24281"
      unitRef="audPershares">0.004</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <athe:SharePriceAtGrantDate
      contextRef="c184"
      decimals="3"
      id="ixv-24282"
      unitRef="audPershares">0.004</athe:SharePriceAtGrantDate>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c184"
      decimals="4"
      id="ixv-24283"
      unitRef="pure">1.5831</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <athe:YearsToExpiry contextRef="c184" id="ixv-24284">P5Y</athe:YearsToExpiry>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c184"
      decimals="2"
      id="ixv-24285"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <athe:RiskfreeInterestRate
      contextRef="c184"
      decimals="4"
      id="ixv-24286"
      unitRef="pure">0.0347</athe:RiskfreeInterestRate>
    <athe:FairValuePerOptions
      contextRef="c184"
      decimals="3"
      id="ixv-24287"
      unitRef="audPershares">0.004</athe:FairValuePerOptions>
    <ifrs-full:DateOfGrantOfSharebasedPaymentArrangement contextRef="c185" id="ixv-24288">March 21, 2024</ifrs-full:DateOfGrantOfSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c185"
      decimals="3"
      id="ixv-24289"
      unitRef="audPershares">0.003</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <athe:SharePriceAtGrantDate
      contextRef="c185"
      decimals="3"
      id="ixv-24290"
      unitRef="audPershares">0.004</athe:SharePriceAtGrantDate>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c185"
      decimals="4"
      id="ixv-24291"
      unitRef="pure">1.5883</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <athe:YearsToExpiry contextRef="c185" id="ixv-24292">P5Y</athe:YearsToExpiry>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="c185"
      decimals="2"
      id="ixv-24293"
      unitRef="pure">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <athe:RiskfreeInterestRate
      contextRef="c185"
      decimals="4"
      id="ixv-24294"
      unitRef="pure">0.0348</athe:RiskfreeInterestRate>
    <athe:FairValuePerOptions
      contextRef="c185"
      decimals="3"
      id="ixv-24295"
      unitRef="audPershares">0.004</athe:FairValuePerOptions>
    <athe:ScheduleOfNumberOfSharesIssuedTableTextBlock contextRef="c0" id="ixv-20197">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Information with respect to the number of shares issued under the stock
option plan as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Beginning of the year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,277,715&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,277,715&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,277,715&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Issued during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;End of the financial year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,277,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,277,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,277,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</athe:ScheduleOfNumberOfSharesIssuedTableTextBlock>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c186"
      decimals="0"
      id="ixv-24296"
      unitRef="shares">13277715</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c187"
      decimals="0"
      id="ixv-24297"
      unitRef="shares">13277715</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c188"
      decimals="0"
      id="ixv-24298"
      unitRef="shares">13277715</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c186"
      decimals="0"
      id="ixv-24299"
      unitRef="shares">13277715</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c187"
      decimals="0"
      id="ixv-24300"
      unitRef="shares">13277715</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c188"
      decimals="0"
      id="ixv-24301"
      unitRef="shares">13277715</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c0" id="ixv-20292">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;b&gt;17. SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On July 3, 2025, the Group issued 15,000,000 options with exercise
price of $0.01 and 5 year expiry under the Group&#x2019;s ASX Employee Share Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On July 28, 2025, Alterity Therapeutics announced positive topline
data form the open-label phase 2 clinical trial of ATH434 in Multiple System Atrophy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On August 15, 2025, the Group issued 11,500,000 options with exercise
price of $0.013 and 5 year expiry under the Group&#x2019;s ASX Employee Share Plan, and 314,400,200 options with exercise price of US$0.0086
and 5 year expiry under the Group&#x2019;s ADS Employee Share Plan,&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;No other matter or circumstance has occurred subsequent to year end
that has significantly affected, or may&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;significantly affect, the operations of the Group, the results of those
operations or the state of affairs of the Group or&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;economic entity in subsequent financial years.&#160;&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c192"
      decimals="0"
      id="ixv-24302"
      unitRef="shares">15000000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="c192"
      decimals="2"
      id="ixv-24303"
      unitRef="usdPershares">0.01</ifrs-full:ParValuePerShare>
    <athe:ExercisePriceExpiryTerm contextRef="c193" id="ixv-24304">P5Y</athe:ExercisePriceExpiryTerm>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c194"
      decimals="0"
      id="ixv-24305"
      unitRef="shares">11500000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="c194"
      decimals="3"
      id="ixv-24306"
      unitRef="usdPershares">0.013</ifrs-full:ParValuePerShare>
    <athe:ExercisePriceExpiryTerm contextRef="c195" id="ixv-24307">P5Y</athe:ExercisePriceExpiryTerm>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c196"
      decimals="0"
      id="ixv-24308"
      unitRef="shares">314400200</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="c196"
      decimals="4"
      id="ixv-24309"
      unitRef="usdPershares">0.0086</ifrs-full:ParValuePerShare>
    <athe:ExercisePriceExpiryTerm contextRef="c197" id="ixv-24310">P5Y</athe:ExercisePriceExpiryTerm>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c0" id="ixv-20331">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;b&gt;18. LOSS PER SHARE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Basic and diluted loss per share (cents per share)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;(0.19&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;(0.52&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;(0.57&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Weighted average number of ordinary shares on issue used in the calculation of basic and diluted loss per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,396,924,117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,648,875,564&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,427,841,917&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The options and warrants in place do not have the effect of diluting
the loss per share. Therefore, they have been excluded from the calculation of diluted loss per share. Please refer to Note 11 and Note
16 for options and warrants on issue which were assessed to be antidilutive.&lt;/p&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory contextRef="c0" id="ixv-20335">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Basic and diluted loss per share (cents per share)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;(0.19&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;(0.52&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;(0.57&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Weighted average number of ordinary shares on issue used in the calculation of basic and diluted loss per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,396,924,117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,648,875,564&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,427,841,917&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-24311"
      unitRef="audPershares">-0.19</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-24312"
      unitRef="audPershares">-0.19</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c4"
      decimals="2"
      id="ixv-24313"
      unitRef="audPershares">-0.52</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c4"
      decimals="2"
      id="ixv-24314"
      unitRef="audPershares">-0.52</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c5"
      decimals="2"
      id="ixv-24315"
      unitRef="audPershares">-0.57</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c5"
      decimals="2"
      id="ixv-24316"
      unitRef="audPershares">-0.57</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c0"
      decimals="0"
      id="ixv-24317"
      unitRef="shares">6396924117</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c0"
      decimals="0"
      id="ixv-24318"
      unitRef="shares">6396924117</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c4"
      decimals="0"
      id="ixv-24319"
      unitRef="shares">3648875564</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c4"
      decimals="0"
      id="ixv-24320"
      unitRef="shares">3648875564</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c5"
      decimals="0"
      id="ixv-24321"
      unitRef="shares">2427841917</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c5"
      decimals="0"
      id="ixv-24322"
      unitRef="shares">2427841917</ifrs-full:WeightedAverageShares>
    <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory contextRef="c0" id="ixv-20411">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;b&gt;19. KEY MANAGEMENT PERSONNEL COMPENSATION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Short-term employee benefits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,522,550&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,551,075&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,727,020&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Post-employment benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,444&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long-term benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,616&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Termination benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Share-based payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;802,128&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;520,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;764,175&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,343,398&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,113,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,540,854&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
    <athe:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock contextRef="c0" id="ixv-20415">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Short-term employee benefits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,522,550&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,551,075&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,727,020&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Post-employment benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,444&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long-term benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,616&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Termination benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Share-based payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;802,128&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;520,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;764,175&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,343,398&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,113,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,540,854&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</athe:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c0" decimals="0" id="ixv-24323" unitRef="aud">1522550</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c4" decimals="0" id="ixv-24324" unitRef="aud">1551075</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c5" decimals="0" id="ixv-24325" unitRef="aud">1727020</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c0" decimals="0" id="ixv-24326" unitRef="aud">18720</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c4" decimals="0" id="ixv-24327" unitRef="aud">38486</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c5" decimals="0" id="ixv-24328" unitRef="aud">42444</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <athe:KeyManagementPersonnelCompensationLongtermBenefits contextRef="c4" decimals="0" id="ixv-24329" unitRef="aud">-6616</athe:KeyManagementPersonnelCompensationLongtermBenefits>
    <athe:KeyManagementPersonnelCompensationLongtermBenefits contextRef="c5" decimals="0" id="ixv-24330" unitRef="aud">7215</athe:KeyManagementPersonnelCompensationLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="c4" decimals="0" id="ixv-24331" unitRef="aud">10215</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c0" decimals="0" id="ixv-24332" unitRef="aud">802128</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c4" decimals="0" id="ixv-24333" unitRef="aud">520055</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c5" decimals="0" id="ixv-24334" unitRef="aud">764175</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c0" decimals="0" id="ixv-24335" unitRef="aud">2343398</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c4" decimals="0" id="ixv-24336" unitRef="aud">2113215</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c5" decimals="0" id="ixv-24337" unitRef="aud">2540854</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfAuditorsRemunerationExplanatory contextRef="c0" id="ixv-20534">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;20. AUDITORS&#x2019; REMUNERATION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;- Audit and review of financial statements (1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;248,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;248,200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;246,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;- Other audit services (2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;72,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;95,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;320,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;343,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;298,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Audit and review of financial statements consist of fees billed for assurance and related services that generally only the statutory auditor could reasonably provide to a client. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Included in the balance are amounts related to additional regulatory filings during the 2025 financial year. All services provided are considered audit services for the purpose of SEC classification. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;PricewaterhouseCoopers was appointed as the Group&#x2019;s principal
independent registered public accounting firm on November 30, 2006. Australian law does not require the Group&#x2019;s Auditors to be appointed
at the Group&#x2019;s annual general meeting of shareholders. There is an annual engagement letter which is signed, subject to the Group&#x2019;s
audit committee approval, with PricewaterhouseCoopers for audit and review work. No non-audit services were provided by PricewaterhouseCoopers
during the 2025, 2024 and 2023 financial years.&lt;/p&gt;</ifrs-full:DisclosureOfAuditorsRemunerationExplanatory>
    <athe:ScheduleOfAuditorRemunerationTableTextBlock contextRef="c0" id="ixv-20538">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;- Audit and review of financial statements (1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;248,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;248,200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;246,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;- Other audit services (2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;72,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;95,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;320,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;343,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;298,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Audit and review of financial statements consist of fees billed for assurance and related services that generally only the statutory auditor could reasonably provide to a client. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Included in the balance are amounts related to additional regulatory filings during the 2025 financial year. All services provided are considered audit services for the purpose of SEC classification. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</athe:ScheduleOfAuditorRemunerationTableTextBlock>
    <ifrs-full:AuditorsRemunerationForAuditServices contextRef="c0" decimals="0" id="ix_25_fact" unitRef="aud">248000</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices contextRef="c4" decimals="0" id="ix_26_fact" unitRef="aud">248200</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices contextRef="c5" decimals="0" id="ix_27_fact" unitRef="aud">246400</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForOtherServices contextRef="c0" decimals="0" id="ix_28_fact" unitRef="aud">72000</ifrs-full:AuditorsRemunerationForOtherServices>
    <ifrs-full:AuditorsRemunerationForOtherServices contextRef="c4" decimals="0" id="ix_29_fact" unitRef="aud">95500</ifrs-full:AuditorsRemunerationForOtherServices>
    <ifrs-full:AuditorsRemunerationForOtherServices contextRef="c5" decimals="0" id="ix_30_fact" unitRef="aud">52000</ifrs-full:AuditorsRemunerationForOtherServices>
    <ifrs-full:AuditorsRemuneration contextRef="c0" decimals="0" id="ixv-24344" unitRef="aud">320000</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration contextRef="c4" decimals="0" id="ixv-24345" unitRef="aud">343700</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration contextRef="c5" decimals="0" id="ixv-24346" unitRef="aud">298400</ifrs-full:AuditorsRemuneration>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="c0" id="ixv-20664">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;21. RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Equity Interests in Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Alterity Therapeutics Limited owns 100% of its subsidiaries, Alterity
Therapeutics Inc. and Alterity Therapeutics UK Ltd.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Key Management Personnel Remuneration&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Directors of Alterity during the year:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Mr. Geoffrey Kempler, Chairman&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Mr. Brian Meltzer, Independent Non-Executive Director&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Mr. Peter Marks, Independent Non-Executive Director&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Mr. Lawrence Gozlan, Non-Executive Director&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Key Management Personnel of the Group during the year:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 30%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr. David Stamler&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 70%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chief Executive Officer &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Remuneration of all key management personnel of the Group is determined
by the Board of Directors following recommendation by the Remuneration Committee.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group is committed to remunerating senior executives in a manner
that is market competitive and consistent with &#x2018;best practice&#x2019; including the interests of shareholders. Remuneration packages
are based on fixed and variable components, determined by the executive&#x2019;s position, experience and performance, and may be satisfied
via cash or equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Please refer to Note 19 for Key Management Personnel Remuneration detail.&lt;/p&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c0" decimals="2" id="ixv-24349" unitRef="pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c0" id="ixv-20737">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;22. SEGMENT INFORMATION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group&#x2019;s Chief Executive Officer (Chief Operating Decision
Maker) examines internal reports to assess the Group&#x2019;s performance and determine the allocation of resources. The Group has identified
one reportable segment as a whole and this covers research into Parkinsonian movement disorders, Alzheimer&#x2019;s disease, Huntington
disease, and other neurodegenerative disorders.&lt;/p&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <athe:NumberOfReportableSegment contextRef="c0" decimals="0" id="ixv-24350" unitRef="pure">1</athe:NumberOfReportableSegment>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="c0" id="ixv-20746">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;23. FINANCIAL INSTRUMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group&#x2019;s activities expose it to a variety of financial risks
including market risk, credit risk and liquidity risk. The Group&#x2019;s overall risk management program focuses on the unpredictability
of financial markets and seeks to minimize potential adverse effects on the financial performance of the Group. Risk management is carried
out under policies approved by the Board of Directors and overseen by the Audit Committee.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Market Risk&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;(i)&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign Currency Risk&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group engages in international purchase transactions and is exposed
to foreign currency risk arising from various currency exposures, primarily with respect to the Australian dollar. The parent entity also
has exposure to foreign exchange risk in the currency cash reserves it holds to meet its foreign currency payments. The Group does not
make use of derivative financial instruments to hedge foreign exchange risk.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following financial assets and liabilities are subject to foreign
currency risk, the currency of the original amounts are displayed in brackets, all the amounts in the table below are displayed in A$
at year-end spot rates:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Consolidated Entity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash and cash equivalents (USD)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,544,448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;225,722&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Trade and other payables (USD)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(495,145&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(507,820&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade and other payables (&#xa3;GBP)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;796&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,834&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Trade and other payables (JPY)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,992&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total exposure&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,050,099&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(288,924&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As shown in the table above, the Group is primarily exposed to changes
in USD/AUD exchange rates. The sensitivity of profit or loss to changes in the exchange rates arises mainly from US-dollar denominated
financial instruments and there is no impact on other components of equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;Based on the financial instruments held as of June 30, 2025, had the
Australian dollar weakened/strengthened by 1.77%&lt;br/&gt; (2024: 0.35%, 2023: 3.6%) against the USD with all other variables held constant, the
Group&#x2019;s post-tax loss for the year would have been A$18,933 higher/lower (2024: A$1,000 higher/lower).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;(ii)&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest Rate Risk&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Interest rate risk is the risk to the Group&#x2019;s earnings and equity
arising from movements in interest rates. The Group&#x2019;s main interest rate risk arises from cash deposits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group&#x2019;s exposure to interest rate risk has not changed since
the prior year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At June 30, 2025, the Group had the following cash accounts:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A$2,423,027 in an Australian dollar transaction account at an interest rate of 0.00% as of June 30, 2025;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A$40,142 in an Australian dollar transaction account at an interest rate of 0.00% as of June 30, 2025;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A$8,027,852 in an Australian dollar cash maximiser account at an interest rate of 3.6%&#160;as of June 30, 2025;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A$500,266 in an Australian dollar transaction account at an interest rate of 1.05% as of June 30, 2025;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;A$28,125,744 in six Australian dollar term deposit accounts with interest rates within a range of 1.5% to 4.82%&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;as of June 30, 2025;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S.$160,769 (A$246,146) in a U.S. checking account at an interest rate of 0.00% as of June 30, 2025;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S.$29,069 (A$44,381) in U.S. Airwallex accounts at an interest rate of 0.00% as of June 30, 2025;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S.$821,384 (A$1,254,022) in a U.S. checking account at an interest rate of 0.00% as of June 30, 2025;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;(A$2,835) in a Visa Credit card account at an interest rate of 0.00% as of June 30, 2025.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At June 30, 2024, the Group had the following cash accounts:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A$11,529,456 in an Australian dollar cash maximiser account at an interest rate of 2.7%&#160;as of June 30, 2024;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A$705,952 in an Australian dollar transaction account at an interest rate of 0.00% as of June 30, 2024;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A$182,048 in an Australian dollar transaction account at an interest rate of 0.00% as of June 30, 2024;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S.$138,388 (A$207,581) in U.S. checking accounts at an interest rate of 0.00% as of June 30, 2024;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S.$12,094 (A$18,141) in U.S. Airwallex accounts at an interest rate of 0.00% as of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(A$4,293) in a Visa Credit card account at an interest rate of 0.00% as of June 30, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At June 30, 2023, the Group had the following cash accounts:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A$27,457 in an Australian dollar cash maximiser account at an interest rate of 1.44%&#160;as of June 30, 2023;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A$61,518 in an Australian dollar transaction account at an interest rate of 0.00% as of June 30, 2023;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A$18,864 in an Australian dollar transaction account at an interest rate of 0.00% as of June 30, 2023;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S.$10,279,099 (A$15,473,231) in U.S. checking accounts at an interest rate of 0.00% as of June 30, 2023;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A$42,713 in a 90 days term deposit at a fixed interest rate of 3.85% which matures on August 28, 2023;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A$150,000 in a 90 days term deposit at a fixed interest rate of 3.85% which matures on September 2, 2023;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The weighted average interest rate is 3.36% for cash and cash equivalents
and 4.75% for other current assets and apart from usual variances in general rates of interest the Group is not exposed to any significant
interest rate risk.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Receivables and payables are non-interest bearing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group&#x2019;s exposure to interest rates and the effective weighted
average interest rate for classes of financial assets and liabilities is set out below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Floating &lt;br/&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fixed Interest &lt;br/&gt; Maturing in&lt;br/&gt; (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Non-Interest&lt;br/&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Average&lt;br/&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;June 30, 2025&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Interest&#160;Rate &lt;br/&gt; (A$)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;1 year&lt;br/&gt; or less&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;1-5 years&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;bearing&lt;br/&gt; (A$)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Total&lt;br/&gt; (A$)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Interest Rate&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Financial Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;30,698,409&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,835&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,463,168&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33,158,642&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.130&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Trade and other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,937,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,937,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,531,050&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,765&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,541,815&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;4.40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Financial Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30,698,409&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,528,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,411,540&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;44,638,064&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financial Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,575,490&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,575,490&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(66,912&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(88,545&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(155,457&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Financial Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(66,912&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(88,545&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,575,490&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,730,947&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Floating &lt;br/&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fixed Interest &lt;br/&gt; Maturing in&lt;br/&gt; (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Non-Interest&lt;br/&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Average&lt;br/&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;June 30, 2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Interest&#160;Rate &lt;br/&gt; (A$)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;1 year&lt;br/&gt; or less&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;1-5 years&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;bearing&lt;br/&gt; (A$)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Total&lt;br/&gt; (A$)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Interest Rate&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Financial Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,529,456&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,293&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,113,722&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12,638,885&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.463&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Trade and other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,041,675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,041,675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30,091&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,577&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40,668&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;3.515&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Financial Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,529,456&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,798&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,165,974&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,721,228&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financial Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,619,947&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,619,947&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(107,131&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(51,914&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(159,045&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(100,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(100,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Financial Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(107,131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(51,914&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,719,947&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,878,992&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Credit Risk&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Credit risk refers to the risk that a counterparty will default on
its contractual obligations resulting in financial loss to the Group. The Group has no significant concentration of credit risk and it
is not the Group&#x2019;s policy to hedge credit risk.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group ensures that surplus cash is invested with financial institutions
of appropriate credit worthiness and limits the amount of credit exposure to any one counter party.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;There has been no significant change in the Group&#x2019;s exposure
to credit risk since the previous year. The carrying amount of the Group&#x2019;s financial assets represents the maximum credit exposure.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(c)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liquidity Risk&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Prudent liquidity risk management implies maintaining sufficient cash
and the availability of funding through an adequate amount of committed credit facilities. The Group manages liquidity risk by maintaining
sufficient bank balances to fund its operations and the availability of funding through committed credit facilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Management monitors rolling forecasts of the Group&#x2019;s liquidity
reserve on the basis of expected cash flows. See Note 1 (Going Concern Basis) of our accompanying financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Maturities of Financial Liabilities&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Less than &lt;br/&gt; 6 months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;6-12 months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Greater than &lt;br/&gt;
12 months &lt;br/&gt;
and less than
    &lt;br/&gt;
5 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;br/&gt; contracted&lt;br/&gt; cash flows&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Carrying&lt;br/&gt; amounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,575,490&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,575,490&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,575,490&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(33,456&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(33,456&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(88,545&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(155,457&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(155,457&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,608,946&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(33,456&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(88,545&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,730,947&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,730,947&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Less than&lt;br/&gt; 6 months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;6-12 months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Greater than&lt;br/&gt;
 12 months &lt;br/&gt;
and less than&lt;br/&gt;

    5 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;br/&gt; contracted&lt;br/&gt; cash flows&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Carrying&lt;br/&gt; amounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,619,947&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,619,947&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,619,947&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(53,566&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(53,565&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(51,914&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(159,045&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(159,045&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,673,513&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(53,565&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(51,914&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,778,992&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,778,992&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(d)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Capital Risk Management&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group&#x2019;s objectives when managing capital are to safeguard
the Group&#x2019;s ability to continue as a going concern and to maintain an optimal capital structure so as to maximize shareholder value.
In order to maintain or achieve an optimal capital structure, the Group may issue new shares or reduce its capital, subject to the provisions
of the Group&#x2019;s constitution. The capital structure of the Group consists of equity attributed to equity holders of the Group, comprising
contributed equity, reserves and accumulated losses disclosed in Notes 10, 11 and 12. By monitoring undiscounted cash flow forecasts and
actual cash flows provided to the Board by the Group&#x2019;s Management, the Board monitors the need to raise additional equity from the
equity markets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(e)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair Value Estimation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The carrying amount of financial assets and financial liabilities recorded
in the financial statements represents their respective fair values, determined in accordance with the accounting policies disclosed in
Note 1 to the financial statements.&lt;/p&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory contextRef="c0" id="ixv-20770">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following financial assets and liabilities are subject to foreign
currency risk, the currency of the original amounts are displayed in brackets, all the amounts in the table below are displayed in A$
at year-end spot rates:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Consolidated Entity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;A$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash and cash equivalents (USD)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,544,448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;225,722&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Trade and other payables (USD)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(495,145&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(507,820&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade and other payables (&#xa3;GBP)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;796&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,834&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Trade and other payables (JPY)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,992&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total exposure&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,050,099&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(288,924&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingExplanatory>
    <athe:FinancialInstrumentsTotalExposure contextRef="c244" decimals="0" id="ixv-24351" unitRef="aud">1544448</athe:FinancialInstrumentsTotalExposure>
    <athe:FinancialInstrumentsTotalExposure contextRef="c245" decimals="0" id="ixv-24352" unitRef="aud">225722</athe:FinancialInstrumentsTotalExposure>
    <athe:FinancialInstrumentsTotalExposure contextRef="c246" decimals="0" id="ixv-24353" unitRef="aud">-495145</athe:FinancialInstrumentsTotalExposure>
    <athe:FinancialInstrumentsTotalExposure contextRef="c247" decimals="0" id="ixv-24354" unitRef="aud">-507820</athe:FinancialInstrumentsTotalExposure>
    <athe:FinancialInstrumentsTotalExposure contextRef="c248" decimals="0" id="ixv-24355" unitRef="aud">796</athe:FinancialInstrumentsTotalExposure>
    <athe:FinancialInstrumentsTotalExposure contextRef="c249" decimals="0" id="ixv-24356" unitRef="aud">-3834</athe:FinancialInstrumentsTotalExposure>
    <athe:FinancialInstrumentsTotalExposure contextRef="c251" decimals="0" id="ixv-24357" unitRef="aud">-2992</athe:FinancialInstrumentsTotalExposure>
    <athe:FinancialInstrumentsTotalExposure contextRef="c2" decimals="0" id="ixv-24358" unitRef="aud">1050099</athe:FinancialInstrumentsTotalExposure>
    <athe:FinancialInstrumentsTotalExposure contextRef="c3" decimals="0" id="ixv-24359" unitRef="aud">-288924</athe:FinancialInstrumentsTotalExposure>
    <athe:AverageAnnualMovementForeignExchangeRate contextRef="c0" decimals="4" id="ixv-24360" unitRef="pure">0.0177</athe:AverageAnnualMovementForeignExchangeRate>
    <athe:AverageAnnualMovementForeignExchangeRate
      contextRef="c198"
      decimals="4"
      id="ixv-24361"
      unitRef="pure">0.0035</athe:AverageAnnualMovementForeignExchangeRate>
    <athe:AverageAnnualMovementForeignExchangeRate
      contextRef="c199"
      decimals="3"
      id="ixv-24362"
      unitRef="pure">0.036</athe:AverageAnnualMovementForeignExchangeRate>
    <athe:SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar contextRef="c2" decimals="0" id="ixv-24363" unitRef="aud">18933</athe:SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar>
    <athe:SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar contextRef="c3" decimals="0" id="ixv-24364" unitRef="aud">1000</athe:SensitivityAnalysisOfPostTaxProfitImpactOfPercentChangeInAustralianDollarAgainstUsDollar>
    <ifrs-full:Cash contextRef="c200" decimals="0" id="ixv-24365" unitRef="aud">2423027</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c201"
      decimals="4"
      id="ixv-24366"
      unitRef="pure">0</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c202" decimals="0" id="ixv-24367" unitRef="aud">40142</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c203"
      decimals="4"
      id="ixv-24368"
      unitRef="pure">0</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c204" decimals="0" id="ixv-24369" unitRef="aud">8027852</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c205"
      decimals="3"
      id="ixv-24370"
      unitRef="pure">0.036</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c206" decimals="0" id="ixv-24371" unitRef="aud">500266</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c207"
      decimals="4"
      id="ixv-24372"
      unitRef="pure">0.0105</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c208" decimals="0" id="ixv-24373" unitRef="aud">28125744</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c209"
      decimals="3"
      id="ixv-24374"
      unitRef="pure">0.015</athe:PercentageOfInterestRate>
    <athe:PercentageOfInterestRate
      contextRef="c210"
      decimals="4"
      id="ixv-24375"
      unitRef="pure">0.0482</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c211" decimals="0" id="ixv-24376" unitRef="usd">160769</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c211" decimals="0" id="ixv-24377" unitRef="aud">246146</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c212"
      decimals="4"
      id="ixv-24378"
      unitRef="pure">0</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c213" decimals="0" id="ixv-24379" unitRef="usd">29069</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c213" decimals="0" id="ixv-24380" unitRef="aud">44381</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c214"
      decimals="4"
      id="ixv-24381"
      unitRef="pure">0</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c215" decimals="0" id="ixv-24382" unitRef="usd">821384</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c215" decimals="0" id="ixv-24383" unitRef="aud">1254022</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c216"
      decimals="4"
      id="ixv-24384"
      unitRef="pure">0</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c217" decimals="0" id="ixv-24385" unitRef="usd">2835</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c218"
      decimals="4"
      id="ixv-24386"
      unitRef="pure">0</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c219" decimals="0" id="ixv-24387" unitRef="aud">11529456</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c220"
      decimals="3"
      id="ixv-24388"
      unitRef="pure">0.027</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c221" decimals="0" id="ixv-24389" unitRef="aud">705952</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c222"
      decimals="4"
      id="ixv-24390"
      unitRef="pure">0</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c223" decimals="0" id="ixv-24391" unitRef="aud">182048</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c224"
      decimals="4"
      id="ixv-24392"
      unitRef="pure">0</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c225" decimals="0" id="ixv-24393" unitRef="usd">138388</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c225" decimals="0" id="ixv-24394" unitRef="aud">207581</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c226"
      decimals="4"
      id="ixv-24395"
      unitRef="pure">0</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c227" decimals="0" id="ixv-24396" unitRef="usd">12094</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c227" decimals="0" id="ixv-24397" unitRef="aud">18141</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c228"
      decimals="4"
      id="ixv-24398"
      unitRef="pure">0</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c229" decimals="0" id="ixv-24399" unitRef="aud">4293</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c230"
      decimals="4"
      id="ixv-24400"
      unitRef="pure">0</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c231" decimals="0" id="ixv-24401" unitRef="aud">27457</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c232"
      decimals="4"
      id="ixv-24402"
      unitRef="pure">0.0144</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c233" decimals="0" id="ixv-24403" unitRef="aud">61518</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c234"
      decimals="4"
      id="ixv-24404"
      unitRef="pure">0</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c235" decimals="0" id="ixv-24405" unitRef="aud">18864</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c236"
      decimals="4"
      id="ixv-24406"
      unitRef="pure">0</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c237" decimals="0" id="ixv-24407" unitRef="usd">10279099</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c237" decimals="0" id="ixv-24408" unitRef="aud">15473231</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c238"
      decimals="4"
      id="ixv-24409"
      unitRef="pure">0</athe:PercentageOfInterestRate>
    <ifrs-full:Cash contextRef="c239" decimals="0" id="ixv-24410" unitRef="aud">42713</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c240"
      decimals="4"
      id="ixv-24411"
      unitRef="pure">0.0385</athe:PercentageOfInterestRate>
    <athe:MaturityDate contextRef="c240" id="ixv-24412">2023-08-28</athe:MaturityDate>
    <ifrs-full:Cash contextRef="c241" decimals="0" id="ixv-24413" unitRef="aud">150000</ifrs-full:Cash>
    <athe:PercentageOfInterestRate
      contextRef="c242"
      decimals="4"
      id="ixv-24414"
      unitRef="pure">0.0385</athe:PercentageOfInterestRate>
    <athe:MaturityDate contextRef="c242" id="ixv-24415">2023-09-02</athe:MaturityDate>
    <athe:PercentageOfInterestRate
      contextRef="c243"
      decimals="4"
      id="ixv-24416"
      unitRef="pure">0.0336</athe:PercentageOfInterestRate>
    <athe:PercentageOfInterestRate contextRef="c0" decimals="4" id="ixv-24417" unitRef="pure">0.0475</athe:PercentageOfInterestRate>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="c0" id="ixv-21162">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Group&#x2019;s exposure to interest rates and the effective weighted
average interest rate for classes of financial assets and liabilities is set out below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Floating &lt;br/&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fixed Interest &lt;br/&gt; Maturing in&lt;br/&gt; (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Non-Interest&lt;br/&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Average&lt;br/&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;June 30, 2025&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Interest&#160;Rate &lt;br/&gt; (A$)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;1 year&lt;br/&gt; or less&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;1-5 years&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;bearing&lt;br/&gt; (A$)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Total&lt;br/&gt; (A$)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Interest Rate&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Financial Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;30,698,409&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,835&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,463,168&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33,158,642&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.130&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Trade and other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,937,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,937,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,531,050&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,765&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,541,815&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;4.40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Financial Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30,698,409&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,528,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,411,540&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;44,638,064&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financial Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,575,490&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,575,490&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(66,912&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(88,545&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(155,457&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Financial Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(66,912&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(88,545&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,575,490&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,730,947&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Floating &lt;br/&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fixed Interest &lt;br/&gt; Maturing in&lt;br/&gt; (A$)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Non-Interest&lt;br/&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Average&lt;br/&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;June 30, 2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Interest&#160;Rate &lt;br/&gt; (A$)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;1 year&lt;br/&gt; or less&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;1-5 years&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;bearing&lt;br/&gt; (A$)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Total&lt;br/&gt; (A$)&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Interest Rate&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Financial Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,529,456&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,293&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,113,722&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12,638,885&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.463&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Trade and other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,041,675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,041,675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;30,091&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,577&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40,668&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;3.515&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Financial Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,529,456&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,798&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,165,974&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,721,228&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financial Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,619,947&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,619,947&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(107,131&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(51,914&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(159,045&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(100,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(100,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Financial Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(107,131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(51,914&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,719,947&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,878,992&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <ifrs-full:FinancialAssets contextRef="c252" decimals="0" id="ixv-24418" unitRef="aud">30698409</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c253" decimals="0" id="ixv-24419" unitRef="aud">-2835</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c255" decimals="0" id="ixv-24420" unitRef="aud">2463168</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c256" decimals="0" id="ixv-24421" unitRef="aud">33158642</ifrs-full:FinancialAssets>
    <athe:AverageInterestRate
      contextRef="c257"
      decimals="5"
      id="ixv-24422"
      unitRef="pure">0.0313</athe:AverageInterestRate>
    <ifrs-full:FinancialAssets contextRef="c261" decimals="0" id="ixv-24423" unitRef="aud">3937607</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c262" decimals="0" id="ixv-24424" unitRef="aud">3937607</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c264" decimals="0" id="ixv-24425" unitRef="aud">7531050</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c266" decimals="0" id="ixv-24426" unitRef="aud">10765</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c267" decimals="0" id="ixv-24427" unitRef="aud">7541815</ifrs-full:FinancialAssets>
    <athe:AverageInterestRate
      contextRef="c268"
      decimals="4"
      id="ixv-24428"
      unitRef="pure">0.044</athe:AverageInterestRate>
    <ifrs-full:FinancialAssets contextRef="c269" decimals="0" id="ixv-24429" unitRef="aud">30698409</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c270" decimals="0" id="ixv-24430" unitRef="aud">7528215</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c272" decimals="0" id="ixv-24431" unitRef="aud">6411540</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c2" decimals="0" id="ixv-24432" unitRef="aud">44638064</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities contextRef="c276" decimals="0" id="ixv-24433" unitRef="aud">-2575490</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c277" decimals="0" id="ixv-24434" unitRef="aud">-2575490</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c279" decimals="0" id="ixv-24435" unitRef="aud">-66912</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c280" decimals="0" id="ixv-24436" unitRef="aud">-88545</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c282" decimals="0" id="ixv-24437" unitRef="aud">-155457</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c270" decimals="0" id="ixv-24438" unitRef="aud">-66912</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c271" decimals="0" id="ixv-24439" unitRef="aud">-88545</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c272" decimals="0" id="ixv-24440" unitRef="aud">-2575490</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c2" decimals="0" id="ixv-24441" unitRef="aud">-2730947</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialAssets contextRef="c283" decimals="0" id="ixv-24442" unitRef="aud">11529456</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c284" decimals="0" id="ixv-24443" unitRef="aud">-4293</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c286" decimals="0" id="ixv-24444" unitRef="aud">1113722</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c287" decimals="0" id="ixv-24445" unitRef="aud">12638885</ifrs-full:FinancialAssets>
    <athe:AverageInterestRate
      contextRef="c288"
      decimals="5"
      id="ixv-24446"
      unitRef="pure">0.02463</athe:AverageInterestRate>
    <ifrs-full:FinancialAssets contextRef="c292" decimals="0" id="ixv-24447" unitRef="aud">4041675</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c293" decimals="0" id="ixv-24448" unitRef="aud">4041675</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c295" decimals="0" id="ixv-24449" unitRef="aud">30091</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c297" decimals="0" id="ixv-24450" unitRef="aud">10577</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c298" decimals="0" id="ixv-24451" unitRef="aud">40668</ifrs-full:FinancialAssets>
    <athe:AverageInterestRate
      contextRef="c299"
      decimals="5"
      id="ixv-24452"
      unitRef="pure">0.03515</athe:AverageInterestRate>
    <ifrs-full:FinancialAssets contextRef="c300" decimals="0" id="ixv-24453" unitRef="aud">11529456</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c301" decimals="0" id="ixv-24454" unitRef="aud">25798</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c303" decimals="0" id="ixv-24455" unitRef="aud">5165974</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c3" decimals="0" id="ixv-24456" unitRef="aud">16721228</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities contextRef="c307" decimals="0" id="ixv-24457" unitRef="aud">-4619947</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c308" decimals="0" id="ixv-24458" unitRef="aud">-4619947</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c310" decimals="0" id="ixv-24459" unitRef="aud">-107131</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c311" decimals="0" id="ixv-24460" unitRef="aud">-51914</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c313" decimals="0" id="ixv-24461" unitRef="aud">-159045</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c317" decimals="0" id="ixv-24462" unitRef="aud">-100000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c318" decimals="0" id="ixv-24463" unitRef="aud">-100000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c301" decimals="0" id="ixv-24464" unitRef="aud">-107131</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c302" decimals="0" id="ixv-24465" unitRef="aud">-51914</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c303" decimals="0" id="ixv-24466" unitRef="aud">-4719947</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c3" decimals="0" id="ixv-24467" unitRef="aud">-4878992</ifrs-full:FinancialLiabilities>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="c0" id="ixv-22035">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Management monitors rolling forecasts of the Group&#x2019;s liquidity
reserve on the basis of expected cash flows. See Note 1 (Going Concern Basis) of our accompanying financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Maturities of Financial Liabilities&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Less than &lt;br/&gt; 6 months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;6-12 months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Greater than &lt;br/&gt;
12 months &lt;br/&gt;
and less than
    &lt;br/&gt;
5 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;br/&gt; contracted&lt;br/&gt; cash flows&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Carrying&lt;br/&gt; amounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,575,490&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,575,490&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,575,490&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(33,456&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(33,456&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(88,545&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(155,457&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(155,457&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,608,946&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(33,456&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(88,545&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,730,947&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,730,947&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Less than&lt;br/&gt; 6 months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;6-12 months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Greater than&lt;br/&gt;
 12 months &lt;br/&gt;
and less than&lt;br/&gt;

    5 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;br/&gt; contracted&lt;br/&gt; cash flows&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Carrying&lt;br/&gt; amounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,619,947&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,619,947&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,619,947&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(53,566&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(53,565&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(51,914&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(159,045&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(159,045&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,673,513&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(53,565&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(51,914&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,778,992&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,778,992&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <ifrs-full:TradeAndOtherPayables contextRef="c319" decimals="0" id="ixv-24468" unitRef="aud">2575490</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c322" decimals="0" id="ixv-24469" unitRef="aud">2575490</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c323" decimals="0" id="ixv-24470" unitRef="aud">2575490</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c324" decimals="0" id="ixv-24471" unitRef="aud">33456</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c325" decimals="0" id="ixv-24472" unitRef="aud">33456</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c326" decimals="0" id="ixv-24473" unitRef="aud">88545</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c327" decimals="0" id="ixv-24474" unitRef="aud">155457</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c328" decimals="0" id="ixv-24475" unitRef="aud">155457</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c329" decimals="0" id="ixv-24476" unitRef="aud">2608946</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c330" decimals="0" id="ixv-24477" unitRef="aud">33456</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c331" decimals="0" id="ixv-24478" unitRef="aud">88545</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c332" decimals="0" id="ixv-24479" unitRef="aud">2730947</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c333" decimals="0" id="ixv-24480" unitRef="aud">2730947</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c334" decimals="0" id="ixv-24481" unitRef="aud">4619947</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c337" decimals="0" id="ixv-24482" unitRef="aud">4619947</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c338" decimals="0" id="ixv-24483" unitRef="aud">4619947</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c339" decimals="0" id="ixv-24484" unitRef="aud">53566</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c340" decimals="0" id="ixv-24485" unitRef="aud">53565</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c341" decimals="0" id="ixv-24486" unitRef="aud">51914</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c342" decimals="0" id="ixv-24487" unitRef="aud">159045</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c343" decimals="0" id="ixv-24488" unitRef="aud">159045</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c344" decimals="0" id="ixv-24489" unitRef="aud">4673513</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c345" decimals="0" id="ixv-24490" unitRef="aud">53565</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c346" decimals="0" id="ixv-24491" unitRef="aud">51914</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c347" decimals="0" id="ixv-24492" unitRef="aud">4778992</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c348" decimals="0" id="ixv-24493" unitRef="aud">4778992</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:DisclosureOfInterimFinancialReportingExplanatory contextRef="c0" id="ixv-22322">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;24. PARENT ENTITY FINANCIAL INFORMATION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The individual financial statements for the parent entity show the
following aggregate amounts:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Statement of financial position&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Current assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;44,678,130&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;19,018,719&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Non-current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68,329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;147,018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;44,746,459&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,165,737&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,514,494&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,101,935&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Non-current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,421&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,151,157&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,515,915&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,253,092&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Shareholders&#x2019; equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Contributed equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;262,948,046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;223,151,570&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Reserves&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,342,304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,806,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accumulated losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(227,059,806&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(215,045,128&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41,230,544&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,912,645&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Statement of profit or loss and other comprehensive loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,448,395&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,355,765&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total comprehensive loss for the year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(12,448,395&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(19,355,765&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInterimFinancialReportingExplanatory>
    <athe:DisclosureOfParentEntityFinancialStatementsExplanatory contextRef="c0" id="ixv-22326">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The individual financial statements for the parent entity show the
following aggregate amounts:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Statement of financial position&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Current assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;44,678,130&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;19,018,719&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Non-current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68,329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;147,018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;44,746,459&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,165,737&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,514,494&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,101,935&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Non-current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,421&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,151,157&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,515,915&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,253,092&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Shareholders&#x2019; equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Contributed equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;262,948,046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;223,151,570&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Reserves&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,342,304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,806,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accumulated losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(227,059,806&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(215,045,128&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41,230,544&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,912,645&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Statement of profit or loss and other comprehensive loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,448,395&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,355,765&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total comprehensive loss for the year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(12,448,395&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(19,355,765&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</athe:DisclosureOfParentEntityFinancialStatementsExplanatory>
    <ifrs-full:CurrentAssets contextRef="c349" decimals="0" id="ixv-24494" unitRef="usd">44678130</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c350" decimals="0" id="ixv-24495" unitRef="usd">19018719</ifrs-full:CurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c349" decimals="0" id="ixv-24496" unitRef="usd">68329</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c350" decimals="0" id="ixv-24497" unitRef="usd">147018</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c349" decimals="0" id="ixv-24498" unitRef="usd">44746459</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c350" decimals="0" id="ixv-24499" unitRef="usd">19165737</ifrs-full:Assets>
    <ifrs-full:CurrentLiabilities contextRef="c349" decimals="0" id="ixv-24500" unitRef="usd">-3514494</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c350" decimals="0" id="ixv-24501" unitRef="usd">-5101935</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c349" decimals="0" id="ixv-24502" unitRef="usd">-1421</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c350" decimals="0" id="ixv-24503" unitRef="usd">-1151157</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities contextRef="c349" decimals="0" id="ixv-24504" unitRef="usd">-3515915</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c350" decimals="0" id="ixv-24505" unitRef="usd">-6253092</ifrs-full:Liabilities>
    <ifrs-full:IssuedCapital contextRef="c349" decimals="0" id="ixv-24506" unitRef="usd">262948046</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c350" decimals="0" id="ixv-24507" unitRef="usd">223151570</ifrs-full:IssuedCapital>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c349" decimals="0" id="ixv-24508" unitRef="usd">5342304</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c350" decimals="0" id="ixv-24509" unitRef="usd">4806203</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:RetainedEarnings contextRef="c349" decimals="0" id="ixv-24510" unitRef="usd">-227059806</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c350" decimals="0" id="ixv-24511" unitRef="usd">-215045128</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity contextRef="c349" decimals="0" id="ixv-24512" unitRef="usd">41230544</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c350" decimals="0" id="ixv-24513" unitRef="usd">12912645</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c351" decimals="0" id="ixv-24514" unitRef="usd">-12448395</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c352" decimals="0" id="ixv-24515" unitRef="usd">-19355765</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c351" decimals="0" id="ixv-24516" unitRef="usd">-12448395</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c352" decimals="0" id="ixv-24517" unitRef="usd">-19355765</ifrs-full:ComprehensiveIncome>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c3"
      decimals="0"
      id="hidden-fact-0"
      unitRef="shares">5245115318</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c2"
      decimals="0"
      id="hidden-fact-1"
      unitRef="shares">9127370686</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <athe:ForfeitedOptionsFromReserves
      contextRef="c0"
      id="hidden-fact-2"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:ForfeitedOptionsFromReserves
      contextRef="c4"
      id="hidden-fact-3"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c0"
      id="hidden-fact-4"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c4"
      id="hidden-fact-5"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="c5"
      id="hidden-fact-6"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:ProceedsFromResearchAndDevelopmentTaxRefund
      contextRef="c5"
      id="hidden-fact-7"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="c0"
      id="hidden-fact-8"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:PaymentsForRentalSecurityDeposits
      contextRef="c0"
      id="hidden-fact-9"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:PaymentsForRentalSecurityDeposits
      contextRef="c4"
      id="hidden-fact-10"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="c0"
      id="hidden-fact-11"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="c4"
      id="hidden-fact-12"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="c5"
      id="hidden-fact-13"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IssuanceOfSharesNetOfCostsValue
      contextRef="c12"
      id="hidden-fact-14"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IssuanceOfSharesNetOfCostsValue
      contextRef="c13"
      id="hidden-fact-15"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees
      contextRef="c11"
      id="hidden-fact-16"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees
      contextRef="c13"
      id="hidden-fact-17"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughIssuanceOfOptionsToConsultants
      contextRef="c11"
      id="hidden-fact-18"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughIssuanceOfOptionsToConsultants
      contextRef="c12"
      id="hidden-fact-19"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughIssuanceOfOptionsToConsultants
      contextRef="c13"
      id="hidden-fact-20"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughIssuanceOfOptionsToConsultants
      contextRef="c5"
      id="hidden-fact-21"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars
      contextRef="c11"
      id="hidden-fact-22"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars
      contextRef="c12"
      id="hidden-fact-23"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars
      contextRef="c13"
      id="hidden-fact-24"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars
      contextRef="c5"
      id="hidden-fact-25"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c12"
      id="hidden-fact-26"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c13"
      id="hidden-fact-27"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement
      contextRef="c11"
      id="hidden-fact-28"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement
      contextRef="c5"
      id="hidden-fact-29"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:ForfeitedOptionsReversedToProfitOrLoss
      contextRef="c11"
      id="hidden-fact-30"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:ForfeitedOptionsReversedToProfitOrLoss
      contextRef="c13"
      id="hidden-fact-31"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c11"
      id="hidden-fact-32"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c12"
      id="hidden-fact-33"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c11"
      id="hidden-fact-34"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c12"
      id="hidden-fact-35"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IssuanceOfSharesNetOfCostsValue
      contextRef="c18"
      id="hidden-fact-36"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IssuanceOfSharesNetOfCostsValue
      contextRef="c19"
      id="hidden-fact-37"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees
      contextRef="c17"
      id="hidden-fact-38"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees
      contextRef="c19"
      id="hidden-fact-39"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c17"
      id="hidden-fact-40"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c19"
      id="hidden-fact-41"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars
      contextRef="c18"
      id="hidden-fact-42"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars
      contextRef="c19"
      id="hidden-fact-43"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c18"
      id="hidden-fact-44"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c19"
      id="hidden-fact-45"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement
      contextRef="c17"
      id="hidden-fact-46"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement
      contextRef="c18"
      id="hidden-fact-47"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement
      contextRef="c19"
      id="hidden-fact-48"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement
      contextRef="c4"
      id="hidden-fact-49"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:ForfeitedOptionsReversedToProfitOrLoss
      contextRef="c17"
      id="hidden-fact-50"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:ForfeitedOptionsReversedToProfitOrLoss
      contextRef="c4"
      id="hidden-fact-51"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c17"
      id="hidden-fact-52"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c18"
      id="hidden-fact-53"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c17"
      id="hidden-fact-54"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c18"
      id="hidden-fact-55"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IssuanceOfSharesNetOfCostsValue
      contextRef="c24"
      id="hidden-fact-56"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IssuanceOfSharesNetOfCostsValue
      contextRef="c25"
      id="hidden-fact-57"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees
      contextRef="c23"
      id="hidden-fact-58"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughIssuanceOfOptionsToEmployees
      contextRef="c25"
      id="hidden-fact-59"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c23"
      id="hidden-fact-60"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c24"
      id="hidden-fact-61"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c25"
      id="hidden-fact-62"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c0"
      id="hidden-fact-63"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars
      contextRef="c25"
      id="hidden-fact-64"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IssuanceOfSharesInConnectionWithExerciseOfOptionsNetOfCostsinDollars
      contextRef="c0"
      id="hidden-fact-65"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c24"
      id="hidden-fact-66"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c25"
      id="hidden-fact-67"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement
      contextRef="c23"
      id="hidden-fact-68"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:IncreaseDecreaseThroughOptionsExpiredInShareBasedPaymentArrangement
      contextRef="c0"
      id="hidden-fact-69"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:ForfeitedOptionsReversedToProfitOrLoss
      contextRef="c23"
      id="hidden-fact-70"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:ForfeitedOptionsReversedToProfitOrLoss
      contextRef="c0"
      id="hidden-fact-71"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c23"
      id="hidden-fact-72"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c24"
      id="hidden-fact-73"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c23"
      id="hidden-fact-74"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c24"
      id="hidden-fact-75"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="c4"
      id="hidden-fact-76"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="c0"
      id="hidden-fact-77"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="c4"
      id="hidden-fact-78"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="c5"
      id="hidden-fact-79"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:CurrentAccruedIncomeIncludingCurrentContractAssets
      contextRef="c2"
      id="hidden-fact-80"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c3"
      id="hidden-fact-81"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentProvisions
      contextRef="c39"
      id="hidden-fact-82"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentProvisions
      contextRef="c40"
      id="hidden-fact-83"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="c50"
      id="hidden-fact-84"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:SharesOfIssuedCapital
      contextRef="c55"
      id="hidden-fact-85"
      unitRef="shares"
      xsi:nil="true"/>
    <athe:SharesOfIssuedCapital
      contextRef="c56"
      id="hidden-fact-86"
      unitRef="shares"
      xsi:nil="true"/>
    <athe:SharesOfIssuedCapital
      contextRef="c57"
      id="hidden-fact-87"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c55"
      id="hidden-fact-88"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c56"
      id="hidden-fact-89"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c70"
      id="hidden-fact-90"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="c78"
      id="hidden-fact-91"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:WarrantReserve
      contextRef="c132"
      id="hidden-fact-92"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:WarrantReserve
      contextRef="c133"
      id="hidden-fact-93"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:WarrantReserve
      contextRef="c134"
      id="hidden-fact-94"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:WarrantReserve
      contextRef="c2"
      id="hidden-fact-95"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:WarrantReserve
      contextRef="c3"
      id="hidden-fact-96"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:WarrantReserve
      contextRef="c6"
      id="hidden-fact-97"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:ReserveOfOptionsIssuedDuringTheYear
      contextRef="c0"
      id="hidden-fact-98"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:ReserveOfOptionsIssuedDuringTheYear
      contextRef="c4"
      id="hidden-fact-99"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:ShareBasedPaymentNumberOfOptionsOptionsIssuedDuringTheYear
      contextRef="c5"
      id="hidden-fact-100"
      unitRef="Options"
      xsi:nil="true"/>
    <athe:ReserveOfOptionsIssuedDuringTheYear
      contextRef="c5"
      id="hidden-fact-101"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:ShareBasedPaymentNumberOfOptionsOptionsExpiredDuringTheYearinDollarsPerShare
      contextRef="c4"
      id="hidden-fact-102"
      unitRef="Options"
      xsi:nil="true"/>
    <athe:ReserveOfShareBasedPaymentsExpiredDuringTheYear
      contextRef="c4"
      id="hidden-fact-103"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:NumberOfOptionsOptionsExercisedDuringTheYear
      contextRef="c4"
      id="hidden-fact-104"
      unitRef="Options"
      xsi:nil="true"/>
    <athe:OptionsExercisedDuringTheYear
      contextRef="c4"
      id="hidden-fact-105"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:NumberOfOptionsOptionsExercisedDuringTheYear
      contextRef="c5"
      id="hidden-fact-106"
      unitRef="Options"
      xsi:nil="true"/>
    <athe:OptionsExercisedDuringTheYear
      contextRef="c5"
      id="hidden-fact-107"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:NumberOfOptionsSharesToBeIssued
      contextRef="c0"
      id="hidden-fact-108"
      unitRef="Options"
      xsi:nil="true"/>
    <athe:SharesToBeIssued
      contextRef="c0"
      id="hidden-fact-109"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:NumberOfOptionsSharesToBeIssued
      contextRef="c4"
      id="hidden-fact-110"
      unitRef="Options"
      xsi:nil="true"/>
    <athe:NumberOfOptionsSharesToBeIssued
      contextRef="c5"
      id="hidden-fact-111"
      unitRef="Options"
      xsi:nil="true"/>
    <athe:SharesToBeIssued
      contextRef="c5"
      id="hidden-fact-112"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:ShareBasedPaymentExpenseForOptionsIssuedI
      contextRef="c0"
      id="hidden-fact-113"
      unitRef="Options"
      xsi:nil="true"/>
    <athe:ShareBasedPaymentExpenseForOptionsIssuedI
      contextRef="c4"
      id="hidden-fact-114"
      unitRef="Options"
      xsi:nil="true"/>
    <athe:ShareBasedPaymentExpenseForOptionsIssuedI
      contextRef="c5"
      id="hidden-fact-115"
      unitRef="Options"
      xsi:nil="true"/>
    <athe:ReclassifyExpiredOptionsFromReservesOne
      contextRef="c4"
      id="hidden-fact-116"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:ReclassifyForfeitedOptionsFromReserves
      contextRef="c5"
      id="hidden-fact-117"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:ExpensesRelatingToShorttermLeases
      contextRef="c0"
      id="hidden-fact-118"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities
      contextRef="c0"
      id="hidden-fact-119"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities
      contextRef="c4"
      id="hidden-fact-120"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities
      contextRef="c5"
      id="hidden-fact-121"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:OtherCashPaymentsFromOperatingActivities
      contextRef="c4"
      id="hidden-fact-122"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:OtherCashPaymentsFromOperatingActivities
      contextRef="c5"
      id="hidden-fact-123"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:FixedAssetWriteOff
      contextRef="c0"
      id="hidden-fact-124"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:FixedAssetWriteOff
      contextRef="c4"
      id="hidden-fact-125"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities
      contextRef="c5"
      id="hidden-fact-126"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c146"
      id="hidden-fact-127"
      unitRef="Options"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c148"
      id="hidden-fact-128"
      unitRef="Options"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c148"
      id="hidden-fact-129"
      unitRef="audPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c147"
      id="hidden-fact-130"
      unitRef="Options"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c147"
      id="hidden-fact-131"
      unitRef="audPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c148"
      id="hidden-fact-132"
      unitRef="Options"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c148"
      id="hidden-fact-133"
      unitRef="audPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="c147"
      id="hidden-fact-134"
      unitRef="Options"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="c147"
      id="hidden-fact-135"
      unitRef="audPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c160"
      id="hidden-fact-136"
      unitRef="Options"
      xsi:nil="true"/>
    <athe:ExercisePriceOfOutstandingShareOption1
      contextRef="c149"
      id="hidden-fact-137"
      unitRef="audPershares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c189"
      id="hidden-fact-138"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c190"
      id="hidden-fact-139"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c191"
      id="hidden-fact-140"
      unitRef="pure"
      xsi:nil="true"/>
    <athe:KeyManagementPersonnelCompensationLongtermBenefits
      contextRef="c0"
      id="hidden-fact-141"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits
      contextRef="c0"
      id="hidden-fact-142"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits
      contextRef="c5"
      id="hidden-fact-143"
      unitRef="aud"
      xsi:nil="true"/>
    <athe:FinancialInstrumentsTotalExposure
      contextRef="c250"
      id="hidden-fact-144"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssets
      contextRef="c254"
      id="hidden-fact-145"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssets
      contextRef="c258"
      id="hidden-fact-146"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssets
      contextRef="c259"
      id="hidden-fact-147"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssets
      contextRef="c260"
      id="hidden-fact-148"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssets
      contextRef="c263"
      id="hidden-fact-149"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssets
      contextRef="c265"
      id="hidden-fact-150"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssets
      contextRef="c271"
      id="hidden-fact-151"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c273"
      id="hidden-fact-152"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c274"
      id="hidden-fact-153"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c275"
      id="hidden-fact-154"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c278"
      id="hidden-fact-155"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c281"
      id="hidden-fact-156"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c269"
      id="hidden-fact-157"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssets
      contextRef="c285"
      id="hidden-fact-158"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssets
      contextRef="c289"
      id="hidden-fact-159"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssets
      contextRef="c290"
      id="hidden-fact-160"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssets
      contextRef="c291"
      id="hidden-fact-161"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssets
      contextRef="c294"
      id="hidden-fact-162"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssets
      contextRef="c296"
      id="hidden-fact-163"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialAssets
      contextRef="c302"
      id="hidden-fact-164"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c304"
      id="hidden-fact-165"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c305"
      id="hidden-fact-166"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c306"
      id="hidden-fact-167"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c309"
      id="hidden-fact-168"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c312"
      id="hidden-fact-169"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c314"
      id="hidden-fact-170"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c315"
      id="hidden-fact-171"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c316"
      id="hidden-fact-172"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:FinancialLiabilities
      contextRef="c300"
      id="hidden-fact-173"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayables
      contextRef="c320"
      id="hidden-fact-174"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayables
      contextRef="c321"
      id="hidden-fact-175"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayables
      contextRef="c335"
      id="hidden-fact-176"
      unitRef="aud"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayables
      contextRef="c336"
      id="hidden-fact-177"
      unitRef="aud"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-24698">0001131343</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-24699">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-24700">FY</dei:DocumentFiscalPeriodFocus>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A 43.5% R&amp;D Tax incentive refundable tax offset, is available to eligible small companies with an annual aggregate turnover of less than $20 million. For the years ended June 30, 2025, June 30, 2024 and June 30, 2023, the Group was eligible to receive the refundable tax offset. Management, with input from an independent expert, has applied judgement when assessing activities and expenditures that are likely to be eligible under the incentive scheme and therefore recorded $5,438,918, $4,019,285 and $3,914,230 in other income, respectively.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-76"
          xlink:label="hidden-fact-76"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Miscellaneous income is comprised of other income of $1,975,056 in relation to settlement of a dispute with Catalent, and other income of $227,542 in relation to settlement of an insurance claim in relation to a U.S. employment case.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-76"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses mainly consist of expenses paid for contracted research and development activities conducted by third parties on behalf of the Group.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of June 30, 2025, the Group had a potential tax benefit related to gross tax losses carried forward of $187,632,492 (2024: $179,125,289) and a non-refundable R&amp;D tax offset of $2,126,801 (2024: $3,703,478).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unused tax loss amounts are only attributable to the Group&#x2019;s operations in Australia, as the subsidiary in the United States has no carryforward tax losses as of June 30, 2025. Tax losses can be carried forward indefinitely subject to continuity of ownership and same business test rules.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-81"
          xlink:label="hidden-fact-81"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Term deposit of 150-day term and maturity date of October
17, 2025.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-81"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_21_fact"
          xlink:label="ix_21_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_18_fact"
          xlink:label="ix_18_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_20_fact"
          xlink:label="ix_20_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_19_fact"
          xlink:label="ix_19_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Movements in provisions</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_19_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-82"
          xlink:label="hidden-fact-82"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-83"
          xlink:label="hidden-fact-83"
          xlink:type="locator"/>
        <link:footnote id="ix_7_footnote" xlink:label="ix_7_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts not expected to be settled within the next 12 months</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-82"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-83"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_24_fact"
          xlink:label="ix_24_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-92"
          xlink:label="hidden-fact-92"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_22_fact"
          xlink:label="ix_22_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_23_fact"
          xlink:label="ix_23_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-94"
          xlink:label="hidden-fact-94"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-93"
          xlink:label="hidden-fact-93"
          xlink:type="locator"/>
        <link:footnote id="ix_8_footnote" xlink:label="ix_8_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 8, 2024 a total of 457,142,830 free attaching options with an exercise price of A$0.01, expiring on August 31, 2026 were issued.</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 8, 2024 a total of 1,371,428,567 free attaching options with an exercise price of A$0.007, expiring on August 31, 2024 were issued.</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 2, 2024 a total of 190,476,123 free attaching options with an exercise price of A$0.002, expiring on August 31, 2026 were issued.</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 2, 2024 a total of 571,428,556 free attaching options with an exercise price of A$0.007, expiring on August 31, 2024 were issued.</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 15, 2024 a total of 285,087,715 free attaching options with an exercise price of A$0.01, expiring on August 31, 2026 were issued.</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</xhtml:p><xhtml:p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 23, 2025 a total of 1,222,300,911 free attaching options with an exercise price if A$0.028, expiring on February 26, 2027 were issued.</xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_24_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-92"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_22_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_23_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-94"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-93"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_27_fact"
          xlink:label="ix_27_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_26_fact"
          xlink:label="ix_26_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_25_fact"
          xlink:label="ix_25_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_9_footnote" xlink:label="ix_9_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Audit and review of financial statements consist of fees billed for assurance and related services that generally only the statutory auditor could reasonably provide to a client.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_27_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_26_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_25_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_28_fact"
          xlink:label="ix_28_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_30_fact"
          xlink:label="ix_30_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_29_fact"
          xlink:label="ix_29_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_10_footnote" xlink:label="ix_10_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in the balance are amounts related to additional regulatory filings during the 2025 financial year. All services provided are considered audit services for the purpose of SEC classification.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_28_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_30_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_29_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
